<SEC-DOCUMENT>0001654954-21-013417.txt : 20211221
<SEC-HEADER>0001654954-21-013417.hdr.sgml : 20211221
<ACCEPTANCE-DATETIME>20211221163358
ACCESSION NUMBER:		0001654954-21-013417
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211221
DATE AS OF CHANGE:		20211221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		211509870

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cvm_10k.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:cvm="http://cvm.com/20210930"><head><title>cvm_10k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2020-10-01to2021-09-30">0000725363</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2020-10-01to2021-09-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="From2020-10-01to2021-09-30">No</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2020-10-01to2021-09-30">--09-30</ix:nonNumeric><ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="From2020-10-01to2021-09-30">No</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2020-10-01to2021-09-30">FY</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2020-10-01to2021-09-30">2021</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" unitRef="USDPShares" decimals="INF">.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" unitRef="USDPShares" decimals="INF">.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-09-30" unitRef="Shares" decimals="0">200000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-09-30" unitRef="Shares" decimals="0">200000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" unitRef="USDPShares" decimals="INF">.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-09-30" unitRef="Shares" decimals="0">600000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-09-30" unitRef="Shares" decimals="0">43207183</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-09-30" unitRef="Shares" decimals="0">38730150</ix:nonFraction><ix:nonNumeric name="cvm:SuppliesUsedForRDAndManufacturingPolicytextblock" contextRef="From2020-10-01to2021-09-30"></ix:nonNumeric><ix:nonFraction name="cvm:WarrantsExercised" contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember" unitRef="Shares" decimals="0">72900</ix:nonFraction><ix:nonFraction name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="From2019-10-01to2020-09-30" unitRef="USD" decimals="0">664000</ix:nonFraction><ix:nonFraction name="cvm:WarrantsIssuedDuringPeriod" contextRef="From2020-06-01to2020-06-20_cvm_SeriesXXWarrantsMember" unitRef="Shares" decimals="0">461963</ix:nonFraction><ix:nonFraction name="cvm:WarrantsIssuedDuringPeriod" contextRef="From2020-06-01to2020-06-20_cvm_SeriesUUWarrantsMember" unitRef="Shares" decimals="0">101839</ix:nonFraction><ix:nonFraction name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="From2020-10-01to2021-09-30_cvm_SeriesYMember" unitRef="USD" decimals="0">103000</ix:nonFraction><ix:nonFraction name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="From2020-01-01to2020-01-23_cvm_SeriesYMember" unitRef="USD" decimals="0">22000</ix:nonFraction><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2021-09-30" unitRef="USD" decimals="0">13456123</ix:nonFraction><ix:nonFraction name="cvm:ResearchAndDevelopmentCredit" contextRef="AsOf2021-09-30_cvm_IncomeTaxMember" unitRef="USD" decimals="0">1200000.0</ix:nonFraction><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2020-09-30_cvm_IncomeTaxMember" unitRef="USD" decimals="0">188900000.0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-10-01to2020-09-30" unitRef="Pure" decimals="INF">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-10-01to2021-09-30" unitRef="Pure" decimals="INF">0</ix:nonFraction><ix:nonNumeric name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember">P7Y8M5D</ix:nonNumeric><ix:nonFraction name="cvm:AggregateIntrinsicValueOutstandingEnding" contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember" unitRef="USD" decimals="0">29090662</ix:nonFraction><ix:nonNumeric name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember">P8Y10M17D</ix:nonNumeric><ix:nonFraction name="cvm:AggregateIntrinsicValue" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" unitRef="USD" decimals="0">56193415</ix:nonFraction><ix:nonFraction name="cvm:NumberOfUnvestedOptionsBeginning" contextRef="From2020-10-01to2021-09-30" unitRef="Shares" decimals="0">5356474</ix:nonFraction><ix:nonFraction name="cvm:WeightedAverageGrantDateFairValueEnding" contextRef="From2019-10-01to2020-09-30" unitRef="USDPShares" decimals="INF">4.76</ix:nonFraction><ix:nonFraction name="cvm:SharesForfeited" contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="cvm:VestedShares" contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="cvm:NumberOfUnvestedSharesEnding" contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember" unitRef="Shares" decimals="0">304500</ix:nonFraction><ix:nonFraction name="cvm:WeightedAverageGrantDateFairValueBeginning" contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember" unitRef="USDPShares" decimals="INF">13.75</ix:nonFraction><ix:nonFraction name="cvm:RemainingCompensationExpense" contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" unitRef="USD" decimals="0">3800000.0</ix:nonFraction><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2021-09-30" unitRef="USD" decimals="0">4825000</ix:nonFraction><ix:nonFraction name="us-gaap:DerivativeVariableInterestRate" contextRef="AsOf2021-09-30" unitRef="Pure" decimals="INF">0.001019</ix:nonFraction><ix:nonFraction name="us-gaap:DerivativeVariableInterestRate" contextRef="AsOf2020-09-30" unitRef="Pure" decimals="INF">0.001</ix:nonFraction><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-10-01to2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" unitRef="USD" decimals="0">200000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" unitRef="USD" decimals="0">1732000</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" unitRef="USD" decimals="0">1717000</ix:nonFraction><ix:nonFraction name="cvm:CashPaidRelatedToFinanceLeasesInterest" contextRef="From2019-10-01to2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" unitRef="USD" decimals="0">1200000.0</ix:nonFraction><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" unitRef="Pure" decimals="INF">0.000845</ix:nonFraction><ix:nonFraction name="us-gaap:LeaseIncentivePayableCurrent" contextRef="AsOf2021-09-30_cvm_LandlordMember" unitRef="USD" decimals="0">1600000.0</ix:nonFraction><ix:nonFraction name="cvm:AdditionalClinicalTrial" contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember" unitRef="USD" decimals="0">2000000</ix:nonFraction><ix:nonFraction name="cvm:NetOfDiscount" contextRef="From2019-10-01to2020-09-30_cvm_ErgomedMember" unitRef="USD" decimals="0">600000.0</ix:nonFraction><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember">P7Y1M6D</ix:nonNumeric><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2019-10-01to2020-09-30_cvm_ErgomedMember" unitRef="USD" decimals="0">1400000.0</ix:nonFraction><ix:nonFraction name="cvm:FinanceLeaseObligationsNetOfCurrentPortion" contextRef="AsOf2021-09-30" unitRef="USD" decimals="0">200000</ix:nonFraction><ix:nonFraction name="cvm:FinanceLeaseObligationsNetOfCurrentPortion" contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">100000</ix:nonFraction><ix:nonNumeric name="cvm:ExpirationDateDescription" contextRef="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember">from December 31, 2020 to June 30, 2021</ix:nonNumeric><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2021-04-01to2021-06-30_cvm_SeriesXWarrantsMember" unitRef="USD" decimals="0">265000</ix:nonFraction><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2020-10-01to2021-09-30_cvm_SeriesXWarrantsMember" unitRef="USD" decimals="0">265000</ix:nonFraction><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNWarrantsMember" unitRef="USD" decimals="0">265000</ix:nonFraction><ix:nonFraction name="cvm:WarrantsIssued" contextRef="AsOf2020-12-07_cvm_SeriesUUWarrantsMember" unitRef="Shares" decimals="0">93603</ix:nonFraction><ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUWarrantsMember" unitRef="USD" decimals="0">24000</ix:nonFraction><ix:nonFraction name="cvm:ProceedsFromPublicOffering" contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">90959</ix:nonFraction><ix:nonFraction name="cvm:IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants" contextRef="From2019-10-01to2020-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='cvm-20210930.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2020-10-01to2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_FairValueInputsLevelThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">cvm:FairValueInputsLevelThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_FairValueInputsLevelThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">cvm:FairValueInputsLevelThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_FairValueInputsLevelThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">cvm:FairValueInputsLevelThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_FairValueInputsLevelThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">cvm:FairValueInputsLevelThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-12-01to2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-01-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-03-01to2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-05-01to2020-05-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-06-01to2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-12-01to2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-01-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_OfficerAndDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-28_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-07_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-05-08_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesNAndXWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNAndXWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesNWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesXWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_cvm_SeriesXWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_cvm_SeriesNWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesNWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-12-01to2020-12-07_cvm_SeriesNWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_us-gaap_LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_VendorObligationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvm:VendorObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-05-14_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-04-20_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_StockCompensationPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:StockCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_IncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_IncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_IncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-01-23_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-01-23_cvm_SeriesNWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesNAndXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNAndXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-05-01to2020-05-08_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-06-01to2020-06-20_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-06-01to2020-06-20_cvm_SeriesYYWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYYWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesYYWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYYWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-06-01to2020-06-20_cvm_SeriesXXWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXXWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesXXWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXXWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-10-28_cvm_SeriesWMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-08-01to2021-08-22_cvm_SeriesBBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-05-26_cvm_SeriesVWarrantsMember_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-05-26_srt_MaximumMember_cvm_SeriesVWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-06-01to2020-06-25_cvm_SeriesVWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-05-01to2020-05-26_cvm_SeriesVWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesVVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesVVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesOOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesOOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesLLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesLLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesLLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesLLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesJJMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesJJMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesJJMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesJJMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesFFMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesFFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesFFMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesFFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesBBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesBBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesZZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesZZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesWMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesWMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesTTMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesTTMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesTTMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesTTMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesAAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesAAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesAAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesAAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesHHMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesHHMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesHHMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesHHMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesCCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesCCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesCCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesCCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesBBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesBBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesZZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesZZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesWMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesWMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-10-01to2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span id="font2e58ea52-b2f8-462c-885d-fa8fb40b821d" style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:DocumentType">10-K</ix:nonNumeric></span> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Mark One)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160; ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the fiscal year ended <ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">September 30, 2021</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OR</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the transition period from _________ to __________.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Commission file number <ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityFileNumber">1-11889</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span id="font63ff3c8e-a41f-4644-8286-59a8d6e76aa7" style="font-size:18pt"><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityRegistrantName">CEL-SCI CORPORATION</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Colorado</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityTaxIdentificationNumber">84-0916344</ix:nonNumeric> </strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of incorporation or organization)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(I.R.S. Employer Identification No.)</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityAddressAddressLine1">8229 Boone Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityAddressAddressLine2">Suite 802</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityAddressCityOrTown">Vienna</ix:nonNumeric>, <ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityAddressPostalZipCode">22182</ix:nonNumeric> </strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Registrant's telephone number, including area code: (<ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:CityAreaCode">703</ix:nonNumeric>) <ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:LocalPhoneNumber">506-9460</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Title of each class</p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Trading Symbol</p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of each exchange </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">on which registered</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:Security12bTitle">Common Stock</ix:nonNumeric> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:TradingSymbol">CVM</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(g) of the Act: None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an &#8220;emerging growth company&#8221;. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large accelerated filer </p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer </p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging Growth Company </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes <ix:nonNumeric contextRef="From2020-10-01to2021-09-30" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The aggregate market value of the voting stock held by non-affiliates of the Registrant, based upon the closing sale price of the registrant&#8217;s common stock on March 31, 2021, as quoted on the NYSE American, was $<ix:nonFraction contextRef="AsOf2021-03-31" name="dei:EntityPublicFloat" format="ixt:numdotdecimal" scale="0" decimals="0" unitRef="USD">595,537,907</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 10, 2021, the Registrant had <ix:nonFraction contextRef="AsOf2021-12-10" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,244,498</ix:nonFraction> issued and outstanding shares of common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Documents Incorporated by Reference: None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORWARD-LOOKING STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This report contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;future,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;continues&#8221; and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font5096b24a-f147-4cf2-91f7-b7606118395a" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font9161b4a8-2cb7-41ac-80c1-fd87ec20e7b3" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations regarding the timing, costs and outcome of any pending or future litigation matters, lawsuits or arbitration proceeding;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font9eb36645-d1a3-413c-85eb-bd21b3969351" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the success of our clinical studies for our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font880ccb9a-716e-4752-a005-558a451ed7e9" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontfdf302b2-e59d-475b-9213-519c5f867647" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations regarding federal, state and foreign regulatory requirements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontfd41dbb6-dc69-453c-a954-5eaba9313bac" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the therapeutic benefits and effectiveness of our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font0098849b-cbcf-4874-bae1-f36f24a79ac4" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the safety profile and related adverse events of our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font8a02c416-2183-475f-81ea-b6b8a63901ff" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fonta34f9398-0534-4586-86ca-63d7907829ac" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our plans with respect to collaborations and licenses related to the development, manufacture or sale of our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font30be6cce-2550-4829-bb40-07729db3d9ac" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">business disruption and related risks resulting from the recent pandemic of the novel coronavirus 2019 (COVID-19);</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font5ee81396-4f8c-477c-92f7-ad42c504365d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations as to future financial performance, expense levels and liquidity sources;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontaee7533f-fafb-4ce8-92ff-6bc1213a2571" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font47af3db4-5378-4fde-a4df-bcb47a7ebc63" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">anticipated trends and challenges in our potential markets;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontf8d5e4e0-0a44-4951-a9e1-ca3be24e690d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to attract, retain and motivate key personnel;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font12a2a77d-cab4-4f99-b654-3206376f1af5" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to continue as a going concern; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font929f5551-674a-43d2-a101-9cc2103831ed" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our liquidity.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">All forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained in this report, speak only as of their respective dates. Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect new information, events or circumstances or to reflect the occurrence of unanticipated events. In light of these risks and uncertainties, the forward-looking events and circumstances described in this report may not occur and actual results could differ materially from those anticipated or implied in such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PART I</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">ITEM 1. BUSINESS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI Corporation (CEL-SCI) is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. For its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection) CEL-SCI&#160;has&#160;announced top line data from its&#160;pivotal Phase 3 clinical trial for patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck for which CEL-SCI has received Orphan Drug Status from the U.S. Food and Drug Administration, or FDA. The study was fully enrolled with 928 patients in September 2016. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine&#174; (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6% survival, Multikine arm 62.7% survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The study used the standard of care treatment for advanced primary head and neck cancer patients as a comparison. The patients received surgery followed by either radiation or chemoradiation (chemotherapy and radiation at the same time), as determined by the physician. This means that there were 2 treatment arms, 1) surgery plus radiation or 2) surgery plus chemoradiation. The arm that received Multikine treatment followed by surgery and radiation showed great survival benefit, but when chemotherapy was added in the second treatment arm, the immunological effect of Multikine was negated. Therefore when the two treatment arms were combined the study did not achieve its primary endpoint of a 10% improvement in overall survival. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">However, the analysis of the separate treatment arms was prespecified in the protocol and carried out prior to the Company becoming unblinded. The OS benefit of 14.1% at 5 years for this treatment arm exceeded the 10% OS benefit set out for the study population as a whole. The OS results for this treatment arm are significant (two-sided p=0.0236, HR=0.68) and the effect is robust, durable and increasing over time. The results from the Phase 3 cancer study proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this the Company will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population of about 210,000 patients annually worldwide.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s investigational immunotherapy Multikine is being used in a different way than cancer immunotherapy is usually used. It is given before any other therapy has been administered because that is when the immune system is thought to be strongest (i.e., as a neoadjuvant). It is also administered locally around the tumors and near the draining lymph node. In the Phase 3 clinical trial, Multikine was given locally for three weeks, five days per week as a first line treatment before surgery, radiation or radiochemotherapy. The goal is to help the intact immune system &#8220;see&#8221; the cancer and kill the micro metastases that usually cause recurrence of the cancer. In short, CEL-SCI believes that local administration and administration of Multikine before weakening of the immune system by surgery, radiation and chemotherapy will result in improved outcomes and better overall survival rates for patients suffering from head and neck cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI is investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI was formed as a Colorado corporation in 1983. CEL-SCI&#8217;s principal office is located at 8229 Boone Boulevard, Suite 802, Vienna, VA 22182. CEL-SCI&#8217;s telephone number is 703-506-9460 and its website is www.cel-sci.com. CEL-SCI does not incorporate the information on its website into this report, and you should not consider it part of this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI makes its electronic filings with the Securities and Exchange Commission (SEC), including its annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to these reports available on its website free of charge as soon as practicable after they are filed or furnished to the SEC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI&#8217;S PRODUCTS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1) </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2) </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with CEL-4000 as a product candidate under development for the potential treatment of rheumatoid arthritis.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>MULTIKINE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s lead investigational therapy, Multikine, is currently being developed as a potential therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Data from Phase 1 and Phase 2 clinical trials suggest that Multikine may help the immune system &#8220;see&#8221; the tumor and then attack it, enabling the body&#8217;s own anti-tumor immune response to fight the tumor. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to review by the FDA, in connection with CEL-SCI&#8217;s future anticipated regulatory submission for approval in the United States. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency, such as the European Medicine Agency, or EMA, and neither its safety nor its efficacy been established.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines. If commercial approval is obtained, CEL-SCI intends to manufacture Multikine in a proprietary manner in CEL-SCI&#8217;s manufacturing facility. CEL-SCI spent over 10 years and more than $100 million developing and validating the manufacturing process for Multikine. The pro-inflammatory cytokine mixture includes interleukins, interferons, chemokines and colony-stimulating factors, which contain elements of the body&#8217;s natural mix of defenses against cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine is designed to be used in a different way than cancer immunotherapy is generally being used. Generally, cancer immunotherapy is given to patients who have already failed other treatments such as surgery, radiation and/or chemotherapy and most of the time it is administered systemically. Multikine on the other hand is administered locally to treat tumors and their microenvironment before any other therapy has been administered because it is believed that this is the time when the immune system would be strongest and most amenable to activation against the tumor. For example, in the Phase 3 clinical trial, Multikine was injected locally around the tumor and near the adjacent draining lymph nodes for three weeks, five days a week as a first treatment before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system recognize and kill the tumor micro metastases that usually cause recurrence of the cancer. In short, CEL-SCI believes that the local administration of Multikine before weakening of the immune system by surgery, chemotherapy and radiation will result in better anti-tumor response than if Multikine were administered after surgery, radiation and chemotherapy. In clinical studies of Multikine, administration of the investigational therapy to head and neck cancer patients has demonstrated the potential for lesser or no appreciable toxicity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg1.jpg" alt="cvm_10kimg1.jpg" /></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Source: Adapted from Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The first indication CEL-SCI is pursuing for its investigational drug product candidate Multikine is an indication for the neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck, or SCCHN (hereafter also referred to as advanced primary head and neck cancer). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine&#174; (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6% survival, Multikine arm 62.7% survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The study used the standard of care treatment for advanced primary head and neck cancer patients as a comparison. The patients received surgery followed by either radiation or chemoradiation (chemotherapy and radiation at the same time), as determined by the physician. This means that there were 2 treatment arms, 1) surgery plus radiation or 2) surgery plus chemoradiation. The arm that received Multikine treatment followed by surgery and radiation showed great survival benefit, but when chemotherapy was added in the second treatment arm, the immunological effect of Multikine was negated. Therefore when the two treatment arms were combined the study did not achieve its primary endpoint of a 10% improvement in overall survival. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">However, the analysis of the separate treatment arms was prespecified in the protocol and carried out prior to the Company becoming unblinded. The OS benefit of 14.1% at 5 years for this treatment arm exceeded the 10% OS benefit set out for the study population as a whole. The OS results for this treatment arm are significant (two-sided p=0.0236, HR=0.68) and the effect is robust, durable and increasing over time. The results from the Phase 3 cancer study proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this the Company will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population of about 210,000 patients annually worldwide.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">This trial was under the management of two clinical research organizations, or CROs: ICON plc., or ICON, and Ergomed Clinical Research Limited, or Ergomed. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Since CEL-SCI launched its Phase 3 clinical trial for Multikine, CEL-SCI has incurred expenses of approximately $62.2 million as of September 30, 2021 on direct costs for the Phase 3 clinical trial. CEL-SCI estimates it will incur additional expenses of approximately $1.1 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report to the FDA. It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., preparations for the potential commercial manufacture of the drug. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Ultimately, the decision as to whether CEL-SCI&#8217;s drug product candidate is safe and effective can only be made by the FDA and/or by other regulatory authorities based upon an assessment of all of the data from an entire drug development program submitted as part of an application for marketing approval. As detailed in the Risk Factors section of this report, the current Phase 3 clinical study for CEL-SCI&#8217;s investigational drug may or may not be able to be used as the pivotal study supporting a marketing application in the United States, and, if not, at least one entirely new Phase 3 pivotal study would need to be conducted to support a marketing application in the United States. However, CEL-SCI does not believe that this is likely.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Development Agreements for Multikine </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In August 2008, CEL-SCI signed an agreement with Teva Pharmaceutical Industries Ltd., or Teva, that gives Teva the exclusive right and license to market, distribute and sell Multikine, if approved, in Israel and Turkey for treatment of head and neck cancer. The agreement terminates on a country-by-country basis 10 years after the product launch in each country or upon a material breach or upon bankruptcy of either party. The agreement will automatically extend for additional two year terms unless either party gives notice of its intent not to extend the agreement. If CEL-SCI develops Multikine for other oncology indications and Teva indicates a desire to participate, the parties have agreed to negotiate in good faith with respect to Teva&#8217;s participation and contribution in future clinical trials.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Teva has agreed to use all reasonable efforts to obtain regulatory approval to market and sell Multikine in its territory at its own cost and expense. Pursuant to the agreement, it is CEL-SCI&#8217;s responsibility to supply Multikine and Teva&#8217;s responsibility to sell Multikine, if approved by regulatory authorities in the relevant countries. Net sales will be divided 50/50 between the two parties. Teva also initially agreed to fund certain activities relating to the conduct of a clinical trial in Israel as part of the global Phase 3 trial for Multikine. In January 2012, pursuant to an assignment and assumption agreement between CEL-SCI, Teva and GCP Clinical Studies Ltd., or GCP, Teva transferred all of its rights and obligations concerning the Phase 3 trial in Israel to GCP. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In July 2011, Serbia and Croatia were added to Teva&#8217;s territory, pursuant to a joinder agreement between CEL-SCI and PLIVA Hrvatska d.o.o., or PLIVA, an affiliate of Teva&#8217;s, subject to similar terms as described above.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In consideration for the rights granted by CEL-SCI to PLIVA under the joinder agreement, CEL-SCI will be paid by PLIVA (in U.S. dollars):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontb5e57cf2-a0a1-4831-acdf-227cdc1da48a" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">$100,000 upon EMA grant of Marketing Authorization for Multikine;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font6ced6ee0-3316-447a-b19e-4cebf446514f" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">$50,000 upon Croatia&#8217;s grant of reimbursement status for Multikine in Croatia; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font2da23b74-9780-4e13-aa8f-a3e9dde74b11" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">$50,000 upon Serbia&#8217;s grant of reimbursement status for Multikine in Serbia.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In November 2000, CEL-SCI signed an agreement with Orient Europharma Co., Ltd., or Orient Europharma, of Taiwan, which was amended in October 2008 and again in June 2010. Pursuant to this agreement, as amended, Orient Europharma has the exclusive marketing and distribution rights to Multikine, if approved by regulatory authorities, for head and neck cancer, naso-pharyngeal cancer and potentially cervical cancer indications in Taiwan, Singapore, Malaysia, Hong Kong, the Philippines, South Korea, Australia and New Zealand. CEL-SCI has granted Orient Europharma the first right of negotiation with respect to Thailand and China.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The agreement requires Orient Europharma to fund 10% of the cost of the clinical trials needed to obtain marketing approvals in these countries for head and neck cancer, naso-pharyngeal cancer and potentially cervical cancer. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If Multikine is approved for sale, Orient Europharma will purchase Multikine from CEL-SCI for 35% of the gross selling price in each country. Orient Europharma is obligated to use the same diligent efforts to develop, register, market, sell and distribute Multikine in its territory as with its own products or other licensed products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The agreement will terminate on a country-by-country basis 15 years after the product approval for Multikine in each country, at which point the agreement will be automatically extended for successive two year periods, unless either party gives notice of its intent not to extend the agreement. The agreement may also be terminated upon the bankruptcy of either party or material misrepresentations that are not cured within 60 days. If the agreement ends before the 15 year term through no fault of either party, CEL-SCI will reimburse Orient Europharma for a prorated part of Orient Europhorma&#8217;s costs towards the clinical trials of Multikine. If Orient Europharma fails to make certain minimum purchases of Multikine during the term of the agreement, Orient Europhorma&#8217;s rights to the territory will become non-exclusive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a licensing agreement with Byron Biopharma LLC, or Byron, under which CEL-SCI granted Byron an exclusive license to market and distribute Multikine in the Republic of South Africa, if approved. This license will terminate 20 years after marketing approval in South Africa or after the bankruptcy or uncured material breach by either party. After the 20-year period has expired, the agreement will be automatically extended for successive two year periods, unless either party gives notice of its intent not to extend the agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the agreement, Byron will be responsible for registering Multikine in South Africa. If Multikine is approved for sale in South Africa, CEL-SCI will be responsible for manufacturing the product, while Byron will be responsible for sales in South Africa. Sales revenues will be divided equally between CEL-SCI and Byron.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">LEAPS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s patented T-cell Modulation Process, referred to as LEAPS (Ligand Epitope Antigen Presentation System), uses &#8220;heteroconjugates&#8221; to direct the body to choose a specific immune response. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. LEAPS combines T-cell binding ligands with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The ability to generate a specific immune response is important because many diseases are often not combated effectively due to the body&#8217;s selection of the &#8220;inappropriate&#8221; immune response. The capability to specifically reprogram an immune response may offer a more effective approach than existing vaccines and drugs in attacking an underlying disease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">LEAPS Candidate: </span><span style="text-decoration:underline">LEAPS COV-19</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI began developing an immunotherapy with the potential to treat the COVID-19 coronavirus using its patented LEAPS peptide technology. On March 23, 2020, CEL-SCI signed a collaboration agreement with the University of Georgia&#8217;s Center for Vaccines and Immunology to develop LEAPS COV-19 immunotherapy. The LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell mediated T cell responses and reduce viral load. The LEAPS peptide technology can be used to construct immunotherapeutic peptides that exhibit both antiviral and anti-inflammatory properties. Consequently, these products not only target the virus infection against which they are directed, but also elicit the appropriate protective response(s) against it.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On July 24, 2020, CEL-SCI announced it had concluded animal experiments using its LEAPS COV-19 conjugate that provide the basis for moving forward into animal challenge studies with live virus SARS-CoV-2, the causative agent of COVID-19, at the UGA&#8217;s Center for Vaccines and Immunology. The animal experiments showed that LEAPS COV-19 conjugates induced faster and much higher than expected antibody responses against a non-mutating region of the virus that causes COVID-19 after only one injection. It is important to note that IgG antibodies response was generated within 10 days of a single immunization. Generation of IgG requires activation of dendritic, T and B cells in order to promote the class switch from IgM to IgG antibody.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On December 1, 2020, CEL-SCI announced that LEAPS COV-19 peptides, delivered as a therapeutic treatment following SARS-CoV-2 virus challenge, achieved a 40% survival rate in transgenic mouse models as compared to 0% survival in the two control groups in studies conducted at the University of Georgia Center for Vaccines and Immunology. The animals were therapeutically treated with CEL-SCI&#8217;s LEAPS COV-19 peptides one day after infection with a lethal dose of SARS-CoV-2. Of the LEAPS treated mice, forty percent (40%) were alive, recovering and regained lost weight, attaining &gt; 90% of their starting weight, by the study&#8217;s end. In contrast, mice in the two control groups lost 20% or more of their body weight by day 8 and all of them died between day 5 and day 8 post challenge. The success of this therapy was statistically significant at a 95% level. An additional study conducted using LEAPS as a vaccine to prevent disease resulted in similar findings to the above described study, but with a slightly lower level of statistical significance. In this study, the Human(h) ACE2 transgenic mice were dosed twice with the LEAPS conjugate 28 and 14 days prior to being challenged with a lethal dose of SARS-CoV-2 virus. CEL-SCI will not continue with this project since its resources need to be focused on the approval of Multikne.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">LEAPS Candidates: CEL-2000, CEL-4000 and DerG-PG275(Cit)</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On September 19, 2017, CEL-SCI announced that it had been awarded a Phase 2 Small Business Innovation Research (SBIR) grant in the amount of $1.5 million from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, or NIAMS, which is part of the U.S. National Institutes of Health (NIH). This grant provided funding to allow CEL-SCI to advance its first LEAPS product candidate, CEL-4000, towards an Investigational New Drug (IND) application for a Phase 1 safety study, by funding IND enabling studies and additional mechanism of action studies, among other preclinical development activities. Work on CEL-4000 was conducted at CEL-SCI&#8217;s research laboratory and Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Jorge O. Galante Professor of Orthopedic Surgery and Katalin Mikecz, MD, Ph.D. Professor of Orthopedic Surgery &amp; Biochemistry. The SBIR grant was awarded based on published data described below by Dr. Glant's team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental proteoglycan induced arthritis (PGIA or GIA) when it was administered after the disease was induced in animals. This grant has been fully expended.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In May 2019, CEL-SCI announced that a newly discovered LEAPS conjugate acts alone and can complement CEL-4000 therapeutically when administered in combination to an animal model of Rheumatoid Arthritis (RA). This new LEAPS conjugate appears to act on T cell pathways by a new mechanism that is different from the pathways used by the CEL-4000 vaccine. The data was presented at the American Association of Immunologists 103rd Annual Meeting (Immunology 2019) by Daniel Zimmerman, Ph.D., CEL-SCI&#8217;s Senior Vice President of Research, Cellular Immunology. The work was performed in conjunction with researchers at Rush University Medical Center, Chicago, Illinois and was funded by the SBIR Phase 2 Grant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In July 2019, one of CEL-SCI&#8217;s collaborators from Rush, Dr. Adrienn Markovics presented new LEAPS data at i-Chem2019, International Conference on Immunity and Immunochemistry. Data presented was for a new second RA conjugate discovered which acts alone and can complement the existing CEL-4000 RA vaccine in an animal model of RA. The combination of the two RA conjugates provided not only broader epitope coverage, but also a greater therapeutic effect than either conjugate alone. The LEAPS work was performed in conjunction with researchers at CEL-SCI on CEL-4000 and a newly discovered LEAPS conjugate, DerG-PG275Cit. Both conjugates were evaluated alone and in combination in the model of proteoglycan [PG] induced arthritis (PGIA) called recombinant PG G1 domain-induced arthritis (GIA), an autoimmune mouse model of RA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In February 2017 and November 2016, CEL-SCI announced preclinical data that demonstrate its investigational new drug candidate CEL-4000 has the potential to treat rheumatoid arthritis. This study was supported in part by the SBIR Phase I Grant and was conducted in collaboration with Drs. Katalin Mikecz and Tibor Glant, and their research team at Rush University Medical Center in Chicago, IL. This work was published in an article entitled &#8220;<em>An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis</em>&#8221; and can be found online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568759/. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Prior to the SBIR Phase 2 grant in 2014, CEL-SCI was awarded a Phase 1 SBIR grant in the amount of $225,000 from NIAMS. This grant funded the development of CEL-SCI&#8217;s LEAPS technology as a potential treatment for rheumatoid arthritis, an autoimmune disease of the joints. The work was conducted at Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Katalin Mikecz, MD, Ph.D., and Allison Finnegan, Ph.D. Professor of Medicine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">With the support of these SBIR grants, CEL-SCI is developing several new drug candidates, CEL-2000 and CEL-4000, as potential rheumatoid arthritis therapeutic treatments. The data from animal studies using the CEL-2000 treatment suggests that it could be used against rheumatoid arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments currently on the market for arthritic conditions associated with the Th17 signature cytokine TNF-a. The preclinical data indicates these peptides could be used against rheumatoid arthritis where a Th1 signature cytokine (IFN-&#947;) is dominant. CEL-2000 and CEL-4000 each have the potential to become a personalized, disease-specific therapy, that acts at an earlier step in the disease process than current therapies, and which may be useful in patients not responding to existing rheumatoid arthritis therapies. CEL-SCI believes this represents a large unmet medical need in the rheumatoid arthritis market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In March 2015, CEL-SCI and its collaborators published a review article on vaccine therapies for rheumatoid arthritis based in part on work supported by the SBIR Phase 1 grant. The article is entitled &#8220;Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic Ligand Epitope Antigen Presentation System vaccines for models of rheumatoid arthritis&#8221; and was published in Expert Review of Vaccines 1 - 18 and can be found online at http://www.ncbi.nlm.nih.gov/pubmed/25787143. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Other LEAPS experiments: </span><span style="text-decoration:underline">LEAPS-H1N1-DC</span><span style="text-decoration:underline"> </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Using the LEAPS technology, CEL-SCI has also tested in preclinical studies a potential peptide treatment for H1N1 (swine flu) hospitalized patients, a disease which does not represent a problem any more. Therefore CEL-SCI is no longer developing a treatment against H1N1. This LEAPS flu treatment was designed to focus on the conserved, non-changing epitopes of the different strains of Type A Influenza viruses (H1N1, H5N1, H3N1, etc.), including &#8220;swine&#8221;, &#8220;avian or bird&#8221;, and &#8220;Spanish Influenza&#8221;, in order to minimize the chance of viral &#8220;escape by mutations&#8221; from immune recognition. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In May 2011 NIAID scientists presented data at the Keystone Conference on &#8220;Pathogenesis of Influenza: Virus-Host Interactions&#8221; in Hong Kong, China, showing the positive results of efficacy studies in mice of LEAPS H1N1 activated dendritic cells (DCs) to treat the H1N1 virus. Scientists at the NIAID found that H1N1-infected mice treated with LEAPS-H1N1 DCs showed a survival advantage over mice treated with control DCs. The work was performed in collaboration with scientists led by Kanta Subbarao, M.D., Chief of the Emerging Respiratory Diseases Section in NIAID&#8217;s Division of Intramural Research, part of the National Institutes of Health, USA. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In July 2013, CEL-SCI announced the publication of the results of influenza studies by researchers from the NIAID in the Journal of Clinical Investigation (www.jci.org/articles/view/67550). The studies described in the publication show that when CEL-SCI&#8217;s investigational J-LEAPS Influenza Virus treatments were used &#8220;in vitro&#8221; to activate DCs, these activated DCs, when injected into influenza infected mice, arrested the progression of lethal influenza virus infection in these mice. The work was performed in the laboratory of Dr. Subbarao.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Accordingly, even though the various LEAPS candidates have not yet been given to humans, they have been tested in vitro with human cells. They have induced similar cytokine responses that were seen in these animal models, which may indicate that the LEAPS technology might translate to humans. The LEAPS candidates have demonstrated protection against lethal herpes simplex virus (HSV1) and H1N1 influenza infection, as a prophylactic or therapeutic agent in animals. They have also shown some level of activity in animals in two autoimmune conditions, curtailing and sometimes preventing disease progression in arthritis and myocarditis animal models. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">None of the LEAPS investigational products have been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from the early-phase, preclinical-trials data involving these investigational products. Before obtaining marketing approval from the FDA in the United States, and by comparable agencies in most foreign countries, these product candidates must undergo rigorous preclinical and clinical testing which is costly and time consuming and subject to unanticipated delays. There can be no assurance that these approvals will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">INTELLECTUAL PROPERTY</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Patents and other proprietary rights are essential to CEL-SCI&#8217;s business. CEL-SCI files patent applications to protect its technologies, inventions and improvements to its inventions that CEL-SCI considers important to the development of its business. CEL-SCI&#8217;S intellectual property portfolio covers its proprietary technologies, including Multikine and LEAPS, by multiple issued patents and pending patent applications in the United States and in key foreign markets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine is protected by a U.S. patent, which is a composition-of-matter patent issued in May 2005 that, in its current format, expires in 2023. Additional composition-of-matter patents for Multikine have been issued in Germany (issued in June 2011 and currently set to expire in 2025), China (issued in May 2011 and currently set to expire in 2024), Japan (issued in November 2012 and currently set to expire in 2025), and three in Europe (issued in September 2015, May 2016 and October 2017, currently set to expire in 2025 and 2026). The most recent patent issued in October 2017, patent # EP 1 879 618 B1, titled &#8220;A Method for Modulating HLA Class II Tumor Cell Surface Expression With A Cytokine Mixture,&#8221; addresses Multikine&#8217;s mechanism of action to make tumors more visible to the immune system. This new patent is important because, along with the other Multikine issued patents, it addresses how Multikine enables the immune system to recognize and attack the tumor. One way tumor cells evade the immune system is by expressing human leukocyte antigens (HLA) on the tumor cell surface, thus appearing as &#8216;self&#8217; to the immune cells and therefore the tumor cells are not attacked. It is important to note that the tumors of the Multikine-treated best responders in CEL-SCI&#8217;s prior Phase 2 studies had no HLA Class II expressed on the cell surface following Multikine treatment as compared to controls. This points to Multikine&#8217;s ability to modulate HLA expression on the tumor cell surface, thereby allowing the immune system to recognize and attack the tumor.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition to the patents that offer certain protections for Multikine, the method of manufacture for Multikine, a complex biological product, is held by CEL-SCI as a trade secret. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">LEAPS is protected by patents in the United States issued in February 2006, April 2007, August 2007, January 2019 and March 2019. The LEAPS patents, which expire in 2021, 2022, 2021 and three in 2032, respectively, include overlapping claims, with composition of both matter (new chemical entity), process and methods-of-use, to maximize and extend the coverage in their current format. One issued U.S. application is a joint application with Northeast Ohio Medical University (&#8220;Neoucom&#8221;) and CEL-SCI will share the ability to use the patent, unless CEL-SCI licenses the rights to the patent from Neoucom. In October 2017 and October 2020, patents were issued in Europe for LEAPS, which expire in 2029 and 2034, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has five patent applications pending in the United States for LEAPS, which, if issued, would extend protection through 2040, subject to any potential patent term extensions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of December 9, 2021, there were no contested proceedings and/or third party claims with respect to CEL-SCI&#8217;s patents or patent applications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">MANUFACTURING FACILITY</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Before starting the Phase 3 clinical trial, for reasons related to regulatory considerations, CEL-SCI built a dedicated manufacturing facility to produce its investigational biological product candidate Multikine. This facility produced multiple clinical lots for the Phase 3 clinical trial and has also passed quality systems review by a European Union Qualified Person on several occasions. CEL-SCI is currently expanding the manufacturing facility so CEL-SCI will be able to meet the expected demand for Multikine, if a license is granted. This expansion was completed in the fall of 2021, allowing CEL-SCI employees to return to work inside the manufacturing facility.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s lease on the manufacturing facility expires on October 31, 2028. At that time CEL-SCI can either purchase the facility or extend its lease. See Item 2 of this report for more information concerning the terms of this lease. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">GOVERNMENT REGULATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The FDA and other regulatory authorities at federal, state and local levels and in foreign countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing and post-approval monitoring and reporting of biologics such as those CEL-SCI is developing. CEL-SCI, along with third party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which it wishes to conduct studies or seek approval or licensure of its product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>U.S. Food and Drug Administration Regulation of Biological Products</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. The process required by the FDA before biological product candidates may be marketed in the United States generally involves the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font2443d9a8-7d89-4bf6-aed0-c197b8a299cc" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font50efe090-3b67-47ee-a7bb-6af246692361" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical trials may begin and must be updated annually;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font86e602cd-c84b-40d8-be9c-aa12a2fd5f51" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is initiated;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontb4f705ee-9602-4367-80af-4e43ccc237e0" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">performance of adequate and well-controlled human clinical trials in compliance with Good Clinical Practice, or GCP, regulations to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font8d71157a-6216-4ba5-b3ba-c8ea52f6cb05" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">preparation of and submission to the FDA of a Biologics License Application, or BLA, after completion of clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font1bca4b90-1c40-462c-968f-b469e9670805" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">satisfactory completion of an FDA Advisory Committee review, if applicable;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontf6357716-8f8d-478e-b5b9-489e9b9f6b3d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font660285ee-f1db-4de3-abd2-d87f3408d041" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigations to assess compliance with GCPs; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontdbfa194b-91ce-4517-ae60-c2286d9a58da" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Prior to commencing the first clinical trial with a product candidate in the U.S., CEL-SCI must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to commence a clinical trial.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial commences at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board (DSMB) or independent data monitoring committee (IDMC), which provides recommendations for whether or not a study should move forward at designated check points based on access to certain data from the study and may suggest halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">For purposes of approval of a Biologics License Application, or BLA, human clinical trials are typically conducted in three or four sequential phases that may overlap.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#9679;&#160;&#160;&#160;&#160; Phase 1 &#8212; The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#9679;&#160;&#160;&#160;&#160; Phase 2 &#8212; The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#9679;&#160;&#160;&#160;&#160; Phase 3 &#8212; The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#9679;&#160;&#160;&#160;&#160; Phase 4 &#8212; In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. The FDA may also make these so-called Phase 4 or post-marketing studies a condition to approval of the BLA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within a specified period, if at all, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>BLA Submission and Review by the FDA</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In most cases, the submission of a BLA is subject to a substantial application user fee. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA&#8217;s goal is to review the BLA within ten months after it accepts the application for filing, or, if the product relates to an unmet medical need in a serious or life-threatening indication and has received a priority review designation, six months after the FDA accepts the application for filing. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">After filing the marketing application, the FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve a biological product for marketing unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the data provided in the application, or the manufacturing process or manufacturing facilities for the product are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. The FDA also may refer applications for novel biologic candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the biological product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete but the application is not ready for approval. A Complete Response Letter may request additional information or clarification, including new clinical studies. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the re-submitted BLA does not satisfy the criteria for approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">If a product receives regulatory approval, such approval is limited to the conditions of use (e.g., patient population, indication) described in the application. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a Risk Evaluation and Mitigation Strategy, or REMS, plan if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the biological product, which can materially affect the potential market and profitability of the product. The REMS plan could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. The FDA may prevent or limit further marketing of a product based on the results of post- marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Expedited Review and Approval</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted if relevant criteria are met. A fast track designated product candidate may also qualify for priority review. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted and signed into law in 2012, established the new Breakthrough Therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Sponsors may request the FDA to designate a breakthrough therapy at the time of or any time after the submission of an IND, but ideally before an end-of-phase 2 meeting with the FDA. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Fast Track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Post-Approval Requirements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">All therapeutic products manufactured or distributed pursuant to FDA approval or licensure are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements under the Prescription Drug User Fee Act (PDUFA) for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications containing clinical data. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements, which impose significant procedural and documentation requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements on manufacturers. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. CEL-SCI cannot be certain that it, or CEL-SCI&#8217;s present or future suppliers, will be able to comply with the cGMP regulations and other FDA regulatory requirements. If CEL-SCI is not able to comply with these requirements, the FDA may, among other things, take enforcement action or seek sanctions against use, impose restrictions on a product or its manufacturer, require CEL-SCI to recall a product from distribution, or withdraw approval of the BLA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font841a4a58-dea2-494a-b71f-3f3ec7d2d3ce" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font975b5fca-02a1-4b2a-910f-a330e2f0da9d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">fines, warning letters or holds on post-approval clinical studies;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font0803f58d-2a4c-48f9-b866-03c1ba605e3e" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontd53025c1-8289-4674-ad0e-fd98e4cf70cd" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product seizure or detention, or refusal to permit the import or export of products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontf964915f-6730-4892-878c-10442d6a1b16" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">injunctions or the imposition of civil or criminal penalties; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font2c3b2b69-d397-4a20-b6a5-1fbc0524f481" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The FDA closely regulates the marketing, labeling, advertising and promotion of drugs and biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of unapproved, or &#8220;off-label,&#8221; uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Orphan Drug Designation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition will be recovered from sales in the United States.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market a drug for the same indication for a period of 7 years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. Orphan drug exclusivity also could block the approval of one of CEL-SCI&#8217;s products for seven years if a competitor obtains approval of a product before CEL-SCI does, as defined by the FDA, for the same indication CEL-SCI is seeking, or if CEL-SCI&#8217;s product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of CEL-SCI&#8217;s products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Orphan drug designation must be requested before submitting a BLA to the FDA for review and approval. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Multikine has received Orphan Drug Status from the FDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Other U.S. Health Care Laws</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s sales, promotion, medical education and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Federal Trade Commission, the Department of Justice, the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services and state and local governments. CEL-SCI&#8217;s promotional and scientific/educational programs must comply with the anti-kickback provisions of the Social Security Act, the Foreign Corrupt Practices Act, the False Claims Act, the Physician Payments Sunshine Act, the Veterans Health Care Act and similar state laws.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Depending on the circumstances, failure to meet these applicable regulatory requirements can result in criminal prosecution, fines or other penalties, exclusion from government health care programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private &#8220;qui tam&#8221; actions brought by individual whistleblowers under the False Claims Act in the name of the government or refusal to allow CEL-SCI to enter into supply contracts, including government contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Coverage, Pricing and Reimbursement in the U.S.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Sales of pharmaceutical products depend significantly on the availability of third-party coverage and reimbursement. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products and new drug classes, including biological products such as CEL-SCI&#8217;s product candidates. CEL-SCI may need to conduct expensive clinical studies to demonstrate the comparative cost-effectiveness of its products. The product candidates that CEL-SCI develops may not be considered cost-effective. It is time consuming and expensive for CEL-SCI to seek reimbursement from third- party payors. Reimbursement may not be available or sufficient to allow CEL-SCI to sell its products on a competitive and profitable basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect CEL-SCI&#8217;s ability to sell its products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Foreign Regulation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In addition to regulations in the United States, CEL-SCI will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products to the extent CEL-SCI chooses to develop or sell any products outside of the United States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 1B. RISK FACTORS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The risks described below could adversely affect the price of CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risk Factor Summary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><br />CEL-SCI will require substantial additional capital to remain in operation. A failure to obtain this necessary capital when needed could force CEL-SCI to delay, limit, reduce or terminate the product candidates&#8217; development or commercialization efforts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The costs of the product candidates development and clinical trials are difficult to estimate and will be very high for many years, preventing CEL-SCI from making a profit for the foreseeable future, if ever.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI has not established a definite plan for the marketing of Multikine, if approved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI depends heavily on the success of Multikine, for which top line Phase 3 data has been announced, while its other candidates are still in preclinical phases. CEL-SCI&#8217;s product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing any products. If CEL-SCI is unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately commercialize its product candidates, or experience significant delays in doing so, CEL-SCI&#8217;s business will be materially harmed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Even if CEL-SCI obtains regulatory approval for its investigational products, CEL-SCI will be subject to stringent, ongoing government regulation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCI&#8217;s operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The current and future relationships with healthcare professionals, principal investigators, consultants, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s commercial success depends, in part, upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and major operators of cancer clinics.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s patents might not protect its technology from competitors, in which case CEL-SCI may not have any advantage over competitors in selling any products that CEL-SCI may develop.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Much of CEL-SCI&#8217;s intellectual property is protected as trade secrets or confidential know-how, not by patents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You may experience future dilution as a result of future equity offerings or other equity issuances by CEL-SCI.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The price of CEL-SCI&#8217;s common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for CEL-SCI&#8217;s shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI faces business disruption and related risks resulting from the recent pandemic of COVID-19 which could have a material adverse effect on CEL-SCI's business plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to CEL-SCI</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI faces business disruption and related risks resulting from the recent pandemic of COVID-19 which could have a material adverse effect on our business plan.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The development of CEL-SCI&#8217;s product candidates could be disrupted and materially adversely affected by the outbreak of COVID-19. As a result of measures imposed by the governments in affected regions, businesses and schools have been suspended due to quarantines intended to contain this outbreak. The spread of SARS CoV-2 from China to other countries has resulted in the Director General of the World Health Organization declaring COVID-19 a pandemic on March 11, 2020. International stock markets have reflected the uncertainty associated with the slow-down in the world economies and the significant declines in the Dow Industrial Average early in 2020 were largely attributed to the effects of COVID-19. CEL-SCI knows that COVID delayed the time to reach data lock for its Phase 3 clinical trial and that COVID has delayed the expansion of CEL-SCI&#8217;s manufacturing facility for Multikine. CEL-SCI is still assessing our business plans and the impact COVID-19 may have on our ability to conduct the preclinical studies and clinical trials other than CEL-SCI&#8217;s Phase 3 trial, but there can be no assurance that this analysis will enable CEL-SCI to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally. The extent to which the COVID-19 pandemic and global efforts to contain its spread will impact CEL-SCI&#8217;s operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a history of net losses, expects to incur substantial losses and have negative operating cash flow for the foreseeable future, and may never achieve or maintain profitability. Since the date of its formation and through September 30, 2021, CEL-SCI incurred net losses of approximately $418 million. CEL-SCI has relied principally upon the proceeds from the public and private sales of its securities to finance its activities to date. To date, CEL-SCI has not commercialized any products or generated any revenue from the sale of products, and CEL-SCI does not expect to generate any product revenue for the foreseeable future. CEL-SCI does not know whether or when it will generate product revenue or become profitable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is heavily dependent on the success of Multikine for which top line Phase 3 data has been announced. CEL-SCI cannot be certain that Multikine will receive regulatory approval or be successfully commercialized even if CEL-SCI receives regulatory approval. Multikine is the only product candidate in late-stage clinical development and CEL-SCI&#8217;s business currently depends heavily on its successful development, regulatory approval and commercialization. CEL-SCI has no drug products for sale currently and may never be able to develop approved and marketable drug products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI succeeds in developing and commercializing one or more of its product candidates, CEL-SCI expects to continue to incur significant operating and capital expenditures as CEL-SCI:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font2fae83d7-289a-48c5-a4f6-c4992142fab8" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">continues to undertake preclinical development and clinical trials for product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font926eebde-4a9e-43b8-a23b-b90093918631" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">seeks regulatory approvals for product candidates; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font1df7b751-ebde-4914-a4e5-eadc859fc50c" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">implements additional internal systems and infrastructure.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">To become and remain profitable, CEL-SCI must succeed in developing and commercializing product candidates which must generate significant revenue. This will require CEL-SCI to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of its product candidates, discovering or acquiring additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which CEL-SCI may obtain regulatory approval. CEL-SCI is only in the preliminary stages of most of these activities. CEL-SCI may never succeed in these activities and, even if CEL-SCI does, may never generate revenue that is significant enough to achieve profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. The failure to become and remain profitable could depress the value of CEL-SCI&#8217;s common stock and could impair its ability to raise capital, expand its business, maintain research and development efforts, diversify product offerings or even continue in operation. A decline in the value of CEL-SCI&#8217;s common stock could cause its stockholders to lose all or part of their investment. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has identified conditions and events that raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements, however, this concern has been alleviated by management&#8217;s plans.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Primarily as a result of CEL-SCI&#8217;s losses incurred to date, CEL-SCI&#8217;s expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI&#8217;s ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that because there is more than enough cash on hand to meet the Company&#8217;s budgeted cash requirements, the substantial doubt about the Company&#8217;s ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI will require substantial additional capital to remain in operation. A failure to obtain this necessary capital when needed could force CEL-SCI to delay, limit, reduce or terminate the product candidates&#8217; development or commercialization efforts.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2021, CEL-SCI had cash and cash equivalents of approximately $36.1 million. CEL-SCI believes that it will continue to expend substantial resources for the foreseeable future developing Multikine, LEAPS and any other product candidates or technologies that it may develop or acquire. These expenditures will include costs associated with research and development, potentially obtaining regulatory approvals and having the products manufactured, as well as marketing and selling products approved for sale, if any. In addition, other unanticipated costs may arise. Because the outcome of the current and anticipated clinical trials is highly uncertain, CEL-SCI cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of the product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s future capital requirements depend on many factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font122a2196-e7fc-4966-a813-a28465b6091b" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the rate of progress of, results of and cost of completing Phase 3 clinical development of Multikine for the treatment of certain head and neck cancers;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontba93f8b2-0eec-4326-b989-e27f211d2971" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the results of the applications to and meetings with the FDA, the EMA and other regulatory authorities and the consequential effect on operating costs;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font353b7a91-95c8-48ab-a294-b2bdc80d3dfe" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost, timing and outcome of the efforts to obtain marketing approval for Multikine in the United States, Europe and in other jurisdictions, including the preparation and filing of regulatory submissions for Multikine with the FDA, the EMA and other regulatory authorities;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontda123790-2139-4dfa-bc5b-ab085842a47d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the scope, progress, results and costs of additional preclinical, clinical, or other studies for additional indications for Multikine, LEAPS and other product candidates and technologies that CEL-SCI may develop or acquire;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontf6d8a84e-6db2-43bb-ac87-bc655f88b208" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the timing of, and the costs involved in, obtaining regulatory approvals for LEAPS if clinical studies are successful;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontaf79076d-077a-4245-81ab-512f1be40aa9" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost and timing of future commercialization activities for the products, if any of the product candidates are approved for marketing, including product manufacturing, marketing, sales and distribution costs;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontceefa21d-8700-4d05-bef0-6a42b96890f7" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the revenue, if any, received from commercial sales of the product candidates for which CEL-SCI receives marketing approval;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font55795b26-9cf5-4356-90e3-305af484c6ad" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost of having the product candidates manufactured for clinical trials and in preparation for commercialization;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font600b0c63-7e35-4d85-9b0e-9db60e465ecc" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font9acc441f-465c-4208-bd54-b42d55d234c0" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the costs involved in preparing, filing and prosecuting patent applications and maintaining, defending and enforcing its intellectual property rights, including litigation costs, and the outcome of such litigation; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font1aa73807-51c3-47c7-ab52-dbd1a15d9f79" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the extent to which CEL-SCI acquires or in-licenses other products or technologies.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI will need to raise additional funds in order to continue its operations and additional funds may not be available when CEL-SCI needs them on terms that are acceptable to CEL-SCI, or at all. If adequate funds are not available to CEL-SCI on a timely basis, CEL-SCI may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for Multikine, LEAPS, or any other product candidates or technologies that CEL-SCI develops or acquires, or delay, limit, reduce or terminate its sales and marketing activities that may be necessary to commercialize its product candidates. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The costs of the product candidates development and clinical trials are difficult to estimate and will be very high for many years, preventing CEL-SCI from making a profit for the foreseeable future, if ever.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical and other studies necessary to obtain approval of a new drug or biologic can be time consuming and costly, especially in the United States, but also in foreign countries. The estimates of the costs associated with future clinical trials and research may be substantially lower than what CEL-SCI actually experiences. It is impossible to predict what CEL-SCI will face in the development of a product candidate such as Multikine. The purpose of clinical trials is to provide both CEL-SCI and regulatory authorities with safety and efficacy data in humans. The difficult and often complex steps necessary to obtain regulatory approval, especially that of the FDA and the EMA, involve significant costs and may require several years to complete. CEL-SCI expects that it will need substantial additional financing over an extended period of time in order to fund the costs of future clinical trials, related research, and general and administrative expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s LEAPS technology may not result in a viable drug candidate</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Using CEL-SCI&#8217;s LEAPS technology, CEL-SCI is also developing a LEAPS immunotherapy for the potential treatment of Rheumatoid Arthritis. However, the development of this technology is in a preliminary stage. There can be no assurance that the LEAPS technology will be successful in treating any disease. CEL-SCI&#8217;s primary focus right now is seeking the approval of Multikine for the treatment of head and neck cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>An adverse determination in any future legal proceedings could have a material adverse effect on CEL-SCI.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may be the target of claims asserting violations of securities fraud and derivative actions, or other litigation or arbitration proceedings in the future. Any future litigation could result in substantial costs and divert management&#8217;s attention and resources. These legal proceedings may result in large judgments or settlements against CEL-SCI, any of which could have a material adverse effect on its business, operating results, financial condition and liquidity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Compliance with changing regulations concerning corporate governance and public disclosure may result in additional expenses.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Changing laws, regulations and standards relating to corporate governance and public disclosure may create uncertainty regarding compliance matters. New or changed laws, regulations and standards are subject to varying interpretations in many cases. As a result, their application in practice may evolve over time. CEL-SCI is committed to maintaining high standards of corporate governance and public disclosure. Complying with evolving interpretations of new or changing legal requirements may cause CEL-SCI to incur higher costs as CEL-SCI revises current practices, policies and procedures, and may divert management time and attention from potential revenue-generating activities to compliance matters. If the efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, CEL-SCI&#8217;s reputation may also be harmed. Further, CEL-SCI&#8217;s board members, chief executive officer, and other executive officers could face an increased risk of personal liability in connection with the performance of their duties. As a result, CEL-SCI may have difficulty attracting and retaining qualified board members and executive officers, which could harm its business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has not established a definite plan for the marketing of Multikine, if approved.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has not established a definitive plan for marketing Multikine nor has CEL-SCI established a price structure for any of its product candidates, if approved. However, CEL-SCI intends, if it is in a position to do so, to sell Multikine itself in certain markets where it is approved, and or to enter into written marketing agreements with various third parties with established sales forces in such markets. The sales forces in turn would, CEL-SCI believes, focus on selling Multikine to targeted cancer centers, physicians and clinics involved in the treatment of head and neck cancer. CEL-SCI has already licensed future sales of Multikine, if approved, to three companies: Teva Pharmaceutical Industries Ltd. in Israel, Turkey, Serbia and Croatia; Orient Europharma in Taiwan, Singapore, Hong Kong, Malaysia, South Korea, the Philippines, Australia and New Zealand; and Byron BioPharma, LLC in South Africa. CEL-SCI believes that these companies will have the resources to market Multikine appropriately in their respective territories, if approved, but there is no guarantee that they will. There is no assurance that CEL-SCI will be able to find qualified third-party partners to market its products in other areas, on terms that are favorable to CEL-SCI, or at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may encounter problems, delays and additional expenses in developing marketing plans with third parties. In addition, even if Multikine, if approved, is cost-effective and demonstrated to increase overall patient survival, CEL-SCI may experience other limitations involving the proposed sale of Multikine, such as uncertainty of third-party coverage and reimbursement. There is no assurance that CEL-SCI can successfully market Multikine, if approved, or any other product candidates it may develop.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI hopes to expand its clinical development capabilities in the future, and any difficulties hiring or retaining key personnel or managing this growth could disrupt its operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is highly dependent on the principal members of its management and development staff. CEL-SCI expects to expand its clinical development and manufacturing capabilities, which will involve hiring additional employees. Future growth will require CEL-SCI to continue to implement and improve its managerial, operational and financial systems and continue to retain, recruit and train additional qualified personnel, which may impose a strain on its administrative and its operational infrastructure. The competition for qualified personnel in the biopharmaceutical field is intense. CEL-SCI is highly dependent on its ability to attract, retain and motivate highly qualified management and specialized personnel required for clinical development. Due to limited resources, CEL-SCI may not be able to manage effectively the expansion of its operations or recruit and train additional qualified personnel. If CEL-SCI is unable to retain key personnel or manage its future growth effectively, CEL-SCI may not be able to implement its business plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>If product liability or patient injury lawsuits are brought against CEL-SCI, CEL-SCI may incur substantial liabilities and may be required to limit clinical testing or future commercialization of Multikine or its other product candidates.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI faces an inherent risk of product liability as a result of the clinical testing of Multikine and other product candidates, and will face an even greater risk if CEL-SCI is able to commercialize any of its product candidates. For example, CEL-SCI may be sued if its Multikine or LEAPS product candidates, or any other future product candidates, allegedly cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing or, if approved, marketing, sale or during administration to patients. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Furthermore, Multikine is made, in part, from components of human blood. There are inherent risks associated with products that involve human blood such as possible contamination with viruses, including hepatitis or HIV. Any possible contamination could cause injuries to patients who receive contaminated Multikine, or could require CEL-SCI to destroy batches of Multikine, thereby subjecting CEL-SCI to possible financial losses, lawsuits and harm to its business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI cannot successfully defend itself against product liability claims, CEL-SCI may incur substantial liabilities or be required to limit or cease the clinical testing or commercialization of its product candidates, if approved. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fontac6ed8c7-3258-450d-8621-8f6bb96d82cd" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">decreased demand for Multikine or other product candidates, if approved and commercialized, or clinical holds or suspension of the IND while the candidates are still in clinical development;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font17bce29f-da2a-4ec4-8dab-59534939c36f" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">injury to CEL-SCI&#8217;s reputation;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font51b38ea1-09f5-409a-a107-100972b2c3fd" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">withdrawal of existing, or failure to enroll additional, clinical trial participants;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fonte212c77b-7a76-4313-bc80-51ed609171fd" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">costs to defend any related litigation;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fontb2596743-1658-440f-b0ef-70f54341063c" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a diversion of management&#8217;s time and resources;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font170eecb2-1270-4a40-8746-8a4387d4cb2b" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">substantial monetary awards to trial participants or patients;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fontb337c3a4-1bcf-4afb-975c-3f8e334e3a72" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">recalls of approved products, withdrawal of BLA approvals or new labeling, marketing or promotional restrictions;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font40eea23d-4d51-41e8-b0e8-0953202736fb" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">loss of revenue;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font454a3164-383e-4543-b185-24ae529467c3" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">inability to commercialize Multikine or other product candidates; and</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font5ab7fcd1-bff8-4bfa-9ce5-8949fbfe47c2" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a decline in the price of CEL-SCI&#8217;s common stock.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Although CEL-SCI has product liability insurance for Multikine in the amount of $10 million, the successful prosecution of a product liability case against CEL-SCI could have a materially adverse effect upon its business if the amount of any judgment exceeds the insurance coverage. Any claim that may be brought against CEL-SCI could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by CEL-SCI&#8217;s insurance or that is in excess of the limits of the insurance coverage. CEL-SCI&#8217;s insurance policies also have various exclusions, and CEL-SCI may be subject to a claim for which CEL-SCI has no coverage. CEL-SCI may have to pay any amounts awarded by a court or negotiated in a settlement that exceed the coverage limitations or that are not covered by its insurance, and CEL-SCI may not have, or be able to obtain, sufficient capital to pay such amounts. CEL-SCI commenced the Phase 3 clinical trial for Multikine in December 2010. Although no claims have been brought to date, participants in the clinical trials could bring civil actions against CEL-SCI for any unanticipated harmful effects allegedly arising from the use of Multikine or any other product candidate that CEL-SCI may attempt to develop.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s commercial success depends, in part, upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and major operators of cancer clinics.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI obtains regulatory approval for its product candidates, any resulting product may not gain market acceptance among physicians, healthcare payors, patients and the medical community, which are critical to commercial success. Market acceptance of any product candidate for which CEL-SCI receives approval depends on a number of factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font13e3a907-0a63-4487-9b66-a9922de302bc" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the efficacy and safety of the products as demonstrated in clinical trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font03c8ff06-c83e-4e3e-8a87-eeef9cfbc093" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the timing of market introduction of such product as well as competitive products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font0f4ee367-c9ff-48ae-8318-da110bdc2a06" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the clinical indications for which the biological product is approved;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fontcb7202f5-989d-47ee-a5a2-2d42493f7888" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the approval, availability, market acceptance and reimbursement for the companion diagnostic, if appropriate or necessary;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font4b82f174-3f74-4a84-bba1-061117324523" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">acceptance by physicians, major operators of cancer clinics and patients of the biologic as a safe and effective treatment;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fontf5edf7a4-d78d-4866-8b70-7ebd38763986" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the potential and perceived advantages of such product candidate over alternative treatments, especially with respect to patient subsets that are targeted with such product;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font6694fd6c-a9b0-4b43-a982-ff3fd7811b2f" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the safety of such product seen in a broader patient group, including its use outside the approved indications;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font1a5407ac-6fd2-42f6-9989-76b61a9bc278" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the cost of treatment in relation to alternative treatments;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fontafd6e2d7-cad7-430a-86fe-dffc9ddd5475" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the availability of adequate reimbursement and pricing by third-party payors and government authorities;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font8cede3bb-493d-4f4e-9413-9549f8252863" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">relative convenience and ease of administration;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font646c77dd-bdfa-4eef-87ba-7dbc801e6b4b" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the prevalence and severity of adverse side effects; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fonte83fdb17-a2a0-4ee5-be63-881846c400a2" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the effectiveness of sales and marketing efforts.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI&#8217;s product candidates are approved, but fail to achieve an adequate level of acceptance by physicians, healthcare payors and patients, CEL-SCI will not be able to generate significant revenues, and CEL-SCI may not become or remain profitable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Under CEL-SCI&#8217;s amended bylaws, stockholders that initiate certain proceedings may be obligated to reimburse CEL-SCI and its officers and directors for all fees, costs and expenses incurred in connection with such proceedings if the claim proves unsuccessful.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On February 18, 2015, CEL-SCI adopted new bylaws which include a fee-shifting provision in Article X for stockholder claims. Article X provides that in the event any stockholder initiates or asserts a claim against CEL-SCI, or any of its officers or directors, including any derivative claim or claim purportedly filed on CEL-SCI&#8217;s behalf, and the stockholder does not obtain a judgment on the merits that substantially achieves, in substance and amount, the full remedy sought, then the stockholder will be obligated to reimburse CEL-SCI and any of its officers or directors named in the action, for all fees, costs and expenses of every kind and description that CEL-SCI or its officers or directors may incur in connection with the claim. In adopting Article X, it is the intent that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontf1ec1cd5-336d-4be8-b5a7-0dec8a0b105d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">all actions, including federal securities law claims, would be subject to Article X;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font3e431005-27db-442b-bddd-4a3a4e1537dc" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the phrase &#8220;a judgment on the merits&#8221; means the determination by a court of competent jurisdiction on the matters submitted to the court;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font061a703a-62a6-4caf-8783-af912f013870" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the phrase &#8220;substantially achieves, in both substance and amount&#8221; means the plaintiffs in the action would be awarded at least 90% of the relief sought;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontb2acd1b6-3ee4-4590-9f15-3a601452449f" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">only persons who were stockholders at the time an action was brought would be subject to Article X; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font164c3fa5-f313-4501-bbac-71c713874d4d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">only the directors or officers named in the action would be allowed to recover.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The fee-shifting provision contained in Article X of the bylaws is not limited to specific types of actions, but is rather potentially applicable to the fullest extent permitted by law. Fee-shifting bylaws are relatively new and untested. The case law and potential legislative action on fee-shifting bylaws are evolving and there exists considerable uncertainty regarding the validity of, and potential judicial and legislative responses to, such bylaws. For example, it is unclear whether the ability to invoke the fee-shifting bylaw in connection with claims under the federal securities laws would be pre-empted by federal law. Similarly, it is unclear how courts might apply the standard that a claiming stockholder must obtain a judgment that substantially achieves, in substance and amount, the full remedy sought. The application of the fee-shifting bylaw in connection with such claims, if any, will depend in part on future developments of the law. CEL-SCI cannot assure its shareholders that CEL-SCI will or will not invoke the fee-shifting bylaw in any particular dispute. In addition, given the unsettled state of the law related to fee-shifting bylaws, such as CEL-SCI&#8217;s, CEL-SCI may incur significant additional costs associated with resolving disputes with respect to such bylaw, which could adversely affect CEL-SCI&#8217;s business and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If a stockholder that brings any such claim, suit, action or proceeding is unable to obtain the required judgment, the attorneys&#8217; fees and other litigation expenses that might be shifted to a claiming stockholder are potentially significant. This fee-shifting bylaw may therefore dissuade or discourage stockholders and their attorneys from initiating lawsuits or claims against CEL-SCI or its directors and officers. In addition, it may impact the fees, contingency or otherwise, required by potential plaintiffs&#8217; attorneys to represent the stockholders or otherwise discourage plaintiffs&#8217; attorneys from representing the stockholders at all. As a result, this bylaw may limit the ability of stockholders to alter CEL-SCI&#8217;s management and direction, particularly through litigation or the threat of litigation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The provision of the amended bylaws requiring exclusive venue in the U.S. District Court for Delaware for certain types of lawsuits may have the effect of discouraging lawsuits against CEL-SCI and its directors and officers.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Article X of CEL-SCI&#8217;s amended bylaws provides that stockholder claims brought against CEL-SCI, or its officers or directors, including any derivative claim or claim purportedly filed on its behalf, must be brought in the U.S. District Court for the district of Delaware and that with respect to any such claim, the laws of Delaware will apply.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum the stockholder finds favorable for disputes with CEL-SCI or its directors or officers, and may have the effect of discouraging lawsuits with respect to claims that may benefit CEL-SCI or its stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A provision in our Bylaws regarding shareholder claims may not be enforceable.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Article X of our bylaws provides that stockholder claims brought against us, or our officers or directors, including any derivative claim or claim purportedly filed on our behalf, must be brought in the U.S. District Court for the district of Delaware.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Although it is our intent that this provision applies to actions arising under the Securities Act of 1933 and the Securities Exchange Act of 1934 there is uncertainty as to whether a court would enforce this provision since Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations under the Securities Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition, since this provision in our bylaws applies to state law claims there is uncertainty as to whether any court would enforce this provision.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to Clinical Development, Government Approvals and the Marketing of Biopharmaceutical Products</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI depends heavily on the success of Multikine, for which top line&#160;Phase 3 data has been announced, while our other candidates are still in preclinical phases. CEL-SCI&#8217;s product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing any products. If CEL-SCI is unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately commercialize its product candidates, or experience significant delays in doing so, CEL-SCI&#8217;s business will be materially harmed.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI currently has no products approved for sale and CEL-SCI cannot guarantee that it will ever have marketable products. CEL-SCI&#8217;s product candidates are subject to premarket approval from the FDA in the United States, the EMA in the European Union, and by comparable agencies in most foreign countries before they can be sold. Before obtaining marketing approval, these product candidates must undergo costly and time consuming preclinical and clinical testing which could subject CEL-SCI to unanticipated delays and may prevent CEL-SCI from marketing the product candidates in the future. There can be no assurance that such approvals will be granted on a timely basis, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of the product candidates may not be predictive of the results of later-stage clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. CEL-SCI&#8217;s current and future clinical trials may not be successful.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is in the early development stages for the candidates designed using its LEAPS technology and has not yet initiated any clinical studies for any of those product candidates. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font7c77828c-b083-4152-8742-81c84d881a6f" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the availability of financial resources needed to commence and complete the planned trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font3bbb488f-ddcc-4f23-96de-92bf19d34bae" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">obtaining regulatory approval to commence a trial;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font247c013e-5187-411e-84ef-7b2bcd2893ec" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font5511c056-0aa9-41db-8b8b-a4ad14803d0e" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">obtaining Institutional Review Board, or IRB, approval at each clinical trial site;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontef95f864-eba8-4c86-978f-e23e102bc9b8" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">recruiting suitable patients to participate in a trial;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font720d8ff0-14f7-4a56-ba90-ac407fc2f40a" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">having patients complete a trial or return for post-treatment follow-up;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font4e56dbc2-8e66-4eb5-afc4-6e30ba72a24e" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">clinical trial sites deviating from trial protocol or dropping out of a trial;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font98b7a32b-8c18-4c6a-97df-6dc54a39fc42" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">adding new clinical trial sites; or</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font7a927a47-2b4c-400f-a973-47948df1a9b0" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">manufacturing sufficient quantities of the product candidate for use in clinical trials.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the competence of the CRO running the study, size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians' and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications CEL-SCI is investigating. Furthermore, CEL-SCI relies on CROs and clinical trial sites to ensure the proper and timely conduct of the clinical trials and while CEL-SCI has agreements governing their committed activities, CEL-SCI has limited influence over their actual performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI could also encounter significant delays and/or need to terminate a development program for a product candidate if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of the product candidates while existing treatments have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by CEL-SCI, one or more of the IRBs for the institutions in which such trials are being conducted, by CEL-SCI upon a final recommendation by the Independent Data Monitoring Committee, or IDMC, with which CEL-SCI agrees for such trial, or by FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or the clinical protocols, as a result of inspection of the clinical trial operations or trial site(s) by FDA or other regulatory authorities, the imposition of a clinical hold or partial clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. The occurrence of any one or more of these events would have significant and severe material consequences for CEL-SCI and could impact CEL-SCI&#8217;s ability to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI experiences termination of, or delays in the completion of, any clinical trial of its product candidates, the commercial prospects for the product candidates will be harmed, and the ability to generate product revenues will be delayed. In addition, any delays in completing the clinical trials will increase the costs, slow the product development and approval process and jeopardize the ability to commence product sales and generate revenues. Any of these occurrences may harm CEL-SCI&#8217;s business, prospects, financial condition and results of operations significantly. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to a delay or the denial of regulatory approval for the product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI cannot be certain when or under what conditions it will undertake future clinical trials. Early trials for the other product candidates, or the plans for later trials, may not satisfy the requirements of regulatory authorities, such as the FDA. CEL-SCI may fail to find subjects willing to enroll in the trials. Accordingly, the clinical trials relating to the product candidates may not be completed on schedule, the FDA or foreign regulatory agencies may order CEL-SCI to stop or modify research, or these agencies may not ultimately approve any of the product candidates for commercial sale. Varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent regulatory approval of the product candidates. The data collected from the clinical trials may not be sufficient to support regulatory approval of the various product candidates, including Multikine. The failure to adequately demonstrate the safety and efficacy of any of the product candidates would delay or prevent regulatory approval of the product candidates in the United States, which could prevent CEL-SCI from achieving profitability. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The development and testing of product candidates and the process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, termination of the Phase 3 study, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, and payment of civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on CEL-SCI.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The requirements governing the conduct of clinical trials, manufacturing and marketing of the product candidates, including Multikine, outside the United States vary from country to country. Foreign approvals may take longer to obtain than FDA approvals and can require, among other things, additional testing and different trial designs. Foreign regulatory approval processes include all of the risks associated with the FDA approval process. Some of those agencies also must approve prices for products approved for marketing. Approval of a product by the FDA or the EMA does not ensure approval of the same product by the health authorities of other countries. In addition, changes in regulatory requirements for product approval in any country during the clinical trial process and regulatory agency review of each submitted new application may cause delays or rejections.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has only limited experience in filing and pursuing applications necessary to gain regulatory approvals. The lack of experience may impede its ability to obtain timely approvals from regulatory agencies, if at all. CEL-SCI will not be able to commercialize Multikine and other product candidates until CEL-SCI has obtained regulatory approval. In addition, regulatory authorities may also limit the types of patients to which CEL-SCI or its third-party partners may market Multikine (if approved) or the other product candidates. Any failure to obtain or any delay in obtaining required regulatory approvals may adversely affect CEL-SCI&#8217;s or its third-party partners&#8217; ability to successfully market the product candidates after they are approved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Even if CEL-SCI obtains regulatory approval for its investigational products, CEL-SCI will be subject to stringent, ongoing government regulation.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI&#8217;s investigational products receive regulatory approval, either in the United States or internationally, those products will be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, and may contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance of the safety and efficacy of the investigational products. CEL-SCI will continue to be subject to extensive regulatory requirements. These regulations are wide-ranging and govern, among other things:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font8b362141-664b-4508-9747-8593ce0782e6" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product design, development and manufacture;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font807698d2-8635-40f4-8e90-31fab48edb16" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product application and use</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font3add5619-2a41-49e1-af25-eae9254d0d21" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">adverse drug experience monitoring reporting;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font22112c69-737c-4e2c-8aec-ffd59fc13ad6" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product advertising and promotion;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font2b8d2b8c-7aba-47c1-9730-ffd017366297" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product manufacturing, including compliance with good manufacturing practices</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontfc52b034-40d9-4661-ae8d-6af3ae24768a" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">record keeping requirements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font0046f988-d574-44ec-9b7f-233b5b8f2e3d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">registration and listing of products with the FDA, EMA and other state and national agencies;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontf259ba42-4a24-4918-aa2c-9c38c56f7ca0" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product storage and shipping;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fonte23765ab-a1a0-41d5-a9f7-3854fcf78330" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">drug sampling and distribution requirements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fonte7d8e2a1-2e20-4bb8-8968-91b7cde6e83e" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">electronic record and signature requirements; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontde4b9efd-93c5-4f59-84dd-843207a9e8a7" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">labeling changes or modifications.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI and any of its third-party manufacturers or suppliers must continually adhere to federal regulations setting forth human drug and biologic manufacturing requirements, known as current Good Manufacturing Practices, or cGMPs, and their foreign equivalents, which are enforced by the FDA, the EMA and other national regulatory bodies through their facilities inspection programs. If the facilities, or the facilities of the contract manufacturers or suppliers, cannot pass a pre-approval inspection by regulators or fail such inspections in the future, the FDA, EMA or other national regulators will not approve the marketing applications for the product candidates, or may withdraw any prior approval. In complying with cGMP and foreign regulatory requirements, CEL-SCI and any of its potential third-party manufacturers or suppliers will be obligated to expend time, money and effort in production, record-keeping and quality control to ensure that the product candidates meet applicable specifications and other requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI does not comply with regulatory requirements at any stage, whether before or after marketing approval is obtained, CEL-SCI may be subject to, among other things, license suspension or revocation, criminal prosecution, seizure, injunction, fines, be forced to remove a product from the market or experience other adverse consequences, including restrictions or delays in obtaining regulatory marketing approval for such products or for other product candidates for which CEL-SCI seeks approval. This could materially harm CEL-SCI&#8217;s financial results, reputation and stock price. Additionally, CEL-SCI may not be able to obtain the labeling claims necessary or desirable for product promotion. If CEL-SCI or other parties identify adverse effects after any of the products are on the market, or if manufacturing problems occur, regulatory approval may be suspended or withdrawn. CEL-SCI may be required to reformulate products, conduct additional clinical trials, make changes in product labeling or indications of use, or submit additional marketing applications to support any changes. If CEL-SCI encounters any of the foregoing problems, its business and results of operations will be harmed and the market price of its common stock may decline.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The FDA and other governmental authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of CEL-SCI&#8217;s product candidates. If CEL-SCI is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if CEL-SCI is not able to maintain regulatory compliance, CEL-SCI may lose any marketing approval that it may have obtained, which would adversely affect its business, prospects and ability to achieve or sustain profitability. CEL-SCI cannot predict the extent of adverse government regulations which might arise from future legislative or administrative action. Without government approval, CEL-SCI will be unable to sell any of its product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Undesirable side effects caused by its product candidates could cause CEL-SCI or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of the clinical trials could reveal a high and unacceptable severity and/or prevalence of these or other side effects. In such an event, the trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order CEL-SCI to cease further development of, or deny approval of, the product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm CEL-SCI&#8217;s business, financial condition and prospects significantly.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Additionally, if one or more of the product candidates receives marketing approval, and CEL-SCI or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font2c15977d-b6fb-4505-8293-4f6be0759da7" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">regulatory authorities may withdraw approvals of such product or require product recalls;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font26cab2c1-1751-4c17-a4c5-b714fcd4eef4" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">regulatory authorities may require additional warnings on the label or impose restrictions on product distribution or use;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font32f9169f-7af6-4b05-a1ba-477170721593" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">regulatory authorities may require CEL-SCI to conduct new post-marketing studies or clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontdb43be39-1ec0-4087-94fa-abd0f8baca3d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI could receive warning or untitled letters from the FDA or comparable notices of violations from foreign regulatory authorities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font41aedcc3-b79a-49b3-94cd-6ddc0404b056" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font071e9dee-0942-421a-b910-7505cb92e3a0" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI could be sued and held liable for harm caused to patients; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font33dccad3-1281-4cbe-be5a-1b890e8e43eb" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s reputation may suffer.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Any of these events could prevent CEL-SCI from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm its business, results of operations and prospects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI relies on third parties to conduct its preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties and meet regulatory requirements, or meet expected deadlines, CEL-SCI may not be able to obtain regulatory approval for or commercialize the product candidates and its business could be substantially harmed.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI does not have the ability to independently conduct large clinical trials. CEL-SCI has relied upon and plans to continue to rely upon third-party CROs to prepare for, conduct, monitor and manage data for its ongoing preclinical and clinical programs, including the global Phase 3 trial for Multikine. CEL-SCI relies on these parties for all aspects of the execution of its clinical trials and although CEL-SCI diligently oversees and carefully manages the CROs, CEL-SCI directly controls only certain aspects of their activities and relies upon them to provide timely, complete, and accurate reports on the conduct of the studies. Although such third parties provide support and represent CEL-SCI for regulatory purposes in the context of the clinical trials, ultimately CEL-SCI is responsible for ensuring that each of the studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and the reliance on the CROs does not relieve CEL-SCI of its regulatory responsibilities. CEL-SCI and the CROs acting on CEL-SCI&#8217;s behalf, as well as principal investigators and trial sites, are required to comply with Good Clinical Practice, or GCP, and other applicable requirements, which are implemented through regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for all of the products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If CEL-SCI or any of the CROs fail to comply with applicable GCPs or other applicable regulations, the clinical data generated in the clinical trials may be determined to be unreliable and CEL-SCI may therefore need to enroll additional subjects in the clinical trials, or the FDA, EMA or comparable foreign regulatory authorities may require CEL-SCI to perform an additional clinical trial or trials before approving the marketing applications. Moreover, if CEL-SCI or any of the CROs, principal investigators, or trial sites, fail to comply with applicable regulatory and GCP requirements, CEL-SCI, the CROs, principal investigators, or trial sites may be subject to enforcement actions, such as fines, warning letters, untitled letters, clinical holds, civil or criminal penalties, and/or injunctions. CEL-SCI cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of the clinical trials comply with cGCP regulations. In addition, the clinical trials must be conducted with product produced under cGMP regulations. The failure to comply with these regulations may require CEL-SCI to delay or repeat clinical trials, which would delay the regulatory approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If any of the relationships with the third-party CROs terminate, CEL-SCI may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, the CROs are not CEL-SCI&#8217;s employees, and except for remedies available to CEL-SCI under the agreements with such CROs, CEL-SCI cannot control whether or not they devote sufficient time and resources to the on-going clinical, nonclinical and preclinical programs. If CROs do not successfully fulfill their regulatory obligations, carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to the clinical protocols, regulatory requirements or for other reasons, the clinical trials may be extended, delayed or terminated, and CEL-SCI may not be able to obtain regulatory approval for, or successfully commercialize, the product candidates. As a result, CEL-SCI&#8217;s results of operations and the commercial prospects for the product candidates would be harmed, the costs could increase and the ability to generate revenues could be delayed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact CEL-SCI&#8217;s ability to meet the desired clinical development timelines. Though CEL-SCI diligently oversees and carefully manages its relationships with the CROs, there can be no assurance that CEL-SCI will not encounter similar challenges or delays in clinical development in the future or that these delays or challenges will not have a material adverse impact on CEL-SCI&#8217;s business, financial condition and prospects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has obtained orphan drug designation from the FDA for Multikine for neoadjuvant, or primary, therapy in patients with squamous cell carcinoma of the head and neck, but CEL-SCI may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even though CEL-SCI has received orphan drug designation for Multikine for the treatment of squamous cell carcinoma of the head and neck, CEL-SCI may not be the first to obtain marketing approval of a product for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. CEL-SCI believes this to be unlikely since it does not know of any other company with a similar technology in Phase 3 studies. In addition, exclusive marketing rights in the United States may be limited if CEL-SCI seeks approval for an indication broader than the orphan-designated indication, or may be lost if the FDA later determines that the request for designation was materially defective or if CEL-SCI is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if CEL-SCI obtains orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCI&#8217;s operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The successful discovery, development, manufacturing and sale of biological products like CEL-SCI&#8217;s candidates is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and governmental regulations restrict access to and regulate the transport and use of such materials. In addition, the development, manufacturing and sale of biologics is subject to regulations that are often more complex and extensive than the regulations applicable to other pharmaceutical products. Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedures. Biologics are also frequently costly to manufacture because production inputs are derived from living animal or plant material, and some biologics cannot be made synthetically. Failure to successfully discover, develop, manufacture and sell its biological product candidates would adversely impact CEL-SCI&#8217;s business and future results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may face substantial competition, which may result in others discovering, developing or commercializing competing products more quickly or more successfully than CEL-SCI.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The development and commercialization of new drug and biological products is highly competitive. CEL-SCI expects to face competition with respect to any product candidates that CEL-SCI may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Many of the companies which CEL-SCI may compete with in the future have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical studies, conducting clinical trials, obtaining marketing approvals and marketing approved products than CEL-SCI. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of CEL-SCI&#8217;s potential competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties may compete with CEL-SCI in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, CEL-SCI&#8217;s programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may be unable to successfully scale-up manufacturing of its lead product candidate Multikine in sufficient quality and quantity, which would delay or prevent CEL-SCI from commercializing this product, if approved for marketing by the FDA or other regulatory agencies.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In order to commercialize its product candidates, CEL-SCI will need to manufacture them in large quantities. At the present time, CEL-SCI is not manufacturing Multikine while the manufacturing plant for Multikine is being validated to produce commercial quantities of Multikine, if approved. CEL-SCI may be unable to successfully increase the manufacturing capacity for its lead product candidate Multikine in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Further, in order to release product and demonstrate stability of product candidates for future commercial use, CEL-SCI&#8217;s analytical methods must be validated in accordance with regulatory guidelines. CEL-SCI may not be able to successfully validate, or maintain validation of its analytical methods during scale-up or demonstrate adequate purity, stability or comparability of its biological product candidates in a timely or cost-effective manner, or at all. Even if CEL-SCI believes its manufacturing processes meets all of the regulatory manufacturing requirements, the FDA will review those processes and the manufacturing facility as part of the review of the future BLA for Multikine, if submitted after completion of the Phase 3 trial in advanced head and neck cancer. If CEL-SCI is unable to successfully scale up the manufacture of Multikine in sufficient quality and quantity, or if CEL-SCI encounters validation issues, the development, testing, and clinical trials of future product candidates, may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product, including Multikine, may be delayed or may not be successfully achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The current and future relationships with healthcare professionals, principal investigators, consultants, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Although CEL-SCI does not currently have any products on the market, if CEL-SCI begins commercializing its product candidates, CEL-SCI will be subject to additional healthcare statutory and regulatory requirements and oversight by federal and state governments as well as foreign governments in the jurisdictions in which CEL-SCI conducts its business. Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which CEL-SCI obtains marketing approval. The current and future arrangements with healthcare professionals, principal investigators, consultants, potential customers and third-party payors may expose CEL-SCI to broadly applicable healthcare laws, including, without limitation:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontefc14586-0a3f-4b46-8b25-f0f254997966" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font058cf12f-e2c5-471d-b60e-dd26cbe82253" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontca95bde7-ce51-4530-922e-22631fbe013c" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font4b7f2e9a-940c-4cdb-86e8-d7df48816a6b" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">HIPAA, which also imposes obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontf91b3165-44f5-4b1b-8cc8-0333914acde2" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the U.S. federal physicians payment transparency requirements, sometimes called the &#8220;Sunshine Act&#8221; and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to physician payments and &#8220;other transfers of value&#8221; to physicians and teaching hospitals (and, beginning in 2021, for transfers of value to other healthcare providers), as well as the ownership and investment interests held by physicians and their immediate family members;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font551e1717-db08-48c5-b1b2-37000c3e651f" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fonta3c1f088-35c5-49f9-b8b0-374a04d19574" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal healthcare programs; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontcddefcff-6b14-420c-9d2c-ddf919efb45b" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">state and foreign laws that govern the privacy and security of health information in certain circumstances, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Efforts to ensure that the future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that the business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If CEL-SCI&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations, CEL-SCI may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of the operations, all of which could significantly harm CEL-SCI&#8217;s business. If any of the physicians or other healthcare providers or entities with whom CEL-SCI expects to do business, including current and future collaborators, are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also adversely affect CEL-SCI&#8217;s business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Failure to obtain or maintain adequate coverage and reimbursement for the product candidates, if approved, could limit the ability to market those products and decrease CEL-SCI&#8217;s ability to generate revenue.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Sales of CEL-SCI&#8217;s product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of the approved products will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health insurers and other third-party payors. CEL-SCI anticipates that government authorities and other third-party payors will continue efforts to contain healthcare costs by limiting the coverage and reimbursement levels for new drugs and biologics. If coverage and reimbursement are not available, or are available only to limited levels, CEL-SCI may not be able to successfully commercialize its product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow CEL-SCI to establish or maintain pricing sufficient to realize a return on its investment. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for CEL-SCI&#8217;s product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Moreover, in some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, CEL-SCI may be required to conduct a clinical trial that compares the cost-effectiveness of its product candidate to other available therapies. If reimbursement of its products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, CEL-SCI&#8217;s business could be harmed, possibly materially.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Even if any product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI&#8217;s product candidates do not achieve an adequate level of acceptance, CEL-SCI may not generate significant product revenues and CEL-SCI may not become profitable. The degree of market acceptance of its product candidates, including Multikine if approved for commercial sale, will depend on a number of factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font5b266f0c-1630-41b4-a88a-7205110e7aa6" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the timing of CEL-SCI&#8217;s receipt of any marketing approvals;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font42656d76-abf6-442e-8f17-5118caa27fb5" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the terms of any approvals and the countries in which approvals are obtained;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font1f54a919-c496-4fb4-a4bf-b551ba1f8af5" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the efficacy and safety and potential advantages and disadvantages compared to alternative treatments, including future alternative treatments;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fonta91057b6-c830-4b96-8437-f284376d4789" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the prevalence and severity of any side effects associated with CEL-SCI&#8217;s product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font274f6f63-cc28-47b2-8fc7-2d33660d7d5d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the indications for which its products are approved and the scope of risk information required to be included in the product labeling;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontac53442a-4f69-407d-88fe-823f475447d0" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">adverse publicity about CEL-SCI&#8217;s products or favorable publicity about competing products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font069d5354-0914-4ff7-bc9a-4ae4e7edff9f" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the approval of other products for the same indications as CEL-SCI&#8217;s products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font0d66e702-ae03-400e-bca1-5309839df00c" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s ability to offer its products for sale at competitive prices;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontb3bab084-718d-4dea-88d9-6be3948b28bc" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the convenience and ease of administration compared to alternative treatments;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontd3acc8bd-5984-4b1f-ba60-26b746480a2e" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font8c4f1b0d-e086-4819-a02f-9bbdfdc0f648" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the success of CEL-SCI&#8217;s physician education programs;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font926ab297-0498-4955-a104-b4185e18ce58" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the strength of CEL-SCI&#8217;s marketing and distribution support; and</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font1446d622-36b7-44c2-83ae-b7f2efcad772" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the availability of third-party coverage and adequate reimbursement.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If any product candidate CEL-SCI commercializes fails to achieve market acceptance, it could have a material and adverse effect on CEL-SCI&#8217;s business, financial condition, results of operation and prospects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI currently has no marketing and sales force. If CEL-SCI is unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market its product candidates, CEL-SCI may not be able to effectively sell or market its product candidates, if approved, or generate product revenues.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI currently has a no sales and marketing infrastructure due to the fact that all of its product candidates are still in clinical development. To achieve commercial success for any approved product candidate for which CEL-SCI retains sales and marketing responsibilities, CEL-SCI must build its sales, marketing, managerial, and other non-technical capabilities or make arrangements with third parties to perform these services. For example, CEL-SCI has entered into agreements with certain foreign distributors to commercialize Multikine, if approved, within their respective territories. However, CEL-SCI may determine that there is a need to building its own sales force in the United States for the future marketing of Multikine, if approved, rather than seeking a U.S. co-marketing partner or relying on a contracted sales force. There are risks involved with either establishing its own sales and marketing capabilities or entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which CEL-SCI recruits a sales force and establishes marketing capabilities is delayed or does not occur for any reason, CEL-SCI would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and its investment would be lost if CEL-SCI cannot retain or reposition its sales and marketing personnel.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Factors that may inhibit CEL-SCI&#8217;s efforts to commercialize its product candidates on its own include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:5%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font5bda9fdd-fb7b-49d0-868a-bcb920edf7f2" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s inability to recruit, hire, retain and incentivize adequate numbers of effective sales and marketing personnel;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font7e5940c0-31a9-4d93-a1dc-2d2e32242549" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to use and administer CEL-SCI&#8217;s future products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontcd7c375d-1449-48d5-bbcd-ba45b691f074" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the lack of complementary products to be offered by sales personnel, which may put CEL-SCI at a competitive disadvantage relative to companies with more extensive product lines; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font2f2d010b-dd61-478b-b4b4-28b3beb4786a" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">unforeseen costs and expenses associated with establishing an independent sales and marketing organization.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI does not establish sales and marketing capabilities successfully, either on its own or in collaboration with third parties, CEL-SCI will not be successful in commercializing Multikine, if approved, or any of its other product candidates that receive marketing approval or any such commercialization may experience delays or limitations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws of other countries in which CEL-SCI operates or will operate in the future.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has conducted and has ongoing studies in international locations, and may in the future initiate additional studies in countries other than the United States. Moreover, CEL-SCI has entered into agreements with foreign distributors to commercialize Multikine, if approved, in various territories outside of the United States. As a result, CEL-SCI&#8217;s business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which CEL-SCI operates. The FCPA generally prohibits offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who prescribe biopharmaceuticals are employed by their government, and the purchasers of biopharmaceuticals are government entities; therefore, CEL-SCI&#8217;s dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of CEL-SCI&#8217;s employees, agents or contractors conducting business abroad will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against CEL-SCI, its officers or employees, the closing of CEL-SCI&#8217;s facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of CEL-SCI&#8217;s business. Any such violations could include prohibitions on CEL-SCI&#8217;s ability to offer its product candidates, if approved, in one or more countries and could materially damage its reputation, its brand, its future international marketing efforts, its ability to attract and retain employees and its business, prospects, operating results and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Healthcare legislative reform measures may have a material adverse effect on CEL-SCI&#8217;s business and results of operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of CEL-SCI&#8217;s product candidates. CEL-SCI cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If CEL-SCI is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if CEL-SCI is not able to maintain regulatory compliance, CEL-SCI may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs that may result in more limited coverage or downward pressure on the price CEL-SCI may otherwise receive for its product candidates. For example, in March 2010, Congress passed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, which expanded healthcare coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and which included changes to the coverage and reimbursement of drug products under federal healthcare programs. The ACA contains a number of provisions that affect coverage and reimbursement of drug and biological products and/or that could potentially reduce the demand for pharmaceutical products such as increasing drug rebates under state Medicaid programs for brand name prescription drugs and extending those rebates to Medicaid managed care and assessing a fee on manufacturers and importers of brand name prescription drugs reimbursed under certain government programs, including Medicare and Medicaid. Under the Trump administration, there have been ongoing efforts to modify or repeal all or certain provisions of the ACA. For example, tax reform legislation was enacted at the end of 2017 that eliminates the tax penalty established under the ACA for individuals who do not maintain mandated health insurance coverage beginning in 2019. In a May 2018 report, the Congressional Budget Office estimated that, compared to 2018, the number of uninsured will increase by 3 million in 2019 and 6 million in 2028, in part due to the elimination of the individual mandate. The ACA has also been subject to judicial challenge. In December 2018, a federal district court, in a challenge brought by a number of state attorneys general, found the ACA unconstitutional in its entirety because, once Congress repealed the individual mandate provision, there was no longer a basis to rely on Congressional taxing authority to support enactment of the law. Pending appeals, which could take some time, the ACA is still operational in all respects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">39</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s industry continues to face potential changes in the legal and regulatory landscape on the federal, state and international levels. Additional legislative actions to control U.S. healthcare or other costs have passed. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare (but not Medicaid) payments to providers in 2013 and will remain in effect through 2027 unless additional Congressional action is taken. There has also been increasing and considerable public and government interest in the United States with respect to specialty drug pricing practices, including proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, put in place limits and caps on pharmaceutical prices, request rebates for certain pharmaceutical products, and reform government program reimbursement methodologies for drugs. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what biopharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and control the prices of medicinal products for human use. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI expects that current or future healthcare reform measures may result in more rigorous coverage criteria and in additional downward pressure on the price that it receives for any approved product, including Multikine if it is approved for commercialization. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent CEL-SCI from being able to generate revenue, attain profitability or commercialize its product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Legislative and regulatory proposals also have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. CEL-SCI cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations for biological products will be changed, or what the impact of such changes on the marketing approvals of its product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval and decision-making processes may significantly delay or prevent marketing approval, as well as subject CEL-SCI to more stringent product labeling and post-marketing testing and other requirements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Foreign governments often impose strict price controls, which may adversely affect CEL-SCI&#8217;s future profitability.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI intends to seek approval to market its lead investigational product, Multikine, in both the United States and foreign jurisdictions. If CEL-SCI obtains approval in one or more foreign jurisdictions, CEL-SCI will be subject to rules and regulations in those jurisdictions relating to Multikine. In some foreign countries, particularly in the European Union, prescription drug pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug candidate. Coverage and reimbursement decisions in one foreign jurisdiction may impact decisions in other countries. To obtain reimbursement or pricing approval in some countries, CEL-SCI may be required to conduct clinical trials that demonstrate the product candidate is more effective than current treatments and that compare the cost-effectiveness of Multikine to other available therapies. If reimbursement of Multikine is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, CEL-SCI may be unable to achieve or sustain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>If CEL-SCI fails to comply with environmental, health and safety laws and regulations, CEL-SCI could become subject to fines or penalties or incur costs that could harm its business.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">40</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes generated in its biologic manufacturing facility. CEL-SCI cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from its use of hazardous materials, including radioactive materials used in its research laboratory, CEL-SCI could be held liable for any resulting damages, and the amount of the liability could exceed its resources. CEL-SCI also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to Intellectual Property</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may not be able to achieve or maintain a competitive position, and other technological developments may result in its proprietary technologies becoming uneconomical or obsolete.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is involved in a biomedical field that is undergoing rapid and significant technological change. The pace of change continues to accelerate. The successful development of product candidates from the compounds, compositions and processes, through research financed by CEL-SCI, or as a result of possible third-party licensing arrangements with pharmaceutical or other companies, is not assured. CEL-SCI may fail to apply for patents on important technologies or product candidates in a timely fashion, or at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Many companies are working on drugs designed to cure or treat cancer. Many of these companies have financial, research and development, and marketing resources, which are much greater than CEL-SCI&#8217;s, and are capable of providing significant long-term competition either by establishing in-house research groups or by forming collaborative ventures with other entities. In addition, smaller companies and non-profit institutions are active in research relating to cancer and infectious diseases. The future market share of Multikine or the other product candidates, if approved, will be reduced or eliminated if the competitors develop and obtain approval for products that are safer or more effective than CEL-SCI&#8217;S product candidates. Moreover, the patent positions of pharmaceutical companies are highly uncertain and involve complex legal and factual questions for which important legal principles are often evolving and remain unresolved. As a result, the validity and enforceability of patents cannot be predicted with certainty. In addition, CEL-SCI does not know whether:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font58aacd41-84a3-4fae-a127-a10e368b8383" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI was the first to make the inventions covered by each of its issued patents and pending patent applications;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontbf3202e2-49bc-4f1c-bb10-242fa43fa973" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI was the first to file patent applications for these inventions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontaeadfffa-c9d8-4245-8347-dd05ed6ccde6" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">others will independently develop similar or alternative technologies or duplicate any of CEL-SCI&#8217;s technologies;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font6463bdc9-267a-40e4-b3e2-16365db493c1" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any of the pending patent applications will result in issued patents;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font8f1199f2-f0c7-43a6-8b4e-17c8bf21684c" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any of the patents will be valid or enforceable;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font46e79def-d08d-42f4-b016-cdf4b2e38dc4" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any patents issued to CEL-SCI or its collaboration partners will provide CEL-SCI with any competitive advantages, or will be challenged by third parties;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontb2a726a5-a0cc-489c-96a1-a21d95d02179" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI will be able to develop additional proprietary technologies that are patentable;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontd6de1f77-10d1-4e2d-a3fd-253f3a810d3b" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the U.S. government will exercise any of its statutory rights to CEL-SCI&#8217;s intellectual property that was developed with government funding; or</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font753629a2-40b1-4456-93ce-8ab9fe37a9b1" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">its business may infringe the patents or other proprietary rights of others.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">41</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s patents might not protect its technology from competitors, in which case CEL-SCI may not have any advantage over competitors in selling any products that CEL-SCI may develop.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s commercial success will depend in part on its ability to obtain additional patents and protect its existing patent position, as well as its ability to maintain adequate intellectual property protection for the technologies, product candidates, and any future products in the United States and other countries. If CEL-SCI does not adequately protect its technology, product candidates and future products, competitors may be able to use or practice them and erode or negate any competitive advantage CEL-SCI may have, which could harm CEL-SCI&#8217;s business and its ability to achieve profitability. The laws of some foreign countries do not protect the proprietary rights to the same extent or in the same manner as U.S. laws, and CEL-SCI may encounter significant problems in protecting and defending its proprietary rights in these countries. CEL-SCI will be able to protect its proprietary rights from unauthorized use by third parties only to the extent that its proprietary technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Certain aspects of CEL-SCI&#8217;s technologies are covered by U.S. and foreign patents. In addition, CEL-SCI has a number of new patent applications pending. There is no assurance that the applications which are pending or which may be filed in the future will result in the issuance of any patents. Furthermore, there is no assurance as to the breadth and degree of protection any issued patents might afford CEL-SCI. Disputes may arise between CEL-SCI and others as to the scope and validity of these or other patents. Any defense of the patents could prove costly and time consuming and there can be no assurance that CEL-SCI will be in a position, or will deem it advisable, to carry on such a defense. A suit for patent infringement could result in increasing costs, delaying or halting development, or even forcing CEL-SCI to abandon a product candidate. Other private and public concerns, including universities, may have filed applications for, may have been issued, or may obtain additional patents and other proprietary rights to technology potentially useful or necessary to CEL-SCI. CEL-SCI is not currently aware of any such patents, but the scope and validity of such patents, if any, and the cost and availability of such rights are impossible to predict.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Much of CEL-SCI&#8217;s intellectual property is protected as trade secrets or confidential know-how, not as a patent.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI considers proprietary trade secrets and/or confidential and unpatented know-how to be important to its business. Much of the intellectual property pertains to CEL-SCI&#8217;s manufacturing methodologies, certain aspects of which may not be suitable for patent filings and must be protected as trade secrets and/or confidential know-how. This type of information must be protected diligently by CEL-SCI to protect its disclosure to competitors, since legal protections after disclosure may be minimal or non-existent. Accordingly, much of the value of this intellectual property is dependent upon the ability of CEL-SCI to keep its trade secrets and know-how confidential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">To protect this type of information against disclosure or appropriation by competitors, CEL-SCI&#8217;s policy is to require its employees, consultants, contractors and advisors to enter into confidentiality agreements with CEL-SCI. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose the confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition, in some cases a regulator considering the application for product candidate approval may require the disclosure of some or all of the proprietary information. In such a case, CEL-SCI must decide whether to disclose the information or forego approval in a particular country. If CEL-SCI is unable to market its product candidates in key countries, CEL-SCI&#8217;s opportunities and value may suffer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">42</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Failure to obtain or maintain trade secrets and/or confidential know-how trade protection could adversely affect CEL-SCI&#8217;S competitive position. Moreover, competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, competitors could limit the use of such trade secrets and/or confidential know-how.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in its patents or other intellectual property. CEL-SCI may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing the product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If CEL-SCI fails in defending any such claims, in addition to paying monetary damages, CEL-SCI may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on its business. Even if CEL-SCI is successful in defending against such claims, litigation could result in substantial costs and be a distraction to CEL-SCI&#8217;s management and employees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to CEL-SCI&#8217;s common stock</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Future equity offerings or other equity issuances may result in dilution to existing shareholders.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI expects that significant additional capital will be needed in the future to continue its planned operations. To raise additional capital, CEL-SCI may in the future offer additional shares of its common stock or other securities convertible into or exchangeable for its common stock. To the extent CEL-SCI raises additional capital by issuing equity securities, CEL-SCI&#8217;s stockholders may experience substantial dilution and new investors could gain rights superior to existing stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The exercise of outstanding warrants and options will cause dilution.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2021, there were outstanding warrants which allow the holders to purchase 1,621,667 shares of common stock, with a weighted average exercise price of $4.88 per share, and outstanding options which allow the holders to purchase up to 11,049,709 shares of common stock, with a weighted average exercise price of $10.08 per share. The exercise of these outstanding warrants and options will cause dilution to holders of our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Since CEL-SCI does not intend to pay dividends on its common stock, any potential return to investors will result only from any increases in the price of its common stock.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">At the present time, CEL-SCI intends to use available funds to finance its operations. Accordingly, while payment of dividends rests within the discretion of its board of directors, no common stock dividends have been declared or paid by CEL-SCI and CEL-SCI has no intention of paying any common stock dividends in the foreseeable future. Additionally, any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on CEL-SCI&#8217;s common stock. Any return to CEL-SCI&#8217;s shareholders will therefore be limited to appreciation in the price of its common stock, which may never occur. If CEL-SCI&#8217;s stock price does not increase, CEL-SCI&#8217;S shareholders are unlikely to receive any return on their investments in CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">43</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The price of CEL-SCI&#8217;s common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for CEL-SCI&#8217;s shareholders.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s stock price has been, and is likely to continue to be, volatile. As a result of this volatility, CEL-SCI&#8217;s shareholders may not be able to sell their shares at or above its current market price. The market price for CEL-SCI&#8217;s common stock may be influenced by many factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font563c95ee-d205-4be1-8067-2edc278e6583" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">actual or anticipated fluctuations in CEL-SCI&#8217;s financial condition and operating results;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font11870a4b-4a3c-4cbb-8dc2-377d7f4827f5" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">actual or anticipated changes in CEL-SCI&#8217;s growth rate relative to competitors;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font66221742-5106-4c56-b94a-5fa91062c60b" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">competition from existing products or new products or product candidates that may emerge;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontdc61b305-c074-4e89-8773-af6bf12a3239" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">development of new technologies that may make CEL-SCI&#8217;s technology less attractive;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontc0465bf8-d45a-48c1-b54c-bf967407beb7" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">changes in physician, hospital or healthcare provider practices that may make CEL-SCI&#8217;s product candidates less useful;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font0400eb49-ff36-4dc2-8957-d9ac6f0df113" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">announcements by CEL-SCI, its partners or competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontbbec1bb1-a473-407d-b368-8e4a973cdeaf" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font2f7e4a96-a3db-45e5-9513-ba8e63ae11ae" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the recruitment or departure of key personnel;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font8662c728-d954-474f-85aa-482f6b2f0aa8" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">failure to meet or exceed financial estimates and projections of the investment community;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font5f4e8f88-e0c7-455f-8222-688db9a9e22d" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontf8d51dbb-3d96-47d8-82cd-d06aa6527d22" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">variations in its financial results or those of companies that are perceived to be similar to CEL-SCI;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontfd705ca5-1d5d-4502-b903-ca5e8807bffc" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">changes to coverage and reimbursement levels by commercial third-party payors and government payors, including Medicare, and any announcements relating to reimbursement levels;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font7168b13d-daab-4526-bd6f-f6463d0016e2" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">general economic, industry and market conditions; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font6b584d64-f10a-4fd2-9be1-2bb76b240920" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the other factors described in this &#8220;Risk Factors&#8221; section.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>ITEM 1B. <span style="text-decoration:underline">UNRESOLVED SEC COMMENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 2. <span style="text-decoration:underline">PROPERTIES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI leases office space at 8229 Boone Blvd., Suite 802, Vienna, Virginia at a monthly rental of approximately $8,000. The lease on the office space expires on November 30, 2025. CEL-SCI believes this arrangement is adequate for the conduct of its present business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a 17,900 square foot laboratory located in Baltimore, Maryland. The laboratory is leased by CEL-SCI at a cost of approximately $20,000 per month. During the period ended September 30, 2021, the laboratory lease was extended ten years and expires on February 28, 2032.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">44</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In August 2007, CEL-SCI leased a building near Baltimore, Maryland (the San Tomas lease). The building, which consists of approximately 73,000 square feet, has been remodeled in accordance with CEL-SCI&#8217;s specifications so that it can be used by CEL-SCI to manufacture Multikine for CEL-SCI&#8217;s Phase 3 clinical trial and sales of the drug, if approved by the FDA. The lease expires on October 31, 2028 and required annual base rent payments of approximately $2.2 million during the twelve months ended September 30, 2021. The annual base rent escalates each year at 3% beginning on November 1st. CEL-SCI is also required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities, which were approximately $44,000 per month as of September 30, 2021. The lease allows CEL-SCI, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. In August 2011, CEL-SCI was required to deposit approximately $1.7 million, the equivalent of one year of base rent. The $1.7 million was required to be deposited when the amount of CEL-SCI&#8217;s cash balance had dropped below the amount stipulated in the lease and is included in non-current assets at September 30, 2021.<strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $10.7 million, of which approximately $10.5 million has been incurred as of September 30, 2021. The landlord agreed to finance the final $2.4 million of the costs incurred. The Company started repaying these costs on March 1, 2021 through increased lease payments which will continue over the remaining lease term. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year on the $2.4 million financed. An additional deposit of $240,000 was made at that time and is included in non-current assets at September 30, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 3. <span style="text-decoration:underline">LEGAL PROCEEDINGS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 4.</strong><strong> </strong><strong><span style="text-decoration:underline">MINE SAFETY DISCLOSURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.<strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 5. <span style="text-decoration:underline">MARKET FOR CEL-SCI'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2021, there were approximately 559 record holders of CEL-SCI&#8217;s common stock. CEL-SCI&#8217;s common stock is traded on the NYSE American under the symbol &#8220;CVM&#8221;. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Shown below are the range of high and low quotations for CEL-SCI&#8217;s common stock for the periods indicated as reported on the NYSE American. The market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions and may not necessarily represent actual transactions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Quarter Ending</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">High</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Low</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12/31/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.74</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3/31/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">6/30/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.64</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">9/30/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.29</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12/31/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16.70</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.76</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3/31/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40.91</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">6/30/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.20</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">9/30/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.90</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">45</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of common stock are entitled to receive dividends as may be declared by CEL-SCI&#8217;s Board of Directors out of legally available funds and, in the event of liquidation, to share pro rata in any distribution of CEL-SCI&#8217;s assets after payment of liabilities. CEL-SCI&#8217;s Board of Directors is not obligated to declare a dividend. CEL-SCI has not paid any dividends on its common stock and CEL-SCI does not have any current plans to pay any common stock dividends.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The provisions in CEL-SCI&#8217;s Articles of Incorporation relating to CEL-SCI&#8217;s preferred stock allow CEL-SCI&#8217;s directors to issue preferred stock with rights to multiple votes per share and dividend rights which would have priority over any dividends paid with respect to CEL-SCI&#8217;s common stock. The issuance of preferred stock with such rights may make more difficult the removal of management even if such removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in certain transactions such as mergers or tender offers if such transactions are not favored by incumbent management.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The market price of CEL-SCI&#8217;s common stock, as well as the securities of other biopharmaceutical and biotechnology companies, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as fluctuations in CEL-SCI&#8217;s operating results, announcements of technological innovations or new therapeutic products by CEL-SCI or its competitors, governmental regulation, developments in patent or other proprietary rights, public concern as to the safety of products which may be developed by CEL-SCI or other biotechnology and pharmaceutical companies, and general market conditions may have a significant effect on the market price of CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 6. </strong><strong><span style="text-decoration:underline">SELECTED FINANCIAL DATA</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Commission and is not required to provide the information required under this item. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 7. <span style="text-decoration:underline">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following discussion should be read in conjunction with the financial statements and the related notes thereto appearing elsewhere in this report. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On June 28, 2021, CEL-SCI announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine<sup>&#174;</sup> (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The study used the standard of care treatment for advanced primary head and neck cancer patients as a comparison. The patients received surgery followed by either radiation or chemoradiation (chemotherapy and radiation at the same time), as determined by the physician. This means that there were 2 treatment arms, 1) surgery plus radiation or 2) surgery plus chemoradiation. The arm that received Multikine treatment followed by surgery and radiation showed great survival benefit, but when chemotherapy was added in the second treatment arm, the immunological effect of Multikine was negated. Therefore when the two treatment arms were combined the study did not achieve its primary endpoint of a 10% improvement in overall survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">46</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">However, the analysis of the separate treatment arms was prespecified in the protocol and carried out prior to CEL-SCI becoming unblinded. The OS benefit of 14.1% at 5 years for this treatment arm exceeded the 10% OS benefit set out for the study population as a whole. The OS results for this treatment arm are significant (two-sided p=0.0236, HR=0.68) and the effect is robust, durable and increasing over time. The results from the Phase 3 cancer study proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this CEL-SCI will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population of about 210,000 patients annually worldwide.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System). CEL-SCI is using its LEAPS technology platform to investigate its lead peptide-based immunotherapy (CEL-4000) as a vaccine treatment for rheumatoid arthritis. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All of CEL-SCI&#8217;s projects are under development. As a result, CEL-SCI cannot predict when it will be able to generate any revenue from the sale of any of its products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Since inception, CEL-SCI has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. CEL-SCI will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as CEL-SCI becomes profitable, any or all of these financing vehicles or others may be utilized to assist CEL-SCI&#8217;s capital requirements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Results of Operations</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">No grant income was received during the year ended September 30, 2021. Prior year grant income included amounts earned on a Small Business Innovation Research (SBIR) grant, which was not received in the current year. The nature and amount of grants awarded depends on the timing and availability of such funds.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2021, research and development expenses increased by approximately $5.3 million, or 30%, compared to the year ended September 30, 2020. Major components of this increase include approximately $0.5 million in expenses to prepare for the potential filing of a Biologics License Application (BLA) and commercial manufacture of Multikine, approximately $2.4 million increase in employee stock compensation expense, and an approximate $2.7 million increase in expenses related to the Phase 3 clinical trial. This increase was offset by a net decrease in other miscellaneous research and development expenses of approximately $0.3 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2021, general and administrative expenses increased by approximately $1.4 million, or 12%, compared to the year ended September 30, 2020. A major component of the increase is an approximate $1.1 million increase in employee stock compensation costs, most of which related to the options granted under the 2021 Non-Qualified Stock Option Plan, and an approximately $0.3 million net increase in other general and administrative costs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">47</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">During the years ended September 30, 2021 and 2020, CEL-SCI recorded derivative losses of approximately $0.7 million and $0.3 million, respectively. This variation was the result of the change in fair value of the derivative liabilities during the period which was caused by fluctuations in the share price of CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Other non-operating gain increased by approximately $0.8 million from approximately $0.9 million for the year ended September 30, 2020 to approximately $1.7 million for the year ended September 30, 2021. This gain relates to the Securities Purchase Agreement described in Note 12 to the financial statements included as part of this report. The amount of the gain or loss is a result of the timing of shares issued to Ergomed and the subsequent re-sale of those shares. No shares were issued to Ergomed during the year ended September 30, 2021. During the year ended September 30, 2020, the Company issued 150,000 shares to Ergomed and recorded a non-operating loss equal to the fair value of those shares of approximately $1.8 million. During the years ended September 30, 2021 and 2020, Ergomed received approximately $1.7 million and $2.7 million, respectively, from the resale of these shares. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Net interest expense increased by approximately $0.1 million for the year ended September 30, 2021 compared to the year ended September 30, 2020 primarily due to the amortization of the Company&#8217;s lease liabilities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Research and Development Expenses</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s research and development efforts involved Multikine and LEAPS. The table below shows the research and development expenses associated with each project during the reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,508,026</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,146,248</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">LEAPS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600,871</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,694,042</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">23,108,897</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,840,290</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s Phase 3 clinical trial began in December 2010 after the completion and validation of CEL-SCI&#8217;s dedicated manufacturing facility. The Phase 3 clinical trial was fully enrolled in September 2016, reached its primary endpoint in April 2020 and achieved database lock in December 2020. The data was unblinded in June 2021, and the primary endpoint results were announced in June 2021. CEL-SCI is currently preparing the BLA to submit to the FDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As explained in Item 1 of this report, clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company&#8217;s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">48</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Liquidity and Capital Resources </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI has had only limited revenues from operations since its inception in March 1983. CEL-SCI has relied primarily upon capital generated from the public and private offerings of its common stock and convertible notes. In addition, CEL-SCI has utilized short-term loans to meet its capital requirements. Capital raised by CEL-SCI has been used to acquire an exclusive worldwide license to use, and later purchase, certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system and for clinical trials. Capital has also been used for patent applications, debt repayment, research and development, administrative costs, and for CEL-SCI&#8217;s laboratory and manufacturing facilities. CEL-SCI does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result, CEL-SCI has been dependent primarily upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future. During fiscal year 2021 and 2020, CEL-SCI raised net proceeds of approximately $54.0 million and $25.8 million, respectively, through a combination of the sale of common stock and the exercise of warrants and options. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">In August 2007, CEL-SCI leased a building near Baltimore, Maryland. The building, which consists of approximately 73,000 square feet, has been remodeled in accordance with CEL-SCI&#8217;s specifications so that it can be used by CEL-SCI to manufacture Multikine for CEL-SCI&#8217;s Phase III clinical trials and sales of the drug if approved by the FDA. The lease expires on October 31, 2028, and required annual base rent payments of approximately $2.2 million during the twelve months ended September 30, 2021. See Item 2 of this report for more information concerning the terms of this lease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In June 2021, the Company sold 1,400,000 shares of common stock at a public offering price of $22.62 per share and received aggregate net proceeds of approximately $29.4 million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 30-day option to purchase up to an additional 210,000 shares of common stock solely to cover over-allotments. The underwriter fully exercised this option in June 2021 resulting in additional net proceeds to the Company of approximately $4.4 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In December 2020, the Company sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate net proceeds of approximately $13.6 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The following charts list the warrants that were exercised and the proceeds received during the years ended September 30, 2021 and 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Fiscal Year 2021</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,089,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">275,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,375,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">132,798</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">663,990</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,201</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">863,414</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,755</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">349,663</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">165,888</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">273,715</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,064</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263,474</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">370,964</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">830,959</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,597,870</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,984,215</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">49</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Fiscal Year 2020</span></p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">128,820</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">644,100</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series FF </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,048</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.91</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">265,812</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,300</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series JJ </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,450</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,531</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series LL </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,398</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,867</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,858</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">178,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">124,956</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">314,889</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series OO</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,467</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,121</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">156,580</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">327,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,125</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">421,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,207</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">171,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series V</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">674,164</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,269,755</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series VV</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">82,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">144,375</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,711,873</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,072,465</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI entered into Securities Purchase Agreements (SPAs) with Ergomed plc, one of CEL-SCI&#8217;s Clinical Research Organizations responsible for managing the Phase 3 clinical trial, to facilitate payment of amounts due Ergomed. Under the Agreements, CEL-SCI issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed. Upon issuance, CEL-SCI expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2021 and 2020, CEL-SCI issued Ergomed 0 and 150,000 shares, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The following table summarizes the Other Non-operating gains for the years ended September 30 relating to these agreements:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amount realized through the resale of shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,652,605</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of shares upon issuance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,769,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other non-operating gain (loss)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">883,105</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As of September 30, 2021, Ergomed had no shares remaining for resale. As of September 30, 2020, Ergomed held 102,521 shares. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2021, the Company&#8217;s cash increased by approximately $20.6 million after the purchase of $6.1 million of U.S. Treasury bills (T-bills). Net of the purchase of the T-bills, cash increased by approximately $26.7 million. Significant components of the increase include approximately $47.1 million in net proceeds from the sale of common stock through public offerings, approximately $6.7 million in proceeds from the exercise of warrants and options, the receipt of approximately $1.6 million in lease incentives and $0.2 million in sales of stock to employees, offset by net cash used to fund the Company&#8217;s operations, including its Phase 3 clinical trial, of approximately $18.8 million, approximately $9.0 million of equipment and leasehold improvement expenditures and approximately $1.1 million in lease payments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">50</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2021, 1,597,870 warrants were exercised at a weighted average exercise price of $3.75 for total proceeds of approximately $6.0 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Prepaid expenses decreased by approximately $0.3 million during the year ended September 30, 2021 as compared to September 30, 2020 primarily due to the timing of payments and recognition of related expenses relating to the Company&#8217;s Phase 3 clinical trial status. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Supplies are purchased for use in the Company&#8217;s manufacturing and R&amp;D efforts and vary with the study requirements. During the year ended September 30, 2021, the supplies increased by approximately $1.2 million in support of the work on modifications of the manufacturing facility to prepare the facility to produce Multikine for commercial purposes and before the Company&#8217;s Biologics License Application (BLA) can be submitted to the FDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Primarily as a result of CEL-SCI&#8217;s losses incurred to date, its expected continued future losses, and limited cash balances, CEL-SCI has included a disclosure in its financial statements expressing substantial doubt about its ability to continue as a going concern. CEL-SCI has included this disclosure on numerous occasions in the preceding years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Future Capital Requirements</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s material capital commitments include funding operating losses, funding its research and development program and making required lease payments. Additionally, the Company recently completed upgrading the manufacturing facility to prepare for the potential commercial production of Multikine. Total costs of this upgrade are approximately $10.6 million. The landlord of the property agreed to finance the final $2.4 million of costs and allow for the repayment through increased lease payments which began on March 1, 2021. As of September 30, 2021, the landlord had provided approximately $1.6 million of the total funding. Because of the change in lease payments, the new financing arrangement was considered a lease modification. The remaining $0.8 million lease incentive is expected to be realized in quarter ended December 31, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">For information on employment contracts, see Item 11 of this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Further, CEL-SCI has contingent obligations with vendors for work that will be completed in relation to the Phase 3 trial. The timing of these obligations cannot be determined at this time. CEL-SCI estimates it will incur additional expenses of approximately $1.1 million for the filing of the clinical study report to the FDA. It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI will need to raise additional funds, either through the exercise of outstanding warrants/options, through debt or equity financings or a partnering arrangement, to bring Multikine to market. The ability of CEL-SCI to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. However, it is possible that CEL-SCI will not be able to generate enough cash to continue operations at its current level. CEL-SCI&#8217;s management has engaged in fundraising for over 25 years and believes that the manner in which it is proceeding will produce the best possible outcome for the shareholders. There can be no assurances that CEL-SCI will be successful in raising additional funds.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of CEL-SCI&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to CEL-SCI and the extent to which CEL-SCI has received regulatory approvals for clinical trials. The inability of CEL-SCI to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent CEL-SCI from completing the studies and research required to obtain regulatory approval for any products which CEL-SCI is developing. Without regulatory approval, CEL-SCI will be unable to sell any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">51</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the absence of revenues, CEL-SCI will be required to raise additional funds through the sale of securities, debt financings or other arrangements in order to continue with its research efforts. However, there can be no assurance that such financing will be available or be available on favorable terms. Ultimately, CEL-SCI must complete the development of its products, obtain appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Since all of CEL-SCI&#8217;s projects are under development, CEL-SCI cannot predict with any certainty the funds required for future research and clinical trials, the timing of future research and development projects, or when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI's cash flow and earnings are subject to fluctuations due to changes in interest rates on its bank accounts, and, to an immaterial extent, foreign currency exchange rates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Critical Accounting Policies</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI's significant accounting policies are more fully described in Note 3 to the financial statements included as part of this report. However, certain accounting policies are particularly important to the portrayal of CEL-SCI&#8217;s financial position and results of operations and require the application of significant judgments by management. As a result, the financial statements are subject to an inherent degree of uncertainty. In applying those policies, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. These estimates are based on CEL-SCI's historical experience, terms of existing contracts, observance of trends in the industry and information available from outside sources, as appropriate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Management believes that the following critical accounting policies require the most significant judgments and estimates with respect to the preparation of CEL-SCI&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><em>Lease Accounting</em> -The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incrernental borrowing rate, which involves complex judgment by management. The determination of the incremental borrowing rates for new and modified lease contracts is a critical accounting policy. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><em>Share-based Compensation</em>&#8211; Share-based compensation cost to employees is measured at fair value as of the grant date in accordance with the provisions of ASC 718. The fair value of the stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The compensation cost is recognized as expense over the requisite service or vesting period. Performance-based options are valued using a Monte-Carlo simulation model, which requires inputs based on estimates, including the likelihood of the occurrence of performance and market conditions, volatility and expected option life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In October 2019, the Company adopted ASU 2018-07, <em>Compensation &#8212; Stock Compensation (Topic 718)</em>, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. Adoption of the new guidance had no impact on the financial statements and related disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">52</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><em>Derivative Instruments&#8212;</em>CEL-SCI enters into financing arrangements that consist of freestanding derivative instruments or hybrid instruments that contain embedded derivative features. CEL-SCI accounts for these arrangements in accordance with ASC 815, <em>Accounting for Derivative Instruments and Hedging Activities</em>, as well as related interpretations of these standards. In accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the statement of financial position and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments.&#160;Fair value is generally calculated using a Black-Scholes valuation model. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and recognized at fair value with changes in fair value recognized as either a gain or loss in earnings if they can be reliably measured. When the fair value of embedded derivative features cannot be reliably measured, CEL-SCI measures and reports the entire hybrid instrument at fair value with changes in fair value recognized as either a gain or loss in earnings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 7A. <span style="text-decoration:underline">Quantitative and Qualitative Disclosure About Market Risks</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 8. </strong><strong><span style="text-decoration:underline">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">See the financial statements included with this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9. <span style="text-decoration:underline">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Not applicable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9A. </strong><strong><span style="text-decoration:underline">CONTROLS AND PROCEDURES </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><em>Evaluation of Disclosure Controls and Procedures</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Under the direction and with the participation of CEL-SCI&#8217;s management, including CEL-SCI&#8217;s Chief Executive Officer and Chief Financial Officer, CEL-SCI carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of September 30, 2021. CEL-SCI maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and regulations, and that such information is accumulated and communicated to CEL-SCI&#8217;s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. CEL-SCI&#8217;s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s Chief Executive and Principal Financial Officer has concluded that CEL-SCI&#8217;s disclosure controls were effective as of September 30, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Management&#8217;s Report on Internal Control over Financial Reporting</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the Securities and Exchange Commission, internal control over financial reporting is a process designed by, or under the supervision of CEL-SCI&#8217;s principal executive officer and principal financial officer and implemented by CEL-SCI&#8217;s Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of CEL-SCI&#8217;s financial statements in accordance with U.S. generally accepted accounting principles.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">53</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Under the supervision and with the participation of management, including CEL-SCI&#8217;s Chief Executive and Principal Financial Officer, CEL-SCI evaluated the effectiveness of its internal control over financial reporting as of September 30, 2021 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or the COSO Framework. Management&#8217;s assessment included an evaluation of the design of CEL-SCI&#8217;s internal control over financial reporting and testing of the operational effectiveness of those controls. CEL-SCI's Chief Executive and Financial Officer concluded that as of such date, CEL-SCI's internal controls over financial reporting were effective.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the fiscal year ended September 30, 2021, CEL-SCI implemented additional controls over financial reporting which include a thorough review of all leases and relevant accounting guidance such that the accounting for any leases complies with U.S. generally accepted accounting principles.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">No other changes in CEL-SCI&#8217;s internal control over financial reporting occurred during the fiscal year ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, CEL-SCI&#8217;s internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9B. <span style="text-decoration:underline">OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">None. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 10. </strong><strong><span style="text-decoration:underline">DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Officers and Directors</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:20%;vertical-align:top;">Name&#160; </td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Age</p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Position</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Geert R. Kersten, Esq. </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">62 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Director, Chief Executive and Financial Officer and Treasurer</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patricia B. Prichep&#160; </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">70</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Operations and Corporate Secretary</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Dr. Eyal Talor</td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">65 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Scientific Officer</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Dr. Daniel H. Zimmerman&#160; </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">80</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Research, Cellular Immunology</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">John Cipriano </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">79 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Regulatory Affairs</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Dr. Peter R. Young </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">76</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Bruno Baillavoine </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">69 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Robert Watson </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">64</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The directors of CEL-SCI serve in such capacity until the next annual meeting of CEL-SCI's shareholders or until their successors have been duly elected and qualified. The officers of CEL-SCI serve at the discretion of CEL-SCI's directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">54</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">All of CEL-SCI&#8217;s directors have served as directors for a significant period of time. Consequently, their long-standing experience with CEL-SCI benefits both CEL-SCI and its shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The principal occupations of CEL-SCI's officers and directors, during the past several years, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Geert Kersten has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley &amp; Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Patricia B. Prichep joined CEL-SCI in 1992 and has been CEL-SCI's Senior Vice President of Operations since March 1994. Between December 1992 and March 1994, Ms. Prichep was CEL-SCI's Director of Operations. Ms. Prichep became CEL-SCI's Corporate Secretary in May 2000. She is responsible for all day-to-day operations of CEL-SCI, including human resources and is the liaison with CEL-SCI&#8217;s independent registered public accounting firm for financial reporting. From June 1990 to December 1992, Ms. Prichep was the Manager of Quality and Productivity for the NASD&#8217;s Management, Systems and Support Department and was responsible for the internal auditing and work flow analysis of operations. Between 1982 and 1990, Ms. Prichep was Vice President and Operations Manager for Source Capital, Ltd. She handled all operations and compliance for Source Capital and was licensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug development for immunotherapy application; pre-clinical to Phase III clinical trials, in the biopharmaceutical industry. His expertise includes biopharmaceutical R&amp;D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre-clinical and clinical trials (Phase I &#8211; III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw material specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL-SCI, he was Director of R&amp;D and Clinical Development at CBL, Inc., Principal Scientist - Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full-time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine&#8217;s composition of matter and method of use in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T-cells (&#8216;Adapt&#8217;) and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation rejection and infectious diseases. He also is responsible for numerous product and process inventions as well as a number of pending US and PCT patent applications. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post-doctoral training in clinical and cellular immunology at The Johns Hopkins University, Baltimore, Maryland, USA. He holds an Associate teaching position at the Johns Hopkins University Medical Institutions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">55</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Daniel H. Zimmerman, Ph.D. was CEL-SCI's Senior Vice President of Research, Cellular Immunology between 1996 and December 2008 and again since November 2009. He joined CEL-SCI in January 1996 as the Vice President of Research, Cellular Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its president from 1987-1995. From 1973-1987, Dr. Zimmerman served in various positions at Electronucleonics, Inc. His positions included: Scientist, Senior Scientist, Technical Director and Program Manager. Dr. Zimmerman held various teaching positions at Montgomery College between 1987 and 1995. Dr. Zimmerman has invented technologies which are covered by over a dozen US patents as well as many foreign equivalent patents. He is the author of over 50 scientific publications in the area of immunology and infectious diseases. He has been awarded numerous grants from National Institutes of Health, or NIH, and the Department of Defense, or DOD. From 1969-1973, Dr. Zimmerman was a Senior Staff Fellow at NIH. For the following 25 years, he continued on at NIH as a guest worker. Dr. Zimmerman received a Ph.D. in Biochemistry in 1969, and a Masters in Zoology in 1966 from the University of Florida as well as a B.S. in Biology from Emory and Henry College in 1963. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">John Cipriano was CEL-SCI&#8217;s Senior Vice President of Regulatory Affairs between March 2004 and December 2008 and again since October 2009. Mr. Cipriano brings to CEL-SCI over 30 years of experience with both biotech and pharmaceutical companies. In addition, he held positions at the United States Food and Drug Administration (FDA) as Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review and was the Deputy Director, IND Branch, Division of Biologics Evaluation, Office of Biologics. Mr. Cipriano completed his B.S. in Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette, Indiana. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Peter R. Young, Ph.D. has been a Director of CEL-SCI since August 2002. Dr. Young has been a senior executive within the pharmaceutical industry in the United States and Canada for most of his career, originally in organizations that are now part of Sanofi S.A. Over the last 20 years he has primarily held positions of Chief Executive Officer or Chief Financial Officer and has extensive experience with acquisitions and equity financing. Since November 2001, Dr. Young has been the President of Agnus Dei, LLC, which has acted as a partner in an organization managing immune system clinics which treat patients with diseases such as cancer, multiple sclerosis and hepatitis. Dr. Young was also the President and Chief Executive Officer of SRL Technology, Inc., a company involved in the development of pharmaceutical drug delivery systems. Between 1998 and 2001, Dr. Young was the Chief Financial Officer of Adams Laboratories, Inc., the developer of Mucinex&#174;. Dr. Young received his Ph.D. in Organic Chemistry from the University of Bristol, England after obtaining his Bachelor's degree in Honors Chemistry, Mathematics and Economics. Subsequently, he qualified as a Fellow of the Chartered Institute of Management Accountants.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Bruno Baillavoine joined CEL-SCI&#8217;s board of directors in June 2015. Since 2017 Mr. Baillavoine has been the Director, Head of Pericles Group UK the subsidiary of the Paris based leading French consulting firm, Pericles Consulting Holdings SAS. Pericles is an expert in the fields of Banking, Finance, Asset Management and Insurance with over 350 institutional clients. He has also been an advisor to the Board of CSL Inc, Combatives Sports League a US Mixed Martial Arts company since 2017 and was appointed to the Board in 2019. Between 2010-2016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects from concept through final operations. From 2012-2016 Mr. Baillavoine was the Executive Chairman of Globomass Holdings. Globomass was acquired by CleanBay Inc. in 2016. Mr. Baillavoine remains a significant shareholder in CleanBay Inc. Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group (later acquired by Grand Metropolitan). During this time Mr. Baillavoine became the UK Business Manager where he restored market share and profit for United Distillers. From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years. Mr. Baillavoine was with Grand Metropolitan Plc between 1986-1988 (now Diageo Plc), an FTSE 100 beverage, food, hotel and leisure company, as director in the Special Operations division. In this capacity, he developed plans for Grand Met&#8217;s trouble-shooting division for over 20,000 Grand Met retail outlets. From 1988-1991 he was the Managing Director of Nutri Systems (UK) Ltd., a subsidiary of the US based provider of professionally supervised weight loss programs. Between 1991 and 1995, Mr. Baillavoine was Director of BET Group plc, a multinational business support services group, and in 1992, was promoted to the Managing Director for the manufacturing businesses. The &#163;2.3 billion turnaround of BET during his tenure is one of the most successful turnarounds of a top 100 FTSE company. Since 1995, Mr. Baillavoine has held a number of CEO positions across a wide range of industries and geographical locations. Mr. Baillavoine has European and American educations (US high school and University of Wisconsin Eau Claire 1972-1976).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">56</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Robert Watson has been a director of CEL-SCI since December 2017. Mr. Watson has been the President and CEO of Juvare, LLC (formerly Intermedix, Inc.) since July 2017. Immediately prior to joining Intermedix, now Juvare, he was the President and Chief Growth Officer of NantHealth, Inc. (Nasdaq: NH) from January 2015 to May 2017. Prior to NantHealth, he was President and CEO of Streamline Health, Inc. (Nasdaq: STRM) from January 2011 to January 2015. Mr. Watson has over 35 years of experience in the healthcare information technology industry as a CEO, board member and advisor to multiple healthcare information technology companies. He has participated in over 75 acquisitions, raised nearly $750 million in capital, completed three public offerings and successfully sold four companies. Mr. Watson holds a MBA from the Wharton School of Business at the University of Pennsylvania and a BA degree from Syracuse University. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">All of CEL-SCI's officers devote substantially all of their time to CEL-SCI's business. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s Board of Directors does not have a &#8220;leadership structure&#8221;, as such, since each director is entitled to introduce resolutions to be considered by the Board and each director is entitled to one vote on any resolution considered by the Board. CEL-SCI&#8217;s Chief Executive Officer is not the Chairman of CEL-SCI&#8217;s Board of Directors. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s Board of Directors has the ultimate responsibility to evaluate and respond to risks facing CEL-SCI. CEL-SCI&#8217;s Board of Directors fulfills its obligations in this regard by meeting on a regular basis and communicating, when necessary, with CEL-SCI&#8217;s officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Dr. Peter R. Young, Bruno Baillavoine and Robert Watson are independent directors as that term is defined in section 803 of the listing standards of the NYSE American.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has adopted a Code of Ethics which is applicable to CEL-SCI&#8217;S principal executive, financial, and accounting officers and persons performing similar functions. The Code of Ethics is available on CEL-SCI&#8217;s website, located at <em>www.cel-sci.com.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If a violation of this code of ethics act is discovered or suspected, any person (anonymously, if desired) may send a detailed note, with relevant documents, to CEL-SCI&#8217;s Audit Committee, c/o Dr. Peter Young, 208 Hewitt Drive, Suite 103-143, Waco, TX 76712<strong>.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">For purposes of electing directors at its annual meeting, CEL-SCI has a nominating committee that is made up of CEL-SCI&#8217;s independent directors. The nominating committee selects the nominees to the Board of Directors which are subject to election by CEL-SCI&#8217;s shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">57</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI does not have any policy regarding the consideration of director candidates recommended by shareholders and under Colorado law, any shareholder can nominate a person for election as a director at the annual shareholders&#8217; meeting. However, CEL-SCI&#8217;s Board of Directors will consider candidates recommended by shareholders. To submit a candidate for the Board of Directors the shareholder should send the name, address and telephone number of the candidate, together with any relevant background or biographical information, to CEL-SCI&#8217;s Chief Executive Officer, at the address shown on the cover page of this report. The Board has not established any specific qualifications or skills a nominee must meet to serve as a director. Although the Board does not have any process for identifying and evaluating director nominees, the Board does not believe there would be any differences in the manner in which the Board evaluates nominees submitted by shareholders as opposed to nominees submitted by any other person. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI does not have a policy with regard to Board member&#8217;s attendance at annual meetings. All Board members attended the last annual shareholder&#8217;s meeting held on July 1, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of CEL-SCI&#8217;s common stock can send written communications to CEL-SCI&#8217;s entire Board of Directors, or to one or more Board members, by addressing the communication to &#8220;the Board of Directors&#8221; or to one or more directors, specifying the director or directors by name, and sending the communication to CEL-SCI&#8217;s offices in Vienna, Virginia. Communications addressed to the Board of Directors as whole will be delivered to each Board member. Communications addressed to a specific director (or directors) will be delivered to the director (or directors) specified.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A security holder communication not sent to the Board of Directors as a whole is not relayed to Board members which did not receive the communication.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 11. </strong><strong><span style="text-decoration:underline">EXECUTIVE COMPENSATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Components of Compensation &#8212; Executive Officers</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s executive officers are compensated through the following three components:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font5c1015d7-9242-4dde-9fd5-15631f817518" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Base Salary</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fonteea5eb1e-66eb-4468-9b30-4c7d0dc557f3" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Long-Term Incentives (&#8220;LTIs&#8221;) (stock options and/or grants of stock)</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font760f4945-c647-41ec-b045-60f7886f6b29" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Benefits</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These components provide a balanced mix of base compensation and compensation that is contingent upon each executive officer&#8217;s individual performance. A goal of the compensation program is to provide executive officers with a reasonable level of security through base salary and benefits. CEL-SCI wants to ensure that the compensation programs are appropriately designed to encourage executive officer retention and motivation to create shareholder value. The Compensation Committee believes that CEL-SCI&#8217;s stockholders are best served when CEL-SCI can attract and retain talented executives by providing compensation packages that are competitive but fair. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Base Salaries</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Base salaries generally have been targeted to be competitive when compared to the salary levels of persons holding similar positions in other pharmaceutical companies and other publicly traded companies of comparable size. Each executive officer&#8217;s respective responsibilities, experience, expertise and individual performance are considered.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">A further consideration in establishing compensation for the senior employees is their long term history with CEL-SCI. Taken into consideration are factors that have helped CEL-SCI survive in times when it was financially weak, such as: willingness to accept salary cuts, willingness not to be paid at all for extended time periods, and in general an attitude that helped CEL-SCI survive during financially difficult times. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">58</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Long-Term Incentives</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Stock grants and option grants help to align the interests of CEL-SCI&#8217;s employees with those of its shareholders. Options and stock grants are made under CEL-SCI&#8217;s Stock Option, Incentive Stock Bonus, Stock Bonus and Stock Compensation Plans. Options are granted with exercise prices equal to the closing price of CEL-SCI&#8217;s common stock on the day immediately preceding the date of grant, with pro rata vesting at the end of each of the following three years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI believes that grants of equity-based compensation:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font49f8f70d-a816-47a4-8d2f-ea26cae7fa25" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Enhance the link between the creation of shareholder value and long-term executive incentive compensation;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font79995bca-ee51-4d86-91a3-cb7b4313cbd8" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Provide focus, motivation and retention incentive; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fontcfdf29f4-841f-41ef-a95d-72d36df8681f" style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Provide competitive levels of total compensation.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Benefits</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition to cash and equity compensation programs, executive officers participate in the health and welfare benefit programs available to other employees. In a few limited circumstances, CEL-SCI provides other benefits to certain executive officers, such as car allowances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All executive officers are eligible to participate in CEL-SCI&#8217;s 401(k) plan on the same basis as its other employees. CEL-SCI matches 100% of each employee&#8217;s contribution up to 6% of his or her salary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table sets forth in summary form the compensation received by (i) the Chief Executive and Financial Officer of CEL-SCI and (ii) by each other executive officer of CEL-SCI who received in excess of $100,000 during the two fiscal years ended September 30, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name and Principal Position</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Fiscal Year</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Salary (1)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Bonus (2)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Stock Awards (3)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Option Awards (4)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">All Other Compensation</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(5)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">580,017</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">17,325</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">201,280</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">55,631</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">854,253</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive and Financial Officer and Treasurer</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">756,102</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">13,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">17,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,492,320</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">55,631</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3,335,103</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia B. Prichep,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">261,021</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">16,201</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">97,920</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">384,173</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Operations and Secretary</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">366,722</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">14,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,212,480</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,610,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D.,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">314,833</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">97,920</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">428,384</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Scientific Officer</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">308,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,212,480</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,539,561</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Daniel Zimmerman, Ph.D.,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">242,978</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">14,939</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">54,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">318,348</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Research, Cellular Immunology</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">239,608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,900</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">13,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">673,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">935,899</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">225,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">54,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">279,764</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Regulatory Affairs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">235,212</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">673,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">910,643</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">59</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1) </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The dollar value of base salary (cash and non-cash) earned. The 2020 amounts in the case of Mr. Kersten and Ms. Prichep are substantially higher than the person&#8217;s annual salary because they include voluntarily deferred salary payments from prior years that were paid in 2020.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2) </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The dollar value of bonus (cash and non-cash) earned.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(3) </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For all persons listed in the table, the shares issued as CEL-SCI's contribution on behalf of the named officer who participates in CEL-SCI's 401(k) retirement plan. The value of all stock awarded during the periods covered by the table is calculated according to ASC 718-10-30-3 which represented the grant date fair value.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(4) </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fair value of all stock options granted during the periods covered by the table are calculated on the grant date in accordance with ASC 718-10-30-3 which represented the grant date fair value.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(5) </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All other compensation received that CEL-SCI could not properly report in any other column of the table including the dollar value of any insurance premiums paid by, or on behalf of, CEL-SCI with respect to term life insurance for the benefit of the named executive officer and car allowances paid by CEL-SCI. Includes board of directors fees for Mr. Kersten.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Employee Pension, Profit Sharing or Other Retirement Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">CEL-SCI has a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code and covering substantially all CEL-SCI&#8217;s employees.&#160; CEL-SCI&#8217;s contribution to the plan is made in shares of CEL-SCI's common stock. Each participant's contribution is matched by CEL-SCI with shares of common stock which have a value equal to 100% of the participant's contribution, not to exceed the lesser of $10,000 or 6% of the participant's total compensation.&#160; CEL-SCI's contribution of common stock is valued each quarter based upon the closing price of its common stock.&#160; The fiscal 2021 expenses for this plan were approximately $6,000. Other than the 401(k) Plan, CEL-SCI does not have a defined benefit, pension plan, profit sharing or other retirement plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Compensation of Directors During Year Ended September 30, 20</span></strong><strong><span style="text-decoration:underline">21</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Fees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Stock Awards (1)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 10.35pt; text-align:center;">Option Awards (2)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201,280</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">241,280</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Peter R. Young </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,520</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,520</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,520</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">88,520</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,520</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">88,520</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1) </p></td><td style="vertical-align:top;">The fair value of stock issued for services.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2) </p></td><td style="vertical-align:top;">The fair value of options granted computed in accordance with ASC 718-10-30-3 on the date of grant which represents their grant date fair value.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Directors&#8217; fees paid to Geert Kersten are included in the Executive Compensation table.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Employment Contracts</span></strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Geert Kersten</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 31, 2019, CEL-SCI entered into a four-year employment agreement with Geert Kersten, CEL-SCI&#8217;s Chief Executive Officer. The employment agreement with Mr. Kersten, which is essentially the same as Mr. Kersten&#8217;s prior employment agreement, as amended on August 30, 2016, provided that, during the term of the agreement, CEL-SCI would pay Mr. Kersten an annual salary of $559,052, plus any increases in proportion to salary increases granted to other senior executive officers of CEL-SCI, as well any increases approved by the Board of Directors during the term of the employment agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">60</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the employment term, Mr. Kersten will be entitled to receive any other benefits which are provided to CEL-SCI's executive officers or other full time employees in accordance with CEL-SCI's policies and practices and subject to Mr. Kersten&#8217;s satisfaction of any applicable conditions of eligibility. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If Mr. Kersten resigns within ninety (90) days of the occurrence of any of the following events: (i) a reduction in Mr. Kersten&#8217;s salary (ii) a relocation (or demand for relocation) of Mr. Kersten&#8217;s place of employment to a location more than ten (10) miles from his current place of employment, (iii) a significant and material reduction in Mr. Kersten&#8217;s authority, job duties or level of responsibility or the imposition of significant and material limitations on the Mr. Kersten&#8217;s autonomy in his position, or (iv) a Change in Control, then the employment agreement will be terminated and Mr. Kersten will be entitled to receive a lump-sum payment from CEL-SCI equal to 24 months of salary ($1,174,010) and the unvested portion of any stock options would vest immediately. For purposes of the employment agreement a change in the control of CEL-SCI means: (1) the merger of CEL-SCI with another entity if after such merger the shareholders of CEL-SCI do not own at least 50% of voting capital stock of the surviving corporation; (2) the sale of substantially all of the assets of CEL-SCI; (3) the acquisition by any person of more than 50% of CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's directors which has not been approved by the incumbent directors. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The employment agreement will also terminate upon the death of Mr. Kersten or Mr. Kersten&#8217;s physical or mental disability. If the employment agreement is terminated for any of these reasons, Mr. Kersten, or his legal representatives, as the case may be, will be paid the salary provided by the employment agreement through the date of termination, any options or bonus shares of CEL-SCI then held by Mr. Kersten will become fully vested and the expiration date of any options which would expire during the four year period following his termination of employment will be extended to the date which is four years after his termination of employment. The employment agreement will also terminate upon the willful misconduct, an act of fraud against CEL-SCI, or a breach of the employment agreement by Mr. Kersten, in which case Mr. Kersten will be paid the salary provided by the employment agreement through the date of termination.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Patricia B. Prichep / Eyal Talor, Ph.D.</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 31, 2019, CEL-SCI entered into a three-year employment agreement with Patricia B. Prichep, CEL-SCI&#8217;s Senior Vice President of Operations. The employment agreement with Ms. Prichep, which is essentially the same as Ms. Prichep&#8217;s prior employment agreement entered into on August 30, 2016 provided that, during the term of the agreement, CEL-SCI would pay Ms. Prichep an annual salary of $245,804 plus any increases approved by the Board of Directors during the period of the employment agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 31, 2019, CEL-SCI entered into a three-year employment agreement with Eyal Talor, Ph.D., CEL-SCI&#8217;s Chief Scientific Officer. The employment agreement with Dr. Talor, which is essentially the same as Dr. Talor&#8217;s prior employment agreement entered into on August 30, 2016, provided that, during the term of the agreement, CEL-SCI would pay Dr. Talor an annual salary of $303,453 plus any increases approved by the Board of Directors during the period of the employment agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If Ms. Prichep or Dr. Talor resigns within ninety (90) days of the occurrence of any of the following events: (i) a relocation (or demand for relocation) of employee&#8217;s place of employment to a location more than ten (10) miles from the employee&#8217;s current place of employment, (ii) a significant and material reduction in the employee&#8217;s authority, job duties or level of responsibility or (iii) the imposition of significant and material limitations on the employee&#8217;s autonomy in her or his position, the employment agreement will be terminated and the employee will be paid the salary provided by the employment agreement through the date of termination and the unvested portion of any stock options held by the employee will vest immediately.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">61</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the event there is a change in the control of CEL-SCI, the employment agreements with Ms. Prichep and Dr. Talor allow Ms. Prichep and/or Dr. Talor (as the case may be) to resign from her or his position at CEL-SCI and receive a lump-sum payment from CEL-SCI equal to 18 months of salary ($387,141 and $477,939 respectively). In addition, the unvested portion of any stock options held by the employee will vest immediately. For purposes of the employment agreements, a change in the control of CEL-SCI means: (1) the merger of CEL-SCI with another entity if after such merger the shareholders of CEL-SCI do not own at least 50% of voting capital stock of the surviving corporation; (2) the sale of substantially all of the assets of CEL-SCI; (3) the acquisition by any person of more than 50% of CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's directors which has not been approved by the incumbent directors. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The employment agreements with Ms. Prichep and Dr. Talor will also terminate upon the death of the employee, the employee&#8217;s physical or mental disability, willful misconduct, an act of fraud against CEL-SCI, or a breach of the employment agreement by the employee. If the employment agreement is terminated for any of these reasons the employee, or her or his legal representatives, as the case may be, will be paid the salary provided by the employment agreement through the date of termination.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Compensation Committee Interlocks and Insider Participation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a compensation committee comprised of Mr. Bruno Baillavoine, Dr. Peter Young and Mr. Robert Watson, all of whom are independent directors. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2021, no director of CEL-SCI was also an executive officer of another entity, which had an executive officer of CEL-SCI serving as a director of such entity or as a member of the compensation committee of such entity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Stock Option, Bonus and Compensation Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Bonus Plans, Stock Compensation Plans and an Incentive Stock Bonus Plan. All Stock Option, Bonus and Compensation Plans have been approved by the stockholders. A summary description of these Plans follows. In some cases these Plans are collectively referred to as the "Plans".</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Option Plan</span><span style="text-decoration:underline">s</span>. The Incentive Stock Option Plans authorize the issuance of shares of CEL-SCI's common stock to persons who exercise options granted pursuant to the Plans. Only CEL-SCI&#8217;s employees may be granted options pursuant to the Incentive Stock Option Plans. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Options may not be exercised until one year following the date of grant. Options granted to an employee then owning more than 10% of the common stock of CEL-SCI may not be exercisable by its terms after five years from the date of grant. Any other option granted pursuant to the Plans may not be exercisable by its terms after ten years from the date of grant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The option exercise price is determined by the CEL-SCI&#8217;s Compensation Committee but cannot be less than the fair market value of the common stock on the date of the grant of the option (or 110% of the fair market value in the case of a person owning more than 10% of CEL-SCI's outstanding shares).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">62</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Non-Qualified Stock Option Plans</span>. The Non-Qualified Stock Option Plans authorize the issuance of shares of CEL-SCI's common stock to persons that exercise options granted pursuant to the Plans. CEL-SCI's employees, directors, officers, consultants and advisors are eligible to be granted options pursuant to the Plans, provided however that bona fide services must be rendered by such consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock. The option exercise price is determined by CEL-SCI&#8217;s Compensation Committee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Stock Bonus Plan</span><span style="text-decoration:underline">s</span>. Under the Stock Bonus Plans shares of CEL-SCI&#8217;s common stock may be issued to CEL-SCI's employees, directors, officers, consultants and advisors, provided however that bona fide services must be rendered by consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Stock Compensation Plan</span><span style="text-decoration:underline">s</span>. Under the Stock Compensation Plans, shares of CEL-SCI&#8217;s common stock may be issued to CEL-SCI&#8217;s employees, directors, officers, consultants and advisors in payment of salaries, fees and other compensation owed to these persons. However, bona fide services must be rendered by consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Bonus</span><span style="text-decoration:underline"> Plan</span>. Under the 2014 Incentive Stock Bonus Plan, shares of CEL-SCI&#8217;s common stock may be issued to executive officers and other employees who contribute significantly to the success of CEL-SCI. The purpose of the Plan is to provide long term incentive for outstanding service to CEL-SCI and its shareholders, to assist in recruiting and retaining people of outstanding ability and initiative in executive and management positions to allow officers and employees to participate in CEL-SCI's future prosperity and growth, and to align the interests of CEL-SCI's officers and employees with those of its shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Other Information Regarding the Plans</span>. The Plans are administered by CEL-SCI's Compensation Committee (&#8220;the Committee&#8221;), each member of which is a director of CEL-SCI. The members of the Committee were selected by CEL-SCI's Board of Directors and serve for a one-year tenure and until their successors are elected. A member of the Committee may be removed at any time by action of the Board of Directors. Any vacancies which may occur on the Committee will be filled by the Board of Directors. The Committee is vested with the authority to interpret the provisions of the Plans and supervise the administration of the Plans. In addition, the Committee is empowered to select those persons to whom shares or options are to be granted, to determine the number of shares subject to each grant of a stock bonus or an option and to determine when, and upon what conditions, shares or options granted under the Plans will vest or otherwise be subject to forfeiture and cancellation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During fiscal year ended September 30, 2021, the Company adopted the 2021 Non-Qualified Stock Option Plan, which provides for the issuance of up to 1,800,000 options to purchase shares of common stock, was approved by shareholders. On May 14, 2021, the Company granted 1,800,000 performance-based stock options from the 2021 Non-Qualified Stock Option Plan and 72,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $20.61 per share, the fair value on the date of issuance. The stock options will vest 100% upon the achievement of the following performance goal: (a) the filing of the first marketing application for any pharmaceutical based upon the Company&#8217;s Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company&#8217;s common stock exceeds $42.00. None of the options will be exercisable before May 13, 2022. All options which have not vested as of May 13, 2031, will be canceled and will no longer be exercisable. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">63</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In the discretion of the Committee, any option granted pursuant to the Plans may include installment exercise terms such that the option becomes fully exercisable in a series of cumulating portions. The Committee may also accelerate the date upon which any option (or any part of any options) is first exercisable. Any shares issued pursuant to the Stock Bonus Plans or Stock Compensation Plans and any options granted pursuant to the Incentive Stock Option Plans or the Non-Qualified Stock Option Plans will be forfeited if the "vesting" schedule established by the Committee administering the Plans at the time of the grant is not met. For this purpose, vesting means the period during which the employee must remain an employee of CEL-SCI or the period of time a non-employee must provide services to CEL-SCI. At the time an employee ceases working for CEL-SCI (or at the time a non-employee ceases to perform services for CEL-SCI), any shares or options not fully vested will be forfeited and cancelled. At the discretion of the Committee payment for the shares of common stock underlying options may be paid through the delivery of shares of CEL-SCI's common stock having an aggregate fair market value equal to the option price, provided such shares have been owned by the option holder for at least one year prior to such exercise. A combination of cash and shares of common stock may also be permitted at the discretion of the Committee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Options are generally non-transferable except upon death of the option holder. Shares issued pursuant to the Stock Bonus Plans will generally not be transferable until the person receiving the shares satisfies the vesting requirements imposed by the Committee when the shares were issued. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Board of Directors of CEL-SCI may at any time, and from time to time, amend, terminate, or suspend one or more of the Plans in any manner it deems appropriate, provided that such amendment, termination or suspension may not adversely affect rights or obligations with respect to shares or options previously granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Stock Options</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table show information concerning the options granted during the fiscal year ended September 30, 2021, to the persons named below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="text-decoration:underline">Options Granted</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Grant Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options Granted</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price Per Share</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/14/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">592,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/13/2031</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/14/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">318,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/13/2031</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/14/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">288,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/13/2031</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/14/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">130,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/13/2031</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dan Zimmerman</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/14/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/13/2031</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/14/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">128,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/13/2031</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Peter Young</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/14/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">128,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/13/2031</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/14/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">128,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/13/2031</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">64</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table shows the outstanding options held by the persons named below on September 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares underlying unexercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Option which are:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration</p></td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Unexercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/17/22</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,584</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,416</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/17/22</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/30/23</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">530,121</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">542,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">271,060</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">444,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">592,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia B. Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/17/22</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/17/22</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/30/23</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">222,607</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">270,421</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">135,210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">216,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">288,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/17/22</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/17/22</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/30/23</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">193,934</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.55</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">09/20/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,142</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127,570</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">216,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">318,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dan Zimmerman, Ph.D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">900</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/17/22</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">900</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/30/23</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/05/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/25/25</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/21/26</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.87</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/28/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">09/17/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,194</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,973</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70,486</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">900</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/17/22</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">900</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/30/23</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,347</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">137,920</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,960</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">130,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">Summary</span>. The following shows certain information as of September 30, 2021 concerning the stock options and stock bonuses granted by CEL-SCI. Each option represents the right to purchase one share of CEL-SCI's common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">65</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name of Plan</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total Shares Reserved Under Plans</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Reserved for Outstanding Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issued</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Remaining Options/Shares Under Plans</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,829</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,972,880</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">363,086</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">420,641</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">153,195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,395</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Of the shares issued pursuant to CEL-SCI's Stock Bonus Plans, 280,764 shares were issued as part of CEL-SCI's contribution to its 401(k) plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The following table shows the weighted average exercise price of the outstanding options granted pursuant to CEL-SCI&#8217;s Incentive and Non-Qualified Stock Option Plans as of September 30, 2021, CEL-SCI&#8217;s most recent fiscal year end. CEL-SCI's Incentive and Non-Qualified Stock Option Plans have been approved by CEL-SCI's shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Plan category</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Securities to be Issued Upon Exercise of Outstanding Options (a)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted-Average Exercise Price of Outstanding Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Securities Remaining Available For Future Issuance Under Equity Compensation Plans, Excluding Securities </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Reflected in Column (a)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,829</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,972,880</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.94</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 12. <span style="text-decoration:underline">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table shows, as of December 1, 2021, information with respect to the only persons owning beneficially 5% or more of CEL-SCI&#8217;s outstanding common stock and the number and percentage of outstanding shares owned by each director and officer of CEL-SCI and by the officers and directors as a group. Unless otherwise indicated, each owner has sole voting and investment powers over his shares of common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">66</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name and Address</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Number of Shares (1)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Percent of Class (2)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert R. Kersten </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,571,542</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.8</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Patricia B. Prichep</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">921,968</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Eyal Talor, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">856,775</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.9</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Daniel H. Zimmerman, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">469,288</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">John Cipriano</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">482,975</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Peter R. Young, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">208 Hewitt Drive, Suite 103-143</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Waco, TX 76712</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,681</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,140</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">245 N. Highland Ave. NE</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Suite 230-296</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Atlanta, GA 30307</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201,098</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All Officers and Directors</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">as a Group (8 persons)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,028,467</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14.47</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">State Street Corporation</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">State Street Financial Center</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">One Lincoln Street</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Boston, MA 02111</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,576,724</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.59</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* Less than 1%</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1) </p></td><td style="vertical-align:top;">Includes shares issuable prior to February 28, 2022 upon the exercise of options or warrants granted to the following persons:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options or Warrants Exercisable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Prior to February 28, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert R. Kersten, Esq.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,424,849</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Patricia B. Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">714,387</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Eyal Talor, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">751,876</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Daniel Zimmerman, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">352,767</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">John Cipriano</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">419,867</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Peter R. Young, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">265,767</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">224,167</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">196,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2) </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amount includes shares referred to in (1) above but excludes shares which may be issued upon the exercise of options and warrants previously issued by CEL-SCI.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">67</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(3) </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amount includes 321,421 shares and 390,928 warrants held in the de Clara Trust, of which Mr. Kersten is a beneficiary. Mr. Kersten is not the trustee of the de Clara Trust and does not control the voting or the trading of the shares held by the Trust.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 13. </strong><strong><span style="text-decoration:underline">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2021, officers and a director of the Company purchased 27,500 restricted shares of the Company&#8217;s common stock at an aggregate market value of approximately $220,000 During the year ended September 30, 2020, officers of the Company purchased 20,512 restricted shares of the Company&#8217;s common stock at an aggregate fair market value of approximately $185,000. The shares are subject to the conditions of Rule 144 under the Securities Act of 1933.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">See Note 11 to the financial statements included as part of this report for additional information concerning related party transactions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 14</strong>.<strong> <span style="text-decoration:underline">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">BDO USA, LLP served as CEL-SCI&#8217;s independent registered public accountant for the two years ended September 30, 2021. The following table shows the aggregate fees billed to CEL-SCI for these years by BDO USA, LLP: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year Ended September 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Audit Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">391,240</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">553,700</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Audit Related Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Tax Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">All Other Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Audit fees represent amounts billed for professional services rendered for the audit of CEL-SCI&#8217;s annual financial statements and the reviews of the financial statements included in CEL-SCI&#8217;s 10-Q reports for the fiscal year and all regulatory filings. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Before BDO USA, LLP was engaged by CEL-SCI to render audit or non-audit services, the engagement was approved by CEL-SCI&#8217;s audit committee. CEL-SCI&#8217;s Board of Directors is of the opinion that the Audit Fees charged by BDO USA, LLP are consistent with BDO USA, LLP maintaining its independence from CEL-SCI.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">68</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">ITEM 15. </span></strong><strong><span style="text-decoration:underline">EXHIBITS</span></strong><strong><span style="text-decoration:underline"> AND</span></strong><strong><span style="text-decoration:underline"> FINANCIAL STATEMENT SCHEDULES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">3(a)</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:39%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Articles of Incorporation</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:50%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's combined Registration Statement on Form S-1 and Post-Effective Amendment ("Registration Statement"), Registration Nos. 2-85547-D and 33-7531.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">3(b)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Amended Articles</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's Registration Statement on Form S-1, Registration Nos. 2-85547-D and 33-7531.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">3(c)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Amended Articles (Name change only)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 3(c) of CEL-SCI's &#160;Registration Statement on Form S-1 Registration Statement (No. 33-34878).</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">3(d)</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:39%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">By laws (as amended)</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:50%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 3(d) of CEL-SCI's Post-Effective Amendment No. 3 to Registration Statement on Form S-1 (No. 333-229295).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">4</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Shareholders Rights Agreement, as Amended</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 4&#160;filed with CEL-SCI&#8217;s 8-K report dated October 30, 2020.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">4(b)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incentive Stock Option Plan</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on September 25, 2012 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-184092.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">4(c)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Non-Qualified Stock Option Plan</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on August 19, 2014 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-198244).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">4(d)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock Bonus Plan</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 4 (d) filed on September 25, 2012 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-184092.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">4(e)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock Compensation Plan</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 4 (e) filed on September 25, 2012 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-184092.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">4(f)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2014 Incentive Stock Bonus Plan</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Filed with this Amendment No. 2 to CEL-SCI&#8217;s annual report on Form 10-K for the year ended September 30, 2014.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">69</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10(l)</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:39%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">First Amendment to Development Supply&#160;and Distribution Agreement with Orient&#160;Europharma.</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:50%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(m)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2010.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10(m)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Exclusive License and Distribution&#160;Agreement with Teva&#160;Pharmaceutical Industries&#160;Ltd.</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(n)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2010.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10(n)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Lease Agreement</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(o)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2010.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10(p)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Licensing Agreement with Byron&#160;Biopharma</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(i) of&#160;CEL-SCI&#8217;s report on Form 8-K dated March&#160;27, 2009</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10(z)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Development, Supply and Distribution&#160;Agreement with Orient Europharma</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit&#160;10(z)&#160;filed with CEL-SCI&#8217;s report on Form&#160;10-K for the year ended September 30, 2003.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (rr)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Assignment and Assumption Agreement with Teva Pharmaceutical Industries, Ltd. and GCP Clinical Studies, Ltd.</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(rr) of CEL-SCI&#8217;s report on Form 10-K/A report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (ss)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Service Agreement with GCP Clinical Studies, Ltd., together with Amendment 1 thereto*</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(ss) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (tt)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Joinder Agreement with PLIVA Hrvatska d.o.o.</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(tt) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (uu)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Master Service Agreement with Ergomed Clinical Research, Ltd.,&#160;&#160;and Clinical Trial Orders thereunder</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(uu) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (vv)</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:39%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research Ltd., dated April 19, 2013, as amended</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:50%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(vv) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (ww)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Co-Development and Revenue Sharing Agreement II:&#160;&#160;Cervical Intraepithelial Neoplasia in HIV/HPV co-infected women, with Ergomed Clinical Research Ltd., dated October 10, 2013, as amended</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(ww) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (xx)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Co-Development and Revenue Sharing Agreement III: Anal warts and anal intraepithelial neoplasia in HIV/HPV co-infected patients, with Ergomed Clinical Research Ltd., dated October 24, 2013</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(xx) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">70</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (yy)</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:39%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Master Services Agreement with Aptiv Solutions, Inc.</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:50%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(yy) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (zz)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Project Agreement Number 1 with Aptiv Solutions, Inc. together with Amendments 1 and 2 thereto*</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(zz) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (aaa)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Second Amendment to Development Supply and Distribution Agreement with Orient Europharma</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(aaa) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (iii)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Amendment to Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research, Ltd., dated&#160; September 15, 2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10 (iii)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (mmm)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Employment Agreement with Geert Kersten (2019-2023)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(10.7) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (nnn)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Employment Agreement with Patricia Prichep (2019-2022)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(10.8) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10 (ooo)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Employment Agreement with Eyal Taylor (2019-2022)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10(10.9) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10.7</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2019 Non-Qualified Stock Option Plan</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10.7 of CEL-SCI&#8217;s report on Form 8-K dated October 15, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">10.8</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2019 Stock Compensation Plan</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 10.8 of CEL-SCI&#8217;s report on Form 8-K dated October 15, 2019.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex231.htm">23.1 </a></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="cvm_ex231.htm">Consent of BDO USA, LLP</a></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">31 </a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="cvm_ex31.htm">Rule 13a-14(a) Certifications</a></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">32 </a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="cvm_ex32.htm">Section 1350 Certifications</a></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission under Rule 24b-2 of the Securities Exchange Act of 1934. The omitted confidential material has been filed separately with the Commission. The location of the omitted confidential information is indicated in the exhibit with asterisks (*)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">71</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 95.85pt; text-align:justify;"><strong><span id="font026355d1-6668-4992-b11f-eba44af57331" style="font-size:18pt">CEL-SCI CORPORATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 95.85pt; text-align:justify;"><strong>Financial Statements for the Years</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 95.85pt; text-align:justify;"><strong>Ended September 30, </strong><strong>2021 and 2020</strong><strong>, and</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 95.85pt; text-align:justify;"><strong>Report of Independent Registered Public Accounting Firm</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="tocfs">TABLE OF CONTENTS</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Page</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><a href="#report">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </a></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">FINANCIAL STATEMENTS FOR THE YEARS ENDED SEPTEMBER 30, 2021 and 2020:</td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 30px;vertical-align:top;"><a href="#bs">Balance Sheets </a></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;"><a href="#sto">Statements of Operations </a></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;"><a href="#eqt">Statements of Stockholders&#8217; Equity</a></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;"><a href="#cf">Statements of Cash Flows </a></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 7</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;"><a href="#nots">Notes to Financial Statements </a></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 9</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-1</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="report">Report of Independent Registered Public Accounting Firm</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stockholders and Board of Directors</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, Virginia</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>Opinion on the Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">We have audited the accompanying balance sheets of CEL-SCI Corporation (the &#8220;Company&#8221;) as of September 30, 2021 and 2020, the related statements of operations, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>Basis for Opinion</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>Critical Audit Matter</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Determination of Incremental Borrowing Rates for Leases</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As described in Note 10 of the financial statements, the Company modified two leases during the year. The remeasurement of the lease liability requires the determination of an incremental borrowing rate, which involves complex judgment by management. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We identified the determination of the incremental borrowing rates for modified lease contracts as a critical audit matter. Significant judgment is required by management to develop the incremental borrowing rate for lease contracts. Auditing the reasonableness of the incremental borrowing rate involved especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters including the extent of specialized skill or knowledge needed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The primary procedures we performed to address this critical audit matter included:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Utilizing professionals with specialized skill and knowledge in valuation to assist with developing independent estimates of fully collateralized incremental borrowing rates for modified lease contracts by (i) developing synthetic credit ratings for the Company; (ii) identifying market interest rates based on the synthetic credit ratings and applicable lease terms; and (iii) comparing the independently developed estimates to the Company&#8217;s incremental borrowing rates.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/BDO USA, LLP</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have served as the Company's auditor since 2005.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Potomac, Maryland<br />December 21, 2021</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="bs">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">BALANCE SHEETS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">SEPTEMBER 30, 2021 and 2020</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">ASSETS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current Assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1970" contextRef="AsOf2021-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,060,148</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1971" contextRef="AsOf2020-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,508,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">U.S. Treasury Bills</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1972" contextRef="AsOf2021-09-30" name="us-gaap:ShortTermInvestments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,151,385</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1973" contextRef="AsOf2020-09-30" name="us-gaap:ShortTermInvestments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Receivables</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1974" contextRef="AsOf2021-09-30" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,922</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1975" contextRef="AsOf2020-09-30" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,922</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1976" contextRef="AsOf2021-09-30" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998,482</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1977" contextRef="AsOf2020-09-30" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,313,432</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1978" contextRef="AsOf2021-09-30" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,006,584</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1979" contextRef="AsOf2020-09-30" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">820,052</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1980" contextRef="AsOf2021-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,271,521</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1981" contextRef="AsOf2020-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,697,315</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1982" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,691,921</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1983" contextRef="AsOf2020-09-30" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,811,849</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1984" contextRef="AsOf2021-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,056,178</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1985" contextRef="AsOf2020-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198,958</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1986" contextRef="AsOf2021-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,663,562</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1987" contextRef="AsOf2020-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,843,993</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patent costs, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1988" contextRef="AsOf2021-09-30" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,866</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1989" contextRef="AsOf2020-09-30" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">313,422</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1990" contextRef="AsOf2021-09-30" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,910,917</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1991" contextRef="AsOf2020-09-30" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,670,917</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1992" contextRef="AsOf2021-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,869,965</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1993" contextRef="AsOf2020-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,536,454</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current Liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1996" contextRef="AsOf2021-09-30" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,675,813</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1997" contextRef="AsOf2020-09-30" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,023,067</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1998" contextRef="AsOf2021-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">859,216</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1999" contextRef="AsOf2020-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">510,515</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Due to employees </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2000" contextRef="AsOf2021-09-30" name="us-gaap:DueToOfficersOrStockholdersCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,993</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2001" contextRef="AsOf2020-09-30" name="us-gaap:DueToOfficersOrStockholdersCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">448,022</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Derivative instruments, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2002" contextRef="AsOf2021-09-30" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,380</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2003" contextRef="AsOf2020-09-30" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,787</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Lease liabilities, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2004" contextRef="AsOf2021-09-30" name="cvm:LeaseLiabilitiesCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">698,665</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2005" contextRef="AsOf2020-09-30" name="cvm:LeaseLiabilitiesCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,070,123</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2006" contextRef="AsOf2021-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,937,067</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2007" contextRef="AsOf2020-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,265,514</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Derivative instruments, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2008" contextRef="AsOf2021-09-30" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2009" contextRef="AsOf2020-09-30" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,551,826</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2010" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,252,364</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2011" contextRef="AsOf2020-09-30" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,753,100</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2012" contextRef="AsOf2021-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,021,308</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2013" contextRef="AsOf2020-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,114,340</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2014" contextRef="AsOf2021-09-30" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2015" contextRef="AsOf2020-09-30" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2016" contextRef="AsOf2021-09-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,335,739</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2017" contextRef="AsOf2020-09-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,809,780</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commitments and Contingencies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock, $.01 par value- 200,000 shares authorized;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">-0- shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock, $<ix:nonFraction id="fid_2041" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockParOrStatedValuePerShare" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction> par value - <ix:nonFraction id="fid_2043" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">600,000,000</ix:nonFraction> shares authorized;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"><ix:nonFraction id="fid_2046" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,207,183</ix:nonFraction> and <ix:nonFraction id="fid_2047" contextRef="AsOf2020-09-30" name="us-gaap:CommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,730,150</ix:nonFraction> shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">at September 30, 2021 and 2020, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2022" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2023" contextRef="AsOf2020-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,302</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2024" contextRef="AsOf2021-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,298,566</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2025" contextRef="AsOf2020-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,174,675</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2026" contextRef="AsOf2021-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">418,196,412</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2027" contextRef="AsOf2020-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">381,835,303</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2028" contextRef="AsOf2021-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,534,226</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2029" contextRef="AsOf2020-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,726,674</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2030" contextRef="AsOf2021-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,869,965</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2031" contextRef="AsOf2020-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,536,454</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="sto">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF OPERATIONS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2021 AND 2020</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Grant income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2048" contextRef="From2020-10-01to2021-09-30" name="us-gaap:OtherIncome" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2049" contextRef="From2019-10-01to2020-09-30" name="us-gaap:OtherIncome" format="ixt:numdotdecimal" decimals="0" unitRef="USD">558,664</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2051" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,108,897</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2052" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,840,290</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2053" contextRef="From2020-10-01to2021-09-30" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,085,232</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2054" contextRef="From2019-10-01to2020-09-30" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,703,429</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2055" contextRef="From2020-10-01to2021-09-30" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,194,129</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2056" contextRef="From2019-10-01to2020-09-30" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,543,719</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2057" contextRef="From2020-10-01to2021-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,194,129</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2058" contextRef="From2019-10-01to2020-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">28,985,055</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other (expense) income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2059" contextRef="From2020-10-01to2021-09-30" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,213</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2060" contextRef="From2019-10-01to2020-09-30" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,763</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Loss on derivative instruments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2061" contextRef="From2020-10-01to2021-09-30" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">694,858</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2062" contextRef="From2019-10-01to2020-09-30" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">349,078</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant inducement expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2063" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2064" contextRef="From2019-10-01to2020-09-30" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,753</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other non-operating gain</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2065" contextRef="From2020-10-01to2021-09-30" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,685,379</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2066" contextRef="From2019-10-01to2020-09-30" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">887,604</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2067" contextRef="From2020-10-01to2021-09-30" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,149,288</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2068" contextRef="From2019-10-01to2020-09-30" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,041,725</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2069" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,361,109</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2070" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,255,244</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2071" contextRef="From2020-10-01to2021-09-30" name="cvm:ModificationOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">350,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2072" contextRef="From2019-10-01to2020-09-30" name="cvm:ModificationOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">21,734</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2073" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,711,970</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2074" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,276,978</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2075" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EarningsPerShareBasic" decimals="INF" unitRef="USDPShares" sign="-">0.90</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2076" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EarningsPerShareBasic" decimals="INF" unitRef="USDPShares" sign="-">0.82</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2077" contextRef="From2020-10-01to2021-09-30" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,662,137</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2078" contextRef="From2019-10-01to2020-09-30" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">36,759,115</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share - diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2079" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.93</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2080" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.82</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding - diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2081" contextRef="From2020-10-01to2021-09-30" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,694,248</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2082" contextRef="From2019-10-01to2020-09-30" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">36,759,115</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="eqt">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF STOCKHOLDERS' EQUITY</p></td></tr><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2021 AND 2020</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2431" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">35,231,776</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2432" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,318</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2433" contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,507,603</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2434" contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">353,726,254</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2435" contextRef="AsOf2019-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,133,667</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Adoption of ASC 842, Leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2438" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="cvm:AdoptionOfAsc842Leases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,146,195</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2439" contextRef="From2019-10-01to2020-09-30" name="cvm:AdoptionOfAsc842Leases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,146,195</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2440" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:ProceedsFromTheSaleOfCommonStockShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,422,429</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2441" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,225</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2442" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,978,214</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2443" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2444" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,992,439</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2445" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:WarrantIssuances" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2446" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:WarrantIssuances" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2447" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="cvm:WarrantIssuances" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2448" contextRef="From2019-10-01to2020-09-30" name="cvm:WarrantIssuances" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2449" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,711,873</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2450" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,118</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2451" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,127,122</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2452" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="cvm:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2453" contextRef="From2019-10-01to2020-09-30" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,144,240</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2454" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:ModificationOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2455" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ModificationOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,554</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2457" contextRef="From2019-10-01to2020-09-30" name="cvm:ModificationOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,554</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2458" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,870</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2459" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2460" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,201</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2461" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2462" contextRef="From2019-10-01to2020-09-30" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,340</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2463" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">79,950</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2464" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">799</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2465" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">971,868</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2466" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2467" contextRef="From2019-10-01to2020-09-30" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">972,667</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2468" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2469" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,112,968</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2470" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2471" contextRef="From2019-10-01to2020-09-30" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,112,968</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Option exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2472" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">99,740</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2473" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2474" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">337,330</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2475" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2476" contextRef="From2019-10-01to2020-09-30" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,328</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Purchase of stock by officers and directors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2477" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,512</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2478" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2479" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,785</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2480" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2481" contextRef="From2019-10-01to2020-09-30" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,990</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2482" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2483" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">787,723</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2484" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2485" contextRef="From2019-10-01to2020-09-30" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">787,723</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares issued for settlement of clinical research costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2486" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:SharesIssuedForSettlementOfClinicalResearchCostsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">150,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2487" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2488" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,768,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2489" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2490" contextRef="From2019-10-01to2020-09-30" name="cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,769,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2491" contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2492" contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2493" contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,255,244</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2494" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,255,244</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2495" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,730,150</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2496" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,302</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2497" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,174,675</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2498" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">381,835,303</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2499" contextRef="AsOf2020-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,726,674</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2500" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="cvm:ProceedsFromTheSaleOfCommonStockShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,610,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2501" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,100</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2502" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,337,326</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2503" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2504" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,363,426</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2505" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="cvm:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,597,870</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2506" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,978</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2507" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,991,328</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2508" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="cvm:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2509" contextRef="From2020-10-01to2021-09-30" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,007,306</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2510" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="cvm:ModificationOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2511" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ModificationOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,387</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2512" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="cvm:ModificationOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2513" contextRef="From2020-10-01to2021-09-30" name="cvm:ModificationOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,387</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2514" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,990</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2515" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2516" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,919</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2517" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2518" contextRef="From2020-10-01to2021-09-30" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,099</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2519" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">75,885</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2520" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">759</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2521" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,194,945</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2522" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2523" contextRef="From2020-10-01to2021-09-30" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,195,704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2524" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">2,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2525" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2526" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,685,066</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2527" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2528" contextRef="From2020-10-01to2021-09-30" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,685,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Option exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2529" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">149,788</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2530" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,498</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2531" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,730</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2532" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2533" contextRef="From2020-10-01to2021-09-30" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,228</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Purchase of stock by officers and directors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2534" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">27,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2535" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2536" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,725</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2537" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2538" contextRef="From2020-10-01to2021-09-30" name="cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2539" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2540" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">274,535</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2541" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2542" contextRef="From2020-10-01to2021-09-30" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">274,535</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2543" contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2544" contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2545" contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,361,109</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2546" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,361,109</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2547" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,207,183</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2548" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,072</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2549" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,298,566</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2550" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">418,196,412</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2551" contextRef="AsOf2021-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,534,226</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="cf">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF CASH FLOWS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2021 AND 2020</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2335" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,361,109</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2336" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,255,244</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2338" contextRef="From2020-10-01to2021-09-30" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,231,108</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2339" contextRef="From2019-10-01to2020-09-30" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,159,729</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Share-based payments for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2340" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,226,690</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2341" contextRef="From2019-10-01to2020-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">862,796</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Equity based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2342" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,685,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2343" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,112,968</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Common stock contributed to 401(k) plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2344" contextRef="From2020-10-01to2021-09-30" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,099</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2345" contextRef="From2019-10-01to2020-09-30" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,340</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Shares issued for settlement of clinical research costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2346" contextRef="From2020-10-01to2021-09-30" name="cvm:SharesIssuedForSettlementOfClinicalResearchCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2347" contextRef="From2019-10-01to2020-09-30" name="cvm:SharesIssuedForSettlementOfClinicalResearchCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,769,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Gain on short-term investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2348" contextRef="From2020-10-01to2021-09-30" name="cvm:ShortTermInvestment" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">5,621</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2349" contextRef="From2019-10-01to2020-09-30" name="cvm:ShortTermInvestment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Loss on derivative instruments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2350" contextRef="From2020-10-01to2021-09-30" name="cvm:LossOnDerivativesInstruments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">694,858</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2351" contextRef="From2019-10-01to2020-09-30" name="cvm:LossOnDerivativesInstruments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,078</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Warrant inducement expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2352" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2353" contextRef="From2019-10-01to2020-09-30" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2354" contextRef="From2020-10-01to2021-09-30" name="cvm:ModificationOfWarrant" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,387</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2355" contextRef="From2019-10-01to2020-09-30" name="cvm:ModificationOfWarrant" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,554</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">(Increase)/decrease in assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Receivables</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2357" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2358" contextRef="From2019-10-01to2020-09-30" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,843</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Prepaid expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2359" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">283,964</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2360" contextRef="From2019-10-01to2020-09-30" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">623,608</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2361" contextRef="From2020-10-01to2021-09-30" name="cvm:SuppliesUsedForRDAndManufacturing" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,186,532</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2362" contextRef="From2019-10-01to2020-09-30" name="cvm:SuppliesUsedForRDAndManufacturing" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">37,689</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2363" contextRef="From2020-10-01to2021-09-30" name="cvm:ShortTermDeposits" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">240,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2364" contextRef="From2019-10-01to2020-09-30" name="cvm:ShortTermDeposits" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Increase/(decrease) in liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2366" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,981</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2367" contextRef="From2019-10-01to2020-09-30" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">766,073</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2368" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,701</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2369" contextRef="From2019-10-01to2020-09-30" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">406,083</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2370" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">182,029</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2371" contextRef="From2019-10-01to2020-09-30" name="us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">261,420</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2372" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,441</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2373" contextRef="From2019-10-01to2020-09-30" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,229</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:32pt">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2374" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">18,787,016</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2375" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,276,161</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net purchases of U.S. Treasury Bills</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2377" contextRef="From2020-10-01to2021-09-30" name="cvm:NetPurchasesOfUSTreasuryBills" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,145,764</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2378" contextRef="From2019-10-01to2020-09-30" name="cvm:NetPurchasesOfUSTreasuryBills" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2379" contextRef="From2020-10-01to2021-09-30" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,016,329</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2380" contextRef="From2019-10-01to2020-09-30" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,654,906</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Expenditures for patent costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2381" contextRef="From2020-10-01to2021-09-30" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,641</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2382" contextRef="From2019-10-01to2020-09-30" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,975</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:32pt">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2383" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,184,734</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2384" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,694,881</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2386" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,363,426</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2387" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,992,439</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of stock issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2388" contextRef="From2020-10-01to2021-09-30" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">325,034</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2389" contextRef="From2019-10-01to2020-09-30" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">752,804</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2390" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,984,215</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2391" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,072,465</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="MARGIN: 0px 0px 0px 15px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from exercises of options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2392" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,228</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2393" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,328</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from the purchase of stock by officers and directors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2394" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2395" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,990</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from landlord funding of leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2396" contextRef="From2020-10-01to2021-09-30" name="cvm:ProceedsFromLandlordFundingOfLeaseholdImprovements" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,613,546</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2397" contextRef="From2019-10-01to2020-09-30" name="cvm:ProceedsFromLandlordFundingOfLeaseholdImprovements" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments on obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2398" contextRef="From2020-10-01to2021-09-30" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,079,392</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2399" contextRef="From2019-10-01to2020-09-30" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,241</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:32pt">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2400" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,522,989</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2401" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,035,177</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET INCREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2402" contextRef="From2020-10-01to2021-09-30" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,551,239</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2403" contextRef="From2019-10-01to2020-09-30" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,064,135</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2404" contextRef="AsOf2020-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,508,909</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2405" contextRef="AsOf2019-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,444,774</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, END OF YEAR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2406" contextRef="AsOf2021-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,060,148</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2407" contextRef="AsOf2020-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,508,909</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF CASH FLOWS</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2021 AND 2020</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="4" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment included in accrued expenses and accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2409" contextRef="From2020-10-01to2021-09-30" name="cvm:PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">435,412</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2418" contextRef="From2019-10-01to2020-09-30" name="cvm:PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,184,723</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalizable patent costs included in accrued expenses and accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2410" contextRef="From2020-10-01to2021-09-30" name="cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,510</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2419" contextRef="From2019-10-01to2020-09-30" name="cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Changes to right of use assets and liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2411" contextRef="From2020-10-01to2021-09-30" name="cvm:ChangesToRightOfUseAssetsAndLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">551,444</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2420" contextRef="From2019-10-01to2020-09-30" name="cvm:ChangesToRightOfUseAssetsAndLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,032</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease obligation included in accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2412" contextRef="From2020-10-01to2021-09-30" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">855</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2421" contextRef="From2019-10-01to2020-09-30" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">790</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid consulting services paid with issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2413" contextRef="From2020-10-01to2021-09-30" name="cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,911</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2422" contextRef="From2019-10-01to2020-09-30" name="cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,871</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of warrants liabilities on date of exercise</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2414" contextRef="From2020-10-01to2021-09-30" name="cvm:FairValueOfWarrantsLiabilitiesOnDateOfExercise" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,023,091</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2423" contextRef="From2019-10-01to2020-09-30" name="cvm:FairValueOfWarrantsLiabilitiesOnDateOfExercise" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,071,775</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Financing costs included in accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2415" contextRef="From2020-10-01to2021-09-30" name="cvm:FinancingCostsIncludedInAccountsPayable" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2424" contextRef="From2019-10-01to2020-09-30" name="cvm:FinancingCostsIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,499</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued consulting services to be paid with common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2416" contextRef="From2020-10-01to2021-09-30" name="cvm:AccruedConsultingServicesToBePaidWithCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2425" contextRef="From2019-10-01to2020-09-30" name="cvm:AccruedConsultingServicesToBePaidWithCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2417" contextRef="From2020-10-01to2021-09-30" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,173,702</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2426" contextRef="From2019-10-01to2020-09-30" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,155,026</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong><span class="atag" style="display: inline" id="nots">CEL-SCI CORPORATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>NOTES TO FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_2284" contextRef="From2020-10-01to2021-09-30" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. </strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ORGANIZATION</strong><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has recently&#160;announced top line&#160;Phase 3 data for its lead investigational therapy, Multikine&#174; (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI is investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><ix:nonNumeric id="fid_2285" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NatureOfOperations" escape="true" continuedAt="cont_234539"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font76426394-2f38-4e90-98a8-d495869e96f0" style="font-family:symbol"><strong>2</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>OPERATIONS AND FINANCING</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine&#174; (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Liquidity</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similarly to the way it has substantially funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Primarily as a result of CEL-SCI's losses incurred to date, CEL-SCI's expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI's ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that because there is more than enough cash on hand to meet the Company's budgeted cash requirements, the substantial doubt about the Company's ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_234539"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Impact of COVID-19 Pandemic</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In response to the global outbreak of COVID-19 and the World Health Organization&#8217;s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention&#8217;s (&#8220;CDC&#8221;) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company&#8217;s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><ix:nonNumeric id="fid_2286" contextRef="From2020-10-01to2021-09-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_5b1e2e"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font6d9af7c4-49e2-4b76-a099-aabe7e6ed090" style="font-family:symbol"><strong>3</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_2283" contextRef="From2020-10-01to2021-09-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_2311" contextRef="From2020-10-01to2021-09-30" name="cvm:USTreasuryBills" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>U.S. Treasury Bills &#8211; </em>U.S. Treasury Bills (&#8220;T-bills&#8221;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing</em> &#8211; Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_2299" contextRef="From2020-10-01to2021-09-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_2300" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (<ix:nonNumeric id="fid_371" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear">17</ix:nonNumeric> years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_2301" contextRef="From2020-10-01to2021-09-30" name="cvm:LeasesPolicyTextBlock" escape="true" continuedAt="cont_135587"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Leases &#8211;</em> On October 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, <em>Leases </em>and its related amendments (collectively referred to as Topic 842 and codified as &#8220;ASC 842&#8221;). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company&#8217;s statements of operations or cash flows.</p></ix:nonNumeric></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_5b1e2e" continuedAt="cont_f00fe8"><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><ix:continuation id="cont_135587">The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as&#160;leases with initial terms of 12 months or less,&#160;are not reflected on the balance sheet. Lease expense for such short-term leases is not material. </ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2302" contextRef="From2020-10-01to2021-09-30" name="us-gaap:DerivativesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Derivative Instruments</em> &#8211; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, &#8220;<em>Accounting for Derivative Instruments and Hedging Activities</em>.&#8221; In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the FASB issued ASU No. 2020-06 (&#8220;ASU 2020-06&#8221;) <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity.</em> The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2303" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true" continuedAt="cont_9a20be"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation</em> &#8211; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 &#8220;<em>Compensation &#8211; Stock Compensation</em>.&#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, <em>Compensation &#8212; Stock Compensation (Topic 718</em>), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.</p></ix:nonNumeric></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_f00fe8" continuedAt="cont_c27ce0"><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><ix:continuation id="cont_9a20be"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2304" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2305" contextRef="From2020-10-01to2021-09-30" name="cvm:GrantIncomePolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Grant Income</em> &#8211; The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2306" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2307" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FairValueConcentrationOfRiskTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $<ix:nonFraction id="fid_375" contextRef="AsOf2021-09-30" name="us-gaap:CashFDICInsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction> at September 30, 2021. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2308" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="cont_1bc10d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.</p></ix:nonNumeric></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_c27ce0"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_1bc10d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, the FASB issued ASU No. 2019-12, <em>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</em>. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.</p></ix:continuation></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_2309" contextRef="From2020-10-01to2021-09-30" name="us-gaap:UseOfEstimates" escape="true"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets,&#160;right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the&#160;lease assets and liabilities to be significant.</ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>New Accounting Pronouncements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_2310" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</p></ix:nonNumeric></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160;&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><ix:nonNumeric id="fid_2287" contextRef="From2020-10-01to2021-09-30" name="cvm:WarrantsAndNonEmployeeOptionstextblock" escape="true" continuedAt="cont_ecc866"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. </strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2021: </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><ix:nonNumeric id="fid_2313" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock" escape="true" continuedAt="cont_e136c0"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Warrant/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/ Options</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1424" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNMember" name="cvm:Issuedate2">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1481" contextRef="AsOf2021-09-30_cvm_SeriesNMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1536" contextRef="AsOf2021-09-30_cvm_SeriesNMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1592" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNMember" name="cvm:ExpirationDate1">8/18/2022</ix:nonNumeric> </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1471" contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember" name="cvm:Issuedate2">6/11/2018</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1529" contextRef="AsOf2021-09-30_cvm_SeriesUUMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1583" contextRef="AsOf2021-09-30_cvm_SeriesUUMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1639" contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUMember" name="cvm:ExpirationDate1">6/30/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1427" contextRef="From2020-10-01to2021-09-30_cvm_SeriesXMember" name="cvm:Issuedate2">1/13/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1484" contextRef="AsOf2021-09-30_cvm_SeriesXMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">120,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1539" contextRef="AsOf2021-09-30_cvm_SeriesXMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">9.25</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1595" contextRef="From2020-10-01to2021-09-30_cvm_SeriesXMember" name="cvm:ExpirationDate1">7/13/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1428" contextRef="From2020-10-01to2021-09-30_cvm_SeriesYMember" name="cvm:Issuedate2">2/15/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1485" contextRef="AsOf2021-09-30_cvm_SeriesYMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1540" contextRef="AsOf2021-09-30_cvm_SeriesYMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1596" contextRef="From2020-10-01to2021-09-30_cvm_SeriesYMember" name="cvm:ExpirationDate1">8/15/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1431" contextRef="From2020-10-01to2021-09-30_cvm_SeriesZMember" name="cvm:Issuedate2">5/23/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1488" contextRef="AsOf2021-09-30_cvm_SeriesZMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">184,800</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1543" contextRef="AsOf2021-09-30_cvm_SeriesZMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1599" contextRef="From2020-10-01to2021-09-30_cvm_SeriesZMember" name="cvm:ExpirationDate1">11/23/2021</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1433" contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember" name="cvm:Issuedate2">12/8/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1490" contextRef="AsOf2021-09-30_cvm_SeriesCCMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,845</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1545" contextRef="AsOf2021-09-30_cvm_SeriesCCMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1601" contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember" name="cvm:ExpirationDate1">12/8/2021</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1434" contextRef="From2020-10-01to2021-09-30_cvm_SeriesHHMember" name="cvm:Issuedate2">2/23/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1491" contextRef="AsOf2021-09-30_cvm_SeriesHHMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1546" contextRef="AsOf2021-09-30_cvm_SeriesHHMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">3.13</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1602" contextRef="From2020-10-01to2021-09-30_cvm_SeriesHHMember" name="cvm:ExpirationDate1">2/16/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1435" contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember" name="cvm:Issuedate2">8/26/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1492" contextRef="AsOf2021-09-30_cvm_SeriesAAMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1547" contextRef="AsOf2021-09-30_cvm_SeriesAAMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1603" contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember" name="cvm:ExpirationDate1">2/22/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1438" contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember" name="cvm:Issuedate2">6/22/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1495" contextRef="AsOf2021-09-30_cvm_SeriesMMMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">333,432</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1550" contextRef="AsOf2021-09-30_cvm_SeriesMMMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1606" contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember" name="cvm:ExpirationDate1">6/22/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1439" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember" name="cvm:Issuedate2">7/24/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1496" contextRef="AsOf2021-09-30_cvm_SeriesNNMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">210,087</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1551" contextRef="AsOf2021-09-30_cvm_SeriesNNMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1607" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember" name="cvm:ExpirationDate1">7/24/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1472" contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember" name="cvm:Issuedate2">10/30/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1525" contextRef="AsOf2021-09-30_cvm_SeriesRRMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">251,761</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1579" contextRef="AsOf2021-09-30_cvm_SeriesRRMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1635" contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember" name="cvm:ExpirationDate1">10/30/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1473" contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember" name="cvm:Issuedate2">12/19/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1526" contextRef="AsOf2021-09-30_cvm_SeriesSSMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1580" contextRef="AsOf2021-09-30_cvm_SeriesSSMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1636" contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember" name="cvm:ExpirationDate1">12/18/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1474" contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember" name="cvm:Issuedate2">2/5/2018</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1527" contextRef="AsOf2021-09-30_cvm_SeriesTTMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">600</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1581" contextRef="AsOf2021-09-30_cvm_SeriesTTMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1637" contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember" name="cvm:ExpirationDate1">2/5/2023</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:center;"><ix:nonNumeric id="fid_1441" contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember" name="cvm:Issuedate2">7/28/2017</ix:nonNumeric> &#8211; 11/18/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1498" contextRef="AsOf2021-09-30_cvm_ConsultantsMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><ix:nonFraction id="fid_1553" contextRef="AsOf2021-09-30_cvm_ConsultantsMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction> - $11.61</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;">11/17/2022 - <ix:nonNumeric id="fid_1609" contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember" name="cvm:ExpirationDate1">7/27/2027</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_ecc866" continuedAt="cont_fa026b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2020: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_e136c0"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Warrant</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1444" contextRef="From2019-10-01to2020-09-30_cvm_SeriesNMember" name="cvm:Issuedate2">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1501" contextRef="AsOf2020-09-30_cvm_SeriesNMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1556" contextRef="AsOf2020-09-30_cvm_SeriesNMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1612" contextRef="From2019-10-01to2020-09-30_cvm_SeriesNMember" name="cvm:ExpirationDate1">2/18/2021</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1470" contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUMember" name="cvm:Issuedate2">6/11/2018</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1535" contextRef="AsOf2020-09-30_cvm_SeriesUUMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1589" contextRef="AsOf2020-09-30_cvm_SeriesUUMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1640" contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember" name="cvm:ExpirationDate1">12/31/2020</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1446" contextRef="From2019-10-01to2020-09-30_cvm_SeriesWMember" name="cvm:Issuedate2">10/28/2015</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1504" contextRef="AsOf2020-09-30_cvm_SeriesWMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">688,930</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1559" contextRef="AsOf2020-09-30_cvm_SeriesWMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">16.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1615" contextRef="From2019-10-01to2020-09-30_cvm_SeriesWMember" name="cvm:ExpirationDate1">10/28/2020</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1447" contextRef="From2019-10-01to2020-09-30_cvm_SeriesXMember" name="cvm:Issuedate2">1/13/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1505" contextRef="AsOf2020-09-30_cvm_SeriesXMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">120,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1560" contextRef="AsOf2020-09-30_cvm_SeriesXMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">9.25</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1616" contextRef="From2019-10-01to2020-09-30_cvm_SeriesXMember" name="cvm:ExpirationDate1">1/13/2021</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1448" contextRef="From2019-10-01to2020-09-30_cvm_SeriesYMember" name="cvm:Issuedate2">2/15/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1506" contextRef="AsOf2020-09-30_cvm_SeriesYMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1561" contextRef="AsOf2020-09-30_cvm_SeriesYMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1617" contextRef="From2019-10-01to2020-09-30_cvm_SeriesYMember" name="cvm:ExpirationDate1">2/15/2021</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1449" contextRef="From2019-10-01to2020-09-30_cvm_SeriesZZMember" name="cvm:Issuedate2">5/23/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1507" contextRef="AsOf2020-09-30_cvm_SeriesZZMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1562" contextRef="AsOf2020-09-30_cvm_SeriesZZMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1618" contextRef="From2019-10-01to2020-09-30_cvm_SeriesZZMember" name="cvm:ExpirationDate1">5/18/2021</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1450" contextRef="From2019-10-01to2020-09-30_cvm_SeriesBBMember" name="cvm:Issuedate2">8/26/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1508" contextRef="AsOf2020-09-30_cvm_SeriesBBMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">16,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1563" contextRef="AsOf2020-09-30_cvm_SeriesBBMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1619" contextRef="From2019-10-01to2020-09-30_cvm_SeriesBBMember" name="cvm:ExpirationDate1">8/22/2021</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1451" contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember" name="cvm:Issuedate2">5/23/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1509" contextRef="AsOf2020-09-30_cvm_SeriesZMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">264,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1564" contextRef="AsOf2020-09-30_cvm_SeriesZMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1620" contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember" name="cvm:ExpirationDate1">11/23/2021</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1453" contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember" name="cvm:Issuedate2">12/8/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1511" contextRef="AsOf2020-09-30_cvm_SeriesCCMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">148,643</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1566" contextRef="AsOf2020-09-30_cvm_SeriesCCMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1622" contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember" name="cvm:ExpirationDate1">12/8/2021</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1454" contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember" name="cvm:Issuedate2">2/23/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1512" contextRef="AsOf2020-09-30_cvm_SeriesHHMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1567" contextRef="AsOf2020-09-30_cvm_SeriesHHMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">3.13</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1623" contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember" name="cvm:ExpirationDate1">2/16/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1455" contextRef="From2019-10-01to2020-09-30_cvm_SeriesAAMember" name="cvm:Issuedate2">8/26/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1513" contextRef="AsOf2020-09-30_cvm_SeriesAAMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1568" contextRef="AsOf2020-09-30_cvm_SeriesAAMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1624" contextRef="From2019-10-01to2020-09-30_cvm_SeriesAAMember" name="cvm:ExpirationDate1">2/22/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1458" contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember" name="cvm:Issuedate2">6/22/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1516" contextRef="AsOf2020-09-30_cvm_SeriesMMMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">797,633</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1571" contextRef="AsOf2020-09-30_cvm_SeriesMMMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1627" contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember" name="cvm:ExpirationDate1">6/22/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1459" contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember" name="cvm:Issuedate2">7/24/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1517" contextRef="AsOf2020-09-30_cvm_SeriesNNMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">348,842</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1572" contextRef="AsOf2020-09-30_cvm_SeriesNNMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1628" contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember" name="cvm:ExpirationDate1">7/24/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1466" contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember" name="cvm:Issuedate2">10/30/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1530" contextRef="AsOf2020-09-30_cvm_SeriesRRMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">417,649</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1584" contextRef="AsOf2020-09-30_cvm_SeriesRRMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1641" contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember" name="cvm:ExpirationDate1">10/30/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1467" contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember" name="cvm:Issuedate2">12/19/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1531" contextRef="AsOf2020-09-30_cvm_SeriesSSMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">326,064</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1585" contextRef="AsOf2020-09-30_cvm_SeriesSSMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1642" contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember" name="cvm:ExpirationDate1">12/18/2022</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1468" contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember" name="cvm:Issuedate2">2/5/2018</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1532" contextRef="AsOf2020-09-30_cvm_SeriesTTMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">371,564</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1586" contextRef="AsOf2020-09-30_cvm_SeriesTTMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1643" contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember" name="cvm:ExpirationDate1">2/5/2023</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1649" contextRef="From2019-10-01to2020-09-30_cvm_ConsultantsMember" name="cvm:Issuedate2">7/28/17</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1524" contextRef="AsOf2020-09-30_cvm_ConsultantsMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1650" contextRef="AsOf2020-09-30_cvm_ConsultantsMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1648" contextRef="From2019-10-01to2020-09-30_cvm_ConsultantsMember" name="cvm:ExpirationDate1">7/27/2027</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A. Warrant Liabilities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Warrant liabilities outstanding at September 30 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2316" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_607" contextRef="AsOf2021-09-30_cvm_SeriesWMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_606" contextRef="AsOf2020-09-30_cvm_SeriesWMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,570</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_608" contextRef="AsOf2021-09-30_cvm_SeriesZMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,787</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_609" contextRef="AsOf2020-09-30_cvm_SeriesZMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,207,902</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_611" contextRef="AsOf2021-09-30_cvm_SeriesZZMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_610" contextRef="AsOf2020-09-30_cvm_SeriesZZMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,044</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_612" contextRef="AsOf2021-09-30_cvm_SeriesAAMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,035</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_613" contextRef="AsOf2020-09-30_cvm_SeriesAAMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,082,212</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_615" contextRef="AsOf2021-09-30_cvm_SeriesBBMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_614" contextRef="AsOf2020-09-30_cvm_SeriesBBMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,173</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_616" contextRef="AsOf2021-09-30_cvm_SeriesCCMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,961</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_617" contextRef="AsOf2020-09-30_cvm_SeriesCCMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,259,712</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_620" contextRef="AsOf2021-09-30_cvm_SeriesHHMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,597</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_621" contextRef="AsOf2020-09-30_cvm_SeriesHHMember" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total warrant liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_628" contextRef="AsOf2021-09-30" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,380</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_627" contextRef="AsOf2020-09-30" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,765,613</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The (losses)/gains on the warrant liabilities for the years ended September 30 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2317" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series V Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_632" contextRef="From2020-10-01to2021-09-30_cvm_SeriesVMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_633" contextRef="From2019-10-01to2020-09-30_cvm_SeriesVMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,652</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_635" contextRef="From2020-10-01to2021-09-30_cvm_SeriesWMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,570</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_634" contextRef="From2019-10-01to2020-09-30_cvm_SeriesWMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,119,937</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_636" contextRef="From2020-10-01to2021-09-30_cvm_SeriesZMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">252,115</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_637" contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">98,357</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_639" contextRef="From2020-10-01to2021-09-30_cvm_SeriesZZMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">98,692</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_638" contextRef="From2019-10-01to2020-09-30_cvm_SeriesZZMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,594</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_640" contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">318,823</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_641" contextRef="From2019-10-01to2020-09-30_cvm_SeriesAAMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">165,304</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_643" contextRef="From2020-10-01to2021-09-30_cvm_SeriesBBMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,173</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_642" contextRef="From2019-10-01to2020-09-30_cvm_SeriesBBMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,207</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_644" contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">668,605</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_645" contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">875,040</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series FF warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_650" contextRef="From2020-10-01to2021-09-30_cvm_SeriesFFMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_651" contextRef="From2019-10-01to2020-09-30_cvm_SeriesFFMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">319,706</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_654" contextRef="From2020-10-01to2021-09-30_cvm_SeriesHHMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">404</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_655" contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">34,589</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series JJ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_658" contextRef="From2020-10-01to2021-09-30_cvm_SeriesJJMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_659" contextRef="From2019-10-01to2020-09-30_cvm_SeriesJJMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">64,992</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series LL warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_662" contextRef="From2020-10-01to2021-09-30_cvm_SeriesLLMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_663" contextRef="From2019-10-01to2020-09-30_cvm_SeriesLLMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">98,066</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss on warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_665" contextRef="From2020-10-01to2021-09-30" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">694,858</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_664" contextRef="From2019-10-01to2020-09-30" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">349,078</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:continuation id="cont_fa026b" continuedAt="cont_efcd5d"><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#8217;s stock because future equity offerings or sales of the Company&#8217;s stock are not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option on equity shares, and equity classification is therefore precluded.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Changes in Warrant Liabilities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 22, 2021, <ix:nonFraction id="fid_1694" contextRef="From2021-08-01to2021-08-22_cvm_SeriesBBMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">16,000</ix:nonFraction> Series BB warrants, with an exercise price of $<ix:nonFraction id="fid_1695" contextRef="From2021-08-01to2021-08-22_cvm_SeriesBBMember" name="cvm:WarrantExercise" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction> expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 28, 2020, <ix:nonFraction id="fid_1702" contextRef="From2020-10-01to2020-10-28_cvm_SeriesWMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">688,930</ix:nonFraction> Series W warrants, with an exercise price of $<ix:nonFraction id="fid_1703" contextRef="From2020-10-01to2020-10-28_cvm_SeriesWMember" name="cvm:WarrantExercise" decimals="INF" unitRef="USDPShares">16.75</ix:nonFraction> expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 26, 2020, the Company lowered the exercise price of <ix:nonFraction id="fid_1705" contextRef="From2020-05-01to2020-05-26_cvm_SeriesVWarrantsMember" name="cvm:WarrantsExercisedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">810,127</ix:nonFraction> Series V warrants from $<ix:nonFraction id="fid_707" contextRef="AsOf2020-05-26_srt_MaximumMember_cvm_SeriesVWarrantsMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" unitRef="USDPShares">19.75</ix:nonFraction> to $<ix:nonFraction id="fid_708" contextRef="AsOf2020-05-26_cvm_SeriesVWarrantsMember_srt_MinimumMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction> per share and <ix:nonNumeric id="fid_709" contextRef="From2020-05-01to2020-05-26_cvm_SeriesVWarrantsMember" name="cvm:ExpirationDateDescription">extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020</ix:nonNumeric>. The incremental cost of this modification was approximately $<ix:nonFraction id="fid_710" contextRef="From2020-10-01to2021-09-30" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">664,000</ix:nonFraction>, which was included in the net loss on derivatives for the year ended September 30, 2020. On June 25, 2020, <ix:nonFraction id="fid_1704" contextRef="From2020-06-01to2020-06-25_cvm_SeriesVWarrantsMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">135,963</ix:nonFraction> Series V warrants, with an exercise price of $<ix:nonFraction id="fid_1022" contextRef="From2020-06-01to2020-06-25_cvm_SeriesVWarrantsMember" name="cvm:WarrantExercise" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction> expired. The warrants were valued at approximately $<ix:nonFraction id="fid_713" contextRef="From2020-06-01to2020-06-25_cvm_SeriesVWarrantsMember" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,000</ix:nonFraction> on the date of expiration.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Exercise of Warrant Liabilities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following warrants recorded as liabilities were exercised during the year ended September 30, 2021:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_2315" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" escape="true" continuedAt="cont_34822c"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1668" contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1670" contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,089,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series ZZ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1680" contextRef="From2020-10-01to2021-09-30_cvm_SeriesZZMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1682" contextRef="From2020-10-01to2021-09-30_cvm_SeriesZZMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1681" contextRef="From2020-10-01to2021-09-30_cvm_SeriesZZMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1684" contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1685" contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1683" contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,375,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_672" contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">132,798</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_671" contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_670" contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">663,990</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_706" contextRef="From2020-10-01to2021-09-30" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">331,998</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_705" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,402,990</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The following warrants recorded as liabilities were exercised during the year ended September 30, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_34822c"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series V</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_666" contextRef="From2019-10-01to2020-09-30_cvm_SeriesVMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">674,164</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_667" contextRef="From2019-10-01to2020-09-30_cvm_SeriesVMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_668" contextRef="From2019-10-01to2020-09-30_cvm_SeriesVMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,269,755</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_673" contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">128,820</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_674" contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_669" contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">644,100</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series FF</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1678" contextRef="From2020-10-01to2021-09-30_cvm_SeriesFFMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">68,048</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1677" contextRef="From2020-10-01to2021-09-30_cvm_SeriesFFMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">3.91</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1679" contextRef="From2020-10-01to2021-09-30_cvm_SeriesFFMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,812</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_680" contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_679" contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">3.13</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_703" contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series JJ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_687" contextRef="From2019-10-01to2020-09-30_cvm_SeriesJJMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,450</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_688" contextRef="From2019-10-01to2020-09-30_cvm_SeriesJJMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">3.13</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_689" contextRef="From2019-10-01to2020-09-30_cvm_SeriesJJMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,531</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series LL</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_692" contextRef="From2019-10-01to2020-09-30_cvm_SeriesLLMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,398</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_691" contextRef="From2019-10-01to2020-09-30_cvm_SeriesLLMember" name="cvm:ExercisePriceWarrants" decimals="INF" unitRef="USDPShares">3.59</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_690" contextRef="From2019-10-01to2020-09-30_cvm_SeriesLLMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,867</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_704" contextRef="From2019-10-01to2020-09-30" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">913,180</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_678" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,323,752</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_efcd5d" continuedAt="cont_abb25c"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>B. </strong></p></td><td style="vertical-align:top;"><strong>Equity Warrants</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Changes in Equity Warrants</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration dates of the Series N, Series X, Series Y and Series UU warrants were extended six months. On June 28, 2021, the expiration dates of these same warrants were extended one year. The incremental costs of both warrant extensions were recorded consistent with the accounting for the initial warrant issuances. The incremental costs of the Series N and Series X warrant extensions were recorded as a deemed dividend and totaled approximately $<ix:nonFraction id="fid_1713" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNAndXMember" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,000</ix:nonFraction> for the year ended September 30, 2021. The Series N and Series X warrants are held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary. The incremental cost of the Series Y warrants&#160;extension approximated $103,000 and had no impact on&#160;the financial statements for the year ended September 30,2021&#160;due to offsetting entries recorded within additional paid in capital. The incremental cost of the Series UU warrant extension was recorded as interest expense, because these warrants were initially issued as an inducement to convert notes payable into common stock, and totaled approximately $<ix:nonFraction id="fid_727" contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUWarrantsMember" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction> for the year ended September 30, 2021. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 26, 2020, the Company provided that for each Series V liability warrant exercised on or before June 10, 2020, the former holder of the Series V warrant received one Series XX warrant. Each Series XX warrant allowed the holder to purchase one share of the Company's common stock at a price of $<ix:nonFraction id="fid_721" contextRef="AsOf2020-09-30_cvm_SeriesXXWarrantsMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" unitRef="USDPShares">18.00</ix:nonFraction> per share at any time on or before September 10, 2020. For each Series V liability warrant exercised after June 10, 2020 but on or before June 25, 2020, the former holder of the Series V warrant received one Series YY warrant. Every two Series YY warrants allowed the holder to purchase one share of the Company's common stock at a price of $<ix:nonFraction id="fid_1714" contextRef="AsOf2020-09-30_cvm_SeriesYYWarrantsMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction> per share at any time on or before September 25, 2020. In June 2020, 461,953 Series XX warrants and <ix:nonFraction id="fid_1739" contextRef="From2020-06-01to2020-06-20_cvm_SeriesYYWarrantsMember" name="cvm:WarrantsIssuedDuringPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">101,839</ix:nonFraction> Series YY warrants were issued to the former holders of the Series V warrants. The Series XX and YY warrants qualified for equity treatment in accordance with ASC 815. The Company recognized a warrant inducement expense equal to the fair value of the Series XX and Series YY warrants issued as of the date the inducement offers were accepted. The fair values of the Series XX and Series YY warrants were calculated to be approximately $<ix:nonFraction id="fid_1720" contextRef="From2020-06-01to2020-06-20_cvm_SeriesXXWarrantsMember" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629,000</ix:nonFraction> and $<ix:nonFraction id="fid_1721" contextRef="From2020-06-01to2020-06-20_cvm_SeriesYYWarrantsMember" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177,000</ix:nonFraction>, respectively. The total expense of approximately $<ix:nonFraction id="fid_1722" contextRef="From2019-10-01to2020-09-30" name="cvm:WarrantInducementExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">806,000</ix:nonFraction> is reported as warrant inducement expense in the statement of operations for the year ended September 30, 2020. All Series XX and YY warrants expired in September 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 8, 2020, the expiration dates of <ix:nonFraction id="fid_1741" contextRef="From2020-05-01to2020-05-08_cvm_SeriesUUWarrantsMember" name="cvm:WarrantsIssuedDuringPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,593</ix:nonFraction> Series UU warrants were <ix:nonNumeric id="fid_726" contextRef="From2020-05-01to2020-05-08_cvm_SeriesUUWarrantsMember" name="cvm:ExpirationDateDescription">extended from June 11, 2020 to December 31, 2020</ix:nonNumeric>. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_1723" contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUWarrantsMember" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction> and was recorded as interest expense during the year ended September 30, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2020, <ix:nonNumeric id="fid_728" contextRef="From2020-01-01to2020-01-23_cvm_SeriesNWarrantsMember" name="cvm:ExpirationDateDescription">the expiration date of the Series N warrants was extended to February 18, 2021</ix:nonNumeric>. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_729" contextRef="From2020-01-01to2020-01-23_cvm_SeriesNWarrantsMember" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction>, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:continuation id="cont_abb25c"><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Exercise of Equity Warrants </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following equity warrants were exercised during the year ended September 30, 2021.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_2314" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock" escape="true" continuedAt="cont_ce3006"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1687" contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,201</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1688" contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1686" contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">863,414</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_748" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">138,755</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_749" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_750" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,663</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_760" contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">165,888</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_761" contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_762" contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,715</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_765" contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">126,064</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_764" contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_763" contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,474</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_772" contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">370,964</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_773" contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_774" contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">830,959</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_793" contextRef="From2020-10-01to2021-09-30" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,265,872</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_794" contextRef="From2020-10-01to2021-09-30" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,581,225</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The following equity warrants were exercised during the year ended September 30, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_ce3006"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_742" contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">95,858</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_743" contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_744" contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_747" contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">124,956</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_746" contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_745" contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,889</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series OO</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_754" contextRef="From2019-10-01to2020-09-30_cvm_SeriesOOMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_755" contextRef="From2019-10-01to2020-09-30_cvm_SeriesOOMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_756" contextRef="From2019-10-01to2020-09-30_cvm_SeriesOOMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_759" contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">39,467</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_758" contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_757" contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,121</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_766" contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">156,580</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_767" contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_768" contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">327,252</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_771" contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">188,125</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_770" contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_769" contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">421,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_778" contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">61,207</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_779" contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_780" contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,380</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series VV</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_783" contextRef="From2019-10-01to2020-09-30_cvm_SeriesVVMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">82,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_782" contextRef="From2019-10-01to2020-09-30_cvm_SeriesVVMember" name="cvm:EquityWarrantsExercisePrice" decimals="INF" unitRef="USDPShares">1.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_781" contextRef="From2019-10-01to2020-09-30_cvm_SeriesVVMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,375</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_791" contextRef="From2019-10-01to2020-09-30" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">798,693</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_792" contextRef="From2019-10-01to2020-09-30" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,748,713</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>C. </strong></p></td><td style="vertical-align:top;"><strong>Options and Shares Issued to Consultants</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2021 and 2020 the Company issued <ix:nonFraction id="fid_730" contextRef="From2020-10-01to2021-09-30" name="cvm:CommonStockIssuedForServiceShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">75,885</ix:nonFraction> and <ix:nonFraction id="fid_1724" contextRef="From2019-10-01to2020-09-30" name="cvm:CommonStockIssuedForServiceShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">79,950</ix:nonFraction> shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $<ix:nonFraction id="fid_1730" contextRef="AsOf2021-09-30_cvm_ConsultantsMember" name="us-gaap:SharePrice" decimals="INF" unitRef="USDPShares">6.86</ix:nonFraction> to $<ix:nonFraction id="fid_1731" contextRef="AsOf2020-09-30_cvm_ConsultantsMember" name="us-gaap:SharePrice" decimals="INF" unitRef="USDPShares">24.95</ix:nonFraction> per share. The weighted average grant price was $<ix:nonFraction id="fid_733" contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_srt_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" decimals="INF" unitRef="USDPShares">15.46</ix:nonFraction> and $<ix:nonFraction id="fid_1729" contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_srt_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" decimals="INF" unitRef="USDPShares">12.01</ix:nonFraction>, respectively, for stock issued during the years ended September 30, 2021 and 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the years ended September 30, 2021 and 2020, the Company recorded total expense of approximately $<ix:nonFraction id="fid_735" contextRef="From2020-10-01to2021-09-30_cvm_ConsultingAgreementsMember" name="us-gaap:CostsAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,000</ix:nonFraction> and $<ix:nonFraction id="fid_1725" contextRef="From2019-10-01to2020-09-30_cvm_ConsultingAgreementsMember" name="us-gaap:CostsAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">863,000</ix:nonFraction>, respectively, relating to these consulting agreements. At September 30, 2021 and 2020, costs of approximately $<ix:nonFraction id="fid_1727" contextRef="AsOf2021-09-30_cvm_ConsultingAgreementsMember" name="cvm:PrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,000</ix:nonFraction> and $<ix:nonFraction id="fid_736" contextRef="AsOf2020-09-30_cvm_ConsultingAgreementsMember" name="cvm:PrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">395,000</ix:nonFraction>, respectively, are included in prepaid expenses.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2021, the Company issued <ix:nonFraction id="fid_739" contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember" name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000</ix:nonFraction> options to a consultant to purchase common stock with an exercise price of $11.61 and an expiration of <ix:nonNumeric id="fid_1728" contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember" name="cvm:OptionExpirationDate" format="ixt:datemonthdayyearen">November 17, 2022</ix:nonNumeric>. No options were issued to consultants during the year ended September 30, 2020. As of September 30, 2021, <ix:nonFraction id="fid_740" contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember" name="cvm:OptionIssuedToRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction> options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option plan and are fully vested.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_2288" contextRef="From2020-10-01to2021-09-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true" continuedAt="cont_c5723b"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; &#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5. </strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PROPERTY AND</strong><strong> EQUIPMENT</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment consisted of the following at September 30:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></ix:nonNumeric><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:continuation id="cont_c5723b"><ix:nonNumeric id="fid_2318" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_797" contextRef="AsOf2021-09-30" name="us-gaap:FixturesAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,211,124</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_798" contextRef="AsOf2020-09-30" name="us-gaap:FixturesAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,898,242</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_800" contextRef="AsOf2021-09-30" name="us-gaap:FurnitureAndFixturesGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,768</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_799" contextRef="AsOf2020-09-30" name="us-gaap:FurnitureAndFixturesGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,768</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,465,123</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_802" contextRef="AsOf2020-09-30" name="us-gaap:LeaseholdImprovementsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,519,161</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_804" contextRef="AsOf2021-09-30" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,776,015</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_803" contextRef="AsOf2020-09-30" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,517,171</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_805" contextRef="AsOf2021-09-30" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,112,453</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_806" contextRef="AsOf2020-09-30" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,673,178</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_808" contextRef="AsOf2021-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,663,562</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_807" contextRef="AsOf2020-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,843,993</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">Depreciation expense for the years ended September 30, 2021 and 2020 totaled approximately $<ix:nonFraction id="fid_1732" contextRef="From2020-10-01to2021-09-30" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,000</ix:nonFraction> and $<ix:nonFraction id="fid_1422" contextRef="From2019-10-01to2020-09-30" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,000</ix:nonFraction> respectively.</td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160; </p><ix:nonNumeric id="fid_2289" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font66386e05-b0ba-43df-a9f7-ebad16078e27" style="font-family:symbol"><strong>6</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><strong>PATENTS</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">Patents consist of the following at September 30:</td></tr></tbody></table><ix:nonNumeric id="fid_2319" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_822" contextRef="AsOf2021-09-30_us-gaap_PatentsMember" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">910,523</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_823" contextRef="AsOf2020-09-30_us-gaap_PatentsMember" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">896,372</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_818" contextRef="AsOf2021-09-30_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">634,657</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_819" contextRef="AsOf2020-09-30_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">582,950</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_821" contextRef="AsOf2021-09-30_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,866</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_820" contextRef="AsOf2020-09-30_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">313,422</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the years ended September 30, 2021 and 2020, there was no impairment of patent costs. Amortization expense for the years ended September 30, 2021 and 2020 totaled approximately $<ix:nonFraction id="fid_832" contextRef="From2020-10-01to2021-09-30" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction> and $<ix:nonFraction id="fid_831" contextRef="From2019-10-01to2020-09-30" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction>, respectively. The total estimated future amortization is as follows:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_2320" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years ending September 30, </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_824" contextRef="AsOf2021-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_825" contextRef="AsOf2021-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_826" contextRef="AsOf2021-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_827" contextRef="AsOf2021-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_828" contextRef="AsOf2021-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_829" contextRef="AsOf2021-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_830" contextRef="AsOf2021-09-30" name="cvm:Total" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160; </p><ix:nonNumeric id="fid_2290" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="cont_37f4d9"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:1%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font0df12115-a745-4aa7-8f47-83deaf9f47d1" style="font-family:symbol"><strong>7</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><strong>INCOME TAXES</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At September 30, 2021 and 2020, the Company had net deferred tax assets of $44.1 million and $35.5 million, respectively. Due to uncertainties surrounding the Company&#8217;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax asset will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income. Management has considered the history of the Company&#8217;s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;</p><ix:continuation id="cont_37f4d9" continuedAt="cont_63452e"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company&#8217;s net operating loss <ix:nonNumeric id="fid_1733" contextRef="From2020-10-01to2021-09-30_cvm_IncomeTaxMember" name="cvm:CumulativeChangeInOwnershipPercentage">(NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.</ix:nonNumeric> Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes for the year ended September 30, 2021 occurred and no such shifts were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company had federal NOL carryforwards of approximately $<ix:nonFraction id="fid_878" contextRef="AsOf2021-09-30_cvm_IncomeTaxMember" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">77.1</ix:nonFraction> million and $<ix:nonFraction id="fid_877" contextRef="AsOf2020-09-30_cvm_IncomeTaxMember" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">51.5</ix:nonFraction> million at September 30, 2021 and 2020, respectively. <ix:nonNumeric id="fid_880" contextRef="From2020-10-01to2021-09-30_cvm_IncomeTaxMember" name="us-gaap:TaxCreditCarryforwardDescription">Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards</ix:nonNumeric>, which were generated post Tax Cuts and Jobs Act, have an indefinite life. In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#8220;R&amp;D credit&#8221;) of approximately $<ix:nonFraction id="fid_881" contextRef="AsOf2020-09-30_cvm_IncomeTaxMember" name="cvm:ResearchAndDevelopmentCredit" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.2</ix:nonFraction> million at September 30, 2021 and 2020. <ix:nonNumeric id="fid_883" contextRef="From2020-10-01to2021-09-30_cvm_IncomeTaxMember" name="cvm:ResearchAndDevelopmentCreditDescription">The R&amp;D credit expires during the fiscal year ended 2029.</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Significant components of the Company&#8217;s deferred tax assets as of September 30, 2021 and 2020 are listed below:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_2321" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NOL carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_834" contextRef="AsOf2021-09-30" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,789,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_833" contextRef="AsOf2020-09-30" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,407,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_856" contextRef="AsOf2021-09-30" name="cvm:LeaseLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,101,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_857" contextRef="AsOf2020-09-30" name="cvm:LeaseLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,631,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">R&amp;D credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_835" contextRef="AsOf2021-09-30" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,221,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_836" contextRef="AsOf2020-09-30" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,221,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_838" contextRef="AsOf2021-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,785,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_837" contextRef="AsOf2020-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,297,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized R&amp;D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_839" contextRef="AsOf2021-09-30" name="cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,040,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_840" contextRef="AsOf2020-09-30" name="cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,853,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vacation and other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_842" contextRef="AsOf2021-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_841" contextRef="AsOf2020-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_843" contextRef="AsOf2021-09-30" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,062,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_844" contextRef="AsOf2020-09-30" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,534,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_858" contextRef="AsOf2021-09-30" name="cvm:RightOfUseAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,786,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_855" contextRef="AsOf2020-09-30" name="cvm:RightOfUseAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,911,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_846" contextRef="AsOf2021-09-30" name="cvm:FixedAssetsAndIntangibles" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">172,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_845" contextRef="AsOf2020-09-30" name="cvm:FixedAssetsAndIntangibles" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">169,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_847" contextRef="AsOf2021-09-30" name="us-gaap:DeferredTaxLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,958,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_848" contextRef="AsOf2020-09-30" name="us-gaap:DeferredTaxLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,080,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_850" contextRef="AsOf2021-09-30" name="cvm:NetDeferredTaxAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,104,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_849" contextRef="AsOf2020-09-30" name="cvm:NetDeferredTaxAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">35,454,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_851" contextRef="AsOf2021-09-30" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,104,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_852" contextRef="AsOf2020-09-30" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,454,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending Balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_854" contextRef="AsOf2021-09-30" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_853" contextRef="AsOf2020-09-30" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The Company has no federal or state current or deferred tax expense or benefit. The Company&#8217;s effective tax rate differs from the applicable federal statutory tax rate. The reconciliation of these rates is as follows at for the years ended September 30:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><ix:nonNumeric id="fid_2322" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Federal Rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_859" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_860" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">State rate change </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_861" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" decimals="INF" unitRef="Pure" sign="-" scale="-2">1.37</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_862" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" decimals="INF" unitRef="Pure" sign="-" scale="-2">1.40</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">State tax rate, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_864" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" decimals="INF" unitRef="Pure" scale="-2">4.72</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_863" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" decimals="INF" unitRef="Pure" scale="-2">5.15</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_865" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" decimals="INF" unitRef="Pure" sign="-" scale="-2">0.79</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_866" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" decimals="INF" unitRef="Pure" sign="-" scale="-2">3.24</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Permanent differences</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_868" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" decimals="INF" unitRef="Pure" scale="-2">0.23</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_867" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" decimals="INF" unitRef="Pure" scale="-2">0.42</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_869" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" sign="-" scale="-2">23.79</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_870" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" sign="-" scale="-2">21.93</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_872" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" decimals="INF" unitRef="Pure" scale="-2">0.00</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_871" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" decimals="INF" unitRef="Pure" scale="-2">0.00</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_63452e"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company applies the provisions of ASC 740, <em>&#8220;Accounting for Uncertainty in Income Taxes,&#8221;</em> which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained. The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense. The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2021. The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2018.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_2291" contextRef="From2020-10-01to2021-09-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="cont_fc646b"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fontc40a34ae-8897-44de-9460-8912f1bf5730" style="font-family:symbol"><strong>8</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><strong>STOCK COMPENSATION</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><ix:nonNumeric id="fid_2323" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 19.1pt; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_885" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,685,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_884" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,112,968</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_887" contextRef="From2020-10-01to2021-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,226,690</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_886" contextRef="From2019-10-01to2020-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">862,796</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">During the years ended September 30, 2021 and 2020 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_2324" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfFairValueOfEachOptionGrantedTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected stock price volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_889" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" decimals="INF" unitRef="Pure" scale="-2">90.42</ix:nonFraction> &#8211; <ix:nonFraction id="fid_891" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" decimals="INF" unitRef="Pure" scale="-2">97.22</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_888" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" decimals="INF" unitRef="Pure" scale="-2">87.36</ix:nonFraction> &#8211; <ix:nonFraction id="fid_890" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" decimals="INF" unitRef="Pure" scale="-2">90.26</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_893" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" decimals="INF" unitRef="Pure" scale="-2">0.85</ix:nonFraction> &#8211; <ix:nonFraction id="fid_895" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" decimals="INF" unitRef="Pure" scale="-2">1.65</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_892" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" decimals="INF" unitRef="Pure" scale="-2">0.62</ix:nonFraction> &#8211; <ix:nonFraction id="fid_894" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" decimals="INF" unitRef="Pure" scale="-2">1.87</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life of options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_897" contextRef="From2020-10-01to2021-09-30" name="cvm:ExpectedLifeOfOptionsMin1" format="ixt-sec:duryear">9.68</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_898" contextRef="From2019-10-01to2020-09-30" name="cvm:ExpectedLifeOfOptionsMax" format="ixt-sec:duryear">9.69</ix:nonNumeric> Years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_896" contextRef="From2019-10-01to2020-09-30" name="cvm:ExpectedLifeOfOptionsMin1" format="ixt-sec:duryear">9.68</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_899" contextRef="From2020-10-01to2021-09-30" name="cvm:ExpectedLifeOfOptionsMax" format="ixt-sec:duryear">9.69</ix:nonNumeric> Years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Non-Qualified Stock Option Plan</span><span style="text-decoration:underline">s</span> &#8211;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2021, the Company adopted the 2021 Non-Qualified Stock Option Plan, which provides for the issuance of up to <ix:nonFraction id="fid_1944" contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,800,000</ix:nonFraction> options to purchase shares of common stock. On May 14, 2021, the Company granted <ix:nonFraction id="fid_1945" contextRef="AsOf2021-05-14_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:PerformanceBasedStockOptionsSharesGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,800,000</ix:nonFraction> performance-based stock options from the 2021 Non-Qualified Stock Option Plan and <ix:nonFraction id="fid_1953" contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:PerformanceBasedStockOptionsSharesGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">72,000</ix:nonFraction> performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $<ix:nonFraction id="fid_1946" contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" decimals="INF" unitRef="USDPShares">20.61</ix:nonFraction> per share, the fair value on the date of issuance. The stock options will vest 100% upon the achievement of the following performance goals: (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $42.00. None of the options will be exercisable before May 13, 2022. All options which have not vested as of May 13, 2031, will be canceled and will no longer be exercisable. The options were recorded in permanent equity in accordance with ASC 718, Compensation &#8211; Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. That valuation resulted in a per share fair value of $<ix:nonFraction id="fid_1948" contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:FairValuePerShare" decimals="INF" unitRef="USDPShares">0.34</ix:nonFraction> and an aggregate value of approximately $636,000 on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was determined to be <ix:nonNumeric id="fid_1951" contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear">1.3</ix:nonNumeric> years. This resulted in compensation expense of approximately $<ix:nonFraction id="fid_1943" contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:RemainingCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,000</ix:nonFraction> recorded during the year ended September 30, 2021. The remaining $<ix:nonFraction id="fid_1954" contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:GrantDateFairValueRemaining" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,000</ix:nonFraction> will be expensed over the next <ix:nonNumeric id="fid_1952" contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:ExpenseLifeOverNext" format="ixt-sec:duryear">11</ix:nonNumeric> months.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:continuation id="cont_fc646b" continuedAt="cont_0b52ee"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2020, the Company adopted the 2020 Non-Qualified Stock Option Plan, which provides for the issuance of up to <ix:nonFraction id="fid_1955" contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,600,000</ix:nonFraction> options to purchase shares of common stock. On April 20, 2020, the Company granted <ix:nonFraction id="fid_1957" contextRef="AsOf2020-04-20_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:PerformanceBasedStockOptionsSharesGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,872,000</ix:nonFraction> performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $<ix:nonFraction id="fid_1958" contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" decimals="INF" unitRef="USDPShares">10.93</ix:nonFraction> per share, the fair value on the date of issuance. <ix:nonNumeric id="fid_1959" contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ConversionOfStockDescription">The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days.</ix:nonNumeric> Additionally, 100% of the options will vest when either (a) the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia is filed, i.e., the performance condition, or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. All options which have not vested as of April 19, 2030, will be canceled and will no longer be exercisable. The options were recorded as permanent equity in accordance with ASC 718, Compensation &#8211; Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. That valuation resulted in a per share fair value of $<ix:nonFraction id="fid_1960" contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:FairValuePerShare" decimals="INF" unitRef="USDPShares">4.21</ix:nonFraction> and an aggregate value of approximately $<ix:nonFraction id="fid_1961" contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:RemainingOutstandingFairValueOfShares" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">7.9</ix:nonFraction> million on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was originally determined to be <ix:nonNumeric id="fid_1962" contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear">1.7</ix:nonNumeric> years. In May 2021, it became probable that the performance condition would be met approximately 8 months later than originally estimated. Because the valuation and related requisite service period were based on achievement of the performance condition, the Company adjusted the requisite service period when it became probable that the marketing application would be filed within a different period. Compensation expense relating to this Plan was approximately $<ix:nonFraction id="fid_1942" contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">3.8</ix:nonFraction> million and $<ix:nonFraction id="fid_1965" contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.1</ix:nonFraction> million during the years ended September 30, 2021 and 2020, respectively. The remaining $<ix:nonFraction id="fid_1950" contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:GrantDateFairValueRemaining" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.0</ix:nonFraction> million will be expensed over the next <ix:nonNumeric id="fid_1964" contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:ExpenseLifeOverNext" format="ixt-sec:duryear">11</ix:nonNumeric> months.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At September 30, 2021, the Company has collectively authorized the issuance of <ix:nonFraction id="fid_1933" contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,787,200</ix:nonFraction> shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the plans. The Company&#8217;s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Option Plan</span><span style="text-decoration:underline">s</span> &#8211; At September 30, 2021, the Company had collectively authorized the issuance of <ix:nonFraction id="fid_1934" contextRef="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">138,400</ix:nonFraction> shares of common stock under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the Plans. Only the Company&#8217;s employees are eligible to be granted options under the Incentive Stock Option Plans.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Activity in the Company&#8217;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2021 is summarized as follows:</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_0b52ee" continuedAt="cont_5c5379"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Non-Qualified and Incentive Stock Option Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2325" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="14"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="14"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1046" contextRef="AsOf2019-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,218,216</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1052" contextRef="AsOf2019-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">5.54</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1066" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" format="ixt-sec:duryear">8.88</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1126" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="cvm:AggregateIntrinsicValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,562,594</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1083" contextRef="AsOf2019-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,392,241</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1089" contextRef="AsOf2019-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">9.15</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1095" contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" format="ixt-sec:duryear">7.68</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1122" contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember" name="cvm:AggregateIntrinsicValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,869,555</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1103" contextRef="AsOf2019-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptionsVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,014,501</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1108" contextRef="AsOf2019-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageExercisePriceVested" decimals="INF" unitRef="USDPShares">4.06</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1047" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,563,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1053" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">10.93</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1081" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="cvm:NumberOfOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">99,740</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1054" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">3.39</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1085" contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">99,740</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1091" contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">3.39</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1049" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">18,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1055" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">10.34</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1079" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="cvm:NumberOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,773</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1056" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="cvm:WeightedAverageExercisePriceExpired" decimals="INF" unitRef="USDPShares">132.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1087" contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,773</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1093" contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageExercisePriceExpired" decimals="INF" unitRef="USDPShares">132.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1039" contextRef="AsOf2020-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,653,703</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1057" contextRef="AsOf2020-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">7.01</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1119" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" format="ixt-sec:duryear">8.39</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1127" contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember" name="cvm:AggregateIntrinsicValueOutstandingEnding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,193,415</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1088" contextRef="AsOf2020-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,297,229</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1094" contextRef="AsOf2020-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">5.85</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1118" contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" format="ixt-sec:duryear">7.48</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1123" contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember" name="cvm:AggregateIntrinsicValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,090,662</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1104" contextRef="AsOf2020-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptionsVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,401,961</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1109" contextRef="AsOf2020-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageExercisePriceVested" decimals="INF" unitRef="USDPShares">6.26</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1040" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,605,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1060" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">20.58</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1082" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="cvm:NumberOfOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">149,788</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1061" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">4.98</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1101" contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">149,788</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1110" contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">4.98</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1042" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">49,832</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1062" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">9.56</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1080" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="cvm:NumberOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,374</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1063" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="cvm:WeightedAverageExercisePriceExpired" decimals="INF" unitRef="USDPShares">172.73</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1105" contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,374</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1111" contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageExercisePriceExpired" decimals="INF" unitRef="USDPShares">172.73</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1064" contextRef="AsOf2021-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,049,709</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1065" contextRef="AsOf2021-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">10.08</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1070" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" format="ixt-sec:duryear">7.93</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1129" contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember" name="cvm:AggregateIntrinsicValueOutstandingEnding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,843,283</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1106" contextRef="AsOf2021-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,540,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1112" contextRef="AsOf2021-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">5.77</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1115" contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" format="ixt-sec:duryear">6.96</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1125" contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember" name="cvm:AggregateIntrinsicValueOutstandingEnding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,589,598</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">______________</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;(a)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Includes 1,872,000 performance based options issued to officers and directors, 728,000 options issued to employees and 5,000 options issued to Consultants.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">A summary of the status of the Company&#8217;s non-vested options for the two years ended September 30, 2021 is presented below:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_2326" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfNonVestedOptionsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_990" contextRef="From2019-10-01to2020-09-30" name="cvm:NumberOfUnvestedOptionsBeginning" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,825,975</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1000" contextRef="From2019-10-01to2020-09-30" name="cvm:WeightedAverageGrantDateFairValueBeginning" decimals="INF" unitRef="USDPShares">3.79</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_992" contextRef="From2019-10-01to2020-09-30" name="cvm:VestedOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">2,014,501</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_994" contextRef="From2019-10-01to2020-09-30" name="cvm:GrantedOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,563,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_996" contextRef="From2019-10-01to2020-09-30" name="cvm:ForfeitedOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">18,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_998" contextRef="From2019-10-01to2020-09-30" name="cvm:NumberOfUnvestedOptionsEnding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,356,474</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1001" contextRef="From2020-10-01to2021-09-30" name="cvm:WeightedAverageGrantDateFairValueBeginning" decimals="INF" unitRef="USDPShares">4.76</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_993" contextRef="From2020-10-01to2021-09-30" name="cvm:VestedOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">2,401,961</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_995" contextRef="From2020-10-01to2021-09-30" name="cvm:GrantedOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,605,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_997" contextRef="From2020-10-01to2021-09-30" name="cvm:ForfeitedOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">49,832</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_999" contextRef="From2020-10-01to2021-09-30" name="cvm:NumberOfUnvestedOptionsEnding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,509,681</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1003" contextRef="From2020-10-01to2021-09-30" name="cvm:WeightedAverageGrantDateFairValueEnding" decimals="INF" unitRef="USDPShares">5.17</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Bonus Plan</span> &#8211; On September 30, 2021, <ix:nonFraction id="fid_1935" contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlanMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">614,500</ix:nonFraction> of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which <ix:nonFraction id="fid_1966" contextRef="From2020-10-01to2021-09-30_cvm_IncentiveStockBonusPlanMember" name="cvm:VestedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">463,250</ix:nonFraction> shares are fully vested. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company&#8217;s Multikine technology, or specified increases in the market price of the Company&#8217;s stock. The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of shares issued that remain outstanding as of September 30, 2021 was approximately $<ix:nonFraction id="fid_1967" contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlanMember" name="cvm:RemainingOutstandingFairValueOfShares" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">8.6</ix:nonFraction> million. The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service period is not rendered. During each of the years ended September 30, 2021 and 2020, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $<ix:nonFraction id="fid_1939" contextRef="From2020-10-01to2021-09-30_cvm_IncentiveStockBonusPlanMember" name="cvm:IssuanceOfRestrictedStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.3</ix:nonFraction> million. At September 30, 2021, the Company has unrecognized compensation expense of approximately $<ix:nonFraction id="fid_1940" contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlanMember" name="us-gaap:DeferredCompensationEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000</ix:nonFraction> which is expected to be fully recognized in the next quarter.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:continuation id="cont_5c5379"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the status of the Company&#8217;s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2021 is presented below:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_2327" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Shares</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Grant Date Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1004" contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember" name="cvm:NumberOfUnvestedSharesBeginning" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">304,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1023" contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember" name="cvm:WeightedAverageGrantDateFairValueBeginning" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1005" contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember" name="cvm:NumberOfUnvestedSharesBeginning" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">304,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1013" contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember" name="cvm:WeightedAverageGrantDateFairValue" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1006" contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember" name="cvm:SharesForfeited" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">2,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1008" contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember" name="cvm:VestedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">151,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1010" contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember" name="cvm:NumberOfUnvestedSharesEnding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">151,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1012" contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember" name="cvm:WeightedAverageGrantDateFairValue" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Stock Bonus Plans</span><span style="text-decoration:underline"> </span>&#8211; As of September 30, 2021, the Company has issued a total of <ix:nonFraction id="fid_1927" contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">363,086</ix:nonFraction> shares of common stock from the Stock Bonus Plans and was authorized to issue up to <ix:nonFraction id="fid_1936" contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">783,760</ix:nonFraction> shares of common stock under its Stock Bonus Plans. All employees, directors, officers, consultants, and advisors are eligible to be granted shares.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Stock Compensation Plan</span><span style="text-decoration:underline">s</span> &#8211; On September 30, 2021, <ix:nonFraction id="fid_1937" contextRef="AsOf2021-09-30_cvm_StockCompensationPlansMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">634,000</ix:nonFraction> shares were authorized for use in the Company&#8217;s Stock Compensation Plans, of which <ix:nonFraction id="fid_1928" contextRef="AsOf2021-09-30_cvm_StockCompensationPlansMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">154,195</ix:nonFraction> shares were issued and outstanding. No shares were issued from the Stock Compensation Plans to consultants for payment of services during the years ended September 30, 2021, and 2020.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160; </p><ix:nonNumeric id="fid_2292" contextRef="From2020-10-01to2021-09-30" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontfd048409-0460-4364-bd1a-6b54d9dd4d63" style="font-family:symbol"><strong>9</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>EMPLOYEE BENEFIT PLAN</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant&#8217;s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant&#8217;s contribution, not to exceed the lesser of $<ix:nonFraction id="fid_1744" contextRef="From2020-10-01to2021-09-30" name="cvm:TotalCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction> or <ix:nonFraction id="fid_1745" contextRef="From2020-10-01to2021-09-30" name="cvm:ParticipantCompensation" decimals="INF" unitRef="Pure" scale="-2">6</ix:nonFraction>% of the participant&#8217;s total compensation. The Company&#8217;s contribution of common stock is valued each quarter based upon the closing bid price of the Company&#8217;s common stock. During the year ended September 30, 2021, <ix:nonFraction id="fid_1747" contextRef="From2019-10-01to2020-09-30" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,990</ix:nonFraction> shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $<ix:nonFraction id="fid_1743" contextRef="From2019-10-01to2020-09-30" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,000</ix:nonFraction>. During the year ended September 30, 2020, <ix:nonFraction id="fid_1746" contextRef="From2020-10-01to2021-09-30" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,870</ix:nonFraction> shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $<ix:nonFraction id="fid_1742" contextRef="From2020-10-01to2021-09-30" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,000</ix:nonFraction>.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_2293" contextRef="From2020-10-01to2021-09-30" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_ac31ba"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font1fee1043-38b7-4ec7-92f5-34f01644823c" style="font-family:symbol"><strong>10</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><strong>COMMITMENTS AND CONTINGENCIES </strong></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Clinical Research Agreements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $<ix:nonFraction id="fid_1801" contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember" name="cvm:ClinicalServiceTrial" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">10</ix:nonFraction> million towards the Company&#8217;s Phase III clinical study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;. The Company determined the payments to Ergomed are within the scope of ASC 730 &#8220;Research and Development.&#8221; Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $<ix:nonFraction id="fid_1800" contextRef="From2020-10-01to2021-09-30" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">35.1</ix:nonFraction> million related to Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $<ix:nonFraction id="fid_1808" contextRef="From2020-10-01to2021-09-30" name="cvm:NetOfDiscount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">11.6</ix:nonFraction> million. During the years ended September 30, 2021 and 2020, the Company recorded approximately $<ix:nonFraction id="fid_1803" contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.6</ix:nonFraction> million and $2.0 million, respectively, as research and development expense related to Ergomed&#8217;s services. These amounts were net of Ergomed&#8217;s discount of approximately $<ix:nonFraction id="fid_1804" contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember" name="cvm:NetOfDiscount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.6</ix:nonFraction> million during both the years ended September 30, 2021 and 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Lease Agreements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon adoption of ASC 842 on October 1, 2019, the Company recorded a finance lease right of use asset of approximately $<ix:nonFraction id="fid_1784" contextRef="From2020-10-01to2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">16.5</ix:nonFraction> million and a finance lease liability of approximately $<ix:nonFraction id="fid_1785" contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">13.5</ix:nonFraction> million. As of September 30, 2021 and 2020, respectively, the net book value of the finance lease right of use asset is approximately $<ix:nonFraction id="fid_1787" contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">12.7</ix:nonFraction> million and $<ix:nonFraction id="fid_1786" contextRef="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">13.8</ix:nonFraction> million and the balance of the finance lease liability is approximately $<ix:nonFraction id="fid_1788" contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:BalanceOfTheFinanceLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">13.8</ix:nonFraction> million and $<ix:nonFraction id="fid_1789" contextRef="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:BalanceOfTheFinanceLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">12.7</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1790" contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:CurrentBalance" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction id="fid_1791" contextRef="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:CurrentBalance" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.9</ix:nonFraction> million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being amortized using a straight-line method over the underlying lease terms and totaled approximately&#160;$1,732,000&#160;and $1,717,000&#160;&#160;in&#160;the years ended September 30, 2021 and 2020, respectively. Total cash paid related to finance leases during the years ended September 30, 2021 and 2020, respectively, was approximately $<ix:nonFraction id="fid_1792" contextRef="From2020-10-01to2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:CashPaidRelatedToFinanceLeases" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.2</ix:nonFraction> million and $<ix:nonFraction id="fid_1793" contextRef="From2019-10-01to2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:CashPaidRelatedToFinanceLeases" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.9</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1794" contextRef="From2020-10-01to2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:CashPaidRelatedToFinanceLeasesInterest" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.2</ix:nonFraction> million was for interest in both years. The weighted average discount rate of the Company&#8217;s finance leases is <ix:nonFraction id="fid_1766" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">8.45</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_1771" contextRef="From2020-10-01to2021-09-30" name="cvm:MaturityYears" format="ixt-sec:duryear">7.1</ix:nonNumeric> years.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $<ix:nonFraction id="fid_1816" contextRef="From2020-10-01to2021-09-30_cvm_LandlordMember" name="cvm:EstimatedCost" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">10.7</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1815" contextRef="From2020-10-01to2021-09-30_cvm_LandlordMember" name="cvm:CostIncurredInitial" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">10.5</ix:nonFraction> million has been incurred as of September 30, 2021. The landlord agreed to finance the final $2.4 million of the costs incurred which will be repaid through increased lease payments over the remaining lease term starting on March 1, 2021. <ix:nonNumeric id="fid_1809" contextRef="From2020-10-01to2021-09-30_cvm_LandlordMember" name="us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases">The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.</ix:nonNumeric> The Company remeasured the lease liability to account for the modified payments using a <ix:nonFraction id="fid_1770" contextRef="AsOf2021-09-30_cvm_LandlordMember" name="us-gaap:DerivativeVariableInterestRate" decimals="INF" unitRef="Pure" scale="-2">8.45</ix:nonFraction>% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. Approximately $1.6 million was received from the landlord as of September 30, 2021. The leasehold improvements are recorded in property and equipment and will be amortized over the remaining lease term when the assets are placed in service.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_ac31ba" continuedAt="cont_a93da3"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During June 2021, the Company determined that it used an incorrect discount rate to calculate the opening ROU asset and lease liability balances upon adoption of ASC 842. Management engaged an outside valuation specialist to perform a synthetic credit rating analysis which resulted in a <ix:nonNumeric id="fid_1810" contextRef="From2020-10-01to2021-09-30" name="us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases">revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%</ix:nonNumeric>. This change resulted in an immaterial difference to the September 30, 2020 financial statements, and was corrected in the quarterly period ended June 30, 2021 as an out of period adjustment.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company was required to deposit the equivalent of one year of base rent in accordance with the original lease. Under the landlord&#8217;s $<ix:nonFraction id="fid_1819" contextRef="From2020-10-01to2021-09-30_cvm_LandlordMember" name="cvm:FinancingLeaseContractualArrangement" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.4</ix:nonFraction> million financing arrangement, the Company was required to deposit an additional $<ix:nonFraction id="fid_1814" contextRef="AsOf2021-09-30_cvm_LandlordMember" name="us-gaap:DepositsAssetsNoncurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million in March 2021. As September 30, 2021 and 2020, respectively, the approximate $<ix:nonFraction id="fid_1817" contextRef="AsOf2021-09-30_cvm_LandlordMember" name="us-gaap:AssetsNoncurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.9</ix:nonFraction> million and $<ix:nonFraction id="fid_1818" contextRef="AsOf2020-09-30_cvm_LandlordMember" name="us-gaap:AssetsNoncurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.7</ix:nonFraction> million deposit is included in non-current assets.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Approximate future minimum lease payments under finance leases as of September 30, 2021 are as follows:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><ix:nonNumeric id="fid_2328" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1748" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,699,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1749" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,569,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1750" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,648,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1751" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,733,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1752" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,824,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1753" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,186,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation *</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1754" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,659,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,825,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of lease finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1756" contextRef="AsOf2021-09-30" name="cvm:NetPresentValueOfLeaseFinancingObligation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,834,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;"><em>* Amount is net of landlord incentive of approximately $0.8 million expected to be realized in quarter ended December 31, 2021. </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective April 30, 2020, the Company terminated a month-to-month arrangement with a sub-lessee as the sub-leased space was needed to prepare the facility to produce Multikine for commercial purposes and before the Company&#8217;s Biologics License Application (BLA) can be submitted to the FDA. The sublease rental income for the year ended September 30, 2020 was approximately $<ix:nonFraction id="fid_1813" contextRef="From2019-10-01to2020-09-30_us-gaap_LicenseMember" name="us-gaap:SubleaseIncome" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,000</ix:nonFraction>.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on March 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $<ix:nonFraction id="fid_1923" contextRef="From2020-10-01to2021-09-30_cvm_VendorObligationsMember" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.1</ix:nonFraction> million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon adoption of ASC 842 on October 1, 2019, the Company recorded an operating lease right of use asset and an operating lease liability of approximately $<ix:nonFraction id="fid_1773" contextRef="From2020-10-01to2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.0</ix:nonFraction> million. As of September 30, 2021, the net book value of the operating lease right of use asset is approximately $<ix:nonFraction id="fid_1776" contextRef="AsOf2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:NetBookValueOperatingLeaseRightOfUseAssets" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.1</ix:nonFraction> million and the balance of the operating lease liability is approximately $<ix:nonFraction id="fid_1780" contextRef="AsOf2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.1</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1778" contextRef="AsOf2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:CurrentBalance" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million is current. As of September 30, 2020, the net book value of the operating lease right of use asset is approximately $<ix:nonFraction id="fid_1781" contextRef="AsOf2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.2</ix:nonFraction> million and the balance of the operating lease liability is approximately $<ix:nonFraction id="fid_1777" contextRef="AsOf2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:NetBookValueOperatingLeaseRightOfUseAssets" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.2</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1779" contextRef="AsOf2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="cvm:CurrentBalance" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million is current. The Company incurred lease expense under operating leases of approximately $<ix:nonFraction id="fid_1775" contextRef="From2019-10-01to2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="us-gaap:OperatingLeasePayments" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million for each of the years ended September 30, 2021 and 2020. Total cash paid related to operating leases during the years ended September 30, 2021 and 2020 was approximately $<ix:nonFraction id="fid_1774" contextRef="From2020-10-01to2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="us-gaap:OperatingLeasePayments" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.3</ix:nonFraction> million and $<ix:nonFraction id="fid_1782" contextRef="From2020-10-01to2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember" name="us-gaap:LeaseAndRentalExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million, respectively. The weighted average discount rate of the Company&#8217;s operating leases is <ix:nonFraction id="fid_1767" contextRef="AsOf2021-09-30" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">9.12</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_1772" contextRef="From2020-10-01to2021-09-30" name="cvm:OperatingLeaseMaturityYears" format="ixt-sec:duryear">9.7</ix:nonNumeric> years.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_a93da3"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">As of September 30, 2021, future minimum lease payments on operating leases are as follows:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><ix:nonNumeric id="fid_2329" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1757" contextRef="AsOf2021-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">309,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1758" contextRef="AsOf2021-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1759" contextRef="AsOf2021-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1760" contextRef="AsOf2021-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1761" contextRef="AsOf2021-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1762" contextRef="AsOf2021-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,602,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1763" contextRef="AsOf2021-09-30" name="cvm:LesseeOperatingLeaseLiabilityPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,269,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1764" contextRef="AsOf2021-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,130,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1765" contextRef="AsOf2021-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,139,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Vendor Obligations</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has contingent obligations with vendors for work that will be completed in relation to the Phase 3 clinical trial. The timing of these obligations cannot be determined at this time. The Company estimates it will incur additional expenses of approximately $1.1 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report with the FDA. This estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160;&#160; </p><ix:nonNumeric id="fid_2294" contextRef="From2020-10-01to2021-09-30" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true" continuedAt="cont_aceaa7"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontdbb63aaa-97d8-4a2c-a795-4ccbe55f6879" style="font-family:symbol"><strong>1</strong><strong>1</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>RELATED PARTY TRANSACTIONS</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2021, the de Clara Trust, of which the Company&#8217;s CEO, Geert Kerston, is a beneficiary, and two directors purchased <ix:nonFraction id="fid_1839" contextRef="From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember" name="cvm:NumberOfRestrictedSharesPurchasedByRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">27,500</ix:nonFraction> restricted shares of the Company&#8217;s common stock at an aggregate fair market value of approximately $<ix:nonFraction id="fid_1841" contextRef="From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember" name="cvm:ProceedsFromRestrictedSharesPurchasedByRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,000</ix:nonFraction>. During the year ended September 30, 2020, officers and directors of the Company purchased <ix:nonFraction id="fid_1838" contextRef="From2019-10-01to2020-09-30_cvm_OfficerAndDirectorMember" name="cvm:NumberOfRestrictedSharesPurchasedByRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,512</ix:nonFraction> shares of restricted common stock at market price at an aggregate fair market value of approximately $<ix:nonFraction id="fid_1840" contextRef="From2019-10-01to2020-09-30_cvm_OfficerAndDirectorMember" name="cvm:ProceedsFromRestrictedSharesPurchasedByRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,000</ix:nonFraction>. The shares are subject to the conditions of Rule 144 under the Securities Act of 1933.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2021, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary, were extended by twelve months (Note 4). The incremental cost of these modifications was approximately $<ix:nonFraction id="fid_1826" contextRef="From2021-04-01to2021-06-30_cvm_SeriesNWarrantsMember" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,000</ix:nonFraction> and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2021, the expiration date of <ix:nonFraction id="fid_1833" contextRef="AsOf2021-06-28_cvm_SeriesUUWarrantsMember" name="cvm:WarrantsIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction> Series UU warrants was extended by twelve months (Note 4). The incremental cost of this extension was $<ix:nonFraction id="fid_1834" contextRef="From2021-04-01to2021-06-30_cvm_SeriesUUWarrantsMember" name="us-gaap:InterestExpenseRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction> and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and the de Clara Trust and were originally issued with convertible debt.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary, were extended by six months (Note 4). The incremental cost of these modifications was approximately $<ix:nonFraction id="fid_1830" contextRef="From2020-10-01to2021-09-30_cvm_SeriesNAndXWarrantsMember" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction> and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_aceaa7"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, <ix:nonNumeric id="fid_1823" contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUWarrantsMember" name="cvm:ExpirationDateDescription">the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021</ix:nonNumeric>. The incremental cost of this extension was $<ix:nonFraction id="fid_1837" contextRef="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember" name="us-gaap:InterestExpenseRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192</ix:nonFraction> and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 8, 2020, the expiration date of <ix:nonFraction id="fid_1831" contextRef="AsOf2020-05-08_cvm_SeriesUUWarrantsMember" name="cvm:WarrantsIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,593</ix:nonFraction> Series UU warrants were extended from June 11, 2020 to December 31, 2020. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_1835" contextRef="From2020-05-01to2020-05-08_cvm_SeriesUUWarrantsMember" name="us-gaap:InterestExpenseRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction> and was recorded as interest expense for the year ended September 30, 2020. The Series UU warrants are held by the Company&#8217;s officers and were originally issued with convertible debt.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2020, <ix:nonNumeric id="fid_1820" contextRef="From2020-12-01to2020-12-07_cvm_SeriesNWarrantsMember" name="cvm:ExpirationDateDescription">the expiration date of the Series N warrants was extended to February 18, 2021</ix:nonNumeric>. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_1825" contextRef="From2019-10-01to2020-09-30_cvm_SeriesNWarrantsMember" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction>, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160; </p><ix:nonNumeric id="fid_2295" contextRef="From2020-10-01to2021-09-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_91005b"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>12. </strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>STOCKHOLDERS&#8217; EQUITY </strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Exercise of Warrants</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the years ended September 30, 2021 and 2020, the Company received proceeds of approximately $<ix:nonFraction id="fid_1868" contextRef="From2020-10-01to2021-09-30" name="cvm:ProceedFromIssuanceOrSaleOfEquity" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">6.0</ix:nonFraction> million and $<ix:nonFraction id="fid_1867" contextRef="From2019-10-01to2020-09-30" name="cvm:ProceedFromIssuanceOrSaleOfEquity" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">12.1</ix:nonFraction> million, respectively, from the exercise of warrants, as detailed in Note 4. Upon exercise, <ix:nonFraction id="fid_1870" contextRef="From2020-10-01to2021-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,597,870</ix:nonFraction> and <ix:nonFraction id="fid_1869" contextRef="From2019-10-01to2020-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,711,873</ix:nonFraction> shares of common stock were issued during the years ended September 30, 2021 and 2020, respectively.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Sales of Securities</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June 2021, the Company sold <ix:nonFraction id="fid_1873" contextRef="AsOf2021-06-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,400,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_1853" contextRef="AsOf2021-06-30" name="us-gaap:SaleOfStockPricePerShare" decimals="INF" unitRef="USDPShares">22.62</ix:nonFraction> per share and received aggregate net proceeds of approximately $<ix:nonFraction id="fid_1852" contextRef="From2021-06-01to2021-06-30" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">29.4</ix:nonFraction> million. At that time, the underwriters fully exercised their option to purchase up to <ix:nonFraction id="fid_2553" contextRef="AsOf2021-06-30" name="cvm:ProceedsFromPublicOffering" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,000</ix:nonFraction> additional shares of common stock to cover over-allotments, resulting in additional net proceeds to the Company of approximately $<ix:nonFraction id="fid_1866" contextRef="From2021-06-01to2021-06-30" name="cvm:ProceedFromIssuanceOrSaleOfEquity" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">4.4</ix:nonFraction> million.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2020, the Company sold <ix:nonFraction id="fid_1850" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_1854" contextRef="AsOf2020-12-31" name="us-gaap:SaleOfStockPricePerShare" decimals="INF" unitRef="USDPShares">14.65</ix:nonFraction> per share and received aggregate proceeds of approximately $<ix:nonFraction id="fid_1849" contextRef="From2020-12-01to2020-12-31" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">13.6</ix:nonFraction> million.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In March 2020, the Company sold <ix:nonFraction id="fid_1848" contextRef="AsOf2020-03-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">630,500</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_1855" contextRef="AsOf2020-03-31" name="us-gaap:SaleOfStockPricePerShare" decimals="INF" unitRef="USDPShares">12.22</ix:nonFraction> per share and received aggregate net proceeds of approximately $<ix:nonFraction id="fid_1859" contextRef="From2020-03-01to2020-03-31" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">7.1</ix:nonFraction> million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 45-day option to purchase up to an additional <ix:nonFraction id="fid_2556" contextRef="AsOf2020-03-31" name="cvm:ProceedsFromPublicOffering" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,575</ix:nonFraction> shares of common stock solely to cover over-allotments. The underwriter fully exercised this option in May 2020 resulting in additional net proceeds to the Company of approximately $<ix:nonFraction id="fid_1858" contextRef="From2020-05-01to2020-05-31" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.1</ix:nonFraction> million.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, the Company sold <ix:nonFraction id="fid_1851" contextRef="AsOf2019-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">606,395</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_1857" contextRef="AsOf2019-12-31" name="us-gaap:SaleOfStockPricePerShare" decimals="INF" unitRef="USDPShares">9.07</ix:nonFraction> per share and received aggregate net proceeds of approximately $<ix:nonFraction id="fid_1861" contextRef="From2019-12-01to2019-12-31" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.0</ix:nonFraction> million. In January 2020, the underwriters of that offering fully exercised the option to purchase <ix:nonFraction id="fid_2554" contextRef="AsOf2020-01-31" name="cvm:ProceedsFromPublicOffering" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,959</ix:nonFraction> additional shares of common stock at the public offering price of $<ix:nonFraction id="fid_1856" contextRef="AsOf2020-01-31" name="us-gaap:SaleOfStockPricePerShare" decimals="INF" unitRef="USDPShares">9.07</ix:nonFraction> per share for aggregate net proceeds to the Company of approximately $<ix:nonFraction id="fid_1860" contextRef="From2020-01-01to2020-01-31" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.8</ix:nonFraction> million.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-27</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_91005b"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Other Equity Transactions</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company entered into Securities Purchase Agreements (SPA) with Ergomed plc, one of the Company&#8217;s Clinical Research Organizations responsible for managing the Company&#8217;s Phase 3 clinical trial, to facilitate payment of amounts due Ergomed. Under the Agreements, the Company issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed. Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2020, the Company issued Ergomed <ix:nonFraction id="fid_1872" contextRef="AsOf2020-09-30_cvm_ErgomedMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">150,000</ix:nonFraction> shares. No shares were issued during the year ended September 30, 2021. All outstanding shares have been resold as of September 30, 2021 and the Company has approximately $<ix:nonFraction id="fid_1871" contextRef="AsOf2021-09-30_cvm_ErgomedMember" name="cvm:PrepaidAmountOfResold" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction> in amounts prepaid to Ergomed.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes the Other Non-operating gains (losses) for the years ended September 30 relating to these agreements:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_2330" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amount realized through the resale of shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1843" contextRef="From2020-10-01to2021-09-30" name="cvm:AmountRealizedThroughTheResaleOfShares" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,685,379</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1842" contextRef="From2019-10-01to2020-09-30" name="cvm:AmountRealizedThroughTheResaleOfShares" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,652,605</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of shares upon issuance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1845" contextRef="From2020-10-01to2021-09-30" name="cvm:SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1844" contextRef="From2019-10-01to2020-09-30" name="cvm:SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,769,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other non-operating gain</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1847" contextRef="From2020-10-01to2021-09-30" name="cvm:SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,685,379</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1846" contextRef="From2019-10-01to2020-09-30" name="cvm:SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">883,105</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">As of September 30, 2021, all shares held for resale were sold.</p></td></tr><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160;&#160; </p><ix:nonNumeric id="fid_2296" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="cont_14e1e0"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>3</strong><strong>. </strong></p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FAIR VALUE MEASUREMENTS</strong></p></td></tr><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the provisions of ASC 820, &#8220;<em>Fair Value Measurements</em>,&#8221; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">o </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">o </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs other than quoted prices that are observable for the asset or liability</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">o </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-28</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_14e1e0"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company purchased short-term T-bills during the year ended September 30, 2021 that are classified as trading securities. Quoted market prices were applied to determine the fair value of short-term investments, therefore they were categorized as Level 1 on the fair value hierarchy. The T-bills were recorded at fair market value, which includes an unrealized gain of approximately $<ix:nonFraction id="fid_1892" contextRef="From2020-10-01to2021-09-30" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction>. The T-bills mature in December 2021 and yield a weighted average interest rate of <ix:nonFraction id="fid_1893" contextRef="From2020-10-01to2021-09-30" name="cvm:WeightedAverageRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.10</ix:nonFraction>%.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2021 and 2020, all of the Company&#8217;s derivative liabilities are classified as Level 3.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September 30:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_2331" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1875" contextRef="AsOf2020-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,765,613</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1874" contextRef="AsOf2019-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,488,310</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1877" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1876" contextRef="From2019-10-01to2020-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1879" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,023,091</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1878" contextRef="From2019-10-01to2020-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,071,775</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">N Net realized and unrealized derivative loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1881" contextRef="From2020-10-01to2021-09-30" name="cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" format="ixt:numdotdecimal" decimals="0" unitRef="USD">694,858</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1880" contextRef="From2019-10-01to2020-09-30" name="cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,078</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1883" contextRef="AsOf2021-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,380</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1882" contextRef="AsOf2020-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,765,613</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fair values of the Company&#8217;s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company&#8217;s stock. At September 30, 2021, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $<ix:nonFraction id="fid_1885" contextRef="AsOf2021-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:WeightedAverageFairValueDerivativeInstruments" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction> per share and a weighted average exercise price of $<ix:nonFraction id="fid_1887" contextRef="AsOf2021-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:WeightedAverageExercisePriceDerivativeInstruments" decimals="INF" unitRef="USDPShares">13.28</ix:nonFraction> per share. Fair values were determined using a weighted average risk free interest rate of <ix:nonFraction id="fid_1889" contextRef="From2020-10-01to2021-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:WeightedAverageRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.05</ix:nonFraction>% and volatility of <ix:nonFraction id="fid_1891" contextRef="From2020-10-01to2021-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:VolatilityRate" decimals="INF" unitRef="Pure" scale="-2">109</ix:nonFraction>%. The instruments have a weighted average time to maturity of <ix:nonNumeric id="fid_1895" contextRef="From2020-10-01to2021-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:WeightedAverageTimeToMaturityYear" format="ixt-sec:duryear">0.3</ix:nonNumeric> years. At September 30, 2020, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $<ix:nonFraction id="fid_1884" contextRef="AsOf2020-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:WeightedAverageFairValueDerivativeInstruments" decimals="INF" unitRef="USDPShares">2.81</ix:nonFraction> per share and a weighted average exercise price of $<ix:nonFraction id="fid_1886" contextRef="AsOf2020-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:WeightedAverageExercisePriceDerivativeInstruments" decimals="INF" unitRef="USDPShares">14.32</ix:nonFraction> per share. Fair values were determined using a weighted average risk free interest rate of <ix:nonFraction id="fid_1888" contextRef="From2019-10-01to2020-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:WeightedAverageRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.12</ix:nonFraction>% and volatility of <ix:nonFraction id="fid_1890" contextRef="From2019-10-01to2020-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:VolatilityRate" decimals="INF" unitRef="Pure" scale="-2">95</ix:nonFraction>%. The instruments have a weighted average time to maturity of <ix:nonNumeric id="fid_1894" contextRef="From2019-10-01to2020-09-30_cvm_FairValueInputsLevelThreeMember" name="cvm:WeightedAverageTimeToMaturityYear" format="ixt-sec:duryear">1.2</ix:nonNumeric> years.</p></td></tr></tbody></table></ix:continuation><ix:nonNumeric id="fid_2297" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="cont_c91929"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font1979c11c-b28b-499c-aafb-834c09537173" style="font-family:symbol"><strong>1</strong><strong>4</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NET LOSS PER COMMON SHARE</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock have not been included in the computation of diluted net loss per share for all periods presented, as the result would be anti-dilutive. For the years presented, the gain on derivative instruments is not included in net loss available to common shareholders for purposes of computing dilutive loss per share because its effect is anti-dilutive.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><ix:nonNumeric id="fid_2332" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Net loss available to common shareholders - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1896" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,711,970</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1897" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,276,978</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1898" contextRef="From2020-10-01to2021-09-30" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,662,137</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1899" contextRef="From2019-10-01to2020-09-30" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">36,759,115</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt">Basic loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1900" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EarningsPerShareBasic" decimals="INF" unitRef="USDPShares" sign="-">0.90</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1901" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EarningsPerShareBasic" decimals="INF" unitRef="USDPShares" sign="-">0.82</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Net loss available to common shareholders - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1903" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,711,970</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1904" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,276,978</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Unrealized gain on derivatives <sup>(1)</sup></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1906" contextRef="From2020-10-01to2021-09-30" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,085,540</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1905" contextRef="From2019-10-01to2020-09-30" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Net loss available to common shareholders - diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1907" contextRef="From2020-10-01to2021-09-30" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">37,797,510</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1908" contextRef="From2019-10-01to2020-09-30" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,276,978</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,662,137</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1910" contextRef="From2019-10-01to2020-09-30" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">36,759,115</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Incremental shares underlying dilutive warrants <sup>(1)</sup></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1912" contextRef="From2020-10-01to2021-09-30" name="cvm:IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">32,111</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Weighted average shares outstanding - diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1913" contextRef="From2020-10-01to2021-09-30" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,694,248</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1914" contextRef="From2019-10-01to2020-09-30" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">36,759,115</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt">Diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1915" contextRef="From2020-10-01to2021-09-30" name="us-gaap:EarningsPerShareDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.93</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1916" contextRef="From2019-10-01to2020-09-30" name="us-gaap:EarningsPerShareDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.82</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-29</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#tocfs">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_c91929"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font7d035306-f9b9-45fc-87bc-b43e5ea6ceb6" style="font-family:symbol"><em><sup>(1)</sup></em><em> </em></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Includes Series Z, AA, CC and HH warrants for the year ended September 30, 2021.</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_2333" contextRef="From2020-10-01to2021-09-30" name="cvm:ScheduleOfAntiDilutiveSecuritiestabletextblock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1920" contextRef="From2020-10-01to2021-09-30_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,604,850</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1919" contextRef="From2019-10-01to2020-09-30_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,221,696</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1922" contextRef="From2020-10-01to2021-09-30_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">151,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1921" contextRef="From2019-10-01to2020-09-30_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">308,814</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1918" contextRef="From2020-10-01to2021-09-30" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,756,100</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1917" contextRef="From2019-10-01to2020-09-30" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,530,510</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2298" contextRef="From2020-10-01to2021-09-30" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>15. SUBSEQUENT EVENTS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-30</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In accordance with Section 13 or 15(a) of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 21<sup>st</sup> day of December 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160;</td><td colspan="2">CEL-SCI CORPORATION</td><td></td></tr><tr style="height:15px"><td style="width:47%;">&#160;</td><td style="width:3%;">&#160;</td><td style="width:30%;">&#160;</td><td style="width:15%;">&#160;</td></tr><tr style="height:15px"><td></td><td>By:</td><td style="BORDER-BOTTOM: black 1px solid;">/s/ Geert Kersten</td><td></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>Geert Kersten, Chief Executive Officer</td><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Act of l934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;">Signature </td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Title </p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;">/s/ Geert Kersten </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive, Principal</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Geert R. Kersten </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Accounting, Principal Financial</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Officer and a Director </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">December 21, 2021</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;">/s/ Peter Young </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Director </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">December 21, 2021</p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Dr. Peter R. Young</td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;">/s/ Bruno Baillavoine </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Director </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">December 21, 2021</p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Bruno Baillavoine</td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;">/s/ Robert Waton </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Director </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">December 21, 2021</p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Robert Watson</td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM 10-K</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBITS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>cvm_ex231.htm
<DESCRIPTION>CONSENTS OF EXPERTS AND COUNSEL
<TEXT>
<html><head><title>cvm_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consent of Independent Registered Public Accounting Firm</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Vienna, Virginia</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File numbers 333-162039, 333-161504, 333-162792, 333-184094, 333-186103, 333-196243, 333-205444 and 333-226558) and Form S-8 (File numbers 333-117088, 333-140792, 333-162265, 333-179477, 333-184092, 333-198244, 333-206538, 333-214031, 333-222969, 333-228252, 333-236063 and 333-237845) of CEL-SCI Corporation of our report dated December 21, 2021, relating to the financial statements, which appear in this Form 10-K.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"></td> <td style="width:3%;"></td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/BDO USA, LLP</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>Potomac, Maryland</td> <td>&nbsp;</td> <td></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>December 21, 2021</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html><head><title>cvm_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, of CEL-SCI Corporation, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this annual report on Form 10-K of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">c) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">d) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any fraud, whether or not material, that involves management or other employees who have significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">December 21, 2021 </td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Geert R. Kersten</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Principal Executive Officer</td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, of CEL-SCI Corporation, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this annual report on Form 10-K of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">c) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">d) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5. </p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b) </p></td> <td style="vertical-align:top;">any fraud, whether or not material, that involves management or other employees who have significant role in the registrant&#8217;s internal control over financial reporting.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">December 21, 2021 </td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Geert R. Kersten</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Principal Financial Officer</td> <td>&nbsp;</td></tr></table><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html><head><title>cvm_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In connection with the Annual Report of CEL-SCI Corporation (the &#8220;Company&#8221;) on Form 10-K for the period ending September 30, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Geert Kersten, the Chief Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1) </p></td> <td style="vertical-align:top;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2) </p></td> <td style="vertical-align:top;">The information contained in the Report fairly presents, in all material respects the financial condition and results of the Company.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">December 21, 2021 </td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert Kersten, Chief Executive and Principal</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial and Accounting Officer</p></td> <td>&nbsp;</td></tr></table><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>cvm_10kimg1.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_10kimg1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $7 BX# 2(  A$! Q$!_\0
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MJQTYM+BS)\ODED8Y&.6RB\_6N>7X6^'[;3=)M=)U#6-)N-+M6L8;VQN_+G>
MMN,;D@AANY&1D'H1S0!5C^)W]H2Z-#X;\+:AJUUJUG<720O-%;FW,,JQ21RE
MSP0Q(XW<CWS52X^*2Z+INKW=[9W%Y+#K\FCQB9XK:"%A$DGSS$[409(#OR3@
M=Q74Z3X#\.Z%?Z3=:;#- VE6<MA;IYI9?+D=7=FSDLY90=Q.<D^M13> ]/\
M)U&'3]8U?2WU'47U.>6SN K-(Z*C+AE*E,*/E(.#S0!S=Q\1O%4OB/PC9:3X
M3@O;76[2YN)@FI0OM,;(,I(I*,H#9]\@<$&G77QBTVQ\?0^%KS3XC%/?KIR7
M5K?1W#+(YVIOC7E.< @G(SR*U8OA;X?M+?1TTV\U73KG2YIYX[RVN=LTK3L&
MF\S*E6#D D8&,<8IJ_"?P['=Q&/4=9CL8=1758=-2\Q;17 E\TL%QD@N22&)
M'/&* .;7XF>*G\+>+]5U7P^=*M]&U*6SAO+6:*9FVW"1A#&Q^]AN6Z>E=;_P
MG&H7GB>\TOP_X5N]6LM-N5L[_4%N8H4AE(5F5%<@R;592<8ZX&34=S\,]#ND
MUZWDU#55L==F^TW-BMR/)68NCM(@*Y4ED&><<GCFK5QX#T]_$MQKECJVL:7)
M=RI/>6UA=F*"[D4 !G7!P2% )4KD 9S0!V]%%% !1110 E)T%+6+J\?VZUN=
M)M=4_L^^GB)22(J98QTWA3^6:3T0F[(CM]:TN^U.]TVQOX9[ZR"_:(4;+1;N
MF[\NE?/FN:MK-YXEGFU3Q!-J$UI>/';V\6ZWAB5"1O"*<DY'4DFOH#P[X;TS
MPOIBZ;I<>Q,[I)&Y>9SU=V[L:Y:^^%>E7FHW4TEQ(+2YD,SVX7E7)RQ5\Y )
M[8-=6'=.,E*HKV/*QM&O5II4M)>NAF^'_B=8K916NN0RK-&-IE3Y]_ID'!SC
MZUVL'C+P[=6CW$.H;HT*AR8W&S<<#/'%<7JWPDTA(7N+'6+RR"C.V0B9/R.#
M^M<1J.BWEU966AZ+,\L4$SS/,J;?-<C&[;S@#&!_]>M<4\/R.I2OS=CGPLL9
M2O&M%2BENMV^B/=[76]/OK^6RM9A))$H=B.F"<=?\]16MW]:^>%_X6=X7QN@
MGDB7^(H>?Q6ND\+_ !.US4-;M-%NM,/GW#[ [#(7C))QSP*\:-=-\LDTSLIX
MM.2C*+BWW1[317.6_B&V8W'FE3'!(83,IVJ[CJHW8Z?4UN1S1RQ)(K?*P!&:
MZ')+=GI$]%%%6 4444 %%%% !116'<:Q:VVMVFCR2.U[=1O,J(A;9&F,NYZ*
MN2!D]2<"@#<KSK7/B)#H?C.\\/W6FL8X[..2VN%EYN;J0OLM@N.&8(<'///I
M7<)>V<B2R1W,3I%_K&5P0G&>?3BLG['X?75)=<S;O<7B1+YK2!E<1EO+*C.,
M@NW(YYH Q-'^(FEWGA8:UJ5O)8S16%O?W=O&#*(1,S*H# #?RK=JBA^(%R=>
MM]+;1)KDW.J7M@KVK ^6L !#,&(ZYYQTQ5>W\.^ =4:'1;-;H1_V;;$PK/-"
ML]MYCF$/D@L0P? ////!K=N/#7AE)HYFD-G<+?27B31W11Q-+Q( <]&Z%>E
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M=I)BKC<'901DGOBNLT/H5;BW8N%FC)C.UP&'RGT/I3&NK94:1KB((K;68N,
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M\:]SKZ7#5XUZ:DCT(3YXW%HHHKI+"BBB@#A]=\$VNJZS#KNGW4VCZS#@"\M
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M0M/\(6AM;=A=:M(O[N#=PG^T_P#AU/ZU\XZMK&I:YJ4NH:I=/<W$AY9CT'8
M=A[56N;JXO+J2ZNIGFFE8L[N<EB>Y-6M&T?4->U:'3=,MVGN)3@ = .Y)[ >
MM?*U\34Q4[+;HCS9U)5&1:;IM[JVH1V.GV[SW$AVJJ#DU]&> ?AO9>%8$O\
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MP20<9K-T/X<^+-*T1--NM4M;Z;=:.EV9'C:V2*X5WME4#!C*@D-PQ)(;/!H
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MG  8^IZ$X!KTL+"T@F\M2<?>V\_G7S=I/[-<EGXGAN[SQ )],@F$HB6$K+(
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M?26=U=*A^Y;1>8WUQV'O7B7[-^A2-#K_ (PN(R!>RK:6KG^*-.7(]BQ _P"
MU]"=ZZH:1/OL#!PH1BSSOP_:ZMJ7A:_U32]5@L;O6+I[K<$\WR5/ 3KPPQR>
M<>E7-*\*^(%TZ*'6?%^H%T)&VT=5!&>/G*[C5?P_JFEZ$_B5M0NH[.U&JR!
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M1YF[.!7L%% 'E%YXA\71:9/=3,]I)/K$UC"?L>(K6%&?:\C$,2&  #!2"2,
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M>"XC<2,JW,#KT4 @,P8?J:]#AU"6SN(['4+=X=\GD6TH8R^> N2[8'R=^IH
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MEI]]:I=6EY#+"^=KJXP<'']*L_:+?_GO'_WT*]$YB:BHOM$&?]='_P!]"I:
M"J=]8VFI6$UC?0I/;3*4DC<9# U<JM<7$-K;27%Q*L4,:EG=S@*!U)-"\@/
M=>^#NMZ7<RS>%Y4U"Q)RMM*VV2/VR>#_ )XKG%^'OQ&OK@6EGX=2S)X-U=SJ
ML:>^!DG\!7H'B;XO1VL3S6-Q!INGAMJ7=RI>2?\ W(_3W/Z5REG\9M?F!N--
MU*VU2%#\\$]N(B?Q7!%>S3J8A1Y>97MLWK;T//EA8N+J*#Y4[-I.U^USTCX<
M_"_3OA_;3WDEP=2UR] ^U7SC''78@[+G\3^0'IM<)X%\?Z/XVL)I+/=;ZA:D
M+=64I^>(]B/[RGL?Y5W->54YN9\^YVPY>5<NPZBBBLRPHHHH **** "BBB@
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M +#'H?\ 9/-=37F'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6LRX8=P>S ]B#S6V'JNC44S*M3]I!Q/C?7;"XF>"^T^PM[F[C/#R'D <C R
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M8* JY&3DCBL=OB)X=;6?#.EPRW%Q/XBC,MJT,64C786!E.?DSM8 =<JP[&N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .!\/?#V
MX\,&W@T[QIKATRWF>9=.E%L8B'=G9"WE;]N6/\6?>LKPW\*K&Q^&FM>%=4VV
M[>()IYKXV,A(A$C';%$SC.U$VJ,CL>.:]3HH YB;PCITWB.;79)KC[5-I?\
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cvm-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:cvm="http://cvm.com/20210930" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cvm.com/20210930">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cvm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
        <link:definition>000002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" id="CondensedStatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
        <link:definition>000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/ORGANIZATION" id="ORGANIZATION">
        <link:definition>000007 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/OperationsAndFinancing" id="OperationsAndFinancing">
        <link:definition>000008 - Disclosure - OPERATIONS AND FINANCING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptions" id="WarrantsAndNonEmployeeOptions">
        <link:definition>000010 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PlantPropertyAndEquipment" id="PlantPropertyAndEquipment">
        <link:definition>000011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PATENTS" id="PATENTS">
        <link:definition>000012 - Disclosure - PATENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>000013 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockCompensation" id="StockCompensation">
        <link:definition>000014 - Disclosure - STOCK COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
        <link:definition>000015 - Disclosure - EMPLOYEE BENEFIT PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000017 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000018 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>000019 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
        <link:definition>000020 - Disclosure - NET LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000021 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" id="WarrantsAndNonEmployeeOptionsTables">
        <link:definition>000023 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PlantPropertyAndEquipmentTables" id="PlantPropertyAndEquipmentTables">
        <link:definition>000024 - Disclosure - PLANT, PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsTables" id="PatentsTables">
        <link:definition>000025 - Disclosure - PATENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>000026 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockCompensationTables" id="StockCompensationTables">
        <link:definition>000027 - Disclosure - STOCK COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>000029 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>000030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
        <link:definition>000031 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" id="WarrantsAndNonemployeeOptionsDetails">
        <link:definition>000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1" id="WarrantsAndNonEmployeeOptionsDetails1">
        <link:definition>000034 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" id="WarrantsAndNonEmployeeOptionsDetails2">
        <link:definition>000035 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" id="WarrantsAndNonEmployeeOptionsDetails3">
        <link:definition>000036 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" id="WarrantsAndNonEmployeeOptionsDetailsNarrative">
        <link:definition>000037 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <link:definition>000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
        <link:definition>000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails" id="PatentsDetails">
        <link:definition>000040 - Disclosure - PATENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails1" id="PatentsDetails1">
        <link:definition>000041 - Disclosure - PATENTS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
        <link:definition>000042 - Disclosure - PATENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>000043 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>000044 - Disclosure - INCOME TAXES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
        <link:definition>000045 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockCompensationDetails" id="StockCompensationDetails">
        <link:definition>000046 - Disclosure - STOCK COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockCompensationDetails1" id="StockCompensationDetails1">
        <link:definition>000047 - Disclosure - STOCK COMPENSATION (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockCompensationDetails2" id="StockCompensationDetails2">
        <link:definition>000048 - Disclosure - STOCK COMPENSATION (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockCompensationDetails3" id="StockCompensationDetails3">
        <link:definition>000049 - Disclosure - STOCK COMPENSATION (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockCompensationDetails4" id="StockCompensationDetails4">
        <link:definition>000050 - Disclosure - STOCK COMPENSATION (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockCompensationDetailsNarrative" id="StockCompensationDetailsNarrative">
        <link:definition>000051 - Disclosure - STOCK COMPENSATION (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" id="EmployeeBenefitPlanDetailNarrative">
        <link:definition>000052 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>000056 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>000057 - Disclosure - STOCKHOLDERS EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000058 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
        <link:definition>000059 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
        <link:definition>000060 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" id="NetLossPerCommonShareDetails">
        <link:definition>000061 - Disclosure - NET LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" id="NetLossPerCommonShareDetails1">
        <link:definition>000062 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <element id="cvm_LeaseLiabilitiesCurrentPortion" name="LeaseLiabilitiesCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrants" name="ModificationOfWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AdoptionOfAsc842Leases" name="AdoptionOfAsc842Leases" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromTheSaleOfCommonStockShares" name="ProceedsFromTheSaleOfCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantIssuances" name="WarrantIssuances" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesShares" name="WarrantExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesAmount" name="WarrantExercisesAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrantsAmount" name="ModificationOfWarrantsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" name="StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" name="StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShareIssuanceCosts" name="ShareIssuanceCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares" name="SharesIssuedForSettlementOfClinicalResearchCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount" name="SharesIssuedForSettlementOfClinicalResearchCostsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockContributedToEmployeeBenefitPlan" name="CommonStockContributedToEmployeeBenefitPlan" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuedForSettlementOfClinicalResearchCosts" name="SharesIssuedForSettlementOfClinicalResearchCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShortTermInvestment" name="ShortTermInvestment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LossOnDerivativesInstruments" name="LossOnDerivativesInstruments" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrant" name="ModificationOfWarrant" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SuppliesUsedForRDAndManufacturing" name="SuppliesUsedForRDAndManufacturing" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShortTermDeposits" name="ShortTermDeposits" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetPurchasesOfUSTreasuryBills" name="NetPurchasesOfUSTreasuryBills" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements" name="ProceedsFromLandlordFundingOfLeaseholdImprovements" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable" name="PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" name="CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ChangesToRightOfUseAssetsAndLiabilities" name="ChangesToRightOfUseAssetsAndLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseObligationIncludedInAccountsPayable" name="FinanceLeaseObligationIncludedInAccountsPayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" name="PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise" name="FairValueOfWarrantsLiabilitiesOnDateOfExercise" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingCostsIncludedInAccountsPayable" name="FinancingCostsIncludedInAccountsPayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AccruedConsultingServicesToBePaidWithCommonStock" name="AccruedConsultingServicesToBePaidWithCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsAndNonEmployeeOptionstextblock" name="WarrantsAndNonEmployeeOptionstextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_USTreasuryBills" name="USTreasuryBills" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingPolicytextblock" name="SuppliesUsedForRDAndManufacturingPolicytextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeasesPolicyTextBlock" name="LeasesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock" name="ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" name="ScheduleOfEquityWarrantsWereExercisedTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" name="ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" name="ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock" name="ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock" name="ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock" name="ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock" name="ScheduleOfFairValueOfEachOptionGrantedTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" name="ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfNonVestedOptionsTableTextBlock" name="ScheduleOfNonVestedOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock" name="ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock" name="ScheduleOfOtherNonOperatingGainsLossesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" name="ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock" name="ScheduleOfAntiDilutiveSecuritiestabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_Issuedate2" name="Issuedate2" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuableUponExerciseOfwarrant" name="SharesIssuableUponExerciseOfwarrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDate1" name="ExpirationDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetLossGainOnWarrantLiabilities" name="NetLossGainOnWarrantLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsExercised" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePriceWarrants" name="ExercisePriceWarrants" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercised" name="EquityWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromEquityWarrantsExercised" name="ProceedsFromEquityWarrantsExercised" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercisePrice" name="EquityWarrantsExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockIssuedForServiceShares" name="CommonStockIssuedForServiceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantInducementExpense" name="WarrantInducementExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsExercisedShares" name="WarrantsExercisedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercise" name="WarrantExercise" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDateDescription" name="ExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsExpired" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsIssuedDuringPeriod" name="WarrantsIssuedDuringPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PrepaidExpenses" name="PrepaidExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OptionIssuedToRelatedParty" name="OptionIssuedToRelatedParty" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OptionExpirationDate" name="OptionExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_Total" name="Total" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeaseLiabilities" name="LeaseLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" name="DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RightOfUseAssets" name="RightOfUseAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FixedAssetsAndIntangibles" name="FixedAssetsAndIntangibles" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetDeferredTaxAsset" name="NetDeferredTaxAsset" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ResearchAndDevelopmentCredit" name="ResearchAndDevelopmentCredit" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ResearchAndDevelopmentCreditDescription" name="ResearchAndDevelopmentCreditDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpectedLifeOfOptionsMin1" name="ExpectedLifeOfOptionsMin1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpectedLifeOfOptionsMax" name="ExpectedLifeOfOptionsMax" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfOptionsVested" name="NumberOfOptionsVested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfOptionsExercised" name="NumberOfOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfOptions" name="NumberOfOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageExercisePriceVested" name="WeightedAverageExercisePriceVested" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageExercisePriceExpired" name="WeightedAverageExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" name="WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" name="WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AggregateIntrinsicValue" name="AggregateIntrinsicValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AggregateIntrinsicValueOutstandingEnding" name="AggregateIntrinsicValueOutstandingEnding" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfUnvestedOptionsBeginning" name="NumberOfUnvestedOptionsBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_VestedOptions" name="VestedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GrantedOptions" name="GrantedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ForfeitedOptions" name="ForfeitedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfUnvestedOptionsEnding" name="NumberOfUnvestedOptionsEnding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageGrantDateFairValueBeginning" name="WeightedAverageGrantDateFairValueBeginning" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageGrantDateFairValueEnding" name="WeightedAverageGrantDateFairValueEnding" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfUnvestedSharesBeginning" name="NumberOfUnvestedSharesBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesForfeited" name="SharesForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_VestedShares" name="VestedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfUnvestedSharesEnding" name="NumberOfUnvestedSharesEnding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageGrantDateFairValue" name="WeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RemainingOutstandingFairValueOfShares" name="RemainingOutstandingFairValueOfShares" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssuanceOfRestrictedStock" name="IssuanceOfRestrictedStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RemainingCompensationExpense" name="RemainingCompensationExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PerformanceBasedStockOptionsSharesGranted" name="PerformanceBasedStockOptionsSharesGranted" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValuePerShare" name="FairValuePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GrantDateFairValueRemaining" name="GrantDateFairValueRemaining" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpenseLifeOverNext" name="ExpenseLifeOverNext" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_TotalCompensation" name="TotalCompensation" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ParticipantCompensation" name="ParticipantCompensation" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetPresentValueOfLeaseFinancingObligation" name="NetPresentValueOfLeaseFinancingObligation" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LesseeOperatingLeaseLiabilityPayments" name="LesseeOperatingLeaseLiabilityPayments" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_MaturityYears" name="MaturityYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseMaturityYears" name="OperatingLeaseMaturityYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" name="IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetBookValueOperatingLeaseRightOfUseAssets" name="NetBookValueOperatingLeaseRightOfUseAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CurrentBalance" name="CurrentBalance" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" name="NetBookValueOfTheFinanceLeaseRightOfUseAsset" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_BalanceOfTheFinanceLeaseLiability" name="BalanceOfTheFinanceLeaseLiability" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CashPaidRelatedToFinanceLeases" name="CashPaidRelatedToFinanceLeases" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CashPaidRelatedToFinanceLeasesInterest" name="CashPaidRelatedToFinanceLeasesInterest" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ClinicalServiceTrial" name="ClinicalServiceTrial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AdditionalClinicalTrial" name="AdditionalClinicalTrial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetOfDiscount" name="NetOfDiscount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseObligationsNetOfCurrentPortion" name="FinanceLeaseObligationsNetOfCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CostIncurredInitial" name="CostIncurredInitial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EstimatedCost" name="EstimatedCost" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingLeaseContractualArrangement" name="FinancingLeaseContractualArrangement" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsIssued" name="WarrantsIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfRestrictedSharesPurchasedByRelatedParty" name="NumberOfRestrictedSharesPurchasedByRelatedParty" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty" name="ProceedsFromRestrictedSharesPurchasedByRelatedParty" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AmountRealizedThroughTheResaleOfShares" name="AmountRealizedThroughTheResaleOfShares" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance" name="SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses" name="SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromPublicOffering" name="ProceedsFromPublicOffering" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedFromIssuanceOrSaleOfEquity" name="ProceedFromIssuanceOrSaleOfEquity" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PrepaidAmountOfResold" name="PrepaidAmountOfResold" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" name="FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageFairValueDerivativeInstruments" name="WeightedAverageFairValueDerivativeInstruments" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageExercisePriceDerivativeInstruments" name="WeightedAverageExercisePriceDerivativeInstruments" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageRiskFreeInterestRate" name="WeightedAverageRiskFreeInterestRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_VolatilityRate" name="VolatilityRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageTimeToMaturityYear" name="WeightedAverageTimeToMaturityYear" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants" name="IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNAndXMember" id="cvm_SeriesNAndXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LandlordMember" id="cvm_LandlordMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TransactionTwoMember" id="cvm_TransactionTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberOneTwothousandNineTeenMember" id="cvm_OctoberOneTwothousandNineTeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNMember" id="cvm_SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesVMember" id="cvm_SeriesVMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesWMember" id="cvm_SeriesWMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXMember" id="cvm_SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYMember" id="cvm_SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesZZMember" id="cvm_SeriesZZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesBBMember" id="cvm_SeriesBBMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesZMember" id="cvm_SeriesZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesFFMember" id="cvm_SeriesFFMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesCCMember" id="cvm_SeriesCCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesHHMember" id="cvm_SeriesHHMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAAMember" id="cvm_SeriesAAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesJJMember" id="cvm_SeriesJJMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesLLMember" id="cvm_SeriesLLMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMMember" id="cvm_SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncomeTaxMember" id="cvm_IncomeTaxMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="cvm_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsMember" id="cvm_ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsMember" id="cvm_ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OutstandingMember" id="cvm_OutstandingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ExercisableMember" id="cvm_ExercisableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStockAwardsMember" id="cvm_RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TransactionOneMember" id="cvm_TransactionOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedMember" id="cvm_ErgomedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNWarrantsMember" id="cvm_SeriesNWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUWarrantsMember" id="cvm_SeriesUUWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXWarrantsMember" id="cvm_SeriesXWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNAndXWarrantsMember" id="cvm_SeriesNAndXWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OfficerAndDirectorMember" id="cvm_OfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FairValueInputsLevelThreeMember" id="cvm_FairValueInputsLevelThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsMember" id="cvm_OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedRestrictedStockMember" id="cvm_UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="VendorObligationsMember" id="cvm_VendorObligationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockCompensationPlansMember" id="cvm_StockCompensationPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockBonusPlansMember" id="cvm_StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonQualifiedStockOptionsPlansMember" id="cvm_NonQualifiedStockOptionsPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockOptionPlansMember" id="cvm_IncentiveStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlanMember" id="cvm_IncentiveStockBonusPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNNMember" id="cvm_SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesOOMember" id="cvm_SeriesOOMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRMember" id="cvm_SeriesRRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesSSMember" id="cvm_SeriesSSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesTTMember" id="cvm_SeriesTTMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesVVMember" id="cvm_SeriesVVMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUMember" id="cvm_SeriesUUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesVWarrantsMember" id="cvm_SeriesVWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXXWarrantsMember" id="cvm_SeriesXXWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYYWarrantsMember" id="cvm_SeriesYYWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cvm-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20210930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20210930.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20210930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20210930.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20210930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20210930.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/ORGANIZATION" xlink:href="cvm-20210930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/OperationsAndFinancing" xlink:href="cvm-20210930.xsd#OperationsAndFinancing" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20210930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptions" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PlantPropertyAndEquipment" xlink:href="cvm-20210930.xsd#PlantPropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20210930.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxes" xlink:href="cvm-20210930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensation" xlink:href="cvm-20210930.xsd#StockCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlan" xlink:href="cvm-20210930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20210930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20210930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20210930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20210930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShare" xlink:href="cvm-20210930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20210930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20210930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:href="cvm-20210930.xsd#PlantPropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20210930.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesTables" xlink:href="cvm-20210930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationTables" xlink:href="cvm-20210930.xsd#StockCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20210930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20210930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20210930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20210930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:href="cvm-20210930.xsd#WarrantsAndNonemployeeOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:href="cvm-20210930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20210930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20210930.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails1" xlink:href="cvm-20210930.xsd#PatentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20210930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails" xlink:href="cvm-20210930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails1" xlink:href="cvm-20210930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cvm-20210930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails" xlink:href="cvm-20210930.xsd#StockCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails1" xlink:href="cvm-20210930.xsd#StockCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails2" xlink:href="cvm-20210930.xsd#StockCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails3" xlink:href="cvm-20210930.xsd#StockCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails4" xlink:href="cvm-20210930.xsd#StockCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetailsNarrative" xlink:href="cvm-20210930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20210930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20210930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20210930.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20210930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20210930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="cvm-20210930.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20210930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20210930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LeaseLiabilitiesCurrentPortion" xlink:label="loc_cvmLeaseLiabilitiesCurrentPortion" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cvmLeaseLiabilitiesCurrentPortion" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="loc_us-gaapOtherNonoperatingGainsLosses" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingGainsLosses" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_cvmModificationOfWarrants" xlink:type="arc" weight="1" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ShortTermDeposits" xlink:label="loc_cvmShortTermDeposits" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmShortTermDeposits" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SuppliesUsedForRDAndManufacturing" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturing" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturing" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ModificationOfWarrant" xlink:label="loc_cvmModificationOfWarrant" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmModificationOfWarrant" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LossOnDerivativesInstruments" xlink:label="loc_cvmLossOnDerivativesInstruments" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmLossOnDerivativesInstruments" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ShortTermInvestment" xlink:label="loc_cvmShortTermInvestment" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmShortTermInvestment" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuedForSettlementOfClinicalResearchCosts" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalResearchCosts" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalResearchCosts" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetPurchasesOfUSTreasuryBills" xlink:label="loc_cvmNetPurchasesOfUSTreasuryBills" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_cvmNetPurchasesOfUSTreasuryBills" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements" xlink:label="loc_cvmProceedsFromLandlordFundingOfLeaseholdImprovements" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_cvmProceedsFromLandlordFundingOfLeaseholdImprovements" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
    <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:calculationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/OperationsAndFinancing" xlink:title="000008 - Disclosure - OPERATIONS AND FINANCING" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptions" xlink:title="000010 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PlantPropertyAndEquipment" xlink:title="000011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxes" xlink:title="000013 - Disclosure - INCOME TAXES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensation" xlink:title="000014 - Disclosure - STOCK COMPENSATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlan" xlink:title="000015 - Disclosure - EMPLOYEE BENEFIT PLAN" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000017 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000018 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000019 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShare" xlink:title="000020 - Disclosure - NET LOSS PER COMMON SHARE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000021 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" xlink:title="000023 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:title="000024 - Disclosure - PLANT, PROPERTY AND EQUIPMENT (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000025 - Disclosure - PATENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - INCOME TAXES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationTables" xlink:title="000027 - Disclosure - STOCK COMPENSATION (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000029 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareTables" xlink:title="000031 - Disclosure - NET LOSS PER COMMON SHARE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:title="000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1" xlink:title="000034 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" xlink:title="000035 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" xlink:title="000036 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" xlink:title="000037 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:title="000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000040 - Disclosure - PATENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails1" xlink:title="000041 - Disclosure - PATENTS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000042 - Disclosure - PATENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails" xlink:title="000043 - Disclosure - INCOME TAXES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails1" xlink:title="000044 - Disclosure - INCOME TAXES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:title="000045 - Disclosure - INCOME TAXES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails" xlink:title="000046 - Disclosure - STOCK COMPENSATION (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails1" xlink:title="000047 - Disclosure - STOCK COMPENSATION (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails2" xlink:title="000048 - Disclosure - STOCK COMPENSATION (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails3" xlink:title="000049 - Disclosure - STOCK COMPENSATION (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails4" xlink:title="000050 - Disclosure - STOCK COMPENSATION (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetailsNarrative" xlink:title="000051 - Disclosure - STOCK COMPENSATION (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="000052 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000056 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000057 - Disclosure - STOCKHOLDERS EQUITY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000058 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000059 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="000060 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:title="000061 - Disclosure - NET LOSS PER COMMON SHARE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:title="000062 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cvm-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20210930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20210930.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20210930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20210930.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20210930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20210930.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/ORGANIZATION" xlink:href="cvm-20210930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/OperationsAndFinancing" xlink:href="cvm-20210930.xsd#OperationsAndFinancing" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20210930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptions" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PlantPropertyAndEquipment" xlink:href="cvm-20210930.xsd#PlantPropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20210930.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxes" xlink:href="cvm-20210930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensation" xlink:href="cvm-20210930.xsd#StockCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlan" xlink:href="cvm-20210930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20210930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20210930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20210930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20210930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShare" xlink:href="cvm-20210930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20210930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20210930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:href="cvm-20210930.xsd#PlantPropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20210930.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesTables" xlink:href="cvm-20210930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationTables" xlink:href="cvm-20210930.xsd#StockCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20210930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20210930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20210930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20210930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:href="cvm-20210930.xsd#WarrantsAndNonemployeeOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:href="cvm-20210930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20210930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20210930.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails1" xlink:href="cvm-20210930.xsd#PatentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20210930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails" xlink:href="cvm-20210930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails1" xlink:href="cvm-20210930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cvm-20210930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails" xlink:href="cvm-20210930.xsd#StockCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails1" xlink:href="cvm-20210930.xsd#StockCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails2" xlink:href="cvm-20210930.xsd#StockCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails3" xlink:href="cvm-20210930.xsd#StockCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails4" xlink:href="cvm-20210930.xsd#StockCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetailsNarrative" xlink:href="cvm-20210930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20210930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20210930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20210930.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20210930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20210930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="cvm-20210930.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20210930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20210930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AdoptionOfAsc842Leases" xlink:label="loc_cvmAdoptionOfAsc842Leases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAdoptionOfAsc842Leases" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromTheSaleOfCommonStockShares" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockShares" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantIssuances" xlink:label="loc_cvmWarrantIssuances" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantIssuances" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesAmount" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ModificationOfWarrantsAmount" xlink:label="loc_cvmModificationOfWarrantsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmModificationOfWarrantsAmount" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" xlink:label="loc_cvmStockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" xlink:label="loc_cvmStockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmShareIssuanceCosts" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalResearchCostsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalResearchCostsShares" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalResearchCostsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalResearchCostsAmount" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" order="23" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/OperationsAndFinancing" xlink:title="000008 - Disclosure - OPERATIONS AND FINANCING" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptions" xlink:title="000010 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PlantPropertyAndEquipment" xlink:title="000011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxes" xlink:title="000013 - Disclosure - INCOME TAXES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensation" xlink:title="000014 - Disclosure - STOCK COMPENSATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlan" xlink:title="000015 - Disclosure - EMPLOYEE BENEFIT PLAN" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000017 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000018 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000019 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShare" xlink:title="000020 - Disclosure - NET LOSS PER COMMON SHARE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000021 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" xlink:title="000023 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:title="000024 - Disclosure - PLANT, PROPERTY AND EQUIPMENT (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000025 - Disclosure - PATENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - INCOME TAXES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationTables" xlink:title="000027 - Disclosure - STOCK COMPENSATION (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000029 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareTables" xlink:title="000031 - Disclosure - NET LOSS PER COMMON SHARE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:title="000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesNMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesWMember" xlink:label="loc_cvmSeriesWMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesWMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesXMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesYMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZZMember" xlink:label="loc_cvmSeriesZZMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZZMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesBBMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesCCMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesHHMember" xlink:label="loc_cvmSeriesHHMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesHHMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesAAMember" xlink:label="loc_cvmSeriesAAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesAAMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesMMMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesNNMember" order="72" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="73" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesRRMember" order="74" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesSSMember" order="75" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesTTMember" order="76" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesUUMember" order="77" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_Issuedate2" xlink:label="loc_cvmIssuedate2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssuedate2" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_cvmSharesIssuableUponExerciseOfwarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuableUponExerciseOfwarrant" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpirationDate1" xlink:label="loc_cvmExpirationDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate1" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1" xlink:title="000034 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesWMember" xlink:label="loc_cvmSeriesWMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesWMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZZMember" xlink:label="loc_cvmSeriesZZMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZZMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesBBMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesCCMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesHHMember" xlink:label="loc_cvmSeriesHHMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesHHMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesAAMember" xlink:label="loc_cvmSeriesAAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesAAMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesFFMember" xlink:label="loc_cvmSeriesFFMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesFFMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesJJMember" xlink:label="loc_cvmSeriesJJMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesJJMember" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesLLMember" xlink:label="loc_cvmSeriesLLMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesLLMember" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVMember" xlink:label="loc_cvmSeriesVMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesVMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetLossGainOnWarrantLiabilities" xlink:label="loc_cvmNetLossGainOnWarrantLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetLossGainOnWarrantLiabilities" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" xlink:title="000035 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZZMember" xlink:label="loc_cvmSeriesZZMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZZMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesCCMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesHHMember" xlink:label="loc_cvmSeriesHHMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesHHMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesAAMember" xlink:label="loc_cvmSeriesAAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesAAMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesFFMember" xlink:label="loc_cvmSeriesFFMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesFFMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesJJMember" xlink:label="loc_cvmSeriesJJMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesJJMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesLLMember" xlink:label="loc_cvmSeriesLLMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesLLMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVMember" xlink:label="loc_cvmSeriesVMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesVMember" order="19" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsExercised" xlink:label="loc_cvmWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsExercised" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExercisePriceWarrants" xlink:label="loc_cvmExercisePriceWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePriceWarrants" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" xlink:title="000036 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesMMMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesNNMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesRRMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesSSMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesTTMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesUUMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesOOMember" xlink:label="loc_cvmSeriesOOMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesOOMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVVMember" xlink:label="loc_cvmSeriesVVMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesVVMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercised" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercisePrice" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" xlink:title="000037 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="80" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="90" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="110" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesWMember" xlink:label="loc_cvmSeriesWMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesWMember" order="91" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesYMember" order="92" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesBBMember" order="93" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVWarrantsMember" xlink:label="loc_cvmSeriesVWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesVWarrantsMember" order="94" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="95" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="96" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesXXWarrantsMember" xlink:label="loc_cvmSeriesXXWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXXWarrantsMember" order="97" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesYYWarrantsMember" xlink:label="loc_cvmSeriesYYWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesYYWarrantsMember" order="98" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUWarrantsMember" xlink:label="loc_cvmSeriesUUWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUWarrantsMember" order="99" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNAndXMember" xlink:label="loc_cvmSeriesNAndXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNAndXMember" order="100" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNWarrantsMember" xlink:label="loc_cvmSeriesNWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNWarrantsMember" order="101" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmRestrictedStocksMember" order="102" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="103" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsMember" order="104" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaapDefinedBenefitPlanInterestCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDefinedBenefitPlanInterestCost" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CommonStockIssuedForServiceShares" xlink:label="loc_cvmCommonStockIssuedForServiceShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCommonStockIssuedForServiceShares" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantInducementExpense" xlink:label="loc_cvmWarrantInducementExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantInducementExpense" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsExercisedShares" xlink:label="loc_cvmWarrantsExercisedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsExercisedShares" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantExercise" xlink:label="loc_cvmWarrantExercise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercise" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpirationDateDescription" xlink:label="loc_cvmExpirationDateDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDateDescription" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsExpired" xlink:label="loc_cvmWarrantsExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsExpired" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsIssuedDuringPeriod" xlink:label="loc_cvmWarrantsIssuedDuringPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsIssuedDuringPeriod" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PrepaidExpenses" xlink:label="loc_cvmPrepaidExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPrepaidExpenses" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OptionIssuedToRelatedParty" xlink:label="loc_cvmOptionIssuedToRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmOptionIssuedToRelatedParty" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OptionExpirationDate" xlink:label="loc_cvmOptionExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmOptionExpirationDate" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="17" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:title="000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000040 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedPatentsGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails1" xlink:title="000041 - Disclosure - PATENTS (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000042 - Disclosure - PATENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails" xlink:title="000043 - Disclosure - INCOME TAXES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails1" xlink:title="000044 - Disclosure - INCOME TAXES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:title="000045 - Disclosure - INCOME TAXES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncomeTaxMember" xlink:label="loc_cvmIncomeTaxMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_cvmIncomeTaxMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ResearchAndDevelopmentCredit" xlink:label="loc_cvmResearchAndDevelopmentCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmResearchAndDevelopmentCredit" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ResearchAndDevelopmentCreditDescription" xlink:label="loc_cvmResearchAndDevelopmentCreditDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmResearchAndDevelopmentCreditDescription" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CumulativeChangeInOwnershipPercentage" xlink:label="loc_cvmCumulativeChangeInOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCumulativeChangeInOwnershipPercentage" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails" xlink:title="000046 - Disclosure - STOCK COMPENSATION (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails1" xlink:title="000047 - Disclosure - STOCK COMPENSATION (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails2" xlink:title="000048 - Disclosure - STOCK COMPENSATION (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExercisableMember" xlink:label="loc_cvmExercisableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_cvmExercisableMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OutstandingMember" xlink:label="loc_cvmOutstandingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmOutstandingMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfOptionsVested" xlink:label="loc_cvmNumberOfOptionsVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfOptionsVested" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfOptionsExercised" xlink:label="loc_cvmNumberOfOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfOptionsExercised" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfOptions" xlink:label="loc_cvmNumberOfOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfOptions" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageExercisePriceVested" xlink:label="loc_cvmWeightedAverageExercisePriceVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageExercisePriceVested" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageExercisePriceExpired" xlink:label="loc_cvmWeightedAverageExercisePriceExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageExercisePriceExpired" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AggregateIntrinsicValue" xlink:label="loc_cvmAggregateIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAggregateIntrinsicValue" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AggregateIntrinsicValueOutstandingEnding" xlink:label="loc_cvmAggregateIntrinsicValueOutstandingEnding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAggregateIntrinsicValueOutstandingEnding" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="18" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails3" xlink:title="000049 - Disclosure - STOCK COMPENSATION (Details 3)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails4" xlink:title="000050 - Disclosure - STOCK COMPENSATION (Details 4)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmRestrictedStockAwardsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedSharesBeginning" xlink:label="loc_cvmNumberOfUnvestedSharesBeginning" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfUnvestedSharesBeginning" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesForfeited" xlink:label="loc_cvmSharesForfeited" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesForfeited" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VestedShares" xlink:label="loc_cvmVestedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmVestedShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedSharesEnding" xlink:label="loc_cvmNumberOfUnvestedSharesEnding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfUnvestedSharesEnding" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageGrantDateFairValueBeginning" xlink:label="loc_cvmWeightedAverageGrantDateFairValueBeginning" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageGrantDateFairValueBeginning" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageGrantDateFairValue" xlink:label="loc_cvmWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageGrantDateFairValue" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetailsNarrative" xlink:title="000051 - Disclosure - STOCK COMPENSATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmStockBonusPlansMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockCompensationPlansMember" xlink:label="loc_cvmStockCompensationPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmStockCompensationPlansMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="loc_cvmIncentiveStockOptionPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmIncentiveStockOptionPlansMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmIncentiveStockBonusPlanMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RemainingCompensationExpense" xlink:label="loc_cvmRemainingCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmRemainingCompensationExpense" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PerformanceBasedStockOptionsSharesGranted" xlink:label="loc_cvmPerformanceBasedStockOptionsSharesGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPerformanceBasedStockOptionsSharesGranted" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockDescription" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValuePerShare" xlink:label="loc_cvmFairValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFairValuePerShare" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RemainingOutstandingFairValueOfShares" xlink:label="loc_cvmRemainingOutstandingFairValueOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmRemainingOutstandingFairValueOfShares" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_GrantDateFairValueRemaining" xlink:label="loc_cvmGrantDateFairValueRemaining" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmGrantDateFairValueRemaining" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpenseLifeOverNext" xlink:label="loc_cvmExpenseLifeOverNext" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpenseLifeOverNext" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VestedShares" xlink:label="loc_cvmVestedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmVestedShares" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IssuanceOfRestrictedStock" xlink:label="loc_cvmIssuanceOfRestrictedStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssuanceOfRestrictedStock" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaapDeferredCompensationEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredCompensationEquity" order="16" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="000052 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="80" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="80" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="90" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="100" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="110" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" order="120" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VendorObligationsMember" xlink:label="loc_cvmVendorObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cvmVendorObligationsMember" order="101" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmLandlordMember" order="102" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_TransactionTwoMember" xlink:label="loc_cvmTransactionTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_cvmTransactionTwoMember" order="103" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OctoberOneTwothousandNineTeenMember" xlink:label="loc_cvmOctoberOneTwothousandNineTeenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cvmOctoberOneTwothousandNineTeenMember" order="104" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_TransactionOneMember" xlink:label="loc_cvmTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_cvmTransactionOneMember" order="105" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="106" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" order="107" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeVariableInterestRate" xlink:label="loc_us-gaapDerivativeVariableInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeVariableInterestRate" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_MaturityYears" xlink:label="loc_cvmMaturityYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmMaturityYears" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OperatingLeaseMaturityYears" xlink:label="loc_cvmOperatingLeaseMaturityYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmOperatingLeaseMaturityYears" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetOfDiscount" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinanceLeaseObligationsNetOfCurrentPortion" xlink:label="loc_cvmFinanceLeaseObligationsNetOfCurrentPortion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinanceLeaseObligationsNetOfCurrentPortion" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaapLeaseIncentivePayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseIncentivePayableCurrent" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CostIncurredInitial" xlink:label="loc_cvmCostIncurredInitial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCostIncurredInitial" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_EstimatedCost" xlink:label="loc_cvmEstimatedCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEstimatedCost" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrent" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinancingLeaseContractualArrangement" xlink:label="loc_cvmFinancingLeaseContractualArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinancingLeaseContractualArrangement" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" xlink:label="loc_cvmIncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetBookValueOperatingLeaseRightOfUseAssets" xlink:label="loc_cvmNetBookValueOperatingLeaseRightOfUseAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetBookValueOperatingLeaseRightOfUseAssets" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CurrentBalance" xlink:label="loc_cvmCurrentBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCurrentBalance" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" xlink:label="loc_cvmNetBookValueOfTheFinanceLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetBookValueOfTheFinanceLeaseRightOfUseAsset" order="25" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_BalanceOfTheFinanceLeaseLiability" xlink:label="loc_cvmBalanceOfTheFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmBalanceOfTheFinanceLeaseLiability" order="26" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CashPaidRelatedToFinanceLeases" xlink:label="loc_cvmCashPaidRelatedToFinanceLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCashPaidRelatedToFinanceLeases" order="27" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CashPaidRelatedToFinanceLeasesInterest" xlink:label="loc_cvmCashPaidRelatedToFinanceLeasesInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCashPaidRelatedToFinanceLeasesInterest" order="28" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmClinicalServiceTrial" order="29" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AdditionalClinicalTrial" xlink:label="loc_cvmAdditionalClinicalTrial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAdditionalClinicalTrial" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" order="31" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubleaseIncome" order="32" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000056 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNWarrantsMember" xlink:label="loc_cvmSeriesNWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNWarrantsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUWarrantsMember" xlink:label="loc_cvmSeriesUUWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUWarrantsMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesXWarrantsMember" xlink:label="loc_cvmSeriesXWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXWarrantsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNAndXWarrantsMember" xlink:label="loc_cvmSeriesNAndXWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNAndXWarrantsMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OfficerAndDirectorMember" xlink:label="loc_cvmOfficerAndDirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmOfficerAndDirectorMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpirationDateDescription" xlink:label="loc_cvmExpirationDateDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDateDescription" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsIssued" xlink:label="loc_cvmWarrantsIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsIssued" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseRelatedParty" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfRestrictedSharesPurchasedByRelatedParty" xlink:label="loc_cvmNumberOfRestrictedSharesPurchasedByRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfRestrictedSharesPurchasedByRelatedParty" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty" xlink:label="loc_cvmProceedsFromRestrictedSharesPurchasedByRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromRestrictedSharesPurchasedByRelatedParty" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000057 - Disclosure - STOCKHOLDERS EQUITY (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000058 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromPublicOffering" xlink:label="loc_cvmProceedsFromPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromPublicOffering" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:label="loc_cvmProceedFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedFromIssuanceOrSaleOfEquity" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PrepaidAmountOfResold" xlink:label="loc_cvmPrepaidAmountOfResold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPrepaidAmountOfResold" order="7" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000059 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="000060 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValueInputsLevelThreeMember" xlink:label="loc_cvmFairValueInputsLevelThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_cvmFairValueInputsLevelThreeMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageRiskFreeInterestRate" xlink:label="loc_cvmWeightedAverageRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageRiskFreeInterestRate" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageFairValueDerivativeInstruments" xlink:label="loc_cvmWeightedAverageFairValueDerivativeInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageFairValueDerivativeInstruments" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageExercisePriceDerivativeInstruments" xlink:label="loc_cvmWeightedAverageExercisePriceDerivativeInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageExercisePriceDerivativeInstruments" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VolatilityRate" xlink:label="loc_cvmVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmVolatilityRate" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageTimeToMaturityYear" xlink:label="loc_cvmWeightedAverageTimeToMaturityYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageTimeToMaturityYear" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:title="000061 - Disclosure - NET LOSS PER COMMON SHARE (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:title="000062 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedRestrictedStockMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cvm-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_26b5e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_26b5e6" xml:lang="en-US">CONDENSED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_146a10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_146a10" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_c1bf07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_c1bf07" xml:lang="en-US">Current Assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_84fbd4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_84fbd4" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl_1c4681" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl_1c4681" xml:lang="en-US">U.S. Treasury Bills</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl_192914" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl_192914" xml:lang="en-US">Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_1355ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_1355ba" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_7014d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl_7014d9" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_a7cad0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_a7cad0" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_9" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_9c1a11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_9c1a11" xml:lang="en-US">Finance lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_b10ade" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_b10ade" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_19ee41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_19ee41" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl_1a98b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl_1a98b5" xml:lang="en-US">Patent costs, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl_bf8047" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl_bf8047" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_1e57ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_1e57ee" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_15" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_df801b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_df801b" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_fde42d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_fde42d" xml:lang="en-US">Current Liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_a74a2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_a74a2e" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_456359" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_456359" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent_lbl_c6a31a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent_lbl_c6a31a" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl_11195f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl_11195f" xml:lang="en-US">Derivative instruments, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LeaseLiabilitiesCurrentPortion" xlink:label="cvm_LeaseLiabilitiesCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeaseLiabilitiesCurrentPortion" xlink:to="cvm_LeaseLiabilitiesCurrentPortion_lbl_847313" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeaseLiabilitiesCurrentPortion_lbl_847313" xml:lang="en-US">Lease liabilities, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_715724" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_715724" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_23" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl_508903" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl_508903" xml:lang="en-US">Derivative instruments, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_523248" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_523248" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_d2ab80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_d2ab80" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_5078a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_5078a1" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_eeb21f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_eeb21f" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_28" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_17fe7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_17fe7f" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_58900e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_58900e" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_85ac34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_85ac34" xml:lang="en-US">Preferred stock, $.01 par value- 200,000 shares authorized; -0- shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_44c8dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_44c8dc" xml:lang="en-US">Common stock, $.01 par value - 600,000,000 shares authorized;43,207,183 and 38,730,150 shares issued and outstanding at September 30, 2021 and 2020, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_437fa2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_437fa2" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_41f77b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_41f77b" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_a24dfd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_a24dfd" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_35" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_ae15f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_ae15f5" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_36" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_5227ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_5227ea" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_8ca307" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_8ca307" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_ccd1ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_ccd1ef" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_884121" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_884121" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_ab1952" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_ab1952" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_ef4d78" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_ef4d78" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_711a77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_711a77" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_041311" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_041311" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_83f993" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_83f993" xml:lang="en-US">CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl_d2772c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl_d2772c" xml:lang="en-US">Grant income</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_af7bf6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_af7bf6" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_42e089" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_42e089" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_188060" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_188060" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_d964cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_d964cf" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_6" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_d10a26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_d10a26" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_7" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_d0416b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_d0416b" xml:lang="en-US">Other (expense) income</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_3af0d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_3af0d6" xml:lang="en-US">Loss on derivative instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl_06562c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl_06562c" xml:lang="en-US">Warrant inducement expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl_10" xml:lang="en-US">[Fair Value Adjustment of Warrants]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="us-gaap_OtherNonoperatingGainsLosses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingGainsLosses" xlink:to="us-gaap_OtherNonoperatingGainsLosses_lbl_4692d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingGainsLosses_lbl_4692d3" xml:lang="en-US">Other non-operating gain</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl_0ffb19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl_0ffb19" xml:lang="en-US">Interest expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_0212c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_0212c8" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_13" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ModificationOfWarrants" xlink:label="cvm_ModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrants" xlink:to="cvm_ModificationOfWarrants_lbl_ef8f86" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrants_lbl_ef8f86" xml:lang="en-US">Modification of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_b603c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_b603c9" xml:lang="en-US">Net loss available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_15" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl_094ba1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl_094ba1" xml:lang="en-US">Net loss per common share - basic</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_9f4e27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_9f4e27" xml:lang="en-US">Weighted average common shares outstanding - basic</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl_20e374" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl_20e374" xml:lang="en-US">Net loss per common share - diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_4781bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_4781bd" xml:lang="en-US">Weighted average common shares outstanding - diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_7213b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_7213b6" xml:lang="en-US">STATEMENTS OF STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_e13741" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_e13741" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_0c617e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_0c617e" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_905579" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_905579" xml:lang="en-US">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_da7f91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_da7f91" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_5a6fcb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_5a6fcb" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_d11938" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_d11938" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_e3e8d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_e3e8d7" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_1b3be2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_1b3be2" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AdoptionOfAsc842Leases" xlink:label="cvm_AdoptionOfAsc842Leases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AdoptionOfAsc842Leases" xlink:to="cvm_AdoptionOfAsc842Leases_lbl_475a5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AdoptionOfAsc842Leases_lbl_475a5f" xml:lang="en-US">Adoption of ASC 842, Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromTheSaleOfCommonStockShares" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromTheSaleOfCommonStockShares" xlink:to="cvm_ProceedsFromTheSaleOfCommonStockShares_lbl_ed330f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockShares_lbl_ed330f" xml:lang="en-US">Proceeds from the sale of common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_e20ec2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_e20ec2" xml:lang="en-US">Proceeds from the sale of common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantIssuances" xlink:label="cvm_WarrantIssuances" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantIssuances" xlink:to="cvm_WarrantIssuances_lbl_bdf9cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantIssuances_lbl_bdf9cc" xml:lang="en-US">Warrant issuances</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantExercisesShares" xlink:label="cvm_WarrantExercisesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesShares" xlink:to="cvm_WarrantExercisesShares_lbl_39cdb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesShares_lbl_39cdb3" xml:lang="en-US">Warrant exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantExercisesAmount" xlink:label="cvm_WarrantExercisesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesAmount" xlink:to="cvm_WarrantExercisesAmount_lbl_cf0433" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesAmount_lbl_cf0433" xml:lang="en-US">Warrant exercises, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrantsAmount" xlink:to="cvm_ModificationOfWarrantsAmount_lbl_70d3c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ModificationOfWarrantsAmount_lbl_70d3c8" xml:lang="en-US">Modification of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ModificationOfWarrantsAmount" xlink:label="cvm_ModificationOfWarrantsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrantsAmount" xlink:to="cvm_ModificationOfWarrantsAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrantsAmount_lbl_10" xml:lang="en-US">[Modification of warrants]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_045177" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_045177" xml:lang="en-US">401(k) contributions paid in common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_9b093f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_9b093f" xml:lang="en-US">401(k) contributions paid in common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_4d163b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_4d163b" xml:lang="en-US">Stock issued to nonemployees for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_a4cfb8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_a4cfb8" xml:lang="en-US">Stock issued to nonemployees for service, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_cefb8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_cefb8f" xml:lang="en-US">Equity based compensation - employees</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_aa601d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_aa601d" xml:lang="en-US">Option exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_b7a971" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_b7a971" xml:lang="en-US">Option exercises, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" xlink:label="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" xlink:to="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues_lbl_4c7821" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues_lbl_4c7821" xml:lang="en-US">Purchase of stock by officers and directors, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" xlink:label="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" xlink:to="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount_lbl_3b810e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount_lbl_3b810e" xml:lang="en-US">Purchase of stock by officers and directors, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ShareIssuanceCosts" xlink:label="cvm_ShareIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_lbl_4f1c0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShareIssuanceCosts_lbl_4f1c0e" xml:lang="en-US">Share issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares" xlink:label="cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares" xlink:to="cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares_lbl_a20b62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares_lbl_a20b62" xml:lang="en-US">Shares issued for settlement of clinical research costs, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount" xlink:label="cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount" xlink:to="cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount_lbl_6acaa2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount_lbl_6acaa2" xml:lang="en-US">Shares issued for settlement of clinical research costs, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_1c5930" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_1c5930" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_6f7bf6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_6f7bf6" xml:lang="en-US">Equity based compensation - employees, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_1462ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_1462ff" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_9e2982" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_9e2982" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_3640f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_3640f0" xml:lang="en-US">CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_3f129f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_3f129f" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_a71852" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_a71852" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e188e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e188e0" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_703e1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_703e1e" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_af440c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_af440c" xml:lang="en-US">Share-based payments for services</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_e756a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_e756a8" xml:lang="en-US">Equity based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:to="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_7156f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_7156f0" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuedForSettlementOfClinicalResearchCosts" xlink:label="cvm_SharesIssuedForSettlementOfClinicalResearchCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuedForSettlementOfClinicalResearchCosts" xlink:to="cvm_SharesIssuedForSettlementOfClinicalResearchCosts_lbl_a02ec7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuedForSettlementOfClinicalResearchCosts_lbl_a02ec7" xml:lang="en-US">Shares issued for settlement of clinical research costs</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ShortTermInvestment" xlink:label="cvm_ShortTermInvestment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShortTermInvestment" xlink:to="cvm_ShortTermInvestment_lbl_020aaf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShortTermInvestment_lbl_020aaf" xml:lang="en-US">Gain on short-term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LossOnDerivativesInstruments" xlink:to="cvm_LossOnDerivativesInstruments_lbl_04a215" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LossOnDerivativesInstruments_lbl_04a215" xml:lang="en-US">Loss on derivative instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LossOnDerivativesInstruments" xlink:label="cvm_LossOnDerivativesInstruments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LossOnDerivativesInstruments" xlink:to="cvm_LossOnDerivativesInstruments_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LossOnDerivativesInstruments_lbl_11" xml:lang="en-US">[Loss on derivative instruments]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl_4db086" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl_4db086" xml:lang="en-US">Warrant inducement expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrant" xlink:to="cvm_ModificationOfWarrant_lbl_bffc66" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ModificationOfWarrant_lbl_bffc66" xml:lang="en-US">Modification of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ModificationOfWarrant" xlink:label="cvm_ModificationOfWarrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrant" xlink:to="cvm_ModificationOfWarrant_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrant_lbl_13" xml:lang="en-US">[Modification of warrants 1]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_e1dd1a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_e1dd1a" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl_a4b7e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl_a4b7e9" xml:lang="en-US">Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl_15" xml:lang="en-US">[Increase (Decrease) in Receivables]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_f3260b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_f3260b" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_16" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturing" xlink:to="cvm_SuppliesUsedForRDAndManufacturing_lbl_cac5e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_SuppliesUsedForRDAndManufacturing_lbl_cac5e4" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SuppliesUsedForRDAndManufacturing" xlink:label="cvm_SuppliesUsedForRDAndManufacturing" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturing" xlink:to="cvm_SuppliesUsedForRDAndManufacturing_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturing_lbl_17" xml:lang="en-US">[Supplies used for R&amp;D and manufacturing]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShortTermDeposits" xlink:to="cvm_ShortTermDeposits_lbl_499d9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ShortTermDeposits_lbl_499d9a" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ShortTermDeposits" xlink:label="cvm_ShortTermDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShortTermDeposits" xlink:to="cvm_ShortTermDeposits_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShortTermDeposits_lbl_18" xml:lang="en-US">[Deposits]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_29c490" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_29c490" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_f597d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_f597d6" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_20" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_64f8d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_64f8d9" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_21" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl_e0a155" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl_e0a155" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl_22" xml:lang="en-US">[Increase (Decrease) in Due to Officers and Stockholders]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl_840298" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl_840298" xml:lang="en-US">Other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl_23" xml:lang="en-US">[Increase (Decrease) in Other Operating Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_a133ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_a133ea" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_24" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_995c48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_995c48" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetPurchasesOfUSTreasuryBills" xlink:to="cvm_NetPurchasesOfUSTreasuryBills_lbl_0fd380" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_NetPurchasesOfUSTreasuryBills_lbl_0fd380" xml:lang="en-US">Net purchases of U.S. Treasury Bills</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetPurchasesOfUSTreasuryBills" xlink:label="cvm_NetPurchasesOfUSTreasuryBills" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetPurchasesOfUSTreasuryBills" xlink:to="cvm_NetPurchasesOfUSTreasuryBills_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetPurchasesOfUSTreasuryBills_lbl_26" xml:lang="en-US">[Net purchases of U.S. Treasury Bills]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_59e24d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_59e24d" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_27" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_b3c78e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_b3c78e" xml:lang="en-US">Expenditures for patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_28" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_d01ca7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_d01ca7" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_29" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_f89112" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_f89112" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_48d3b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_48d3b5" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_1f9990" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_1f9990" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_32" xml:lang="en-US">[Payments of Stock Issuance Costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_80563f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_80563f" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl_8f9388" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl_8f9388" xml:lang="en-US">Proceeds from exercises of options</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl_eede2c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl_eede2c" xml:lang="en-US">Proceeds from the purchase of stock by officers and directors</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements" xlink:label="cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements" xlink:to="cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements_lbl_122011" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements_lbl_122011" xml:lang="en-US">Proceeds from landlord funding of leasehold improvements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_79080c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_79080c" xml:lang="en-US">Payments on obligations under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_37" xml:lang="en-US">[Repayments of Debt and Lease Obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_b55710" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_b55710" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_38" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_6681db" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_6681db" xml:lang="en-US">NET INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_39" xml:lang="en-US">[Cash and Cash Equivalents, Period Increase (Decrease)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_0bd342" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_0bd342" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_ce4d6d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_ce4d6d" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF YEAR</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_137e55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_137e55" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable" xlink:label="cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable" xlink:to="cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable_lbl_21e6dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable_lbl_21e6dc" xml:lang="en-US">Property and equipment included in accrued expenses and accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" xlink:label="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" xlink:to="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable_lbl_b105f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable_lbl_b105f2" xml:lang="en-US">Capitalizable patent costs included in accrued expenses and accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ChangesToRightOfUseAssetsAndLiabilities" xlink:label="cvm_ChangesToRightOfUseAssetsAndLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ChangesToRightOfUseAssetsAndLiabilities" xlink:to="cvm_ChangesToRightOfUseAssetsAndLiabilities_lbl_230814" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ChangesToRightOfUseAssetsAndLiabilities_lbl_230814" xml:lang="en-US">Changes to right of use assets and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:to="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_31677b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_31677b" xml:lang="en-US">Finance lease obligation included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" xlink:to="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock_lbl_ed2e75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock_lbl_ed2e75" xml:lang="en-US">Prepaid consulting services paid with issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise" xlink:label="cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise" xlink:to="cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise_lbl_3e3342" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise_lbl_3e3342" xml:lang="en-US">Fair value of warrants liabilities on date of exercise</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinancingCostsIncludedInAccountsPayable" xlink:label="cvm_FinancingCostsIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingCostsIncludedInAccountsPayable" xlink:to="cvm_FinancingCostsIncludedInAccountsPayable_lbl_01e370" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingCostsIncludedInAccountsPayable_lbl_01e370" xml:lang="en-US">Financing costs included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AccruedConsultingServicesToBePaidWithCommonStock" xlink:label="cvm_AccruedConsultingServicesToBePaidWithCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AccruedConsultingServicesToBePaidWithCommonStock" xlink:to="cvm_AccruedConsultingServicesToBePaidWithCommonStock_lbl_65b606" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AccruedConsultingServicesToBePaidWithCommonStock_lbl_65b606" xml:lang="en-US">Accrued consulting services to be paid with common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_0aec38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_0aec38" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_5bbab0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_5bbab0" xml:lang="en-US">ORGANIZATION</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_52cc00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_52cc00" xml:lang="en-US">1. ORGANIZATION</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl_4456fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl_4456fb" xml:lang="en-US">OPERATIONS AND FINANCING</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl_36eac6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl_36eac6" xml:lang="en-US">2. OPERATIONS AND FINANCING</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_364b71" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_364b71" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_0a9e07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_0a9e07" xml:lang="en-US">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract_lbl_6de6b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAbstract_lbl_6de6b9" xml:lang="en-US">WARRANTS AND NON-EMPLOYEE OPTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsAndNonEmployeeOptionstextblock" xlink:label="cvm_WarrantsAndNonEmployeeOptionstextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsAndNonEmployeeOptionstextblock" xlink:to="cvm_WarrantsAndNonEmployeeOptionstextblock_lbl_9b8b5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsAndNonEmployeeOptionstextblock_lbl_9b8b5a" xml:lang="en-US">4. WARRANTS AND NON-EMPLOYEE OPTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_5b4d8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_5b4d8f" xml:lang="en-US">PLANT, PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_1cbcb8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_1cbcb8" xml:lang="en-US">5. PLANT, PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_7ad4dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_7ad4dd" xml:lang="en-US">PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_77ab1f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_77ab1f" xml:lang="en-US">6. PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl_867569" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl_867569" xml:lang="en-US">INCOME TAXES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_9d5c6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_9d5c6b" xml:lang="en-US">7. INCOME TAXES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_18193f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_18193f" xml:lang="en-US">STOCK COMPENSATION</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_6f6e72" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_6f6e72" xml:lang="en-US">8. STOCK COMPENSATION</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl_f1da16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl_f1da16" xml:lang="en-US">EMPLOYEE BENEFIT PLAN</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_60720f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_60720f" xml:lang="en-US">9. EMPLOYEE BENEFIT PLAN</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_35f8f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_35f8f6" xml:lang="en-US">10. COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_58662d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_58662d" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_817292" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_817292" xml:lang="en-US">11. RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_00205d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_00205d" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_1ef2c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_1ef2c2" xml:lang="en-US">12. STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl_52719b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl_52719b" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_b40960" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_b40960" xml:lang="en-US">13. FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_257b30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_257b30" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_6a90b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_6a90b2" xml:lang="en-US">14. NET LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_20dd38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_20dd38" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_c1518c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_c1518c" xml:lang="en-US">15. SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_c4e936" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_c4e936" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_USTreasuryBills" xlink:to="cvm_USTreasuryBills_lbl_51511d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_USTreasuryBills_lbl_51511d" xml:lang="en-US">U.S. Treasury Bills</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_USTreasuryBills" xlink:label="cvm_USTreasuryBills" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_USTreasuryBills" xlink:to="cvm_USTreasuryBills_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_USTreasuryBills_lbl_3" xml:lang="en-US">[U.S. Treasury Bills]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingPolicytextblock" xlink:to="cvm_SuppliesUsedForRDAndManufacturingPolicytextblock_lbl_adaa4e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_SuppliesUsedForRDAndManufacturingPolicytextblock_lbl_adaa4e" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SuppliesUsedForRDAndManufacturingPolicytextblock" xlink:label="cvm_SuppliesUsedForRDAndManufacturingPolicytextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingPolicytextblock" xlink:to="cvm_SuppliesUsedForRDAndManufacturingPolicytextblock_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingPolicytextblock_lbl_4" xml:lang="en-US">[Supplies used for R&amp;D and manufacturing 1]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_7f3b5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_7f3b5f" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_e7b01c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_e7b01c" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LeasesPolicyTextBlock" xlink:label="cvm_LeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeasesPolicyTextBlock" xlink:to="cvm_LeasesPolicyTextBlock_lbl_c9c75f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeasesPolicyTextBlock_lbl_c9c75f" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl_da307b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl_da307b" xml:lang="en-US">Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl_8ef6c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl_8ef6c4" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_9706ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_9706ec" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_GrantIncomePolicyTextBlock" xlink:label="cvm_GrantIncomePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GrantIncomePolicyTextBlock" xlink:to="cvm_GrantIncomePolicyTextBlock_lbl_d546cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GrantIncomePolicyTextBlock_lbl_d546cb" xml:lang="en-US">Grant Income</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_5f60f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_5f60f4" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:to="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl_32b9ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl_32b9ff" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_d7b614" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_d7b614" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_5d522c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_5d522c" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_5f7e53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_5f7e53" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock" xlink:to="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock_lbl_8ae0d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock_lbl_8ae0d8" xml:lang="en-US">Schedule of warrants and non-employee options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" xlink:label="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" xlink:to="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock_lbl_e7176a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock_lbl_e7176a" xml:lang="en-US">Schedule of equity warrants were exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" xlink:label="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" xlink:to="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock_lbl_33112c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock_lbl_33112c" xml:lang="en-US">Schedule of warrants recorded as liabilities were exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl_55ee83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl_55ee83" xml:lang="en-US">Schedule of warrant liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" xlink:label="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" xlink:to="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock_lbl_1b4b04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock_lbl_1b4b04" xml:lang="en-US">Schedule of (losses)/gains on the warrant liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl_304062" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl_304062" xml:lang="en-US">Schedule of plant, property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl_a1d67e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl_a1d67e" xml:lang="en-US">Schedule of patents</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl_3cc003" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl_3cc003" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock" xlink:label="cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock" xlink:to="cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock_lbl_f4c371" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock_lbl_f4c371" xml:lang="en-US">Schedule of components of the Company's deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock" xlink:label="cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock" xlink:to="cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock_lbl_f268f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock_lbl_f268f2" xml:lang="en-US">Schedule of federal or state current or deferred tax expense or benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock" xlink:label="cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock" xlink:to="cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock_lbl_51c8a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock_lbl_51c8a8" xml:lang="en-US">Schedule of expenses for options issued or vested and restricted stock awarded</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock" xlink:label="cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock" xlink:to="cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock_lbl_21ffb9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock_lbl_21ffb9" xml:lang="en-US">Schedule of fair value of each option granted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" xlink:label="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" xlink:to="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_lbl_051388" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_lbl_051388" xml:lang="en-US">Schedule of non-qualified and incentive stock option plans</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfNonVestedOptionsTableTextBlock" xlink:label="cvm_ScheduleOfNonVestedOptionsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfNonVestedOptionsTableTextBlock" xlink:to="cvm_ScheduleOfNonVestedOptionsTableTextBlock_lbl_3a553c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfNonVestedOptionsTableTextBlock_lbl_3a553c" xml:lang="en-US">Schedule of non-vested options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock" xlink:label="cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock" xlink:to="cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock_lbl_ef3589" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock_lbl_ef3589" xml:lang="en-US">Schedule of restricted common stock issued from the incentive stock bonus plan</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_9ef0cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_9ef0cb" xml:lang="en-US">Schedule of future minimum payments under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl_6df417" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl_6df417" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock" xlink:label="cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock" xlink:to="cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock_lbl_81ac74" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock_lbl_81ac74" xml:lang="en-US">Schedule of other non-operating gains (losses)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl_d67b8b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl_d67b8b" xml:lang="en-US">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" xlink:to="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock_lbl_a857f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock_lbl_a857f3" xml:lang="en-US">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock" xlink:to="cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock_lbl_7e3d6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock_lbl_7e3d6b" xml:lang="en-US">Schedule of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_4eb937" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_4eb937" xml:lang="en-US">Patent useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl_562529" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl_562529" xml:lang="en-US">Fully insured amount of non-interest bearing cash balances</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl_a1951c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl_a1951c" xml:lang="en-US">WARRANTS AND NONEMPLOYEE OPTIONS (Details)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl_459b11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl_459b11" xml:lang="en-US">Derivative Instrument Risk Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_6f47a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_6f47a1" xml:lang="en-US">Class Of Warrant Or Right Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_ea8399" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_ea8399" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNMember" xlink:label="cvm_SeriesNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNMember" xlink:to="cvm_SeriesNMember_lbl_746cd7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNMember_lbl_746cd7" xml:lang="en-US">Series N [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesWMember" xlink:label="cvm_SeriesWMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesWMember" xlink:to="cvm_SeriesWMember_lbl_940b69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesWMember_lbl_940b69" xml:lang="en-US">Series W [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesXMember" xlink:label="cvm_SeriesXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXMember" xlink:to="cvm_SeriesXMember_lbl_c8c02d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXMember_lbl_c8c02d" xml:lang="en-US">Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesYMember" xlink:label="cvm_SeriesYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYMember" xlink:to="cvm_SeriesYMember_lbl_01f729" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYMember_lbl_01f729" xml:lang="en-US">Series Y [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZZMember" xlink:label="cvm_SeriesZZMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesZZMember" xlink:to="cvm_SeriesZZMember_lbl_df4d04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesZZMember_lbl_df4d04" xml:lang="en-US">Series ZZ [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesBBMember" xlink:label="cvm_SeriesBBMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesBBMember" xlink:to="cvm_SeriesBBMember_lbl_6b6a2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesBBMember_lbl_6b6a2b" xml:lang="en-US">Series BB [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZMember" xlink:label="cvm_SeriesZMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesZMember" xlink:to="cvm_SeriesZMember_lbl_96d134" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesZMember_lbl_96d134" xml:lang="en-US">Series Z [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesCCMember" xlink:label="cvm_SeriesCCMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesCCMember" xlink:to="cvm_SeriesCCMember_lbl_77570a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesCCMember_lbl_77570a" xml:lang="en-US">Series CC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesHHMember" xlink:label="cvm_SeriesHHMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesHHMember" xlink:to="cvm_SeriesHHMember_lbl_1cf43b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesHHMember_lbl_1cf43b" xml:lang="en-US">Series HH [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesAAMember" xlink:label="cvm_SeriesAAMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesAAMember" xlink:to="cvm_SeriesAAMember_lbl_d328ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesAAMember_lbl_d328ed" xml:lang="en-US">Series AA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesMMMember" xlink:label="cvm_SeriesMMMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMMember" xlink:to="cvm_SeriesMMMember_lbl_9d277b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMMember_lbl_9d277b" xml:lang="en-US">Series MM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNNMember" xlink:label="cvm_SeriesNNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNNMember" xlink:to="cvm_SeriesNNMember_lbl_476832" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNNMember_lbl_476832" xml:lang="en-US">Series NN [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ConsultantsMember" xlink:label="cvm_ConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_b057ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsMember_lbl_b057ea" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesRRMember" xlink:label="cvm_SeriesRRMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_d66776" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRMember_lbl_d66776" xml:lang="en-US">Series RR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesSSMember" xlink:label="cvm_SeriesSSMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesSSMember" xlink:to="cvm_SeriesSSMember_lbl_2a2842" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesSSMember_lbl_2a2842" xml:lang="en-US">Series SS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesTTMember" xlink:label="cvm_SeriesTTMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesTTMember" xlink:to="cvm_SeriesTTMember_lbl_af658b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesTTMember_lbl_af658b" xml:lang="en-US">Series TT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUMember" xlink:label="cvm_SeriesUUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUMember" xlink:to="cvm_SeriesUUMember_lbl_daba6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUMember_lbl_daba6c" xml:lang="en-US">Series UU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_Issuedate2" xlink:label="cvm_Issuedate2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_Issuedate2" xlink:to="cvm_Issuedate2_lbl_6326a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_Issuedate2_lbl_6326a7" xml:lang="en-US">Issue Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuableUponExerciseOfwarrant" xlink:label="cvm_SharesIssuableUponExerciseOfwarrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuableUponExerciseOfwarrant" xlink:to="cvm_SharesIssuableUponExerciseOfwarrant_lbl_095b98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuableUponExerciseOfwarrant_lbl_095b98" xml:lang="en-US">Shares Issuable upon Exercise of Warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExercisePrice" xlink:label="cvm_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePrice" xlink:to="cvm_ExercisePrice_lbl_190749" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePrice_lbl_190749" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpirationDate1" xlink:label="cvm_ExpirationDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate1" xlink:to="cvm_ExpirationDate1_lbl_aa6afc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDate1_lbl_aa6afc" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesFFMember" xlink:label="cvm_SeriesFFMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesFFMember" xlink:to="cvm_SeriesFFMember_lbl_a92553" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesFFMember_lbl_a92553" xml:lang="en-US">Series FF [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesJJMember" xlink:label="cvm_SeriesJJMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesJJMember" xlink:to="cvm_SeriesJJMember_lbl_cb7efa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesJJMember_lbl_cb7efa" xml:lang="en-US">Series JJ [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesLLMember" xlink:label="cvm_SeriesLLMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesLLMember" xlink:to="cvm_SeriesLLMember_lbl_1a3608" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesLLMember_lbl_1a3608" xml:lang="en-US">Series LL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVMember" xlink:label="cvm_SeriesVMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesVMember" xlink:to="cvm_SeriesVMember_lbl_e6787d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesVMember_lbl_e6787d" xml:lang="en-US">Series V [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl_c67e9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl_c67e9a" xml:lang="en-US">Total warrant liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetLossGainOnWarrantLiabilities" xlink:label="cvm_NetLossGainOnWarrantLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetLossGainOnWarrantLiabilities" xlink:to="cvm_NetLossGainOnWarrantLiabilities_lbl_4bc075" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetLossGainOnWarrantLiabilities_lbl_4bc075" xml:lang="en-US">Net (loss) gain on warrant liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl_f5cb3b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl_f5cb3b" xml:lang="en-US">Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsExercised" xlink:label="cvm_WarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsExercised" xlink:to="cvm_WarrantsExercised_lbl_bc7003" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsExercised_lbl_bc7003" xml:lang="en-US">Warrants Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePriceWarrants" xlink:to="cvm_ExercisePriceWarrants_lbl_8d296a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ExercisePriceWarrants_lbl_8d296a" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExercisePriceWarrants" xlink:label="cvm_ExercisePriceWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePriceWarrants" xlink:to="cvm_ExercisePriceWarrants_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePriceWarrants_lbl_4" xml:lang="en-US">[Exercise Price]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesOOMember" xlink:label="cvm_SeriesOOMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesOOMember" xlink:to="cvm_SeriesOOMember_lbl_c4acc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesOOMember_lbl_c4acc2" xml:lang="en-US">Series OO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVVMember" xlink:label="cvm_SeriesVVMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesVVMember" xlink:to="cvm_SeriesVVMember_lbl_e87d6e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesVVMember_lbl_e87d6e" xml:lang="en-US">Series VV [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_EquityWarrantsExercised" xlink:label="cvm_EquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercised" xlink:to="cvm_EquityWarrantsExercised_lbl_93c639" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercised_lbl_93c639" xml:lang="en-US">Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="cvm_ProceedsFromEquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromEquityWarrantsExercised" xlink:to="cvm_ProceedsFromEquityWarrantsExercised_lbl_abcd5e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromEquityWarrantsExercised_lbl_abcd5e" xml:lang="en-US">Proceeds from Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="cvm_EquityWarrantsExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercisePrice" xlink:to="cvm_EquityWarrantsExercisePrice_lbl_eb65ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercisePrice_lbl_eb65ec" xml:lang="en-US">Equity Warrants Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_f8ca70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_f8ca70" xml:lang="en-US">Range Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_8e5b9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_8e5b9a" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_a0f354" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_a0f354" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVWarrantsMember" xlink:label="cvm_SeriesVWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesVWarrantsMember" xlink:to="cvm_SeriesVWarrantsMember_lbl_2e96d5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesVWarrantsMember_lbl_2e96d5" xml:lang="en-US">Series V Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_0fd2f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_0fd2f6" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_32857d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_32857d" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesXXWarrantsMember" xlink:label="cvm_SeriesXXWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXXWarrantsMember" xlink:to="cvm_SeriesXXWarrantsMember_lbl_fb5d27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXXWarrantsMember_lbl_fb5d27" xml:lang="en-US">Series XX Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesYYWarrantsMember" xlink:label="cvm_SeriesYYWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYYWarrantsMember" xlink:to="cvm_SeriesYYWarrantsMember_lbl_4bbcf4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYYWarrantsMember_lbl_4bbcf4" xml:lang="en-US">Series YY Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUWarrantsMember" xlink:label="cvm_SeriesUUWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUWarrantsMember" xlink:to="cvm_SeriesUUWarrantsMember_lbl_858785" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUWarrantsMember_lbl_858785" xml:lang="en-US">Series UU warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNAndXMember" xlink:label="cvm_SeriesNAndXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNAndXMember" xlink:to="cvm_SeriesNAndXMember_lbl_65de0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNAndXMember_lbl_65de0d" xml:lang="en-US">Series N and Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNWarrantsMember" xlink:label="cvm_SeriesNWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNWarrantsMember" xlink:to="cvm_SeriesNWarrantsMember_lbl_2c73b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNWarrantsMember_lbl_2c73b1" xml:lang="en-US">Series N Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RestrictedStocksMember" xlink:label="cvm_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStocksMember" xlink:to="cvm_RestrictedStocksMember_lbl_9d8bce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStocksMember_lbl_9d8bce" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_d73b17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ConsultantsMember_lbl_d73b17" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ConsultingAgreementsMember" xlink:label="cvm_ConsultingAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsMember" xlink:to="cvm_ConsultingAgreementsMember_lbl_35b54d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsMember_lbl_35b54d" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanInterestCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_lbl_ddf2b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl_ddf2b2" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CommonStockIssuedForServiceShares" xlink:label="cvm_CommonStockIssuedForServiceShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockIssuedForServiceShares" xlink:to="cvm_CommonStockIssuedForServiceShares_lbl_4399c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockIssuedForServiceShares_lbl_4399c7" xml:lang="en-US">Common stock issued for service, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantInducementExpense" xlink:to="cvm_WarrantInducementExpense_lbl_38d2db" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_WarrantInducementExpense_lbl_38d2db" xml:lang="en-US">Warrant inducement expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantInducementExpense" xlink:label="cvm_WarrantInducementExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantInducementExpense" xlink:to="cvm_WarrantInducementExpense_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantInducementExpense_lbl_4" xml:lang="en-US">[Warrant inducement expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsExercisedShares" xlink:label="cvm_WarrantsExercisedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsExercisedShares" xlink:to="cvm_WarrantsExercisedShares_lbl_858a5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsExercisedShares_lbl_858a5a" xml:lang="en-US">Warrants exercised shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantExercise" xlink:label="cvm_WarrantExercise" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercise" xlink:to="cvm_WarrantExercise_lbl_e153f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercise_lbl_e153f2" xml:lang="en-US">Warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpirationDateDescription" xlink:label="cvm_ExpirationDateDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDateDescription" xlink:to="cvm_ExpirationDateDescription_lbl_26dc62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDateDescription_lbl_26dc62" xml:lang="en-US">Expiration date description</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsExpired" xlink:label="cvm_WarrantsExpired" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsExpired" xlink:to="cvm_WarrantsExpired_lbl_036e33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsExpired_lbl_036e33" xml:lang="en-US">Warrants expired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl_edddcc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl_edddcc" xml:lang="en-US">Fair value of warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_d8c73c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_d8c73c" xml:lang="en-US">Common stock price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsIssuedDuringPeriod" xlink:label="cvm_WarrantsIssuedDuringPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsIssuedDuringPeriod" xlink:to="cvm_WarrantsIssuedDuringPeriod_lbl_d785dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsIssuedDuringPeriod_lbl_d785dd" xml:lang="en-US">Warrants issued during period</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_2208c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_2208c3" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl_21561b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl_21561b" xml:lang="en-US">Total expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidExpenses" xlink:to="cvm_PrepaidExpenses_lbl_07e78c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_PrepaidExpenses_lbl_07e78c" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PrepaidExpenses" xlink:label="cvm_PrepaidExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidExpenses" xlink:to="cvm_PrepaidExpenses_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PrepaidExpenses_lbl_14" xml:lang="en-US">[Prepaid expenses]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_ce1b4b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_ce1b4b" xml:lang="en-US">Options issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OptionIssuedToRelatedParty" xlink:label="cvm_OptionIssuedToRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionIssuedToRelatedParty" xlink:to="cvm_OptionIssuedToRelatedParty_lbl_0e6658" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionIssuedToRelatedParty_lbl_0e6658" xml:lang="en-US">Option issued to related party</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OptionExpirationDate" xlink:label="cvm_OptionExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionExpirationDate" xlink:to="cvm_OptionExpirationDate_lbl_304182" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionExpirationDate_lbl_304182" xml:lang="en-US">Option expiration date</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_78957e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl_78957e" xml:lang="en-US">Stock prices per share</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="us-gaap_FixturesAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FixturesAndEquipmentGross" xlink:to="us-gaap_FixturesAndEquipmentGross_lbl_44ceaf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FixturesAndEquipmentGross_lbl_44ceaf" xml:lang="en-US">Research equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl_a3ef64" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl_a3ef64" xml:lang="en-US">Furniture and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl_dd2f80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl_dd2f80" xml:lang="en-US">Leasehold improvements</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl_8ac7bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl_8ac7bc" xml:lang="en-US">Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_8bdc2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_8bdc2f" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_6" xml:lang="en-US">[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_165ccb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_165ccb" xml:lang="en-US">Net property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl_7223f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl_7223f4" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl_5bd494" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl_5bd494" xml:lang="en-US">PATENTS (Details)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_b53d42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_b53d42" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl_c90fd6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl_c90fd6" xml:lang="en-US">Patents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl_4730c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl_4730c0" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_1b96eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_1b96eb" xml:lang="en-US">Accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_7cffe7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_7cffe7" xml:lang="en-US">Patents, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_eb6bfc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_eb6bfc" xml:lang="en-US">2022</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_c42fd6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_c42fd6" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_1e8708" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_1e8708" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_21aee8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_21aee8" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_b0005b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_b0005b" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_b9384e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_b9384e" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_Total" xlink:to="cvm_Total_lbl_d7f3a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_Total_lbl_d7f3a0" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_Total" xlink:label="cvm_Total" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_Total" xlink:to="cvm_Total_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_Total_lbl_8" xml:lang="en-US">[Total]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_488988" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_488988" xml:lang="en-US">Amortization of patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_d4093c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_d4093c" xml:lang="en-US">NOL carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LeaseLiabilities" xlink:label="cvm_LeaseLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeaseLiabilities" xlink:to="cvm_LeaseLiabilities_lbl_bc7023" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeaseLiabilities_lbl_bc7023" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl_590b57" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl_590b57" xml:lang="en-US">R&amp;D credit</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl_8af796" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl_8af796" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:to="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl_be655e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl_be655e" xml:lang="en-US">Capitalized R&amp;D</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl_129ace" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl_129ace" xml:lang="en-US">Vacation and other</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl_4a7351" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl_4a7351" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RightOfUseAssets" xlink:label="cvm_RightOfUseAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RightOfUseAssets" xlink:to="cvm_RightOfUseAssets_lbl_924386" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RightOfUseAssets_lbl_924386" xml:lang="en-US">Right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FixedAssetsAndIntangibles" xlink:label="cvm_FixedAssetsAndIntangibles" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FixedAssetsAndIntangibles" xlink:to="cvm_FixedAssetsAndIntangibles_lbl_eb1d3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FixedAssetsAndIntangibles_lbl_eb1d3f" xml:lang="en-US">Fixed assets and intangibles</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl_87c9d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl_87c9d1" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl_11" xml:lang="en-US">[Deferred Tax Liabilities, Net]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetDeferredTaxAsset" xlink:label="cvm_NetDeferredTaxAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetDeferredTaxAsset" xlink:to="cvm_NetDeferredTaxAsset_lbl_dc50e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetDeferredTaxAsset_lbl_dc50e8" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_e7bfd5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_e7bfd5" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_13" xml:lang="en-US">[Deferred Tax Assets, Valuation Allowance]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl_ed20d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl_ed20d4" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_5304da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_5304da" xml:lang="en-US">Federal Rate</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl_d52876" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl_d52876" xml:lang="en-US">Federal rate change</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl_302419" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl_302419" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl_27cb1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl_27cb1e" xml:lang="en-US">Other adjustments</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl_f351a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl_f351a7" xml:lang="en-US">Permanent differences</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_64ca7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_64ca7f" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_be70e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_be70e5" xml:lang="en-US">Effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl_66252a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl_66252a" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncomeTaxMember" xlink:label="cvm_IncomeTaxMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncomeTaxMember" xlink:to="cvm_IncomeTaxMember_lbl_7c29f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncomeTaxMember_lbl_7c29f6" xml:lang="en-US">Income Tax [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ResearchAndDevelopmentCredit" xlink:label="cvm_ResearchAndDevelopmentCredit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ResearchAndDevelopmentCredit" xlink:to="cvm_ResearchAndDevelopmentCredit_lbl_75a5b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ResearchAndDevelopmentCredit_lbl_75a5b4" xml:lang="en-US">Research and development credit</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ResearchAndDevelopmentCreditDescription" xlink:label="cvm_ResearchAndDevelopmentCreditDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ResearchAndDevelopmentCreditDescription" xlink:to="cvm_ResearchAndDevelopmentCreditDescription_lbl_2e42c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ResearchAndDevelopmentCreditDescription_lbl_2e42c7" xml:lang="en-US">Research and development credit, description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_596f1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_596f1d" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CumulativeChangeInOwnershipPercentage" xlink:label="cvm_CumulativeChangeInOwnershipPercentage" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CumulativeChangeInOwnershipPercentage" xlink:to="cvm_CumulativeChangeInOwnershipPercentage_lbl_be38f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CumulativeChangeInOwnershipPercentage_lbl_be38f3" xml:lang="en-US">Cumulative change in ownership percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl_0558b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl_0558b6" xml:lang="en-US">Net operating loss carryforwards, description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl_5a33c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl_5a33c8" xml:lang="en-US">Estimated net operating loss carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_3491c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_3491c8" xml:lang="en-US">Employees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_058930" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_058930" xml:lang="en-US">Non-employees</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl_4084fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl_4084fa" xml:lang="en-US">Expected stock price volatility, min</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl_8ffabb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl_8ffabb" xml:lang="en-US">Expected stock price volatility, max</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl_a93c87" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl_a93c87" xml:lang="en-US">Risk-free interest rate, min</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl_913197" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl_913197" xml:lang="en-US">Risk-free interest rate, max</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpectedLifeOfOptionsMin1" xlink:label="cvm_ExpectedLifeOfOptionsMin1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpectedLifeOfOptionsMin1" xlink:to="cvm_ExpectedLifeOfOptionsMin1_lbl_459312" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpectedLifeOfOptionsMin1_lbl_459312" xml:lang="en-US">Expected life of options, min</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpectedLifeOfOptionsMax" xlink:label="cvm_ExpectedLifeOfOptionsMax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpectedLifeOfOptionsMax" xlink:to="cvm_ExpectedLifeOfOptionsMax_lbl_8cf86b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpectedLifeOfOptionsMax_lbl_8cf86b" xml:lang="en-US">Expected life of options, max</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_6f6a2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_6f6a2e" xml:lang="en-US">Expected dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl_302dc9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl_302dc9" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl_a9c66b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl_a9c66b" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExercisableMember" xlink:label="cvm_ExercisableMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisableMember" xlink:to="cvm_ExercisableMember_lbl_21e565" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisableMember_lbl_21e565" xml:lang="en-US">Exercisable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OutstandingMember" xlink:label="cvm_OutstandingMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OutstandingMember" xlink:to="cvm_OutstandingMember_lbl_b857a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OutstandingMember_lbl_b857a9" xml:lang="en-US">Outstanding [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_d14df7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_d14df7" xml:lang="en-US">Number of Options Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xml:lang="en-US">[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsVested" xlink:to="cvm_NumberOfOptionsVested_lbl_2132d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvm_NumberOfOptionsVested_lbl_2132d8" xml:lang="en-US">Number of Options Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfOptionsVested" xlink:label="cvm_NumberOfOptionsVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsVested" xlink:to="cvm_NumberOfOptionsVested_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfOptionsVested_lbl_3" xml:lang="en-US">[Number of Options Vested]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfOptionsExercised" xlink:label="cvm_NumberOfOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsExercised" xlink:to="cvm_NumberOfOptionsExercised_lbl_afe965" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfOptionsExercised_lbl_afe965" xml:lang="en-US">Number of Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfOptions" xlink:label="cvm_NumberOfOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptions" xlink:to="cvm_NumberOfOptions_lbl_c271cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfOptions_lbl_c271cf" xml:lang="en-US">Number of Options Expired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_933179" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_933179" xml:lang="en-US">Number of Options Outstanding, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_70aaf1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_70aaf1" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_7" xml:lang="en-US">[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceVested" xlink:to="cvm_WeightedAverageExercisePriceVested_lbl_e107a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvm_WeightedAverageExercisePriceVested_lbl_e107a7" xml:lang="en-US">Weighted Average Exercise Price Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageExercisePriceVested" xlink:label="cvm_WeightedAverageExercisePriceVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceVested" xlink:to="cvm_WeightedAverageExercisePriceVested_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageExercisePriceVested_lbl_8" xml:lang="en-US">[Weighted Average Exercise Price Vested]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_71b3b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_71b3b9" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageExercisePriceExpired" xlink:label="cvm_WeightedAverageExercisePriceExpired" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceExpired" xlink:to="cvm_WeightedAverageExercisePriceExpired_lbl_5404a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageExercisePriceExpired_lbl_5404a2" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_8ef738" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_8ef738" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:to="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_e6f25b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_e6f25b" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:to="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl_03a5d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl_03a5d2" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AggregateIntrinsicValue" xlink:label="cvm_AggregateIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AggregateIntrinsicValue" xlink:to="cvm_AggregateIntrinsicValue_lbl_4d6e01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AggregateIntrinsicValue_lbl_4d6e01" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AggregateIntrinsicValueOutstandingEnding" xlink:label="cvm_AggregateIntrinsicValueOutstandingEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AggregateIntrinsicValueOutstandingEnding" xlink:to="cvm_AggregateIntrinsicValueOutstandingEnding_lbl_939a4b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AggregateIntrinsicValueOutstandingEnding_lbl_939a4b" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_31ed40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_31ed40" xml:lang="en-US">Number of Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl_b1ead2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl_b1ead2" xml:lang="en-US">Number of Options Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_e9a0b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_e9a0b5" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_8f769c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_8f769c" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedOptionsBeginning" xlink:label="cvm_NumberOfUnvestedOptionsBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfUnvestedOptionsBeginning" xlink:to="cvm_NumberOfUnvestedOptionsBeginning_lbl_f3c556" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfUnvestedOptionsBeginning_lbl_f3c556" xml:lang="en-US">Number of unvested options, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VestedOptions" xlink:label="cvm_VestedOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VestedOptions" xlink:to="cvm_VestedOptions_lbl_3d5a9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_VestedOptions_lbl_3d5a9b" xml:lang="en-US">Vested options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_GrantedOptions" xlink:label="cvm_GrantedOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GrantedOptions" xlink:to="cvm_GrantedOptions_lbl_c268b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GrantedOptions_lbl_c268b0" xml:lang="en-US">Granted options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ForfeitedOptions" xlink:label="cvm_ForfeitedOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ForfeitedOptions" xlink:to="cvm_ForfeitedOptions_lbl_208277" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ForfeitedOptions_lbl_208277" xml:lang="en-US">Forfeited options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedOptionsEnding" xlink:label="cvm_NumberOfUnvestedOptionsEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfUnvestedOptionsEnding" xlink:to="cvm_NumberOfUnvestedOptionsEnding_lbl_bf1cdc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfUnvestedOptionsEnding_lbl_bf1cdc" xml:lang="en-US">Number of unvested options, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageGrantDateFairValueBeginning" xlink:label="cvm_WeightedAverageGrantDateFairValueBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageGrantDateFairValueBeginning" xlink:to="cvm_WeightedAverageGrantDateFairValueBeginning_lbl_9e8344" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageGrantDateFairValueBeginning_lbl_9e8344" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageGrantDateFairValueEnding" xlink:label="cvm_WeightedAverageGrantDateFairValueEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageGrantDateFairValueEnding" xlink:to="cvm_WeightedAverageGrantDateFairValueEnding_lbl_6dfeeb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageGrantDateFairValueEnding_lbl_6dfeeb" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_b5d525" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_b5d525" xml:lang="en-US">Award Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="cvm_RestrictedStockAwardsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStockAwardsMember" xlink:to="cvm_RestrictedStockAwardsMember_lbl_6cc807" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStockAwardsMember_lbl_6cc807" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedSharesBeginning" xlink:label="cvm_NumberOfUnvestedSharesBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfUnvestedSharesBeginning" xlink:to="cvm_NumberOfUnvestedSharesBeginning_lbl_1dbda1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfUnvestedSharesBeginning_lbl_1dbda1" xml:lang="en-US">Number of unvested shares, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesForfeited" xlink:label="cvm_SharesForfeited" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesForfeited" xlink:to="cvm_SharesForfeited_lbl_c20ad1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesForfeited_lbl_c20ad1" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VestedShares" xlink:label="cvm_VestedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VestedShares" xlink:to="cvm_VestedShares_lbl_d1bee8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_VestedShares_lbl_d1bee8" xml:lang="en-US">Vested shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedSharesEnding" xlink:label="cvm_NumberOfUnvestedSharesEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfUnvestedSharesEnding" xlink:to="cvm_NumberOfUnvestedSharesEnding_lbl_0689b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfUnvestedSharesEnding_lbl_0689b7" xml:lang="en-US">Number of unvested shares, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageGrantDateFairValueBeginning" xlink:to="cvm_WeightedAverageGrantDateFairValueBeginning_lbl_6952a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_WeightedAverageGrantDateFairValueBeginning_lbl_6952a2" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageGrantDateFairValue" xlink:to="cvm_WeightedAverageGrantDateFairValue_lbl_a15ee8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_WeightedAverageGrantDateFairValue_lbl_a15ee8" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageGrantDateFairValue" xlink:label="cvm_WeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageGrantDateFairValue" xlink:to="cvm_WeightedAverageGrantDateFairValue_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageGrantDateFairValue_lbl_7" xml:lang="en-US">[Weighted Average Grant Date Fair Value, Ending]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockBonusPlansMember" xlink:label="cvm_StockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockBonusPlansMember" xlink:to="cvm_StockBonusPlansMember_lbl_bff044" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockBonusPlansMember_lbl_bff044" xml:lang="en-US">Stock Bonus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockCompensationPlansMember" xlink:label="cvm_StockCompensationPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockCompensationPlansMember" xlink:to="cvm_StockCompensationPlansMember_lbl_338895" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockCompensationPlansMember_lbl_338895" xml:lang="en-US">Stock Compensation Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="cvm_NonQualifiedStockOptionsPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_6fa7d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_6fa7d0" xml:lang="en-US">Non-Qualified Stock Options Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="cvm_IncentiveStockOptionPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockOptionPlansMember" xlink:to="cvm_IncentiveStockOptionPlansMember_lbl_e9c63a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockOptionPlansMember_lbl_e9c63a" xml:lang="en-US">Incentive Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="cvm_IncentiveStockBonusPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlanMember" xlink:to="cvm_IncentiveStockBonusPlanMember_lbl_33b2b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlanMember_lbl_33b2b6" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_898beb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_898beb" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_ddcc5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_ddcc5a" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_09febe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_09febe" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_4" xml:lang="en-US">[Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RemainingCompensationExpense" xlink:label="cvm_RemainingCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RemainingCompensationExpense" xlink:to="cvm_RemainingCompensationExpense_lbl_ba26b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RemainingCompensationExpense_lbl_ba26b2" xml:lang="en-US">Remaining compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl_b1dea0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl_b1dea0" xml:lang="en-US">Issuance of common stock options purchase shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PerformanceBasedStockOptionsSharesGranted" xlink:label="cvm_PerformanceBasedStockOptionsSharesGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PerformanceBasedStockOptionsSharesGranted" xlink:to="cvm_PerformanceBasedStockOptionsSharesGranted_lbl_93834b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PerformanceBasedStockOptionsSharesGranted_lbl_93834b" xml:lang="en-US">Performance based stock options shares granted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl_78ef8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl_78ef8d" xml:lang="en-US">Stock price</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="us-gaap_ConversionOfStockDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl_0d30b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl_0d30b1" xml:lang="en-US">Stock options vest description</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValuePerShare" xlink:label="cvm_FairValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValuePerShare" xlink:to="cvm_FairValuePerShare_lbl_27c7f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValuePerShare_lbl_27c7f6" xml:lang="en-US">Fair value per share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RemainingOutstandingFairValueOfShares" xlink:label="cvm_RemainingOutstandingFairValueOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RemainingOutstandingFairValueOfShares" xlink:to="cvm_RemainingOutstandingFairValueOfShares_lbl_9148f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RemainingOutstandingFairValueOfShares_lbl_9148f2" xml:lang="en-US">Grant date fair value remaining outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_GrantDateFairValueRemaining" xlink:label="cvm_GrantDateFairValueRemaining" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GrantDateFairValueRemaining" xlink:to="cvm_GrantDateFairValueRemaining_lbl_d085da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GrantDateFairValueRemaining_lbl_d085da" xml:lang="en-US">Grant date fair value remaining</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl_0fc42d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl_0fc42d" xml:lang="en-US">Implicit life of options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpenseLifeOverNext" xlink:label="cvm_ExpenseLifeOverNext" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpenseLifeOverNext" xlink:to="cvm_ExpenseLifeOverNext_lbl_c4c519" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpenseLifeOverNext_lbl_c4c519" xml:lang="en-US">Expense life over next</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VestedShares" xlink:to="cvm_VestedShares_lbl_4e7370" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_VestedShares_lbl_4e7370" xml:lang="en-US">Vested shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IssuanceOfRestrictedStock" xlink:label="cvm_IssuanceOfRestrictedStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssuanceOfRestrictedStock" xlink:to="cvm_IssuanceOfRestrictedStock_lbl_8b8883" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssuanceOfRestrictedStock_lbl_8b8883" xml:lang="en-US">Issuance of restricted stock</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="us-gaap_DeferredCompensationEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationEquity" xlink:to="us-gaap_DeferredCompensationEquity_lbl_7a2ce7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationEquity_lbl_7a2ce7" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl_5e0471" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl_5e0471" xml:lang="en-US">EMPLOYEE BENEFIT PLAN (Detail Narrative)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl_4529ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl_4529ae" xml:lang="en-US">Expense for Company's contribution to employee benefit plan</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_TotalCompensation" xlink:label="cvm_TotalCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TotalCompensation" xlink:to="cvm_TotalCompensation_lbl_8ee41d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TotalCompensation_lbl_8ee41d" xml:lang="en-US">Total compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ParticipantCompensation" xlink:label="cvm_ParticipantCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ParticipantCompensation" xlink:to="cvm_ParticipantCompensation_lbl_2a83cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ParticipantCompensation_lbl_2a83cb" xml:lang="en-US">Participant compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_ea9bd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_ea9bd2" xml:lang="en-US">Shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_4f9c12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_4f9c12" xml:lang="en-US">2022</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_d52bdd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_d52bdd" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_7fde80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_7fde80" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_4" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_0cf1ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_0cf1ea" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_5" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6f958a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6f958a" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_82f762" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_82f762" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xml:lang="en-US">[Finance Lease, Liability, to be Paid, after Year Five]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_3da678" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_3da678" xml:lang="en-US">Total future minimum lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_b53970" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_b53970" xml:lang="en-US">Less imputed interest on financing obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetPresentValueOfLeaseFinancingObligation" xlink:to="cvm_NetPresentValueOfLeaseFinancingObligation_lbl_4d7c11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_NetPresentValueOfLeaseFinancingObligation_lbl_4d7c11" xml:lang="en-US">Net present value of lease financing obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetPresentValueOfLeaseFinancingObligation" xlink:label="cvm_NetPresentValueOfLeaseFinancingObligation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetPresentValueOfLeaseFinancingObligation" xlink:to="cvm_NetPresentValueOfLeaseFinancingObligation_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetPresentValueOfLeaseFinancingObligation_lbl_10" xml:lang="en-US">[Net present value of lease financing obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_acd48f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_acd48f" xml:lang="en-US">2022</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_1d64c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_1d64c4" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_bdb67d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_bdb67d" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_52419c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_52419c" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_606c75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_606c75" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_ad6ece" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_ad6ece" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LesseeOperatingLeaseLiabilityPayments" xlink:to="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_513dfb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_513dfb" xml:lang="en-US">Total future minimum lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LesseeOperatingLeaseLiabilityPayments" xlink:label="cvm_LesseeOperatingLeaseLiabilityPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LesseeOperatingLeaseLiabilityPayments" xlink:to="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_8" xml:lang="en-US">[Total future minimum lease obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_191fbe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_191fbe" xml:lang="en-US">Less imputed interest on operating lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_9" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_c72d04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_c72d04" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_10" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl_10832d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl_10832d" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl_94e6d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl_94e6d3" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_f8a694" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_f8a694" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl_e6c6a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl_e6c6a5" xml:lang="en-US">Product Or Service Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VendorObligationsMember" xlink:label="cvm_VendorObligationsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VendorObligationsMember" xlink:to="cvm_VendorObligationsMember_lbl_00d77b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_VendorObligationsMember_lbl_00d77b" xml:lang="en-US">Vendor Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LandlordMember" xlink:label="cvm_LandlordMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LandlordMember" xlink:to="cvm_LandlordMember_lbl_6065b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LandlordMember_lbl_6065b4" xml:lang="en-US">Landlord [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_TransactionTwoMember" xlink:label="cvm_TransactionTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TransactionTwoMember" xlink:to="cvm_TransactionTwoMember_lbl_f39e5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TransactionTwoMember_lbl_f39e5a" xml:lang="en-US">TransactionTwoMember [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OctoberOneTwothousandNineTeenMember" xlink:label="cvm_OctoberOneTwothousandNineTeenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OctoberOneTwothousandNineTeenMember" xlink:to="cvm_OctoberOneTwothousandNineTeenMember_lbl_f6719f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OctoberOneTwothousandNineTeenMember_lbl_f6719f" xml:lang="en-US">October 1, 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_TransactionOneMember" xlink:label="cvm_TransactionOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TransactionOneMember" xlink:to="cvm_TransactionOneMember_lbl_7313c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TransactionOneMember_lbl_7313c4" xml:lang="en-US">Transaction One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ErgomedMember" xlink:label="cvm_ErgomedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_ccfcaa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedMember_lbl_ccfcaa" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl_bc6475" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl_bc6475" xml:lang="en-US">Biologics License Application [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_3a3a12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_3a3a12" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_a028af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_a028af" xml:lang="en-US">Weighted average discount rate operating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeVariableInterestRate" xlink:label="us-gaap_DerivativeVariableInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeVariableInterestRate" xlink:to="us-gaap_DerivativeVariableInterestRate_lbl_0236ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeVariableInterestRate_lbl_0236ae" xml:lang="en-US">Interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_MaturityYears" xlink:label="cvm_MaturityYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_MaturityYears" xlink:to="cvm_MaturityYears_lbl_bc76cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_MaturityYears_lbl_bc76cd" xml:lang="en-US">Maturity years</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OperatingLeaseMaturityYears" xlink:label="cvm_OperatingLeaseMaturityYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseMaturityYears" xlink:to="cvm_OperatingLeaseMaturityYears_lbl_1570cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseMaturityYears_lbl_1570cc" xml:lang="en-US">Operating lease maturity years</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_9f6715" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_9f6715" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetOfDiscount" xlink:label="cvm_NetOfDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetOfDiscount" xlink:to="cvm_NetOfDiscount_lbl_7c295a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetOfDiscount_lbl_7c295a" xml:lang="en-US">Net of discount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases_lbl_705271" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases_lbl_705271" xml:lang="en-US">Lease description</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinanceLeaseObligationsNetOfCurrentPortion" xlink:label="cvm_FinanceLeaseObligationsNetOfCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseObligationsNetOfCurrentPortion" xlink:to="cvm_FinanceLeaseObligationsNetOfCurrentPortion_lbl_080c38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseObligationsNetOfCurrentPortion_lbl_080c38" xml:lang="en-US">Finance lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl_80e712" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl_80e712" xml:lang="en-US">Additional expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="us-gaap_LeaseIncentivePayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncentivePayableCurrent" xlink:to="us-gaap_LeaseIncentivePayableCurrent_lbl_6a711b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseIncentivePayableCurrent_lbl_6a711b" xml:lang="en-US">Lease incentive payable current</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_5d7224" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_5d7224" xml:lang="en-US">Additional deposit</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CostIncurredInitial" xlink:label="cvm_CostIncurredInitial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CostIncurredInitial" xlink:to="cvm_CostIncurredInitial_lbl_2a6e6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CostIncurredInitial_lbl_2a6e6a" xml:lang="en-US">Cost incurred, initial</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_EstimatedCost" xlink:label="cvm_EstimatedCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EstimatedCost" xlink:to="cvm_EstimatedCost_lbl_64c477" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EstimatedCost_lbl_64c477" xml:lang="en-US">Estimated cost</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl_713253" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl_713253" xml:lang="en-US">Non current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinancingLeaseContractualArrangement" xlink:label="cvm_FinancingLeaseContractualArrangement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingLeaseContractualArrangement" xlink:to="cvm_FinancingLeaseContractualArrangement_lbl_a58180" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingLeaseContractualArrangement_lbl_a58180" xml:lang="en-US">Financing arrangement</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" xlink:label="cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" xlink:to="cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability_lbl_8140e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability_lbl_8140e9" xml:lang="en-US">Change in right of use of assets and liability</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl_2e1244" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl_2e1244" xml:lang="en-US">Cash paid related to operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetBookValueOperatingLeaseRightOfUseAssets" xlink:label="cvm_NetBookValueOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetBookValueOperatingLeaseRightOfUseAssets" xlink:to="cvm_NetBookValueOperatingLeaseRightOfUseAssets_lbl_97921b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetBookValueOperatingLeaseRightOfUseAssets_lbl_97921b" xml:lang="en-US">Net book value operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CurrentBalance" xlink:label="cvm_CurrentBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CurrentBalance" xlink:to="cvm_CurrentBalance_lbl_837d0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CurrentBalance_lbl_837d0e" xml:lang="en-US">Current balance</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_28b13f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_28b13f" xml:lang="en-US">Operating lease - liability</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl_a8c5d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl_a8c5d3" xml:lang="en-US">Operating lease expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_b6714d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_b6714d" xml:lang="en-US">Operating lease - liability</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_24" xml:lang="en-US">[Operating Lease, Liability, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_9dfa4f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_9dfa4f" xml:lang="en-US">Finance lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" xlink:label="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" xlink:to="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset_lbl_a179c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset_lbl_a179c3" xml:lang="en-US">Net book value of the finance lease right of use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_BalanceOfTheFinanceLeaseLiability" xlink:label="cvm_BalanceOfTheFinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_BalanceOfTheFinanceLeaseLiability" xlink:to="cvm_BalanceOfTheFinanceLeaseLiability_lbl_e7b722" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_BalanceOfTheFinanceLeaseLiability_lbl_e7b722" xml:lang="en-US">Balance of the finance lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CashPaidRelatedToFinanceLeases" xlink:label="cvm_CashPaidRelatedToFinanceLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CashPaidRelatedToFinanceLeases" xlink:to="cvm_CashPaidRelatedToFinanceLeases_lbl_344949" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CashPaidRelatedToFinanceLeases_lbl_344949" xml:lang="en-US">Cash paid related to finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CashPaidRelatedToFinanceLeasesInterest" xlink:label="cvm_CashPaidRelatedToFinanceLeasesInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CashPaidRelatedToFinanceLeasesInterest" xlink:to="cvm_CashPaidRelatedToFinanceLeasesInterest_lbl_8adc53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CashPaidRelatedToFinanceLeasesInterest_lbl_8adc53" xml:lang="en-US">Cash paid related to finance leases interest</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ClinicalServiceTrial" xlink:label="cvm_ClinicalServiceTrial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ClinicalServiceTrial" xlink:to="cvm_ClinicalServiceTrial_lbl_fd4cea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ClinicalServiceTrial_lbl_fd4cea" xml:lang="en-US">Clinical service trial</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AdditionalClinicalTrial" xlink:label="cvm_AdditionalClinicalTrial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AdditionalClinicalTrial" xlink:to="cvm_AdditionalClinicalTrial_lbl_85ea2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AdditionalClinicalTrial_lbl_85ea2b" xml:lang="en-US">Additional clinical trial</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_64553b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_64553b" xml:lang="en-US">Weighted average time to maturity</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl_afa99a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl_afa99a" xml:lang="en-US">Sublease rental income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNWarrantsMember" xlink:to="cvm_SeriesNWarrantsMember_lbl_1fdbc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_SeriesNWarrantsMember_lbl_1fdbc5" xml:lang="en-US">Series N Warrants [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUWarrantsMember" xlink:to="cvm_SeriesUUWarrantsMember_lbl_8d985e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_SeriesUUWarrantsMember_lbl_8d985e" xml:lang="en-US">Series UU warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesXWarrantsMember" xlink:label="cvm_SeriesXWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXWarrantsMember" xlink:to="cvm_SeriesXWarrantsMember_lbl_a8fead" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXWarrantsMember_lbl_a8fead" xml:lang="en-US">Series X Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNAndXWarrantsMember" xlink:label="cvm_SeriesNAndXWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNAndXWarrantsMember" xlink:to="cvm_SeriesNAndXWarrantsMember_lbl_5ba83f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNAndXWarrantsMember_lbl_5ba83f" xml:lang="en-US">Series N and X Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OfficerAndDirectorMember" xlink:label="cvm_OfficerAndDirectorMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OfficerAndDirectorMember" xlink:to="cvm_OfficerAndDirectorMember_lbl_114537" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OfficerAndDirectorMember_lbl_114537" xml:lang="en-US">Officer and Director [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDateDescription" xlink:to="cvm_ExpirationDateDescription_lbl_d0350a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ExpirationDateDescription_lbl_d0350a" xml:lang="en-US">Expiration date description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl_760bc7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl_760bc7" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl_3" xml:lang="en-US">[Other Cost and Expense, Operating]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsIssued" xlink:label="cvm_WarrantsIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsIssued" xlink:to="cvm_WarrantsIssued_lbl_7fc901" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsIssued_lbl_7fc901" xml:lang="en-US">Warrants issued</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="us-gaap_InterestExpenseRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl_9c4795" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl_9c4795" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfRestrictedSharesPurchasedByRelatedParty" xlink:label="cvm_NumberOfRestrictedSharesPurchasedByRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfRestrictedSharesPurchasedByRelatedParty" xlink:to="cvm_NumberOfRestrictedSharesPurchasedByRelatedParty_lbl_e9a0c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfRestrictedSharesPurchasedByRelatedParty_lbl_e9a0c7" xml:lang="en-US">Restricted Common shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty" xlink:label="cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty" xlink:to="cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty_lbl_df5028" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty_lbl_df5028" xml:lang="en-US">Restricted Common shares, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AmountRealizedThroughTheResaleOfShares" xlink:label="cvm_AmountRealizedThroughTheResaleOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AmountRealizedThroughTheResaleOfShares" xlink:to="cvm_AmountRealizedThroughTheResaleOfShares_lbl_cfd50e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AmountRealizedThroughTheResaleOfShares_lbl_cfd50e" xml:lang="en-US">Amount realized through the resale of shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance" xlink:label="cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance" xlink:to="cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance_lbl_b2fb09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance_lbl_b2fb09" xml:lang="en-US">Fair value of shares upon issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses" xlink:label="cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses" xlink:to="cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses_lbl_efe82e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses_lbl_efe82e" xml:lang="en-US">Other non-operating gain (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_11be08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ErgomedMember_lbl_11be08" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_84d325" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_84d325" xml:lang="en-US">Common stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromPublicOffering" xlink:label="cvm_ProceedsFromPublicOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromPublicOffering" xlink:to="cvm_ProceedsFromPublicOffering_lbl_4da155" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromPublicOffering_lbl_4da155" xml:lang="en-US">Proceeds from public offering</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_8cc5f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_8cc5f9" xml:lang="en-US">Proceeds from initial public offering</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_55007b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_55007b" xml:lang="en-US">Public offering price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:label="cvm_ProceedFromIssuanceOrSaleOfEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:to="cvm_ProceedFromIssuanceOrSaleOfEquity_lbl_85e7ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedFromIssuanceOrSaleOfEquity_lbl_85e7ed" xml:lang="en-US">Proceeds from issuance of warrant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl_508b5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl_508b5c" xml:lang="en-US">Warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl_7" xml:lang="en-US">[Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PrepaidAmountOfResold" xlink:label="cvm_PrepaidAmountOfResold" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidAmountOfResold" xlink:to="cvm_PrepaidAmountOfResold_lbl_edf336" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PrepaidAmountOfResold_lbl_edf336" xml:lang="en-US">Prepaid of resold amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_b26f97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_b26f97" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_2" xml:lang="en-US">[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl_e69c44" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl_e69c44" xml:lang="en-US">Issuances</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_ec3e52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_ec3e52" xml:lang="en-US">Exercises</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_4" xml:lang="en-US">[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" xlink:label="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" xlink:to="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_lbl_8abc36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_lbl_8abc36" xml:lang="en-US">Net realized and unrealized derivative loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_206099" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_206099" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_dc8d88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_dc8d88" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValueInputsLevelThreeMember" xlink:label="cvm_FairValueInputsLevelThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueInputsLevelThreeMember" xlink:to="cvm_FairValueInputsLevelThreeMember_lbl_7bf2d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueInputsLevelThreeMember_lbl_7bf2d0" xml:lang="en-US">Fair Value Inputs Level 3 (Level 3)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl_d60c46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl_d60c46" xml:lang="en-US">unrealized gain on short-term T-bills</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageRiskFreeInterestRate" xlink:label="cvm_WeightedAverageRiskFreeInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRiskFreeInterestRate" xlink:to="cvm_WeightedAverageRiskFreeInterestRate_lbl_8554de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageRiskFreeInterestRate_lbl_8554de" xml:lang="en-US">Weighted average risk free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageFairValueDerivativeInstruments" xlink:label="cvm_WeightedAverageFairValueDerivativeInstruments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageFairValueDerivativeInstruments" xlink:to="cvm_WeightedAverageFairValueDerivativeInstruments_lbl_7dede4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageFairValueDerivativeInstruments_lbl_7dede4" xml:lang="en-US">Weighted average fair value, Derivative instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageExercisePriceDerivativeInstruments" xlink:label="cvm_WeightedAverageExercisePriceDerivativeInstruments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceDerivativeInstruments" xlink:to="cvm_WeightedAverageExercisePriceDerivativeInstruments_lbl_2a5ee3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageExercisePriceDerivativeInstruments_lbl_2a5ee3" xml:lang="en-US">Weighted average exercise price, Derivative instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VolatilityRate" xlink:label="cvm_VolatilityRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VolatilityRate" xlink:to="cvm_VolatilityRate_lbl_b0d22f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_VolatilityRate_lbl_b0d22f" xml:lang="en-US">Volatility rate</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageTimeToMaturityYear" xlink:label="cvm_WeightedAverageTimeToMaturityYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageTimeToMaturityYear" xlink:to="cvm_WeightedAverageTimeToMaturityYear_lbl_9673db" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageTimeToMaturityYear_lbl_9673db" xml:lang="en-US">Weighted average time to maturity year</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl_1bf670" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl_1bf670" xml:lang="en-US">Net loss available to common shareholders - basic</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_955021" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_955021" xml:lang="en-US">Weighted average shares outstanding - basic</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl_329014" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl_329014" xml:lang="en-US">Basic loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl_febe70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl_febe70" xml:lang="en-US">Loss per share- diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_965cdb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_965cdb" xml:lang="en-US">Net loss available to common shareholders -basic</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl_b338f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl_b338f6" xml:lang="en-US">Unrealized gain on derivatives</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl_eecef2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl_eecef2" xml:lang="en-US">Net loss available to common shareholders - diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_452c81" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_452c81" xml:lang="en-US">Weighted average shares outstanding - basic</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants" xlink:label="cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants" xlink:to="cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants_lbl_360f5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants_lbl_360f5d" xml:lang="en-US">Incremental shares underlying dilutive "in the money" warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_fefb53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_fefb53" xml:lang="en-US">Weighted average shares outstanding - diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_ea4d13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_ea4d13" xml:lang="en-US">Diluted loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OptionsMember" xlink:label="cvm_OptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsMember" xlink:to="cvm_OptionsMember_lbl_4eea3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsMember_lbl_4eea3e" xml:lang="en-US">Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="cvm_UnvestedRestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedRestrictedStockMember" xlink:to="cvm_UnvestedRestrictedStockMember_lbl_24bb18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedRestrictedStockMember_lbl_24bb18" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_736fbe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_736fbe" xml:lang="en-US">Antidilutive securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_ShortTermInvestment" xlink:to="cvm_ShortTermInvestment_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_ShortTermInvestment_d">Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_LossOnDerivativesInstruments" xlink:to="cvm_LossOnDerivativesInstruments_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_LossOnDerivativesInstruments_d">Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_NetLossGainOnWarrantLiabilities" xlink:to="cvm_NetLossGainOnWarrantLiabilities_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_NetLossGainOnWarrantLiabilities_d">Amount of increase in the fair value of derivatives recognized in the income statement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_NetDeferredTaxAsset" xlink:to="cvm_NetDeferredTaxAsset_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_NetDeferredTaxAsset_d">Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_CommonStockIssuedForServiceShares" xlink:to="cvm_CommonStockIssuedForServiceShares_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_CommonStockIssuedForServiceShares_d">Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_ShareIssuanceCosts_d">Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:to="cvm_ProceedFromIssuanceOrSaleOfEquity_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_ProceedFromIssuanceOrSaleOfEquity_d">The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_AmountRealizedThroughTheResaleOfShares" xlink:to="cvm_AmountRealizedThroughTheResaleOfShares_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_AmountRealizedThroughTheResaleOfShares_d">Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_WarrantsExpired" xlink:to="cvm_WarrantsExpired_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_WarrantsExpired_d">Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_AggregateIntrinsicValueOutstandingEnding" xlink:to="cvm_AggregateIntrinsicValueOutstandingEnding_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_AggregateIntrinsicValueOutstandingEnding_d">Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_NetPresentValueOfLeaseFinancingObligation" xlink:to="cvm_NetPresentValueOfLeaseFinancingObligation_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_NetPresentValueOfLeaseFinancingObligation_d">Present value of lessee's discounted obligation for lease payments from finance lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_MaturityYears" xlink:to="cvm_MaturityYears_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_MaturityYears_d">Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_VolatilityRate" xlink:to="cvm_VolatilityRate_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_VolatilityRate_d">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cvm-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20210930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20210930.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20210930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20210930.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20210930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20210930.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/ORGANIZATION" xlink:href="cvm-20210930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/OperationsAndFinancing" xlink:href="cvm-20210930.xsd#OperationsAndFinancing" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20210930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptions" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PlantPropertyAndEquipment" xlink:href="cvm-20210930.xsd#PlantPropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20210930.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxes" xlink:href="cvm-20210930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensation" xlink:href="cvm-20210930.xsd#StockCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlan" xlink:href="cvm-20210930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20210930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20210930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20210930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20210930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShare" xlink:href="cvm-20210930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20210930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20210930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:href="cvm-20210930.xsd#PlantPropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20210930.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesTables" xlink:href="cvm-20210930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationTables" xlink:href="cvm-20210930.xsd#StockCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20210930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20210930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20210930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20210930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:href="cvm-20210930.xsd#WarrantsAndNonemployeeOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" xlink:href="cvm-20210930.xsd#WarrantsAndNonEmployeeOptionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:href="cvm-20210930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20210930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20210930.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails1" xlink:href="cvm-20210930.xsd#PatentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20210930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails" xlink:href="cvm-20210930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails1" xlink:href="cvm-20210930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cvm-20210930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails" xlink:href="cvm-20210930.xsd#StockCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails1" xlink:href="cvm-20210930.xsd#StockCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails2" xlink:href="cvm-20210930.xsd#StockCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails3" xlink:href="cvm-20210930.xsd#StockCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetails4" xlink:href="cvm-20210930.xsd#StockCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockCompensationDetailsNarrative" xlink:href="cvm-20210930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20210930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20210930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20210930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20210930.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20210930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20210930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="cvm-20210930.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20210930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20210930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_c4d5ad" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_bf0f14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c4d5ad" xlink:to="loc_us-gaapAssetsAbstract_bf0f14" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_f0935b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_bf0f14" xlink:to="loc_us-gaapAssetsCurrentAbstract_f0935b" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_5750e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_5750e5" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_1da9c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapShortTermInvestments_1da9c2" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_d4a068" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_d4a068" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_18073f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapPrepaidExpenseCurrent_18073f" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_c1408f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapInventoryNet_c1408f" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_bc496e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapAssetsCurrent_bc496e" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_b3f5c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_b3f5c1" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_3c1956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_3c1956" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_774f20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_774f20" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross_42995e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapFiniteLivedPatentsGross_42995e" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_5444d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapDepositsAssetsCurrent_5444d1" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_9a8452" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapAssets_9a8452" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_1f3dfc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_f0935b" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_1f3dfc" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_f50503" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_1f3dfc" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_f50503" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_13d782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapAccountsPayableCurrent_13d782" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_94a981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_94a981" order="18" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent_dd0046" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent_dd0046" order="19" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_7954be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_7954be" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LeaseLiabilitiesCurrentPortion" xlink:label="loc_cvmLeaseLiabilitiesCurrentPortion_ffac89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_cvmLeaseLiabilitiesCurrentPortion_ffac89" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_6e9e64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapLiabilitiesCurrent_6e9e64" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_faacd0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_faacd0" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_cc1a8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_cc1a8a" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_dd29bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_dd29bc" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_e74232" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_e74232" order="26" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_8933ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapLiabilities_8933ef" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4b7d8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_f50503" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4b7d8e" order="28" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_dda614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4b7d8e" xlink:to="loc_us-gaapStockholdersEquityAbstract_dda614" order="29" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_868c9d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_dda614" xlink:to="loc_us-gaapPreferredStockValue_868c9d" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_27da01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_dda614" xlink:to="loc_us-gaapCommonStockValue_27da01" order="31" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_e85c66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_dda614" xlink:to="loc_us-gaapAdditionalPaidInCapital_e85c66" order="32" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_8424aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_dda614" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_8424aa" order="33" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_4e1e82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_dda614" xlink:to="loc_us-gaapStockholdersEquity_4e1e82" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_ce9f64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_dda614" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_ce9f64" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_ee7802" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_a0273c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_ee7802" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_a0273c" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_1b2203" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_ee7802" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_1b2203" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_0783fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_ee7802" xlink:to="loc_us-gaapPreferredStockSharesIssued_0783fc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_104493" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_ee7802" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_104493" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_93aa2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_ee7802" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_93aa2c" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_1ad45f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_ee7802" xlink:to="loc_us-gaapCommonStockSharesAuthorized_1ad45f" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_b9ee76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_ee7802" xlink:to="loc_us-gaapCommonStockSharesIssued_b9ee76" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_a33d0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_ee7802" xlink:to="loc_us-gaapCommonStockSharesOutstanding_a33d0a" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_eb9122" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome_e77fee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_eb9122" xlink:to="loc_us-gaapOtherIncome_e77fee" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_0783d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_eb9122" xlink:to="loc_us-gaapOperatingExpensesAbstract_0783d7" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_407173" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_407173" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_19aba0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_19aba0" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_247378" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapOperatingExpenses_247378" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_6ae150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapOperatingIncomeLoss_6ae150" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_7cca55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_7cca55" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_e8dd6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_e8dd6d" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_a52baa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_a52baa" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="loc_us-gaapOtherNonoperatingGainsLosses_6986ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapOtherNonoperatingGainsLosses_6986ad" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_06f91e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapInterestIncomeExpenseNet_06f91e" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_a545fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapNetIncomeLoss_a545fd" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants_25f98d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_cvmModificationOfWarrants_25f98d" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_0caf89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_0caf89" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_91723b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapEarningsPerShareBasic_91723b" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_975685" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_975685" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_f2f641" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_f2f641" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_0ce73d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_0783d7" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_0ce73d" order="18" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_bfdffc" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_eea2d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_bfdffc" xlink:to="loc_us-gaapStatementTable_eea2d5" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f45e6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eea2d5" xlink:to="loc_us-gaapStatementLineItems_f45e6b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_d9877a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eea2d5" xlink:to="loc_us-gaapStatementEquityComponentsAxis_d9877a" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_8eb1e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_d9877a" xlink:to="loc_us-gaapEquityComponentDomain_8eb1e7" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_d57a38" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_8eb1e7" xlink:to="loc_us-gaapCommonStockMember_d57a38" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_8dc000" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_8eb1e7" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_8dc000" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_1a2366" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_8eb1e7" xlink:to="loc_us-gaapRetainedEarningsMember_1a2366" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_48c894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapSharesIssued_48c894" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_868f8c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockholdersEquity_868f8c" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AdoptionOfAsc842Leases" xlink:label="loc_cvmAdoptionOfAsc842Leases_902dfa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmAdoptionOfAsc842Leases_902dfa" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromTheSaleOfCommonStockShares" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockShares_3de95a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockShares_3de95a" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_3ec0eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_3ec0eb" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantIssuances" xlink:label="loc_cvmWarrantIssuances_df5aed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmWarrantIssuances_df5aed" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares_9efd5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmWarrantExercisesShares_9efd5f" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount_637e14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmWarrantExercisesAmount_637e14" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ModificationOfWarrantsAmount" xlink:label="loc_cvmModificationOfWarrantsAmount_f67e9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmModificationOfWarrantsAmount_f67e9b" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_09dbb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_09dbb2" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_81a9b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_81a9b5" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_eb9929" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_eb9929" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_b8fc8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_b8fc8e" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_118df2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_118df2" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_bf5d81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_bf5d81" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_1f79bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_1f79bd" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues" xlink:label="loc_cvmStockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues_f3d598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmStockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues_f3d598" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount" xlink:label="loc_cvmStockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount_c0118c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmStockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount_c0118c" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts_40b38d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmShareIssuanceCosts_40b38d" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalResearchCostsShares_93fc0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalResearchCostsShares_93fc0e" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalResearchCostsAmount_7e2aa3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalResearchCostsAmount_7e2aa3" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_6485f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapNetIncomeLoss_6485f8" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_f79ccd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_f79ccd" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_61789a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapSharesIssued_61789a" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_9e7cf0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f45e6b" xlink:to="loc_us-gaapStockholdersEquity_9e7cf0" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_4a4eac" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d2f62c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_4a4eac" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d2f62c" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_aad3fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d2f62c" xlink:to="loc_us-gaapNetIncomeLoss_aad3fa" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d2f62c" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_7eaa73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_us-gaapDepreciationAndAmortization_7eaa73" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_cd1f4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_cd1f4d" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_b7f250" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_us-gaapShareBasedCompensation_b7f250" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan_6ab2ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan_6ab2ac" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuedForSettlementOfClinicalResearchCosts" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalResearchCosts_ba737b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalResearchCosts_ba737b" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ShortTermInvestment" xlink:label="loc_cvmShortTermInvestment_f30e83" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_cvmShortTermInvestment_f30e83" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LossOnDerivativesInstruments" xlink:label="loc_cvmLossOnDerivativesInstruments_56f52e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_cvmLossOnDerivativesInstruments_56f52e" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_77022b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_77022b" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ModificationOfWarrant" xlink:label="loc_cvmModificationOfWarrant_3d06a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_cvmModificationOfWarrant_3d06a2" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_528f9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5520c6" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_528f9c" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables_be3e21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_528f9c" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables_be3e21" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_b63cf1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_528f9c" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_b63cf1" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SuppliesUsedForRDAndManufacturing" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturing_f87e65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_528f9c" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturing_f87e65" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ShortTermDeposits" xlink:label="loc_cvmShortTermDeposits_19fac7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_528f9c" xlink:to="loc_cvmShortTermDeposits_19fac7" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_38d533" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_528f9c" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_38d533" order="18" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_732ce4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_38d533" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_732ce4" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_9a1380" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_38d533" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_9a1380" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders_34a0fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_38d533" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders_34a0fd" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities_51d34b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_38d533" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities_51d34b" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_600b48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_38d533" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_600b48" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_b52ef6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_38d533" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_b52ef6" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetPurchasesOfUSTreasuryBills" xlink:label="loc_cvmNetPurchasesOfUSTreasuryBills_c82dd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_b52ef6" xlink:to="loc_cvmNetPurchasesOfUSTreasuryBills_c82dd5" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_da4f1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_b52ef6" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_da4f1c" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_6df451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_b52ef6" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_6df451" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_93e11a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_b52ef6" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_93e11a" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_b52ef6" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" order="29" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_e1c58d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_e1c58d" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_290da6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_290da6" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_a51392" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapProceedsFromWarrantExercises_a51392" order="32" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_0b2c39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_0b2c39" order="33" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_6a5035" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_6a5035" order="34" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements" xlink:label="loc_cvmProceedsFromLandlordFundingOfLeaseholdImprovements_5e586d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_cvmProceedsFromLandlordFundingOfLeaseholdImprovements_5e586d" order="35" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_872e42" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_872e42" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_718009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_718009" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_62994c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_62994c" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_6ea83c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_6ea83c" order="39" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_9f9ac0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_9f9ac0" order="40" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ceed11" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" order="41" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable" xlink:label="loc_cvmPropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable_e426fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" xlink:to="loc_cvmPropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable_e426fb" order="42" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" xlink:label="loc_cvmCapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable_97a588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" xlink:to="loc_cvmCapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable_97a588" order="43" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ChangesToRightOfUseAssetsAndLiabilities" xlink:label="loc_cvmChangesToRightOfUseAssetsAndLiabilities_b5d520" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" xlink:to="loc_cvmChangesToRightOfUseAssetsAndLiabilities_b5d520" order="44" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_336104" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" xlink:to="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_336104" order="45" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="loc_cvmPrepaidConsultingServicesPaidWithIssuanceOfCommonStock_6dc2e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" xlink:to="loc_cvmPrepaidConsultingServicesPaidWithIssuanceOfCommonStock_6dc2e6" order="46" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise" xlink:label="loc_cvmFairValueOfWarrantsLiabilitiesOnDateOfExercise_d36570" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" xlink:to="loc_cvmFairValueOfWarrantsLiabilitiesOnDateOfExercise_d36570" order="47" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinancingCostsIncludedInAccountsPayable" xlink:label="loc_cvmFinancingCostsIncludedInAccountsPayable_1b1799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" xlink:to="loc_cvmFinancingCostsIncludedInAccountsPayable_1b1799" order="48" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AccruedConsultingServicesToBePaidWithCommonStock" xlink:label="loc_cvmAccruedConsultingServicesToBePaidWithCommonStock_0c74ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" xlink:to="loc_cvmAccruedConsultingServicesToBePaidWithCommonStock_0c74ef" order="49" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_f66881" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_623a1d" xlink:to="loc_us-gaapInterestPaidNet_f66881" order="50" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7535f6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1b4b94" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7535f6" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1b4b94" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/OperationsAndFinancing" xlink:title="000008 - Disclosure - OPERATIONS AND FINANCING">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_965337" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations_3be894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_965337" xlink:to="loc_us-gaapNatureOfOperations_3be894" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_c6877d" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_749993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c6877d" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_749993" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptions" xlink:title="000010 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="loc_us-gaapLineOfCreditFacilityAbstract_a99e0a" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsAndNonEmployeeOptionstextblock" xlink:label="loc_cvmWarrantsAndNonEmployeeOptionstextblock_69557f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_a99e0a" xlink:to="loc_cvmWarrantsAndNonEmployeeOptionstextblock_69557f" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PlantPropertyAndEquipment" xlink:title="000011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_475e0a" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_6e0266" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_475e0a" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_6e0266" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_19d1f5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_f9230f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_19d1f5" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_f9230f" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxes" xlink:title="000013 - Disclosure - INCOME TAXES">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_dbb3f4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock_62b916" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_dbb3f4" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock_62b916" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensation" xlink:title="000014 - Disclosure - STOCK COMPENSATION">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8949e1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_90d5d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8949e1" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_90d5d6" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlan" xlink:title="000015 - Disclosure - EMPLOYEE BENEFIT PLAN">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract_38affe" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock_3498f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract_38affe" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock_3498f3" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ee611c" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_37a3f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ee611c" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_37a3f1" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000017 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_65d702" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_ba747c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_65d702" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_ba747c" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000018 - Disclosure - STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_ba1e73" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_5cb806" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_ba1e73" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_5cb806" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000019 - Disclosure - FAIR VALUE MEASUREMENTS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_8fa05e" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_35b0b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_8fa05e" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_35b0b7" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShare" xlink:title="000020 - Disclosure - NET LOSS PER COMMON SHARE">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_e55edf" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_6fc3e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_e55edf" xlink:to="loc_us-gaapEarningsPerShareTextBlock_6fc3e5" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000021 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_b16f20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_dc411e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_b16f20" xlink:to="loc_us-gaapSubsequentEventsTextBlock_dc411e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_c9eaba" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_d394de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_d394de" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_USTreasuryBills" xlink:label="loc_cvmUSTreasuryBills_18a22d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_cvmUSTreasuryBills_18a22d" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SuppliesUsedForRDAndManufacturingPolicytextblock" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingPolicytextblock_602a87" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingPolicytextblock_602a87" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_baa281" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_baa281" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_df7e47" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_df7e47" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LeasesPolicyTextBlock" xlink:label="loc_cvmLeasesPolicyTextBlock_c571d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_cvmLeasesPolicyTextBlock_c571d9" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock_06e9f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapDerivativesPolicyTextBlock_06e9f6" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock_95b42a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock_95b42a" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_2f1835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_2f1835" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_GrantIncomePolicyTextBlock" xlink:label="loc_cvmGrantIncomePolicyTextBlock_55702e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_cvmGrantIncomePolicyTextBlock_55702e" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_2eb5b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_2eb5b6" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaapFairValueConcentrationOfRiskTextBlock_8cb950" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapFairValueConcentrationOfRiskTextBlock_8cb950" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_2fdcc7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_2fdcc7" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_974043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapUseOfEstimates_974043" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_62054d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c9eaba" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_62054d" order="15" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" xlink:title="000023 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="loc_us-gaapLineOfCreditFacilityAbstract_ca5241" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock" xlink:label="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock_5a88f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_ca5241" xlink:to="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock_5a88f4" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" xlink:label="loc_cvmScheduleOfEquityWarrantsWereExercisedTableTextBlock_c8402f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_ca5241" xlink:to="loc_cvmScheduleOfEquityWarrantsWereExercisedTableTextBlock_c8402f" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" xlink:label="loc_cvmScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock_4f8e6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_ca5241" xlink:to="loc_cvmScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock_4f8e6c" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock_606f62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_ca5241" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock_606f62" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" xlink:label="loc_cvmScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock_75deb5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_ca5241" xlink:to="loc_cvmScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock_75deb5" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:title="000024 - Disclosure - PLANT, PROPERTY AND EQUIPMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_2cd2bd" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_bd5251" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_2cd2bd" xlink:to="loc_us-gaapScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_bd5251" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000025 - Disclosure - PATENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_53271d" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6d99ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_53271d" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6d99ab" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e90976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_53271d" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e90976" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - INCOME TAXES (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_7042da" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock" xlink:label="loc_cvmScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock_9405e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_7042da" xlink:to="loc_cvmScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock_9405e2" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock" xlink:label="loc_cvmScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock_dd3fc0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_7042da" xlink:to="loc_cvmScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock_dd3fc0" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationTables" xlink:title="000027 - Disclosure - STOCK COMPENSATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8631b" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock" xlink:label="loc_cvmScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock_60503b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8631b" xlink:to="loc_cvmScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock_60503b" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock" xlink:label="loc_cvmScheduleOfFairValueOfEachOptionGrantedTableTextBlock_371b75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8631b" xlink:to="loc_cvmScheduleOfFairValueOfEachOptionGrantedTableTextBlock_371b75" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" xlink:label="loc_cvmScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_1f073a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8631b" xlink:to="loc_cvmScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_1f073a" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfNonVestedOptionsTableTextBlock" xlink:label="loc_cvmScheduleOfNonVestedOptionsTableTextBlock_419a35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8631b" xlink:to="loc_cvmScheduleOfNonVestedOptionsTableTextBlock_419a35" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock" xlink:label="loc_cvmScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock_96a374" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8631b" xlink:to="loc_cvmScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock_96a374" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_df5e77" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_295053" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_df5e77" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_295053" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_d26670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_df5e77" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_d26670" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000029 - Disclosure - STOCKHOLDERS EQUITY (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_88ab4b" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock" xlink:label="loc_cvmScheduleOfOtherNonOperatingGainsLossesTableTextBlock_4f863e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_88ab4b" xlink:to="loc_cvmScheduleOfOtherNonOperatingGainsLossesTableTextBlock_4f863e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_7ba4fd" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_185eb4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_7ba4fd" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_185eb4" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareTables" xlink:title="000031 - Disclosure - NET LOSS PER COMMON SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_a47090" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" xlink:label="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock_e8f83f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_a47090" xlink:to="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock_e8f83f" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock" xlink:label="loc_cvmScheduleOfAntiDilutiveSecuritiestabletextblock_2f0362" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_a47090" xlink:to="loc_cvmScheduleOfAntiDilutiveSecuritiestabletextblock_2f0362" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_5421c5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_638814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5421c5" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_638814" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_c13605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5421c5" xlink:to="loc_us-gaapCashFDICInsuredAmount_c13605" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:title="000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1ecc1b" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_76b331" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1ecc1b" xlink:to="loc_us-gaapStatementTable_76b331" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_30609e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_76b331" xlink:to="loc_us-gaapStatementLineItems_30609e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_badb11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_76b331" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_badb11" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_053429" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_badb11" xlink:to="loc_us-gaapDerivativeContractTypeDomain_053429" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_2a12a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_76b331" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_2a12a4" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_84d1c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_2a12a4" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_84d1c3" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_2191c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_76b331" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_2191c9" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_1a77c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_2191c9" xlink:to="loc_us-gaapRelatedPartyDomain_1a77c6" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember_2f9696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_053429" xlink:to="loc_cvmSeriesNMember_2f9696" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesWMember" xlink:label="loc_cvmSeriesWMember_f3545a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_84d1c3" xlink:to="loc_cvmSeriesWMember_f3545a" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_718a58" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_053429" xlink:to="loc_cvmSeriesXMember_718a58" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_6ff84f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_053429" xlink:to="loc_cvmSeriesYMember_6ff84f" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZZMember" xlink:label="loc_cvmSeriesZZMember_e8760f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_84d1c3" xlink:to="loc_cvmSeriesZZMember_e8760f" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember_9efe0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_84d1c3" xlink:to="loc_cvmSeriesBBMember_9efe0c" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember_79a04a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_84d1c3" xlink:to="loc_cvmSeriesZMember_79a04a" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember_8dac48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_84d1c3" xlink:to="loc_cvmSeriesCCMember_8dac48" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesHHMember" xlink:label="loc_cvmSeriesHHMember_d21994" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_84d1c3" xlink:to="loc_cvmSeriesHHMember_d21994" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesAAMember" xlink:label="loc_cvmSeriesAAMember_613a03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_84d1c3" xlink:to="loc_cvmSeriesAAMember_613a03" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_6ff2e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_053429" xlink:to="loc_cvmSeriesMMMember_6ff2e7" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_317d27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_053429" xlink:to="loc_cvmSeriesNNMember_317d27" order="72" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_6e3681" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_1a77c6" xlink:to="loc_cvmConsultantsMember_6e3681" order="73" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_5e451c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_053429" xlink:to="loc_cvmSeriesRRMember_5e451c" order="74" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember_94a518" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_053429" xlink:to="loc_cvmSeriesSSMember_94a518" order="75" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember_61843d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_053429" xlink:to="loc_cvmSeriesTTMember_61843d" order="76" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_0f90a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_053429" xlink:to="loc_cvmSeriesUUMember_0f90a8" order="77" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_Issuedate2" xlink:label="loc_cvmIssuedate2_279929" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_30609e" xlink:to="loc_cvmIssuedate2_279929" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_cvmSharesIssuableUponExerciseOfwarrant_a76ae4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_30609e" xlink:to="loc_cvmSharesIssuableUponExerciseOfwarrant_a76ae4" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice_5abac7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_30609e" xlink:to="loc_cvmExercisePrice_5abac7" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpirationDate1" xlink:label="loc_cvmExpirationDate1_5f6818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_30609e" xlink:to="loc_cvmExpirationDate1_5f6818" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1" xlink:title="000034 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_549bab" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_221465" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_549bab" xlink:to="loc_us-gaapStatementTable_221465" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_4431f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_221465" xlink:to="loc_us-gaapStatementLineItems_4431f9" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_190e7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_221465" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_190e7c" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_190e7c" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesWMember" xlink:label="loc_cvmSeriesWMember_73ae99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesWMember_73ae99" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZZMember" xlink:label="loc_cvmSeriesZZMember_68f919" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesZZMember_68f919" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember_bda216" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesBBMember_bda216" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember_acdeb6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesZMember_acdeb6" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember_28bf2e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesCCMember_28bf2e" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesHHMember" xlink:label="loc_cvmSeriesHHMember_cd886c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesHHMember_cd886c" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesAAMember" xlink:label="loc_cvmSeriesAAMember_f31abc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesAAMember_f31abc" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesFFMember" xlink:label="loc_cvmSeriesFFMember_5b7720" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesFFMember_5b7720" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesJJMember" xlink:label="loc_cvmSeriesJJMember_28781f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesJJMember_28781f" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesLLMember" xlink:label="loc_cvmSeriesLLMember_416ffe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesLLMember_416ffe" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVMember" xlink:label="loc_cvmSeriesVMember_995894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_0984e1" xlink:to="loc_cvmSeriesVMember_995894" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_07ad8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4431f9" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_07ad8d" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetLossGainOnWarrantLiabilities" xlink:label="loc_cvmNetLossGainOnWarrantLiabilities_38fcd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4431f9" xlink:to="loc_cvmNetLossGainOnWarrantLiabilities_38fcd5" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" xlink:title="000035 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e89aa1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_60c982" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e89aa1" xlink:to="loc_us-gaapStatementTable_60c982" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_bb49ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_60c982" xlink:to="loc_us-gaapStatementLineItems_bb49ef" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_3780ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_60c982" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_3780ba" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_3780ba" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZZMember" xlink:label="loc_cvmSeriesZZMember_160970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" xlink:to="loc_cvmSeriesZZMember_160970" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember_9975b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" xlink:to="loc_cvmSeriesZMember_9975b6" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember_2c95ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" xlink:to="loc_cvmSeriesCCMember_2c95ba" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesHHMember" xlink:label="loc_cvmSeriesHHMember_ba8bda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" xlink:to="loc_cvmSeriesHHMember_ba8bda" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesAAMember" xlink:label="loc_cvmSeriesAAMember_4f150d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" xlink:to="loc_cvmSeriesAAMember_4f150d" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesFFMember" xlink:label="loc_cvmSeriesFFMember_d1030a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" xlink:to="loc_cvmSeriesFFMember_d1030a" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesJJMember" xlink:label="loc_cvmSeriesJJMember_737dda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" xlink:to="loc_cvmSeriesJJMember_737dda" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesLLMember" xlink:label="loc_cvmSeriesLLMember_e4977b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" xlink:to="loc_cvmSeriesLLMember_e4977b" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVMember" xlink:label="loc_cvmSeriesVMember_26d4da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_67b0d7" xlink:to="loc_cvmSeriesVMember_26d4da" order="19" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_62536b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bb49ef" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_62536b" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsExercised" xlink:label="loc_cvmWarrantsExercised_7bb90c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bb49ef" xlink:to="loc_cvmWarrantsExercised_7bb90c" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExercisePriceWarrants" xlink:label="loc_cvmExercisePriceWarrants_e937bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bb49ef" xlink:to="loc_cvmExercisePriceWarrants_e937bc" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" xlink:title="000036 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e96884" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_fea3a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e96884" xlink:to="loc_us-gaapStatementTable_fea3a5" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_feb830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fea3a5" xlink:to="loc_us-gaapStatementLineItems_feb830" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_2239fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fea3a5" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_2239fe" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_2239fe" xlink:to="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_f64c0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" xlink:to="loc_cvmSeriesMMMember_f64c0f" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_6f461c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" xlink:to="loc_cvmSeriesNNMember_6f461c" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_f226d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" xlink:to="loc_cvmSeriesRRMember_f226d7" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember_29259c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" xlink:to="loc_cvmSeriesSSMember_29259c" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember_09812d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" xlink:to="loc_cvmSeriesTTMember_09812d" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_8da641" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" xlink:to="loc_cvmSeriesUUMember_8da641" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesOOMember" xlink:label="loc_cvmSeriesOOMember_66648b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" xlink:to="loc_cvmSeriesOOMember_66648b" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVVMember" xlink:label="loc_cvmSeriesVVMember_bc02a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4ecd0c" xlink:to="loc_cvmSeriesVVMember_bc02a6" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised_6bba6f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_feb830" xlink:to="loc_cvmEquityWarrantsExercised_6bba6f" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised_d1c7ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_feb830" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised_d1c7ed" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice_94d62a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_feb830" xlink:to="loc_cvmEquityWarrantsExercisePrice_94d62a" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" xlink:title="000037 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_2d7121" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f876ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_2d7121" xlink:to="loc_us-gaapStatementTable_f876ee" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_7c7a66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f876ee" xlink:to="loc_us-gaapStatementLineItems_7c7a66" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_bb5b01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f876ee" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_bb5b01" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_bb5b01" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_42a0f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f876ee" xlink:to="loc_srtRangeAxis_42a0f1" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_e1de02" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_42a0f1" xlink:to="loc_srtRangeMember_e1de02" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_a97bb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f876ee" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_a97bb9" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_0aa57b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_a97bb9" xlink:to="loc_us-gaapDerivativeContractTypeDomain_0aa57b" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e71fb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f876ee" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e71fb2" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_b34b6e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e71fb2" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_b34b6e" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_110a58" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f876ee" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_110a58" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_0eebbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_110a58" xlink:to="loc_us-gaapRelatedPartyDomain_0eebbe" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_3ec1f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f876ee" xlink:to="loc_us-gaapPlanNameAxis_3ec1f6" order="90" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_6edea7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_3ec1f6" xlink:to="loc_us-gaapPlanNameDomain_6edea7" order="90" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesWMember" xlink:label="loc_cvmSeriesWMember_a9ad56" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" xlink:to="loc_cvmSeriesWMember_a9ad56" order="91" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_641ae3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_0aa57b" xlink:to="loc_cvmSeriesYMember_641ae3" order="92" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember_152558" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" xlink:to="loc_cvmSeriesBBMember_152558" order="93" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesVWarrantsMember" xlink:label="loc_cvmSeriesVWarrantsMember_be9807" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" xlink:to="loc_cvmSeriesVWarrantsMember_be9807" order="94" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_df021b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_e1de02" xlink:to="loc_srtMaximumMember_df021b" order="95" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_e939df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_e1de02" xlink:to="loc_srtMinimumMember_e939df" order="96" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesXXWarrantsMember" xlink:label="loc_cvmSeriesXXWarrantsMember_81c3eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" xlink:to="loc_cvmSeriesXXWarrantsMember_81c3eb" order="97" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesYYWarrantsMember" xlink:label="loc_cvmSeriesYYWarrantsMember_aae493" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" xlink:to="loc_cvmSeriesYYWarrantsMember_aae493" order="98" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUWarrantsMember" xlink:label="loc_cvmSeriesUUWarrantsMember_ecae9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" xlink:to="loc_cvmSeriesUUWarrantsMember_ecae9b" order="99" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNAndXMember" xlink:label="loc_cvmSeriesNAndXMember_0f52a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" xlink:to="loc_cvmSeriesNAndXMember_0f52a6" order="100" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNWarrantsMember" xlink:label="loc_cvmSeriesNWarrantsMember_58858d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c5e437" xlink:to="loc_cvmSeriesNWarrantsMember_58858d" order="101" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember_9beecb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_b34b6e" xlink:to="loc_cvmRestrictedStocksMember_9beecb" order="102" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_eee42c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_0eebbe" xlink:to="loc_cvmConsultantsMember_eee42c" order="103" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember_f7d148" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_6edea7" xlink:to="loc_cvmConsultingAgreementsMember_f7d148" order="104" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaapDefinedBenefitPlanInterestCost_ff0f87" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_us-gaapDefinedBenefitPlanInterestCost_ff0f87" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CommonStockIssuedForServiceShares" xlink:label="loc_cvmCommonStockIssuedForServiceShares_2e6eed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmCommonStockIssuedForServiceShares_2e6eed" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantInducementExpense" xlink:label="loc_cvmWarrantInducementExpense_7c380c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmWarrantInducementExpense_7c380c" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsExercisedShares" xlink:label="loc_cvmWarrantsExercisedShares_d1056e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmWarrantsExercisedShares_d1056e" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantExercise" xlink:label="loc_cvmWarrantExercise_664157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmWarrantExercise_664157" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpirationDateDescription" xlink:label="loc_cvmExpirationDateDescription_4eaa24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmExpirationDateDescription_4eaa24" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsExpired" xlink:label="loc_cvmWarrantsExpired_043e3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmWarrantsExpired_043e3f" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_672429" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_672429" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6b69e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6b69e7" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsIssuedDuringPeriod" xlink:label="loc_cvmWarrantsIssuedDuringPeriod_3dcd82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmWarrantsIssuedDuringPeriod_3dcd82" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_db6528" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_db6528" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_478c4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_us-gaapCostsAndExpenses_478c4f" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PrepaidExpenses" xlink:label="loc_cvmPrepaidExpenses_14ec95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmPrepaidExpenses_14ec95" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_d6d28c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_d6d28c" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OptionIssuedToRelatedParty" xlink:label="loc_cvmOptionIssuedToRelatedParty_94d62e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmOptionIssuedToRelatedParty_94d62e" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OptionExpirationDate" xlink:label="loc_cvmOptionExpirationDate_bf3fcf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_cvmOptionExpirationDate_bf3fcf" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_834644" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7c7a66" xlink:to="loc_us-gaapSharePrice_834644" order="17" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:title="000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_164119" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaapFixturesAndEquipmentGross_573216" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_164119" xlink:to="loc_us-gaapFixturesAndEquipmentGross_573216" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross_3c95b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_164119" xlink:to="loc_us-gaapFurnitureAndFixturesGross_3c95b3" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross_1a8ea4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_164119" xlink:to="loc_us-gaapLeaseholdImprovementsGross_1a8ea4" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_fea3f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_164119" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_fea3f5" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b8a09b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_164119" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b8a09b" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_606785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_164119" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_606785" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_6b9be5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_cb86a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_6b9be5" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_cb86a4" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000040 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_a63ef4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b4078a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_a63ef4" xlink:to="loc_us-gaapStatementTable_b4078a" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_09e1a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b4078a" xlink:to="loc_us-gaapStatementLineItems_09e1a1" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_05c48a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b4078a" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_05c48a" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_e94964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_05c48a" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_e94964" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_348141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_e94964" xlink:to="loc_us-gaapPatentsMember_348141" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross_0d9736" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_09e1a1" xlink:to="loc_us-gaapFiniteLivedPatentsGross_0d9736" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_74417e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_09e1a1" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_74417e" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_d1ca08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_09e1a1" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_d1ca08" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails1" xlink:title="000041 - Disclosure - PATENTS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_f5274c" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_40f4bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_f5274c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_40f4bb" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0efd46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_f5274c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0efd46" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_81c993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_f5274c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_81c993" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_965f22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_f5274c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_965f22" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_05cf87" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_f5274c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_05cf87" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_4515d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_f5274c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_4515d0" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_Total" xlink:label="loc_cvmTotal_79af62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_f5274c" xlink:to="loc_cvmTotal_79af62" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000042 - Disclosure - PATENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_befba5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_0c9815" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_befba5" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_0c9815" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails" xlink:title="000043 - Disclosure - INCOME TAXES (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_2edcde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_2edcde" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LeaseLiabilities" xlink:label="loc_cvmLeaseLiabilities_f5d16b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_cvmLeaseLiabilities_f5d16b" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_7225e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_7225e2" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bdeced" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bdeced" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="loc_cvmDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_661356" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_cvmDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_661356" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_3e258f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_3e258f" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_51126c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_us-gaapDeferredTaxAssetsGross_51126c" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RightOfUseAssets" xlink:label="loc_cvmRightOfUseAssets_f4da95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_cvmRightOfUseAssets_f4da95" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FixedAssetsAndIntangibles" xlink:label="loc_cvmFixedAssetsAndIntangibles_654724" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_cvmFixedAssetsAndIntangibles_654724" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities_bbf984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_us-gaapDeferredTaxLiabilities_bbf984" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetDeferredTaxAsset" xlink:label="loc_cvmNetDeferredTaxAsset_25e0ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_cvmNetDeferredTaxAsset_25e0ac" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_3b7b63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_3b7b63" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_10e050" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1a428a" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_10e050" order="13" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails1" xlink:title="000044 - Disclosure - INCOME TAXES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_0031bf" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15f333" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_0031bf" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15f333" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_7a797a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_0031bf" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_7a797a" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_44f1c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_0031bf" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_44f1c4" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_38c54d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_0031bf" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_38c54d" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_06f342" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_0031bf" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_06f342" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a3209c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_0031bf" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a3209c" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_0c3356" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_0031bf" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_0c3356" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:title="000045 - Disclosure - INCOME TAXES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_3349c5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_63fa23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_3349c5" xlink:to="loc_us-gaapStatementTable_63fa23" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_075b52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_63fa23" xlink:to="loc_us-gaapStatementLineItems_075b52" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis_b041f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_63fa23" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis_b041f9" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_5e0ba6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis_b041f9" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_5e0ba6" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncomeTaxMember" xlink:label="loc_cvmIncomeTaxMember_39c146" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain_5e0ba6" xlink:to="loc_cvmIncomeTaxMember_39c146" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ResearchAndDevelopmentCredit" xlink:label="loc_cvmResearchAndDevelopmentCredit_4ef102" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_075b52" xlink:to="loc_cvmResearchAndDevelopmentCredit_4ef102" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ResearchAndDevelopmentCreditDescription" xlink:label="loc_cvmResearchAndDevelopmentCreditDescription_3b3804" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_075b52" xlink:to="loc_cvmResearchAndDevelopmentCreditDescription_3b3804" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_519e69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_075b52" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_519e69" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CumulativeChangeInOwnershipPercentage" xlink:label="loc_cvmCumulativeChangeInOwnershipPercentage_06996c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_075b52" xlink:to="loc_cvmCumulativeChangeInOwnershipPercentage_06996c" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription_f6bce8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_075b52" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription_f6bce8" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_aebbe4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_075b52" xlink:to="loc_us-gaapDeferredTaxAssetsGross_aebbe4" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails" xlink:title="000046 - Disclosure - STOCK COMPENSATION (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18de02" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_efe057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18de02" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_efe057" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_a69b9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18de02" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_a69b9b" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails1" xlink:title="000047 - Disclosure - STOCK COMPENSATION (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_989e80" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c5042e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_989e80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c5042e" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_df004f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_989e80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_df004f" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8590a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_989e80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8590a9" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6fdad1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_989e80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6fdad1" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpectedLifeOfOptionsMin1" xlink:label="loc_cvmExpectedLifeOfOptionsMin1_211564" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_989e80" xlink:to="loc_cvmExpectedLifeOfOptionsMin1_211564" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpectedLifeOfOptionsMax" xlink:label="loc_cvmExpectedLifeOfOptionsMax_314f37" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_989e80" xlink:to="loc_cvmExpectedLifeOfOptionsMax_314f37" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_134a6f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_989e80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_134a6f" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails2" xlink:title="000048 - Disclosure - STOCK COMPENSATION (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3fbd73" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_2a179a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3fbd73" xlink:to="loc_us-gaapStatementTable_2a179a" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_6f0c71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2a179a" xlink:to="loc_us-gaapStatementLineItems_6f0c71" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_119b40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2a179a" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_119b40" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_b16850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_119b40" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_b16850" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_878212" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2a179a" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_878212" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_ef2276" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_878212" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_ef2276" order="40" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExercisableMember" xlink:label="loc_cvmExercisableMember_c65465" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_b16850" xlink:to="loc_cvmExercisableMember_c65465" order="41" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OutstandingMember" xlink:label="loc_cvmOutstandingMember_c7ccdc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_ef2276" xlink:to="loc_cvmOutstandingMember_c7ccdc" order="42" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_940949" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_940949" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfOptionsVested" xlink:label="loc_cvmNumberOfOptionsVested_0c255c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_cvmNumberOfOptionsVested_0c255c" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfOptionsExercised" xlink:label="loc_cvmNumberOfOptionsExercised_5bb214" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_cvmNumberOfOptionsExercised_5bb214" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfOptions" xlink:label="loc_cvmNumberOfOptions_57952e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_cvmNumberOfOptions_57952e" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e556d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e556d" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f249ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f249ac" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageExercisePriceVested" xlink:label="loc_cvmWeightedAverageExercisePriceVested_24e94c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_cvmWeightedAverageExercisePriceVested_24e94c" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a1cf8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a1cf8a" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageExercisePriceExpired" xlink:label="loc_cvmWeightedAverageExercisePriceExpired_fd8b2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_cvmWeightedAverageExercisePriceExpired_fd8b2c" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_099fc9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_099fc9" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_2db66c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_2db66c" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_80e183" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_80e183" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AggregateIntrinsicValue" xlink:label="loc_cvmAggregateIntrinsicValue_4ecc2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_cvmAggregateIntrinsicValue_4ecc2c" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AggregateIntrinsicValueOutstandingEnding" xlink:label="loc_cvmAggregateIntrinsicValueOutstandingEnding_2a2dad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_cvmAggregateIntrinsicValueOutstandingEnding_2a2dad" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f060f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f060f1" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6d475f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6d475f" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eae93e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eae93e" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_dfef92" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f0c71" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_dfef92" order="18" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails3" xlink:title="000049 - Disclosure - STOCK COMPENSATION (Details 3)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e068c4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedOptionsBeginning" xlink:label="loc_cvmNumberOfUnvestedOptionsBeginning_d693ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e068c4" xlink:to="loc_cvmNumberOfUnvestedOptionsBeginning_d693ce" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VestedOptions" xlink:label="loc_cvmVestedOptions_e59d5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e068c4" xlink:to="loc_cvmVestedOptions_e59d5a" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_GrantedOptions" xlink:label="loc_cvmGrantedOptions_da8d8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e068c4" xlink:to="loc_cvmGrantedOptions_da8d8a" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ForfeitedOptions" xlink:label="loc_cvmForfeitedOptions_c690c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e068c4" xlink:to="loc_cvmForfeitedOptions_c690c3" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedOptionsEnding" xlink:label="loc_cvmNumberOfUnvestedOptionsEnding_9e2358" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e068c4" xlink:to="loc_cvmNumberOfUnvestedOptionsEnding_9e2358" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageGrantDateFairValueBeginning" xlink:label="loc_cvmWeightedAverageGrantDateFairValueBeginning_e044bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e068c4" xlink:to="loc_cvmWeightedAverageGrantDateFairValueBeginning_e044bc" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageGrantDateFairValueEnding" xlink:label="loc_cvmWeightedAverageGrantDateFairValueEnding_76bda3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e068c4" xlink:to="loc_cvmWeightedAverageGrantDateFairValueEnding_76bda3" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetails4" xlink:title="000050 - Disclosure - STOCK COMPENSATION (Details 4)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b852b" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_963e5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b852b" xlink:to="loc_us-gaapStatementTable_963e5a" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_904a2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_963e5a" xlink:to="loc_us-gaapStatementLineItems_904a2c" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_606f8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_963e5a" xlink:to="loc_us-gaapAwardTypeAxis_606f8e" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c24c05" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_606f8e" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c24c05" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember_89ceb6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c24c05" xlink:to="loc_cvmRestrictedStockAwardsMember_89ceb6" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedSharesBeginning" xlink:label="loc_cvmNumberOfUnvestedSharesBeginning_9a78e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_904a2c" xlink:to="loc_cvmNumberOfUnvestedSharesBeginning_9a78e8" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SharesForfeited" xlink:label="loc_cvmSharesForfeited_97386b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_904a2c" xlink:to="loc_cvmSharesForfeited_97386b" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VestedShares" xlink:label="loc_cvmVestedShares_d58b33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_904a2c" xlink:to="loc_cvmVestedShares_d58b33" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfUnvestedSharesEnding" xlink:label="loc_cvmNumberOfUnvestedSharesEnding_c6ca00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_904a2c" xlink:to="loc_cvmNumberOfUnvestedSharesEnding_c6ca00" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageGrantDateFairValueBeginning" xlink:label="loc_cvmWeightedAverageGrantDateFairValueBeginning_0131a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_904a2c" xlink:to="loc_cvmWeightedAverageGrantDateFairValueBeginning_0131a8" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageGrantDateFairValue" xlink:label="loc_cvmWeightedAverageGrantDateFairValue_6bbd82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_904a2c" xlink:to="loc_cvmWeightedAverageGrantDateFairValue_6bbd82" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockCompensationDetailsNarrative" xlink:title="000051 - Disclosure - STOCK COMPENSATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af6b32" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_dfaeb7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af6b32" xlink:to="loc_us-gaapStatementTable_dfaeb7" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_7fe558" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dfaeb7" xlink:to="loc_us-gaapStatementLineItems_7fe558" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_a28b16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dfaeb7" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_a28b16" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_1770aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_a28b16" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_1770aa" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_744966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dfaeb7" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_744966" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_98c29a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_744966" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_98c29a" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember_5a4c80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_1770aa" xlink:to="loc_cvmStockBonusPlansMember_5a4c80" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_StockCompensationPlansMember" xlink:label="loc_cvmStockCompensationPlansMember_9381f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_98c29a" xlink:to="loc_cvmStockCompensationPlansMember_9381f7" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_e83e3d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_1770aa" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_e83e3d" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="loc_cvmIncentiveStockOptionPlansMember_f05717" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_1770aa" xlink:to="loc_cvmIncentiveStockOptionPlansMember_f05717" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember_95e14d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_1770aa" xlink:to="loc_cvmIncentiveStockBonusPlanMember_95e14d" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_e3707c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_us-gaapCommonStockSharesIssued_e3707c" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_818aa6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_us-gaapCommonStockSharesAuthorized_818aa6" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a76037" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a76037" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RemainingCompensationExpense" xlink:label="loc_cvmRemainingCompensationExpense_de25c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_cvmRemainingCompensationExpense_de25c6" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_de7f8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_de7f8b" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PerformanceBasedStockOptionsSharesGranted" xlink:label="loc_cvmPerformanceBasedStockOptionsSharesGranted_c63d36" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_cvmPerformanceBasedStockOptionsSharesGranted_c63d36" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1_34f7a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1_34f7a6" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription_f07465" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_us-gaapConversionOfStockDescription_f07465" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValuePerShare" xlink:label="loc_cvmFairValuePerShare_ef9217" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_cvmFairValuePerShare_ef9217" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_RemainingOutstandingFairValueOfShares" xlink:label="loc_cvmRemainingOutstandingFairValueOfShares_674ac9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_cvmRemainingOutstandingFairValueOfShares_674ac9" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_GrantDateFairValueRemaining" xlink:label="loc_cvmGrantDateFairValueRemaining_322ead" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_cvmGrantDateFairValueRemaining_322ead" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_474a2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_474a2f" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpenseLifeOverNext" xlink:label="loc_cvmExpenseLifeOverNext_117851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_cvmExpenseLifeOverNext_117851" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VestedShares" xlink:label="loc_cvmVestedShares_69bf12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_cvmVestedShares_69bf12" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IssuanceOfRestrictedStock" xlink:label="loc_cvmIssuanceOfRestrictedStock_5a54f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_cvmIssuanceOfRestrictedStock_5a54f2" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaapDeferredCompensationEquity_1547b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7fe558" xlink:to="loc_us-gaapDeferredCompensationEquity_1547b0" order="16" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="000052 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_6c3f68" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_bb074a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_6c3f68" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_bb074a" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_TotalCompensation" xlink:label="loc_cvmTotalCompensation_2adf2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_6c3f68" xlink:to="loc_cvmTotalCompensation_2adf2f" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ParticipantCompensation" xlink:label="loc_cvmParticipantCompensation_20f7b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_6c3f68" xlink:to="loc_cvmParticipantCompensation_20f7b6" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_6fb485" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_6c3f68" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_6fb485" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a88f96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a88f96" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_893390" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_893390" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_996329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_996329" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_ebaec2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_ebaec2" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_cd09d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_cd09d6" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_d2d0df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_d2d0df" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_1a2f88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_1a2f88" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_68beef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_68beef" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetPresentValueOfLeaseFinancingObligation" xlink:label="loc_cvmNetPresentValueOfLeaseFinancingObligation_791850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ede136" xlink:to="loc_cvmNetPresentValueOfLeaseFinancingObligation_791850" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fa6bf8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fa6bf8" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bb8d13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bb8d13" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_263491" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_263491" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_3d0a06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_3d0a06" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_9d66f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_9d66f1" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b8ba8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b8ba8a" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LesseeOperatingLeaseLiabilityPayments" xlink:label="loc_cvmLesseeOperatingLeaseLiabilityPayments_e85503" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" xlink:to="loc_cvmLesseeOperatingLeaseLiabilityPayments_e85503" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fc81f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fc81f5" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_48a9e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_777aeb" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_48a9e0" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_679ee8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_cac174" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_679ee8" xlink:to="loc_us-gaapStatementTable_cac174" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3b715a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cac174" xlink:to="loc_us-gaapStatementLineItems_3b715a" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis_bb3169" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cac174" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis_bb3169" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_8bf25b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis_bb3169" xlink:to="loc_us-gaapSegmentDomain_8bf25b" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_39de30" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cac174" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_39de30" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_a827cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_39de30" xlink:to="loc_us-gaapRelatedPartyDomain_a827cb" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_2c334e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cac174" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_2c334e" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_effb0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_2c334e" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_effb0f" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_b96cb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cac174" xlink:to="loc_us-gaapAwardDateAxis_b96cb8" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_cfa75f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_b96cb8" xlink:to="loc_us-gaapAwardDateDomain_cfa75f" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_74c913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cac174" xlink:to="loc_us-gaapPlanNameAxis_74c913" order="80" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_4ddbbd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_74c913" xlink:to="loc_us-gaapPlanNameDomain_4ddbbd" order="80" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis_cd1612" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cac174" xlink:to="loc_srtProductOrServiceAxis_cd1612" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_f68b32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis_cd1612" xlink:to="loc_srtProductsAndServicesDomain_f68b32" order="100" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VendorObligationsMember" xlink:label="loc_cvmVendorObligationsMember_b01695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_8bf25b" xlink:to="loc_cvmVendorObligationsMember_b01695" order="101" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember_e6480f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_a827cb" xlink:to="loc_cvmLandlordMember_e6480f" order="102" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_TransactionTwoMember" xlink:label="loc_cvmTransactionTwoMember_abcb63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_effb0f" xlink:to="loc_cvmTransactionTwoMember_abcb63" order="103" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OctoberOneTwothousandNineTeenMember" xlink:label="loc_cvmOctoberOneTwothousandNineTeenMember_a04f10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_cfa75f" xlink:to="loc_cvmOctoberOneTwothousandNineTeenMember_a04f10" order="104" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_TransactionOneMember" xlink:label="loc_cvmTransactionOneMember_c2ea63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_effb0f" xlink:to="loc_cvmTransactionOneMember_c2ea63" order="105" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_2336be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_4ddbbd" xlink:to="loc_cvmErgomedMember_2336be" order="106" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_6900b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain_f68b32" xlink:to="loc_us-gaapLicenseMember_6900b1" order="107" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_14482f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_14482f" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_b877b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_b877b1" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeVariableInterestRate" xlink:label="loc_us-gaapDerivativeVariableInterestRate_33cebe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapDerivativeVariableInterestRate_33cebe" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_MaturityYears" xlink:label="loc_cvmMaturityYears_77e1cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmMaturityYears_77e1cb" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OperatingLeaseMaturityYears" xlink:label="loc_cvmOperatingLeaseMaturityYears_e1a531" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmOperatingLeaseMaturityYears_e1a531" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_b9c05f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_b9c05f" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount_a6e6ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmNetOfDiscount_a6e6ca" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases_882eaa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases_882eaa" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinanceLeaseObligationsNetOfCurrentPortion" xlink:label="loc_cvmFinanceLeaseObligationsNetOfCurrentPortion_51e845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmFinanceLeaseObligationsNetOfCurrentPortion_51e845" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a4fe06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a4fe06" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaapLeaseIncentivePayableCurrent_a41e76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapLeaseIncentivePayableCurrent_a41e76" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_5c752f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_5c752f" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CostIncurredInitial" xlink:label="loc_cvmCostIncurredInitial_94b64b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmCostIncurredInitial_94b64b" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_EstimatedCost" xlink:label="loc_cvmEstimatedCost_aafa1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmEstimatedCost_aafa1d" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_1abbe5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapAssetsNoncurrent_1abbe5" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FinancingLeaseContractualArrangement" xlink:label="loc_cvmFinancingLeaseContractualArrangement_8c0c6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmFinancingLeaseContractualArrangement_8c0c6d" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability" xlink:label="loc_cvmIncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability_02aa47" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmIncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability_02aa47" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_2dc31f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapOperatingLeasePayments_2dc31f" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetBookValueOperatingLeaseRightOfUseAssets" xlink:label="loc_cvmNetBookValueOperatingLeaseRightOfUseAssets_172231" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmNetBookValueOperatingLeaseRightOfUseAssets_172231" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CurrentBalance" xlink:label="loc_cvmCurrentBalance_8f4c5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmCurrentBalance_8f4c5d" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_936202" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapOperatingLeaseLiability_936202" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_df4f69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapLeaseAndRentalExpense_df4f69" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_fb5a83" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_fb5a83" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_1dc701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapFinanceLeaseLiability_1dc701" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" xlink:label="loc_cvmNetBookValueOfTheFinanceLeaseRightOfUseAsset_8bf164" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmNetBookValueOfTheFinanceLeaseRightOfUseAsset_8bf164" order="25" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_BalanceOfTheFinanceLeaseLiability" xlink:label="loc_cvmBalanceOfTheFinanceLeaseLiability_2fe528" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmBalanceOfTheFinanceLeaseLiability_2fe528" order="26" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CashPaidRelatedToFinanceLeases" xlink:label="loc_cvmCashPaidRelatedToFinanceLeases_cd78c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmCashPaidRelatedToFinanceLeases_cd78c5" order="27" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_CashPaidRelatedToFinanceLeasesInterest" xlink:label="loc_cvmCashPaidRelatedToFinanceLeasesInterest_1bbdfc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmCashPaidRelatedToFinanceLeasesInterest_1bbdfc" order="28" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial_986cb4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmClinicalServiceTrial_986cb4" order="29" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AdditionalClinicalTrial" xlink:label="loc_cvmAdditionalClinicalTrial_214896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_cvmAdditionalClinicalTrial_214896" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_07eebb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_07eebb" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome_11ab83" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b715a" xlink:to="loc_us-gaapSubleaseIncome_11ab83" order="32" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000056 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_b38466" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_9e3883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_b38466" xlink:to="loc_us-gaapStatementTable_9e3883" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_edf0db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_9e3883" xlink:to="loc_us-gaapStatementLineItems_edf0db" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_af7e17" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_9e3883" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_af7e17" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_1cf665" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_af7e17" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_1cf665" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_a054a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_9e3883" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_a054a1" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_89be61" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_a054a1" xlink:to="loc_us-gaapRelatedPartyDomain_89be61" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNWarrantsMember" xlink:label="loc_cvmSeriesNWarrantsMember_09465f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1cf665" xlink:to="loc_cvmSeriesNWarrantsMember_09465f" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesUUWarrantsMember" xlink:label="loc_cvmSeriesUUWarrantsMember_8e9aa6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1cf665" xlink:to="loc_cvmSeriesUUWarrantsMember_8e9aa6" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesXWarrantsMember" xlink:label="loc_cvmSeriesXWarrantsMember_3eb769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1cf665" xlink:to="loc_cvmSeriesXWarrantsMember_3eb769" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SeriesNAndXWarrantsMember" xlink:label="loc_cvmSeriesNAndXWarrantsMember_3d8dbb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1cf665" xlink:to="loc_cvmSeriesNAndXWarrantsMember_3d8dbb" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OfficerAndDirectorMember" xlink:label="loc_cvmOfficerAndDirectorMember_5b6ae5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_89be61" xlink:to="loc_cvmOfficerAndDirectorMember_5b6ae5" order="25" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ExpirationDateDescription" xlink:label="loc_cvmExpirationDateDescription_5cde45" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edf0db" xlink:to="loc_cvmExpirationDateDescription_5cde45" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_4128d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edf0db" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_4128d7" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WarrantsIssued" xlink:label="loc_cvmWarrantsIssued_78a852" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edf0db" xlink:to="loc_cvmWarrantsIssued_78a852" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty_bab24b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edf0db" xlink:to="loc_us-gaapInterestExpenseRelatedParty_bab24b" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_NumberOfRestrictedSharesPurchasedByRelatedParty" xlink:label="loc_cvmNumberOfRestrictedSharesPurchasedByRelatedParty_1f0a2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edf0db" xlink:to="loc_cvmNumberOfRestrictedSharesPurchasedByRelatedParty_1f0a2d" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty" xlink:label="loc_cvmProceedsFromRestrictedSharesPurchasedByRelatedParty_112adc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edf0db" xlink:to="loc_cvmProceedsFromRestrictedSharesPurchasedByRelatedParty_112adc" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000057 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_db63cc" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_AmountRealizedThroughTheResaleOfShares" xlink:label="loc_cvmAmountRealizedThroughTheResaleOfShares_aef874" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_db63cc" xlink:to="loc_cvmAmountRealizedThroughTheResaleOfShares_aef874" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance" xlink:label="loc_cvmSecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance_8ceac0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_db63cc" xlink:to="loc_cvmSecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance_8ceac0" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses" xlink:label="loc_cvmSecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses_d6ded2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_db63cc" xlink:to="loc_cvmSecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses_d6ded2" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000058 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_abc9d3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_6424c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_abc9d3" xlink:to="loc_us-gaapStatementTable_6424c2" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5d2969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_6424c2" xlink:to="loc_us-gaapStatementLineItems_5d2969" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_3fd5d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_6424c2" xlink:to="loc_us-gaapPlanNameAxis_3fd5d7" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_5f02de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_3fd5d7" xlink:to="loc_us-gaapPlanNameDomain_5f02de" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_98a4ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_5f02de" xlink:to="loc_cvmErgomedMember_98a4ce" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_1d81b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d2969" xlink:to="loc_us-gaapCommonStockSharesIssued_1d81b7" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedsFromPublicOffering" xlink:label="loc_cvmProceedsFromPublicOffering_7ad943" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d2969" xlink:to="loc_cvmProceedsFromPublicOffering_7ad943" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_1037d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d2969" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_1037d3" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_5b7ab4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d2969" xlink:to="loc_us-gaapSaleOfStockPricePerShare_5b7ab4" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:label="loc_cvmProceedFromIssuanceOrSaleOfEquity_4d84ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d2969" xlink:to="loc_cvmProceedFromIssuanceOrSaleOfEquity_4d84ce" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_74fa0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d2969" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_74fa0a" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_PrepaidAmountOfResold" xlink:label="loc_cvmPrepaidAmountOfResold_19dae5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d2969" xlink:to="loc_cvmPrepaidAmountOfResold_19dae5" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000059 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_20c648" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_007c19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_20c648" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_007c19" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_5c67ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_20c648" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_5c67ff" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_3506ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_20c648" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_3506ab" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" xlink:label="loc_cvmFairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_3d42e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_20c648" xlink:to="loc_cvmFairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_3d42e4" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f0af4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_20c648" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f0af4d" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="000060 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_816db9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_585dea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_816db9" xlink:to="loc_us-gaapStatementTable_585dea" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_a06345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_585dea" xlink:to="loc_us-gaapStatementLineItems_a06345" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_52c696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_585dea" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_52c696" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_ecc356" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_52c696" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_ecc356" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_FairValueInputsLevelThreeMember" xlink:label="loc_cvmFairValueInputsLevelThreeMember_2957c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_ecc356" xlink:to="loc_cvmFairValueInputsLevelThreeMember_2957c4" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments_d0e7b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a06345" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments_d0e7b5" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageRiskFreeInterestRate" xlink:label="loc_cvmWeightedAverageRiskFreeInterestRate_bc1df5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a06345" xlink:to="loc_cvmWeightedAverageRiskFreeInterestRate_bc1df5" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageFairValueDerivativeInstruments" xlink:label="loc_cvmWeightedAverageFairValueDerivativeInstruments_5489db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a06345" xlink:to="loc_cvmWeightedAverageFairValueDerivativeInstruments_5489db" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageExercisePriceDerivativeInstruments" xlink:label="loc_cvmWeightedAverageExercisePriceDerivativeInstruments_e7c216" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a06345" xlink:to="loc_cvmWeightedAverageExercisePriceDerivativeInstruments_e7c216" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_VolatilityRate" xlink:label="loc_cvmVolatilityRate_a1f36f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a06345" xlink:to="loc_cvmVolatilityRate_a1f36f" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_WeightedAverageTimeToMaturityYear" xlink:label="loc_cvmWeightedAverageTimeToMaturityYear_fd2152" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a06345" xlink:to="loc_cvmWeightedAverageTimeToMaturityYear_fd2152" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:title="000061 - Disclosure - NET LOSS PER COMMON SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_90ea9c" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_3a6052" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_90ea9c" xlink:to="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_3a6052" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_a2e320" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_90ea9c" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_a2e320" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_8c711a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_90ea9c" xlink:to="loc_us-gaapEarningsPerShareBasic_8c711a" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareDilutedAbstract_acfe12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_90ea9c" xlink:to="loc_us-gaapEarningsPerShareDilutedAbstract_acfe12" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_0d6075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_acfe12" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_0d6075" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives_f19528" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_acfe12" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives_f19528" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_7408d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_acfe12" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_7408d9" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_da99e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_acfe12" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_da99e2" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants" xlink:label="loc_cvmIncrementalSharesUnderlyingDilutiveinTheMoneyWarrants_b894c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_acfe12" xlink:to="loc_cvmIncrementalSharesUnderlyingDilutiveinTheMoneyWarrants_b894c0" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_836661" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_acfe12" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_836661" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_b3d83e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_acfe12" xlink:to="loc_us-gaapEarningsPerShareDiluted_b3d83e" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:title="000062 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_6645c1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_3f30e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_6645c1" xlink:to="loc_us-gaapStatementTable_3f30e2" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_da1dae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3f30e2" xlink:to="loc_us-gaapStatementLineItems_da1dae" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26ba56" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3f30e2" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26ba56" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_a3756b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26ba56" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_a3756b" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember_e6dbeb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_a3756b" xlink:to="loc_cvmOptionsMember_e6dbeb" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20210930.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember_3822eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_a3756b" xlink:to="loc_cvmUnvestedRestrictedStockMember_3822eb" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8d6bc4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_da1dae" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8d6bc4" order="1" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993096886824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 10, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL-SCI CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,244,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,537,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-0916344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8229 Boone Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993097604392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,060,148<span></span>
</td>
<td class="nump">$ 15,508,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">U.S. Treasury Bills</a></td>
<td class="nump">6,151,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">54,922<span></span>
</td>
<td class="nump">54,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">998,482<span></span>
</td>
<td class="nump">1,313,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">2,006,584<span></span>
</td>
<td class="nump">820,052<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">45,271,521<span></span>
</td>
<td class="nump">17,697,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right of use assets</a></td>
<td class="nump">12,691,921<span></span>
</td>
<td class="nump">13,811,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">2,056,178<span></span>
</td>
<td class="nump">1,198,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">13,663,562<span></span>
</td>
<td class="nump">5,843,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patent costs, net</a></td>
<td class="nump">275,866<span></span>
</td>
<td class="nump">313,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">1,910,917<span></span>
</td>
<td class="nump">1,670,917<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">75,869,965<span></span>
</td>
<td class="nump">40,536,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,675,813<span></span>
</td>
<td class="nump">2,023,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">859,216<span></span>
</td>
<td class="nump">510,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Due to employees</a></td>
<td class="nump">265,993<span></span>
</td>
<td class="nump">448,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative instruments, current portion</a></td>
<td class="nump">437,380<span></span>
</td>
<td class="nump">213,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_LeaseLiabilitiesCurrentPortion', window );">Lease liabilities, current portion</a></td>
<td class="nump">698,665<span></span>
</td>
<td class="nump">1,070,123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,937,067<span></span>
</td>
<td class="nump">4,265,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative instruments, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,551,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">13,252,364<span></span>
</td>
<td class="nump">11,753,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">2,021,308<span></span>
</td>
<td class="nump">1,114,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,335,739<span></span>
</td>
<td class="nump">20,809,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value - 600,000,000 shares authorized;43,207,183 and 38,730,150 shares issued and outstanding at September 30, 2021 and 2020, respectively</a></td>
<td class="nump">432,072<span></span>
</td>
<td class="nump">387,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">474,298,566<span></span>
</td>
<td class="nump">401,174,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(418,196,412)<span></span>
</td>
<td class="num">(381,835,303)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">56,534,226<span></span>
</td>
<td class="nump">19,726,674<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 75,869,965<span></span>
</td>
<td class="nump">$ 40,536,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeaseLiabilitiesCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeaseLiabilitiesCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993096661416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,207,183<span></span>
</td>
<td class="nump">38,730,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,207,183<span></span>
</td>
<td class="nump">38,730,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993097590392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Grant income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 558,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">23,108,897<span></span>
</td>
<td class="nump">17,840,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,085,232<span></span>
</td>
<td class="nump">11,703,429<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">36,194,129<span></span>
</td>
<td class="nump">29,543,719<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(36,194,129)<span></span>
</td>
<td class="num">(28,985,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(8,213)<span></span>
</td>
<td class="nump">38,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on derivative instruments</a></td>
<td class="num">(694,858)<span></span>
</td>
<td class="num">(349,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant inducement expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(805,753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingGainsLosses', window );">Other non-operating gain</a></td>
<td class="nump">1,685,379<span></span>
</td>
<td class="nump">887,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(1,149,288)<span></span>
</td>
<td class="num">(1,041,725)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,361,109)<span></span>
</td>
<td class="num">(30,255,244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ModificationOfWarrants', window );">Modification of warrants</a></td>
<td class="num">(350,861)<span></span>
</td>
<td class="num">(21,734)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (36,711,970)<span></span>
</td>
<td class="num">$ (30,276,978)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic</a></td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">40,662,137<span></span>
</td>
<td class="nump">36,759,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - diluted</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">40,694,248<span></span>
</td>
<td class="nump">36,759,115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993095219048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,231,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2019</a></td>
<td class="nump">$ 5,133,667<span></span>
</td>
<td class="nump">$ 352,318<span></span>
</td>
<td class="nump">$ 358,507,603<span></span>
</td>
<td class="num">$ (353,726,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_AdoptionOfAsc842Leases', window );">Adoption of ASC 842, Leases</a></td>
<td class="nump">2,146,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,146,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromTheSaleOfCommonStockShares', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">13,992,439<span></span>
</td>
<td class="nump">$ 14,225<span></span>
</td>
<td class="nump">13,978,214<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantIssuances', window );">Warrant issuances</a></td>
<td class="nump">805,753<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">805,753<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercisesShares', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercisesAmount', window );">Warrant exercises, amount</a></td>
<td class="nump">15,144,240<span></span>
</td>
<td class="nump">$ 17,118<span></span>
</td>
<td class="nump">15,127,122<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ModificationOfWarrantsAmount', window );">Modification of warrants</a></td>
<td class="nump">5,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">163,340<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">163,201<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">972,667<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
<td class="nump">971,868<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">10,112,968<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,112,968<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises, amount</a></td>
<td class="nump">338,328<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
<td class="nump">337,330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues', window );">Purchase of stock by officers and directors, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount', window );">Purchase of stock by officers and directors, amount</a></td>
<td class="nump">184,990<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">184,785<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(787,723)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(787,723)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares', window );">Shares issued for settlement of clinical research costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount', window );">Shares issued for settlement of clinical research costs, amount</a></td>
<td class="nump">1,769,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,768,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(30,255,244)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,255,244)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,730,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2020</a></td>
<td class="nump">19,726,674<span></span>
</td>
<td class="nump">$ 387,302<span></span>
</td>
<td class="nump">401,174,675<span></span>
</td>
<td class="num">(381,835,303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromTheSaleOfCommonStockShares', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">47,363,426<span></span>
</td>
<td class="nump">$ 26,100<span></span>
</td>
<td class="nump">47,337,326<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercisesShares', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,597,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercisesAmount', window );">Warrant exercises, amount</a></td>
<td class="nump">10,007,306<span></span>
</td>
<td class="nump">$ 15,978<span></span>
</td>
<td class="nump">9,991,328<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ModificationOfWarrantsAmount', window );">Modification of warrants</a></td>
<td class="nump">24,387<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">201,099<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">200,919<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">1,195,704<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
<td class="nump">1,194,945<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">13,685,046<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">13,685,066<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises, amount</a></td>
<td class="nump">746,228<span></span>
</td>
<td class="nump">$ 1,498<span></span>
</td>
<td class="nump">744,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues', window );">Purchase of stock by officers and directors, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount', window );">Purchase of stock by officers and directors, amount</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">219,725<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(274,535)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(274,535)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,361,109)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(36,361,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity based compensation - employees, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,207,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2021</a></td>
<td class="nump">$ 56,534,226<span></span>
</td>
<td class="nump">$ 432,072<span></span>
</td>
<td class="nump">$ 474,298,566<span></span>
</td>
<td class="num">$ (418,196,412)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AdoptionOfAsc842Leases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AdoptionOfAsc842Leases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromTheSaleOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromTheSaleOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993097877704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (36,361,109)<span></span>
</td>
<td class="num">$ (30,255,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,231,108<span></span>
</td>
<td class="nump">2,159,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">1,226,690<span></span>
</td>
<td class="nump">862,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">13,685,046<span></span>
</td>
<td class="nump">10,112,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CommonStockContributedToEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">201,099<span></span>
</td>
<td class="nump">163,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuedForSettlementOfClinicalResearchCosts', window );">Shares issued for settlement of clinical research costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,769,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ShortTermInvestment', window );">Gain on short-term investments</a></td>
<td class="num">(5,621)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_LossOnDerivativesInstruments', window );">Loss on derivative instruments</a></td>
<td class="nump">694,858<span></span>
</td>
<td class="nump">349,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant inducement expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">805,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ModificationOfWarrant', window );">Modification of warrants</a></td>
<td class="nump">24,387<span></span>
</td>
<td class="nump">5,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">283,964<span></span>
</td>
<td class="num">(623,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturing', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="num">(1,186,532)<span></span>
</td>
<td class="num">(37,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ShortTermDeposits', window );">Deposits</a></td>
<td class="num">(240,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">445,981<span></span>
</td>
<td class="num">(766,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">363,701<span></span>
</td>
<td class="nump">406,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders', window );">Due to employees</a></td>
<td class="num">(182,029)<span></span>
</td>
<td class="num">(261,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">31,441<span></span>
</td>
<td class="nump">25,229<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,787,016)<span></span>
</td>
<td class="num">(15,276,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetPurchasesOfUSTreasuryBills', window );">Net purchases of U.S. Treasury Bills</a></td>
<td class="num">(6,145,764)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(9,016,329)<span></span>
</td>
<td class="num">(2,654,906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(22,641)<span></span>
</td>
<td class="num">(39,975)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(15,184,734)<span></span>
</td>
<td class="num">(2,694,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">47,363,426<span></span>
</td>
<td class="nump">13,992,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="num">(325,034)<span></span>
</td>
<td class="num">(752,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">5,984,215<span></span>
</td>
<td class="nump">12,072,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of options</a></td>
<td class="nump">746,228<span></span>
</td>
<td class="nump">338,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from the purchase of stock by officers and directors</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">184,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements', window );">Proceeds from landlord funding of leasehold improvements</a></td>
<td class="nump">1,613,546<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under finance leases</a></td>
<td class="num">(1,079,392)<span></span>
</td>
<td class="num">(800,241)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">54,522,989<span></span>
</td>
<td class="nump">25,035,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">20,551,239<span></span>
</td>
<td class="nump">7,064,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</a></td>
<td class="nump">15,508,909<span></span>
</td>
<td class="nump">8,444,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF YEAR</a></td>
<td class="nump">36,060,148<span></span>
</td>
<td class="nump">15,508,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable', window );">Property and equipment included in accrued expenses and accounts payable</a></td>
<td class="nump">435,412<span></span>
</td>
<td class="nump">1,184,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable', window );">Capitalizable patent costs included in accrued expenses and accounts payable</a></td>
<td class="nump">6,510<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ChangesToRightOfUseAssetsAndLiabilities', window );">Changes to right of use assets and liabilities</a></td>
<td class="nump">551,444<span></span>
</td>
<td class="nump">399,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable', window );">Finance lease obligation included in accounts payable</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock', window );">Prepaid consulting services paid with issuance of common stock</a></td>
<td class="nump">363,911<span></span>
</td>
<td class="nump">164,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise', window );">Fair value of warrants liabilities on date of exercise</a></td>
<td class="nump">4,023,091<span></span>
</td>
<td class="nump">3,071,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FinancingCostsIncludedInAccountsPayable', window );">Financing costs included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_AccruedConsultingServicesToBePaidWithCommonStock', window );">Accrued consulting services to be paid with common stock</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 1,173,702<span></span>
</td>
<td class="nump">$ 1,155,026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AccruedConsultingServicesToBePaidWithCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AccruedConsultingServicesToBePaidWithCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ChangesToRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ChangesToRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockContributedToEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockContributedToEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseObligationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LossOnDerivativesInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LossOnDerivativesInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetPurchasesOfUSTreasuryBills">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetPurchasesOfUSTreasuryBills</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuedForSettlementOfClinicalResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuedForSettlementOfClinicalResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100025912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">1. ORGANIZATION</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. </strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ORGANIZATION</strong><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has recently&#160;announced top line&#160;Phase 3 data for its lead investigational therapy, Multikine&#174; (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI is investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099938264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATIONS AND FINANCING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>OPERATIONS AND FINANCING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">2. OPERATIONS AND FINANCING</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font76426394-2f38-4e90-98a8-d495869e96f0" style="font-family:symbol"><strong>2</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>OPERATIONS AND FINANCING</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine&#174; (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Liquidity</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similarly to the way it has substantially funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Primarily as a result of CEL-SCI's losses incurred to date, CEL-SCI's expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI's ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that because there is more than enough cash on hand to meet the Company's budgeted cash requirements, the substantial doubt about the Company's ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Impact of COVID-19 Pandemic</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In response to the global outbreak of COVID-19 and the World Health Organization&#8217;s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention&#8217;s (&#8220;CDC&#8221;) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company&#8217;s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099860968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font6d9af7c4-49e2-4b76-a099-aabe7e6ed090" style="font-family:symbol"><strong>3</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>U.S. Treasury Bills &#8211; </em>U.S. Treasury Bills (&#8220;T-bills&#8221;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing</em> &#8211; Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Leases &#8211;</em> On October 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, <em>Leases </em>and its related amendments (collectively referred to as Topic 842 and codified as &#8220;ASC 842&#8221;). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company&#8217;s statements of operations or cash flows.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as&#160;leases with initial terms of 12 months or less,&#160;are not reflected on the balance sheet. Lease expense for such short-term leases is not material. <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Derivative Instruments</em> &#8211; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, &#8220;<em>Accounting for Derivative Instruments and Hedging Activities</em>.&#8221; In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the FASB issued ASU No. 2020-06 (&#8220;ASU 2020-06&#8221;) <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity.</em> The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation</em> &#8211; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 &#8220;<em>Compensation &#8211; Stock Compensation</em>.&#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, <em>Compensation &#8212; Stock Compensation (Topic 718</em>), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Grant Income</em> &#8211; The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, the FASB issued ASU No. 2019-12, <em>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</em>. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets,&#160;right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the&#160;lease assets and liabilities to be significant.</td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>New Accounting Pronouncements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099912264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsAndNonEmployeeOptionstextblock', window );">4. WARRANTS AND NON-EMPLOYEE OPTIONS</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. </strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2021: </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Warrant/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/ Options</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2022 </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/23/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11/23/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/8/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,845</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/8/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/23/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/16/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/26/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/22/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,432</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,087</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251,761</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/19/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/18/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2023</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:center;">7/28/2017 &#8211; 11/18/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">2.18 - $11.61</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;">11/17/2022 - 7/27/2027</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2020: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Warrant</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/18/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/31/2020</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/28/2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">688,930</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/28/2020</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/23/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/18/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/26/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/22/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/23/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11/23/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/8/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,643</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/8/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/23/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/16/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/26/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/22/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">797,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,842</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">417,649</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/19/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">326,064</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/18/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">371,564</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2023</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/17</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A. Warrant Liabilities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Warrant liabilities outstanding at September 30 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,207,902</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">75,044</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,082,212</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,961</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,259,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total warrant liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The (losses)/gains on the warrant liabilities for the years ended September 30 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series V Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185,652</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,119,937</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,115</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(98,357</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(98,692</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,594</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(318,823</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(165,304</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,207</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(668,605</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(875,040</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series FF warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(319,706</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">404</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(34,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series JJ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(64,992</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series LL warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(98,066</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss on warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(694,858</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(349,078</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#8217;s stock because future equity offerings or sales of the Company&#8217;s stock are not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option on equity shares, and equity classification is therefore precluded.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Changes in Warrant Liabilities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 22, 2021, 16,000 Series BB warrants, with an exercise price of $13.75 expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75 expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 26, 2020, the Company lowered the exercise price of 810,127 Series V warrants from $19.75 to $13.75 per share and extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020. The incremental cost of this modification was approximately $664,000, which was included in the net loss on derivatives for the year ended September 30, 2020. On June 25, 2020, 135,963 Series V warrants, with an exercise price of $13.75 expired. The warrants were valued at approximately $211,000 on the date of expiration.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Exercise of Warrant Liabilities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following warrants recorded as liabilities were exercised during the year ended September 30, 2021:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,089,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series ZZ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">275,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,375,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132,798</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">663,990</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">331,998</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,402,990</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The following warrants recorded as liabilities were exercised during the year ended September 30, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series V</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">674,164</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,269,755</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">128,820</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">644,100</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series FF</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,048</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.91</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">265,812</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,300</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series JJ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,450</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,531</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series LL</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,398</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">94,867</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">913,180</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,323,752</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>B. </strong></p></td><td style="vertical-align:top;"><strong>Equity Warrants</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Changes in Equity Warrants</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration dates of the Series N, Series X, Series Y and Series UU warrants were extended six months. On June 28, 2021, the expiration dates of these same warrants were extended one year. The incremental costs of both warrant extensions were recorded consistent with the accounting for the initial warrant issuances. The incremental costs of the Series N and Series X warrant extensions were recorded as a deemed dividend and totaled approximately $351,000 for the year ended September 30, 2021. The Series N and Series X warrants are held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary. The incremental cost of the Series Y warrants&#160;extension approximated $103,000 and had no impact on&#160;the financial statements for the year ended September 30,2021&#160;due to offsetting entries recorded within additional paid in capital. The incremental cost of the Series UU warrant extension was recorded as interest expense, because these warrants were initially issued as an inducement to convert notes payable into common stock, and totaled approximately $24,000 for the year ended September 30, 2021. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 26, 2020, the Company provided that for each Series V liability warrant exercised on or before June 10, 2020, the former holder of the Series V warrant received one Series XX warrant. Each Series XX warrant allowed the holder to purchase one share of the Company's common stock at a price of $18.00 per share at any time on or before September 10, 2020. For each Series V liability warrant exercised after June 10, 2020 but on or before June 25, 2020, the former holder of the Series V warrant received one Series YY warrant. Every two Series YY warrants allowed the holder to purchase one share of the Company's common stock at a price of $20.00 per share at any time on or before September 25, 2020. In June 2020, 461,953 Series XX warrants and 101,839 Series YY warrants were issued to the former holders of the Series V warrants. The Series XX and YY warrants qualified for equity treatment in accordance with ASC 815. The Company recognized a warrant inducement expense equal to the fair value of the Series XX and Series YY warrants issued as of the date the inducement offers were accepted. The fair values of the Series XX and Series YY warrants were calculated to be approximately $629,000 and $177,000, respectively. The total expense of approximately $806,000 is reported as warrant inducement expense in the statement of operations for the year ended September 30, 2020. All Series XX and YY warrants expired in September 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 8, 2020, the expiration dates of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense during the year ended September 30, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Exercise of Equity Warrants </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following equity warrants were exercised during the year ended September 30, 2021.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,201</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">863,414</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,755</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">349,663</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">165,888</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">273,715</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,064</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263,474</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">370,964</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">830,959</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,265,872</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,581,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The following equity warrants were exercised during the year ended September 30, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,858</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">178,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">124,956</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">314,889</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series OO</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,467</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,121</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">156,580</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">327,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,125</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">421,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,207</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">171,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series VV</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">82,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">144,375</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">798,693</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,748,713</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>C. </strong></p></td><td style="vertical-align:top;"><strong>Options and Shares Issued to Consultants</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2021 and 2020 the Company issued 75,885 and 79,950 shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $6.86 to $24.95 per share. The weighted average grant price was $15.46 and $12.01, respectively, for stock issued during the years ended September 30, 2021 and 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the years ended September 30, 2021 and 2020, the Company recorded total expense of approximately $1,227,000 and $863,000, respectively, relating to these consulting agreements. At September 30, 2021 and 2020, costs of approximately $364,000 and $395,000, respectively, are included in prepaid expenses.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2021, the Company issued 5,000 options to a consultant to purchase common stock with an exercise price of $11.61 and an expiration of November 17, 2022. No options were issued to consultants during the year ended September 30, 2020. As of September 30, 2021, 15,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option plan and are fully vested.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsAndNonEmployeeOptionstextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsAndNonEmployeeOptionstextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099890328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PLANT, PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PLANT, PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">5. PLANT, PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; &#160;&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5. </strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PROPERTY AND</strong><strong> EQUIPMENT</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment consisted of the following at September 30:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,211,124</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,898,242</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,768</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,768</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,465,123</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,519,161</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,776,015</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,517,171</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,112,453</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,673,178</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,663,562</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,843,993</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">Depreciation expense for the years ended September 30, 2021 and 2020 totaled approximately $447,000 and $389,000 respectively.</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100020824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">6. PATENTS</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font66386e05-b0ba-43df-a9f7-ebad16078e27" style="font-family:symbol"><strong>6</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><strong>PATENTS</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">Patents consist of the following at September 30:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">910,523</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">896,372</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(634,657</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(582,950</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">275,866</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">313,422</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the years ended September 30, 2021 and 2020, there was no impairment of patent costs. Amortization expense for the years ended September 30, 2021 and 2020 totaled approximately $52,000 and $53,000, respectively. The total estimated future amortization is as follows:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years ending September 30, </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">103,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">276,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099882296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">7. INCOME TAXES</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:1%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font0df12115-a745-4aa7-8f47-83deaf9f47d1" style="font-family:symbol"><strong>7</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><strong>INCOME TAXES</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At September 30, 2021 and 2020, the Company had net deferred tax assets of $44.1 million and $35.5 million, respectively. Due to uncertainties surrounding the Company&#8217;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax asset will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income. Management has considered the history of the Company&#8217;s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company&#8217;s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes for the year ended September 30, 2021 occurred and no such shifts were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company had federal NOL carryforwards of approximately $77.1 million and $51.5 million at September 30, 2021 and 2020, respectively. Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards, which were generated post Tax Cuts and Jobs Act, have an indefinite life. In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#8220;R&amp;D credit&#8221;) of approximately $1.2 million at September 30, 2021 and 2020. The R&amp;D credit expires during the fiscal year ended 2029.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Significant components of the Company&#8217;s deferred tax assets as of September 30, 2021 and 2020 are listed below:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NOL carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,789,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,407,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,101,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,631,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">R&amp;D credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,785,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,297,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized R&amp;D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,040,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,853,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vacation and other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">126,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,062,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,534,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,786,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,911,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(172,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(169,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,958,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,080,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,104,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,454,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,104,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(35,454,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending Balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The Company has no federal or state current or deferred tax expense or benefit. The Company&#8217;s effective tax rate differs from the applicable federal statutory tax rate. The reconciliation of these rates is as follows at for the years ended September 30:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Federal Rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">State rate change </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.40</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">State tax rate, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.72</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.79</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3.24</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Permanent differences</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.23</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.42</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(23.79</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.93</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company applies the provisions of ASC 740, <em>&#8220;Accounting for Uncertainty in Income Taxes,&#8221;</em> which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained. The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense. The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2021. The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2018.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993101316200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">8. STOCK COMPENSATION</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="fontc40a34ae-8897-44de-9460-8912f1bf5730" style="font-family:symbol"><strong>8</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><strong>STOCK COMPENSATION</strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 19.1pt; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,685,046</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,112,968</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,226,690</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">862,796</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">During the years ended September 30, 2021 and 2020 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected stock price volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">90.42 &#8211; 97.22%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">87.36 &#8211; 90.26%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.85 &#8211; 1.65%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.62 &#8211; 1.87%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life of options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.68 &#8211; 9.69 Years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.68 &#8211; 9.69 Years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Non-Qualified Stock Option Plan</span><span style="text-decoration:underline">s</span> &#8211;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2021, the Company adopted the 2021 Non-Qualified Stock Option Plan, which provides for the issuance of up to 1,800,000 options to purchase shares of common stock. On May 14, 2021, the Company granted 1,800,000 performance-based stock options from the 2021 Non-Qualified Stock Option Plan and 72,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share, the fair value on the date of issuance. The stock options will vest 100% upon the achievement of the following performance goals: (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $42.00. None of the options will be exercisable before May 13, 2022. All options which have not vested as of May 13, 2031, will be canceled and will no longer be exercisable. The options were recorded in permanent equity in accordance with ASC 718, Compensation &#8211; Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. That valuation resulted in a per share fair value of $0.34 and an aggregate value of approximately $636,000 on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was determined to be 1.3 years. This resulted in compensation expense of approximately $189,000 recorded during the year ended September 30, 2021. The remaining $447,000 will be expensed over the next 11 months.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2020, the Company adopted the 2020 Non-Qualified Stock Option Plan, which provides for the issuance of up to 3,600,000 options to purchase shares of common stock. On April 20, 2020, the Company granted 1,872,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share, the fair value on the date of issuance. The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days. Additionally, 100% of the options will vest when either (a) the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia is filed, i.e., the performance condition, or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. All options which have not vested as of April 19, 2030, will be canceled and will no longer be exercisable. The options were recorded as permanent equity in accordance with ASC 718, Compensation &#8211; Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. That valuation resulted in a per share fair value of $4.21 and an aggregate value of approximately $7.9 million on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was originally determined to be 1.7 years. In May 2021, it became probable that the performance condition would be met approximately 8 months later than originally estimated. Because the valuation and related requisite service period were based on achievement of the performance condition, the Company adjusted the requisite service period when it became probable that the marketing application would be filed within a different period. Compensation expense relating to this Plan was approximately $3.8 million and $2.1 million during the years ended September 30, 2021 and 2020, respectively. The remaining $2.0 million will be expensed over the next 11 months.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At September 30, 2021, the Company has collectively authorized the issuance of 11,787,200 shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the plans. The Company&#8217;s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Option Plan</span><span style="text-decoration:underline">s</span> &#8211; At September 30, 2021, the Company had collectively authorized the issuance of 138,400 shares of common stock under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the Plans. Only the Company&#8217;s employees are eligible to be granted options under the Incentive Stock Option Plans.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Activity in the Company&#8217;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2021 is summarized as follows:</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Non-Qualified and Incentive Stock Option Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,218,216</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.54</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">29,562,594</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,392,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.68</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7,869,555</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,014,501</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,563,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">99,740</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">99,740</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,773</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">132.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,773</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">132.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8,653,703</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">56,193,415</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3,297,229</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">29,090,662</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,401,961</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.26</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,605,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">20.58</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">149,788</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.98</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">149,788</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.98</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">49,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.56</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,374</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">172.73</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,374</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">172.73</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">11,049,709</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">54,843,283</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5,540,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.77</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">43,589,598</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">______________</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;(a)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Includes 1,872,000 performance based options issued to officers and directors, 728,000 options issued to employees and 5,000 options issued to Consultants.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">A summary of the status of the Company&#8217;s non-vested options for the two years ended September 30, 2021 is presented below:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,825,975</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.79</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,014,501</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,563,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,356,474</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.76</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,401,961</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,605,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(49,832</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,509,681</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Bonus Plan</span> &#8211; On September 30, 2021, 614,500 of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which 463,250 shares are fully vested. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company&#8217;s Multikine technology, or specified increases in the market price of the Company&#8217;s stock. The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of shares issued that remain outstanding as of September 30, 2021 was approximately $8.6 million. The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service period is not rendered. During each of the years ended September 30, 2021 and 2020, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $0.3 million. At September 30, 2021, the Company has unrecognized compensation expense of approximately $45,000 which is expected to be fully recognized in the next quarter.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the status of the Company&#8217;s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2021 is presented below:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Shares</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Grant Date Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">304,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">304,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Stock Bonus Plans</span><span style="text-decoration:underline"> </span>&#8211; As of September 30, 2021, the Company has issued a total of 363,086 shares of common stock from the Stock Bonus Plans and was authorized to issue up to 783,760 shares of common stock under its Stock Bonus Plans. All employees, directors, officers, consultants, and advisors are eligible to be granted shares.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Stock Compensation Plan</span><span style="text-decoration:underline">s</span> &#8211; On September 30, 2021, 634,000 shares were authorized for use in the Company&#8217;s Stock Compensation Plans, of which 154,195 shares were issued and outstanding. No shares were issued from the Stock Compensation Plans to consultants for payment of services during the years ended September 30, 2021, and 2020.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099961768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>EMPLOYEE BENEFIT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">9. EMPLOYEE BENEFIT PLAN</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontfd048409-0460-4364-bd1a-6b54d9dd4d63" style="font-family:symbol"><strong>9</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>EMPLOYEE BENEFIT PLAN</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant&#8217;s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant&#8217;s contribution, not to exceed the lesser of $10,000 or 6% of the participant&#8217;s total compensation. The Company&#8217;s contribution of common stock is valued each quarter based upon the closing bid price of the Company&#8217;s common stock. During the year ended September 30, 2021, 17,990 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $201,000. During the year ended September 30, 2020, 13,870 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $163,000.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099864568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">10. COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span id="font1fee1043-38b7-4ec7-92f5-34f01644823c" style="font-family:symbol"><strong>10</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><strong>COMMITMENTS AND CONTINGENCIES </strong></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Clinical Research Agreements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Company&#8217;s Phase III clinical study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;. The Company determined the payments to Ergomed are within the scope of ASC 730 &#8220;Research and Development.&#8221; Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $35.1 million related to Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $11.6 million. During the years ended September 30, 2021 and 2020, the Company recorded approximately $1.6 million and $2.0 million, respectively, as research and development expense related to Ergomed&#8217;s services. These amounts were net of Ergomed&#8217;s discount of approximately $0.6 million during both the years ended September 30, 2021 and 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Lease Agreements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon adoption of ASC 842 on October 1, 2019, the Company recorded a finance lease right of use asset of approximately $16.5 million and a finance lease liability of approximately $13.5 million. As of September 30, 2021 and 2020, respectively, the net book value of the finance lease right of use asset is approximately $12.7 million and $13.8 million and the balance of the finance lease liability is approximately $13.8 million and $12.7 million, of which approximately $0.6 million and $0.9 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being amortized using a straight-line method over the underlying lease terms and totaled approximately&#160;$1,732,000&#160;and $1,717,000&#160;&#160;in&#160;the years ended September 30, 2021 and 2020, respectively. Total cash paid related to finance leases during the years ended September 30, 2021 and 2020, respectively, was approximately $2.2 million and $1.9 million, of which approximately $1.2 million was for interest in both years. The weighted average discount rate of the Company&#8217;s finance leases is 8.45% and the weighted average time to maturity is 7.1 years.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $10.7 million, of which approximately $10.5 million has been incurred as of September 30, 2021. The landlord agreed to finance the final $2.4 million of the costs incurred which will be repaid through increased lease payments over the remaining lease term starting on March 1, 2021. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. The Company remeasured the lease liability to account for the modified payments using a 8.45% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. Approximately $1.6 million was received from the landlord as of September 30, 2021. The leasehold improvements are recorded in property and equipment and will be amortized over the remaining lease term when the assets are placed in service.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During June 2021, the Company determined that it used an incorrect discount rate to calculate the opening ROU asset and lease liability balances upon adoption of ASC 842. Management engaged an outside valuation specialist to perform a synthetic credit rating analysis which resulted in a revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%. This change resulted in an immaterial difference to the September 30, 2020 financial statements, and was corrected in the quarterly period ended June 30, 2021 as an out of period adjustment.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company was required to deposit the equivalent of one year of base rent in accordance with the original lease. Under the landlord&#8217;s $2.4 million financing arrangement, the Company was required to deposit an additional $0.2 million in March 2021. As September 30, 2021 and 2020, respectively, the approximate $1.9 million and $1.7 million deposit is included in non-current assets.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Approximate future minimum lease payments under finance leases as of September 30, 2021 are as follows:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,699,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,569,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,648,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,733,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,824,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,186,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation *</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,659,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,825,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of lease finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">13,834,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;"><em>* Amount is net of landlord incentive of approximately $0.8 million expected to be realized in quarter ended December 31, 2021. </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective April 30, 2020, the Company terminated a month-to-month arrangement with a sub-lessee as the sub-leased space was needed to prepare the facility to produce Multikine for commercial purposes and before the Company&#8217;s Biologics License Application (BLA) can be submitted to the FDA. The sublease rental income for the year ended September 30, 2020 was approximately $39,000.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on March 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon adoption of ASC 842 on October 1, 2019, the Company recorded an operating lease right of use asset and an operating lease liability of approximately $1.0 million. As of September 30, 2021, the net book value of the operating lease right of use asset is approximately $2.1 million and the balance of the operating lease liability is approximately $2.1 million, of which approximately $0.1 million is current. As of September 30, 2020, the net book value of the operating lease right of use asset is approximately $1.2 million and the balance of the operating lease liability is approximately $1.2 million, of which approximately $0.1 million is current. The Company incurred lease expense under operating leases of approximately $0.2 million for each of the years ended September 30, 2021 and 2020. Total cash paid related to operating leases during the years ended September 30, 2021 and 2020 was approximately $0.3 million and $0.2 million, respectively. The weighted average discount rate of the Company&#8217;s operating leases is 9.12% and the weighted average time to maturity is 9.7 years.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">As of September 30, 2021, future minimum lease payments on operating leases are as follows:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">309,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,602,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,269,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,130,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,139,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Vendor Obligations</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has contingent obligations with vendors for work that will be completed in relation to the Phase 3 clinical trial. The timing of these obligations cannot be determined at this time. The Company estimates it will incur additional expenses of approximately $1.1 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report with the FDA. This estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099935464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">11. RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="fontdbb63aaa-97d8-4a2c-a795-4ccbe55f6879" style="font-family:symbol"><strong>1</strong><strong>1</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>RELATED PARTY TRANSACTIONS</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2021, the de Clara Trust, of which the Company&#8217;s CEO, Geert Kerston, is a beneficiary, and two directors purchased 27,500 restricted shares of the Company&#8217;s common stock at an aggregate fair market value of approximately $220,000. During the year ended September 30, 2020, officers and directors of the Company purchased 20,512 shares of restricted common stock at market price at an aggregate fair market value of approximately $185,000. The shares are subject to the conditions of Rule 144 under the Securities Act of 1933.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2021, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary, were extended by twelve months (Note 4). The incremental cost of these modifications was approximately $265,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2021, the expiration date of 93,603 Series UU warrants was extended by twelve months (Note 4). The incremental cost of this extension was $24,000 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and the de Clara Trust and were originally issued with convertible debt.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary, were extended by six months (Note 4). The incremental cost of these modifications was approximately $86,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021. The incremental cost of this extension was $192 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 8, 2020, the expiration date of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense for the year ended September 30, 2020. The Series UU warrants are held by the Company&#8217;s officers and were originally issued with convertible debt.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099961208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">12. STOCKHOLDERS' EQUITY</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>12. </strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>STOCKHOLDERS&#8217; EQUITY </strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Exercise of Warrants</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the years ended September 30, 2021 and 2020, the Company received proceeds of approximately $6.0 million and $12.1 million, respectively, from the exercise of warrants, as detailed in Note 4. Upon exercise, 1,597,870 and 1,711,873 shares of common stock were issued during the years ended September 30, 2021 and 2020, respectively.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Sales of Securities</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June 2021, the Company sold 1,400,000 shares of common stock at a public offering price of $22.62 per share and received aggregate net proceeds of approximately $29.4 million. At that time, the underwriters fully exercised their option to purchase up to 210,000 additional shares of common stock to cover over-allotments, resulting in additional net proceeds to the Company of approximately $4.4 million.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2020, the Company sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In March 2020, the Company sold 630,500 shares of common stock at a public offering price of $12.22 per share and received aggregate net proceeds of approximately $7.1 million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 45-day option to purchase up to an additional 94,575 shares of common stock solely to cover over-allotments. The underwriter fully exercised this option in May 2020 resulting in additional net proceeds to the Company of approximately $1.1 million.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, the Company sold 606,395 shares of common stock at a public offering price of $9.07 per share and received aggregate net proceeds of approximately $5.0 million. In January 2020, the underwriters of that offering fully exercised the option to purchase 90,959 additional shares of common stock at the public offering price of $9.07 per share for aggregate net proceeds to the Company of approximately $0.8 million.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Other Equity Transactions</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company entered into Securities Purchase Agreements (SPA) with Ergomed plc, one of the Company&#8217;s Clinical Research Organizations responsible for managing the Company&#8217;s Phase 3 clinical trial, to facilitate payment of amounts due Ergomed. Under the Agreements, the Company issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed. Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2020, the Company issued Ergomed 150,000 shares. No shares were issued during the year ended September 30, 2021. All outstanding shares have been resold as of September 30, 2021 and the Company has approximately $500,000 in amounts prepaid to Ergomed.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes the Other Non-operating gains (losses) for the years ended September 30 relating to these agreements:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amount realized through the resale of shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,652,605</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of shares upon issuance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,769,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other non-operating gain</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">883,105</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">As of September 30, 2021, all shares held for resale were sold.</p></td></tr><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099935464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">13. FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>3</strong><strong>. </strong></p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FAIR VALUE MEASUREMENTS</strong></p></td></tr><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the provisions of ASC 820, &#8220;<em>Fair Value Measurements</em>,&#8221; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">o </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">o </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs other than quoted prices that are observable for the asset or liability</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">o </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company purchased short-term T-bills during the year ended September 30, 2021 that are classified as trading securities. Quoted market prices were applied to determine the fair value of short-term investments, therefore they were categorized as Level 1 on the fair value hierarchy. The T-bills were recorded at fair market value, which includes an unrealized gain of approximately $6,000. The T-bills mature in December 2021 and yield a weighted average interest rate of 0.10%.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2021 and 2020, all of the Company&#8217;s derivative liabilities are classified as Level 3.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September 30:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,488,310</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,023,091</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,071,775</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">N Net realized and unrealized derivative loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">694,858</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">349,078</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fair values of the Company&#8217;s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company&#8217;s stock. At September 30, 2021, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $1.45 per share and a weighted average exercise price of $13.28 per share. Fair values were determined using a weighted average risk free interest rate of 0.05% and volatility of 109%. The instruments have a weighted average time to maturity of 0.3 years. At September 30, 2020, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $2.81 per share and a weighted average exercise price of $14.32 per share. Fair values were determined using a weighted average risk free interest rate of 0.12% and volatility of 95%. The instruments have a weighted average time to maturity of 1.2 years.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099972440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">14. NET LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160;&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font1979c11c-b28b-499c-aafb-834c09537173" style="font-family:symbol"><strong>1</strong><strong>4</strong><strong>. </strong></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NET LOSS PER COMMON SHARE</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock have not been included in the computation of diluted net loss per share for all periods presented, as the result would be anti-dilutive. For the years presented, the gain on derivative instruments is not included in net loss available to common shareholders for purposes of computing dilutive loss per share because its effect is anti-dilutive.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Net loss available to common shareholders - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,711,970</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,662,137</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt">Basic loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.90</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.82</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Net loss available to common shareholders - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(36,711,970</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Unrealized gain on derivatives <sup>(1)</sup></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,085,540</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Net loss available to common shareholders - diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,797,510</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,662,137</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Incremental shares underlying dilutive warrants <sup>(1)</sup></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,111</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Weighted average shares outstanding - diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,694,248</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt">Diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.93</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.82</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span id="font7d035306-f9b9-45fc-87bc-b43e5ea6ceb6" style="font-family:symbol"><em><sup>(1)</sup></em><em> </em></span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Includes Series Z, AA, CC and HH warrants for the year ended September 30, 2021.</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,604,850</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,221,696</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">308,814</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,756,100</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,530,510</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099985528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">15. SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>15. SUBSEQUENT EVENTS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993096719480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_USTreasuryBills', window );">U.S. Treasury Bills</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>U.S. Treasury Bills &#8211; </em>U.S. Treasury Bills (&#8220;T-bills&#8221;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingPolicytextblock', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_LeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Leases &#8211;</em> On October 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, <em>Leases </em>and its related amendments (collectively referred to as Topic 842 and codified as &#8220;ASC 842&#8221;). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company&#8217;s statements of operations or cash flows.</p>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as&#160;leases with initial terms of 12 months or less,&#160;are not reflected on the balance sheet. Lease expense for such short-term leases is not material. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Derivative Instruments</em> &#8211; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, &#8220;<em>Accounting for Derivative Instruments and Hedging Activities</em>.&#8221; In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the FASB issued ASU No. 2020-06 (&#8220;ASU 2020-06&#8221;) <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity.</em> The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation</em> &#8211; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 &#8220;<em>Compensation &#8211; Stock Compensation</em>.&#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, <em>Compensation &#8212; Stock Compensation (Topic 718</em>), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Grant Income</em> &#8211; The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskTextBlock', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2021. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, the FASB issued ASU No. 2019-12, <em>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</em>. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets,&#160;right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the&#160;lease assets and liabilities to be significant.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingPolicytextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingPolicytextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_USTreasuryBills">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_USTreasuryBills</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties.  The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13572-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13587-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100903224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock', window );">Schedule of warrants and non-employee options</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Warrant/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/ Options</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2022 </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/23/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11/23/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/8/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,845</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/8/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/23/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/16/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/26/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/22/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,432</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,087</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251,761</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/19/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/18/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2023</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:center;">7/28/2017 &#8211; 11/18/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">2.18 - $11.61</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;">11/17/2022 - 7/27/2027</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Warrant</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/18/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/31/2020</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/28/2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">688,930</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/28/2020</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/23/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/18/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/26/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/22/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5/23/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11/23/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/8/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,643</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/8/2021</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/23/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/16/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/26/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/22/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">797,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,842</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">417,649</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/19/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">326,064</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/18/2022</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">371,564</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2023</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/17</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock', window );">Schedule of equity warrants were exercised</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,201</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">863,414</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,755</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">349,663</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">165,888</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">273,715</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,064</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263,474</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">370,964</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">830,959</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,265,872</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,581,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,858</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">178,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">124,956</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">314,889</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series OO</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,467</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,121</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">156,580</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">327,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,125</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">421,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,207</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">171,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series VV</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">82,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">144,375</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">798,693</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,748,713</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock', window );">Schedule of warrants recorded as liabilities were exercised</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,089,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series ZZ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">275,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,375,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132,798</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">663,990</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">331,998</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,402,990</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series V</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">674,164</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,269,755</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">128,820</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">644,100</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series FF</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,048</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.91</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">265,812</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,300</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series JJ</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,450</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,531</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series LL</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,398</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">94,867</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">913,180</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,323,752</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of warrant liabilities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,207,902</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">75,044</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,082,212</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,961</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,259,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total warrant liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock', window );">Schedule of (losses)/gains on the warrant liabilities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series V Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185,652</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,119,937</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,115</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(98,357</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(98,692</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,594</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(318,823</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(165,304</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,207</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(668,605</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(875,040</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series FF warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(319,706</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">404</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(34,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series JJ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(64,992</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series LL warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(98,066</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss on warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(694,858</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(349,078</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993101317320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PLANT, PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PLANT, PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock', window );">Schedule of plant, property and equipment</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,211,124</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,898,242</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,768</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,768</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,465,123</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,519,161</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,776,015</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,517,171</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,112,453</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,673,178</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,663,562</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,843,993</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84167750&amp;loc=d3e42232-110370<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993186649896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of patents</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2020</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">910,523</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">896,372</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(634,657</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(582,950</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">275,866</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">313,422</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years ending September 30, </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">103,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">276,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100919032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock', window );">Schedule of components of the Company's deferred tax assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NOL carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,789,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,407,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,101,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,631,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">R&amp;D credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,785,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,297,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized R&amp;D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,040,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,853,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vacation and other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">126,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,062,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,534,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,786,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,911,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(172,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(169,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,958,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,080,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,104,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,454,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,104,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(35,454,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending Balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock', window );">Schedule of federal or state current or deferred tax expense or benefit</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Federal Rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">State rate change </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.40</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">State tax rate, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.72</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.79</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3.24</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Permanent differences</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.23</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.42</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(23.79</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.93</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993096716536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock', window );">Schedule of expenses for options issued or vested and restricted stock awarded</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 19.1pt; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,685,046</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,112,968</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,226,690</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">862,796</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock', window );">Schedule of fair value of each option granted</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected stock price volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">90.42 &#8211; 97.22%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">87.36 &#8211; 90.26%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.85 &#8211; 1.65%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.62 &#8211; 1.87%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life of options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.68 &#8211; 9.69 Years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.68 &#8211; 9.69 Years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock', window );">Schedule of non-qualified and incentive stock option plans</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,218,216</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.54</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">29,562,594</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,392,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.68</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7,869,555</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,014,501</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,563,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">99,740</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">99,740</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,773</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">132.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,773</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">132.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8,653,703</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">56,193,415</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3,297,229</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">29,090,662</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,401,961</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.26</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,605,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">20.58</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">149,788</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.98</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">149,788</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.98</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">49,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.56</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,374</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">172.73</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,374</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">172.73</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">11,049,709</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">54,843,283</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5,540,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.77</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">43,589,598</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfNonVestedOptionsTableTextBlock', window );">Schedule of non-vested options</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,825,975</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.79</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,014,501</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,563,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,356,474</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.76</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,401,961</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,605,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(49,832</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,509,681</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock', window );">Schedule of restricted common stock issued from the incentive stock bonus plan</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Shares</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Grant Date Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">304,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">304,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfNonVestedOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfNonVestedOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100912664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under finance leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,699,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,569,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,648,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,733,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,824,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,186,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation *</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,659,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,825,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of lease finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">13,834,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">309,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,602,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,269,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,130,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,139,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099994312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock', window );">Schedule of other non-operating gains (losses)</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amount realized through the resale of shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,652,605</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of shares upon issuance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,769,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other non-operating gain</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">883,105</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099861688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,488,310</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,023,091</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,071,775</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">N Net realized and unrealized derivative loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">694,858</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">349,078</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100911272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock', window );">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Net loss available to common shareholders - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,711,970</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,662,137</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt">Basic loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.90</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.82</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Net loss available to common shareholders - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(36,711,970</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Unrealized gain on derivatives <sup>(1)</sup></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,085,540</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Net loss available to common shareholders - diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,797,510</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,662,137</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt">Incremental shares underlying dilutive warrants <sup>(1)</sup></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,111</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Weighted average shares outstanding - diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,694,248</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt">Diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.93</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.82</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,604,850</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,221,696</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">308,814</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,756,100</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,530,510</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993099941144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Patent useful life</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Fully insured amount of non-interest bearing cash balances</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993094046728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">7/28/2017<span></span>
</td>
<td class="text">7/28/17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">7/27/2027<span></span>
</td>
<td class="text">7/27/2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember', window );">Series W [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10/28/2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10/28/2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5/23/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5/18/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8/26/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8/22/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">5/23/2016<span></span>
</td>
<td class="text">5/23/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">184,800<span></span>
</td>
<td class="nump">264,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">11/23/2021<span></span>
</td>
<td class="text">11/23/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember', window );">Series CC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">12/8/2016<span></span>
</td>
<td class="text">12/8/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">15,845<span></span>
</td>
<td class="nump">148,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">12/8/2021<span></span>
</td>
<td class="text">12/8/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember', window );">Series HH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">2/23/2017<span></span>
</td>
<td class="text">2/23/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">2/16/2022<span></span>
</td>
<td class="text">2/16/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">8/26/2016<span></span>
</td>
<td class="text">8/26/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">2/22/2022<span></span>
</td>
<td class="text">2/22/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">8/18/2008<span></span>
</td>
<td class="text">8/18/2008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">85,339<span></span>
</td>
<td class="nump">85,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">8/18/2022<span></span>
</td>
<td class="text">2/18/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">1/13/2016<span></span>
</td>
<td class="text">1/13/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">7/13/2022<span></span>
</td>
<td class="text">1/13/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">2/15/2016<span></span>
</td>
<td class="text">2/15/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">8/15/2022<span></span>
</td>
<td class="text">2/15/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">6/22/2017<span></span>
</td>
<td class="text">6/22/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">333,432<span></span>
</td>
<td class="nump">797,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">6/22/2022<span></span>
</td>
<td class="text">6/22/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">7/24/2017<span></span>
</td>
<td class="text">7/24/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">210,087<span></span>
</td>
<td class="nump">348,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">7/24/2022<span></span>
</td>
<td class="text">7/24/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">10/30/2017<span></span>
</td>
<td class="text">10/30/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">251,761<span></span>
</td>
<td class="nump">417,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">10/30/2022<span></span>
</td>
<td class="text">10/30/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">12/19/2017<span></span>
</td>
<td class="text">12/19/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">326,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">12/18/2022<span></span>
</td>
<td class="text">12/18/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember', window );">Series TT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">2/5/2018<span></span>
</td>
<td class="text">2/5/2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">371,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">2/5/2023<span></span>
</td>
<td class="text">2/5/2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">6/11/2018<span></span>
</td>
<td class="text">6/11/2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">93,603<span></span>
</td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">6/30/2022<span></span>
</td>
<td class="text">12/31/2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_Issuedate2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_Issuedate2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuableUponExerciseOfwarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuableUponExerciseOfwarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100105544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">$ 437,380<span></span>
</td>
<td class="nump">$ 3,765,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="num">(694,858)<span></span>
</td>
<td class="num">(349,078)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember', window );">Series W [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">73,570<span></span>
</td>
<td class="nump">1,119,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="num">(98,692)<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">65,173<span></span>
</td>
<td class="num">(1,207)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">64,787<span></span>
</td>
<td class="nump">1,207,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="num">(252,115)<span></span>
</td>
<td class="num">(98,357)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember', window );">Series CC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">94,961<span></span>
</td>
<td class="nump">1,259,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="num">(668,605)<span></span>
</td>
<td class="num">(875,040)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember', window );">Series HH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">1,597<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">404<span></span>
</td>
<td class="num">(34,589)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">276,035<span></span>
</td>
<td class="nump">1,082,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="num">(318,823)<span></span>
</td>
<td class="num">(165,304)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesFFMember', window );">Series FF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(319,706)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesJJMember', window );">Series JJ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(64,992)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesLLMember', window );">Series LL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(98,066)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 185,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetLossGainOnWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetLossGainOnWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesFFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesFFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesJJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesJJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesLLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesLLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993097960792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="nump">$ 3,402,990<span></span>
</td>
<td class="nump">$ 10,323,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="nump">331,998<span></span>
</td>
<td class="nump">913,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,089,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember', window );">Series CC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="nump">$ 663,990<span></span>
</td>
<td class="nump">$ 644,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="nump">132,798<span></span>
</td>
<td class="nump">128,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember', window );">Series HH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="nump">$ 1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesFFMember', window );">Series FF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="nump">$ 265,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="nump">68,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesJJMember', window );">Series JJ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesLLMember', window );">Series LL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,269,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePriceWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePriceWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesFFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesFFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesJJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesJJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesLLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesLLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993097997096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">1,265,872<span></span>
</td>
<td class="nump">798,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="nump">$ 2,581,225<span></span>
</td>
<td class="nump">$ 1,748,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">863,414<span></span>
</td>
<td class="nump">95,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="nump">$ 464,201<span></span>
</td>
<td class="nump">$ 178,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">138,755<span></span>
</td>
<td class="nump">124,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="nump">$ 349,663<span></span>
</td>
<td class="nump">$ 314,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">165,888<span></span>
</td>
<td class="nump">39,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="nump">$ 273,715<span></span>
</td>
<td class="nump">$ 65,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">126,064<span></span>
</td>
<td class="nump">156,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="nump">$ 263,474<span></span>
</td>
<td class="nump">$ 327,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember', window );">Series TT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">370,964<span></span>
</td>
<td class="nump">188,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="nump">$ 830,959<span></span>
</td>
<td class="nump">$ 421,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesOOMember', window );">Series OO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesVVMember', window );">Series VV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromEquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromEquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesOOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesOOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesVVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesVVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993090943976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Aug. 22, 2021</div></th>
<th class="th"><div>Oct. 28, 2020</div></th>
<th class="th"><div>Jun. 25, 2020</div></th>
<th class="th"><div>Jun. 20, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Jan. 23, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="nump">$ 664,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CommonStockIssuedForServiceShares', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,885<span></span>
</td>
<td class="nump">79,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantInducementExpense', window );">Warrant inducement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 806,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">805,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,227,000<span></span>
</td>
<td class="nump">863,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_PrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364,000<span></span>
</td>
<td class="nump">$ 395,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_OptionIssuedToRelatedParty', window );">Option issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_OptionExpirationDate', window );">Option expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 17,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock prices per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.86<span></span>
</td>
<td class="nump">$ 24.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Restricted Stock [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.46<span></span>
</td>
<td class="nump">12.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember', window );">Series W [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercise', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercise', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVWarrantsMember', window );">Series V Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExercisedShares', window );">Warrants exercised shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercise', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVWarrantsMember', window );">Series V Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVWarrantsMember', window );">Series V Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXXWarrantsMember', window );">Series XX Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsIssuedDuringPeriod', window );">Warrants issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYYWarrantsMember', window );">Series YY Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsIssuedDuringPeriod', window );">Warrants issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember', window );">Series UU warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">from December 31, 2020 to June 30, 2021<span></span>
</td>
<td class="text">extended from June 11, 2020 to December 31, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsIssuedDuringPeriod', window );">Warrants issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXMember', window );">Series N and Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember', window );">Series N Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">the expiration date of the Series N warrants was extended to February 18, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the expiration date of the Series N warrants was extended to February 18, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockIssuedForServiceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockIssuedForServiceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OptionExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OptionExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OptionIssuedToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OptionIssuedToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantInducementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantInducementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXXWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXXWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYYWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYYWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993097640440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PLANT, PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FixturesAndEquipmentGross', window );">Research equipment</a></td>
<td class="nump">$ 4,211,124<span></span>
</td>
<td class="nump">$ 3,898,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and equipment</a></td>
<td class="nump">99,768<span></span>
</td>
<td class="nump">99,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">13,456,123<span></span>
</td>
<td class="nump">5,519,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross</a></td>
<td class="nump">17,776,015<span></span>
</td>
<td class="nump">9,517,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(4,112,453)<span></span>
</td>
<td class="num">(3,673,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">$ 13,663,562<span></span>
</td>
<td class="nump">$ 5,843,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FixturesAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FixturesAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100904312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PLANT, PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 447,000<span></span>
</td>
<td class="nump">$ 389,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100857880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">$ 275,866<span></span>
</td>
<td class="nump">$ 313,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">910,523<span></span>
</td>
<td class="nump">896,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(634,657)<span></span>
</td>
<td class="num">(582,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 275,866<span></span>
</td>
<td class="nump">$ 313,422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100858456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">103,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_Total', window );">Total</a></td>
<td class="nump">$ 276,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_Total">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_Total</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100907096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patent costs</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993094397544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 19,789,000<span></span>
</td>
<td class="nump">$ 13,407,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">4,101,000<span></span>
</td>
<td class="nump">3,631,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit</a></td>
<td class="nump">1,221,000<span></span>
</td>
<td class="nump">1,221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">7,785,000<span></span>
</td>
<td class="nump">5,297,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd', window );">Capitalized R&amp;D</a></td>
<td class="nump">15,040,000<span></span>
</td>
<td class="nump">15,853,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Vacation and other</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">48,062,000<span></span>
</td>
<td class="nump">39,534,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_RightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(3,786,000)<span></span>
</td>
<td class="num">(3,911,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FixedAssetsAndIntangibles', window );">Fixed assets and intangibles</a></td>
<td class="num">(172,000)<span></span>
</td>
<td class="num">(169,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(3,958,000)<span></span>
</td>
<td class="num">(4,080,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetDeferredTaxAsset', window );">Net deferred tax asset</a></td>
<td class="nump">44,104,000<span></span>
</td>
<td class="num">(35,454,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(44,104,000)<span></span>
</td>
<td class="num">(35,454,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993093984680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Federal rate change</a></td>
<td class="num">(1.37%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">4.72%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.79%)<span></span>
</td>
<td class="num">(3.24%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">0.23%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.79%)<span></span>
</td>
<td class="num">(21.93%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993094914968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 19,789,000<span></span>
</td>
<td class="nump">$ 13,407,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Estimated net operating loss carryforwards</a></td>
<td class="nump">48,062,000<span></span>
</td>
<td class="nump">39,534,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember', window );">Income Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ResearchAndDevelopmentCredit', window );">Research and development credit</a></td>
<td class="nump">$ 1,200,000.0<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ResearchAndDevelopmentCreditDescription', window );">Research and development credit, description</a></td>
<td class="text">The R&D credit expires during the fiscal year ended 2029.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 77,100,000<span></span>
</td>
<td class="nump">51,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CumulativeChangeInOwnershipPercentage', window );">Cumulative change in ownership percentage</a></td>
<td class="text">(NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Net operating loss carryforwards, description</a></td>
<td class="text">Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Estimated net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,900,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ResearchAndDevelopmentCreditDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ResearchAndDevelopmentCreditDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993196023672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Employees</a></td>
<td class="nump">$ 13,685,046<span></span>
</td>
<td class="nump">$ 10,112,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-employees</a></td>
<td class="nump">$ 1,226,690<span></span>
</td>
<td class="nump">$ 862,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993094920328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, min</a></td>
<td class="nump">90.42%<span></span>
</td>
<td class="nump">87.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, max</a></td>
<td class="nump">97.22%<span></span>
</td>
<td class="nump">90.26%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, min</a></td>
<td class="nump">0.85%<span></span>
</td>
<td class="nump">0.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, max</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpectedLifeOfOptionsMin1', window );">Expected life of options, min</a></td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpectedLifeOfOptionsMax', window );">Expected life of options, max</a></td>
<td class="text">9 years 8 months 8 days<span></span>
</td>
<td class="text">9 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpectedLifeOfOptionsMax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpectedLifeOfOptionsMax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpectedLifeOfOptionsMin1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpectedLifeOfOptionsMin1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993097921864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember', window );">Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">8,653,703<span></span>
</td>
<td class="nump">6,218,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfOptionsExercised', window );">Number of Options Exercised</a></td>
<td class="nump">149,788<span></span>
</td>
<td class="nump">99,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfOptions', window );">Number of Options Expired</a></td>
<td class="nump">9,374<span></span>
</td>
<td class="nump">9,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">11,049,709<span></span>
</td>
<td class="nump">8,653,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 7.01<span></span>
</td>
<td class="nump">$ 5.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">4.98<span></span>
</td>
<td class="nump">3.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">172.73<span></span>
</td>
<td class="nump">132.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 10.08<span></span>
</td>
<td class="nump">$ 7.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</a></td>
<td class="text">7 years 11 months 4 days<span></span>
</td>
<td class="text">8 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</a></td>
<td class="text">8 years 10 months 17 days<span></span>
</td>
<td class="text">8 years 4 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_AggregateIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Beginning</a></td>
<td class="nump">$ 56,193,415<span></span>
</td>
<td class="nump">$ 29,562,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_AggregateIntrinsicValueOutstandingEnding', window );">Aggregate Intrinsic Value Outstanding, Ending</a></td>
<td class="nump">$ 54,843,283<span></span>
</td>
<td class="nump">$ 56,193,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">2,605,000<span></span>
</td>
<td class="nump">2,563,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options Forfeited</a></td>
<td class="nump">49,832<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 20.58<span></span>
</td>
<td class="nump">$ 10.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 9.56<span></span>
</td>
<td class="nump">$ 10.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember', window );">Exercisable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">3,297,229<span></span>
</td>
<td class="nump">1,392,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfOptionsVested', window );">Number of Options Vested</a></td>
<td class="nump">2,401,961<span></span>
</td>
<td class="nump">2,014,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfOptionsExercised', window );">Number of Options Exercised</a></td>
<td class="nump">149,788<span></span>
</td>
<td class="nump">99,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfOptions', window );">Number of Options Expired</a></td>
<td class="nump">9,374<span></span>
</td>
<td class="nump">9,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">5,540,028<span></span>
</td>
<td class="nump">3,297,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="nump">$ 9.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageExercisePriceVested', window );">Weighted Average Exercise Price Vested</a></td>
<td class="nump">6.26<span></span>
</td>
<td class="nump">4.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">4.98<span></span>
</td>
<td class="nump">3.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">172.73<span></span>
</td>
<td class="nump">132.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 5.77<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</a></td>
<td class="text">6 years 11 months 15 days<span></span>
</td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</a></td>
<td class="text">7 years 8 months 5 days<span></span>
</td>
<td class="text">7 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_AggregateIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Beginning</a></td>
<td class="nump">$ 29,090,662<span></span>
</td>
<td class="nump">$ 7,869,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_AggregateIntrinsicValueOutstandingEnding', window );">Aggregate Intrinsic Value Outstanding, Ending</a></td>
<td class="nump">$ 43,589,598<span></span>
</td>
<td class="nump">$ 29,090,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AggregateIntrinsicValueOutstandingEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AggregateIntrinsicValueOutstandingEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageExercisePriceVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageExercisePriceVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100869816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfUnvestedOptionsBeginning', window );">Number of unvested options, Beginning</a></td>
<td class="nump">5,356,474<span></span>
</td>
<td class="nump">4,825,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_VestedOptions', window );">Vested options</a></td>
<td class="num">(2,401,961)<span></span>
</td>
<td class="num">(2,014,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GrantedOptions', window );">Granted options</a></td>
<td class="nump">2,605,000<span></span>
</td>
<td class="nump">2,563,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ForfeitedOptions', window );">Forfeited options</a></td>
<td class="num">(49,832)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfUnvestedOptionsEnding', window );">Number of unvested options, Ending</a></td>
<td class="nump">5,509,681<span></span>
</td>
<td class="nump">5,356,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageGrantDateFairValueBeginning', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageGrantDateFairValueEnding', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 5.17<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ForfeitedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ForfeitedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GrantedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GrantedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfUnvestedOptionsBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfUnvestedOptionsBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfUnvestedOptionsEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfUnvestedOptionsEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_VestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_VestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageGrantDateFairValueBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageGrantDateFairValueBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageGrantDateFairValueEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageGrantDateFairValueEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993094944456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details 4) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageGrantDateFairValueBeginning', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfUnvestedSharesBeginning', window );">Number of unvested shares, Beginning</a></td>
<td class="nump">304,500<span></span>
</td>
<td class="nump">304,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesForfeited', window );">Forfeited</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_VestedShares', window );">Vested shares</a></td>
<td class="num">(151,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfUnvestedSharesEnding', window );">Number of unvested shares, Ending</a></td>
<td class="nump">151,250<span></span>
</td>
<td class="nump">304,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageGrantDateFairValueBeginning', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfUnvestedSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfUnvestedSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfUnvestedSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfUnvestedSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_VestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_VestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageGrantDateFairValueBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageGrantDateFairValueBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993093778184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,207,183<span></span>
</td>
<td class="nump">38,730,150<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,500<span></span>
</td>
<td class="nump">606,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember', window );">Stock Compensation Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">154,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember', window );">Stock Bonus Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">363,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">783,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Options Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">11,787,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_RemainingCompensationExpense', window );">Remaining compensation expense</a></td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="nump">$ 3,800,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock options purchase shares</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_PerformanceBasedStockOptionsSharesGranted', window );">Performance based stock options shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,872,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Stock price</a></td>
<td class="nump">$ 20.61<span></span>
</td>
<td class="nump">$ 10.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Stock options vest description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FairValuePerShare', window );">Fair value per share</a></td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_RemainingOutstandingFairValueOfShares', window );">Grant date fair value remaining outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GrantDateFairValueRemaining', window );">Grant date fair value remaining</a></td>
<td class="nump">$ 447,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Implicit life of options</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpenseLifeOverNext', window );">Expense life over next</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember', window );">Incentive Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">138,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">614,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_RemainingOutstandingFairValueOfShares', window );">Grant date fair value remaining outstanding</a></td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_VestedShares', window );">Vested shares</a></td>
<td class="nump">463,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssuanceOfRestrictedStock', window );">Issuance of restricted stock</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpenseLifeOverNext">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpenseLifeOverNext</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GrantDateFairValueRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GrantDateFairValueRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssuanceOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssuanceOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PerformanceBasedStockOptionsSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PerformanceBasedStockOptionsSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RemainingCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RemainingCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RemainingOutstandingFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RemainingOutstandingFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_VestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_VestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120519210&amp;loc=d3e90205-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100986392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN (Detail Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>EMPLOYEE BENEFIT PLAN (Detail Narrative)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Expense for Company's contribution to employee benefit plan</a></td>
<td class="nump">$ 163,000<span></span>
</td>
<td class="nump">$ 201,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_TotalCompensation', window );">Total compensation</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ParticipantCompensation', window );">Participant compensation</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">13,870<span></span>
</td>
<td class="nump">17,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ParticipantCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ParticipantCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_TotalCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_TotalCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993094915048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,699,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">2,569,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,648,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,733,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">2,824,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">6,186,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease obligation</a></td>
<td class="nump">18,659,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on financing obligation</a></td>
<td class="nump">4,825,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetPresentValueOfLeaseFinancingObligation', window );">Net present value of lease financing obligation</a></td>
<td class="num">$ (13,834,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetPresentValueOfLeaseFinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetPresentValueOfLeaseFinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993094915304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 309,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">348,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">357,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,602,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_LesseeOperatingLeaseLiabilityPayments', window );">Total future minimum lease obligation</a></td>
<td class="nump">3,269,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on operating lease obligation</a></td>
<td class="num">(1,130,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 2,139,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LesseeOperatingLeaseLiabilityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LesseeOperatingLeaseLiabilityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993094097672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate operating lease</a></td>
<td class="nump">9.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Interest rate</a></td>
<td class="nump">0.1019%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_MaturityYears', window );">Maturity years</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_OperatingLeaseMaturityYears', window );">Operating lease maturity years</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 35,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetOfDiscount', window );">Net of discount</a></td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases', window );">Lease description</a></td>
<td class="text">revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FinanceLeaseObligationsNetOfCurrentPortion', window );">Finance lease obligations, net of current portion</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average time to maturity</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Biologics License Application [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">1,400,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetOfDiscount', window );">Net of discount</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ClinicalServiceTrial', window );">Clinical service trial</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_AdditionalClinicalTrial', window );">Additional clinical trial</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average time to maturity</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cvm_TransactionTwoMember', window );">TransactionTwoMember [Member] | October 1, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability', window );">Change in right of use of assets and liability</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid related to operating leases</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetBookValueOperatingLeaseRightOfUseAssets', window );">Net book value operating lease right of use assets</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CurrentBalance', window );">Current balance</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease - liability</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cvm_TransactionOneMember', window );">Transaction One [Member] | October 1, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">0.0845%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability', window );">Change in right of use of assets and liability</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CurrentBalance', window );">Current balance</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease - liability</a></td>
<td class="nump">1,732,000<span></span>
</td>
<td class="nump">1,717,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset', window );">Net book value of the finance lease right of use asset</a></td>
<td class="nump">12,700,000<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_BalanceOfTheFinanceLeaseLiability', window );">Balance of the finance lease liability</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CashPaidRelatedToFinanceLeases', window );">Cash paid related to finance leases</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CashPaidRelatedToFinanceLeasesInterest', window );">Cash paid related to finance leases interest</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">1,200,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_LandlordMember', window );">Landlord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Interest rate</a></td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases', window );">Lease description</a></td>
<td class="text">The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentivePayableCurrent', window );">Lease incentive payable current</a></td>
<td class="nump">$ 1,600,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Additional deposit</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CostIncurredInitial', window );">Cost incurred, initial</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EstimatedCost', window );">Estimated cost</a></td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non current assets</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FinancingLeaseContractualArrangement', window );">Financing arrangement</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvm_VendorObligationsMember', window );">Vendor Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Additional expenses</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AdditionalClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AdditionalClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_BalanceOfTheFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_BalanceOfTheFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CashPaidRelatedToFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CashPaidRelatedToFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CashPaidRelatedToFinanceLeasesInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CashPaidRelatedToFinanceLeasesInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ClinicalServiceTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ClinicalServiceTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CostIncurredInitial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CostIncurredInitial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CurrentBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CurrentBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EstimatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EstimatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseObligationsNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseObligationsNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingLeaseContractualArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingLeaseContractualArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_MaturityYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_MaturityYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetBookValueOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetBookValueOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseMaturityYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseMaturityYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 15<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121601235&amp;loc=d3e32400-112679<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121554914&amp;loc=SL2265659-115463<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121549808&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentivePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121577943&amp;loc=d3e41614-112719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e40019-112707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e40010-112707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentivePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cvm_TransactionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cvm_TransactionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cvm_OctoberOneTwothousandNineTeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cvm_OctoberOneTwothousandNineTeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cvm_TransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cvm_TransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_LandlordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_LandlordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvm_VendorObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvm_VendorObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993090869960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative ) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Jan. 23, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 28, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember', window );">Officer and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NumberOfRestrictedSharesPurchasedByRelatedParty', window );">Restricted Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="nump">20,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty', window );">Restricted Common shares, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember', window );">Series N Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">the expiration date of the Series N warrants was extended to February 18, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the expiration date of the Series N warrants was extended to February 18, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember', window );">Series UU warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">from December 31, 2020 to June 30, 2021<span></span>
</td>
<td class="text">extended from June 11, 2020 to December 31, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsIssued', window );">Warrants issued</a></td>
<td class="nump">93,603<span></span>
</td>
<td class="nump">93,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXWarrantsMember', window );">Series X Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXWarrantsMember', window );">Series N and X Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfRestrictedSharesPurchasedByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfRestrictedSharesPurchasedByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993096713384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_AmountRealizedThroughTheResaleOfShares', window );">Amount realized through the resale of shares</a></td>
<td class="nump">$ 1,685,379<span></span>
</td>
<td class="nump">$ 2,652,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance', window );">Fair value of shares upon issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,769,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses', window );">Other non-operating gain (loss)</a></td>
<td class="nump">$ 1,685,379<span></span>
</td>
<td class="nump">$ 883,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AmountRealizedThroughTheResaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AmountRealizedThroughTheResaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993093752968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,395<span></span>
</td>
<td class="nump">43,207,183<span></span>
</td>
<td class="nump">38,730,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromPublicOffering', window );">Proceeds from public offering</a></td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,575<span></span>
</td>
<td class="nump">$ 90,959<span></span>
</td>
<td class="nump">$ 90,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="nump">$ 29,400,000<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 22.62<span></span>
</td>
<td class="nump">$ 14.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.22<span></span>
</td>
<td class="nump">$ 9.07<span></span>
</td>
<td class="nump">$ 9.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of warrant</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 12,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,597,870<span></span>
</td>
<td class="nump">1,711,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_PrepaidAmountOfResold', window );">Prepaid of resold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PrepaidAmountOfResold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PrepaidAmountOfResold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993097641416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 3,765,613<span></span>
</td>
<td class="nump">$ 6,488,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Exercises</a></td>
<td class="nump">4,023,091<span></span>
</td>
<td class="nump">3,071,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings', window );">Net realized and unrealized derivative loss</a></td>
<td class="nump">694,858<span></span>
</td>
<td class="nump">349,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 437,380<span></span>
</td>
<td class="nump">$ 3,765,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993090871544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">unrealized gain on short-term T-bills</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageRiskFreeInterestRate', window );">Weighted average risk free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=cvm_FairValueInputsLevelThreeMember', window );">Fair Value Inputs Level 3 (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageRiskFreeInterestRate', window );">Weighted average risk free interest rate</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageFairValueDerivativeInstruments', window );">Weighted average fair value, Derivative instruments</a></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageExercisePriceDerivativeInstruments', window );">Weighted average exercise price, Derivative instruments</a></td>
<td class="nump">$ 13.28<span></span>
</td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_VolatilityRate', window );">Volatility rate</a></td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageTimeToMaturityYear', window );">Weighted average time to maturity year</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_VolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_VolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageExercisePriceDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageExercisePriceDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageFairValueDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageFairValueDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageTimeToMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageTimeToMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=cvm_FairValueInputsLevelThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=cvm_FairValueInputsLevelThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993093965496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Net loss available to common shareholders - basic</a></td>
<td class="num">$ (36,711,970)<span></span>
</td>
<td class="num">$ (30,276,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic</a></td>
<td class="nump">40,662,137<span></span>
</td>
<td class="nump">36,759,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share</a></td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Loss per share- diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders -basic</a></td>
<td class="num">$ (36,711,970)<span></span>
</td>
<td class="num">$ (30,276,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain on derivatives</a></td>
<td class="num">(1,085,540)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss available to common shareholders - diluted</a></td>
<td class="num">$ (37,797,510)<span></span>
</td>
<td class="num">$ (30,276,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - basic</a></td>
<td class="nump">40,694,248<span></span>
</td>
<td class="nump">36,759,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants', window );">Incremental shares underlying dilutive "in the money" warrants</a></td>
<td class="nump">32,111<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted</a></td>
<td class="nump">40,694,248<span></span>
</td>
<td class="nump">36,759,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139993100852104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">10,756,100<span></span>
</td>
<td class="nump">7,530,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">10,604,850<span></span>
</td>
<td class="nump">7,221,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">151,250<span></span>
</td>
<td class="nump">308,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>cvm_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvm="http://cvm.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20210930.xsd" xlink:type="simple"/>
    <context id="From2020-10-01to2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_FairValueInputsLevelThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">cvm:FairValueInputsLevelThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_FairValueInputsLevelThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">cvm:FairValueInputsLevelThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_FairValueInputsLevelThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">cvm:FairValueInputsLevelThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_FairValueInputsLevelThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">cvm:FairValueInputsLevelThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2019-12-01to2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-03-01to2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-05-01to2020-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-12-01to2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_OfficerAndDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-04-01to2021-06-30_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-28_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-28</instant>
        </period>
    </context>
    <context id="AsOf2020-12-07_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="AsOf2020-05-08_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-08</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesNAndXWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNAndXWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesNWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesXWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-04-01to2021-06-30_cvm_SeriesXWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-01to2021-06-30_cvm_SeriesNWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesNWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="From2020-12-01to2020-12-07_cvm_SeriesNWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvm:TransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_VendorObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvm:VendorObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-14_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="AsOf2020-04-20_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-20</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_StockCompensationPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:StockCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_IncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_IncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_IncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-01-23_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-23</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-01-23_cvm_SeriesNWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-23</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesNAndXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNAndXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-05-01to2020-05-08_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="From2020-06-01to2020-06-20_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-20</endDate>
        </period>
    </context>
    <context id="From2020-06-01to2020-06-20_cvm_SeriesYYWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYYWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-20</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesYYWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYYWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-06-01to2020-06-20_cvm_SeriesXXWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXXWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-20</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesXXWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXXWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2020-10-28_cvm_SeriesWMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-28</endDate>
        </period>
    </context>
    <context id="From2021-08-01to2021-08-22_cvm_SeriesBBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-22</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-26_cvm_SeriesVWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="AsOf2020-05-26_srt_MaximumMember_cvm_SeriesVWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="From2020-06-01to2020-06-25_cvm_SeriesVWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-25</endDate>
        </period>
    </context>
    <context id="From2020-05-01to2020-05-26_cvm_SeriesVWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesVVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesVVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesOOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesOOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesLLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesLLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesLLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesLLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesJJMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesJJMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesJJMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesJJMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesFFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesFFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesFFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesFFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesBBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesBBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesZZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesZZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesWMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesWMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesTTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesTTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesTTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesTTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesAAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesAAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesAAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesAAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesHHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesHHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesHHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesHHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesBBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesBBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesZZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesZZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesWMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesWMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-01to2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-10-01to2021-09-30">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-10-01to2021-09-30">false</dei:AmendmentFlag>
    <dei:EntityVoluntaryFilers contextRef="From2020-10-01to2021-09-30">No</dei:EntityVoluntaryFilers>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-10-01to2021-09-30">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2020-10-01to2021-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-10-01to2021-09-30">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-10-01to2021-09-30">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="0" unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="0" unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="0" unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-09-30" decimals="0" unitRef="Shares">43207183</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-09-30" decimals="0" unitRef="Shares">38730150</us-gaap:CommonStockSharesIssued>
    <cvm:SuppliesUsedForRDAndManufacturingPolicytextblock contextRef="From2020-10-01to2021-09-30"/>
    <cvm:WarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember"
      decimals="0"
      unitRef="Shares">72900</cvm:WarrantsExercised>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">664000</us-gaap:DefinedBenefitPlanInterestCost>
    <cvm:WarrantsIssuedDuringPeriod
      contextRef="From2020-06-01to2020-06-20_cvm_SeriesXXWarrantsMember"
      decimals="0"
      unitRef="Shares">461963</cvm:WarrantsIssuedDuringPeriod>
    <cvm:WarrantsIssuedDuringPeriod
      contextRef="From2020-06-01to2020-06-20_cvm_SeriesUUWarrantsMember"
      decimals="0"
      unitRef="Shares">101839</cvm:WarrantsIssuedDuringPeriod>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesYMember"
      decimals="0"
      unitRef="USD">103000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2020-01-01to2020-01-23_cvm_SeriesYMember"
      decimals="0"
      unitRef="USD">22000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">13456123</us-gaap:LeaseholdImprovementsGross>
    <cvm:ResearchAndDevelopmentCredit
      contextRef="AsOf2021-09-30_cvm_IncomeTaxMember"
      decimals="0"
      unitRef="USD">1200000.0</cvm:ResearchAndDevelopmentCredit>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2020-09-30_cvm_IncomeTaxMember"
      decimals="0"
      unitRef="USD">188900000.0</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember">P7Y8M5D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <cvm:AggregateIntrinsicValueOutstandingEnding
      contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember"
      decimals="0"
      unitRef="USD">29090662</cvm:AggregateIntrinsicValueOutstandingEnding>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember">P8Y10M17D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <cvm:AggregateIntrinsicValue
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="0"
      unitRef="USD">56193415</cvm:AggregateIntrinsicValue>
    <cvm:NumberOfUnvestedOptionsBeginning
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      unitRef="Shares">5356474</cvm:NumberOfUnvestedOptionsBeginning>
    <cvm:WeightedAverageGrantDateFairValueEnding
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="USDPShares">4.76</cvm:WeightedAverageGrantDateFairValueEnding>
    <cvm:SharesForfeited
      contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="Shares">0</cvm:SharesForfeited>
    <cvm:VestedShares
      contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="Shares">0</cvm:VestedShares>
    <cvm:NumberOfUnvestedSharesEnding
      contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="Shares">304500</cvm:NumberOfUnvestedSharesEnding>
    <cvm:WeightedAverageGrantDateFairValueBeginning
      contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">13.75</cvm:WeightedAverageGrantDateFairValueBeginning>
    <cvm:RemainingCompensationExpense
      contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      unitRef="USD">3800000.0</cvm:RemainingCompensationExpense>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">4825000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:DerivativeVariableInterestRate contextRef="AsOf2021-09-30" decimals="INF" unitRef="Pure">0.001019</us-gaap:DerivativeVariableInterestRate>
    <us-gaap:DerivativeVariableInterestRate contextRef="AsOf2020-09-30" decimals="INF" unitRef="Pure">0.001</us-gaap:DerivativeVariableInterestRate>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-10-01to2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="0"
      unitRef="USD">200000.0</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="0"
      unitRef="USD">1732000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="0"
      unitRef="USD">1717000</us-gaap:OperatingLeaseLiabilityCurrent>
    <cvm:CashPaidRelatedToFinanceLeasesInterest
      contextRef="From2019-10-01to2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="0"
      unitRef="USD">1200000.0</cvm:CashPaidRelatedToFinanceLeasesInterest>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="INF"
      unitRef="Pure">0.000845</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseIncentivePayableCurrent
      contextRef="AsOf2021-09-30_cvm_LandlordMember"
      decimals="0"
      unitRef="USD">1600000.0</us-gaap:LeaseIncentivePayableCurrent>
    <cvm:AdditionalClinicalTrial
      contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember"
      decimals="0"
      unitRef="USD">2000000</cvm:AdditionalClinicalTrial>
    <cvm:NetOfDiscount
      contextRef="From2019-10-01to2020-09-30_cvm_ErgomedMember"
      decimals="0"
      unitRef="USD">600000.0</cvm:NetOfDiscount>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember">P7Y1M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2019-10-01to2020-09-30_cvm_ErgomedMember"
      decimals="0"
      unitRef="USD">1400000.0</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:FinanceLeaseObligationsNetOfCurrentPortion contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">200000</cvm:FinanceLeaseObligationsNetOfCurrentPortion>
    <cvm:FinanceLeaseObligationsNetOfCurrentPortion contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">100000</cvm:FinanceLeaseObligationsNetOfCurrentPortion>
    <cvm:ExpirationDateDescription contextRef="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember">from December 31, 2020 to June 30, 2021</cvm:ExpirationDateDescription>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2021-04-01to2021-06-30_cvm_SeriesXWarrantsMember"
      decimals="0"
      unitRef="USD">265000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesXWarrantsMember"
      decimals="0"
      unitRef="USD">265000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNWarrantsMember"
      decimals="0"
      unitRef="USD">265000</us-gaap:OtherCostAndExpenseOperating>
    <cvm:WarrantsIssued
      contextRef="AsOf2020-12-07_cvm_SeriesUUWarrantsMember"
      decimals="0"
      unitRef="Shares">93603</cvm:WarrantsIssued>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUWarrantsMember"
      decimals="0"
      unitRef="USD">24000</us-gaap:InterestExpenseRelatedParty>
    <cvm:ProceedsFromPublicOffering contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">90959</cvm:ProceedsFromPublicOffering>
    <cvm:IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="Shares">0</cvm:IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants>
    <dei:DocumentType contextRef="From2020-10-01to2021-09-30">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2020-10-01to2021-09-30">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2020-10-01to2021-09-30">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2020-10-01to2021-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2020-10-01to2021-09-30">1-11889</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-10-01to2021-09-30">CEL-SCI CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-10-01to2021-09-30">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-10-01to2021-09-30">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-10-01to2021-09-30">8229 Boone Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-10-01to2021-09-30">Suite 802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-10-01to2021-09-30">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-10-01to2021-09-30">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-10-01to2021-09-30">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-10-01to2021-09-30">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-10-01to2021-09-30">506-9460</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-10-01to2021-09-30">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-10-01to2021-09-30">CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-10-01to2021-09-30">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2020-10-01to2021-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-10-01to2021-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2020-10-01to2021-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-10-01to2021-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-10-01to2021-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-10-01to2021-09-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">595537907</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-12-10" decimals="INF" unitRef="Shares">43244498</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1970"
      unitRef="USD">36060148</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1971"
      unitRef="USD">15508909</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1972"
      unitRef="USD">6151385</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1973"
      unitRef="USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1974"
      unitRef="USD">54922</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1975"
      unitRef="USD">54922</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1976"
      unitRef="USD">998482</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1977"
      unitRef="USD">1313432</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1978"
      unitRef="USD">2006584</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1979"
      unitRef="USD">820052</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1980"
      unitRef="USD">45271521</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1981"
      unitRef="USD">17697315</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1982"
      unitRef="USD">12691921</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1983"
      unitRef="USD">13811849</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1984"
      unitRef="USD">2056178</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1985"
      unitRef="USD">1198958</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1986"
      unitRef="USD">13663562</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1987"
      unitRef="USD">5843993</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1988"
      unitRef="USD">275866</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1989"
      unitRef="USD">313422</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1990"
      unitRef="USD">1910917</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1991"
      unitRef="USD">1670917</us-gaap:DepositsAssetsCurrent>
    <us-gaap:Assets
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1992"
      unitRef="USD">75869965</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1993"
      unitRef="USD">40536454</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1996"
      unitRef="USD">1675813</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1997"
      unitRef="USD">2023067</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1998"
      unitRef="USD">859216</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1999"
      unitRef="USD">510515</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2000"
      unitRef="USD">265993</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2001"
      unitRef="USD">448022</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2002"
      unitRef="USD">437380</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2003"
      unitRef="USD">213787</us-gaap:DerivativeLiabilitiesCurrent>
    <cvm:LeaseLiabilitiesCurrentPortion
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2004"
      unitRef="USD">698665</cvm:LeaseLiabilitiesCurrentPortion>
    <cvm:LeaseLiabilitiesCurrentPortion
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2005"
      unitRef="USD">1070123</cvm:LeaseLiabilitiesCurrentPortion>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2006"
      unitRef="USD">3937067</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2007"
      unitRef="USD">4265514</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2008"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2009"
      unitRef="USD">3551826</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2010"
      unitRef="USD">13252364</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2011"
      unitRef="USD">11753100</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2012"
      unitRef="USD">2021308</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2013"
      unitRef="USD">1114340</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2014"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2015"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2016"
      unitRef="USD">19335739</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2017"
      unitRef="USD">20809780</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      id="fid_2041"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2043"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2046"
      unitRef="Shares">43207183</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2047"
      unitRef="Shares">38730150</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2022"
      unitRef="USD">432072</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2023"
      unitRef="USD">387302</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2024"
      unitRef="USD">474298566</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2025"
      unitRef="USD">401174675</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2026"
      unitRef="USD">-418196412</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2027"
      unitRef="USD">-381835303</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2028"
      unitRef="USD">56534226</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2029"
      unitRef="USD">19726674</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2030"
      unitRef="USD">75869965</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2031"
      unitRef="USD">40536454</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OtherIncome
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2048"
      unitRef="USD">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2049"
      unitRef="USD">558664</us-gaap:OtherIncome>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2051"
      unitRef="USD">23108897</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2052"
      unitRef="USD">17840290</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2053"
      unitRef="USD">13085232</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2054"
      unitRef="USD">11703429</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2055"
      unitRef="USD">36194129</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2056"
      unitRef="USD">29543719</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2057"
      unitRef="USD">-36194129</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2058"
      unitRef="USD">-28985055</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2059"
      unitRef="USD">-8213</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2060"
      unitRef="USD">38763</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2061"
      unitRef="USD">-694858</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2062"
      unitRef="USD">-349078</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2063"
      unitRef="USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2064"
      unitRef="USD">805753</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2065"
      unitRef="USD">1685379</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2066"
      unitRef="USD">887604</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2067"
      unitRef="USD">-1149288</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2068"
      unitRef="USD">-1041725</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2069"
      unitRef="USD">-36361109</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2070"
      unitRef="USD">-30255244</us-gaap:NetIncomeLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2071"
      unitRef="USD">-350861</cvm:ModificationOfWarrants>
    <cvm:ModificationOfWarrants
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2072"
      unitRef="USD">-21734</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2073"
      unitRef="USD">-36711970</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2074"
      unitRef="USD">-30276978</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_2075"
      unitRef="USDPShares">-0.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_2076"
      unitRef="USDPShares">-0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2077"
      unitRef="Shares">40662137</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2078"
      unitRef="Shares">36759115</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_2079"
      unitRef="USDPShares">-0.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_2080"
      unitRef="USDPShares">-0.82</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2081"
      unitRef="Shares">40694248</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2082"
      unitRef="Shares">36759115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2431"
      unitRef="Shares">35231776</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2432"
      unitRef="USD">352318</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2433"
      unitRef="USD">358507603</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2434"
      unitRef="USD">-353726254</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30"
      decimals="0"
      id="fid_2435"
      unitRef="USD">5133667</us-gaap:StockholdersEquity>
    <cvm:AdoptionOfAsc842Leases
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2438"
      unitRef="USD">2146195</cvm:AdoptionOfAsc842Leases>
    <cvm:AdoptionOfAsc842Leases
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2439"
      unitRef="USD">2146195</cvm:AdoptionOfAsc842Leases>
    <cvm:ProceedsFromTheSaleOfCommonStockShares
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2440"
      unitRef="Shares">1422429</cvm:ProceedsFromTheSaleOfCommonStockShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2441"
      unitRef="USD">14225</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2442"
      unitRef="USD">13978214</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2443"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2444"
      unitRef="USD">13992439</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:WarrantIssuances
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2445"
      unitRef="USD">0</cvm:WarrantIssuances>
    <cvm:WarrantIssuances
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2446"
      unitRef="USD">805753</cvm:WarrantIssuances>
    <cvm:WarrantIssuances
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2447"
      unitRef="USD">0</cvm:WarrantIssuances>
    <cvm:WarrantIssuances
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2448"
      unitRef="USD">805753</cvm:WarrantIssuances>
    <cvm:WarrantExercisesShares
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2449"
      unitRef="Shares">1711873</cvm:WarrantExercisesShares>
    <cvm:WarrantExercisesAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2450"
      unitRef="USD">17118</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2451"
      unitRef="USD">15127122</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2452"
      unitRef="USD">0</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2453"
      unitRef="USD">15144240</cvm:WarrantExercisesAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2454"
      unitRef="USD">0</cvm:ModificationOfWarrantsAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2455"
      unitRef="USD">5554</cvm:ModificationOfWarrantsAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2457"
      unitRef="USD">5554</cvm:ModificationOfWarrantsAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2458"
      unitRef="Shares">13870</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2459"
      unitRef="USD">139</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2460"
      unitRef="USD">163201</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2461"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2462"
      unitRef="USD">163340</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2463"
      unitRef="Shares">79950</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2464"
      unitRef="USD">799</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2465"
      unitRef="USD">971868</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2466"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2467"
      unitRef="USD">972667</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2468"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2469"
      unitRef="USD">10112968</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2470"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2471"
      unitRef="USD">10112968</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2472"
      unitRef="Shares">99740</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2473"
      unitRef="USD">998</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2474"
      unitRef="USD">337330</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2475"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2476"
      unitRef="USD">338328</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2477"
      unitRef="Shares">20512</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2478"
      unitRef="USD">205</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2479"
      unitRef="USD">184785</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2480"
      unitRef="USD">0</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2481"
      unitRef="USD">184990</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount>
    <cvm:ShareIssuanceCosts
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2482"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2483"
      unitRef="USD">-787723</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2484"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2485"
      unitRef="USD">-787723</cvm:ShareIssuanceCosts>
    <cvm:SharesIssuedForSettlementOfClinicalResearchCostsShares
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2486"
      unitRef="Shares">150000</cvm:SharesIssuedForSettlementOfClinicalResearchCostsShares>
    <cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2487"
      unitRef="USD">1500</cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount>
    <cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2488"
      unitRef="USD">1768000</cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount>
    <cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2489"
      unitRef="USD">0</cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount>
    <cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2490"
      unitRef="USD">1769500</cvm:SharesIssuedForSettlementOfClinicalResearchCostsAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2491"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2492"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2493"
      unitRef="USD">-30255244</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2494"
      unitRef="USD">-30255244</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2495"
      unitRef="Shares">38730150</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2496"
      unitRef="USD">387302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2497"
      unitRef="USD">401174675</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2498"
      unitRef="USD">-381835303</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2499"
      unitRef="USD">19726674</us-gaap:StockholdersEquity>
    <cvm:ProceedsFromTheSaleOfCommonStockShares
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2500"
      unitRef="Shares">2610000</cvm:ProceedsFromTheSaleOfCommonStockShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2501"
      unitRef="USD">26100</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2502"
      unitRef="USD">47337326</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2503"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2504"
      unitRef="USD">47363426</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:WarrantExercisesShares
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2505"
      unitRef="Shares">1597870</cvm:WarrantExercisesShares>
    <cvm:WarrantExercisesAmount
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2506"
      unitRef="USD">15978</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2507"
      unitRef="USD">9991328</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2508"
      unitRef="USD">0</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2509"
      unitRef="USD">10007306</cvm:WarrantExercisesAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2510"
      unitRef="USD">0</cvm:ModificationOfWarrantsAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2511"
      unitRef="USD">24387</cvm:ModificationOfWarrantsAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2512"
      unitRef="USD">0</cvm:ModificationOfWarrantsAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2513"
      unitRef="USD">24387</cvm:ModificationOfWarrantsAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2514"
      unitRef="Shares">17990</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2515"
      unitRef="USD">180</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2516"
      unitRef="USD">200919</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2517"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2518"
      unitRef="USD">201099</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2519"
      unitRef="Shares">75885</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2520"
      unitRef="USD">759</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2521"
      unitRef="USD">1194945</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2522"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2523"
      unitRef="USD">1195704</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2524"
      unitRef="Shares">-2000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2525"
      unitRef="USD">-20</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2526"
      unitRef="USD">13685066</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2527"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2528"
      unitRef="USD">13685046</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2529"
      unitRef="Shares">149788</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2530"
      unitRef="USD">1498</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2531"
      unitRef="USD">744730</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2532"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2533"
      unitRef="USD">746228</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2534"
      unitRef="Shares">27500</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2535"
      unitRef="USD">275</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2536"
      unitRef="USD">219725</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2537"
      unitRef="USD">0</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount>
    <cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2538"
      unitRef="USD">220000</cvm:StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount>
    <cvm:ShareIssuanceCosts
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2539"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2540"
      unitRef="USD">-274535</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2541"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2542"
      unitRef="USD">-274535</cvm:ShareIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2543"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2544"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2545"
      unitRef="USD">-36361109</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2546"
      unitRef="USD">-36361109</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2547"
      unitRef="Shares">43207183</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2548"
      unitRef="USD">432072</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2549"
      unitRef="USD">474298566</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2550"
      unitRef="USD">-418196412</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2551"
      unitRef="USD">56534226</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2335"
      unitRef="USD">-36361109</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2336"
      unitRef="USD">-30255244</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2338"
      unitRef="USD">2231108</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2339"
      unitRef="USD">2159729</us-gaap:DepreciationAndAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2340"
      unitRef="USD">1226690</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2341"
      unitRef="USD">862796</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2342"
      unitRef="USD">13685046</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2343"
      unitRef="USD">10112968</us-gaap:ShareBasedCompensation>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2344"
      unitRef="USD">201099</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2345"
      unitRef="USD">163340</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:SharesIssuedForSettlementOfClinicalResearchCosts
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2346"
      unitRef="USD">0</cvm:SharesIssuedForSettlementOfClinicalResearchCosts>
    <cvm:SharesIssuedForSettlementOfClinicalResearchCosts
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2347"
      unitRef="USD">1769500</cvm:SharesIssuedForSettlementOfClinicalResearchCosts>
    <cvm:ShortTermInvestment
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2348"
      unitRef="USD">-5621</cvm:ShortTermInvestment>
    <cvm:ShortTermInvestment
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2349"
      unitRef="USD">0</cvm:ShortTermInvestment>
    <cvm:LossOnDerivativesInstruments
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2350"
      unitRef="USD">694858</cvm:LossOnDerivativesInstruments>
    <cvm:LossOnDerivativesInstruments
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2351"
      unitRef="USD">349078</cvm:LossOnDerivativesInstruments>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2352"
      unitRef="USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2353"
      unitRef="USD">805753</us-gaap:FairValueAdjustmentOfWarrants>
    <cvm:ModificationOfWarrant
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2354"
      unitRef="USD">24387</cvm:ModificationOfWarrant>
    <cvm:ModificationOfWarrant
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2355"
      unitRef="USD">5554</cvm:ModificationOfWarrant>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2357"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2358"
      unitRef="USD">7843</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2359"
      unitRef="USD">283964</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2360"
      unitRef="USD">-623608</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <cvm:SuppliesUsedForRDAndManufacturing
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2361"
      unitRef="USD">-1186532</cvm:SuppliesUsedForRDAndManufacturing>
    <cvm:SuppliesUsedForRDAndManufacturing
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2362"
      unitRef="USD">-37689</cvm:SuppliesUsedForRDAndManufacturing>
    <cvm:ShortTermDeposits
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2363"
      unitRef="USD">-240000</cvm:ShortTermDeposits>
    <cvm:ShortTermDeposits
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2364"
      unitRef="USD">0</cvm:ShortTermDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2366"
      unitRef="USD">445981</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2367"
      unitRef="USD">-766073</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2368"
      unitRef="USD">363701</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2369"
      unitRef="USD">406083</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2370"
      unitRef="USD">-182029</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2371"
      unitRef="USD">-261420</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2372"
      unitRef="USD">31441</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2373"
      unitRef="USD">25229</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2374"
      unitRef="USD">-18787016</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2375"
      unitRef="USD">-15276161</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cvm:NetPurchasesOfUSTreasuryBills
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2377"
      unitRef="USD">6145764</cvm:NetPurchasesOfUSTreasuryBills>
    <cvm:NetPurchasesOfUSTreasuryBills
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2378"
      unitRef="USD">0</cvm:NetPurchasesOfUSTreasuryBills>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2379"
      unitRef="USD">9016329</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2380"
      unitRef="USD">2654906</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2381"
      unitRef="USD">22641</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2382"
      unitRef="USD">39975</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2383"
      unitRef="USD">-15184734</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2384"
      unitRef="USD">-2694881</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2386"
      unitRef="USD">47363426</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2387"
      unitRef="USD">13992439</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2388"
      unitRef="USD">325034</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2389"
      unitRef="USD">752804</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2390"
      unitRef="USD">5984215</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2391"
      unitRef="USD">12072465</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2392"
      unitRef="USD">746228</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2393"
      unitRef="USD">338328</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2394"
      unitRef="USD">220000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2395"
      unitRef="USD">184990</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <cvm:ProceedsFromLandlordFundingOfLeaseholdImprovements
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2396"
      unitRef="USD">1613546</cvm:ProceedsFromLandlordFundingOfLeaseholdImprovements>
    <cvm:ProceedsFromLandlordFundingOfLeaseholdImprovements
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2397"
      unitRef="USD">0</cvm:ProceedsFromLandlordFundingOfLeaseholdImprovements>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2398"
      unitRef="USD">1079392</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2399"
      unitRef="USD">800241</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2400"
      unitRef="USD">54522989</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2401"
      unitRef="USD">25035177</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2402"
      unitRef="USD">20551239</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2403"
      unitRef="USD">7064135</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2404"
      unitRef="USD">15508909</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2019-09-30"
      decimals="0"
      id="fid_2405"
      unitRef="USD">8444774</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_2406"
      unitRef="USD">36060148</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_2407"
      unitRef="USD">15508909</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cvm:PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2409"
      unitRef="USD">435412</cvm:PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable>
    <cvm:PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2418"
      unitRef="USD">1184723</cvm:PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable>
    <cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2410"
      unitRef="USD">6510</cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable>
    <cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2419"
      unitRef="USD">15000</cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable>
    <cvm:ChangesToRightOfUseAssetsAndLiabilities
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2411"
      unitRef="USD">551444</cvm:ChangesToRightOfUseAssetsAndLiabilities>
    <cvm:ChangesToRightOfUseAssetsAndLiabilities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2420"
      unitRef="USD">399032</cvm:ChangesToRightOfUseAssetsAndLiabilities>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2412"
      unitRef="USD">855</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2421"
      unitRef="USD">790</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2413"
      unitRef="USD">363911</cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2422"
      unitRef="USD">164871</cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:FairValueOfWarrantsLiabilitiesOnDateOfExercise
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2414"
      unitRef="USD">4023091</cvm:FairValueOfWarrantsLiabilitiesOnDateOfExercise>
    <cvm:FairValueOfWarrantsLiabilitiesOnDateOfExercise
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2423"
      unitRef="USD">3071775</cvm:FairValueOfWarrantsLiabilitiesOnDateOfExercise>
    <cvm:FinancingCostsIncludedInAccountsPayable
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2415"
      unitRef="USD">0</cvm:FinancingCostsIncludedInAccountsPayable>
    <cvm:FinancingCostsIncludedInAccountsPayable
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2424"
      unitRef="USD">50499</cvm:FinancingCostsIncludedInAccountsPayable>
    <cvm:AccruedConsultingServicesToBePaidWithCommonStock
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2416"
      unitRef="USD">55000</cvm:AccruedConsultingServicesToBePaidWithCommonStock>
    <cvm:AccruedConsultingServicesToBePaidWithCommonStock
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2425"
      unitRef="USD">55000</cvm:AccruedConsultingServicesToBePaidWithCommonStock>
    <us-gaap:InterestPaidNet
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_2417"
      unitRef="USD">1173702</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_2426"
      unitRef="USD">1155026</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2284">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1. &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;ORGANIZATION&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has recently&#160;announced top line&#160;Phase 3 data for its lead investigational therapy, Multikine&#xae; (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;CEL-SCI is investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NatureOfOperations contextRef="From2020-10-01to2021-09-30" id="fid_2285">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span id="font76426394-2f38-4e90-98a8-d495869e96f0" style="font-family:symbol"&gt;&lt;strong&gt;2&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;OPERATIONS AND FINANCING&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine&#xae; (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Liquidity&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similarly to the way it has substantially funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Primarily as a result of CEL-SCI's losses incurred to date, CEL-SCI's expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI's ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that because there is more than enough cash on hand to meet the Company's budgeted cash requirements, the substantial doubt about the Company's ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Impact of COVID-19 Pandemic&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In response to the global outbreak of COVID-19 and the World Health Organization&#x2019;s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention&#x2019;s (&#x201c;CDC&#x201d;) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company&#x2019;s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2286">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span id="font6d9af7c4-49e2-4b76-a099-aabe7e6ed090" style="font-family:symbol"&gt;&lt;strong&gt;3&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;U.S. Treasury Bills &#x2013; &lt;/em&gt;U.S. Treasury Bills (&#x201c;T-bills&#x201d;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing&lt;/em&gt; &#x2013; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013;&lt;/em&gt; On October 1, 2019, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-02, &lt;em&gt;Leases &lt;/em&gt;and its related amendments (collectively referred to as Topic 842 and codified as &#x201c;ASC 842&#x201d;). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company&#x2019;s statements of operations or cash flows.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as&#160;leases with initial terms of 12 months or less,&#160;are not reflected on the balance sheet. Lease expense for such short-term leases is not material. &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Derivative Instruments&lt;/em&gt; &#x2013; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, &#x201c;&lt;em&gt;Accounting for Derivative Instruments and Hedging Activities&lt;/em&gt;.&#x201d; In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In August 2020, the FASB issued ASU No. 2020-06 (&#x201c;ASU 2020-06&#x201d;) &lt;em&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity.&lt;/em&gt; The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 &#x201c;&lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt;.&#x201d; The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, &lt;em&gt;Compensation &#x2014; Stock Compensation (Topic 718&lt;/em&gt;), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Grant Income&lt;/em&gt; &#x2013; The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260 &#x201c;Earnings Per Share&#x201d; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2021. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;em&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/em&gt;. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets,&#160;right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the&#160;lease assets and liabilities to be significant.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2283">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <cvm:USTreasuryBills contextRef="From2020-10-01to2021-09-30" id="fid_2311">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;U.S. Treasury Bills &#x2013; &lt;/em&gt;U.S. Treasury Bills (&#x201c;T-bills&#x201d;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.&lt;/p&gt;</cvm:USTreasuryBills>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2299">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2020-10-01to2021-09-30" id="fid_2300">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-10-01to2021-09-30" id="fid_371">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <cvm:LeasesPolicyTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2301">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013;&lt;/em&gt; On October 1, 2019, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-02, &lt;em&gt;Leases &lt;/em&gt;and its related amendments (collectively referred to as Topic 842 and codified as &#x201c;ASC 842&#x201d;). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company&#x2019;s statements of operations or cash flows.&lt;/p&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as&#160;leases with initial terms of 12 months or less,&#160;are not reflected on the balance sheet. Lease expense for such short-term leases is not material. </cvm:LeasesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2302">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Derivative Instruments&lt;/em&gt; &#x2013; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, &#x201c;&lt;em&gt;Accounting for Derivative Instruments and Hedging Activities&lt;/em&gt;.&#x201d; In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In August 2020, the FASB issued ASU No. 2020-06 (&#x201c;ASU 2020-06&#x201d;) &lt;em&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity.&lt;/em&gt; The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption. &lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2303">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 &#x201c;&lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt;.&#x201d; The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, &lt;em&gt;Compensation &#x2014; Stock Compensation (Topic 718&lt;/em&gt;), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-10-01to2021-09-30" id="fid_2304">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cvm:GrantIncomePolicyTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2305">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Grant Income&lt;/em&gt; &#x2013; The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred. &lt;/p&gt;</cvm:GrantIncomePolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2306">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260 &#x201c;Earnings Per Share&#x201d; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2307">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2021. &lt;/p&gt;</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_375"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2308">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;em&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/em&gt;. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-10-01to2021-09-30" id="fid_2309">&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets,&#160;right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the&#160;lease assets and liabilities to be significant.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2310">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cvm:WarrantsAndNonEmployeeOptionstextblock contextRef="From2020-10-01to2021-09-30" id="fid_2287">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;4. &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;WARRANTS AND NON-EMPLOYEE OPTIONS&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following warrants and non-employee options are outstanding at September 30, 2021: &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Warrant/Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2022 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5/23/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;184,800&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;11/23/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/8/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,845&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/8/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/23/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/16/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/26/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;100,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;210,087&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;251,761&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/19/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/18/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;600&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:center;"&gt;7/28/2017 &#x2013; 11/18/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;2.18 - $11.61&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;"&gt;11/17/2022 - 7/27/2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The following warrants and non-employee options are outstanding at September 30, 2020: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Warrant&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/18/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/31/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series W&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/28/2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;688,930&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/28/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series ZZ&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5/23/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;20,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5/18/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series BB&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/26/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/22/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5/23/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;264,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;11/23/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/8/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;148,643&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/8/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/23/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/16/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/26/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;797,633&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;348,842&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;417,649&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/19/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;326,064&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/18/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;371,564&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/17&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.18&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;A. Warrant Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;Warrant liabilities outstanding at September 30 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series W warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73,570&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,207,902&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series ZZ warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;75,044&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;276,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,082,212&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series BB warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,173&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;94,961&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,259,712&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,597&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total warrant liabilities &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,765,613&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The (losses)/gains on the warrant liabilities for the years ended September 30 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series V Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;185,652&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series W warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73,570&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,119,937&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;252,115&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(98,357&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series ZZ warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(98,692&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,594&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(318,823&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(165,304&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series BB warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,173&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,207&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(668,605&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(875,040&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series FF warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(319,706&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;404&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(34,589&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series JJ warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(64,992&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series LL warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(98,066&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Net loss on warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(694,858&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(349,078&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#x2019;s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#x2019;s stock because future equity offerings or sales of the Company&#x2019;s stock are not an input to the fair value of a &#x201c;fixed-for-fixed&#x201d; option on equity shares, and equity classification is therefore precluded.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Changes in Warrant Liabilities&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On August 22, 2021, 16,000 Series BB warrants, with an exercise price of $13.75 expired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75 expired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 26, 2020, the Company lowered the exercise price of 810,127 Series V warrants from $19.75 to $13.75 per share and extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020. The incremental cost of this modification was approximately $664,000, which was included in the net loss on derivatives for the year ended September 30, 2020. On June 25, 2020, 135,963 Series V warrants, with an exercise price of $13.75 expired. The warrants were valued at approximately $211,000 on the date of expiration.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Exercise of Warrant Liabilities&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following warrants recorded as liabilities were exercised during the year ended September 30, 2021:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series Z&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;79,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,089,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series ZZ&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;20,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;275,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series AA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;100,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,375,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;132,798&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;663,990&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;331,998&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,402,990&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The following warrants recorded as liabilities were exercised during the year ended September 30, 2020:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series V&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;674,164&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,269,755&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;128,820&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;644,100&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series FF&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;68,048&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.91&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;265,812&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series HH&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,300&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,687&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series JJ&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,450&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,531&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series LL&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;26,398&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.59&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;94,867&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;913,180&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;10,323,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;B. &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Equity Warrants&lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Changes in Equity Warrants&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2020, the expiration dates of the Series N, Series X, Series Y and Series UU warrants were extended six months. On June 28, 2021, the expiration dates of these same warrants were extended one year. The incremental costs of both warrant extensions were recorded consistent with the accounting for the initial warrant issuances. The incremental costs of the Series N and Series X warrant extensions were recorded as a deemed dividend and totaled approximately $351,000 for the year ended September 30, 2021. The Series N and Series X warrants are held by the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary. The incremental cost of the Series Y warrants&#160;extension approximated $103,000 and had no impact on&#160;the financial statements for the year ended September 30,2021&#160;due to offsetting entries recorded within additional paid in capital. The incremental cost of the Series UU warrant extension was recorded as interest expense, because these warrants were initially issued as an inducement to convert notes payable into common stock, and totaled approximately $24,000 for the year ended September 30, 2021. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 26, 2020, the Company provided that for each Series V liability warrant exercised on or before June 10, 2020, the former holder of the Series V warrant received one Series XX warrant. Each Series XX warrant allowed the holder to purchase one share of the Company's common stock at a price of $18.00 per share at any time on or before September 10, 2020. For each Series V liability warrant exercised after June 10, 2020 but on or before June 25, 2020, the former holder of the Series V warrant received one Series YY warrant. Every two Series YY warrants allowed the holder to purchase one share of the Company's common stock at a price of $20.00 per share at any time on or before September 25, 2020. In June 2020, 461,953 Series XX warrants and 101,839 Series YY warrants were issued to the former holders of the Series V warrants. The Series XX and YY warrants qualified for equity treatment in accordance with ASC 815. The Company recognized a warrant inducement expense equal to the fair value of the Series XX and Series YY warrants issued as of the date the inducement offers were accepted. The fair values of the Series XX and Series YY warrants were calculated to be approximately $629,000 and $177,000, respectively. The total expense of approximately $806,000 is reported as warrant inducement expense in the statement of operations for the year ended September 30, 2020. All Series XX and YY warrants expired in September 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 8, 2020, the expiration dates of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense during the year ended September 30, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;em&gt;Exercise of Equity Warrants &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following equity warrants were exercised during the year ended September 30, 2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;464,201&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;863,414&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,755&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;349,663&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;165,888&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;273,715&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;126,064&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;263,474&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;370,964&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;830,959&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,265,872&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,581,225&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The following equity warrants were exercised during the year ended September 30, 2020.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;95,858&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;178,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;124,956&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;314,889&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series OO&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;50,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;126,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;39,467&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,121&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;156,580&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;327,252&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;188,125&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;421,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;61,207&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;171,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series VV&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;82,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;144,375&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;798,693&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,748,713&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;C. &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Options and Shares Issued to Consultants&lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2021 and 2020 the Company issued 75,885 and 79,950 shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $6.86 to $24.95 per share. The weighted average grant price was $15.46 and $12.01, respectively, for stock issued during the years ended September 30, 2021 and 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the years ended September 30, 2021 and 2020, the Company recorded total expense of approximately $1,227,000 and $863,000, respectively, relating to these consulting agreements. At September 30, 2021 and 2020, costs of approximately $364,000 and $395,000, respectively, are included in prepaid expenses.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2021, the Company issued 5,000 options to a consultant to purchase common stock with an exercise price of $11.61 and an expiration of November 17, 2022. No options were issued to consultants during the year ended September 30, 2020. As of September 30, 2021, 15,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option plan and are fully vested.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:WarrantsAndNonEmployeeOptionstextblock>
    <cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2313">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Warrant/Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2022 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5/23/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;184,800&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;11/23/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/8/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,845&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/8/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/23/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/16/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/26/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;100,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;210,087&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;251,761&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/19/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/18/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;600&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:center;"&gt;7/28/2017 &#x2013; 11/18/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;2.18 - $11.61&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;"&gt;11/17/2022 - 7/27/2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Warrant&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/18/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/31/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series W&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/28/2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;688,930&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/28/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series ZZ&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5/23/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;20,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5/18/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series BB&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/26/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/22/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5/23/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;264,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;11/23/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/8/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;148,643&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/8/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/23/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/16/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/26/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;797,633&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;348,842&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;417,649&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/19/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;326,064&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/18/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;371,564&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/17&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.18&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNMember"
      id="fid_1424">8/18/2008</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesNMember"
      decimals="0"
      id="fid_1481"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesNMember"
      decimals="INF"
      id="fid_1536"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNMember"
      id="fid_1592">8/18/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember"
      id="fid_1471">6/11/2018</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_1529"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_1583"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUMember"
      id="fid_1639">6/30/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesXMember"
      id="fid_1427">1/13/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesXMember"
      decimals="0"
      id="fid_1484"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesXMember"
      decimals="INF"
      id="fid_1539"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesXMember"
      id="fid_1595">7/13/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesYMember"
      id="fid_1428">2/15/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesYMember"
      decimals="0"
      id="fid_1485"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesYMember"
      decimals="INF"
      id="fid_1540"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesYMember"
      id="fid_1596">8/15/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesZMember"
      id="fid_1431">5/23/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesZMember"
      decimals="0"
      id="fid_1488"
      unitRef="Shares">184800</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesZMember"
      decimals="INF"
      id="fid_1543"
      unitRef="USDPShares">13.75</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesZMember"
      id="fid_1599">11/23/2021</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember"
      id="fid_1433">12/8/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_1490"
      unitRef="Shares">15845</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesCCMember"
      decimals="INF"
      id="fid_1545"
      unitRef="USDPShares">5.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember"
      id="fid_1601">12/8/2021</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesHHMember"
      id="fid_1434">2/23/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_1491"
      unitRef="Shares">200</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesHHMember"
      decimals="INF"
      id="fid_1546"
      unitRef="USDPShares">3.13</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesHHMember"
      id="fid_1602">2/16/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember"
      id="fid_1435">8/26/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_1492"
      unitRef="Shares">100000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesAAMember"
      decimals="INF"
      id="fid_1547"
      unitRef="USDPShares">13.75</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember"
      id="fid_1603">2/22/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember"
      id="fid_1438">6/22/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_1495"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_1550"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember"
      id="fid_1606">6/22/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember"
      id="fid_1439">7/24/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_1496"
      unitRef="Shares">210087</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_1551"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember"
      id="fid_1607">7/24/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember"
      id="fid_1472">10/30/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1525"
      unitRef="Shares">251761</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1579"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember"
      id="fid_1635">10/30/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember"
      id="fid_1473">12/19/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_1526"
      unitRef="Shares">200000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_1580"
      unitRef="USDPShares">2.09</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember"
      id="fid_1636">12/18/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember"
      id="fid_1474">2/5/2018</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_SeriesTTMember"
      decimals="0"
      id="fid_1527"
      unitRef="Shares">600</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_SeriesTTMember"
      decimals="INF"
      id="fid_1581"
      unitRef="USDPShares">2.24</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember"
      id="fid_1637">2/5/2023</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember"
      id="fid_1441">7/28/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2021-09-30_cvm_ConsultantsMember"
      decimals="0"
      id="fid_1498"
      unitRef="Shares">15000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2021-09-30_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1553"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember"
      id="fid_1609">7/27/2027</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesNMember"
      id="fid_1444">8/18/2008</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesNMember"
      decimals="0"
      id="fid_1501"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesNMember"
      decimals="INF"
      id="fid_1556"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesNMember"
      id="fid_1612">2/18/2021</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUMember"
      id="fid_1470">6/11/2018</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_1535"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_1589"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember"
      id="fid_1640">12/31/2020</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesWMember"
      id="fid_1446">10/28/2015</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesWMember"
      decimals="0"
      id="fid_1504"
      unitRef="Shares">688930</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesWMember"
      decimals="INF"
      id="fid_1559"
      unitRef="USDPShares">16.75</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesWMember"
      id="fid_1615">10/28/2020</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesXMember"
      id="fid_1447">1/13/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesXMember"
      decimals="0"
      id="fid_1505"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesXMember"
      decimals="INF"
      id="fid_1560"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesXMember"
      id="fid_1616">1/13/2021</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesYMember"
      id="fid_1448">2/15/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesYMember"
      decimals="0"
      id="fid_1506"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesYMember"
      decimals="INF"
      id="fid_1561"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesYMember"
      id="fid_1617">2/15/2021</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesZZMember"
      id="fid_1449">5/23/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesZZMember"
      decimals="0"
      id="fid_1507"
      unitRef="Shares">20000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesZZMember"
      decimals="INF"
      id="fid_1562"
      unitRef="USDPShares">13.75</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesZZMember"
      id="fid_1618">5/18/2021</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesBBMember"
      id="fid_1450">8/26/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesBBMember"
      decimals="0"
      id="fid_1508"
      unitRef="Shares">16000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesBBMember"
      decimals="INF"
      id="fid_1563"
      unitRef="USDPShares">13.75</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesBBMember"
      id="fid_1619">8/22/2021</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember"
      id="fid_1451">5/23/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesZMember"
      decimals="0"
      id="fid_1509"
      unitRef="Shares">264000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesZMember"
      decimals="INF"
      id="fid_1564"
      unitRef="USDPShares">13.75</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember"
      id="fid_1620">11/23/2021</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember"
      id="fid_1453">12/8/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_1511"
      unitRef="Shares">148643</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesCCMember"
      decimals="INF"
      id="fid_1566"
      unitRef="USDPShares">5.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember"
      id="fid_1622">12/8/2021</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember"
      id="fid_1454">2/23/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_1512"
      unitRef="Shares">200</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesHHMember"
      decimals="INF"
      id="fid_1567"
      unitRef="USDPShares">3.13</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember"
      id="fid_1623">2/16/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesAAMember"
      id="fid_1455">8/26/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_1513"
      unitRef="Shares">200000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesAAMember"
      decimals="INF"
      id="fid_1568"
      unitRef="USDPShares">13.75</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesAAMember"
      id="fid_1624">2/22/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember"
      id="fid_1458">6/22/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_1516"
      unitRef="Shares">797633</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_1571"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember"
      id="fid_1627">6/22/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember"
      id="fid_1459">7/24/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_1517"
      unitRef="Shares">348842</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_1572"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember"
      id="fid_1628">7/24/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember"
      id="fid_1466">10/30/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1530"
      unitRef="Shares">417649</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1584"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember"
      id="fid_1641">10/30/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember"
      id="fid_1467">12/19/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_1531"
      unitRef="Shares">326064</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_1585"
      unitRef="USDPShares">2.09</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember"
      id="fid_1642">12/18/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember"
      id="fid_1468">2/5/2018</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_SeriesTTMember"
      decimals="0"
      id="fid_1532"
      unitRef="Shares">371564</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_SeriesTTMember"
      decimals="INF"
      id="fid_1586"
      unitRef="USDPShares">2.24</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember"
      id="fid_1643">2/5/2023</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2019-10-01to2020-09-30_cvm_ConsultantsMember"
      id="fid_1649">7/28/17</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2020-09-30_cvm_ConsultantsMember"
      decimals="0"
      id="fid_1524"
      unitRef="Shares">10000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2020-09-30_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1650"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2019-10-01to2020-09-30_cvm_ConsultantsMember"
      id="fid_1648">7/27/2027</cvm:ExpirationDate1>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2316">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series W warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73,570&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,207,902&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series ZZ warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;75,044&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;276,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,082,212&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series BB warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,173&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;94,961&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,259,712&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,597&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total warrant liabilities &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,765,613&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-09-30_cvm_SeriesWMember"
      decimals="0"
      id="fid_607"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2020-09-30_cvm_SeriesWMember"
      decimals="0"
      id="fid_606"
      unitRef="USD">73570</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-09-30_cvm_SeriesZMember"
      decimals="0"
      id="fid_608"
      unitRef="USD">64787</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2020-09-30_cvm_SeriesZMember"
      decimals="0"
      id="fid_609"
      unitRef="USD">1207902</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-09-30_cvm_SeriesZZMember"
      decimals="0"
      id="fid_611"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2020-09-30_cvm_SeriesZZMember"
      decimals="0"
      id="fid_610"
      unitRef="USD">75044</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_612"
      unitRef="USD">276035</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2020-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_613"
      unitRef="USD">1082212</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-09-30_cvm_SeriesBBMember"
      decimals="0"
      id="fid_615"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2020-09-30_cvm_SeriesBBMember"
      decimals="0"
      id="fid_614"
      unitRef="USD">65173</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_616"
      unitRef="USD">94961</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2020-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_617"
      unitRef="USD">1259712</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_620"
      unitRef="USD">1597</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2020-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_621"
      unitRef="USD">2000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_628"
      unitRef="USD">437380</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_627"
      unitRef="USD">3765613</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <cvm:ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2317">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series V Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;185,652&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series W warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73,570&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,119,937&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;252,115&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(98,357&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series ZZ warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(98,692&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,594&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(318,823&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(165,304&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series BB warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,173&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,207&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(668,605&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(875,040&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series FF warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(319,706&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;404&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(34,589&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series JJ warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(64,992&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series LL warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(98,066&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Net loss on warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(694,858&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(349,078&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesVMember"
      decimals="0"
      id="fid_632"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesVMember"
      decimals="0"
      id="fid_633"
      unitRef="USD">185652</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesWMember"
      decimals="0"
      id="fid_635"
      unitRef="USD">73570</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesWMember"
      decimals="0"
      id="fid_634"
      unitRef="USD">1119937</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesZMember"
      decimals="0"
      id="fid_636"
      unitRef="USD">-252115</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember"
      decimals="0"
      id="fid_637"
      unitRef="USD">-98357</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesZZMember"
      decimals="0"
      id="fid_639"
      unitRef="USD">-98692</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesZZMember"
      decimals="0"
      id="fid_638"
      unitRef="USD">2594</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_640"
      unitRef="USD">-318823</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_641"
      unitRef="USD">-165304</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesBBMember"
      decimals="0"
      id="fid_643"
      unitRef="USD">65173</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesBBMember"
      decimals="0"
      id="fid_642"
      unitRef="USD">-1207</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_644"
      unitRef="USD">-668605</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_645"
      unitRef="USD">-875040</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesFFMember"
      decimals="0"
      id="fid_650"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesFFMember"
      decimals="0"
      id="fid_651"
      unitRef="USD">-319706</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_654"
      unitRef="USD">404</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_655"
      unitRef="USD">-34589</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesJJMember"
      decimals="0"
      id="fid_658"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesJJMember"
      decimals="0"
      id="fid_659"
      unitRef="USD">-64992</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesLLMember"
      decimals="0"
      id="fid_662"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesLLMember"
      decimals="0"
      id="fid_663"
      unitRef="USD">-98066</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_665"
      unitRef="USD">-694858</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_664"
      unitRef="USD">-349078</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:WarrantsExpired
      contextRef="From2021-08-01to2021-08-22_cvm_SeriesBBMember"
      decimals="0"
      id="fid_1694"
      unitRef="Shares">16000</cvm:WarrantsExpired>
    <cvm:WarrantExercise
      contextRef="From2021-08-01to2021-08-22_cvm_SeriesBBMember"
      decimals="INF"
      id="fid_1695"
      unitRef="USDPShares">13.75</cvm:WarrantExercise>
    <cvm:WarrantsExpired
      contextRef="From2020-10-01to2020-10-28_cvm_SeriesWMember"
      decimals="0"
      id="fid_1702"
      unitRef="Shares">688930</cvm:WarrantsExpired>
    <cvm:WarrantExercise
      contextRef="From2020-10-01to2020-10-28_cvm_SeriesWMember"
      decimals="INF"
      id="fid_1703"
      unitRef="USDPShares">16.75</cvm:WarrantExercise>
    <cvm:WarrantsExercisedShares
      contextRef="From2020-05-01to2020-05-26_cvm_SeriesVWarrantsMember"
      decimals="0"
      id="fid_1705"
      unitRef="Shares">810127</cvm:WarrantsExercisedShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-05-26_srt_MaximumMember_cvm_SeriesVWarrantsMember"
      decimals="INF"
      id="fid_707"
      unitRef="USDPShares">19.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-05-26_cvm_SeriesVWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="fid_708"
      unitRef="USDPShares">13.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvm:ExpirationDateDescription
      contextRef="From2020-05-01to2020-05-26_cvm_SeriesVWarrantsMember"
      id="fid_709">extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020</cvm:ExpirationDateDescription>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_710"
      unitRef="USD">664000</us-gaap:DefinedBenefitPlanInterestCost>
    <cvm:WarrantsExpired
      contextRef="From2020-06-01to2020-06-25_cvm_SeriesVWarrantsMember"
      decimals="0"
      id="fid_1704"
      unitRef="Shares">135963</cvm:WarrantsExpired>
    <cvm:WarrantExercise
      contextRef="From2020-06-01to2020-06-25_cvm_SeriesVWarrantsMember"
      decimals="INF"
      id="fid_1022"
      unitRef="USDPShares">13.75</cvm:WarrantExercise>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-06-01to2020-06-25_cvm_SeriesVWarrantsMember"
      decimals="0"
      id="fid_713"
      unitRef="USD">211000</us-gaap:FairValueAdjustmentOfWarrants>
    <cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2315">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series Z&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;79,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,089,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series ZZ&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;20,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;275,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series AA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;100,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,375,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;132,798&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;663,990&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;331,998&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,402,990&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series V&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;674,164&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,269,755&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;128,820&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;644,100&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series FF&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;68,048&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.91&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;265,812&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series HH&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,300&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,687&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series JJ&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,450&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,531&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series LL&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;26,398&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.59&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;94,867&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;913,180&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;10,323,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock>
    <cvm:ExercisePriceWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember"
      decimals="INF"
      id="fid_1668"
      unitRef="USDPShares">13.75</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesZMember"
      decimals="0"
      id="fid_1670"
      unitRef="USD">1089000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesZZMember"
      decimals="0"
      id="fid_1680"
      unitRef="Shares">20000</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesZZMember"
      decimals="INF"
      id="fid_1682"
      unitRef="USDPShares">13.75</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesZZMember"
      decimals="0"
      id="fid_1681"
      unitRef="USD">275000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_1684"
      unitRef="Shares">100000</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember"
      decimals="INF"
      id="fid_1685"
      unitRef="USDPShares">13.75</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_1683"
      unitRef="USD">1375000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_672"
      unitRef="Shares">132798</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember"
      decimals="INF"
      id="fid_671"
      unitRef="USDPShares">5.00</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_670"
      unitRef="USD">663990</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_706"
      unitRef="Shares">331998</cvm:WarrantsExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_705"
      unitRef="USD">3402990</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesVMember"
      decimals="0"
      id="fid_666"
      unitRef="Shares">674164</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesVMember"
      decimals="INF"
      id="fid_667"
      unitRef="USDPShares">13.75</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesVMember"
      decimals="0"
      id="fid_668"
      unitRef="USD">9269755</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_673"
      unitRef="Shares">128820</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember"
      decimals="INF"
      id="fid_674"
      unitRef="USDPShares">5.00</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_669"
      unitRef="USD">644100</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesFFMember"
      decimals="0"
      id="fid_1678"
      unitRef="Shares">68048</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesFFMember"
      decimals="INF"
      id="fid_1677"
      unitRef="USDPShares">3.91</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesFFMember"
      decimals="0"
      id="fid_1679"
      unitRef="USD">265812</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_680"
      unitRef="Shares">6300</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember"
      decimals="INF"
      id="fid_679"
      unitRef="USDPShares">3.13</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_703"
      unitRef="USD">19687</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesJJMember"
      decimals="0"
      id="fid_687"
      unitRef="Shares">9450</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesJJMember"
      decimals="INF"
      id="fid_688"
      unitRef="USDPShares">3.13</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesJJMember"
      decimals="0"
      id="fid_689"
      unitRef="USD">29531</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesLLMember"
      decimals="0"
      id="fid_692"
      unitRef="Shares">26398</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesLLMember"
      decimals="INF"
      id="fid_691"
      unitRef="USDPShares">3.59</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesLLMember"
      decimals="0"
      id="fid_690"
      unitRef="USD">94867</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:WarrantsExercised
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_704"
      unitRef="Shares">913180</cvm:WarrantsExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_678"
      unitRef="USD">10323752</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNAndXMember"
      decimals="0"
      id="fid_1713"
      unitRef="USD">351000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_727"
      unitRef="USD">24000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-09-30_cvm_SeriesXXWarrantsMember"
      decimals="INF"
      id="fid_721"
      unitRef="USDPShares">18.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-09-30_cvm_SeriesYYWarrantsMember"
      decimals="INF"
      id="fid_1714"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvm:WarrantsIssuedDuringPeriod
      contextRef="From2020-06-01to2020-06-20_cvm_SeriesYYWarrantsMember"
      decimals="0"
      id="fid_1739"
      unitRef="Shares">101839</cvm:WarrantsIssuedDuringPeriod>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-06-01to2020-06-20_cvm_SeriesXXWarrantsMember"
      decimals="0"
      id="fid_1720"
      unitRef="USD">629000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-06-01to2020-06-20_cvm_SeriesYYWarrantsMember"
      decimals="0"
      id="fid_1721"
      unitRef="USD">177000</us-gaap:FairValueAdjustmentOfWarrants>
    <cvm:WarrantInducementExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1722"
      unitRef="USD">806000</cvm:WarrantInducementExpense>
    <cvm:WarrantsIssuedDuringPeriod
      contextRef="From2020-05-01to2020-05-08_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_1741"
      unitRef="Shares">93593</cvm:WarrantsIssuedDuringPeriod>
    <cvm:ExpirationDateDescription
      contextRef="From2020-05-01to2020-05-08_cvm_SeriesUUWarrantsMember"
      id="fid_726">extended from June 11, 2020 to December 31, 2020</cvm:ExpirationDateDescription>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_1723"
      unitRef="USD">6000</us-gaap:DefinedBenefitPlanInterestCost>
    <cvm:ExpirationDateDescription
      contextRef="From2020-01-01to2020-01-23_cvm_SeriesNWarrantsMember"
      id="fid_728">the expiration date of the Series N warrants was extended to February 18, 2021</cvm:ExpirationDateDescription>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2020-01-01to2020-01-23_cvm_SeriesNWarrantsMember"
      decimals="0"
      id="fid_729"
      unitRef="USD">22000</us-gaap:DefinedBenefitPlanInterestCost>
    <cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2314">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;464,201&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;863,414&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,755&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;349,663&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;165,888&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;273,715&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;126,064&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;263,474&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;370,964&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;830,959&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,265,872&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,581,225&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;95,858&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;178,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;124,956&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;314,889&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series OO&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;50,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;126,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;39,467&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,121&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;156,580&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;327,252&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;188,125&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;421,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;61,207&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;171,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series VV&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;82,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;144,375&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;798,693&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,748,713&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_1687"
      unitRef="USD">464201</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_1688"
      unitRef="USDPShares">1.86</cvm:EquityWarrantsExercisePrice>
    <cvm:EquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_1686"
      unitRef="Shares">863414</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_748"
      unitRef="Shares">138755</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_749"
      unitRef="USDPShares">2.52</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_750"
      unitRef="USD">349663</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_760"
      unitRef="Shares">165888</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_761"
      unitRef="USDPShares">1.65</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_762"
      unitRef="USD">273715</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_765"
      unitRef="Shares">126064</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_764"
      unitRef="USDPShares">2.09</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_763"
      unitRef="USD">263474</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember"
      decimals="0"
      id="fid_772"
      unitRef="Shares">370964</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember"
      decimals="INF"
      id="fid_773"
      unitRef="USDPShares">2.24</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesTTMember"
      decimals="0"
      id="fid_774"
      unitRef="USD">830959</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_793"
      unitRef="Shares">1265872</cvm:EquityWarrantsExercised>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_794"
      unitRef="USD">2581225</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_742"
      unitRef="Shares">95858</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_743"
      unitRef="USDPShares">1.86</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_744"
      unitRef="USD">178296</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_747"
      unitRef="Shares">124956</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_746"
      unitRef="USDPShares">2.52</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_745"
      unitRef="USD">314889</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesOOMember"
      decimals="0"
      id="fid_754"
      unitRef="Shares">50000</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesOOMember"
      decimals="INF"
      id="fid_755"
      unitRef="USDPShares">2.52</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesOOMember"
      decimals="0"
      id="fid_756"
      unitRef="USD">126000</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_759"
      unitRef="Shares">39467</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_758"
      unitRef="USDPShares">1.65</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_757"
      unitRef="USD">65121</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_766"
      unitRef="Shares">156580</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_767"
      unitRef="USDPShares">2.09</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_768"
      unitRef="USD">327252</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember"
      decimals="0"
      id="fid_771"
      unitRef="Shares">188125</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember"
      decimals="INF"
      id="fid_770"
      unitRef="USDPShares">2.24</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesTTMember"
      decimals="0"
      id="fid_769"
      unitRef="USD">421400</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_778"
      unitRef="Shares">61207</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_779"
      unitRef="USDPShares">2.80</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_780"
      unitRef="USD">171380</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesVVMember"
      decimals="0"
      id="fid_783"
      unitRef="Shares">82500</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesVVMember"
      decimals="INF"
      id="fid_782"
      unitRef="USDPShares">1.75</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesVVMember"
      decimals="0"
      id="fid_781"
      unitRef="USD">144375</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_791"
      unitRef="Shares">798693</cvm:EquityWarrantsExercised>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_792"
      unitRef="USD">1748713</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:CommonStockIssuedForServiceShares
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_730"
      unitRef="Shares">75885</cvm:CommonStockIssuedForServiceShares>
    <cvm:CommonStockIssuedForServiceShares
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1724"
      unitRef="Shares">79950</cvm:CommonStockIssuedForServiceShares>
    <us-gaap:SharePrice
      contextRef="AsOf2021-09-30_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1730"
      unitRef="USDPShares">6.86</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2020-09-30_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1731"
      unitRef="USDPShares">24.95</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_srt_MaximumMember"
      decimals="INF"
      id="fid_733"
      unitRef="USDPShares">15.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_srt_MaximumMember"
      decimals="INF"
      id="fid_1729"
      unitRef="USDPShares">12.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:CostsAndExpenses
      contextRef="From2020-10-01to2021-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_735"
      unitRef="USD">1227000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2019-10-01to2020-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1725"
      unitRef="USD">863000</us-gaap:CostsAndExpenses>
    <cvm:PrepaidExpenses
      contextRef="AsOf2021-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1727"
      unitRef="USD">364000</cvm:PrepaidExpenses>
    <cvm:PrepaidExpenses
      contextRef="AsOf2020-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_736"
      unitRef="USD">395000</cvm:PrepaidExpenses>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1
      contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember"
      decimals="0"
      id="fid_739"
      unitRef="Shares">5000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1>
    <cvm:OptionExpirationDate
      contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember"
      id="fid_1728">2022-11-17</cvm:OptionExpirationDate>
    <cvm:OptionIssuedToRelatedParty
      contextRef="From2020-10-01to2021-09-30_cvm_ConsultantsMember"
      decimals="0"
      id="fid_740"
      unitRef="Shares">15000</cvm:OptionIssuedToRelatedParty>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2288">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160; &#160;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;5. &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;PROPERTY AND&lt;/strong&gt;&lt;strong&gt; EQUIPMENT&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Property and equipment consisted of the following at September 30:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,211,124&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,898,242&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,768&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,768&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,465,123&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,519,161&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,776,015&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,517,171&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,112,453&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,673,178&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,663,562&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;5,843,993&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Depreciation expense for the years ended September 30, 2021 and 2020 totaled approximately $447,000 and $389,000 respectively.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2318">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,211,124&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,898,242&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,768&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,768&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,465,123&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,519,161&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,776,015&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,517,171&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,112,453&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,673,178&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,663,562&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;5,843,993&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock>
    <us-gaap:FixturesAndEquipmentGross
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_797"
      unitRef="USD">4211124</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FixturesAndEquipmentGross
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_798"
      unitRef="USD">3898242</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_800"
      unitRef="USD">99768</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_799"
      unitRef="USD">99768</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_802"
      unitRef="USD">5519161</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_804"
      unitRef="USD">17776015</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_803"
      unitRef="USD">9517171</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_805"
      unitRef="USD">4112453</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_806"
      unitRef="USD">3673178</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_808"
      unitRef="USD">13663562</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_807"
      unitRef="USD">5843993</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1732"
      unitRef="USD">447000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1422"
      unitRef="USD">389000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2289">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span id="font66386e05-b0ba-43df-a9f7-ebad16078e27" style="font-family:symbol"&gt;&lt;strong&gt;6&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;PATENTS&lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Patents consist of the following at September 30:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;910,523&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;896,372&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(634,657&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(582,950&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents, net&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;275,866&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;313,422&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the years ended September 30, 2021 and 2020, there was no impairment of patent costs. Amortization expense for the years ended September 30, 2021 and 2020 totaled approximately $52,000 and $53,000, respectively. The total estimated future amortization is as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Years ending September 30, &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;49,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;39,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;31,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;103,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;276,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2319">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;910,523&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;896,372&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(634,657&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(582,950&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents, net&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;275,866&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;313,422&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2021-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="fid_822"
      unitRef="USD">910523</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2020-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="fid_823"
      unitRef="USD">896372</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="fid_818"
      unitRef="USD">-634657</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="fid_819"
      unitRef="USD">-582950</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="fid_821"
      unitRef="USD">275866</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="fid_820"
      unitRef="USD">313422</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_832"
      unitRef="USD">52000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_831"
      unitRef="USD">53000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2320">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Years ending September 30, &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;49,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;39,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;31,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;103,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;276,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_824"
      unitRef="USD">49000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_825"
      unitRef="USD">39000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_826"
      unitRef="USD">31000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_827"
      unitRef="USD">29000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_828"
      unitRef="USD">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_829"
      unitRef="USD">103000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <cvm:Total
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_830"
      unitRef="USD">276000</cvm:Total>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2290">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span id="font0df12115-a745-4aa7-8f47-83deaf9f47d1" style="font-family:symbol"&gt;&lt;strong&gt;7&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;INCOME TAXES&lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;At September 30, 2021 and 2020, the Company had net deferred tax assets of $44.1 million and $35.5 million, respectively. Due to uncertainties surrounding the Company&#x2019;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax asset will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income. Management has considered the history of the Company&#x2019;s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company&#x2019;s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes for the year ended September 30, 2021 occurred and no such shifts were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company had federal NOL carryforwards of approximately $77.1 million and $51.5 million at September 30, 2021 and 2020, respectively. Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards, which were generated post Tax Cuts and Jobs Act, have an indefinite life. In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#x201c;R&amp;amp;D credit&#x201d;) of approximately $1.2 million at September 30, 2021 and 2020. The R&amp;amp;D credit expires during the fiscal year ended 2029.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Significant components of the Company&#x2019;s deferred tax assets as of September 30, 2021 and 2020 are listed below:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,789,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,407,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,101,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,631,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock-based compensation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,785,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,297,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,040,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,853,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vacation and other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;126,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;125,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;48,062,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;39,534,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,786,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,911,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(172,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(169,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,958,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,080,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;44,104,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,454,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(44,104,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(35,454,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending Balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;The Company has no federal or state current or deferred tax expense or benefit. The Company&#x2019;s effective tax rate differs from the applicable federal statutory tax rate. The reconciliation of these rates is as follows at for the years ended September 30:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Federal Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;State rate change &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.37&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.40&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;State tax rate, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.72&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.15&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.79&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3.24&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.23&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.42&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(23.79&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21.93&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company applies the provisions of ASC 740, &lt;em&gt;&#x201c;Accounting for Uncertainty in Income Taxes,&#x201d;&lt;/em&gt; which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained. The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense. The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2021. The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2018.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <cvm:CumulativeChangeInOwnershipPercentage
      contextRef="From2020-10-01to2021-09-30_cvm_IncomeTaxMember"
      id="fid_1733">(NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.</cvm:CumulativeChangeInOwnershipPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2021-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_878"
      unitRef="USD">77100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2020-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_877"
      unitRef="USD">51500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardDescription
      contextRef="From2020-10-01to2021-09-30_cvm_IncomeTaxMember"
      id="fid_880">Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards</us-gaap:TaxCreditCarryforwardDescription>
    <cvm:ResearchAndDevelopmentCredit
      contextRef="AsOf2020-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_881"
      unitRef="USD">1200000</cvm:ResearchAndDevelopmentCredit>
    <cvm:ResearchAndDevelopmentCreditDescription
      contextRef="From2020-10-01to2021-09-30_cvm_IncomeTaxMember"
      id="fid_883">The R&amp;D credit expires during the fiscal year ended 2029.</cvm:ResearchAndDevelopmentCreditDescription>
    <cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock contextRef="From2020-10-01to2021-09-30" id="fid_2321">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,789,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,407,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,101,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,631,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock-based compensation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,785,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,297,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,040,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,853,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vacation and other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;126,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;125,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;48,062,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;39,534,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,786,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,911,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(172,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(169,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,958,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,080,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;44,104,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,454,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(44,104,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(35,454,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending Balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_834"
      unitRef="USD">19789000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_833"
      unitRef="USD">13407000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <cvm:LeaseLiabilities
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_856"
      unitRef="USD">4101000</cvm:LeaseLiabilities>
    <cvm:LeaseLiabilities
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_857"
      unitRef="USD">3631000</cvm:LeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_835"
      unitRef="USD">1221000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_836"
      unitRef="USD">1221000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_838"
      unitRef="USD">7785000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_837"
      unitRef="USD">5297000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_839"
      unitRef="USD">15040000</cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_840"
      unitRef="USD">15853000</cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_842"
      unitRef="USD">126000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_841"
      unitRef="USD">125000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_843"
      unitRef="USD">48062000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_844"
      unitRef="USD">39534000</us-gaap:DeferredTaxAssetsGross>
    <cvm:RightOfUseAssets
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_858"
      unitRef="USD">-3786000</cvm:RightOfUseAssets>
    <cvm:RightOfUseAssets
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_855"
      unitRef="USD">-3911000</cvm:RightOfUseAssets>
    <cvm:FixedAssetsAndIntangibles
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_846"
      unitRef="USD">-172000</cvm:FixedAssetsAndIntangibles>
    <cvm:FixedAssetsAndIntangibles
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_845"
      unitRef="USD">-169000</cvm:FixedAssetsAndIntangibles>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_847"
      unitRef="USD">3958000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_848"
      unitRef="USD">4080000</us-gaap:DeferredTaxLiabilities>
    <cvm:NetDeferredTaxAsset
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_850"
      unitRef="USD">44104000</cvm:NetDeferredTaxAsset>
    <cvm:NetDeferredTaxAsset
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_849"
      unitRef="USD">-35454000</cvm:NetDeferredTaxAsset>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_851"
      unitRef="USD">44104000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_852"
      unitRef="USD">35454000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_854"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_853"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <cvm:ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock contextRef="From2020-10-01to2021-09-30" id="fid_2322">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Federal Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;State rate change &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.37&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.40&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;State tax rate, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.72&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.15&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.79&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3.24&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.23&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.42&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(23.79&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21.93&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 12.6pt"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_859"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_860"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_861"
      unitRef="Pure">-0.0137</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_862"
      unitRef="Pure">-0.0140</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_864"
      unitRef="Pure">0.0472</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_863"
      unitRef="Pure">0.0515</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_865"
      unitRef="Pure">-0.0079</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_866"
      unitRef="Pure">-0.0324</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_868"
      unitRef="Pure">0.0023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_867"
      unitRef="Pure">0.0042</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_869"
      unitRef="Pure">-0.2379</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_870"
      unitRef="Pure">-0.2193</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_872"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_871"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2291">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span id="fontc40a34ae-8897-44de-9460-8912f1bf5730" style="font-family:symbol"&gt;&lt;strong&gt;8&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;STOCK COMPENSATION&lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Year Ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 19.1pt; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,685,046&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,112,968&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,226,690&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;862,796&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;During the years ended September 30, 2021 and 2020 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;90.42 &#x2013; 97.22%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;87.36 &#x2013; 90.26%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.85 &#x2013; 1.65%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.62 &#x2013; 1.87%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.68 &#x2013; 9.69 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.68 &#x2013; 9.69 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;span style="text-decoration:underline"&gt;Non-Qualified Stock Option Plan&lt;/span&gt;&lt;span style="text-decoration:underline"&gt;s&lt;/span&gt; &#x2013;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2021, the Company adopted the 2021 Non-Qualified Stock Option Plan, which provides for the issuance of up to 1,800,000 options to purchase shares of common stock. On May 14, 2021, the Company granted 1,800,000 performance-based stock options from the 2021 Non-Qualified Stock Option Plan and 72,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share, the fair value on the date of issuance. The stock options will vest 100% upon the achievement of the following performance goals: (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $42.00. None of the options will be exercisable before May 13, 2022. All options which have not vested as of May 13, 2031, will be canceled and will no longer be exercisable. The options were recorded in permanent equity in accordance with ASC 718, Compensation &#x2013; Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. That valuation resulted in a per share fair value of $0.34 and an aggregate value of approximately $636,000 on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was determined to be 1.3 years. This resulted in compensation expense of approximately $189,000 recorded during the year ended September 30, 2021. The remaining $447,000 will be expensed over the next 11 months.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2020, the Company adopted the 2020 Non-Qualified Stock Option Plan, which provides for the issuance of up to 3,600,000 options to purchase shares of common stock. On April 20, 2020, the Company granted 1,872,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share, the fair value on the date of issuance. The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days. Additionally, 100% of the options will vest when either (a) the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia is filed, i.e., the performance condition, or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. All options which have not vested as of April 19, 2030, will be canceled and will no longer be exercisable. The options were recorded as permanent equity in accordance with ASC 718, Compensation &#x2013; Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. That valuation resulted in a per share fair value of $4.21 and an aggregate value of approximately $7.9 million on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was originally determined to be 1.7 years. In May 2021, it became probable that the performance condition would be met approximately 8 months later than originally estimated. Because the valuation and related requisite service period were based on achievement of the performance condition, the Company adjusted the requisite service period when it became probable that the marketing application would be filed within a different period. Compensation expense relating to this Plan was approximately $3.8 million and $2.1 million during the years ended September 30, 2021 and 2020, respectively. The remaining $2.0 million will be expensed over the next 11 months.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;At September 30, 2021, the Company has collectively authorized the issuance of 11,787,200 shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#x2019;s Compensation Committee which administers the plans. The Company&#x2019;s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Incentive Stock Option Plan&lt;/span&gt;&lt;span style="text-decoration:underline"&gt;s&lt;/span&gt; &#x2013; At September 30, 2021, the Company had collectively authorized the issuance of 138,400 shares of common stock under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#x2019;s Compensation Committee which administers the Plans. Only the Company&#x2019;s employees are eligible to be granted options under the Incentive Stock Option Plans.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Activity in the Company&#x2019;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2021 is summarized as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Non-Qualified and Incentive Stock Option Plans&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6,218,216&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.54&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;29,562,594&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,392,241&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.15&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.68&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7,869,555&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,014,501&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.06&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,563,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.93&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;99,740&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;3.39&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;99,740&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;3.39&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;18,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.34&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9,773&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;132.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9,773&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;132.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8,653,703&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.39&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;56,193,415&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;3,297,229&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.85&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.48&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;29,090,662&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,401,961&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.26&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted (a)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,605,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;20.58&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;149,788&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.98&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;149,788&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.98&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;49,832&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.56&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9,374&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;172.73&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9,374&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;172.73&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;11,049,709&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.08&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.93&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;54,843,283&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5,540,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.77&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.96&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;43,589,598&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;______________&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Includes 1,872,000 performance based options issued to officers and directors, 728,000 options issued to employees and 5,000 options issued to Consultants.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;A summary of the status of the Company&#x2019;s non-vested options for the two years ended September 30, 2021 is presented below:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Grant Date Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,825,975&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.79&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,014,501&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,563,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(18,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,356,474&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.76&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,401,961&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,605,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(49,832&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;5,509,681&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.17&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Incentive Stock Bonus Plan&lt;/span&gt; &#x2013; On September 30, 2021, 614,500 of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which 463,250 shares are fully vested. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company&#x2019;s Multikine technology, or specified increases in the market price of the Company&#x2019;s stock. The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of shares issued that remain outstanding as of September 30, 2021 was approximately $8.6 million. The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service period is not rendered. During each of the years ended September 30, 2021 and 2020, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $0.3 million. At September 30, 2021, the Company has unrecognized compensation expense of approximately $45,000 which is expected to be fully recognized in the next quarter.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A summary of the status of the Company&#x2019;s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2021 is presented below:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Number of Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Weighted Average Grant Date Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;304,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;304,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Stock Bonus Plans&lt;/span&gt;&lt;span style="text-decoration:underline"&gt; &lt;/span&gt;&#x2013; As of September 30, 2021, the Company has issued a total of 363,086 shares of common stock from the Stock Bonus Plans and was authorized to issue up to 783,760 shares of common stock under its Stock Bonus Plans. All employees, directors, officers, consultants, and advisors are eligible to be granted shares.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Stock Compensation Plan&lt;/span&gt;&lt;span style="text-decoration:underline"&gt;s&lt;/span&gt; &#x2013; On September 30, 2021, 634,000 shares were authorized for use in the Company&#x2019;s Stock Compensation Plans, of which 154,195 shares were issued and outstanding. No shares were issued from the Stock Compensation Plans to consultants for payment of services during the years ended September 30, 2021, and 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock contextRef="From2020-10-01to2021-09-30" id="fid_2323">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Year Ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 19.1pt; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,685,046&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,112,968&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,226,690&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;862,796&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_885"
      unitRef="USD">13685046</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_884"
      unitRef="USD">10112968</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_887"
      unitRef="USD">1226690</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_886"
      unitRef="USD">862796</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <cvm:ScheduleOfFairValueOfEachOptionGrantedTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2324">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;90.42 &#x2013; 97.22%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;87.36 &#x2013; 90.26%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.85 &#x2013; 1.65%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.62 &#x2013; 1.87%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.68 &#x2013; 9.69 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.68 &#x2013; 9.69 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfFairValueOfEachOptionGrantedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_889"
      unitRef="Pure">0.9042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_891"
      unitRef="Pure">0.9722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_888"
      unitRef="Pure">0.8736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_890"
      unitRef="Pure">0.9026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_893"
      unitRef="Pure">0.0085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_895"
      unitRef="Pure">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_892"
      unitRef="Pure">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_894"
      unitRef="Pure">0.0187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <cvm:ExpectedLifeOfOptionsMin1 contextRef="From2020-10-01to2021-09-30" id="fid_897">P9Y8M4D</cvm:ExpectedLifeOfOptionsMin1>
    <cvm:ExpectedLifeOfOptionsMax contextRef="From2019-10-01to2020-09-30" id="fid_898">P9Y8M8D</cvm:ExpectedLifeOfOptionsMax>
    <cvm:ExpectedLifeOfOptionsMin1 contextRef="From2019-10-01to2020-09-30" id="fid_896">P9Y8M4D</cvm:ExpectedLifeOfOptionsMin1>
    <cvm:ExpectedLifeOfOptionsMax contextRef="From2020-10-01to2021-09-30" id="fid_899">P9Y8M8D</cvm:ExpectedLifeOfOptionsMax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1944"
      unitRef="Shares">1800000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <cvm:PerformanceBasedStockOptionsSharesGranted
      contextRef="AsOf2021-05-14_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1945"
      unitRef="Shares">1800000</cvm:PerformanceBasedStockOptionsSharesGranted>
    <cvm:PerformanceBasedStockOptionsSharesGranted
      contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1953"
      unitRef="Shares">72000</cvm:PerformanceBasedStockOptionsSharesGranted>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_1946"
      unitRef="USDPShares">20.61</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <cvm:FairValuePerShare
      contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_1948"
      unitRef="USDPShares">0.34</cvm:FairValuePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      id="fid_1951">P1Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <cvm:RemainingCompensationExpense
      contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1943"
      unitRef="USD">189000</cvm:RemainingCompensationExpense>
    <cvm:GrantDateFairValueRemaining
      contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1954"
      unitRef="USD">447000</cvm:GrantDateFairValueRemaining>
    <cvm:ExpenseLifeOverNext
      contextRef="From2020-10-01to2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      id="fid_1952">P11Y</cvm:ExpenseLifeOverNext>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1955"
      unitRef="Shares">3600000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <cvm:PerformanceBasedStockOptionsSharesGranted
      contextRef="AsOf2020-04-20_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1957"
      unitRef="Shares">1872000</cvm:PerformanceBasedStockOptionsSharesGranted>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_1958"
      unitRef="USDPShares">10.93</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:ConversionOfStockDescription
      contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      id="fid_1959">The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days.</us-gaap:ConversionOfStockDescription>
    <cvm:FairValuePerShare
      contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_1960"
      unitRef="USDPShares">4.21</cvm:FairValuePerShare>
    <cvm:RemainingOutstandingFairValueOfShares
      contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="-5"
      id="fid_1961"
      unitRef="USD">7900000</cvm:RemainingOutstandingFairValueOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      id="fid_1962">P1Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="-5"
      id="fid_1942"
      unitRef="USD">3800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="-5"
      id="fid_1965"
      unitRef="USD">2100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <cvm:GrantDateFairValueRemaining
      contextRef="AsOf2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="-5"
      id="fid_1950"
      unitRef="USD">2000000.0</cvm:GrantDateFairValueRemaining>
    <cvm:ExpenseLifeOverNext
      contextRef="From2019-10-01to2020-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      id="fid_1964">P11Y</cvm:ExpenseLifeOverNext>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1933"
      unitRef="Shares">11787200</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember"
      decimals="0"
      id="fid_1934"
      unitRef="Shares">138400</us-gaap:CommonStockSharesAuthorized>
    <cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2325">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6,218,216&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.54&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;29,562,594&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,392,241&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.15&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.68&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7,869,555&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,014,501&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.06&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,563,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.93&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;99,740&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;3.39&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;99,740&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;3.39&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;18,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.34&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9,773&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;132.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9,773&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;132.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8,653,703&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.39&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;56,193,415&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;3,297,229&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.85&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.48&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;29,090,662&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,401,961&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.26&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted (a)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,605,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;20.58&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;149,788&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.98&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;149,788&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.98&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;49,832&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.56&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9,374&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;172.73&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9,374&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;172.73&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;11,049,709&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.08&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.93&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;54,843,283&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5,540,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.77&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.96&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;43,589,598&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1046"
      unitRef="Shares">6218216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1052"
      unitRef="USDPShares">5.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      id="fid_1066">P8Y10M17D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning>
    <cvm:AggregateIntrinsicValue
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1126"
      unitRef="USD">29562594</cvm:AggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1083"
      unitRef="Shares">1392241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1089"
      unitRef="USDPShares">9.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning
      contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember"
      id="fid_1095">P7Y8M4D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning>
    <cvm:AggregateIntrinsicValue
      contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1122"
      unitRef="USD">7869555</cvm:AggregateIntrinsicValue>
    <cvm:NumberOfOptionsVested
      contextRef="AsOf2019-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1103"
      unitRef="Shares">2014501</cvm:NumberOfOptionsVested>
    <cvm:WeightedAverageExercisePriceVested
      contextRef="AsOf2019-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1108"
      unitRef="USDPShares">4.06</cvm:WeightedAverageExercisePriceVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1047"
      unitRef="Shares">2563000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1053"
      unitRef="USDPShares">10.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptionsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1081"
      unitRef="Shares">99740</cvm:NumberOfOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1054"
      unitRef="USDPShares">3.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptionsExercised
      contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1085"
      unitRef="Shares">99740</cvm:NumberOfOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1091"
      unitRef="USDPShares">3.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1049"
      unitRef="Shares">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1055"
      unitRef="USDPShares">10.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptions
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1079"
      unitRef="Shares">9773</cvm:NumberOfOptions>
    <cvm:WeightedAverageExercisePriceExpired
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1056"
      unitRef="USDPShares">132.75</cvm:WeightedAverageExercisePriceExpired>
    <cvm:NumberOfOptions
      contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1087"
      unitRef="Shares">9773</cvm:NumberOfOptions>
    <cvm:WeightedAverageExercisePriceExpired
      contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1093"
      unitRef="USDPShares">132.75</cvm:WeightedAverageExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1039"
      unitRef="Shares">8653703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1057"
      unitRef="USDPShares">7.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      id="fid_1119">P8Y4M20D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <cvm:AggregateIntrinsicValueOutstandingEnding
      contextRef="From2019-10-01to2020-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1127"
      unitRef="USD">56193415</cvm:AggregateIntrinsicValueOutstandingEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1088"
      unitRef="Shares">3297229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1094"
      unitRef="USDPShares">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding
      contextRef="From2019-10-01to2020-09-30_cvm_ExercisableMember"
      id="fid_1118">P7Y5M23D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <cvm:AggregateIntrinsicValue
      contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1123"
      unitRef="USD">29090662</cvm:AggregateIntrinsicValue>
    <cvm:NumberOfOptionsVested
      contextRef="AsOf2020-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1104"
      unitRef="Shares">2401961</cvm:NumberOfOptionsVested>
    <cvm:WeightedAverageExercisePriceVested
      contextRef="AsOf2020-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1109"
      unitRef="USDPShares">6.26</cvm:WeightedAverageExercisePriceVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1040"
      unitRef="Shares">2605000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1060"
      unitRef="USDPShares">20.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptionsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1082"
      unitRef="Shares">149788</cvm:NumberOfOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1061"
      unitRef="USDPShares">4.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptionsExercised
      contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1101"
      unitRef="Shares">149788</cvm:NumberOfOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1110"
      unitRef="USDPShares">4.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1042"
      unitRef="Shares">49832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1062"
      unitRef="USDPShares">9.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptions
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1080"
      unitRef="Shares">9374</cvm:NumberOfOptions>
    <cvm:WeightedAverageExercisePriceExpired
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1063"
      unitRef="USDPShares">172.73</cvm:WeightedAverageExercisePriceExpired>
    <cvm:NumberOfOptions
      contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1105"
      unitRef="Shares">9374</cvm:NumberOfOptions>
    <cvm:WeightedAverageExercisePriceExpired
      contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1111"
      unitRef="USDPShares">172.73</cvm:WeightedAverageExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1064"
      unitRef="Shares">11049709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1065"
      unitRef="USDPShares">10.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      id="fid_1070">P7Y11M4D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning>
    <cvm:AggregateIntrinsicValueOutstandingEnding
      contextRef="From2020-10-01to2021-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1129"
      unitRef="USD">54843283</cvm:AggregateIntrinsicValueOutstandingEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1106"
      unitRef="Shares">5540028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1112"
      unitRef="USDPShares">5.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning
      contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember"
      id="fid_1115">P6Y11M15D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning>
    <cvm:AggregateIntrinsicValueOutstandingEnding
      contextRef="From2020-10-01to2021-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1125"
      unitRef="USD">43589598</cvm:AggregateIntrinsicValueOutstandingEnding>
    <cvm:ScheduleOfNonVestedOptionsTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2326">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Grant Date Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,825,975&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.79&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,014,501&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,563,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(18,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,356,474&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.76&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,401,961&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,605,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(49,832&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;5,509,681&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.17&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfNonVestedOptionsTableTextBlock>
    <cvm:NumberOfUnvestedOptionsBeginning
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_990"
      unitRef="Shares">4825975</cvm:NumberOfUnvestedOptionsBeginning>
    <cvm:WeightedAverageGrantDateFairValueBeginning
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_1000"
      unitRef="USDPShares">3.79</cvm:WeightedAverageGrantDateFairValueBeginning>
    <cvm:VestedOptions
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_992"
      unitRef="Shares">-2014501</cvm:VestedOptions>
    <cvm:GrantedOptions
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_994"
      unitRef="Shares">2563000</cvm:GrantedOptions>
    <cvm:ForfeitedOptions
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_996"
      unitRef="Shares">-18000</cvm:ForfeitedOptions>
    <cvm:NumberOfUnvestedOptionsEnding
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_998"
      unitRef="Shares">5356474</cvm:NumberOfUnvestedOptionsEnding>
    <cvm:WeightedAverageGrantDateFairValueBeginning
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_1001"
      unitRef="USDPShares">4.76</cvm:WeightedAverageGrantDateFairValueBeginning>
    <cvm:VestedOptions
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_993"
      unitRef="Shares">-2401961</cvm:VestedOptions>
    <cvm:GrantedOptions
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_995"
      unitRef="Shares">2605000</cvm:GrantedOptions>
    <cvm:ForfeitedOptions
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_997"
      unitRef="Shares">-49832</cvm:ForfeitedOptions>
    <cvm:NumberOfUnvestedOptionsEnding
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_999"
      unitRef="Shares">5509681</cvm:NumberOfUnvestedOptionsEnding>
    <cvm:WeightedAverageGrantDateFairValueEnding
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_1003"
      unitRef="USDPShares">5.17</cvm:WeightedAverageGrantDateFairValueEnding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1935"
      unitRef="Shares">614500</us-gaap:CommonStockSharesAuthorized>
    <cvm:VestedShares
      contextRef="From2020-10-01to2021-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1966"
      unitRef="Shares">463250</cvm:VestedShares>
    <cvm:RemainingOutstandingFairValueOfShares
      contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="-5"
      id="fid_1967"
      unitRef="USD">8600000</cvm:RemainingOutstandingFairValueOfShares>
    <cvm:IssuanceOfRestrictedStock
      contextRef="From2020-10-01to2021-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="-5"
      id="fid_1939"
      unitRef="USD">300000</cvm:IssuanceOfRestrictedStock>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1940"
      unitRef="USD">45000</us-gaap:DeferredCompensationEquity>
    <cvm:ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock contextRef="From2020-10-01to2021-09-30" id="fid_2327">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Number of Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Weighted Average Grant Date Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;304,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;304,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock>
    <cvm:NumberOfUnvestedSharesBeginning
      contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1004"
      unitRef="Shares">304500</cvm:NumberOfUnvestedSharesBeginning>
    <cvm:WeightedAverageGrantDateFairValueBeginning
      contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      id="fid_1023"
      unitRef="USDPShares">13.75</cvm:WeightedAverageGrantDateFairValueBeginning>
    <cvm:NumberOfUnvestedSharesBeginning
      contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1005"
      unitRef="Shares">304500</cvm:NumberOfUnvestedSharesBeginning>
    <cvm:WeightedAverageGrantDateFairValue
      contextRef="From2019-10-01to2020-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      id="fid_1013"
      unitRef="USDPShares">13.75</cvm:WeightedAverageGrantDateFairValue>
    <cvm:SharesForfeited
      contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1006"
      unitRef="Shares">-2000</cvm:SharesForfeited>
    <cvm:VestedShares
      contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1008"
      unitRef="Shares">-151250</cvm:VestedShares>
    <cvm:NumberOfUnvestedSharesEnding
      contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1010"
      unitRef="Shares">151250</cvm:NumberOfUnvestedSharesEnding>
    <cvm:WeightedAverageGrantDateFairValue
      contextRef="From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      id="fid_1012"
      unitRef="USDPShares">13.75</cvm:WeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_1927"
      unitRef="Shares">363086</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_1936"
      unitRef="Shares">783760</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-09-30_cvm_StockCompensationPlansMember"
      decimals="0"
      id="fid_1937"
      unitRef="Shares">634000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-09-30_cvm_StockCompensationPlansMember"
      decimals="0"
      id="fid_1928"
      unitRef="Shares">154195</us-gaap:CommonStockSharesIssued>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2292">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span id="fontfd048409-0460-4364-bd1a-6b54d9dd4d63" style="font-family:symbol"&gt;&lt;strong&gt;9&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;EMPLOYEE BENEFIT PLAN&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant&#x2019;s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant&#x2019;s contribution, not to exceed the lesser of $10,000 or 6% of the participant&#x2019;s total compensation. The Company&#x2019;s contribution of common stock is valued each quarter based upon the closing bid price of the Company&#x2019;s common stock. During the year ended September 30, 2021, 17,990 shares were issued to the Company&#x2019;s 401(k) plan for a cost of approximately $201,000. During the year ended September 30, 2020, 13,870 shares were issued to the Company&#x2019;s 401(k) plan for a cost of approximately $163,000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <cvm:TotalCompensation
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1744"
      unitRef="USD">10000</cvm:TotalCompensation>
    <cvm:ParticipantCompensation
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_1745"
      unitRef="Pure">0.06</cvm:ParticipantCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1747"
      unitRef="Shares">17990</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1743"
      unitRef="USD">201000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1746"
      unitRef="Shares">13870</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1742"
      unitRef="USD">163000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2293">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span id="font1fee1043-38b7-4ec7-92f5-34f01644823c" style="font-family:symbol"&gt;&lt;strong&gt;10&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;COMMITMENTS AND CONTINGENCIES &lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Clinical Research Agreements&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Company&#x2019;s Phase III clinical study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d;. The Company determined the payments to Ergomed are within the scope of ASC 730 &#x201c;Research and Development.&#x201d; Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $35.1 million related to Ergomed&#x2019;s services. This amount is net of Ergomed&#x2019;s discount of approximately $11.6 million. During the years ended September 30, 2021 and 2020, the Company recorded approximately $1.6 million and $2.0 million, respectively, as research and development expense related to Ergomed&#x2019;s services. These amounts were net of Ergomed&#x2019;s discount of approximately $0.6 million during both the years ended September 30, 2021 and 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Lease Agreements&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#x2019;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#x2019;s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Upon adoption of ASC 842 on October 1, 2019, the Company recorded a finance lease right of use asset of approximately $16.5 million and a finance lease liability of approximately $13.5 million. As of September 30, 2021 and 2020, respectively, the net book value of the finance lease right of use asset is approximately $12.7 million and $13.8 million and the balance of the finance lease liability is approximately $13.8 million and $12.7 million, of which approximately $0.6 million and $0.9 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being amortized using a straight-line method over the underlying lease terms and totaled approximately&#160;$1,732,000&#160;and $1,717,000&#160;&#160;in&#160;the years ended September 30, 2021 and 2020, respectively. Total cash paid related to finance leases during the years ended September 30, 2021 and 2020, respectively, was approximately $2.2 million and $1.9 million, of which approximately $1.2 million was for interest in both years. The weighted average discount rate of the Company&#x2019;s finance leases is 8.45% and the weighted average time to maturity is 7.1 years.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $10.7 million, of which approximately $10.5 million has been incurred as of September 30, 2021. The landlord agreed to finance the final $2.4 million of the costs incurred which will be repaid through increased lease payments over the remaining lease term starting on March 1, 2021. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. The Company remeasured the lease liability to account for the modified payments using a 8.45% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. Approximately $1.6 million was received from the landlord as of September 30, 2021. The leasehold improvements are recorded in property and equipment and will be amortized over the remaining lease term when the assets are placed in service.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During June 2021, the Company determined that it used an incorrect discount rate to calculate the opening ROU asset and lease liability balances upon adoption of ASC 842. Management engaged an outside valuation specialist to perform a synthetic credit rating analysis which resulted in a revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%. This change resulted in an immaterial difference to the September 30, 2020 financial statements, and was corrected in the quarterly period ended June 30, 2021 as an out of period adjustment.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company was required to deposit the equivalent of one year of base rent in accordance with the original lease. Under the landlord&#x2019;s $2.4 million financing arrangement, the Company was required to deposit an additional $0.2 million in March 2021. As September 30, 2021 and 2020, respectively, the approximate $1.9 million and $1.7 million deposit is included in non-current assets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Approximate future minimum lease payments under finance leases as of September 30, 2021 are as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,699,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,569,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,648,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,733,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,824,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;6,186,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation *&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,659,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,825,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of lease finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,834,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;"&gt;&lt;em&gt;* Amount is net of landlord incentive of approximately $0.8 million expected to be realized in quarter ended December 31, 2021. &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Effective April 30, 2020, the Company terminated a month-to-month arrangement with a sub-lessee as the sub-leased space was needed to prepare the facility to produce Multikine for commercial purposes and before the Company&#x2019;s Biologics License Application (BLA) can be submitted to the FDA. The sublease rental income for the year ended September 30, 2020 was approximately $39,000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company leases two facilities under operating leases. The lease for the Company&#x2019;s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on March 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Upon adoption of ASC 842 on October 1, 2019, the Company recorded an operating lease right of use asset and an operating lease liability of approximately $1.0 million. As of September 30, 2021, the net book value of the operating lease right of use asset is approximately $2.1 million and the balance of the operating lease liability is approximately $2.1 million, of which approximately $0.1 million is current. As of September 30, 2020, the net book value of the operating lease right of use asset is approximately $1.2 million and the balance of the operating lease liability is approximately $1.2 million, of which approximately $0.1 million is current. The Company incurred lease expense under operating leases of approximately $0.2 million for each of the years ended September 30, 2021 and 2020. Total cash paid related to operating leases during the years ended September 30, 2021 and 2020 was approximately $0.3 million and $0.2 million, respectively. The weighted average discount rate of the Company&#x2019;s operating leases is 9.12% and the weighted average time to maturity is 9.7 years.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;As of September 30, 2021, future minimum lease payments on operating leases are as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;309,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;348,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;357,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,602,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,269,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,130,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,139,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Vendor Obligations&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has contingent obligations with vendors for work that will be completed in relation to the Phase 3 clinical trial. The timing of these obligations cannot be determined at this time. The Company estimates it will incur additional expenses of approximately $1.1 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report with the FDA. This estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cvm:ClinicalServiceTrial
      contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember"
      decimals="-6"
      id="fid_1801"
      unitRef="USD">10000000</cvm:ClinicalServiceTrial>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2020-10-01to2021-09-30"
      decimals="-5"
      id="fid_1800"
      unitRef="USD">35100000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetOfDiscount
      contextRef="From2020-10-01to2021-09-30"
      decimals="-5"
      id="fid_1808"
      unitRef="USD">11600000</cvm:NetOfDiscount>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_1803"
      unitRef="USD">1600000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetOfDiscount
      contextRef="From2020-10-01to2021-09-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_1804"
      unitRef="USD">600000</cvm:NetOfDiscount>
    <cvm:IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability
      contextRef="From2020-10-01to2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1784"
      unitRef="USD">16500000</cvm:IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1785"
      unitRef="USD">13500000</us-gaap:FinanceLeaseLiability>
    <cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset
      contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1787"
      unitRef="USD">12700000</cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset>
    <cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset
      contextRef="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1786"
      unitRef="USD">13800000</cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset>
    <cvm:BalanceOfTheFinanceLeaseLiability
      contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1788"
      unitRef="USD">13800000</cvm:BalanceOfTheFinanceLeaseLiability>
    <cvm:BalanceOfTheFinanceLeaseLiability
      contextRef="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1789"
      unitRef="USD">12700000</cvm:BalanceOfTheFinanceLeaseLiability>
    <cvm:CurrentBalance
      contextRef="AsOf2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1790"
      unitRef="USD">600000</cvm:CurrentBalance>
    <cvm:CurrentBalance
      contextRef="AsOf2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1791"
      unitRef="USD">900000</cvm:CurrentBalance>
    <cvm:CashPaidRelatedToFinanceLeases
      contextRef="From2020-10-01to2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1792"
      unitRef="USD">2200000</cvm:CashPaidRelatedToFinanceLeases>
    <cvm:CashPaidRelatedToFinanceLeases
      contextRef="From2019-10-01to2020-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1793"
      unitRef="USD">1900000</cvm:CashPaidRelatedToFinanceLeases>
    <cvm:CashPaidRelatedToFinanceLeasesInterest
      contextRef="From2020-10-01to2021-09-30_cvm_TransactionOneMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1794"
      unitRef="USD">1200000</cvm:CashPaidRelatedToFinanceLeasesInterest>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-09-30"
      decimals="INF"
      id="fid_1766"
      unitRef="Pure">0.0845</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <cvm:MaturityYears contextRef="From2020-10-01to2021-09-30" id="fid_1771">P7Y1M6D</cvm:MaturityYears>
    <cvm:EstimatedCost
      contextRef="From2020-10-01to2021-09-30_cvm_LandlordMember"
      decimals="-5"
      id="fid_1816"
      unitRef="USD">10700000</cvm:EstimatedCost>
    <cvm:CostIncurredInitial
      contextRef="From2020-10-01to2021-09-30_cvm_LandlordMember"
      decimals="-5"
      id="fid_1815"
      unitRef="USD">10500000</cvm:CostIncurredInitial>
    <us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases
      contextRef="From2020-10-01to2021-09-30_cvm_LandlordMember"
      id="fid_1809">The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.</us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases>
    <us-gaap:DerivativeVariableInterestRate
      contextRef="AsOf2021-09-30_cvm_LandlordMember"
      decimals="INF"
      id="fid_1770"
      unitRef="Pure">0.0845</us-gaap:DerivativeVariableInterestRate>
    <us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases contextRef="From2020-10-01to2021-09-30" id="fid_1810">revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%</us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases>
    <cvm:FinancingLeaseContractualArrangement
      contextRef="From2020-10-01to2021-09-30_cvm_LandlordMember"
      decimals="-5"
      id="fid_1819"
      unitRef="USD">2400000</cvm:FinancingLeaseContractualArrangement>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2021-09-30_cvm_LandlordMember"
      decimals="-5"
      id="fid_1814"
      unitRef="USD">200000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2021-09-30_cvm_LandlordMember"
      decimals="-5"
      id="fid_1817"
      unitRef="USD">1900000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2020-09-30_cvm_LandlordMember"
      decimals="-5"
      id="fid_1818"
      unitRef="USD">1700000</us-gaap:AssetsNoncurrent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2328">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,699,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,569,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,648,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,733,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,824,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;6,186,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation *&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,659,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,825,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of lease finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,834,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1748"
      unitRef="USD">1699000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1749"
      unitRef="USD">2569000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1750"
      unitRef="USD">2648000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1751"
      unitRef="USD">2733000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1752"
      unitRef="USD">2824000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1753"
      unitRef="USD">6186000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1754"
      unitRef="USD">18659000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <cvm:NetPresentValueOfLeaseFinancingObligation
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1756"
      unitRef="USD">13834000</cvm:NetPresentValueOfLeaseFinancingObligation>
    <us-gaap:SubleaseIncome
      contextRef="From2019-10-01to2020-09-30_us-gaap_LicenseMember"
      decimals="0"
      id="fid_1813"
      unitRef="USD">39000</us-gaap:SubleaseIncome>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2020-10-01to2021-09-30_cvm_VendorObligationsMember"
      decimals="-5"
      id="fid_1923"
      unitRef="USD">1100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cvm:IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability
      contextRef="From2020-10-01to2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1773"
      unitRef="USD">1000000.0</cvm:IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability>
    <cvm:NetBookValueOperatingLeaseRightOfUseAssets
      contextRef="AsOf2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1776"
      unitRef="USD">2100000</cvm:NetBookValueOperatingLeaseRightOfUseAssets>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1780"
      unitRef="USD">2100000</us-gaap:OperatingLeaseLiability>
    <cvm:CurrentBalance
      contextRef="AsOf2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1778"
      unitRef="USD">100000</cvm:CurrentBalance>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1781"
      unitRef="USD">1200000</us-gaap:OperatingLeaseLiability>
    <cvm:NetBookValueOperatingLeaseRightOfUseAssets
      contextRef="AsOf2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1777"
      unitRef="USD">1200000</cvm:NetBookValueOperatingLeaseRightOfUseAssets>
    <cvm:CurrentBalance
      contextRef="AsOf2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1779"
      unitRef="USD">100000</cvm:CurrentBalance>
    <us-gaap:OperatingLeasePayments
      contextRef="From2019-10-01to2020-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1775"
      unitRef="USD">200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-10-01to2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1774"
      unitRef="USD">300000</us-gaap:OperatingLeasePayments>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-10-01to2021-09-30_cvm_TransactionTwoMember_cvm_OctoberOneTwothousandNineTeenMember"
      decimals="-5"
      id="fid_1782"
      unitRef="USD">200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-09-30"
      decimals="INF"
      id="fid_1767"
      unitRef="Pure">0.0912</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cvm:OperatingLeaseMaturityYears contextRef="From2020-10-01to2021-09-30" id="fid_1772">P9Y8M12D</cvm:OperatingLeaseMaturityYears>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2329">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;309,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;348,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;357,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,602,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,269,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,130,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,139,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1757"
      unitRef="USD">309000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1758"
      unitRef="USD">348000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1759"
      unitRef="USD">357000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1760"
      unitRef="USD">366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1761"
      unitRef="USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1762"
      unitRef="USD">1602000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <cvm:LesseeOperatingLeaseLiabilityPayments
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1763"
      unitRef="USD">3269000</cvm:LesseeOperatingLeaseLiabilityPayments>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1764"
      unitRef="USD">1130000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1765"
      unitRef="USD">2139000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2294">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span id="fontdbb63aaa-97d8-4a2c-a795-4ccbe55f6879" style="font-family:symbol"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;RELATED PARTY TRANSACTIONS&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2021, the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kerston, is a beneficiary, and two directors purchased 27,500 restricted shares of the Company&#x2019;s common stock at an aggregate fair market value of approximately $220,000. During the year ended September 30, 2020, officers and directors of the Company purchased 20,512 shares of restricted common stock at market price at an aggregate fair market value of approximately $185,000. The shares are subject to the conditions of Rule 144 under the Securities Act of 1933.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 28, 2021, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary, were extended by twelve months (Note 4). The incremental cost of these modifications was approximately $265,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 28, 2021, the expiration date of 93,603 Series UU warrants was extended by twelve months (Note 4). The incremental cost of this extension was $24,000 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and the de Clara Trust and were originally issued with convertible debt.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary, were extended by six months (Note 4). The incremental cost of these modifications was approximately $86,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2020, the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021. The incremental cost of this extension was $192 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 8, 2020, the expiration date of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense for the year ended September 30, 2020. The Series UU warrants are held by the Company&#x2019;s officers and were originally issued with convertible debt.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cvm:NumberOfRestrictedSharesPurchasedByRelatedParty
      contextRef="From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="fid_1839"
      unitRef="Shares">27500</cvm:NumberOfRestrictedSharesPurchasedByRelatedParty>
    <cvm:ProceedsFromRestrictedSharesPurchasedByRelatedParty
      contextRef="From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="fid_1841"
      unitRef="USD">220000</cvm:ProceedsFromRestrictedSharesPurchasedByRelatedParty>
    <cvm:NumberOfRestrictedSharesPurchasedByRelatedParty
      contextRef="From2019-10-01to2020-09-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="fid_1838"
      unitRef="Shares">20512</cvm:NumberOfRestrictedSharesPurchasedByRelatedParty>
    <cvm:ProceedsFromRestrictedSharesPurchasedByRelatedParty
      contextRef="From2019-10-01to2020-09-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="fid_1840"
      unitRef="USD">185000</cvm:ProceedsFromRestrictedSharesPurchasedByRelatedParty>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2021-04-01to2021-06-30_cvm_SeriesNWarrantsMember"
      decimals="0"
      id="fid_1826"
      unitRef="USD">265000</us-gaap:OtherCostAndExpenseOperating>
    <cvm:WarrantsIssued
      contextRef="AsOf2021-06-28_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_1833"
      unitRef="Shares">93603</cvm:WarrantsIssued>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2021-04-01to2021-06-30_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_1834"
      unitRef="USD">24000</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesNAndXWarrantsMember"
      decimals="0"
      id="fid_1830"
      unitRef="USD">86000</us-gaap:OtherCostAndExpenseOperating>
    <cvm:ExpirationDateDescription
      contextRef="From2020-10-01to2021-09-30_cvm_SeriesUUWarrantsMember"
      id="fid_1823">the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021</cvm:ExpirationDateDescription>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_1837"
      unitRef="USD">192</us-gaap:InterestExpenseRelatedParty>
    <cvm:WarrantsIssued
      contextRef="AsOf2020-05-08_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_1831"
      unitRef="Shares">93593</cvm:WarrantsIssued>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2020-05-01to2020-05-08_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_1835"
      unitRef="USD">6000</us-gaap:InterestExpenseRelatedParty>
    <cvm:ExpirationDateDescription
      contextRef="From2020-12-01to2020-12-07_cvm_SeriesNWarrantsMember"
      id="fid_1820">the expiration date of the Series N warrants was extended to February 18, 2021</cvm:ExpirationDateDescription>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2019-10-01to2020-09-30_cvm_SeriesNWarrantsMember"
      decimals="0"
      id="fid_1825"
      unitRef="USD">22000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2295">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;12. &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;STOCKHOLDERS&#x2019; EQUITY &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Exercise of Warrants&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the years ended September 30, 2021 and 2020, the Company received proceeds of approximately $6.0 million and $12.1 million, respectively, from the exercise of warrants, as detailed in Note 4. Upon exercise, 1,597,870 and 1,711,873 shares of common stock were issued during the years ended September 30, 2021 and 2020, respectively.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Sales of Securities&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In June 2021, the Company sold 1,400,000 shares of common stock at a public offering price of $22.62 per share and received aggregate net proceeds of approximately $29.4 million. At that time, the underwriters fully exercised their option to purchase up to 210,000 additional shares of common stock to cover over-allotments, resulting in additional net proceeds to the Company of approximately $4.4 million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In December 2020, the Company sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In March 2020, the Company sold 630,500 shares of common stock at a public offering price of $12.22 per share and received aggregate net proceeds of approximately $7.1 million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 45-day option to purchase up to an additional 94,575 shares of common stock solely to cover over-allotments. The underwriter fully exercised this option in May 2020 resulting in additional net proceeds to the Company of approximately $1.1 million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In December 2019, the Company sold 606,395 shares of common stock at a public offering price of $9.07 per share and received aggregate net proceeds of approximately $5.0 million. In January 2020, the underwriters of that offering fully exercised the option to purchase 90,959 additional shares of common stock at the public offering price of $9.07 per share for aggregate net proceeds to the Company of approximately $0.8 million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Other Equity Transactions&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company entered into Securities Purchase Agreements (SPA) with Ergomed plc, one of the Company&#x2019;s Clinical Research Organizations responsible for managing the Company&#x2019;s Phase 3 clinical trial, to facilitate payment of amounts due Ergomed. Under the Agreements, the Company issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed. Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2020, the Company issued Ergomed 150,000 shares. No shares were issued during the year ended September 30, 2021. All outstanding shares have been resold as of September 30, 2021 and the Company has approximately $500,000 in amounts prepaid to Ergomed.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table summarizes the Other Non-operating gains (losses) for the years ended September 30 relating to these agreements:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Amount realized through the resale of shares&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,685,379&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,652,605&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fair value of shares upon issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,769,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Other non-operating gain&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,685,379&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;883,105&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;As of September 30, 2021, all shares held for resale were sold.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cvm:ProceedFromIssuanceOrSaleOfEquity
      contextRef="From2020-10-01to2021-09-30"
      decimals="-5"
      id="fid_1868"
      unitRef="USD">6000000.0</cvm:ProceedFromIssuanceOrSaleOfEquity>
    <cvm:ProceedFromIssuanceOrSaleOfEquity
      contextRef="From2019-10-01to2020-09-30"
      decimals="-5"
      id="fid_1867"
      unitRef="USD">12100000</cvm:ProceedFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1870"
      unitRef="Shares">1597870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1869"
      unitRef="Shares">1711873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-06-30"
      decimals="0"
      id="fid_1873"
      unitRef="Shares">1400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      id="fid_1853"
      unitRef="USDPShares">22.62</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-06-01to2021-06-30"
      decimals="-5"
      id="fid_1852"
      unitRef="USD">29400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <cvm:ProceedsFromPublicOffering
      contextRef="AsOf2021-06-30"
      decimals="0"
      id="fid_2553"
      unitRef="USD">210000</cvm:ProceedsFromPublicOffering>
    <cvm:ProceedFromIssuanceOrSaleOfEquity
      contextRef="From2021-06-01to2021-06-30"
      decimals="-5"
      id="fid_1866"
      unitRef="USD">4400000</cvm:ProceedFromIssuanceOrSaleOfEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1850"
      unitRef="Shares">1000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="fid_1854"
      unitRef="USDPShares">14.65</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-12-01to2020-12-31"
      decimals="-5"
      id="fid_1849"
      unitRef="USD">13600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2020-03-31"
      decimals="0"
      id="fid_1848"
      unitRef="Shares">630500</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2020-03-31"
      decimals="INF"
      id="fid_1855"
      unitRef="USDPShares">12.22</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-03-01to2020-03-31"
      decimals="-5"
      id="fid_1859"
      unitRef="USD">7100000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <cvm:ProceedsFromPublicOffering
      contextRef="AsOf2020-03-31"
      decimals="0"
      id="fid_2556"
      unitRef="USD">94575</cvm:ProceedsFromPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-05-01to2020-05-31"
      decimals="-5"
      id="fid_1858"
      unitRef="USD">1100000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_1851"
      unitRef="Shares">606395</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      id="fid_1857"
      unitRef="USDPShares">9.07</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2019-12-01to2019-12-31"
      decimals="-5"
      id="fid_1861"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <cvm:ProceedsFromPublicOffering
      contextRef="AsOf2020-01-31"
      decimals="0"
      id="fid_2554"
      unitRef="USD">90959</cvm:ProceedsFromPublicOffering>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2020-01-31"
      decimals="INF"
      id="fid_1856"
      unitRef="USDPShares">9.07</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-01-01to2020-01-31"
      decimals="-5"
      id="fid_1860"
      unitRef="USD">800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2020-09-30_cvm_ErgomedMember"
      decimals="0"
      id="fid_1872"
      unitRef="Shares">150000</us-gaap:CommonStockSharesIssued>
    <cvm:PrepaidAmountOfResold
      contextRef="AsOf2021-09-30_cvm_ErgomedMember"
      decimals="0"
      id="fid_1871"
      unitRef="USD">500000</cvm:PrepaidAmountOfResold>
    <cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2330">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 22.5pt; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Amount realized through the resale of shares&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,685,379&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,652,605&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fair value of shares upon issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,769,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Other non-operating gain&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,685,379&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;883,105&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock>
    <cvm:AmountRealizedThroughTheResaleOfShares
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1843"
      unitRef="USD">1685379</cvm:AmountRealizedThroughTheResaleOfShares>
    <cvm:AmountRealizedThroughTheResaleOfShares
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1842"
      unitRef="USD">2652605</cvm:AmountRealizedThroughTheResaleOfShares>
    <cvm:SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1845"
      unitRef="USD">0</cvm:SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance>
    <cvm:SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1844"
      unitRef="USD">1769500</cvm:SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance>
    <cvm:SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1847"
      unitRef="USD">1685379</cvm:SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses>
    <cvm:SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1846"
      unitRef="USD">883105</cvm:SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2296">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;3&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;FAIR VALUE MEASUREMENTS&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with the provisions of ASC 820, &#x201c;&lt;em&gt;Fair Value Measurements&lt;/em&gt;,&#x201d; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to the future amounts.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;o &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 1 &#x2013; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;o &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 2 &#x2013; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs other than quoted prices that are observable for the asset or liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;o &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 3 &#x2013; Unobservable inputs that reflect management&#x2019;s assumptions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company purchased short-term T-bills during the year ended September 30, 2021 that are classified as trading securities. Quoted market prices were applied to determine the fair value of short-term investments, therefore they were categorized as Level 1 on the fair value hierarchy. The T-bills were recorded at fair market value, which includes an unrealized gain of approximately $6,000. The T-bills mature in December 2021 and yield a weighted average interest rate of 0.10%.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of September 30, 2021 and 2020, all of the Company&#x2019;s derivative liabilities are classified as Level 3.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September 30:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,765,613&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,488,310&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;Issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;Exercises&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,023,091&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,071,775&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;N Net realized and unrealized derivative loss&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;694,858&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;349,078&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,765,613&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The fair values of the Company&#x2019;s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company&#x2019;s stock. At September 30, 2021, the Company&#x2019;s Level 3 derivative instruments have a weighted average fair value of $1.45 per share and a weighted average exercise price of $13.28 per share. Fair values were determined using a weighted average risk free interest rate of 0.05% and volatility of 109%. The instruments have a weighted average time to maturity of 0.3 years. At September 30, 2020, the Company&#x2019;s Level 3 derivative instruments have a weighted average fair value of $2.81 per share and a weighted average exercise price of $14.32 per share. Fair values were determined using a weighted average risk free interest rate of 0.12% and volatility of 95%. The instruments have a weighted average time to maturity of 1.2 years.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1892"
      unitRef="USD">6000</us-gaap:UnrealizedGainLossOnInvestments>
    <cvm:WeightedAverageRiskFreeInterestRate
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_1893"
      unitRef="Pure">0.0010</cvm:WeightedAverageRiskFreeInterestRate>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2331">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,765,613&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,488,310&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;Issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;Exercises&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,023,091&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,071,775&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;N Net realized and unrealized derivative loss&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;694,858&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;349,078&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,765,613&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1875"
      unitRef="USD">3765613</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2019-09-30"
      decimals="0"
      id="fid_1874"
      unitRef="USD">6488310</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1877"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1876"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1879"
      unitRef="USD">-4023091</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1878"
      unitRef="USD">-3071775</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1881"
      unitRef="USD">694858</cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings>
    <cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1880"
      unitRef="USD">349078</cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1883"
      unitRef="USD">437380</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1882"
      unitRef="USD">3765613</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <cvm:WeightedAverageFairValueDerivativeInstruments
      contextRef="AsOf2021-09-30_cvm_FairValueInputsLevelThreeMember"
      decimals="INF"
      id="fid_1885"
      unitRef="USDPShares">1.45</cvm:WeightedAverageFairValueDerivativeInstruments>
    <cvm:WeightedAverageExercisePriceDerivativeInstruments
      contextRef="AsOf2021-09-30_cvm_FairValueInputsLevelThreeMember"
      decimals="INF"
      id="fid_1887"
      unitRef="USDPShares">13.28</cvm:WeightedAverageExercisePriceDerivativeInstruments>
    <cvm:WeightedAverageRiskFreeInterestRate
      contextRef="From2020-10-01to2021-09-30_cvm_FairValueInputsLevelThreeMember"
      decimals="INF"
      id="fid_1889"
      unitRef="Pure">0.0005</cvm:WeightedAverageRiskFreeInterestRate>
    <cvm:VolatilityRate
      contextRef="From2020-10-01to2021-09-30_cvm_FairValueInputsLevelThreeMember"
      decimals="INF"
      id="fid_1891"
      unitRef="Pure">1.09</cvm:VolatilityRate>
    <cvm:WeightedAverageTimeToMaturityYear
      contextRef="From2020-10-01to2021-09-30_cvm_FairValueInputsLevelThreeMember"
      id="fid_1895">P0Y3M18D</cvm:WeightedAverageTimeToMaturityYear>
    <cvm:WeightedAverageFairValueDerivativeInstruments
      contextRef="AsOf2020-09-30_cvm_FairValueInputsLevelThreeMember"
      decimals="INF"
      id="fid_1884"
      unitRef="USDPShares">2.81</cvm:WeightedAverageFairValueDerivativeInstruments>
    <cvm:WeightedAverageExercisePriceDerivativeInstruments
      contextRef="AsOf2020-09-30_cvm_FairValueInputsLevelThreeMember"
      decimals="INF"
      id="fid_1886"
      unitRef="USDPShares">14.32</cvm:WeightedAverageExercisePriceDerivativeInstruments>
    <cvm:WeightedAverageRiskFreeInterestRate
      contextRef="From2019-10-01to2020-09-30_cvm_FairValueInputsLevelThreeMember"
      decimals="INF"
      id="fid_1888"
      unitRef="Pure">0.0012</cvm:WeightedAverageRiskFreeInterestRate>
    <cvm:VolatilityRate
      contextRef="From2019-10-01to2020-09-30_cvm_FairValueInputsLevelThreeMember"
      decimals="INF"
      id="fid_1890"
      unitRef="Pure">0.95</cvm:VolatilityRate>
    <cvm:WeightedAverageTimeToMaturityYear
      contextRef="From2019-10-01to2020-09-30_cvm_FairValueInputsLevelThreeMember"
      id="fid_1894">P1Y2M12D</cvm:WeightedAverageTimeToMaturityYear>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2297">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span id="font1979c11c-b28b-499c-aafb-834c09537173" style="font-family:symbol"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;4&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NET LOSS PER COMMON SHARE&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock have not been included in the computation of diluted net loss per share for all periods presented, as the result would be anti-dilutive. For the years presented, the gain on derivative instruments is not included in net loss available to common shareholders for purposes of computing dilutive loss per share because its effect is anti-dilutive.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Year ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; basic&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt"&gt;Net loss available to common shareholders - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(36,711,970&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(30,276,978&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Weighted average shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;40,662,137&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;36,759,115&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt"&gt;Basic loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.90&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.82&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt"&gt;Net loss available to common shareholders - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(36,711,970&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(30,276,978&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Unrealized gain on derivatives &lt;sup&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,085,540&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt"&gt;Net loss available to common shareholders - diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(37,797,510&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(30,276,978&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Weighted average shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;40,662,137&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;36,759,115&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt"&gt;Incremental shares underlying dilutive warrants &lt;sup&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;32,111&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Weighted average shares outstanding - diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;40,694,248&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;36,759,115&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt"&gt;Diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.93&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.82&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span id="font7d035306-f9b9-45fc-87bc-b43e5ea6ceb6" style="font-family:symbol"&gt;&lt;em&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/em&gt;&lt;em&gt; &lt;/em&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Includes Series Z, AA, CC and HH warrants for the year ended September 30, 2021.&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,604,850&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,221,696&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;308,814&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,756,100&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,530,510&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock contextRef="From2020-10-01to2021-09-30" id="fid_2332">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Year ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; basic&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt"&gt;Net loss available to common shareholders - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(36,711,970&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(30,276,978&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Weighted average shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;40,662,137&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;36,759,115&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt"&gt;Basic loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.90&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.82&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt"&gt;Net loss available to common shareholders - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(36,711,970&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(30,276,978&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Unrealized gain on derivatives &lt;sup&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,085,540&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt"&gt;Net loss available to common shareholders - diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(37,797,510&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(30,276,978&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Weighted average shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;40,662,137&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;36,759,115&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 8.1pt;text-indent:1pt"&gt;Incremental shares underlying dilutive warrants &lt;sup&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;32,111&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Weighted average shares outstanding - diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;40,694,248&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;36,759,115&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt"&gt;Diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.93&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.82&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1896"
      unitRef="USD">-36711970</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1897"
      unitRef="USD">-30276978</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1898"
      unitRef="Shares">40662137</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1899"
      unitRef="Shares">36759115</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_1900"
      unitRef="USDPShares">-0.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_1901"
      unitRef="USDPShares">-0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1903"
      unitRef="USD">-36711970</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1904"
      unitRef="USD">-30276978</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1906"
      unitRef="USD">-1085540</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1905"
      unitRef="USD">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1907"
      unitRef="USD">-37797510</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1908"
      unitRef="USD">-30276978</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1910"
      unitRef="Shares">36759115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <cvm:IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1912"
      unitRef="Shares">32111</cvm:IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1913"
      unitRef="Shares">40694248</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1914"
      unitRef="Shares">36759115</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-10-01to2021-09-30"
      decimals="INF"
      id="fid_1915"
      unitRef="USDPShares">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      id="fid_1916"
      unitRef="USDPShares">-0.82</us-gaap:EarningsPerShareDiluted>
    <cvm:ScheduleOfAntiDilutiveSecuritiestabletextblock contextRef="From2020-10-01to2021-09-30" id="fid_2333">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,604,850&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,221,696&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;308,814&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,756,100&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,530,510&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfAntiDilutiveSecuritiestabletextblock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-01to2021-09-30_cvm_OptionsMember"
      decimals="0"
      id="fid_1920"
      unitRef="Shares">10604850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-10-01to2020-09-30_cvm_OptionsMember"
      decimals="0"
      id="fid_1919"
      unitRef="Shares">7221696</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-01to2021-09-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_1922"
      unitRef="Shares">151250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-10-01to2020-09-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_1921"
      unitRef="Shares">308814</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_1918"
      unitRef="Shares">10756100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      id="fid_1917"
      unitRef="Shares">7530510</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-10-01to2021-09-30" id="fid_2298">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;15. SUBSEQUENT EVENTS &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"&gt;The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MSQXA0.OON%%Y_DS>T3S6#9JLDZBD!/('2PY"77'YO2 ,(4)K\;B1Q4_B6/N
MK'[O]&/(M:";UN@-,!ZB*==%&YJF;_$%!&E='L.V#$%B)R2LM\P3W44&'H;H
MK-OC1N7]D6IF3AX%>M8%K),-5GM)*&,$ K.&CQL9_A&L'!B:;"'X6\(B][B
M)5\FT"K=NG[0R/6/9 NN9Y\4_97LSH[7&D&,_0'4FH&=#0+8Q(OFFPA*SJ/
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MOIS.;N<?P>S/NXO%/[Z#BU;$L%_$)B+/10$J)9;?AN##,42Z-9#@B65:W8Y
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M,\!U@/J^9$R^5O1QV5R/@G]02P,$%     @ /(254XGG@W*J!   DQ   !@
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M6G?@]?M3L4AU2TH>]ZW[-@Y@H6U5[5^?<V[<!..ME*_0GE)TZ,L>AF"O+RS
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M6=8"^OOKHE"/;^KGK79/\)W\"U!+ P04    "  \A)53<QHS[Y,)  !#)@
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M(@($F)U L!$KS^N^ RRMQV+T#<J(D MO30.FG)R-3YY%#E#VF6IDY!%HM K
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MNN:=J&XR:!L[%IR6QH^_@W394+, ^G G(AGE0(/!G%>@E"F5MT)FK*SB5H1
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M/Q,E 1T=P/.-,;Z^( /-E\'K_P!02P,$%     @ /(254[52P.LB#P  U2\
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M]DXTRVI3S,4&VV4FVMOJN&G56F1KT&<SL*^$NLF*#6V<MTL%:36_#('MW3%
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M]MAMXFK3[O#J@"N_SJL?/UI>107<T?G$_<7F3_(M7/2YOAU&@+?]+LI^""+
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M2*-SDG(((!I$'>Q")LIMQRQ,9#J%YI\=ER^)Y7A<-=O'8_"/6DX\ $GJCO>
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MX$:VIM)PW998O@3P*;=C@M$AP8OH7<0[[$80!PRB( K?P8N/!<<.+_[_!;_
M3X[XB<-/WL!/1_"?>_HNHAW+<]WQ F<>S9U&]83>'&R<5P/ 4M'(*K,#WI:
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M\35S@UW2:CQ!K WII:AU"07G0RHC/1IZEK.Z*IZLG$9^['TU8>=1PM"\FLT
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MTI^GI^D2/K:#SD!.ZEA1Y&W4#QS72B-2/[*]C?K4@GLX$X>=#C@%A<G(!&X
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M2]6@)HGEL^%L]-Q/,_Q,L<,#=)V20W*'B&!?($PXB_K*U7>Y40@MGG&&@=#
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MRA_C0ZI0JBB:9D#1/]E>OZ[$U]NC:4K_!FK?A> CX%"\?"[!44:EQ79U_;0
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M,;D+A'L-[@:A_]^-;-]S.CH<N7L=05^4NH=5+T8/ULB>9S6-0SY 7J>#2R
M%44#T'4RKM&"A/30Y93W9<*U96# =2(M!ACH9*A [.Z<:$3 R5:9.QU,UQAW
M#@_J^[Q*LEW)1)21T+X=.3QK'*GVMQG35=$<7,5QEI<E_G</GI,4UUG<6ZN%
M/;2V>X\YM+8//3/KVC+<D%7?Q0>U;ZK.* -)8J%WU!_M'U))QNC00FKR:A<
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MX>V8&J/ZM=(;1K9NE+?2T&)PL*1-C,H&T'DAI3D:]H)AMR_^ E!+ P04
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MHII@1ANKU=A-D>7Q XB5T"]0:T#::]_5[7NS$&-Y.L#"-%(_RL$(_I)"-SP
MHFAE>2]U!Z7[H/"Q7!3UDT1OWT$8D23CA,:)FU 2AHSD20:7=74L^W*$L80D
M.<5QEC"2Y@GLP9!W&/(W8S@5"I$2Q;)!5(SG+9(PTZ*RVR':JWX'1#TDD+8>
M%0LD1L)C70BK"F6?(*=!S.#77S(6AK]!G@:,'4"6!E&R6:0!2P[@1IF'XZF6
M$A2ZZD@&+:P$&F2\DPV#A!_@4L)Z2UEZL/&C4%,?_3J%\@"YZ$P%2>[YW;W>
M*9JH1S61F&]/2A83.,:_/70E'5W)F^FJ,$-^+ 5ZK-K45M585J[;MG"V["T*
M49EMW.VUM8.[JZ4U%HVI:H;!2CU6QK4MN%SZ1$>_;N<"Q>&[;\SHV=FCU'C/
MK*4E7'N67^S?2'>9.;T7V,PTWAL8'-Q)7<*A!_<(SF8S+6>.UL\HH?"*&L,W
MG[#_L_D^*L*^*/PPAX2P,,-_5^8\X#%D09;AF.6$8SGS/,82CW)&6!SB<AZ$
M'%*79.\@)5F"4IS#MZ:-,4+#F'#J!.. )O![4Y^XP9.(4$I]+PGRJ(MZ GE.
MTMAM1$&4/YOA13N5RFE '[OC4>S266EWF*1IY+L5"U+^?/I*]%CG&4EX1%+J
M#J4!.IXYLXA$0L(\(C$&&Q&6I]CD_+(KVC2(6X!H3DF"-=N%'],0FZ0+/\'B
M[\(_%$>XF5#>QL!HP+,>!&&,CGO4XR#/GD\W(.!Z%C'/ D]Z&$1I[().,>CH
M^?0U#$((0^SR:)'F#;PTPQ!SAPB/219C_%D$G/"8$LHRCT*:8H"Y2QG<YADF
M ?JYIXVD71M)_U4;::_'MNEM:Q5[]>UH%9N:O&J[Z8NB\\S!!U=2G]SMTU33
MUVI]7V\M)42+<9)CXKGT3?-U7AQNZN)H2TEL^#ULL_QHKR5,6TXBS-#8\QP'
M:=*SM$[!OJ5UYO4LM:GTBJ70\4YS_"40>M[#=!_+6<=R]F:6>[]ZQG59XJW0
M7!'M3Z2IKDNP<_GB"KFOJZ7Q-\BVK-AK_]6LV-6I_U-21-0Q[SM7Y'K2AH/C
M-6O'K]&]6X=++9\PZP0(.?X@XZ^F$%9]*[C6N8W78>\=44H]\Z\E@T0M*]L\
M*;K5[D%VUKQ#-N+-:^Z+T#.\F*"04SQ*T>( =/-":B:V7OA7R7UM\8WCAW-\
M5$KM!'!_6M=V/7$&NF?JZ&]02P,$%     @ /(254WZ?6#$, P  I@<  !D
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MC08!Z$:1C6-5Y56P4I8TY<V"'C'4+H#6UTK9G>,V:)_%Y!=02P,$%     @
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M+W=O<FMS:&5E=',O<VAE970S,2YX;6RU5MMNVS@0_15"NU@D@&*)LF796=M
MG*9H@>8".VW01UH:6T0H44M2=MNO[Y"ZU LD1@KL/MCF9>;PG.$,Q[.#5,\Z
M!S#D6R%*/?=R8ZK+(-!I#@73 UE!B3M;J0IF<*IV@:X4L,PY%2*(PG <%(R7
MWF+FUA[48B9K(W@)#XKHNBB8^KX$(0]SCWK=PHKO<F,7@L6L8CM8@_E</2B<
M!3U*Q@LH-9<E4;"=>U?T<AE;>V?PA<-!'XV)5;*1\ME./F9S+[2$0$!J+ +#
MGSU<@Q 6"&G\TV)Z_9'6\7C<H;]WVE'+AFFXEN*)9R:?>Q./9+!EM3 K>?@
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M= T'"09'-6VTF1A9N=:UD08;H1OF^,\#E#7 _:V4IIO8 _K_,HN?4$L#!!0
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M@T'P&<(@[*_3>[CZ='T!=M 59N!@!_]=F MD-QW9C2.[^8!L131R#8W"HF'
M:('O5?8R1O\6#DBDNB!GV,D97H2:-XP=@'+52,R!5*(QXD0!7/ OE&N4J#1L
M#!GE6\B(*DUC,,(S5._);KE&CLO.B%T<#@/S1/[N7*-_=HDKE%O7J@HR2][>
MYVZWFP:3M@G^NK>C9$'DUJ@'AH4)#7JW1H)LV[,UM*A=2VR$-@WFEJ69:"BM
M@SDOA- GPQ)T,S+^ U!+ P04    "  \A)536;D[8\0'   L.0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S,RYX;6RUF^MOVS80P/\5P=B'#=@L\2&*+I(
ML9NA!98'XG19.^R#8C.)4=OR)*7I_OOI%9\HD:(J0D#1^'%WNA/O[D?2U,EK
M%']-GH5(G>^[[3XYG3RGZ>&=ZR:K9[$+DVET$/OLF\<HWH5I]C9^<I-#+,)U
MH;3;NMCSF+L+-_O)V4GQV4U\=A*]I-O-7MS$3O*RVX7Q?W.QC5Y/)VCR]L'M
MYNDYS3]PSTX.X9-8BO33X2;.WKE'*^O-3NR33;1W8O%X.CE'[Q8\R!4*B3\W
MXC6IO7;R4!ZBZ&O^YN/Z=.+E'HFM6*6YB3#[\TTLQ':;6\K\^+<R.CE>,U>L
MOWZS_GL1?!;,0YB(1;2]WZS3Y],)GSAK\1B^;-/;Z/6#J +R<WNK:)L4_SNO
MI:S/)L[J)4FC7:6<>;#;[,N_X??J1M04D$X!5PJXJ4 U"J12($6@I6=%6._#
M-#P[B:-7)\ZE,VOYB^+>%-I9-)M]/HS+-,Z^W61ZZ=G]^>WM^=7=TCF_>N]<
M75]=7-[\<?WYXL*YOKG[>'VU='Y^+])PLTU^<7YS?G)<)WD.8Y&<N&EV\=R$
MNZHN-"\OA#470MBYC/;I<^)<[-=B+1MP,Z^/KN,WU^>XT^)2'*8.\7YUL(>1
MPJ%%?W6OPQURO).DL$<U]A;1/LER)]RGB?/WI=@]B/B?#K/T:)9VFOV8)"_"
MR<96J.YYMV[@8IX5- I4=Z>':E-1"L _!N!W6EH6">/D<80/6^&\'++JO?@N
MXM4F$4[TZ-R'<9S=-55XI66_L)PWI&]GR/>\;+2^U2-12'EU*<EM=G2;=;I]
M]/ FWJR4][[4#VJ7Q5/$&[X9A"37@J-K@<&UPR8.BRZHRXMN ]G@9O\\K,R+
M0:I2'/P8!^_.#!%OLLRX[U,NLZ/-V?!R673K(J^J%[_#$>1!9_7&2OQ%9;J>
MTXSS&=$D-:JU>V27UHO*0#UE$9L&ON;*&*Z,+;-V8;#P-CZ=[1I!OT;=#;M*
MOR]?^N0?@GZ-+!KVPJ#LNYCD&<BZ7('.BT9KO0O4[JI8WU41M%5DV5<7J-TS
M$=$G('1-9-LV%P8+OHN*_$-=HP/=#_5J?_-YK_R#!HAL.J!!.0N/F?(/0P?$
MXW5 W.Z B&GS#T,#Q+8-$"L:H#[_,#1 ;-T #1:RT<&F_,/0_W"__M<G_3"T
M/VPS7S4H:]I?=7/L6R>&UHG'F[5BQ8244]Z:MRKD,*/Z'(<>BVWGKMC48RL/
M?Z@58VC%V'H&:[" 4#G<FI7?,&4Y&FCDN%<C7RQZ51(T<FS1R.<&981=KJ^D
M0;KRJA@@0$:#P)PH(.!SVDQ3E1CEC!)UGA* !;&$Q;PRP&J7;GG7)2([!BPA
MMBR9&RQ4@ZRNGV&Z<BRU?9->'/KPH4_Y$  1L0&101E7,%&ND(?IRF$ B,AX
M("+*.7PS/;N%9+<!0<060:3-%C)%I.F=04IV#P!$K %DL(!=E,^4,59FR"!=
M.1; #^F%G_/S7O4#^"$V^#$H:]81U=VQ7X-0P \=#S]4P17/:V] *N2PIU\L
M4^ /M>4/-2U6*@]_:$U#@4/4FD,&"[A:TRCK:)BN' MPB/;BT%6OW?O:]KW5
M_GVW,B\W'#RNO#F#=.4P $-T/ S1-F&X3\BLF:,F,=EU0!&U15%EH#Y#:W*H
M4T1V#"!$K2%DL%"-L:9XC! R3N(H0(CV@M!?O8H'&$1M&&101B[2;R8,TY5_
M  ,&^>,QR%<P""L89):3G0<&^;8,\MMPF4UQ$T$F*=D]()!O32"#A: <:W41
M&72K/.DL(A\(Y/<BT.<^1>0#@7P; AF4LR[A:XMHF*X<1NUGY!%_1U;MM"EJ
MR"0FNPX$\FT)Y+?Q@G#3NTX9V35@D&_-((,%7HZRIGR,#/*-Y0,,\GLQZ/*R
M5_T A'P;"!F463E%56\D#-.5CS, A-AX$&)MN!!"*&FFJ$(NF 6,:*9*#"#$
M;"'$%"N<*6=-!PU2LGL (68-(8,%UK4,&J8KQP(08OV60;W600PHQ&PH9% .
M7$RU531,5PX#*,3&HQ!3X 5E"[2@F:1M.4(YIYIFSVI'FJS/-*G.*_FM,C=(
MR>X!BY@UBPP6JK'65-$@73D68!'KQ:+;VUY5!"QB-BPR*"//)9Z^C(8IRR?8
M@$;!>#0*%-MM/@H8:J2I0HYF8E2SHQ  C0);&@4JSK#FDL@D);L'- JL:62P
M\#;8ZD(:J"Q' SP*>O%HN>Q320'P*+#AD4$991/7F;:2!BK+@0"1@O&(%&@.
M>3471@HYDJV,&-6D*A IL"52H&*-U]P[-$G)[M4.VMJ?M#4<-<!=6W0#E>5H
M@$E!+R;=W?6J)&!28,,D@S)VBRT"Y0;W(%7Y)#+PB(_'(ZXXK-LJ(840"9"O
M*R$.,.*V,.)MS. IIDT'#5*R>P C;@TC@X5RG#%1I<@@53D2 !'O!:)/G_J4
M#P<0<1L0&929FY]ETM3/,%TY#, 0'P]#O(V7&6%>\S<8HYCL.D"(VT*(J_#2
M?-3#("0[!PCBU@@R6&!=<SF#;D8@@K1'[MW:<V<[$3\5C^,ESBIZV:?E<US'
M3X^/_)T7#[HU/I^C=XORP3TP4SY'>!G&3YM]XFS%8V;2F^8SD;A\-*]\DT:'
MXNFVARA-HUWQ\EF$:Q'G MGWCU&4OKW)+W!\0/+L?U!+ P04    "  \A)53
M<"*VSXL$  "Y%0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6RUF&M/
MXS@4AO^*5>T'D+;$EUQ1J=06$#."@B@S:&>U']+6;:-)XF[BTME_O\Z%N,2)
M"0-\:9/TG)/7YXV?N![L6?(SW5#*P:\HC-.SWH;S[:EAI(L-C?STA&UI+'Y9
ML23RN3A-UD:Z3:B_S).BT, 0VD;D!W%O.,BOW27# =OQ,(CI70+2713YR7]C
M&K+]60_UGB_<!^L-SRX8P\'67],9Y=^V=XDX,ZHJRR"B<1JP&"1T==8;H=,)
M(5E"'O$]H/OTX!AD0YDS]C,[^;(\Z\%,$0WI@F<E?/'U1"<T#+-*0L>_9=%>
M=<\L\?#XN?IE/G@QF+F?T@D+'X,EWYSUW!Y8TI6_"_D]VU_1<D!65F_!PC3_
M!/LBUK)[8+%+.8O*9*$@"N+BV_]5-N(@ ;4EX#(!UQ/,E@12)N2=,PIE^;#.
M?>X/!PG;@R2+%M6R@[PW>;8831!G-LYX(GX-1!X?/H[N[T?3AQD83<_!]';:
MO[BYN[[]Z^("W-X]?+F=SL#1.>5^$*8 '8,^^#8[!T=_' \,+FZ>E3 6Y8W&
MQ8UPRXT0!C<LYIL47,1+NGQ9P!"J*^GX6?H8:RO.Z/8$$/@GP!"C!D&3[NE0
M(X=4G21Y/;.EW@/COG#/3Q(_YB ,_'D0!CR@:5.OBE)V7BJ;:4]#DSC$%3J>
M#D>@AA''MFQ$JK@74LU*JJF5.A5X. I9FAZ#M9CI0$RGCKJ+NM:!H+[MF:[E
MUH0WQ!'3@X[;+-RJA%M:X3.:"&'@$?Q]0Z,Y3?[1^&97->V/\\U6QE6W3(UP
MB.7 YG$[E4;GDPQS7I%3B%:C$$*>1YQFV6XEV^UBUX\?7?SRJJ+>Q_GEO>J7
M&N%8T#2;!XZ@Q"K\),?*PB_FCN?:'JX);XC#EM<F_.!]@+IX-AYW\0QA619_
MG&ME+9UM#2&VA9P6,"()<:2G^#M\(Z\H*H6K87V$8<M,0Q+I2,_TY[G6R3;)
M6Z0'[MMLL]0.F([KU#N@AF4-\"!NZ8$D.=*C_!WFJ=CN8PLC9-7%-P1ZKD!J
MBW9)>*1'?.G?9-+)0$E@I$?PVPQTE<%YIF>C>@_4,"30XZ V R7:D9[M[S!0
MY7C?MET;*@8V!+H9\EM>T5@B'^N17SIX==7%02R!C/5 ?I.#9:T7U@AG:CUH
MB!)_^]H:(!F/]8S_??>P2G,3FG75:I!85%JNUZ);,A_KF5\:-QIU,DX2&>N)
M_#;CU!4S=FQ(ZH]O0QR"+L9M<P]+U&,]ZM_AG@KT/D&NB^OOOJ9 9%L$MJQ:
ML"0_UI._M/#RLI.%$LKXL];=6%U2UY<P#2&B;9X#[99N2.CC3NONKU\[=4/2
M&7\6G?'KZ_"&D+YM>E[+<TTDEDDG+%]?=VD&D5@F>BS_?C.(2E_E?[\:(E89
MT&YY,HA$--$CNFS&]TZ].-CY^*Q%,U%W.)1>J"'(M6RK_F 8!YM@$4W6^=Y@
M"A9L%_-B4ZFZ6NT_CO)=M]KU,3J=%+N(LDRQJ7GC)^L@3D%(5Z(D/'&$04FQ
M3UB<<+;-M]KFC',6Y8<;ZB]ID@6(WU>,\>>3[ ;5;NWP?U!+ P04    "  \
MA)53:&[5>8,$  "*%0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6RM
MF%M/XS@4Q[^*%>W#C+1#XN-<4:E4 H@9<:GHS*"=U3Z$UM!HDKCKN)3]]IL;
M<4IJ$[6\T%Q\+O;)^?F/1QO&?^=+2@5Z29,L/S&60JR.33.?+VD:Y4=L1;/B
MS2/C:22*6_YDYBM.HT5EE"8F6)9KIE&<&>-1]6S*QR.V%DF<T2E'^3I-(_[?
M*4W8YL3 QNN#N_AI*<H'YGBTBI[HC(H?JRDO[LS6RR).:9;'+$.</IX8$WP<
MVE9I4(WX&=--WKE&Y50>&/M=WGQ=G!A6F1%-Z%R4+J+BYYF&-$E*3T4>_S9.
MC39F:=B]?O5^44V^F,Q#E-.0)??Q0BQ/#-] "_H8K1-QQS:7M)F04_J;LR2O
M_J)-/=9Q#31?YX*EC7&101IG]6_TTBQ$QP"K#* Q@+<&ML* - :DFFB=636M
MLTA$XQ%G&\3+T86W\J):F\JZF$V<E66<"5Z\C0L[,;Z?W-U-;K[/T.3F#-W<
MWGPYOYY>W?YU?HYNI]^_WM[,T*<S*J(XR1%\1E_0C]D9^O3'YY$IBN"E"W/>
M!#JM X$B$ 9TS3*QS-%YMJ"+;0=FD76;.KRF?@I:CS.Z.D+$^A.!!7A'0N%P
M<TN3#FE7DE3^;(6_*6=S2A?YKJ6I+=W*LFRLYS&Q+0B"(NYS-^/^.&P1()X#
M[<"MW.PV-UN;VWW$>92)8NU?*)_'^=OUK[.L?3C=+ D. O]-DOUA 2;8MW:G
MZ+0I.MH49Y3'-$>_?J&_KVGZ0/D_FIJXK5-W[YJXO;4&S[$LQ32\-J+W 2OM
M]9:PP*XJM-^&]K6A7R.B*8_G=%?8VM[K?E[DR'-VAPW:L,&@P@VI&[8DEJQ]
M*Q<VIMMMX@?*!<0=&.+#JQ<V3KKE\R!01@<9'0XK8-@X&%A!+-&%]>QJ:AB&
M@XHHJ8/UV-&U7V/:+:+KDCX2=XVS;:Q<;<D;K ?.L$YMG#A;*PY>#XJ[QH'O
M@RI-23"L1]C[78W[)'/>9J<;LIV8!!W6DZ[Y9BXO!WTS$F)83S%MX_O]Q@]<
MWU-,11(,ZQ$VL.V#7HE=HOH.09(.]*1[O^L;!]VN)T>8* )+V($>=DT!)Y,A
M!01),=!33-?TC>E6 8EFUP5),- 3;%@W-TZVNM12[[P@20=ZTKW?I8V#@>@&
MB3$8I)LN+@9546(']E=.L$,ZN8Z/%2(5)%+@(\03]-63ZUNVKX@NR0.'ZB?H
M"RAR%&!%8(D?&*2@OGT;4D(BP4+VEU"D+Z$@<(AB*D0RA7R$@")] 178CJ()
MB20/.50_D;Y^4I.4=/[S&R2?KJX&%5!"A>PMGT+2ET6![;N*K9!(G) /4$4A
MZ:L=*,2;H@6)I XY4.R$C8/M"CJ!(K D#QDD9GX.*J D"ME?RY"^E@G #3Q'
ML2,0B1/R$6J&[% SGHU=6W'2(+%C'ZIG[+Z>V;45FIU3K93RI^JP+T=SMLY$
M?4K4/FT/%"?5,=J;YZ?X.*R/!:6;^I3R.N)/<9:CA#X6+JTB!P/Q^N"OOA%L
M59V=/3 A6%I=+FFTH+P<4+Q_9$R\WI0!VN/7\?]02P,$%     @ /(254RKY
M="J\!   =A<  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULM5C);N,X
M$/T5PIA#-S =B46M@6,@43*8!MH+["P8#.:@V'0LM!8W1<?IOQ]M$6514A3'
MN=A:JHJOR,=7)0[W$?L9;RCEZ"7PP_ABL.%\>ZXH\7)# S<^B[8T3-ZL(Q:X
M/+EE3TJ\9=1=94Z!KX"J&DK@>N%@-,R>S=AH&.VX[X5TQE"\"P*7_;ZB?K2_
M&.#!ZX.Y][3AZ0-E--RZ3W1!^=UVQI([I8RR\@(:QEX4(D;7%X-+?.X0(W7(
M+.X]NH\KURA-Y3&*?J8WWU<7 S5%1'VZY&D(-_E[I@[U_312@N-7$710CIDZ
M5J]?H_^5)9\D\^C&U(G\!V_%-Q<#:X!6=.WN?#Z/]G_3(B$]C;>,_#C[1?O<
M5C<&:+F+>104S@F"P OS?_>EF(B* VYS@,(!Z@Y:BP,I'$B6:(XL2^O:Y>YH
MR*(]8JEU$BV]R.8F\TZR\<)T&1><)6^]Q(^/'B[G\\O)[0)=3J[19#KY=C.>
M_9C^<W.#IK/;[]/) GVYIMSU_!B1K^@;NEM<HR]_?!TJ/!D\#:$LBX&N\H&@
M92 ,:!R%?!.CFW!%5X<!E 1U"1U>H5]!9\0%W9XAHOZ)0 7< ,CI[ZYVP"'E
M3)(LGM82[^;7SN._T8/+F!OR),T7RI9>7$\USRP/I6>ATIWVG,R/H5LF#)7G
M:@JRG6E;ADU*LP.H6@E5ZX0Z8]&2TE6,UBP*T+N YX&-"B#0+0R@UX#+=MC4
M+!.W(-=+Y'HG\@5E'HW1>(S^'=/@D;+_.E;.*(,:IULY0UH1RR :UFKYRV:V
M;NE6<_9F"=3\K'4SI?70# U47(,MFV'3 MMHQFV5N*VC)AC-F+>D37#S>&85
MQYEEU,"^870 U2ZAVGT(-IGT(1A6A<JJIZ-8$>M '8AEZO4]UF0'FJVW3 &N
MU 3\63PK(E<91#3;,$@=>X,=UBS+;L$. CN<F&M%P"J/X$RO*_%;5H=P1='
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MFS 0_14+]6%7V@8")+M=)4BY55VI26DNK?KHP"18:VQJ.R']^]J&4+I-HKZ
M9SSGS)FQQX.2BU>9 2ATRBF30R=3JGAV79EDD&/9X04PO;/C(L=*FV+ORD(
M3BTHIZ[O>7TWQX0YT<#Z8A$-^$%1PB 62![R'(M?8Z"\'#I=Y^Q8DGVFC,.-
M!@7>PPK4IHB%MMR&)24Y,$DX0P)V0V?4?9Z$)MX&?"-0RM8:F4JVG+\:XR4=
M.IX1!!0291BP_AUA I0:(BWC9\WI-"D-L+T^LW^TM>M:MEC"A-/O)%79T'ER
M4 H[?*!JR<M/4-?3,WP)I])^45G%]@(')0>I>%Z#M8*<L.J/3W4?6H!N_PK
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ML,M,OU8@3(#>WW&NSH9)T+Q_T6]02P,$%     @ /(254_>6VP$_ @  $P8
M !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULG571;MHP%/T5*]I#*[4D
M."1 %2)1V+0]=$*EW1ZF/9CD E;M.+--:??ULYT0I254:"_$US[GY!QCWR1[
M(9_4%D"C%\X*-?&V6I<WOJ^R+7"B>J*$PJRLA>1$FU)N?%5*(+DC<>;C((A]
M3FCAI8F;6\@T$3O-: $+B=2.<R)?;X&)_<3K>X>)>[K9:COAITE)-K $_5@N
MI*G\1B6G' I%18$DK"?>M'\SBRW> 7Y0V*O6&-DD*R&>;/$MGWB!-00,,FT5
MB'D\PPP8LT+&QI]:TVM>:8GM\4']B\MNLJR(@IE@/VFNMQ-OY*$<UF3']+W8
M?X4Z3V3U,L&4^T7["HL-.-LI+7A--@XX+:HG>:GWH47H#TX0<$W YQ+"FA"Z
MH)4S%VM.-$D3*?9(6K11LP.W-XYMTM#"_HM++<TJ-3R=+J8/G[\_+-'%'#2A
M3%VB:_2XG*.+3Y>)K\T++,S/:K';2@R?$%M"V4-A<(5P@/L=]-GY]. MW3>Q
MFFRXR8:=WN!4-J*AT*HK1T6,'=$>].<4#Z-1'"?^<]OO,2SLAP.,&]@;7V'C
M*SS'%_IU!WP%\O<'40>-Y.!_HU;$J)5AW \B'+Z+>@P;C>-P>")JU/B*/O0U
MS;(=WS'C+D>$"ZGI7V*O;Y?1Z,C!=1P.XFCXSFD'+AKA<11T6XT;J_$Y6WB%
M"M!=]N+SCLPQK//(^*TK:]OE'9$;6BC$8&V(06]H\LFJ!56%%J6[Q2NA34]P
MPZWIVB MP*ROA="'PC:&YCN0_@-02P,$%     @ /(254VD6'/,B @  +P8
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M9G68K>=/=P]/&W*S J2,&_) M::NM /RB3QO5N3FPR -T6[E!&'>8A<--KZ
M'<7D7DFL#+F3!13_ T(;8Q=H? IT$5\E;J >DB3Z2.(H'IT):/E^>70EG*2K
M6^)YR3OK-KC"''?,L6>.+S#G0FED?ZB_WZHD-4602')ET)P[@H8V]337K8=L
M8IO79G?HU^6,5]+W:D(->U=(@-[YSC)V[[W$YI"ZV:YYY_[.OIE?V*9N>O ?
MIGD1[JG>,6D(A](BH^'G24!TTV6-@:KV%W6KT%Y[/ZSLPP3:.=CU4BD\&6Z#
M[JG+_@)02P,$%     @ /(254V25@#]X P  -PP  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&ULE9=O;YLZ%,:_BH6NIDVZ*3;_V4TBK6FG3=K:JMFZ
MO77 2:P:S#5.T]Y/?VV@A,J&=F\:#,]Y^)V#[>/.CUS<UWM")'@L6%DOG+V4
MU4?7K;,]*7!]QBM2JB=;+@HLU5#LW+H2!.=-4,%<#\+(+3 MG>6\N7<CEG-^
MD(R6Y$: ^E 46#R=$\:/"P<YSS=NZ6XO]0UW.:_PCJR)_%G="#5R>Y><%J2L
M*2^!(-N%\PE]7*%0!S2*.TJ.]> :Z%0VG-_KP==\X4!-1!C)I+; ZN>!K AC
MVDEQ_-N9.OT[=>#P^MG]<Y.\2F:#:[+B[!?-Y7[A) [(R18?F+SEQR^D2Z@!
MS#BKF[_@V&I]WP'9H9:\Z((504'+]A<_=H48!*!@),#K KRW!OA=@-\DVI(U
M:5U@B9=SP8] :+5RTQ=-;9IHE0TM]6=<2Z&>4A4GEU^O5M??+\&/3[\OU^#]
M!9&8LOH#F(&?ZPOP_J\/<U>JMVBMFW6.YZVC-^*X)M49\.'?P(,>LH2OWAX.
M7X:[*K<^0:]/T&O\_#<D.&'G]W9^8Q>,V%U=?P,9%N))K: C%GEM*U!K$346
M>AT]+%$:)RF$*J&'82DL0C^ \5#X@C+H*8-)RF]$S6S *-Y01B4E5LK6(AR\
M/$ 0F9"FSH]\-,H8]HSA)./M.UQ4_UR 3)"<2AM@:+P8>9X%\'7="\"H!XPF
M =>29_<SO4?D(..%VCAKK+<>&VID(,1Q$IJHIB[TTO'O'?>H\23J"E=48D;_
M4ZA=76V4L5FH$ ;0Q+0)D] ?Y4QZSF22\PYGN-V]RQQPN2?"AIE8OF=D0MID
MX2ABVB.FDX@_N"JD;@1$J(D))'X$N*Z)M"ZAU%Q""8P\D]44^FGH!Z.T")[V
M;SB]C'2? GP+#FK%CY-V+D."F1\GEK):E2D:7T]HT&O0).MG^JA*VD(V4X"6
M$I<[NF'V':JS>X&"8DMYK<(H'4<^=0_D_>ET>-Y6GZS(GJUZ86)AMB@#F,!Q
MZ%./0J\T*77\,V>P%=<W9[#J H$%UU3._# ()^;PJ5NAZ79UA]FAVQ>8.E?B
M,B-66+,3S<9H+=)7:$]]"TTWKLLRI^4.G&,V"AH:?=T G)*T8.[@5*>/U-^Q
MV-&R!HQL50P\BY6%:$^I[4#RJCGH;;A4Q\;F<J].]D1H@7J^Y5P^#_39L?]?
M8?D_4$L#!!0    ( #R$E5.+2XY$X (  +\)   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;)66VV[B,!"&7\6*5(F5JIR!4@%2H53;BVY1V=.M228D
M6\=F;5/8MU_;"2F@8-H;8CO^O\SOP1X/MXR_BAQ HEU)J!@YN93K6\\320XE
M%BY; U5O,L9++%67KSRQYH!3(RJ)%_I^SRMQ09WQT(S-^7C(-I(4%.8<B4U9
M8OYO H1M1T[@[ =>BE4N]8 W'J[Q"A8@?ZSG7/6\AI(6)5!1,(HX9"/G+KB=
M!KX6F!D_"]B*@S;25I:,O>K.8SIR?!T1$$BD1F#U>(,I$*))*HZ_-=1IOJF%
MA^T]_<&85V:66,"4D5]%*O.1<^.@%#*\(?*%;;]";:BK>0DCPORB;34W&C@H
MV0C)REJL(B@+6CWQKEZ( T'0.R,(:T%X*HC/"*):$!FC563&UCV6>#SD;(NX
MGJUHNF'6QJB5FX+J-"XD5V\+I9/CQV_3YZ<9^G[W>[9 G7N0N" "!5^&GE1T
M/<=+:M*D(H5G2$&(GAB5N4 SFD)Z#/!46$ULX3ZV26@E+F#MHLB_1J$?!BT!
M33\N]RWA1,U21887?6"I++BXP<4&%Y_!/4 *'!/T@B6TK;9='0:N[U^U+<KG
M=4?A=YOPNQ\*GZOP49)CNFIU88=T C?J7[7]V:87A;%_*CSRT6M\]*RDA=0&
M)-X9)]>(JJ.392BK[2V!0E;(-FMV;NSVP];\V&5=-^C:TM-O;/6MG&>9 T<X
M_:..$'7J2M'FP([H^&Y_T)Z<"\+(#6-K<FX:%S=6TAS424U5^"@ML@PXT 1:
MG=@QOAM&K;FX)(M/4WCD8M"X&%@Y4[,[4$'1&R8;7)4OH@HH5G;:W-AQG3 Z
MFYA+RL =1-;,!/Y[X?"ML)E*B*G!S>9IK1EVB'_N%/N\KK+A'93"$OC*W! $
M2MB&RJKR-*/-+>3.U-Z3\8F^G9@2^XZIKC9/F*\**A"!3"'5)E%'%:]N"U5'
MLK4IN$LF5?DVS5S=L(#K">I]QIC<=_0'FCO;^#]02P,$%     @ /(254Y?$
M?'B_ P  * L  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULM59M;]LV
M$/XK!Z,;$J"U7OPF=[:!Q$FQ $L:Q.DV8-@'6CI;1"51):G8_O<[4K(JQ[8R
M;.@76R3O'CYWQWN9;(3\JF)$#=LTR=2T$VN=?W0<%<:8,M45.69TLA(R99J6
M<NVH7"*+K%*:.+[K#IV4\:PSF]B]1SF;B$(G/,-'":I(4R9WUYB(S;3C=?8;
M3WP=:[/AS"8Y6^,"]9?\4=+*J5$BGF*FN,A XFK:N?(^SCVK8"5^Y[A1C6\P
MIBR%^&H6=]&TXQI&F&"H#02COQ><8Y(8).+QK0+MU'<:Q>;W'OV3-9Z,63*%
M<Y'\P2,=3SM!!R)<L2+13V+S*U8&#0Q>*!)E?V%3RO:''0@+I45:*1.#E&?E
M/]M6CF@H!.X9!;]2\%\I>.=NZ%4*/6MHR<R:=<,TFTVDV( TTH1F/JQOK#99
MPS,3QH66=,I)3\_N'N:?[V_A^>K/VP5<W*!F/%'PP*1DQK^7\ &^+&[@XMWE
MQ-%TG]%RP@K[NL3VSV![/MR+3,<*;K,(HT, AXC6;/T]VVN_%7&!>1=Z[GOP
M7=\[06C^[]7=%CJ]VGD]B]<_@_<)(Y0L@8S2C1++N"Q;0R*4@I \N*,LVS 9
MJ5.N*Y&'%MGDVLO,&X^"L>L2L9>F22<$>WUWU!0\(-^OR?=;R=\JS2D-,/I/
M]$OL08-5/W"'_C']8\'>>$ &G*,_J.D/6NG?9:%($9[9%OZZQW2)\N^6B YK
MU&$KZA,J9#*,@64158,7*G,Y%2T-H<2(ZU.>&!['Q[CAR!'#(T>\ECM@/*H9
MC_X/X_>TIT+)<U,T3]%O1W^.$9Y^9FG^RTT%"+C-N40%42'-<]$DL>(JI#38
M$1% D^HFP<;=EG@$M77!#\NPX"@PHY%W*C+!460&WJ E-..:_+B5_+Q(B\26
M40ACEJT1> 9BDZ%4,<^!S DI4-0L3[%OA[YX^/S;Y:$+J"OL8(F0\)2;K*:[
M3&SH1=!C8-1+6LF(%:1"(JFP# ;N3R#"L)"*NI&.29#1@43\8$-,Q+F(VL+K
MN=_;C]MJR,,;@7WS_;Z!?Y7G4FQMH4MV\,X;=WUJHTEB1@BRV7B(7/G*DTM<
M&^^)ZJTWGWKCC5,WT;;P[%N*;W-PB;8PK8J$+BP!:'-' KW "K!#2H-1=]RD
M=$2GS<^--N_]N&H_K\ /BEQ@F]51CCB-621%N;8C&ETABDR78TF]6X^!5W;X
M<;Z+ES/D/9,4!P4)KDC5[8XH164YEI4++7([V2R%ICG)?L8TRJ(T G2^$D+O
M%^:">CB>_0-02P,$%     @ /(254T4U!>0_ @  B@4  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#8N>&ULC53;;N(P$/T5*]J'5MJ2Q($4JA")VVJK%1>5
M=O?9D(%$=>RL;4C[]VL[(4LIH+[$GO&<XS,3ST0E%Z\R!5#H+:=,]IU4J>+!
M=>4ZA9S(%B^ Z9,-%SE1VA1;5Q8"2&)!.76QYX5N3C+FQ)'U+40<\9VB&8.%
M0'*7YT2\#X'RLN_XSL'QE&U391QN'!5D"TM0+\5":,MM6)(L!R8SSI" 3=\9
M^ ^CCHFW ;\S*.71'IE,5IR_&N,QZ3N>$004ULHP$+WL8024&B(MXV_-Z317
M&N#Q_L#^P^:N<UD1"2-._V2)2OM.UT$);,B.JB=>_H0Z'RMPS:FT7U16L4'/
M0>N=5#ROP5I!GK%J)6]U'8X ?G@!@&L /@6T+P""&A#81"ME-JTQ422.!"^1
M,-&:S6QL;2Q:9Y,Q\Q>72NC33.-4O'R>CWZAT7RZF,R6@^?'^0S=C$&1C,I;
M=(=>EF-T\^TV<I6^RR#<=<T[K'CQ!5X?HREG*I5HPA)(/A*X6F2C%!^4#O%5
MQB44+11XWQ'VL']&T.CK<.^*G* I7&#Y@B\7[@IINR%M6]+V!=))7E#^#B#/
M%;R"AA9JFG,?^T'8[7CM,'+WQX4X$^CY/NZ%W2;P@[I.HZYS5=V,LSNXIK#S
M^6*,P[#GG0C\'-<-\7TO/)'G'CWK',36=KM$:[YCJGHWC;<9* /;1R?^H1XT
MU5SX3U--J2D1VXQ)1&&C*;W6O98FJLZO#,4+VSPKKG0KVFVJAR4($Z#/-YRK
M@V$N:,9O_ ]02P,$%     @ /(254^H$#WW7 @  /@H  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#<N>&ULK99O;YLP$,:_BH54:9,Z,) _I$HB-6FG55/;
MJ.FVURX<B16#F>TTR;>?;1*:=(1F7=^ ;?P\W,^'N.NON%C(.8!"ZXSE<N#,
ME2HN/$_&<\B(='D!N7Z2<I$1I:=BYLE" $FL*&->@'''RPC-G6'?KDW$L,^7
MBM$<)@+)9981L1D!XZN!XSN[A0<ZFRNSX W[!9G!%-2/8B+TS*M<$II!+BG/
MD8!TX%SZ%V,?&X'=\9/"2NZ-D4%YXGQA)C?)P,$F(F 0*V-!].T9QL"8<=)Q
M_-Z:.M4[C7!_O'/_:N$US!.1,.;L%TW4?.!$#DH@)4NF'OCJ&VR!VL8OYDS:
M*UJ5>\.N@^*E5#S;BG4$&<W+.UEO#V)/$+2."(*M(#A5$&X%H04M([-85T21
M85_P%1)FMW8S WLV5JUI:&[2.%5"/Z5:IX;3Q_OQ=S2^OYU<WTTO'V_N[]"G
M*U"$,HG\SWU/Z7>8G5Z\]1N5?L$1/S] MSQ7<XFN\P220P-/!U=%&.PB' 6-
MCE,H7!3B<Q3@P*\):'RZ'#>$$U8'%EJ_\.0#:S!M5:8M:]HZ8GJ]+O1G#0G2
M^8X7J! T!O3,&5&44;4Y-YFORT6S:P^[K>"L[LB:=5'7#3MG#5CM"JO]GUAD
M78?5[-KKND$]UALZ[ :-6)T*J]-H]$#EXDLJ !#-%0B0"@FBX&B6FMVP&[5K
M:=Z2=5X?P@%,MX+IOA.F/C?-;K[;J8=Y2Q9UFV"B"B8Z[8-C- 7$4\0+4RSD
MT=0TV_70!HB0*$)9^4]KH81L9!W?!Q@=$/<JXMY[B>OSUVSW5Z#14>(/,#H@
M]O%+R<*G,2?TF2:0)VA#@26UQ:K9";L8UWZN_ZXK6;R]2IR!F-D&1:*8+W-5
MEKQJM6J"+FWI?[4^,LV1K? O-F5G=4O$C.82,4BU)7:[^J\GRF:EG"A>V'K_
MQ)7N'NQPKAL\$&:#?IYRKG83\X*J91S^ 5!+ P04    "  \A)537])4UIL%
M   X'   &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R]6=MNXS80_17"
MZ$,";&5>1%T6CH'$F[;!-IL@V<VB*/J@V+0MK"XN12?9OR]UL6ZD:!L.^F)+
M\O#PS&C(F6-.7E/^(ULS)L!;'"79Q6@MQ.;C>)S-URP.,BO=L$3^LDQY' AY
MRU?C;,-9L"@&Q=$80^B,XR!,1M-)\>R>3R?I5D1APNXYR+9Q'/"?5RQ*7R]&
M:+1[\!"NUB)_,)Y.-L&*/3+Q;7//Y=VX1EF$,4NR,$T 9\N+T27Z."-V/J"P
M> K9:]:Z!KDKSVGZ([^Y65R,8,Z(16PN<HA ?KVP&8NB'$GR^+<"'=5SY@/;
MUSOTWPKGI3//0<9F:?0]7(CUQ<@;@05;!MM(/*2O?[#*(9KCS=,H*S[!:V4+
M1V"^S40:5X,E@SA,RN_@K0I$:P!V!@;@:@ ^= "I!I#"T9)9X=:G0 33"4]?
M <^M)5I^4<2F&"V]"9/\-3X*+G\-Y3@Q??QZ-_L,9G>W]]=?'B^_WMQ] 6>?
MF C"* /X'/P*OCU^ F>_G$_&0LZ6CQG/*^2K$AD/(",,;M-$K#-PG2S8H@LP
MEC1KKGC']0H;$1_9Q@($?@ 88J0A-#M\.#30(77H2(%G#^#=;44F@F01)BOP
M]RV+GQG_QP!KU["V$?;+-D<"Z1+<;?),ST!KH@_@BJW"))&7NC=2(M,".5_
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M,"YX;6RUEEMOVC 4Q[^*%>UADUIR@7"I  EHNU43+2I=^S#MP20'8C6QF>U
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MSF'=0$WG GF.YYX FORYNU.#TRRJUS1ZK0J]%[-*($2C#7"UZM%GCJE$:B8
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M#!'4;Q'4#!K(/&B\5U5(.BUDIC9\6=T]:"ZXD"LCK[4'7:O5#+R)H8JB9NI
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M5WK(V66F/T,@3(!^O^)<[39&H/FPQ;\!4$L#!!0    ( #R$E5.T,W.[M0(
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MK0VQ@[:E5)S58IV T;RZDK=Z(UH"[/<(<"W -G<%LBEG1)$D%OR(A%FMW<S
MEFK5.AS-S;^R4D(_I5JGDNG#8C%?+^Z7ZQ6Z7<[0]&&YGB^_WB^G\_L5NIJ!
M(C23R/\8NTKCC,C=UM9WE37NL5Y!<8T"[Q/"'O:?5S-T]>$?%U>';1+C)C&V
MMD%?8LX85?K%4!*1/$53GBN:[R'?4I!G_(/&/[#^@QY_G19W%5NI(JLR[_IK
M$GACS_-B][6#-FAH@TNTH(M6J<(V;3#JI84-+;Q$&W31PE-:..RE10TMND0+
MNVC1*2V*>FG#AC:\1(NZ:,,3&A[UUS9J:*.SM/4!=!/<*1!=S-$)TX\\W L=
M-]#Q>2A7)$.[4I4"3#.@K&0H ]V4$-]D=$],H^O*,S[=<1SUO[R^][=[>&<3
M?0<I$65%J2!%--?; 5(AW6WUL2&(^2[_*U]-:0?\[/N!UY^PU=_\RWO6R?1/
M/FCL!QV;XK:ZJSFI%D3L:2YU83NM]*Z'.K:HFG\U4;RP#7?#E6[?=GC0!R8(
MLT _WW&NWB>FAS='</('4$L#!!0    ( #R$E5/0MV!V#P<  #<@   9
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M/B6HTB]UW-7%'FH]P=6J/K3._:@*N97#N<BD2@VM7SWJ-61EL;*WI_Z/VR\
M60K]_5.-!)_:/V[O_UV*74;Q:K7#-:W?;6ZE^-3\<7OWS_N O@7]9"1.#1NW
M=^P.D5AF%,5(>&[50:/P1M"OTAO"'VDL4 A;A3,O!XJ&IP^]="+9/GDV;)A4
MCY!DN%./8^!:0'W?,B9?)OHEDC^W)_\!4$L#!!0    ( #R$E5.L,1+:CP(
M &X&   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;(U5;4_;,!#^*U:T
M#R!MY*T)!:61: L";0A&8=,^FN2:6#AV9CLMVZ^?[:19H"_B2^P[W_/XN4ON
MDJRY>)$E@$*O%65RXI1*U>>N*[,2*BQ/> U,GRRYJ+#2IBA<60O N055U T\
M+W8K3)B3)M9W+]*$-XH2!O<"R::JL/@S!<K7$\=W-HX'4I3*.-PTJ7$!"U!/
M];W0EMNSY*0")@EG2,!RXESXY[/8Q-N 'P36<K!')I-GSE^,<9-/',\( @J9
M,@Q8+RN8 :6&2,OXW7$Z_94&.-QOV*]L[CJ79RQAQNE/DJMRXHP=E,,2-U0]
M\/4U=/E$AB_C5-HG6K>QH\A!62,5KSJP5E 1UJ[XM:O# .#'>P!!!PC> T9[
M &$'"&VBK3*;UAPKG":"KY$PT9K-;&QM+%IG0YAYBPLE]"G1.)4N'N]F7Z_O
MOLTO'Q;H\OO3S>,O=#0'A0F5Q^@+>EK,T=&GX\15^C(#<;..>-H2!WN(_0#=
M<J9*B2Y9#OE; E>K[*4&&ZG3X"#C NH3%'J?4> %_@Y!LX_#O0-RPKYRH>4+
M/UZY ZRCGG5D64=[6"\JWC"E^P-3\A=RI$K!FZ+4*VBGQ!007R)98FWL>BDM
M>VS930>O4C\>1^'I6>*NAK7:C@OB*(B]J(][(S_JY4<'Y5]A(M *TV8@$S6U
M[E<B98-9!KM$MYS10(SW3NYVA'\:GT6>MUMNW,N-#\J]TV45B''V18]%@15A
M!2KTZ$-'E$NY\ZN//UC@[;CQ./2WZNL.6K<"4=B))E%FOH*V-7IO/S0O[*QX
MYY_J8=K.OO\T[22^Q:(@3"(*2TWIG9SJ,HIVNK6&XK4=$,]<Z7%CMZ7^(8 P
M ?I\R;G:&.:"_A>3_@-02P,$%     @ /(254ZD"2:7M P  F0X  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3@N>&ULK5==<Z,V%/TK&J8/NS.M07R3L3VS
M_DCLMNFF\:8[G4X?9)!M30"QDAQG_WTE(,0&&7MGFH<8Q#GGWGMT$=+P0-DS
MWV$LP&N6YGQD[(0H;DR3QSN<(3Z@!<[EDPUE&1+REFU-7C",DI*4I:9M6;Z9
M(9(;XV$Y]L#&0[H7*<GQ P-\GV6(?9_@E!Y&!C3>!A[)=B?4@#D>%FB+5U@\
M%0],WIF-2D(RG'-"<\#P9F1\@C=+6!)*Q%\$'_C1-5"EK"E]5C?+9&18*B.<
MXE@H"21_7O 4IZE2DGE\JT6-)J8B'E^_J=^6Q<MBUHCC*4V_DD3L1D9H@ 1O
MT#X5C_2PP'5!GM*+:<K+_^!083W+ /&>"YK59)E!1O+J%[W61AP1I(Z>8-<$
MNTUPSQ"<FN"T"<X9@EL3W&LC>#7!NY;@UP3_6D)0$X(VP3]#"&M">&V$J"9$
M93M4\U=._@P)-!XR>@!,H:6:NB@[J&3+.2>Y:O:58/(ID3PQ7GWY//UM\?GW
MV?QQ!>9_/BV__ T^S+! ).7@#\084LWX$?P"GE8S\.&GCT-3R+"*;,9UB$D5
MPCX3 H)[FHL=!_,\P8F&O[C MWL$3%EO4[3]5O3$[E7\=9\/@&/]#&S+AIJ$
MIOWT&8XE'99T2T.?]=/OT?<^]OP2F_4&O[U0.LI[Z7=7EPXCW53VTU>XZ#5^
M>3W=ZND#IVE^I]1SS^A-:9;)!5>^9/$SX#O$, >$\[VV2R>5EE=JJ6_(RQBZ
MEOH;FB_'S:/!61K<O(OS'<MKP^XT,,MW(N\4MNC"7,>V A@ZI\!E%^B$@6-!
M[SWPB9EN8Z;;:^8#HS'&"0<;1C-0[-<IB0'=;# C^5;G9R7G'R5B0XU-75CD
M>D&K_%L-RHJ\J.7E)=1)X5Y3N/<#A9.<"(+2:PSPN@9$VH[J J'C:X S#1#J
M6J^+"W2XVRXNU,#NNC"OU?$GQOJ-L7Z_L:<6@H*1&(,"L^I=U5E:"0;'EMH#
MWV[YV45!=^"W6FJN0=D#NZ5UVT5% RMH&70!=.).T+@3_$C;R64+Y=(>N@$'
M]=G.A<Z?H#-3KJ[C%EV<KUO#EET<M&'/U(=-<6%O<5^K$CC KYC%A.OW#6%W
MI?6B( S:66IP 81RU=,G&35)1KU)SMF69C@!_]SC;(W9OSU?)&B][\>L_^^;
MM*S%3BTX;S\\VA;""]V%"T02U4XR YHF &5TKVVJ12W5??];29A'V]0,LVUY
MQN$@5KK51[L9;<Y1G\K30VM\ F_NH&9\H<Y=Y;;X7;XZM,E=TY;D'*1X(T-9
M@T ZQJIS4'4C:%%NDM=4R"UW>;F39T?,%$ ^WU JWFY4@.8T.OX/4$L#!!0
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M&['^A1M#;<LW$URY7UB7<]L=#V:%TB+=@(V"E&7E/WW>)&(+$'9W *(-(/H
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
M[3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]
M9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIX
MT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T
M_C6"R0_L?@!02P,$%     @ /(254P4(#>C4!   \B@   \   !X;"]W;W)K
M8F]O:RYX;6S%FM]OHT80@/^5%2]-I;8VOWQWT?DD8J\3=/9" :=-7RIBK\_H
M,%A DO;^^BYPS@T.'O5E["<;L/#'[.Y\L[M\?,F+KX]Y_I7]LTNS<JQMJVI_
M/1B4JZW<Q>5O^5YFZLHF+W9QI0Z++X-R7\AX76ZEK';IP!@.1X-=G&3:IX^'
M>_G% ![DE5Q529ZID_6)^T2^E#^NUX?L.2F3QR1-JG_'6O,]E1K;)5FR2[[)
M]5@;:JS<YB]W>9%\R[,J3L-5D:?I6-/;"_>RJ)+5F]-A#1G%CV5SIHH?@UB!
MC+714-UPDQ1EU?RBN7^L&)^E^G%[]%3ELR2M9#&-*WE;Y$_[)/M2WT8]Q0 \
M1A.'PV<;Q.OB_X0QWVR2E9SFJZ>=S*HVCH5,:\"LW";[4F-9O)-C;9(_RZ)^
M'O4'[KI]MDI!@4@5UXFZ4+CK!H\0Q1-3+D(^93?.W!$3SL([SJ,0T!D(G7$9
M.G;EQX7, *2)0)KG@@PC)^(++A2@-V.>SP,G<@&DA4!:M)!=M##R)I_OO/F4
M!^%/C/^^!) V FE?)I(3)[QCLSF '"&0(UI(+[AUA/N7:EE/ *)W"-$[8J*V
MHWDB9(Z8LIDKU%!QQ2V@>X_0O2?N><O%P@D>FF[GW@IWYDX<$3%G,O&6HC,\
M/B"0'V@A_W""P*E[6QU X8E?^<*?>P^<JU&L(@MS]1!+UD-:3%\EP>@7Y@=U
MDT</#:T:O:Y?#Q4(B1J%6"F^&KJB8Q =4XA.[!!73+P%9Y'S)^\P8<;0B971
MY%^FN'R5[HXSB8YI0B?VQ&N_O^&"S]R(U5T.PF%ZT,G]L%BX4:N%NNLK7T0J
MSW&5[;IMB^E!)_9#P.=J $R9[]0C-%)I)70F37:&A)@N=&)?0/LWZ2-Z@&B8
M*W1B6<P<-V#WSGS)V8([X3)HBP"(AUE")]:$X!&;>V'(5/JMA^_"$ZHB=0(.
MRV5,$ :Q(,+E3:A:5,6,\?NCR!F8% QB*:!5P-\&Q$3G&\2R0.N +B;F#X/8
M'V@=P*X@)B83@U@FWRL!=J7FX*DL?X9<F$<,8H_ DJ 7#O.'0>R/M[5!+R(F
M$(-8(*B'N]T/DXE!/?-XZ[G>4&)&,8B-<D)X!TZXPH%YQ23VRDGQM: 0$[.,
M>5'+F! 3LXQY9LMT)YNPW#;1=2UBR^ R[$03LXQ);!D<TX*8F'1,8NG@F#;$
MQ/1C$NL'QQQ!3$Q!)K&"3I4^4UG%2=K)FYB"3&(%H9B=>M+$+&026^BU4/L>
M/JA'"_..1;W@=03&] X:YAKK/,M</]!$7!1QO>/40<0\8YUQZ:N_;3&]6,1Z
MZ:4[:F!TQX38*_U\KZT,,3&O6,1>Z9LO]#4U)A7K G.:_@;'G&*=8UWL!*71
MH<248IUC5G."TNQ08D:QB(V"45J0TL;T8E,OER&4:J!#3$PU-K%J>A?E#Z0,
MSA=L3#<V^6X]LBS0*79LS#LV^7X]A@FG-3:F'YM8/S@FG-;8Z)8]L7Y.;W<T
M'11B8@:RSV&@X[6@'DW:F(#L\V_,P'P$,3$#V9?9I#F@0DQ,0?:EEM9JS$XZ
M&F$.&EUN::T&A9B8@T;$#D(QN]'$'#1J'#0XO&.WEILDDVNA_J)4YU=QNO(+
M5G^T[PU8=KW?MWE*TXDZYV7S/%X?7MD[O&[XZ3]02P,$%     @ /(254W=+
M<84& @  \20  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W92VKC
M0!2%X:T8+2#E^U*2)LZH)YDVV8!PR@]B6T*EII/=MW$&]A$]Z$FH,Q(EH:L?
M!!^B]/0K'[IIWY_*;C^4Q<?Q<"JK9C=-PX^4RGJ7CUVYZX=\.E_9]..QF\[+
M<9N&;OW>;7/2Y;)-X^V,YOGI=N;B]7/(_S.QWVSVZ_RS7_\^YM/TC\'I3S^^
MEUW.4[-X[<9MGE9-^CA<3Y=T.<C=>7*S>'E;->/+FS2I=I!"D-8/,@BR^D$.
M05X_*" HZ@>U$-36#[J'H/OZ00\0]% _Z!&"'NL'R1)E7!(DS; FT%J0:R'P
M6A!L(1!;D&PA,%L0;2%06Y!M(7!;$&XAD%N0;B&P6Q!O(=!;46\ET%M1;R70
M6V<?VP1Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$
M>AOJ;01Z&^IM!'K;;+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-
M0&]'O9U ;T>]G4!O1[V=0&]'O9U ;Y]M=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW
M$^CMJ+<3Z!VH=Q#H':AW$.@=J'<0Z!VH=Q#H':AW$.@=LY^5!'H'ZAT$>@?J
M'01Z!^H=!'H'ZAT$>K>H=TN@=XMZMP1ZMZAW^YUZE^GSD,NUYVN-S_].JJ?S
MO?GZ^,ORZ^3LO5QP3K<5Y?DO4$L#!!0    ( #R$E5/_)Z=UXP$  &PD   3
M    6T-O;G1E;G1?5'EP97-=+GAM;,W:74_",!0&X+]"=FM8Z=?\B'"CWJH7
M_H&Z'61A6YNV(/Q[NP$F&B4:3'QO6*#M><]ZDN>*ZZ>MHS#:M$T7IMDB1G?%
M6"@7U)J06T==6IE;WYJ8OOH7YDRY-"_$Q&12L-)VD;HXCGV-;'9]2W.S:N+H
M;I-^#K7MIIFG)F2CF]W&/FN:&>>:NC0QK;-U5WU*&>\3\G1RV!,6M0MG:4/&
MODSH5[X/V)][6)/W=46C1^/CO6G3+K9I6(C;AD)^O,07/=KYO"ZILN6J34?R
MX#R9*BR(8MODNZ)GQY-CNF':??*3\X<RQP+3SD=O74@3\_3[N,-(^M-CEPJ1
MC_7Q5WQ/3*5/?C_JIUU1]</L=+VOUB^'>00V/$Z_XX\S?J__RSX$2!\2I \%
MTH<&Z:, Z>,<I(\+D#XN0?K@$Y1&4$3E**1R%%,Y"JH<156.PBI'<96CP,I1
M9!4HL@H4606*K )%5H$BJT"15:#(*E!D%2BR"A19)8JL$D56B2*K1)%5HL@J
M4625*+)*%%DEBJP215:%(JM"D56AR*I09%4HLBH4616*K I%5H4BJT*15:/(
MJE%DU2BR:A19-8JL&D56C2*K1I%5H\BJ460M4&0M4&0M_E/69VN7?QP_///6
MU-TAGPU_,IJ] 5!+ 0(4 Q0    ( #R$E5,'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ /(254X/2
MC,3M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ /(254YE<G",0!@  G"<  !,              ( !RP$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  \A)53=C?_3Y(%  #A
M%P  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ /(254TA[UDA@!@  &A@  !@              ("!U T
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #R$E5,+.PUE
MI0(  "H)   8              " @6H4  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    "  \A)53B>>#<JH$  "3$   &
M@(%%%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ /(25
M4T+B(_3!!P  S2<  !@              ("!)1P  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( #R$E5-S&C/ODPD  $,F   8
M      " @1PD  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M"  \A)53:.[R>BX$  "I"   &               @('E+0  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ /(254V.8^-ZT"0   !<  !@
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M970Q,BYX;6Q02P$"% ,4    "  \A)53.OZ]E*4'  !;$@  &0
M    @(&^6@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M #R$E5/^N!@1$0L  (0C   9              " @9IB  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ /(254T1<6#5L P  _0<  !D
M             ("!XFT  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    "  \A)53JJV]<? -  #U*@  &0              @(&%<0  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #R$E5,-,-AI?@0
M )\/   9              " @:Q_  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ /(254UY:W_8:!@  &Q$  !D              ("!
M880  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  \A)53
M:8-E>GD&  #1$0  &0              @(&RB@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #R$E5.BQP/CQ 0  +D+   9
M      " @6*1  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ /(254Y7 /'LP @  ^ 0  !D              ("!798  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  \A)53)<V:W?H'  "D%P
M&0              @('$F   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( #R$E5,50'F![@8  ,D4   9              " @?6@  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ /(254]UI3(^T
M @  F 4  !D              ("!&J@  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    "  \A)53$;O+K)4"  #G!0  &0
M@($%JP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #R$
ME5.F^D4CR ,  (<(   9              " @=&M  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ /(254T6M+<)A!0  L@X  !D
M         ("!T+$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    "  \A)53?I]8,0P#  "F!P  &0              @(%HMP  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #R$E5/6983[90(  "(%
M   9              " @:NZ  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ /(254QE%AY&P @  F@4  !D              ("!1[T
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  \A)53+S(&
M@I0#  #7"   &0              @($NP   >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( #R$E5,HQL6<4@(  "\%   9
M  " @?G#  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M/(254UFY.V/$!P  +#D  !D              ("!@L8  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    "  \A)53<"*VSXL$  "Y%0  &0
M            @(%]S@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( #R$E5-H;M5Y@P0  (H5   9              " @3_3  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ /(254RKY="J\!
M=A<  !D              ("!^=<  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    "  \A)53T]52$?<&   Q(@  &0              @('L
MW   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( #R$E5-Z
MN$N2R (  +$'   9              " @1KD  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ /(254_WMZGDT @  "P4  !D
M     ("!&><  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #R$E5.+2XY$X (  +\)   9              "
M@5GT  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ /(25
M4Y?$?'B_ P  * L  !D              ("!</<  'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    "  \A)53134%Y#\"  "*!0  &0
M        @(%F^P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( #R$E5/J! ]]UP(  #X*   9              " @=S]  !X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ /(254U_25-:;!0  .!P
M !D              ("!Z@ ! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    "  \A)53_.?TK?T"   D"0  &0              @(&\!@$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( #R$E5,8)ICO
M[0(  #4)   9              " @? ) 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ /(254[I&-A80!@  AAH  !D
M ("!% T! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  \
MA)53U<DL09P"  #D!@  &0              @(%;$P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( #R$E5.T,W.[M0(  +<'   9
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M970U-RYX;6Q02P$"% ,4    "  \A)53J0))I>T#  "9#@  &0
M    @($N*@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M #R$E5-C\H6DM (  (,'   9              " @5(N 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ /(254P1O/Y4T P  MPD  !D
M             ("!/3$! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    "  \A)53L+),H(D#   O#   &0              @(&H- $ >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( #R$E5.JZB3MB0(
M +H&   9              " @6@X 0!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ /(254SP;5<$$ P  +1    T              ( !
M*#L! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  \A)53EXJ[',     3 @
M"P              @ %7/@$ 7W)E;',O+G)E;'-02P$"% ,4    "  \A)53
M!0@-Z-0$  #R*   #P              @ % /P$ >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ /(254W=+<84& @  \20  !H              ( !040!
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ /(254_\G
MIW7C 0  ;"0  !,              ( !?T8! %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&     $8 1@ A$P  DT@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>201</ContextCount>
  <ElementCount>484</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - OPERATIONS AND FINANCING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/OperationsAndFinancing</Role>
      <ShortName>OPERATIONS AND FINANCING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonEmployeeOptions</Role>
      <ShortName>WARRANTS AND NON-EMPLOYEE OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PlantPropertyAndEquipment</Role>
      <ShortName>PLANT, PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PATENTS</Role>
      <ShortName>PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - STOCK COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockCompensation</Role>
      <ShortName>STOCK COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - EMPLOYEE BENEFIT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EmployeeBenefitPlan</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShare</Role>
      <ShortName>NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables</Role>
      <ShortName>WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonEmployeeOptions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - PLANT, PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PlantPropertyAndEquipmentTables</Role>
      <ShortName>PLANT, PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PlantPropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsTables</Role>
      <ShortName>PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PATENTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - STOCK COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockCompensationTables</Role>
      <ShortName>STOCK COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/StockCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1</Role>
      <ShortName>WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2</Role>
      <ShortName>WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3</Role>
      <ShortName>WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative</Role>
      <ShortName>WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000040 - Disclosure - PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails</Role>
      <ShortName>PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000041 - Disclosure - PATENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails1</Role>
      <ShortName>PATENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000042 - Disclosure - PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetailsNarrative</Role>
      <ShortName>PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000043 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000044 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000045 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000046 - Disclosure - STOCK COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockCompensationDetails</Role>
      <ShortName>STOCK COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>000047 - Disclosure - STOCK COMPENSATION (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockCompensationDetails1</Role>
      <ShortName>STOCK COMPENSATION (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>000048 - Disclosure - STOCK COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockCompensationDetails2</Role>
      <ShortName>STOCK COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>000049 - Disclosure - STOCK COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockCompensationDetails3</Role>
      <ShortName>STOCK COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>000050 - Disclosure - STOCK COMPENSATION (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockCompensationDetails4</Role>
      <ShortName>STOCK COMPENSATION (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockCompensationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>000051 - Disclosure - STOCK COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockCompensationDetailsNarrative</Role>
      <ShortName>STOCK COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>000052 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EmployeeBenefitPlanDetailNarrative</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN (Detail Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>000056 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>000057 - Disclosure - STOCKHOLDERS EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>000058 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>000059 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>000060 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>000061 - Disclosure - NET LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareDetails</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>000062 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareDetails1</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="cvm_10k.htm">cvm_10k.htm</File>
    <File>cvm-20210930.xsd</File>
    <File>cvm-20210930_cal.xml</File>
    <File>cvm-20210930_def.xml</File>
    <File>cvm-20210930_lab.xml</File>
    <File>cvm-20210930_pre.xml</File>
    <File>cvm_ex231.htm</File>
    <File>cvm_ex31.htm</File>
    <File>cvm_ex32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvm_10kimg1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cvm_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 201,
   "dts": {
    "calculationLink": {
     "local": [
      "cvm-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvm-20210930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cvm_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cvm-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 532,
   "entityCount": 1,
   "hidden": {
    "http://cvm.com/20210930": 25,
    "http://fasb.org/us-gaap/2020-01-31": 33,
    "http://xbrl.sec.gov/dei/2020-01-31": 7,
    "total": 65
   },
   "keyCustom": 144,
   "keyStandard": 340,
   "memberCustom": 52,
   "memberStandard": 7,
   "nsprefix": "cvm",
   "nsuri": "http://cvm.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "role": "http://cvm.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:WarrantsAndNonEmployeeOptionstextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000010 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS",
     "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptions",
     "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:WarrantsAndNonEmployeeOptionstextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT",
     "role": "http://cvm.com/role/PlantPropertyAndEquipment",
     "shortName": "PLANT, PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000012 - Disclosure - PATENTS",
     "role": "http://cvm.com/role/PATENTS",
     "shortName": "PATENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000013 - Disclosure - INCOME TAXES",
     "role": "http://cvm.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000014 - Disclosure - STOCK COMPENSATION",
     "role": "http://cvm.com/role/StockCompensation",
     "shortName": "STOCK COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000015 - Disclosure - EMPLOYEE BENEFIT PLAN",
     "role": "http://cvm.com/role/EmployeeBenefitPlan",
     "shortName": "EMPLOYEE BENEFIT PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://cvm.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000017 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://cvm.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000018 - Disclosure - STOCKHOLDERS EQUITY",
     "role": "http://cvm.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000019 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://cvm.com/role/FairValueMeasurements",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000002 - Statement - CONDENSED BALANCE SHEETS",
     "role": "http://cvm.com/role/CondensedBalanceSheets",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000020 - Disclosure - NET LOSS PER COMMON SHARE",
     "role": "http://cvm.com/role/NetLossPerCommonShare",
     "shortName": "NET LOSS PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000021 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://cvm.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "cvm:WarrantsAndNonEmployeeOptionstextblock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000023 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)",
     "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables",
     "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "cvm:WarrantsAndNonEmployeeOptionstextblock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000024 - Disclosure - PLANT, PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://cvm.com/role/PlantPropertyAndEquipmentTables",
     "shortName": "PLANT, PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000025 - Disclosure - PATENTS (Tables)",
     "role": "http://cvm.com/role/PatentsTables",
     "shortName": "PATENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000026 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://cvm.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000027 - Disclosure - STOCK COMPENSATION (Tables)",
     "role": "http://cvm.com/role/StockCompensationTables",
     "shortName": "STOCK COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://cvm.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000029 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "role": "http://cvm.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://cvm.com/role/FairValueMeasurementsTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000031 - Disclosure - NET LOSS PER COMMON SHARE (Tables)",
     "role": "http://cvm.com/role/NetLossPerCommonShareTables",
     "shortName": "NET LOSS PER COMMON SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock",
       "cvm:WarrantsAndNonEmployeeOptionstextblock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30_cvm_ConsultantsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:Issuedate2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)",
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock",
       "cvm:WarrantsAndNonEmployeeOptionstextblock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30_cvm_ConsultantsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:Issuedate2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000034 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)",
     "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
     "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000035 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)",
     "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
     "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:EquityWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000036 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)",
     "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
     "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:EquityWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanInterestCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000037 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)",
     "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
     "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanInterestCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FixturesAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "role": "http://cvm.com/role/PropertyAndEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FixturesAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "role": "http://cvm.com/role/PropertyAndEquipmentDetailsNarrative",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedPatentsGross",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000040 - Disclosure - PATENTS (Details)",
     "role": "http://cvm.com/role/PatentsDetails",
     "shortName": "PATENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_PatentsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedPatentsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000041 - Disclosure - PATENTS (Details 1)",
     "role": "http://cvm.com/role/PatentsDetails1",
     "shortName": "PATENTS (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000042 - Disclosure - PATENTS (Details Narrative)",
     "role": "http://cvm.com/role/PatentsDetailsNarrative",
     "shortName": "PATENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000043 - Disclosure - INCOME TAXES (Details)",
     "role": "http://cvm.com/role/IncomeTaxesDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "cvm:LeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000044 - Disclosure - INCOME TAXES (Details 1)",
     "role": "http://cvm.com/role/IncomeTaxesDetails1",
     "shortName": "INCOME TAXES (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000045 - Disclosure - INCOME TAXES (Details Narrative)",
     "role": "http://cvm.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2020-09-30_cvm_IncomeTaxMember",
      "decimals": "-5",
      "lang": null,
      "name": "cvm:ResearchAndDevelopmentCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000046 - Disclosure - STOCK COMPENSATION (Details)",
     "role": "http://cvm.com/role/StockCompensationDetails",
     "shortName": "STOCK COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfFairValueOfEachOptionGrantedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000047 - Disclosure - STOCK COMPENSATION (Details 1)",
     "role": "http://cvm.com/role/StockCompensationDetails1",
     "shortName": "STOCK COMPENSATION (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfFairValueOfEachOptionGrantedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2020-09-30_cvm_OutstandingMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000048 - Disclosure - STOCK COMPENSATION (Details 2)",
     "role": "http://cvm.com/role/StockCompensationDetails2",
     "shortName": "STOCK COMPENSATION (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2019-09-30_cvm_OutstandingMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfNonVestedOptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:NumberOfUnvestedOptionsBeginning",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000049 - Disclosure - STOCK COMPENSATION (Details 3)",
     "role": "http://cvm.com/role/StockCompensationDetails3",
     "shortName": "STOCK COMPENSATION (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfNonVestedOptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:NumberOfUnvestedOptionsBeginning",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://cvm.com/role/StatementsOfStockholdersEquity",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfNonVestedOptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvm:WeightedAverageGrantDateFairValueBeginning",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000050 - Disclosure - STOCK COMPENSATION (Details 4)",
     "role": "http://cvm.com/role/StockCompensationDetails4",
     "shortName": "STOCK COMPENSATION (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember",
      "decimals": "0",
      "lang": null,
      "name": "cvm:NumberOfUnvestedSharesBeginning",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000051 - Disclosure - STOCK COMPENSATION (Details Narrative)",
     "role": "http://cvm.com/role/StockCompensationDetailsNarrative",
     "shortName": "STOCK COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30_cvm_StockCompensationPlansMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000052 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)",
     "role": "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative",
     "shortName": "EMPLOYEE BENEFIT PLAN (Detail Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:NumberOfRestrictedSharesPurchasedByRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000056 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )",
     "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:NumberOfRestrictedSharesPurchasedByRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:AmountRealizedThroughTheResaleOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000057 - Disclosure - STOCKHOLDERS EQUITY (Details)",
     "role": "http://cvm.com/role/StockholdersEquityDetails",
     "shortName": "STOCKHOLDERS EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:AmountRealizedThroughTheResaleOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000058 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "cvm:ProceedsFromPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000059 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "role": "http://cvm.com/role/FairValueMeasurementsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000060 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)",
     "role": "http://cvm.com/role/FairValueMeasurementsDetailsNarrative",
     "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000061 - Disclosure - NET LOSS PER COMMON SHARE (Details)",
     "role": "http://cvm.com/role/NetLossPerCommonShareDetails",
     "shortName": "NET LOSS PER COMMON SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiestabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000062 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)",
     "role": "http://cvm.com/role/NetLossPerCommonShareDetails1",
     "shortName": "NET LOSS PER COMMON SHARE (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiestabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000007 - Disclosure - ORGANIZATION",
     "role": "http://cvm.com/role/ORGANIZATION",
     "shortName": "ORGANIZATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000008 - Disclosure - OPERATIONS AND FINANCING",
     "role": "http://cvm.com/role/OperationsAndFinancing",
     "shortName": "OPERATIONS AND FINANCING",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10k.htm",
      "contextRef": "From2020-10-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "cvm_AccruedConsultingServicesToBePaidWithCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued consulting services to be paid with common stock"
       }
      }
     },
     "localname": "AccruedConsultingServicesToBePaidWithCommonStock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_AdditionalClinicalTrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional clinical trial"
       }
      }
     },
     "localname": "AdditionalClinicalTrial",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_AdoptionOfAsc842Leases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption of ASC 842, Leases"
       }
      }
     },
     "localname": "AdoptionOfAsc842Leases",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_AggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Outstanding, Beginning"
       }
      }
     },
     "localname": "AggregateIntrinsicValue",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_AggregateIntrinsicValueOutstandingEnding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are",
        "label": "Aggregate Intrinsic Value Outstanding, Ending"
       }
      }
     },
     "localname": "AggregateIntrinsicValueOutstandingEnding",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_AmountRealizedThroughTheResaleOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan.",
        "label": "Amount realized through the resale of shares"
       }
      }
     },
     "localname": "AmountRealizedThroughTheResaleOfShares",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_BalanceOfTheFinanceLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance of the finance lease liability"
       }
      }
     },
     "localname": "BalanceOfTheFinanceLeaseLiability",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalizable patent costs included in accrued expenses and accounts payable"
       }
      }
     },
     "localname": "CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CashPaidRelatedToFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid related to finance leases"
       }
      }
     },
     "localname": "CashPaidRelatedToFinanceLeases",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CashPaidRelatedToFinanceLeasesInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid related to finance leases interest"
       }
      }
     },
     "localname": "CashPaidRelatedToFinanceLeasesInterest",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ChangesToRightOfUseAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes to right of use assets and liabilities"
       }
      }
     },
     "localname": "ChangesToRightOfUseAssetsAndLiabilities",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ClinicalServiceTrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical service trial"
       }
      }
     },
     "localname": "ClinicalServiceTrial",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CommonStockContributedToEmployeeBenefitPlan": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock contributed to 401(k) plan"
       }
      }
     },
     "localname": "CommonStockContributedToEmployeeBenefitPlan",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CommonStockIssuedForServiceShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Common stock issued for service, shares"
       }
      }
     },
     "localname": "CommonStockIssuedForServiceShares",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_ConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "verboseLabel": "Consultants [Member]"
       }
      }
     },
     "localname": "ConsultantsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_CostIncurredInitial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost incurred, initial"
       }
      }
     },
     "localname": "CostIncurredInitial",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CumulativeChangeInOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative change in ownership percentage"
       }
      }
     },
     "localname": "CumulativeChangeInOwnershipPercentage",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "cvm_CurrentBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current balance"
       }
      }
     },
     "localname": "CurrentBalance",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized R&amp;D"
       }
      }
     },
     "localname": "DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_EquityWarrantsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercise Price"
       }
      }
     },
     "localname": "EquityWarrantsExercisePrice",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_EquityWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercised"
       }
      }
     },
     "localname": "EquityWarrantsExercised",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_ErgomedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed [Member]",
        "verboseLabel": "Ergomed [Member]"
       }
      }
     },
     "localname": "ErgomedMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_EstimatedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated cost"
       }
      }
     },
     "localname": "EstimatedCost",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ExercisableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable [Member]"
       }
      }
     },
     "localname": "ExercisableMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_ExercisePriceWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Exercise Price]",
        "verboseLabel": "Exercise Price"
       }
      }
     },
     "localname": "ExercisePriceWarrants",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_ExpectedLifeOfOptionsMax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options, max"
       }
      }
     },
     "localname": "ExpectedLifeOfOptionsMax",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_ExpectedLifeOfOptionsMin1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options, min"
       }
      }
     },
     "localname": "ExpectedLifeOfOptionsMin1",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_ExpenseLifeOverNext": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense life over next"
       }
      }
     },
     "localname": "ExpenseLifeOverNext",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_ExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "localname": "ExpirationDate1",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvm_ExpirationDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration date description",
        "verboseLabel": "Expiration date description"
       }
      }
     },
     "localname": "ExpirationDateDescription",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "cvm_FairValueInputsLevelThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Inputs Level 3 (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevelThreeMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net realized and unrealized derivative loss"
       }
      }
     },
     "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants liabilities on date of exercise"
       }
      }
     },
     "localname": "FairValueOfWarrantsLiabilitiesOnDateOfExercise",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FairValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value per share"
       }
      }
     },
     "localname": "FairValuePerShare",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_FinanceLeaseObligationIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation included in accounts payable"
       }
      }
     },
     "localname": "FinanceLeaseObligationIncludedInAccountsPayable",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FinanceLeaseObligationsNetOfCurrentPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligations, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseObligationsNetOfCurrentPortion",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FinancingCostsIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs included in accounts payable"
       }
      }
     },
     "localname": "FinancingCostsIncludedInAccountsPayable",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FinancingLeaseContractualArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing arrangement"
       }
      }
     },
     "localname": "FinancingLeaseContractualArrangement",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FixedAssetsAndIntangibles": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets and intangibles"
       }
      }
     },
     "localname": "FixedAssetsAndIntangibles",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ForfeitedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited options"
       }
      }
     },
     "localname": "ForfeitedOptions",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_GrantDateFairValueRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant date fair value remaining"
       }
      }
     },
     "localname": "GrantDateFairValueRemaining",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_GrantIncomePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Income"
       }
      }
     },
     "localname": "GrantIncomePolicyTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_GrantedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted options"
       }
      }
     },
     "localname": "GrantedOptions",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_IncentiveStockBonusPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Bonus Plan [Member]"
       }
      }
     },
     "localname": "IncentiveStockBonusPlanMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_IncentiveStockOptionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Option Plans [Member]"
       }
      }
     },
     "localname": "IncentiveStockOptionPlansMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_IncomeTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax [Member]"
       }
      }
     },
     "localname": "IncomeTaxMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in right of use of assets and liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental shares underlying dilutive \"in the money\" warrants"
       }
      }
     },
     "localname": "IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_IssuanceOfRestrictedStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted stock"
       }
      }
     },
     "localname": "IssuanceOfRestrictedStock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_Issuedate2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date"
       }
      }
     },
     "localname": "Issuedate2",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvm_LandlordMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Landlord [Member]"
       }
      }
     },
     "localname": "LandlordMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_LeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_LeaseLiabilitiesCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "LeaseLiabilitiesCurrentPortion",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_LeasesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesPolicyTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_LesseeOperatingLeaseLiabilityPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Total future minimum lease obligation]",
        "verboseLabel": "Total future minimum lease obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPayments",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_LossOnDerivativesInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an",
        "label": "[Loss on derivative instruments]",
        "verboseLabel": "Loss on derivative instruments"
       }
      }
     },
     "localname": "LossOnDerivativesInstruments",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_MaturityYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Maturity years"
       }
      }
     },
     "localname": "MaturityYears",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_ModificationOfWarrant": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Modification of warrants 1]",
        "verboseLabel": "Modification of warrants"
       }
      }
     },
     "localname": "ModificationOfWarrant",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ModificationOfWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants"
       }
      }
     },
     "localname": "ModificationOfWarrants",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ModificationOfWarrantsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Modification of warrants]",
        "verboseLabel": "Modification of warrants"
       }
      }
     },
     "localname": "ModificationOfWarrantsAmount",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net book value of the finance lease right of use asset"
       }
      }
     },
     "localname": "NetBookValueOfTheFinanceLeaseRightOfUseAsset",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetBookValueOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net book value operating lease right of use assets"
       }
      }
     },
     "localname": "NetBookValueOperatingLeaseRightOfUseAssets",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Net deferred tax asset"
       }
      }
     },
     "localname": "NetDeferredTaxAsset",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetLossGainOnWarrantLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Net (loss) gain on warrant liabilities"
       }
      }
     },
     "localname": "NetLossGainOnWarrantLiabilities",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetOfDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of discount"
       }
      }
     },
     "localname": "NetOfDiscount",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetPresentValueOfLeaseFinancingObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "[Net present value of lease financing obligation]",
        "negatedLabel": "Net present value of lease financing obligation"
       }
      }
     },
     "localname": "NetPresentValueOfLeaseFinancingObligation",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetPurchasesOfUSTreasuryBills": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Net purchases of U.S. Treasury Bills]",
        "negatedLabel": "Net purchases of U.S. Treasury Bills"
       }
      }
     },
     "localname": "NetPurchasesOfUSTreasuryBills",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NonQualifiedStockOptionsPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Qualified Stock Options Plans [Member]"
       }
      }
     },
     "localname": "NonQualifiedStockOptionsPlansMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_NumberOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Expired"
       }
      }
     },
     "localname": "NumberOfOptions",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_NumberOfOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Exercised"
       }
      }
     },
     "localname": "NumberOfOptionsExercised",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_NumberOfOptionsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Number of Options Vested]",
        "periodStartLabel": "Number of Options Vested"
       }
      }
     },
     "localname": "NumberOfOptionsVested",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_NumberOfRestrictedSharesPurchasedByRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Common shares"
       }
      }
     },
     "localname": "NumberOfRestrictedSharesPurchasedByRelatedParty",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_NumberOfUnvestedOptionsBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of unvested options, Beginning"
       }
      }
     },
     "localname": "NumberOfUnvestedOptionsBeginning",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_NumberOfUnvestedOptionsEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of unvested options, Ending"
       }
      }
     },
     "localname": "NumberOfUnvestedOptionsEnding",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_NumberOfUnvestedSharesBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of unvested shares, Beginning"
       }
      }
     },
     "localname": "NumberOfUnvestedSharesBeginning",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_NumberOfUnvestedSharesEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of unvested shares, Ending"
       }
      }
     },
     "localname": "NumberOfUnvestedSharesEnding",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_OctoberOneTwothousandNineTeenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 1, 2019 [Member]"
       }
      }
     },
     "localname": "OctoberOneTwothousandNineTeenMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_OfficerAndDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer and Director [Member]"
       }
      }
     },
     "localname": "OfficerAndDirectorMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_OperatingLeaseMaturityYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease maturity years"
       }
      }
     },
     "localname": "OperatingLeaseMaturityYears",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_OptionExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option expiration date"
       }
      }
     },
     "localname": "OptionExpirationDate",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "cvm_OptionIssuedToRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued to related party"
       }
      }
     },
     "localname": "OptionIssuedToRelatedParty",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_OptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants"
       }
      }
     },
     "localname": "OptionsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_OutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding [Member]"
       }
      }
     },
     "localname": "OutstandingMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_ParticipantCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Participant compensation"
       }
      }
     },
     "localname": "ParticipantCompensation",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "cvm_PerformanceBasedStockOptionsSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance based stock options shares granted"
       }
      }
     },
     "localname": "PerformanceBasedStockOptionsSharesGranted",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_PrepaidAmountOfResold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid of resold amount"
       }
      }
     },
     "localname": "PrepaidAmountOfResold",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid consulting services paid with issuance of common stock"
       }
      }
     },
     "localname": "PrepaidConsultingServicesPaidWithIssuanceOfCommonStock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_PrepaidExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Prepaid expenses]",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenses",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ProceedFromIssuanceOrSaleOfEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from issuance of warrant"
       }
      }
     },
     "localname": "ProceedFromIssuanceOrSaleOfEquity",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ProceedsFromEquityWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Equity Warrants Exercised"
       }
      }
     },
     "localname": "ProceedsFromEquityWarrantsExercised",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from landlord funding of leasehold improvements"
       }
      }
     },
     "localname": "ProceedsFromLandlordFundingOfLeaseholdImprovements",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ProceedsFromPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from public offering"
       }
      }
     },
     "localname": "ProceedsFromPublicOffering",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Common shares, amount"
       }
      }
     },
     "localname": "ProceedsFromRestrictedSharesPurchasedByRelatedParty",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ProceedsFromTheSaleOfCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, shares"
       }
      }
     },
     "localname": "ProceedsFromTheSaleOfCommonStockShares",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment included in accrued expenses and accounts payable"
       }
      }
     },
     "localname": "PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_RemainingCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining compensation expense"
       }
      }
     },
     "localname": "RemainingCompensationExpense",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_RemainingOutstandingFairValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant date fair value remaining outstanding"
       }
      }
     },
     "localname": "RemainingOutstandingFairValueOfShares",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ResearchAndDevelopmentCredit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCredit",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ResearchAndDevelopmentCreditDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit, description"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCreditDescription",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "cvm_RestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockAwardsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_RestrictedStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStocksMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_RightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets"
       }
      }
     },
     "localname": "RightOfUseAssets",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntiDilutiveSecuritiestabletextblock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of the Company's deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity warrants were exercised"
       }
      }
     },
     "localname": "ScheduleOfEquityWarrantsWereExercisedTableTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expenses for options issued or vested and restricted stock awarded"
       }
      }
     },
     "localname": "ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of each option granted"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfEachOptionGrantedTableTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of federal or state current or deferred tax expense or benefit"
       }
      }
     },
     "localname": "ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of (losses)/gains on the warrant liabilities"
       }
      }
     },
     "localname": "ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non-qualified and incentive stock option plans"
       }
      }
     },
     "localname": "ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfNonVestedOptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non-vested options"
       }
      }
     },
     "localname": "ScheduleOfNonVestedOptionsTableTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of other non-operating gains (losses)"
       }
      }
     },
     "localname": "ScheduleOfOtherNonOperatingGainsLossesTableTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of restricted common stock issued from the incentive stock bonus plan"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants and non-employee options"
       }
      }
     },
     "localname": "ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants recorded as liabilities were exercised"
       }
      }
     },
     "localname": "ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of shares upon issuance"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-operating gain (loss)"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_SeriesAAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series AA [Member]"
       }
      }
     },
     "localname": "SeriesAAMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesBBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series BB [Member]"
       }
      }
     },
     "localname": "SeriesBBMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesCCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CC [Member]"
       }
      }
     },
     "localname": "SeriesCCMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesFFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series FF [Member]"
       }
      }
     },
     "localname": "SeriesFFMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesHHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series HH [Member]"
       }
      }
     },
     "localname": "SeriesHHMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesJJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series JJ [Member]"
       }
      }
     },
     "localname": "SeriesJJMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesLLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series LL [Member]"
       }
      }
     },
     "localname": "SeriesLLMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesMMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM [Member]"
       }
      }
     },
     "localname": "SeriesMMMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesNAndXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N and Series X [Member]"
       }
      }
     },
     "localname": "SeriesNAndXMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesNAndXWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N and X Warrants [Member]"
       }
      }
     },
     "localname": "SeriesNAndXWarrantsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N [Member]"
       }
      }
     },
     "localname": "SeriesNMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesNNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series NN [Member]"
       }
      }
     },
     "localname": "SeriesNNMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesNWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N Warrants [Member]",
        "verboseLabel": "Series N Warrants [Member]"
       }
      }
     },
     "localname": "SeriesNWarrantsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesOOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series OO [Member]"
       }
      }
     },
     "localname": "SeriesOOMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesRRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR [Member]"
       }
      }
     },
     "localname": "SeriesRRMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesSSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series SS [Member]"
       }
      }
     },
     "localname": "SeriesSSMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesTTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series TT [Member]"
       }
      }
     },
     "localname": "SeriesTTMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesUUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU [Member]"
       }
      }
     },
     "localname": "SeriesUUMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesUUWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU warrants [Member]",
        "verboseLabel": "Series UU warrants [Member]"
       }
      }
     },
     "localname": "SeriesUUWarrantsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series V [Member]"
       }
      }
     },
     "localname": "SeriesVMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesVVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series VV [Member]"
       }
      }
     },
     "localname": "SeriesVVMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesVWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series V Warrants [Member]"
       }
      }
     },
     "localname": "SeriesVWarrantsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series W [Member]"
       }
      }
     },
     "localname": "SeriesWMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X [Member]"
       }
      }
     },
     "localname": "SeriesXMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesXWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X Warrants [Member]"
       }
      }
     },
     "localname": "SeriesXWarrantsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesXXWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series XX Warrants [Member]"
       }
      }
     },
     "localname": "SeriesXXWarrantsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Y [Member]"
       }
      }
     },
     "localname": "SeriesYMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesYYWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series YY Warrants [Member]"
       }
      }
     },
     "localname": "SeriesYYWarrantsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesZMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Z [Member]"
       }
      }
     },
     "localname": "SeriesZMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesZZMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series ZZ [Member]"
       }
      }
     },
     "localname": "SeriesZZMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_ShareIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.",
        "label": "Share issuance costs"
       }
      }
     },
     "localname": "ShareIssuanceCosts",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_SharesForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited"
       }
      }
     },
     "localname": "SharesForfeited",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_SharesIssuableUponExerciseOfwarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable upon Exercise of Warrant"
       }
      }
     },
     "localname": "SharesIssuableUponExerciseOfwarrant",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_SharesIssuedForSettlementOfClinicalResearchCosts": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for settlement of clinical research costs"
       }
      }
     },
     "localname": "SharesIssuedForSettlementOfClinicalResearchCosts",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for settlement of clinical research costs, amount"
       }
      }
     },
     "localname": "SharesIssuedForSettlementOfClinicalResearchCostsAmount",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for settlement of clinical research costs, shares"
       }
      }
     },
     "localname": "SharesIssuedForSettlementOfClinicalResearchCostsShares",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_ShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Deposits]",
        "verboseLabel": "Deposits"
       }
      }
     },
     "localname": "ShortTermDeposits",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ShortTermInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Gain on short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestment",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_StockBonusPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Bonus Plans [Member]"
       }
      }
     },
     "localname": "StockBonusPlansMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_StockCompensationPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation Plans [Member]"
       }
      }
     },
     "localname": "StockCompensationPlansMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock by officers and directors, shares"
       }
      }
     },
     "localname": "StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock by officers and directors, amount"
       }
      }
     },
     "localname": "StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_SuppliesUsedForRDAndManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Supplies used for R&amp;D and manufacturing]",
        "verboseLabel": "Supplies used for R&amp;D and manufacturing"
       }
      }
     },
     "localname": "SuppliesUsedForRDAndManufacturing",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_SuppliesUsedForRDAndManufacturingPolicytextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Supplies used for R&amp;D and manufacturing 1]",
        "verboseLabel": "Supplies used for R&amp;D and manufacturing"
       }
      }
     },
     "localname": "SuppliesUsedForRDAndManufacturingPolicytextblock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_Total": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Total]",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "Total",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_TotalCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total compensation"
       }
      }
     },
     "localname": "TotalCompensation",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_TransactionOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction One [Member]"
       }
      }
     },
     "localname": "TransactionOneMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_TransactionTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TransactionTwoMember [Member]"
       }
      }
     },
     "localname": "TransactionTwoMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_USTreasuryBills": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[U.S. Treasury Bills]",
        "verboseLabel": "U.S. Treasury Bills"
       }
      }
     },
     "localname": "USTreasuryBills",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_UnvestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "localname": "UnvestedRestrictedStockMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_VendorObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor Obligations [Member]"
       }
      }
     },
     "localname": "VendorObligationsMember",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_VestedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested options"
       }
      }
     },
     "localname": "VestedOptions",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_VestedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested shares",
        "verboseLabel": "Vested shares"
       }
      }
     },
     "localname": "VestedShares",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails4",
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_VolatilityRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.",
        "label": "Volatility rate"
       }
      }
     },
     "localname": "VolatilityRate",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "cvm_WarrantExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "WarrantExercise",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WarrantExercisesAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, amount"
       }
      }
     },
     "localname": "WarrantExercisesAmount",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_WarrantExercisesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, shares"
       }
      }
     },
     "localname": "WarrantExercisesShares",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WarrantInducementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Warrant inducement expense]",
        "verboseLabel": "Warrant inducement expense"
       }
      }
     },
     "localname": "WarrantInducementExpense",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_WarrantIssuances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issuances"
       }
      }
     },
     "localname": "WarrantIssuances",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_WarrantsAndNonEmployeeOptionstextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4. WARRANTS AND NON-EMPLOYEE OPTIONS"
       }
      }
     },
     "localname": "WarrantsAndNonEmployeeOptionstextblock",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Exercised"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WarrantsExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised shares"
       }
      }
     },
     "localname": "WarrantsExercisedShares",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Warrants expired"
       }
      }
     },
     "localname": "WarrantsExpired",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WarrantsIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued during period"
       }
      }
     },
     "localname": "WarrantsIssuedDuringPeriod",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WeightedAverageExercisePriceDerivativeInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Derivative instruments"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceDerivativeInstruments",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WeightedAverageExercisePriceExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Expired"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExpired",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WeightedAverageExercisePriceVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Exercise Price Vested]",
        "periodStartLabel": "Weighted Average Exercise Price Vested"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceVested",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WeightedAverageFairValueDerivativeInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value, Derivative instruments"
       }
      }
     },
     "localname": "WeightedAverageFairValueDerivativeInstruments",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Grant Date Fair Value, Ending]",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Ending"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValue",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WeightedAverageGrantDateFairValueBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Beginning",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Beginning"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValueBeginning",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails3",
      "http://cvm.com/role/StockCompensationDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WeightedAverageGrantDateFairValueEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Ending"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValueEnding",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeInYearsOutstandingEnding",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_WeightedAverageRiskFreeInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average risk free interest rate"
       }
      }
     },
     "localname": "WeightedAverageRiskFreeInterestRate",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "cvm_WeightedAverageTimeToMaturityYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time to maturity year"
       }
      }
     },
     "localname": "WeightedAverageTimeToMaturityYear",
     "nsuri": "http://cvm.com/20210930",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r358",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r358",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r141",
      "r181",
      "r182",
      "r326",
      "r357",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service Axis"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r141",
      "r181",
      "r182",
      "r326",
      "r357",
      "r359"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r187",
      "r200",
      "r201",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r358",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Axis"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r187",
      "r200",
      "r201",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r358",
      "r360"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r24",
      "r143",
      "r144"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r222"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r66",
      "r151",
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of patent costs"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r76",
      "r128",
      "r133",
      "r139",
      "r146",
      "r251",
      "r253",
      "r281",
      "r341",
      "r350"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r44",
      "r76",
      "r146",
      "r251",
      "r253",
      "r281"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets, Current]",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r76",
      "r146",
      "r251",
      "r253",
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Non current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r206",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r206",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type Axis"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r30",
      "r68"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF YEAR",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "[Cash and Cash Equivalents, Period Increase (Decrease)]",
        "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r69",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Fully insured amount of non-interest bearing cash balances"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r179",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right Axis"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockCompensationDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockCompensationDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Common stock price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "10. COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued",
        "terseLabel": "Common stock shares issued",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
      "http://cvm.com/role/StockCompensationDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $.01 par value - 600,000,000 shares authorized;43,207,183 and 38,730,150 shares issued and outstanding at September 30, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r202",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "9. EMPLOYEE BENEFIT PLAN"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EMPLOYEE BENEFIT PLAN"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockDescription": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Stock options vest description"
       }
      }
     },
     "localname": "ConversionOfStockDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Total expense"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationEquity": {
     "auth_ref": [
      "r42",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.",
        "label": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "DeferredCompensationEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Total deferred tax assets",
        "verboseLabel": "Estimated net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Ending Balance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "NOL carryforwards",
        "verboseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r237",
      "r239",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "R&amp;D credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).",
        "label": "Vacation and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "[Deferred Tax Assets, Valuation Allowance]",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r227",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "[Deferred Tax Liabilities, Net]",
        "negatedLabel": "Total deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r185",
      "r186",
      "r195",
      "r197",
      "r198",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Incremental cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Expense for Company's contribution to employee benefit plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Additional deposit"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r66",
      "r160"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r45",
      "r47",
      "r262",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Total warrant liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Loss on derivative instruments"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r260",
      "r263",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument Risk Axis"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS AND NONEMPLOYEE OPTIONS (Details)"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative instruments, current portion"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative instruments, net of current portion"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeVariableInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DerivativeVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r78",
      "r256",
      "r257",
      "r258",
      "r259",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases": {
     "auth_ref": [
      "r168",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Lease description"
       }
      }
     },
     "localname": "DescriptionOfLesseeLeasingArrangementsCapitalLeases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "8. STOCK COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToOfficersOrStockholdersCurrent": {
     "auth_ref": [
      "r20",
      "r77",
      "r306",
      "r348",
      "r366"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to employees"
       }
      }
     },
     "localname": "DueToOfficersOrStockholdersCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r52",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r93",
      "r96",
      "r99",
      "r100",
      "r101",
      "r105",
      "r106",
      "r346",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per common share - basic",
        "verboseLabel": "Basic loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per common share - diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r52",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r96",
      "r99",
      "r100",
      "r101",
      "r105",
      "r106",
      "r346",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share- diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "14. NET LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r228",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r228",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r228",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "State tax rate, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r228",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r228",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Federal rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EMPLOYEE BENEFIT PLAN (Detail Narrative)"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Employees"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "[Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount]",
        "verboseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS EQUITY"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r108",
      "r147",
      "r176",
      "r178",
      "r219",
      "r220",
      "r221",
      "r242",
      "r243",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r66",
      "r173"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "[Fair Value Adjustment of Warrants]",
        "negatedLabel": "Warrant inducement expense",
        "terseLabel": "Fair value of warrant",
        "verboseLabel": "Warrant inducement expense"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r198",
      "r272",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level Axis"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueConcentrationOfRiskTextBlock": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties.  The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.",
        "label": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "FairValueConcentrationOfRiskTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "13. FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r273",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Issuances"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales]",
        "negatedLabel": "Exercises"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r198",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r295",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Schedule of future minimum payments under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Total future minimum lease obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finance Lease, Liability, to be Paid, after Year Five]",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finance Lease, Liability, to be Paid, Year One]",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finance Lease, Liability, to be Paid, Year Five]",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finance Lease, Liability, to be Paid, Year Four]",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finance Lease, Liability, to be Paid, Year Three]",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finance Lease, Liability, to be Paid, Year Two]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Less imputed interest on financing obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance lease right of use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r300",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Patent useful life",
        "verboseLabel": "Weighted average time to maturity"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r158",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r152",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r155",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Patents, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS (Details)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.",
        "label": "Patent costs, net",
        "verboseLabel": "Patents"
       }
      }
     },
     "localname": "FiniteLivedPatentsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixturesAndEquipmentGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.",
        "label": "Research equipment"
       }
      }
     },
     "localname": "FixturesAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r229",
      "r230",
      "r236",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "7. INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r74",
      "r225",
      "r226",
      "r230",
      "r231",
      "r235",
      "r241",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.",
        "label": "[Increase (Decrease) in Due to Officers and Stockholders]",
        "verboseLabel": "Due to employees"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToOfficersAndStockholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase)/decrease in assets:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) in liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "[Increase (Decrease) in Other Operating Liabilities]",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "[Increase (Decrease) in Receivables]",
        "verboseLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "6. PATENTS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PATENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r74",
      "r154",
      "r323",
      "r324",
      "r325",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Patents"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r61",
      "r63",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r43"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Supplies used for R&amp;D and manufacturing"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Share-based payments for services",
        "verboseLabel": "Non-employees"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StockCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseIncentivePayableCurrent": {
     "auth_ref": [
      "r38",
      "r290",
      "r291",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Lease incentive payable current"
       }
      }
     },
     "localname": "LeaseIncentivePayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r10",
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "[Lessee, Operating Lease, Liability, to be Paid]",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, after Year Five]",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "negatedLabel": "Less imputed interest on operating lease obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r76",
      "r134",
      "r146",
      "r252",
      "r253",
      "r254",
      "r281"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "[Liabilities]",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r76",
      "r146",
      "r281",
      "r342",
      "r352"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "[Liabilities and Equity]",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r76",
      "r146",
      "r252",
      "r253",
      "r254",
      "r281"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "[Liabilities, Current]",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "Biologics License Application [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS AND NON-EMPLOYEE OPTIONS"
       }
      }
     },
     "localname": "LineOfCreditFacilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r109",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "2. OPERATIONS AND FINANCING"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/OperationsAndFinancing"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 30.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 31.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 32.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r48",
      "r49",
      "r51",
      "r67",
      "r76",
      "r83",
      "r85",
      "r86",
      "r87",
      "r88",
      "r91",
      "r92",
      "r97",
      "r128",
      "r132",
      "r135",
      "r138",
      "r140",
      "r146",
      "r281",
      "r345",
      "r354"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r93",
      "r94",
      "r98",
      "r101",
      "r128",
      "r132",
      "r135",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "totalLabel": "Net loss available to common shareholders",
        "verboseLabel": "Net loss available to common shareholders -basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r95",
      "r98",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net loss available to common shareholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "auth_ref": [
      "r94",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.",
        "label": "Net loss available to common shareholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Options issued"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "[Operating Expenses]",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r128",
      "r132",
      "r135",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "[Operating Income (Loss)]",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease - liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "[Operating Lease, Liability, Current]",
        "verboseLabel": "Operating lease - liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r296",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid related to operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r300",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r175",
      "r267",
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2",
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": {
     "auth_ref": [
      "r174",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.",
        "label": "Stock price"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityStrikePrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2",
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "1. ORGANIZATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/ORGANIZATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "[Other Cost and Expense, Operating]",
        "verboseLabel": "Incremental cost"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Grant income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingGainsLosses": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.",
        "label": "Other non-operating gain"
       }
      }
     },
     "localname": "OtherNonoperatingGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "[Payments of Stock Issuance Costs]",
        "negatedLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "[Payments to Acquire Intangible Assets]",
        "negatedLabel": "Expenditures for patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r206",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $.01 par value- 200,000 shares authorized; -0- shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r148",
      "r149"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from the sale of common stock, amount",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from the purchase of stock by officers and directors"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r59",
      "r218"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercises of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PLANT, PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "5. PLANT, PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PlantPropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r163",
      "r353"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "verboseLabel": "Net property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r74",
      "r163",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATIONS AND FINANCING"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r196",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r196",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r196",
      "r305",
      "r307",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r303",
      "r304",
      "r306",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "11. RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "[Repayments of Debt and Lease Obligation]",
        "negatedLabel": "Payments on obligations under finance leases"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r224",
      "r372"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r74",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r178",
      "r222",
      "r351",
      "r364",
      "r365"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r147",
      "r219",
      "r220",
      "r221",
      "r242",
      "r243",
      "r361",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r299",
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Additional expenses"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Public offering price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of warrant liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r152",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of patents"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of future minimum payments under operating leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of total estimated future amortization"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r32",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of plant, property and equipment"
       }
      }
     },
     "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/PlantPropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r142",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Equity based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock price volatility, max"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock price volatility, min"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, max"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, min"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised]",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Number of Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r210",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]",
        "periodEndLabel": "Number of Options Outstanding, Ending",
        "periodStartLabel": "Number of Options Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r204",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Stock prices per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Implicit life of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r180",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r21",
      "r343",
      "r344",
      "r349"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "U.S. Treasury Bills"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r142",
      "r150",
      "r164",
      "r166",
      "r167",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r41",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r108",
      "r147",
      "r176",
      "r178",
      "r219",
      "r220",
      "r221",
      "r242",
      "r243",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative",
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/PatentsDetails",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquity",
      "http://cvm.com/role/StockCompensationDetails2",
      "http://cvm.com/role/StockCompensationDetails4",
      "http://cvm.com/role/StockCompensationDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r108",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative",
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/PatentsDetails",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquity",
      "http://cvm.com/role/StockCompensationDetails2",
      "http://cvm.com/role/StockCompensationDetails4",
      "http://cvm.com/role/StockCompensationDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "401(k) contributions paid in common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r22",
      "r23",
      "r176",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Issuance of common stock options purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock issued to nonemployees for service, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r176",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r176",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Equity based compensation - employees, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r176",
      "r178",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Option exercises, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "401(k) contributions paid in common stock, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock issued to nonemployees for service, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r178",
      "r205",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Equity based compensation - employees"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r176",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Option exercises, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r76",
      "r145",
      "r146",
      "r281"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodEndLabel": "Balance, amount",
        "periodStartLabel": "Balance, amount",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r178",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "12. STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r297",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease rental income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "15. SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/StockCompensationDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward.",
        "label": "Net operating loss carryforwards, description"
       }
      }
     },
     "localname": "TaxCreditCarryforwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized gain on derivatives"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "unrealized gain on short-term T-bills"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r95",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average common shares outstanding - diluted",
        "verboseLabel": "Weighted average shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r93",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding - basic",
        "verboseLabel": "Weighted average shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121554914&loc=SL2265659-115463"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13572-108611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13587-108611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121601235&loc=d3e32400-112679"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e40010-112707"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e40019-112707"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121577943&loc=d3e41614-112719"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(17))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=84167750&loc=d3e42232-110370"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r373": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r375": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r376": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r377": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r378": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r379": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001654954-21-013417-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-21-013417-xbrl.zip
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MVD]AW1UBTL!>%BT9D10ISE&O#/)U*'$H@2L"O26'22Y)B@#GL$>1OT[7%2'
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M#'LE727>?)R8AX*,5D<%?IQ*VE'.\"XE47($B)H]"^#">#Q'+\FBB#BKY<@
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MVKR"S2KFBN]AI3%#+@6AJ'O>#$<0?5M&$9GY1-]A\$0SFMF;V$])C"7A12@
M(J;;F'^3:=DR3OIH$>. ;&MA.0I!<Q ?NG?S CZD&K:,C6'@W0=AD 9(306O
M;>/;VY&WHKL\\,9VOSUH(.E+.HCM+]C8\O5MV:@B8),EFI897!(1$$7ZT@YE
M*))KW3*6^DLTB9W9+/!1@IVD^,I*[98!LB#>].4DP+S![= V E$2/&6OO\K,
M-+D4B#1]:0PX:0#=:Z.+>9M&/O@SVZJP#Q_%2?&@9,'^1$@E [*^OKR&VOH
M'5HY50IX00N<MLUJ.X[\@R9V41 TNO0E:3@<0"8UJWK+QE8QO[3!O8(0IA0$
M$:8O9:,F#*AZRPC;S3:5H@P@"GK/K"^'HR8-K'[;:$L?45+2)\ID0$3IR^D
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M?4AEOC*K/,9J:4++%B,RF2*GF<<8*\U@^-I$)G>LM/,8CZ6)J[Q4D<DI94U
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MC[94\^'(TIE"/AK!>MN!!Z;RD'J]6J!=V"L1=;]5X.QAV#EU28AV[A/2M5T
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M,/#MY+ G%:;O1W 7F60NL9[@[LF-:.L N:WJT$%V H3X7,>C$#PX[MQ<HI3
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M^@:V:^VCGNI61M8>MFOEG&8/H),JX,9-RVK3+?[3-?I7 2#\GJ Y![H91%R
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M4KG7B1@@<OIVN/?0V4>(?L.1_> G6];XKHJHZ7D>M*SGR[\;T/,<2.6>S\0
MD@-$4$///T06/D*^?WNQ0U9=2K^KZ7,FJ*S#"S\:T-LL/.6N3F4 %=(XP-??
MG6<$#'*R-+#%U YT%L3R8,_+&$ ! 2SNH,]D]69IN H2B#.'^*_PPDJL-(A:
M<$# %E=[^B*"7#YV8<D:P!@)>-R#EH,.#F.VLL#WTRF4,<BS8IM48Q]_>+*L
M':41W"9Q]I<RG](__XUL;_$Y\\:[] ,K<'RT @KI>3,G%U SU?YYUJ8JF'--
M]' '_VTTLZ=PII&&[1%7-BZ;FXOUS?WZ GQ:7:]NSM?@_M?U^N'>!$JNXA@F
M<0WYRD+J:,:&ER=448)TQ' RLX8# Z@CPE;)6G%_;Q0E4K,IQ8R*K&J"<,!6
M>5(2)%WB#&UO,#>&+D*(O*P%5/7/)M#GW(J?5X&+_V_]][W_:FT1P'B5G%M1
M](86^5^L[;Z\MFZHJXY>C2J3IYN4(NG;Q<2SW8D!]&L!N4)'I$M3_^)_P&,I
M)A#S_CF,D@<8O5P%KS!.\)1>OATB%E6XNA) +:RF&')TFG$FL\70 %+5(RQS
MZ/'C_4?P$$$KWD=OX)._W1K!GI7CX'"M^ XZ$+':WL(;F+#W@W(J"N=(">B%
MJ5(@3_MN.5H.33!9\DC++#MJ&,&NVPCN+-]=?]_!((9B6G%DU?%)"#9/)*8@
M[9?Q=&I;!C!( F*9.JD*@%3'"/Y@ZQJ@LM\0_SDU+8JH8PL+6IXD^=])P\\'
MPXF[-( ;?&05K^5^M]OZ, 9[_*2"%T;@[E^LE]V_7I#%T(L5[#T+OX\@O(RF
M:I=4NSLB=;7FCN6JVD0GN03O]5NC(K[*60(N"SCIQL@BBB8,468?B*JI;1LM
M1Q 31B@;59D1?Z5B9YDKN(,TX*?3@?H2X35:YT+RH,G&>XPA0<JIK%!#'54D
M@.>)(Q"G'>8,K:$).Q5IH&5ZI8I@BS4!?<XF]/!48)#UV>P@OGL2/#4@7(V.
M.LI)@<^33JA >M,>#JQ<4)0^VC6 6B;>0=5LZMU&(0*:O-TB\,DJ<+%S:8<=
M ?RUJEA%Y4ZG'GIQP\.73_>C$$Y,L';R2*O;'ZI)EK8P4SL# 33BC!598S^!
MU_XK=&^M!+N;?HG"2LK36FFE\ZD(<&DN98G2_K*6"WMJ +.D0%9(122!$\9X
MG68(E2[@#I_SQC(K=XZL.AH)P>9)Q!2D$XVW&$Q,. B3@%BYP9^J:-Q>\[=-
ME/MP.H>J5AR2&^HB,/9.VIR%1+&9F152OV>NZW433'(9#V>#;,2^^-JW;'_K
M)SZ,T;*$I'1Z#K<NC&*\1$G>:@(2Y-75$:5IE?)4DM4EG>LBZSBT#2!<.]25
MT/^KU:>KZZN'J_4]6-U<@/N'S?E__+JYOEC?W?\)K/_S\>KAJV&4E8N:$2EH
MH:5$_ Q?FG2BY\+)R#6+>D*<O$B:G+X1X339$>>M]89/*^5.G,O"ZL^:V7!9
MI\Q%R=2W/[%&)CAG9#!6 OE2';"C2H:0*-I#MSHV^/7FR2NEDAATB4UL8=)9
MD^EL/#7BP$(.)H-36,VH(^>+/7P(-Y[G.VA:WT3Y2;YFJRRAJ'#?+%V-PB:Z
M5HO&;<ZL\="$,(>F>"O;ZST$20C@RVX;OD%#" @C_]7"%SVD[9I81:6SIAYZ
MT6?#EZ?;NN%P.?5,()HTTJH')],$?H!6;"0A8WQV.,DGSU:$)V85<5Y?,)V&
M@^5X0,B$_O W<O)2A7M+/UBJJ(Q"_T22AXUI5"^=AO7.Q\.Q1A(UQ5G9,))C
ML.U1N0%[E&ZTY#98-.9H.)V/5,5:UKH-ZT"*@W%R/6/"!"(];>B=+$ZBSTCG
M>);!5O%%7N>'KTD1.\RI[0;U7_,E1UY+\ZJC6H':A<=1A73C=+!8#DR@62.P
MLLN/ )*0BDY7(=U'D&45?JOE8ZV6GD@R005XT60,%=K%H_%HLC" CXW BJ/*
M"FL:<RE9#&:2)Z6$GJYH,TEBUBK1HXZ192],N)G<$&Y=Y-E[H6?R#*,FD[=(
M02$A:V$7F,B53B? ^<(R(0)-%F>%>UA/;BNA9E%>LQHGM8'0'@U5^6>:[.**
MZ-C;-W.W;?7UT[11D^'$R(0U"A.4:$]FQ%8,/_CET\O$^,9Z&."Y" 8.PG?A
MQ\XVC/<1K#F$;UB&PIP#;2I7R#W0I #JE)U[<&Z"^_@$Z)4#_6-1)%2Y4)@)
M)&X<VV1&-%.S^*6:V)\IVHT/3#CIE\59N?EI:$S2+2H+HM44#;X2Y5QA2BJ]
M3,X#6KI*7A:C9P%3RQF;D(J@%B#C&CE5 #'6. /_S\?!$.RL"+QBY0\ ??=L
M,!B F#YH:>V3YS#R_P'=?P4?!A^R/_MQC",#L(4+NWSRLIM).GW/4YCSIR*F
M=JIE02S/IGD9&JDQ<1:N8P#MQ.A8<V(8L D'/H 991R'=9/QV6@P/QLNQH1M
MX\79?#PX&TX'8BH"*P'WJ!\@SMT,D ; ![!$"A/G#"#5'20)&[<=/#3>0;"4
MZY+D?M;VUO+=J^#<VOEH&\2+Z.%)*PR4$@,NA$FQ12EKQG//&AG :2F0E1"I
M@Q+ V3D^^ %PJ)X)G+J#B>4'T%U;48#&1+QRG/W+?FLET+V GN_XO#6?C*(Z
MILE7(T^Z>BW:M4-O/C<A>KTI7D:T7B8/7*J@Q4=57=/*K=!I?.MHXGJJ KIK
M/59U(-F.JSBG]2=R5S4Q8H;A=TQMM?7N]!KP9VS"Q2<1MHJ3Z[[ %BH.5DD2
M^?8^P9'<. +RUJJ)1U#C7V3>JJEQ.C)UZ#""PZFGJK^:>*<E(%=&_N9A=0W>
MX=4A89<V;"*3;K>U9N78A.S?\DA%3G.RVZ$*1OC/B\X*9--P2#A>KY ]Y"V,
M[O&.3LK3P5?6Y4.JJP[?K<333",U1G-H0BQ_&\RUSJ>#&\ \>I+JQ*N#(T*J
M6:I*NNC(@\^G85F#^A$=:VQ$EO(F6&MI5_$RF4J_*^+;:M DF8)>VA5AUU&.
M2M.;0(X[A":<",KBE*4:=5*:2K/-T6_:H#T*6GH)QZA '>MR*M1Z+";#D0D1
M2HW RO+/W$.:ALM *4TM1SE-%H 2:G2_:0^74Q.<XXT!B\^ C%KWY>HFN>@3
M:F@AG\QR3R!.X_&\B3LW(3I,&JB89$:N\BIU$R[QN-(:2<9?W'%$T[MZ0VMN
MPD9""J04L<Q9TU7J5+^@$ZMHI%?-4DXD3_IP,!F.C<CL+(]4BFV&K>"N B=\
M@8=7"FMB"+G2*A^$$ (NO@W!%*4K[[&W7)IP[5 *)/]-R/N'U</Z\_KFX1YL
M+L'F=GVW>KC:W-R#'Q]O5H\75P_KBY],X!FY=T'KRFF(@H3BZS%%8)7[,/3G
M]%+3?#XR(72+"ZS,E5\B*TB 3R2-8$)V^RM]-:?N^5"!O(9;?3S0S-M\96&Z
MM?+FMF?"X90D3/[MO2R?E!&9[NY@#%$SXC<(+^ KW(8DL7A:-6ZHCE!'9624
M!/AB4)1 @<87C>!@84+2L@90J\^L455R .H>E4W@VR\P0.-@BVJU<E_\P,=#
M!T>ABAE7JZ6.<Y(5R+.N1H7>J%DL!C,3+BDW EN9-*DR(9Y54-<2NU,QU5+3
M#ET7+&<3QYB[HS48V8%X867&,<$ </NDKLI:URWRQ#%RB7) 5HF7.2Y+,ED]
M878'''1M?LUYC(,A1H?"<&"-5#6]_'#EH12D=D"R1@W3:G_45U;+4&U''!-\
MLB)L@@%+I<&/6/XG(R+<R.;Z)@S"8H7$:[LZ)<4^C5KX%3<'5X..^<%D.#/A
M@D43K.ST'S^FZXB?#'*+'#.(_6+Y 1X*F^#X-_YC9Q)Z.G+$U52"G26.HT2C
M9"UOX)JP)FD(MY)E%"F ,$#;65;&."U+EDO+CT@(P,K]KWU,DAYLO-^L"#L.
MV2^)B13HF<AL.NO?3;JDO17 )QS%(%K(-$!<[K!4"O62NW>(CS[;AIA@-J3Z
MKDEC*$WAUSWQAB:X'B1A5I9$6 \017#4Q-G0,ETS%T?8#L;8KO'WP$(5C0LC
M!G3ALB@G3UV7L^7(->$841XI>TD4A,&'HY_E"2F;0+6K((&HI9+""H^_%N*+
MJSR?%D,N'E"S9>F$Y'GVT 0'OAS*,JTRK6RRK'F7L\<>05#%6^J" *W5:#AR
M5(70U7IA!/C*K8Y$C?&\,-M=5#65P[0%*;0^;E #J[*4P$0H^%6:WT5N_2+&
MY]#U/1])^V' 78R*!-6\@"&&F;U\P99*XU<7WD+GEE067YD=>1V\O/R6:NDW
MSZM7R]]BACZ$N;B[],[L)ROVG=JQ6E\$?0MX-A@[JJ;79B:^:0UXDP"PLH+P
M>'?2:$0<AIB69=PL(=_]I[6?MIE&';^->#JX-7"9^2Q/[C34-E_B&2!E&K%E
MSG(!97=L1%3FR*HCK!!LGI9,0;H^74YL(]*$2T#D6D^T&RX83? !V%C=!$+]
M!OVGYP2ZJU>T97^"-WN<'F_C50+4141K6(8Z K:J7)Z8C0H@;%AZ$S@RX0CU
M!.@5QW5:%%H&D+(*9"Y<1#")V<P1BV,'_>T^X5ZPJM72;#ZK%:@UI$<5FEI]
M ,=S$U+5-@+;Q+BZM  32"@:A>5!6,O-MH6987#KJRMK>?DE40?U?#&T37@#
MOHLZG&2+#1H(AWM)J/[-$\Y+Z:K,2-B@,L4DA1**--)I-!S;)D0IM(!<34Z?
MOUIF:@Z\0T4?\%ZPKC52(0V<*\!CDHM(4,?=$,V>)FR?1-@J=,EDP5^)M!$;
M[P.H:S^ 5^B?O(,(EJ &EE1@,IERD*([66<VG)OQ"H88GX Q6 ,0%;-H0^WE
M>?BR"P/RK,QWOY9!;!T-9!*!9_**I4#WF(/I=&["670#J'RVI<EYC\K@KUC=
M".;E/*.?R9L'G(9@R&E)]E $R<GP0(5H9*XU]Y8F3&TU\#BY'(B\"3SAO'(@
MY$R-CO8G)_A<$BK07*76S'-,B$YO %7P" 76_7 5@'-S'Z$04HTGK.^Q"3ZY
MV)+I/:?A<FQ"*BT9C**')"YT/B11DVZJDKX)CN'"5>6,W\'(#UVT.(@2T0$]
M'V2YV3]96_ST=I;PQX2A*Y&A3%=:LL;D,"&+(A-4]44((G4&J)R>VZ@G/<(Q
MM,<V5-7>LN.P!BIW-%HOX?[4S!',:+>5&^YH\-4J=A:3$7D3G17MQA-4$^TF
MAIE%N[&E4M_VU)KJS.DLBZ^ZK*(Z.-)M=7\.D-H9H(H]T.$V"AT(W?@2M?S#
M,[RWMG#C57+(,:HFJZB&+LVJD=%'3HO.G^YX/-!-IS9XJZF::1D -QY(GB&(
M43&8; XC_Y\)RX%\K?'DA UDH=H<VRNAIS)]N&0EB@G$:Y1H5X\&T#%AG=$0
M;EMF]C8UIM'(&726U:N*J+%O/&B9)2O_3B-N76_IZ$S^5X^,>WLU$^^OF]??
M8>3X:%;E3G$\0:5=SH%9ZOB2%+W3O71<6^<E$%E\/!+ 3*F;V4B*#"MB7"0J
MD@GJ(4,1)H\,5(H^'>(-)F/3R,#")T&&N@F@ISY@7UUA]X1(EH8Q#-RQLBM[
MKS"RPQBR-JK-P)Y^,Z?C6UK<X2H6UWECJR5AM&8*D$=8<2OQ*&+$\259E5*'
MU\4^\H.G6^K6(;/-^F6W#=\@_ 0#Z/G)+:J7R,O3J!C%[]JVJ&+%X=:@C#3/
M_'1HQ-,+IZ$O$WHR&/[XQT]H2Q+0^ZF(UC%YA!W@1]@-W4)SFH#D[CB9YOQ2
MM+.\KH(2).<50:,W;#1'F?!PW$G@3Z!X%WMQ!::<_OTRC.YA].I7M_9M"]%.
M\)KJ21OQ2@G41^T.9V,3HA1.P5X-K$)EI:_HX+N801C =(3$P LC$--BWHO]
M/I';O#*T4UM<.5G+S2:'-7$\VX1 B1.@M^>U\4:;5#^[K05='/D(@YAL(5JT
M(Z\@,Q@NKJ8LS=FE4,\*1'PQ?8TB@[],^#0NUL9:>%ER4 ,?P('Y!K.<SE[D
MQPTY\8TSQQ@WZJ5%0=I9+E%-Z64*LQ1J%JW98&C"=;Q3\5=3E!-*=^P+5V"^
M3^>UJ!SMM*ZOI+3MYI+"GEO+N0G1YR?"K^=T;V>Z.>0/X<;ST (HBLDUV @Z
MJ(BX.DAOX#>BP#H2/*TX-6[G+JJ<N:5/*8MNPYSY0NO[YMW6HA*S@" ^HP4(
M]FP3EPBPW]"_Z1?H.U#9-WH\Q#RE?MP3E"X*-9_P[-.8TTND)]SV8CC0>=6Q
MC[J<- 3ZL_,8>!9D<A[&S 2.+"%%%.7".U"N(D$MCS=T]%.H!EO%%4%2I&0Q
M/&AO%O=R)%QQ_R7)-DTB<(YT?<?:9D_R$=#<0)^V!2GD3NMJ%OC5N!2Z-QD-
M[)G. ,.N\#-YFKVHGOK(LF))W&%:,(BREQT)E?N<R1O6DC][MRS(3$IS9NE6
MI= WV2S'LMX;I5GX.Z.TAJ"J;'?9)KFU,T7#1G_XE 1"DW.>BYU5'3C@Q25I
M=^+(5%3>.<GW8<],>43[Y JT<L+73YA]=GW3*YO#R6SDJ3HPH?<(UX'P.2@^
MQ-:W>?L>:VTO<2[A:+E0>XFSKO%K@/9ZA;/SM'CG5OQ\N0V_Q?+9\!@J6I+@
M<:%S<M]5Y*D?8S89>":\NB6/M)+<97-SL;ZY7U^ 8LZ[\]7]K^#R>O/;/?CQ
M\6;U>''UL+[XR00"HC4/KN-M%+[Z+G0_O3VBZ>(J.+RING(2_]5/?%A'RS8%
M*<V=W[*:I=5NPU(H7;SA:&G".?^I^"MT/]+Z\F[S&6QNUW>KAZN;7\#J_.'J
MR]7#U?K^S^]EXV+-AXNIJODM05-6PVW+ 9_)VY;C:X/Q0W@'<4_Y6UBHS$/8
MC<'IYU,J<U?UUU3%E%?=?R=-X+E80!/FZ_YK6,T$<?@B#NB+LF_BI^EH6G(<
MYH?^[:"O@CW>@?D!.#Z+:!V^)S"/*I^,WJ$J^&1WN K<U4L8)?X_1$X%H8;*
M9Z)K@1<?B.:*I[?IQG!H0@)4::!E8N85R0F?E5,U@6K'[ -D]X8JE]U7RX73
M;J+SK>5S4^PV+$/ADYUM*E=XQ[-) 715X$TF YV9!#J SO24?Z".JYWU1LUL
M+D[:B)5.,Q^L?C>KO">5[VN$\^G,,B(X7P*CM#^TA\/"7&:5\^RN%@[RJ+_1
MUUA;S;%@BPIE9X$-5.G<-IS.M+J!3@+-2?=+PV^<8U%X@9C>YMLA!0,.K#LX
M!C7UD/K4XVDZ70U&T-%Y:_ITY!T=2?="5K1,?8#1RU7P"NG.BEE[AI0JRG$!
M'EE5$4G?V!Y8ENX$=;7@RMSXQ<([5ORP$%+\D"!-M(7-5-4>7V'\>!._"2Y@
MY+^B21OAN K01GU/P)0[0B2;IA"P1LJ>-:U)\2(/MMQ#6!/WD'O013UTT.UA
MD,KT@63-5 W;3FDSU!TM+X>PDNA%3!0]^80O+3\BEU2.KC3VT^E2"NF]<GN@
M[!5UB<BC!HBYR?8"=^_0Z1A^QQL6:$9NK?+080K1FT:>Y\P,Z!1)E*:ET9*M
MA=;$6?)L&.K.<U<#33I'%A@:D27K*G BG'_Z M+_SQUII ]^U!RB-2E H1^U
M<;4*3E1I[?20QW6'E@%.K;:XRZ3],2OHIY_=M"A\^F3%:',G.F]2VJ%WT(%H
M,6)OV8E#A IIM@U[#E6])"8QVS= 7.ZPG*"91H7164UJK]=TG,PT93O%9L:!
M";,R@65ZX,=,\R=L#'+*>M;_U?K<1A!G,EO3=:Y<5Q5U2#-XX]%LH"HS5BN[
M( )=S;Q.9+/5OZ'V@=UU#1M"KY7HB'U#$ZX2R".5-1<9#=,"U)H,XK[<[W9;
M'\8X;N<RC.XN5H'[V0KV'EH-D=L2%6=LG0+-8&0Y4SC1;RQ:(*[X\E-U&FV$
M??EW_V*][/[U@H2!O.0+ZL-_+]L_32JLS+??#[F&V@^+Y&%6WQR3IY,&:Y =
M9ES 71C[K .^D@!UMRV7[E+53J]NM(L1,N*ZB%2?1V_EQA2A57[LUJRGASJ#
M5&I@589:)F*Z1^G:MVQ_*Q.:W;00(SQ+@NI)>I<8)=!''9?.9&E"H/0IV,NT
MS<KZ^4<WOU+<'LLQQ=6T<AQ\W2^^M=[PAE>N4TM*=)<V7<Y= \XR6J)F/.M+
MA'&,)98VT_QP>J]I4^@U,IU1<&2F&>%"E=U@'KB8EF"*4PKABO;0S5E'Z;XK
MZ='+^A-OX1KMM*X#SC B6-YP!Q6_&ULTB'93TB4CM6: ;(>V@4TAU,P58HI9
MN=C#0L:_?"8#N>X4E4"/!P?6<&I C%L75:CLAO<0QT\;E4J\72>?U$AZ#9$"
M#H],>#NW+6Y9,Y62>9//RYDOT12;M4F>8<3:+TKNDGGJI,46D\%H:<"CBR?C
MKR34QFKY7;&9MJJV<]NWCV;W3I^L'>D,9SL)M*QQHO0]E*5_+26?PH35P?+:
M-&)G.!Y#50<&29A86Y%-:@N>E2^D-B^!"6:J>5^W;C$S<Q%U0.&1JM-MD8EJ
M@[EBH3!M<2D@*P9G,__QD7+XIYR-.I9FQ(D*I_+T'E8'&;:$!6EGM40U)=@M
M*(6F_%M.G8D)%]-/Q5^78>OJYLOZ7FN&+7RZB6J9O2T0;[S'^P>\8-A';Y_\
M[;9R0BL4IC?</'>\Z-VQO:2]%\ G*X',O)(-T;+FU5VFBR\+/'Z\_PBR @ I
MH8?S>ZG.D*VAJG/]CADTTAEVUP B<U*KXXR>A?9MFGCE(5PY?]_[$40V#4VQ
MR1O.>9"L A?GT]B5[T$WUR:-,UW"T:3W-^+J+<"I\'DOL)"NW:5E$ \/S HP
M88G2O*];MY?*)8E2"H]T1ON=@KEBD[)"L%<R+09DY9P!4M(9X?"A,$,LU%60
MH(KX]A:NR%TGJ5XM*]'[H&-GON@]$=P)]DB,NI+Z"!_.NGZRC]('AW?H@T'2
M13:/G@P0KRN;MHM6<],='T<F[&T:0)6R*4=U0/6-\B@RMFRG;5A)Z[B#H6.I
MFBG:>A1KP==Z%/VLA/?A413T=>L6,]/WT@&%1ZKBE[KQLQPQ-_4H'@I[)Q[%
M2S^P J<#CZ*P(.VLEJBF!+L%I="HV<5R.#0A_.!4_'4>Q<NKF]7-N0DY^U$5
M'0C=^!+]]9A--I>)D;E^JE.B]VH6[M@V*!BJ(>KJK6"J#G #'E_SQ!G[<NDF
MM6[*TC3 W(=59>3IG1EON>S_\D3SK5@]X$JO96O@PW.\7;[#VNU&3-1]#1I$
MQ_:K,^:-33#_<BCY^RW$-:((,DU 5(U8Q^2M8)J*:?T=1HX?<]??8A6%9).
MSINFRO(T@&PPG8U->"-('JEX5H*I4G=9T[HG'1D9FQU.[A5GE70EVH6CIX=^
MPDKP.,A4HMWK+<<+(]Q-S>#*L9$8Q) 69!H;#PO!Z-[:HN5@\85&F15D25$/
M'\75J%V[%[3H-0#HPI$)3UPTQ2NF9/(,#T>_QR6A_8;^G8L$=_T(.HA\?40.
MY.MSC3ZV#2/W<A^X:%>Y\:YQ#"@.0;]ZV:&])^1E^6U3B)H8@_;5RP(/FI=
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M<.D'%@)(,EMD9^%OGRV<^2EYDSHA:%2"PCM@S2M6N DFKTYO(D-OH/4>[,G
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M@O=W:&K<X3GQERB,>5MI@;PZLM2"+AQH\81IX,[$@99G )4D83+N%T"$]QG
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M1+S%#[-2\*OW:3'&;ISX<YV\FN9M%&>6D]4A/3R83A>V":??S="R@GM%YL[
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M5>>II])*5L)]2)$?;%PFR'\7Y#X,[#>0ETL_#LC7SP#Z_@<* % $( ?A#!Q
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M 3^"4&.? ::]>'43!EIE1L*Y@0,2 8;O4&8@%H1/X73Z0JX5C7/K4JA]*2G
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MRDQQE(5(N/'8F3Z1N.7>6M\'$5-3U#-_R O *X310;CV"-UWD&6K*@'BI3+
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M:&!;,4;@7=((&D#$^^&,-\FSI^OT*8J#?^^7?!-[C_LAV5$4* YR0[.U%BR
M$/FJF6:EH5JR<M,'2::E0G%5/0T;CX ""(BOFB4_B3\'7J$CDB5-LS_TFJQ"
M"R" OJ .:7^."G1&MHJQ\F&6:1O$ (+L2[4G1(Y/3B<D8T_3@=C-!N5F+5(
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M$8M8CODC6,0<1[,)D%MV#9E%+6(YE ]H$5--2W* A$VUX5(SH@]I$3-,1_*
M>#\ULZ"U12R'=S*+6"NSC6Q(-IA"(@)4:S+;Y'A.9Q03-RS8MJF?@V&AB;9'
M<$YF$6MG6'!M'<JFWH.X)3PGLXBU,BPXV'+*]=G/CKHE/"<SBK4R+&B^K$M
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MN_LQ1>Q0AKF\-$V#?@:I1-$M('DO1M@N>"3II6XZD4@U^)U5MT>Z+"L&D$1
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MD3^$6MXP--T=4[':T?E6]54)ZDVI1-S*Y5,#Z",XWGI8]C"0+:Z&S'R6E*'
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MN/J;-GT&#UIRA#/X\^8#?.U_>P/KBK+8E0E_G$CA$7+!R]_]FHIA()TDG0>
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MBK2#>M,(=)$H3CBV-15@A@FT?Z,L!J,US00&GY,LP*6![4MZ4.A2K9UP)X@
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M5]V;189./<'IYOP<JH:_Z36J,X1^L&D94<.IUP*;/\';A6XPY<<Z[H=^ ?(
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MYF#C"!&  @(3&<SX7$%S1VY8.%[=\5A*W;R8)F7DOI6OR!"H![;OQMCH)Q7
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M%/^S.$T!CU'3+&B6BY()+<W8)_!B>@2B4(A(H<?53_UOW!X.@_/.!(12:"Q
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M4>;NTBAS(<6Y !L;42@WA:4NUS>DBXO!7)F*4++&[,S%CB\H-TTP>29C/_)
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M1S+.2L;]8 L@K$J:\T?E=)170K45*3[.)T>.5&<-JV<C-9#9UP@,4:O/WA8
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MFK1[DS69Z*IQEJJYM5-TD?&T 6R-QSF!BJ^:P..;5>*495)%V0O<_DV(BGO
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M<JL6<^,D"CR#GX3=V'65.CEZAH+H4#'[/, ^H]AW,DLQ49TJXZH7:\6!2^R
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MF ?2]WF^RSVURQ<352^6FQ4'JBV9H9872K*L+7CA75#&9:Q3P^U@U9(^''K
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M;1!):C[;$5?H"=;M)9#"&U(-&,"#\274NXB145HW(H 5I))!/!F;\A#JXZ2
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M^=)0^47^J=$1>U7NW2N"YKP"1^?3/>8X46H";9 -*>_5V@YGQ)1CG1CS82:
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M;^)OW_\G+?8S%PGTZV##<B71[A3C1#:6*$3\U+R$"%>19(" )P,7V6P#<ZI
MA\HANQUD=#%GF)YL?5K"_N$A[#-[+]GJ@/DSM^:J%?@E3U.X>NYK5_A_+*X2
MI!>H9]36-*Q?<L[N_19'!5H'QGP46 ^8N1D_+\=$FAY;YD'A3"4!A?AZYE[W
MP0J40'._>CA*M"&!P#?]A(B+BJ0<J/!G(K:#DXW$IEKNCXW&#PN'E+DHH[P.
M993/HIFNLI7.-]DZ7LR7FSA93O-XLYK/XDVQ2M/M*M_,LZ=@K,FUQ2?D>H>)
MAH#EVV$//['A!F)*G)!TFQJD3@GG=^P@>2RDEHSE@A1$Q68@9*DS:QE3,:/Q
M]N/J#T^Q1/[H-6FKE)B\^,OBB6[R1[K"/_MF^A)[:+9.,SW?%G&NYBI.=);$
MFQQH(;?+1;)=;+/%JGB"/<0!C*\+C@"1+DOULE0#@K)9NMAH-8NG6R HFVY5
MK&;3=6Q.QNUZGLZS1?$4YAYB@;Q5]]0'H7\M.7:&Y)"//G7=-I7LC.OW=U,]
M#[+V1!GT/ C_7W/9.WGM9>^+A_K</50]G\VS]3J-UVJ]BI/%;!&GV68:+V<Z
M!WF^]>Q)3!:AJ3%#@/$IY!@M"E@0#UW.U\OY*M7DYLOM:ITLXMD*PJED6L3I
M5!?Q>EHLDT4RFZX63\$1J BO;\.;D<XIA]YW287+TKTLW3"* 07$=![/YNMI
MG*AD&F_6R2K>J&2Q6>>)^>@IE%!E\F[7U/H 3;7&4X1V#L#0#OP^4>&\K.'+
M&@[-[V*QSA8JB6=I5I@U7*3Q=KW,XD6QT8M%HA=J/7^"-=QJ\Y?*2]1#9LK+
M(H3!S]=_OQ:J*&8MPWM5"G#2@<H!+G/SO@U#*UI-U34H\EV6_679RV6?&,NM
MYHL\3O+E+$YF>@->Q\8$^<O%?#I?+U;%4YAN*':1<"/V_5U6Y655!JMRF:C%
M;)7$B\U"Q^:_3. VVRSC>:+T<KY-5L94/TE:5,#Q0F#*HPH,S"7[Q,F'R27[
M\"*R#TN5KHLLG\5I49B +BU4O,WT,MYLDVV1%CI99T_A44#;(N0^M4?>E-2.
MV\_UPPJ'7KE#DWV\^D(4JE\>0W!='6X!N!CTY@TQ F5M6QI&M8O5#CI-8!3_
M^VPZ,:]<83\(:F7ZBKUCO:9@6HUA$0 ]T(-0CA.$5*<^1<AQWR,)@8)F^'20
M:[(L)1/]:V9Y6\7[V28/0L]@F3_@"CV#\QPPL"CX2WOPMPLX48B9QSX9(8&H
MQQ;OC\TRP&+8$+#-H9#2TV"=^D?'SF5E6U[A]3RJ 0$:[K_&7O?\=3VG 8#)
M<!YL!ZNY277LB-<&VRC[J$-'/Z%X+(=R1-1=/'P2W_V.N*03SAZ-6$>!+)$.
MV)%&E__&N/682L0I$ ..(T-3SN1^W,PCVX7L"%K^79X,N LQK?.0#%\6O@W/
M&C$XQ@(XB401VHN@^:3D7A5SP\J^%:&]Z+6NQ'(RYZNY4\YMI+ O%OVJS6 O
M?J,S[+F8S*>SJ5G!=G/#\!)@!<<SU;IV"QDRL0@X#'(!O+'[+)6TRE-";)9W
M965IC0;[P?9Q'VO(0<!E858 L06F@+9L)["C9D$A>YJCF#AV>H!C?J ?:JAN
M"T08NSV]X.OMD0K.*RL)1C:7^RDZ@6)$&VD&ACN>)%J*N]&8KIHY*AZ!S8I@
M\4*/H&L3CUP:*8)&<+,(,]A09K$WK46Y_P*.(O8_--0A9+O.J;O\U8/2O^56
M24?JC7:B&V-;Q:UT;B*H>@*'3JCP2!;IQE,8R(D=3MA@FOP<.D+7'7#C(KD6
M<!.:T]IV&L&O,J ^R\BJ#5?BU>3]V.J"AQ]NY <$Z]R0\,HF+O3ZB#8/B%J-
M-<*'=ZC8"R;O$G/X3/Q"+]1VNHZG:K6(DV2SCK?I:A6K[78^S_5B.D^?HHC$
M-$Q$S(SM:$38'+*M(\-4T LM47)T_EXR09=,D%S0TT6V*8KI*LXP$Z3-/S;*
MK&JM=;'-BC2;;I\B$Q1HESO^C?I "YG#NZ#+QBSM>Z#:49WO(KWS2_^RKB_K
M.EC71:+U8K6.LVU1Q,E&F76]F&WB7,UFTS3/YFJZ>J)U[2RNF5.GQ^5=$FYN
M1MD$HD3%]2U8H2YK^;*6 WWJ=#V?SHMEO-UL\SA9:QVKI9K'\SR9)]M%L=YL
M-D^TEKU> PL)89(M&HL(^HPFC@>/.:6,3<]+=5,WQO'-?/Q'M%&4>F'IB,OZ
MOZS_H%J5;N;%;)W$9JDG<:(V29RF )1>S6:S]6*>+.=/X:.(Q9V>@ECWD\D'
MXFZUX2][Z4XK!UO#P8.W@BN6),WRWUTVP&4#R U0+'5>K%42Y^N-.0 V)N#<
MI.MIO-9IOMBL5XOMYJF<&4\AC$M:MYA' >ZO.U6#O$,W\-1]'H8T<ZH#L#&'
M*[P+!("P'YG9 D4+,7:/ZH.@W',,DZ1:).YZV3*7+1,H@J^V29&OLEAMTVF<
MI,G"_-MF'A?%HC"[:#9+YT_1^(7U2I>;";9%!R43K"FE;:. 0L$N\YNV.>YE
M'SZD:K%X<3QTH.7E/3',Z;BHXK+H+XL^U+-=)M.URN)5D<_C9%ZLXJV)&>+U
M*EW-S$;(YNNG"A2@)P,='<?AB\)OE2-0&3\&GDTKT6ON%%M>.L4N=9,_MVZB
MS%FLY_DZSI3Y1[*8JGBS*G2<%T6VS?-\F:R73Y7"$(D++!E:H>0P6T%J&R5J
M/::G'E6T*SN3( 7]P(MH7L[ARSDL5_LFT[E>I&F<; 'Y720ZWB:S1;Q=)MMB
M,U_.-ZNG2%C0<4ML2W>Z)D9C3#$H0L*$M&:757M9M4'(E*RR]3K/XS0O@"M#
M%_%FG:IXG4-3[TROTN0I6A6H@*WO5.76*RKY.G--$$T,A!CTU<>!7U;O9?7J
MC0GLT]DZ5G,UA=6[C%.]6L2;S6QC%G8RG:JG0(,S,H,RN#7#94F!A&!JMF>,
M5;2^% Y\\F>2R0DEU@'G/*3Q0O4/H!G!"!'4M9!,VOMH%< NT0R<3<:/XP,]
M?C#0!NG1$;,<6DCZQCU3(WAD^C40N1'=,@C2P3L61$3ZJL"A_T"6S_Z$JIU5
M:B.]-^QM "8O5%(A.LH2\=-._ZBO^0DLKFD%) U$_.?<\$"MGJ#F+*!&RJ.M
M1F@>X8*!"5?#''EM4J%!@;)Z^9B*FDW)>7%4R\T+T')<EAURR]J>@U>/(_VA
MGGRGT_8(S=VS303 [Z7?-2IO]C!1<!>:=(8Q.();F(>XNRT+BQ^]*SO6>;P&
M@VEVVO^#<R;6"F/)K\0W\(>Y=JN(",_O*#0[!3^V2PS1]D1+V[GN@ %[=J@&
MYM84D/W:)25SKZCSX#5WZ:)-:Q?($40F#X@W+\K*#(S7-O:B@?I6547D8*_R
MV?-&4Y<&P77-8_OVCEJR1^(PB Y\ +B3@20T-G_$'A.A_R-6K4#)@9W.S; A
M0A__7@^>Q:HE/6([?FH$)[6Q#$[(BQ#]T:=W*C!.F6/U-/E8UE;NN,O:<D]9
M0XG'MQSDHW?WA*-GA!-Q]EAKQBQHF&BW]"(69:.VEH-M];C@?C]K_NHIQ^]W
M9K:>X.P,JK8SG<VR?!DO%JL\3E)H_5ZJ=3S-=;91TW0V73X%.](3OA_L92="
M[DUFH7.069+ZY>:@<*S 1*\;]G*YS?>[ I0OL):>XA!>_ D/\*B[/:N1_[,6
M=[AY%SI9&#NXC.?K/(V39)[&:9Z;;:P6*M&SY6*=/P70_PG?#_,LMRVD L%3
MF4^_.N=[X,>SK\Q_@68;_#W7H'UHF=]EQV3!:&RX"'# =WG)^&V^(HE)P][W
M0MY4,#2_?ZYK\++[W_;NGZYF:CU=J'@U5ZLXR12D0C>+6!7;V;R8SA:;]?2E
M[_X'8HNTP4AY&& ,+<.^ J'#LBBZT/GWI[[MLS:^?*65B<RVT_]A(9$M2- 6
M'*4\UR5Y,09OVQBD<Y7ELW05+[1.XF2YG<;;8F;<>K6:SI+E/$FV3P$E>\+W
M:^K*"KN13,N];H/40#<AZ67+3>DVM>I<U__#;CU5:)[EJKKLY[>]GV>K)%L4
M:AD70%B<+*<S:"?(XO4L6\/)GN3)"XO+<3^CG^XR8M"?8%-E([DY<3Q757-O
M4W_(5G+56SVOBZX(9$C/9*Q1I*JL::Q\9MJV;U#VFTEVK)ZG&3;$L9NAGAQ.
M>\IINAP)E+?,#UI%C",62U\A-4-EE@C7H6S:5G? ,(/!U!X"+@R84M2)O)I\
M)Y^:GP:J7A;V8:X*@P/>&HAV=P>=L^HJ>'V0D<'"F /T5_JF[!@QHES05IRY
MB[8RV)S5AC^!6$"'&G E9(#@9:3X=8O*2%8Z^\[,1$Y%_:CW)"8,+9W*DGPL
MZ EH,%-\:%A@FQZI)U5("5QS;^-A0I^EQO'&Y>X)YT H[2.!J8<O.98X9L(;
MTKNCGXTENCJ_F?:MCH$QAF;-?AUG[X-9,)5J01\U?-K;YIZ"X6ZR*Y$7RBR-
M$R?KS8"8(>0&"'H@9%T16?S=L1NK)GS.^@$M(UZRMCO[\>.(\V:S@262=D14
M?" 2#DLN@\N/5"*%I(\GH()A[,F5H5 Z"=)VMV:9!J7(H/+;M+X"_,F5@+0B
M2&9T-',&4MW[XT'WM.IOH.)/1$,UT43! 8!]+^Z!'2^]67\C.\N+QO=J2*-:
M:J)&+81]N:S2TP@$+G':K_SPW:#+QF\G2\/"@H^$N($%0[1H@_J694<+9:C-
MM--#?<$Z^-L&=J]>.[#[2^-75&!9T8@@4UE'-6AGQV#?EL9<VF.S%9""4$F;
M#3,E.UCMT-IH,K?J8!RV6I\ZWE]8+15JP%[1PM=-B4X03PL(P,"HD(TY<T8@
M.$9X'\*4@&TW3SQB!\'RX$%?-&"12V-J54XJN64')Q9PWX5!([D&9>M?BMC8
MN&(/UW;RF[:F/B1^XU*O=V9Q,-B;[1GA\F!EZE5VL!8=B\TUW$[7V<DQRH)N
M<.2G 7!$S@7Q>2P[#?X5T#4V1WM'YVKOI>75Y<@\=$4<%'=-ZR'U W S55>3
M:Z\C#>O%3)6?'=+,E&X.@,\"2 XWW@QL^"Z4MZ>QQA'UYQYZ(1CMRT7(7?WF
M$ZVP . _>U4 J)^)6(EC@\82@4K\$Z\EA/<1C2406P)XS$9;_[CZ<#7YIF3U
MY7=8,P%4Q#?&+;@G<>O6(:5<_.#VB.>O=#!#U("VJRS84/UM9&%49_;1:\<U
M!0'<PSBV'OAH"%0ZQ]D:/0A+^8.P(B2B92@1.OF"._83RXMR ?QG\_INN9&%
M-N_8=P;[YQO[KUWP:W2@,3QY0QK)8 ?\[C:C>]P)N^#-<. [^(7FXT_B/+4X
M-1NM4>!+E^T#M(QOG9O#0MTU%%P73=MSY\\>F2+_$S$2^3>8DO[JX%T@6(QK
M792#$UL>/:_J++@.<8UFP"9?VQ/ YCA$_"FUG1EQK&LS>9EFF/ ;LKPP5K_7
MRAX[-+!PB:<PL/AHG]? OB&[Z*BA*9W5(/C2H2?)5?6[!I-'FAQ2R_?,?,T^
MO_;!Y]6N:5QGV\7"X6C%Q]_^FMTJX]Z+[R6<E:34FDM"*KRG30E:W IE['A3
M]I_5/%6&=T-_=SZWSE_O\4 F&PRQ"340;]Y'P, ZL2E [&K"W!"G^I@:I9J0
MP154VO:A<$$?#QB^"'I[O&E.+:K#$:-Q;(^V_X3)@'&\SXWS&UJS0>A(T]R;
M>[;N-O'M5RW-GL<U/FJU ?__)]?;JSHIJ=3&=\%OYCIKJ.'T+[@" 7;\W_[]
MI[+[V$U^\MG1=Y8U\1N?^HTF?_7]UM=.F<O:@_=>D*N8?%TV>^"&5YD^$H_T
MCTP-Z@IU+_/4?0R%NV.SOM7JKC1G'*/O+(V[9,&/)!=ELY_ ?- S6XV 7!T4
M:BH@RS\DVF&)YY@E!C6)HU7HZ;5UF8>K*DSFM]J18.[AHMU0'&*D-0S/8%PC
M-\VD+6^:%@0BY,5@YCVAL4:I:FGG).EY%V:U4^(HJ8@_&88\AL+5<6<O86$,
M=DC-F@R5!W*S6$^D<=A28XI3*H!TCF_U$Z3DD*[R%.U!9A 9M#)]AI<]H&[.
MY9;@C.(8S3N6_LPT@\))=>HI+)WC?\<ZVMYX3MA^*XL,_,+F9GF#'FX3G:\%
MV&82H:X"VU'GK][==24I<@+PQ5&/Q--R6^XF;(-2E0XZ"[F4=7-4K1EUS3H4
MY8&&%/IC*'"C!8;+QZ^N1W9<"HS.'OH6B;W3R0-8Q8SOOKEVGF^-]>T/!UHE
M\*=OW[M/OSVVS5X;2_^/&L]2>)_T1%2?%*LJR+V6M)!W0 X$660S<+ =:^,W
M:S OF%DVUP/9GAI3V28>N)I\31_02H>5)_:6(R0U/^OT)\U(;\]/_)[_I%V1
MUN.QQL%&VI^P$(*TO;?GJ0 +-5 LNH(N HV,64]8[%3DM&!Q%TJ'[E2T&_ &
M5U%.P@;PSN;U4]657'NEM/*E0O=E*G3K2X7N<UK:_A8M.ZZ)(88%-K'9+ ?U
M$8RE.81/6E$-!.Q2I0^LNH0)V^,!^[A1Z0KV&1INY\I?3;Y3977D[==D4']7
MU(F*9B0_MG8?]Q25L! (>B4_8\D/ZC;H?TESTQV.><D1FL8Z2U\E*11V"*R;
MSRF92V*L>:<]GMK=#QQKL]. HK-_]:O)M5 \87IF;W[2@2==UKF9@Y83B"!$
MA9I6TE?H]"$U.P0OPIY-/GBK_(B>#VXE:/VTBA;0)FII/H@\$9OJ*SAXS+M"
M-A*A, S7VE'>P+XL*)6902PAN.7W&R@;<7R.@ 5"F/2?38QKT/S]5D)CX:/:
MYFM<F<+WG'1$^.J(O?VJS#4L!C/EQ\X26/[]V^L?/YA[9;<U\![3&4R>T<'L
M3,\40-W%@\UAY;]P:3>C1_V5CQJMNA@=EG@:L[^E4&J.&3F-8>UZW8M\<GN@
MSJ7Q]W40USTQC'B=K=>;^2:+T^EF$2>SY3S>K!/SCUFV2?+-9J96+ZPM8(PM
MS\.[ %%V;#.\J,XI:6,U!NGLY4/6]@758 ^<ZM"S!*1?6@'>=BO (DW39+,I
MXCS/LC@IYHMXN\IUO)VGQ6R;+Y)4Z9>UAWW,/)8@"K8L[<WGND N6_-M;\UY
MLLZFLX6.E[/-VARO,QUO$EW$ZW2>9OE\LUWH%]: ;WS/[!9S6#>MUK;MGHG-
M,"FLVQUC+T#H>L^R( !E; '="&A!U6:W)EZZ,1';/Q5WF1@G]]U//S#.HQ>.
M=J5+W]'ES9G.B2W.N/G,(':>8"AM59"Q<LLIK3L@B!(A7W5B%="\Q'@0LEWF
M*2C5YN_]7%?YQ;Z\;?NR7,YFV72YBJ=*;8U]R=-XDV[26"4JGR6;Z2*?OMBC
M__O:_.UPY :1G_1=::[S=:/:'(W%]S]]'8FBT6$"AFG,<#S7%739NV][[^IB
MNRPVJR36J=K$2;99Q=NU\>+U?*%G(,&[39]"Y^))?8.L/9:8TP9 $!7YK'X8
M*B*UMM9$R-&+[W[9G\]V?Z[GTQQ4A>-94AC?79E3-E7;::RR9+HNLGF13-7+
MVI^W"GLIW99TN2[>B<0'?#BV!/O;-]TA]E(X10--]O%Q_UR7S67#ONT-F^CE
M*D^S>;S1JU6<Z'09JR)+XI5>3%.UGJMY\L*<X;$P&&I9W(5(B!=;L#TT68-;
M.&^;_1X!A4>$%5_.V<NV?<;;=KM)UVHQ-Y%K-@,_>*6,'YP7\2K/EHE:;,T6
M?@K-@Z=DF,6R(_YF; =_93;I,UT1E[WXMO?B6FWG:Y6LXWF:9'$RG1:QVJX7
M<;+>)IN\ /G%%T89:;YV+%1V(*@3H'Y,! KN['\= ?F([2/G<$KH!8.$J80Q
M,SKG5=-+_<B:KKINC=-/B&T5(*5@2)O6@FP.1-8 .*QPF") XA !"[7[(**-
M?MP)^ IQZ1(%;^: 8.]^^F'2'NO:4PL<\Q.TO/R3:O6U0A"4G3Y^Z'VSYVZA
MR$[KK]#;BD@ F8[P8!U?7M!F)$K7I50B"MQ!A?"=(N82AM&PMP[?.N)7@<?N
M [1\<0-T7_YGH/)B&190GWK/[66=9=82&M:!:C4^37N\F:2:"#, >)3WA4NI
MU8%Q$16B&UJU+_6@^Q"6#EPNZ),-L=\D,>#T>R<!Z.H.0(TWZ)]>3;X[MG"C
M7=-JSP6$=*D=2D[82LNHGXM=9$B,Q+.XQV:DW,*!@:GG2(USPSF@ZU*KA[TQ
MP+9<U:IC%41>6V6+-67B*H/>OCLT#5'P8TN75M9%=:2%>D?-:$ 68FP,..*Z
M+0"-9#Y]@[@[YEZJ.I@[Q,CK=JP;PTS.OYF5!!@<7-_,RPV9" G5,Y-^TZH=
M(^"&]KDLA(B2N..Q)N8H<W5]N"7T9]<=]9!ABBQ<D!49&OL'@*RTPI!##E>2
MTP0FE*G9#&:[E=TM $T)%(IP68L9M0A1MU4B;*T/=@-OP>[8[8GN ;:@'3 T
MJI['H49FFUWCK>+W/WW=B5WK2BKXGE1#10B^W37FEV1(>'NAOI6[Q>2X1T0^
M *HJI%H$'$;N&-7QCC7U<<$$?@--6.^;NC3V'B[ZCO>8IA+.-^_?130/]"2.
M] -V*3VV?SC\B;D'M'=8NIH '^*E3"U&5PF$,!\Z@>0#HZ,14$+&9 0+76)Y
MNVES;%I@4@%W5R;B88ZW-KR C<JAJNT9<%"#IJ;*>'/F#)F M6/[VK3"+OY+
M]Z^/' 0ZJ,K=ONE*>R.QN*!I'=O ("D/Q&?R@\AL(>A>0;EW7KB\@R3,6:@9
M1G(T<[TS#WYH:4=;G@5,5Q"T=F0SFU,3FZ%Q87J%6EQFOOT7[^[U/QWI(WYB
M(=E.>*TX$MR:)MCLT*,>&6M"N2,\OK7N!V)V![NI8S$G2Y9(2'+):&=U'WT+
M&3;KF.>!*].2EM0V9#"9^&G [^)I-]SCXSJZ:7B'9F:4_MQCYFUWQFPNG3%/
MHKTHFCF[B53M -I52'&ZIDX;.53:?1X \=F:%F<[1_D"W&/J,$O^T!P[];E+
MC7I#O4::V+!.E-'^W HRNA\SO+]'!4<,(/;M[)N-=NGPI<QYUJ(V,KU)![:X
MJYK[X.&E5X54J18XP9T^^,=?=+,''IA_ZO[;.+REO9X7!W4O:E_P:G)M&Q[
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MTW@Q*U2:;'2>SE[HII29$60I[_0S70F7/?BV]^#"^ [+U6P;SY4Y'9.MGID
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M\G#=.U71=0EY"AA);O7+17^2ERWW"0>79A 03+,NH$WB<-LVQYM;>SN502<
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M&7%1UG+]WN[G\#)Y0XJS4M<E4RT@]X\60V9;M8X@XW7$GR%[./3FG&U& E,
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M*9T>GAWFY*M.Y*#L].&VR7USC%^P(_VBPC[Y%L6KAT#BP0*UUXXD[X;]J^A
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MS[.$V^L<TTSG ,70YQ8KLJ%9"(L2.9?+&\:R;MBWN/=H9T@7%.K0/[*1Q<M
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MA>@IKQ113M!N&6MS7*M'"0%1(%=?^NKE6;V.X+H"*J!"NIP-O@TF9ZV":(M
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MHLGHLU['V;X4B(#]L-EI%!>@BK<<5F KPRQ'6QX>NS9W7,TQ$UH.W@>76_%
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MM=1V3>8MU'8.:;-*>;-@I_5&RF02I[,PJT-P>/HXN=R_U9%@G=T:>ZTC =0
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MHB-A50W?U2H<5C-6[6R2JK 8])PA#L.\XI_VA]WI^(\DQEE>L6RH[91L9(1
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M43.GG ]ULC9_%1GR@%O0F)>="PG*@*>[$" !=J1N@/!O,NR Q&9&IFLD 'V
M^O?2A9E52<2TL,GC+,>66.K%K%,5$1H_32%40MGV6O4.#]P\7#7UGL+VM*Z]
MJ$+S F9:'2)%P+,1FP=>2'>%9C<,[0/'&0CB#G(SHB7P7>0G_$8+Q; 1$34@
M+U2JEC%#B0JOZTX5 1],MHP32EVIM!TD+I9+%0I'KV,Z3N=BFK#%(.1XXD >
M(=@; 8H:I^F 5X?"#6?@\C0OPHG!IO@E?J#?H'85'ANRZ3*XR4048G/N>H$O
M;O?@B7&CM)50V\B7FHQ\W/1;,$L("AZ[A2R8.T(3$*;=(LXV<*)KL.TJ,A6)
M"N!39PBJP97VF3)6H!4R['5!;4/-V=AF _^^R9#G$X&<+>UZ45[3)&7J L;F
M=_PO0D_DL<*6XMI -WX[O 7<L((?+I,*FUF8, RV=962C&%M06A6<#N6.?"/
M908OI5F/Z+1"X&OS+ET-U&?HL_:4%EEG;V^@].N(NMA);J;,XE;&\/6-'3"'
M!(";'FQHK^WT: =6!7XFZDN/N_,=F%\"_KY&^ ;2V[6A6=C(SP.R[IB!Y7N;
M"I1LJ,=JR90 HHY@J5#X+>VZ6$0:HX0>5D>!,8^J4PPADM3)RB$B@BX6S-,=
M<%-Z'.OF&E%H492Z='4O/OCQNH8GW=_>)'QU\>;B''L\7UV^.WMW?GGVQGMY
M]NGLB71WNM Z7K$&":9R:>=#Q@X%\"% D,\E[!<1^\<*3(K^8-$9:+"(*W<L
M1N1=_,K8W@@8(1UZ&NH 55@-OX='U<HH'1)28B[);W1S)\(DE&K] \(>3+^F
M;?G=V<\7B SZ7U?4TO[+U=7E^W?4JPQ?O?G'U>65]_Z50\OG[]^]O/RD?_/Q
MXNJ7-Y_H)P@R>89?/)5^>#07EAE:UDC9X,F%%5-FL=(6(KCPA,$!TO>?H,:(
M$,DLU5 I/&N"4*98R6B]KC5O2H8V=48C(LUFHP*"EU%)H6ZI7UI#Y#*3/:7&
MY/>I]]<J58)U.'"PI;39$)DQ'F0<H>*?=\<"UQ*#$P.;KZ'3BK**MM26C#^+
M<?)6QL;$UB+Q_*6H-OB^TQ$B*,._O6=O5/4Y"[>E O\,O/0$_HS!=+A,9;#7
M<QT:*($:2NW !]$-0;UXS^#P<6C!Y>4E'?[EWYZCUEVC2?$,7)J;.*L*1!I*
MZ7H5/2<TNC5\2B$Q+PSR,$YA&[7L7"'1X:U2!5[0LZOS\]?O!/A.OZO>%:#4
M6X+32X!/.XB$XXT9O(OF)\#=BRJ_0;@M[]G[J^?BYI2[;P26"-N-$G6)'+PZ
M^ROF%I;Y<&-P5MB2R8.(Y[#@*N/"/E0_C]"[L@6"0)&G6>48?N&N;F 1;5J1
M#XLCBK.U IY =,"L%%,EP5E+2M@OQ+W/"0VO((0RQ&UB:*F=9UN4(880TC [
M\+*\5VS[[VR8OCY'A"!"RO."10'V-E!*?]3M_Y%I $_?-,,W-@VO@HVEYR*0
M49[!.:3_=SA#&"PB7B9:] ])>NBKQ/7E'29<(K/%SWUS*[SW:-:=_-%W'HP?
M3@;=Z1_-FSPQ#Y"WE- 8B1Y*.&R)IX4$?^"0<V[Y6/-LG?N$T,P!$38M&4%Y
M7&0"96"^-<RCC\YE&!63'V .D@ +5FJ=V4^>T=]::-4X2^/T%0'ZA[!9SWTV
MPI#IM1U&> RK;8&!#,V+:Q5HG]#!YQC4>1]XKO]\#\'A.@>-+^OK%FC'AQ$A
M6J9=XR4[W.A[BZIDO+_:7J& ":+(8O85."LBJK\E"PC6#-H#M0$<NUJ\6:HH
MSDJOEJLE!IP,RB!A+-:VCS<5Z&)!1U$:,HQB,@$\$"$("BT8STQI*HTV-',=
MU0GPQ!]A:03J*1!F.R+I8- I?O2$S^24\'G0A,\MD'[.W,=#$F,#:%LPLJ+:
M8:B P= 9==?R-3!(F8491^% GN?X'>9W*#CM!)U!8@ _H@U1I0MPEB*-6?C^
MRJAV6(-H<K %!)";57E<-(PCG@,KO(V\ZMRFP%&Q56FL %'JV4;B4*PU;E=9
MHLP2C%W;_CA45&YPYQG(G X&JT%1_=]>MS<83GSO]4?XYV3VW#@=(LQB;6SY
MVM)B9YL-(4+4U9:0!DYTC.S2L3-%_<D+,> PR7@K+,%2([Q=.4]S/L9?EUTJ
MV$NR EK?DW_.P;E8!^IVK5/6*A1@;U4;',*-<ZOP63=0)/,%VW_B:1D$6PSE
M+]"12PCQDX:&1FAF?L:_7[T\$YAET!/Z;"N>)&C?_T[GX$ZC0CM^\MXNP> ]
M%DA2@[X@T1L#A "4P1B^S?(D G'[D)A_AV[>V5V_C]?&=OVR@D-.T6HB"B5P
M31S0C'E41N<4&T(PG'TZZ@)4<0)F5 D?DV\NF2E,M-7\=:0[!^?5H8M"Z"*(
M% 9CC0EF0%-7!)1U'1>,@6LDP=[U,9LCQ3AA:WHU\KD6_Y2T&Q(N.IZPVQ8)
M39YJ L#+BF#)W2FY$CG'F05P-QVG([80-G!?4*>8*;\!>X4@V9%G?ER#)N=Y
MO%L)A3O/ ;V9AMNN]TZL8[PIR0J)M><HTT $AI)'04!OD.;%2C8,;PHL^81X
MP(1($/@\NQ6DL[C0Z0?"]$;5V;%8\DZF"@.ZD??FXNS#%3 1$!E&9S=QF6V4
M=P:T .?A?6" -!9%5UN@S_7S&NAZ14H$SXEOY#Q@ P>+05OF%$W(;/@F* 4W
M:E."U.HL2"37PS3/\!DCD'?/667>!&'8=!^ ?%:J6@/Y8&5#7JXPS%P<713X
MWFB+K%IW"P1H[GPA>3YD<B?7U?7.</M8K=NH6HAA-;24</"E>%$8G!$U2(8"
M'!MGGDJN_<@QA5XI:QK@. +23^G6#JWA=-A3BEU>Q9@ZQ?^WX52C6WFC<:!I
M=R0KRIE9!KXN&Y4/:"J5[BQQBO%0;2*>"<60?2_) N%V746 ?$K(VM<YR'%;
M2<1'FL2?$7S3(&B[1YNBR6K2M4E6X* EDKWF]ZR_W%GH-;N'LN 8RBY$JF,P
M#DDLPJHI53"F>WV>!:SP%[AY(M4,%(DKZ@:[(G(">Y$#A$1EN6-@%B;N#NN^
M42LIKI$LJRD0H\D,_Q88^ *'@[1,! "Q%QA#E<+W1R=&[DPFW3>)]%&/REYZ
M[PVQ_DA)H%YWO'= W[N,N0=Y&<A/!DU(!,N9<D)1]?W#33Z0^TD_JMW.(+GS
M= D<<Y*G[(L$WA7F5[T7,NL+C%==#>%]U)S][.K%Y<?G?$\S9230:5-9IO@@
MNDX/5\&.71J(D1<YHS%86'C!+3A)^(YJH^L"R6"-R6FF2[A.DL<@9%*#1"63
MQU8Q<&]J>'G/ _>M[*6$AB,E];P8)_$ AG!CA,.X.W3F/.!]_^A+7-F6Z]RU
M@AZ8XL$_&?-VDZ6FO(8="'ZP)K[FP]WQ$4 Z9L&4?<=XC&J9<B%.,L4J7\0<
M/P7[C^U^[XQQQ3F*_>+-&<<DG,D8[B@D5X_XNT.&1L[BS(MX"ARR;*N4% =2
M_4]:\!/E#?0@;_>6>,-I^PWU:S>*I-I',4DTW=S@EJ9L+#'T@Z=+"A6DJ[D[
MZT3PH3 *&J0*TWU?)IG=F4L]2RA'IYR^ =?IJB@ZZ @D%=9? Q'<J/OQ7=]2
M%_%=?_#U?'<&Q%SC/!W[LM15[%!AO]O_:K*F\2F^MY9I,2S\=TKZV+0DH>Y4
MQR@>M?(N2SO_6\%^4PSUBI[QGB[Q/@!9MG%,@^J(LMT5,V7?<1"T[.])K$\[
M63$])2M^S^#AKY!+^X?;$1OP>"OMS?"\ [*O\OB&.4/\K#8I;W44WLIE0%]7
MU,,=DJWHH9L@E[CWK=0NL[-OAC5QN5V,E1%Q#C]/*F5F"#H+LFTHKJTK$TZM
MM1D&>KIALP:80@+2&O,#EIK>FU3>DU3$64W6K;Y&'_TN;=3KSNSL* RP['P_
MM]^+17:G<O*XQFS/_+U[W:,O%';- 08>E:6GL=FJS@]ZF."9F<A6F_K^+L,R
MF8&^LK56SOI&!56@&P-6E\)]JHWTP_O0JN MD).X1K5.]^*]H+."1%EP21%I
MRXO\&ARRR"3+<! <N/ZX\EQU=%BK7&6%4#3HL'>9O@\E^'=O=G\'\9XV3F-
MGCRQ/^8TD"RF\39&U 0- J1=PH'3B3F'AC2P+]LBE?J6/'?6?R]9J!=I'-4[
M:)/$WL =?^>*/=\&(.%C<U;*.:L?5;*\4Z6=2B=&[A>D2O_K./[K#&!):N(L
ME8BCBB6S:5[&_S;IR[:4$\_KJ[4^'MFA/52XS;J!+QTW\$(\F*,.O=UA:GTY
MJV5(9;^KO 22)MUQDR7U(C/\*>6C6'&P5\!CC["FS)A)7_#!P:C/0%.9,DP:
M$"GY%E?>VZ8(&8%T,.59WVMXT!.:"?.?/?J?!YH-,_F6LV&T./K'/B%>ERN/
ML^_W]E9_>,HZ@FE#FJ(8K.<.XCE-DSKV\^T=ZOE^8W2KW[A*VU=TPDQJ0:GK
M^^/>S.\-3E!UAW,H_8G?'TW\P>@PX*R^'23E;UPE>1"'13E?T"@' 'W^ #K/
MT*<_Z?7\V70'P;95^3P^-Y^HX1M3PWSD]T:#0Z2&P[1)/F5<U=8>YSAH6AX"
MI419M4C43]]$6W[I<5]EW S]/A@WL_GT2Z0Y/ FJ8SO<_M2?C7K^8!>"]1 .
M]_%P0+]OYJ,9%&ZOS/(6ZCJ@0K:7*N0HUZ#7[PGF(B7#L_4F4:7.,MW <R*3
MJ-@!U5-ZCKTM6:/NL""D0L@Z$$-C*9@KQX8C;.[-,VJU@'79\!LL;.(;1('6
M9F#X_1E\F'"NA<IKN'<8Q'@ 9TTI%"SCJ;\P%B;APO WM S3]8@_9)@-JJ#2
MZ<^=!^LF0,IT6@ .]^I:$XA4FR9;*1K4<?$7;\X(0P\[B$J='GKU\NR'3?V?
M%9@\2 )J_8;MNH3#]OJ-9+9O205/@(NHL <RIB6$JBCP-&"[LH74]MLF*=V$
M2,67N%ZJM9<42*U/E&JO)"E,9>U>H:B+7)*V6)+/W""MG_!"3@5;,V/7*-^7
M&XME 8NZSH,U]Z#8I" W]E0;J2>V^7M=<&_A5X4X=++;M+'RFN!;KD#9;9J3
M='++'G%'[4[;P2<JSW-JF=U[TJ:DV,*R\\+8;B3OB]77BCL=..T9>%2PY;Q9
MEK<MR>=VC$W.V++NDRFIK<63\(\FBMI>NPA9=Q"(;HEK -35*PJ<3K&N]_>X
M7&&C:>NZW>MTEU"5ZJ,K"#FQK0V(FV.<KN F7=W=OE1_\#?O6CJ4M-V/7J@X
M.Q4J?J\2@S<$7HVBCI"=13Q]5$56Y:!JO*.N,/AZ"Y*TQBK KAM04(342]J#
MA(3 'CAM>@7W]G&%&O?WH5Y_2Y*X/Y\-ZSC;N4IBT^N/&I!TG]8)6BY%5A@)
MPBAA@%(IIF*@7VZF6[;#<^\T!!+N%0J"W?Y#T_U6K,#T8%PP[AY$#&B%!47E
MO@8X32QY$!=U*%.\,S5A,[82*,"038P FRG"I"JPI-3@$NB></QEI9LSL)PP
MAPW@XD'?=#(R,*O4LU6I^=/M=&_ IWX&!ZNSRFYK0-J$GU:MT1^HP?Q$:DEK
M*:B;F:YOM1/TV^.[4H>U?6'\O>#'!K;;I4"0V07J3T%WW]\9Y+<6ROMF,4U/
M!&PD9.U,H"Y:W1$7/]XBM]NF?O0U@!0(-L,Q$PWI5]2.">J4I+0T;?+!41=8
MGF,=\5K0K:Z#/-*=W_M. U[$W%0,M:+55M$6A*N+O6=LL(0$P%@BUC<8O!7Y
M., 89,,^W]/=;,B3&]H4XR2[+"GX) CD4NR:!@0[8 M<-:>(%4/]ZS6IVL8^
MTDZA=Q^%SHU09@2OF^F*:09?,$65R[@(Q43?6T[.[)@2IJ^\PF[%YGC4[34J
M*L>VB+-94JG;D0-!KJH5[^EMV1%$;*%C6Q=#H=P2D<B[2SO*D17V_<;V )"_
M9]4U@AH.>KVI/:N$*S,#;U'%"3%,BB?[(DA@$5D.8@]4R38)4D$DTC_3_9V$
M2U^4+0<\'7(9\+\J:M(#^O0MW2.^?:0DYA"$6!-,#>94Q=84+@*L%&J5ES$^
M"?9_@_!<**]J2'_D!Z>'SY;=M8DN#H\@)&:;!XFD90"@V)5=MJ&&\.YPU2AX
MV#%5*:?>^[#,J):I3P6I,]_U=R-!R"$WU..Q%2R8V_AET!T8=G%*^\I;A8XU
MT'VYVE_H#'Z.4NSM#QK>/FT*32EP(8P%4MP\12'0E;Z07O.'C9%<UF)0KGL'
M+D3D]?U1KU;AOB-X2@0U8;M)VTJVX^0/@T%W,FB,L[!%Y]?7.:'Y?4EZ#N:V
M.Q"1"G0GG7-0BC^^S7G6@VU^<%])]^+5?H[:-0#:Z43!5L0D-=SJ/HIJ0R:5
M->F AC7ZTYY-@:W#=5/X @&]\/]U<%1(*;8<LD]E%Z!#DR*\!4PH,P:N.2'1
MK:3J:PNJ;6 C>K.[GR-G.W]@PJY%85N)N_>[B+L_ZD[&OYNX^\/NY,?O)/Y4
MP_0&SLK);BN808VI0KJ. MV6&6Q@7/9P'PK$/5I?CFZ#]T0=[A=M>,7FZS^T
M^6JB"X<15_M>Y?#W+AUO3T-^RPK/OPOA'T&][,-6VG_3NEF]J]Z%%B*/N[^G
M _V=!ZK/$=%\PO::WM-A'OAAZA*.#Z+&#[+)Y3'KPZYPI%CA_;_#*A8ZF.+%
MWS :>.X/>J=9S0=4XC[L3L<'N"M/]CS\WFR.#O!C[\QA=AQH@7R2R _6>-0[
M!&H[J">?)/)3??*#,=5T? A<==!&]=G9@1SZ\9-;OW<2XB<A?MCG<81<Y0^/
M4(Q_;U/\_/Q COT'(+CAP)_.'[W7_*">_+AB?-Q]?.Y_HD]^J".<3(;^?+<W
M\:!E^/<VQ=^^/9!#/WYR&TU&_J"W \CPI/;RL&1XOSL[8>H<-U/-0(:/^J/'
M?J.#ML/?O3N00S]^<NL/9_YT?'+?#T>&#[KC'52; ]B4I_#DASK"X6CN@RW^
MV&]TT';XQX\'<NC'3V[]R=B?S4ZQE,.1X?WNY*12CYNI!M.A/^T_^BD>M!U^
M=6" F$=,;OW!Q.]-'MWM.Z@G/[8=WIL?X*8\A2<_V!%B+&7ZZ$QUT';XIT\'
M<NARPR<%8SN<]OSYKM0_!!#;0Z"%@]$$@T>7(8?PY"?%FK,AL.9XQP(X!-;\
MK3[!CTF5!T-\OZ7J:CR?^K/IHV?LG^B3OW"./]KK'LZ3'[G2R9_/1O[@0(([
MCP+8_;011^?W>N8)<?3AL#]Z+O;'"9;C!,MQ@N4X'>@)EN-TF"=8CONVGG@'
M:LL?C+OV%;FVF3\;G)SN _+(3KTGAW0<D]'([S_^B1QT[<.K5R>!_&#T-O-[
MCS]W]J">_+@"8-B=G]IZCING!E@4VG_T2O*#-JI?OS[)\ >3X?[P\2V&@WKR
M8XOP_J,W(#S1)S^8GSKW)[.=,<('+<&_MQ7^U[^>)/A#D=O<'XU/$OPDP0_V
M.(Z/I09S?SQ\=$_JH&WP-V].$OSA?#Y_>,)4.B@1OEM!>@";\A2>_&!6T<B?
M34Y&^-V02B<1_F#D-O9GXY,(/QP1?H)4.GJ>ZD]G_F#^Z*=XT&;X"5+I <M+
M1OY\_.CD=E!/?NP&OA.DTI$SU; /=OCLT9VI@[;#W[\_D$,_?G(;GX8,G$3X
M01_'\?$40=P\/E,=M!G^\>,IE/)@)L/<'SU^Y.Z@GOS8H903*MZ1\]1D[/<'
MQY70/('B'2VU]<<3?SQ[=(OAH)[\V&;X"13OR)EJ.)CZ@\=WI@[:##\T4+PC
M)K?^; 8FP\GN.R09?H*S.W*F&@WZ_NC(0BG?VP[_Y9<#.?3C)[=)WQ_T3I&4
M0Q+A)Z_HR'FJ/^W[P\<_Q8,VP_]V(&=^_-0VF8[\_FF\P &)\-/4]./GJKD_
MF,P/87S>01OB?SLP,?ZT8,P'_GC743P$%/-#((5#T04G5?#T.+,_&OG#W7,_
M!-;\K4[!CTF5!T-\OX'&_&F_[\^FIS[R@SS''^UU#^?)CZS/!WYO.O!'CU_N
M]'@3!A[D(74X_^XX3O<\^/SB3>?J_-(CS&(5>7%:9MZ5"JL\+M$'^5#EX2HH
ME'=VG2NU5@@#_NSJPUGQW+N-RY5WD5]G:[ANDX2^EZ7*RY:>W//__.=LT)_^
M5'CG29SB\7L?5:$"N)_W/K\.TOC?!'Y?>+DJ-O#?&,'MEUGNP>L$<##77KE2
MW@=Z^A!(3&Y2YG&0^!XL<QF$<1*70:F\3;#%M>'3@S4H65AE5"F]NJ[W"P+L
MT_WL>_AZH5Y<%!6\@WZ78A7 DO!>8;9>9XC:GX6?O2"-Z ZI*KV-H"Y[2]A]
M^K0($KZF7&6P8+D';&D5XN=5691P WRK]@7"#M Z@C14=F7JUXU*"[@!/F)9
M)8EW$R25XN>8IP2%]Q[^S($?TDZV43A5 !YT'<3IGY*L*&CI1;4HU+\J>/-D
M"]<O"U7R;>49>!>]-+@K+!UHY=\*WQG,ENN5>4MOL35;A3?6[QB$(5\-AT&#
M"N"(S/L]'&D?%O^\!$812MWBR 8%A!8! VU*M5[ B0Q[/HYQZ--.X3R'O537
MHY_TN8%"3M8GWE!A&=^H9/OC[N(GI.XL2;);VDP><U&M04 #!3*5,H&_VR'P
M@D2&WO^BY0!@#Q/^/1 D_!!)W0B!/W^_+3V,Z1W?U(KXWO;AW2#^!P7>;_YO
M,.B.\<JVP0Q_*<H\2Z__&R7&7_XD?[3M=*NS^]V-QM-Q/]AQ]P[UN \SSWE&
MADJ[C0(J$ZT4,)%8B9X\K=8 QV0V]H?34U'RX9S)P)^,X?]ZA^'\'EQ6[%40
MY];]$=>G<OVFPZ*J)Q64[QQB./Y$!=\[->-/)_-#S9L>IB6S+W#C/</(S?.#
M)N8AD$J45>#6_O1-5.B7'O<@!D^3-(<G075L9SN;#?W^KMET""?[5/((9Q3[
MWHU[^B:^N0HBV&<;&%^#D$-AA^$[=MFZWIZ[])R[J"2"UQCXXT%?[O7CAD7O
M&USVZ2?GV7H3I%N3=@F#8N7%:0A.<@&7+;9>L-GDV:_Q.BA5LO7^,.AU)QY0
M=!*##4WCF>D^&YWR@:/XPZ3;-S^!OW_I7G6]3WC'*M]Z"_BB\)Y]ZM _GG>]
M=ZK4J0GW+OBW_,B_Q[(FW:E^9M>[@BV)ER &P-T/X0VSE')0<E=]'_Q'4D6J
M>:_1U%D_*-7]N9N==(\.*6Q *,4A9DP4G@:\0>,9SG+Q$;NW5WK<*CSB5L_2
MQ6!_MJ$$F"]ABU#%&TYAU1_0=XX)'I#H%X:-B&\4W^H/O>[ _9%)1\G+9)Y:
M;Y)LJS"IP-D?W'K<#SJ0"L\"<VJ59+F:U"36"2V7-QM),X8WV9>A:WF167>F
M%[FSC?-NSZ4T]:\JWE!.#U^/WGF5 >_':[CJAH+WG+F*XK+*91=V-JZ_NW&2
M*ORN8N-)3XW7LS%.4^._MU;H^^/YU)]->U;LW*K<"B1@&& O^ SW#O\"BPNV
MW@JL#<Z')CV 1?><:<M*8'$CY':9?&+Y^,?5S!]RM0GBR.;G([5?H?6Z0R.&
MHGOGBPM2=T'.<GG7)L+#P00I/ $K"3BWB>^']X=CT7).<O1A!GJT%.%*&5'E
M++^1(MV1_NTR'K8\**L?V "[JC:;!,M@L"!"6S01\4%%.KAUL^"!U3((2SYJ
MW/Z/_R=8;WYZZ:DE7"I'<A. !44U-&2"E%6TA6, K9<KT4]?9_X5>JUWV5;]
MAI4 U\""M#5UF^6?/?AFG45D<G%YCGQ9?RNIO=DBP6R0&6"#J$:E]GF&E2'>
MVRHIX\]QRM4]:&2A>$$I4N6;K!#=O5#PK6K=T!=QEF37<5AX;T >8:W*&;XK
M+]![]N+-V7.P8E*X!5:YK..R9*;!>[UZ>=;]4<GS@Y$ 6+N#7A3L=%L%%H:2
MF#*J7 1*!!3AD_V&0B#$'0M!\\4IUJ0L*[2IY#*?+3 0+/0CM!8708+Q=J>$
M"AA#V^"@1[PH+D*X&F\"9(9/6<8I7**%AE22P:-AT042%)8GE:"B\!<8" #%
MM,BJDJX-%H:F]!KYC:\SO!0^"U4.VJ9U,>4J+MSU ,6D%5!@5@%IA_ Z1.3"
MRANTPLFRI6J2HY-LK0_Y"V:V]=WI%Z"M,K;F_UQA91Q(=?4?__V*3_T\V,0E
M5>M98?27/^$]_OO(=J/&2*/QWN<VV06E)>FW4+8"959<,LUJ3Q,])5*U)FRK
MV45_@Z2;ZY)'Y*%(W:@D8Z\&A.-U'JSI\W7P&7\OTC_:<53.P.K'PPJ29%OS
M]<EII((^M!42A0Q:;>"^D58<7Y;:NGQJDY6*V<^5T"3"M=E@!'G7^Y3QOA3:
M%X\+>;(B9=G4.TZH 2Z&QX$ B1+PA$R\(,>-A*51;1;[HB0R1*_ OQ/O#X/N
MR'42^?GD^6'QF'D7?#4N"-5>O%6*]<WU;E<QG,Y"70.+P$W?TF'U6;'N#4B)
MRC7O@+$M=$MCDG[[O7=Y5[:AA4RZW@L5!I6-E("1D5ZK78?5E^K36RU+T;A
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M:W1+@1\&H'WR,E5Y0]E0_\6"/K7>'7P$[LAG53*G::O=^B-LP#._BC(#)Z)
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M#&7(QB/54#C*HM&#6]M(E(=XPB4O)HVW$ML1V-0,.+ "./(XEJ.W)F6Q5LW
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MIL2E3&/X**T'OQ0T$DBN2H:I%C)>NBP43QJF%-=(&57)+]XCGFPM7V^2I1/
MW8QWO>(F02-YHJTPQ'J>Z)GXJ"0##*]72&T_&/-Q)MP><NU%)WC>.ASZ/*7#
MFUT=-AUCQ)J<7' *1>#0/-XSWNTHZK=X0"N-:#(0$$UUWTZ=7J3R9)D6]ID
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M)@,:C$7TFXVQ6"WU.2MR= \C[GB!(H6-X:Y2@?H]<T%1(RNC@/ T_ @^0 .
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M)G'A(6L2EPG1FPD0HP>V,PNF]T0=<D<!J$&NQ]4S1>BG+.?H5L <0%9"^LN
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MB\E/C/Z:.OK+#V1M_O(/69N_PD/>F/DSJVV=_-R2^6M_M,R/5DM'?_F!K*\
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M/@5:#DG_B9SV+BJWI^=5TJ.#L7R$^&SJLP#H'?#7<:$BH4>F,W\PI@$CG@M
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MBH@S$!)ZSPC[SOR!'3 R]>T![]O#GWFIKJ.H/S?JQLV@V/_]I6.9[4\!23Q
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MR)9+(=XES3<RO:.P5.>OZJ&BP%[*"+DP]%/3_M_1[UI/%(K/2@JY,/13U+/
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MCK*+*S:;2QY'ZBK-)EM4BJCZLC"9F?XMC8CFF9PUQ<BY3W6P]W3J_G1]F5)
M946ZBJT2!Y]_]JD;0B T\"9,!2QE0-YD)G"3^;[&0B7#%]@=S_>9M4K-#+U7
M+D [YSC7=\R7AEVZ6>QB=E/L\M+%8UGLLD;U2[-CM!2\SOJMAWP%YV%]HJPA
M:Q(7QLE*+B9GWZ?,#5API *R-%>6 =&:Q,HIGOUT5]ZP@%%_,.8C2H;L@3G>
M%(^D54"?RGRZ =^_:;XU5(R(=NP.SQ*2]809>?/=='7#K'6,3K>M7$!04L@[
M8$'KK>'G5EC0;!N=1LVPNL6Y'G&'JOQGYH)'Z7!-3H<3V[6#$#W,!\5R>+J#
M1,A>_:WJ7Q(:1.]XCLSOE;ZZ4>LT#:O^SF[Y,JAFS<ISK-QXJQG9%BN;1KM6
M-QK6ZY<YJ\#**L8)40^MMY2FT"*HH@@VWWSN%!%8RMR;+[>NMPRSVS#,G B=
M9EYUF+?UYE.P33&OU36:C;K1-O/!O+JO5NW8O&C;+2/D,I%830\T.2)SO$ Q
MOU,]AMS$J+1F^]UNI*A)N0""O7].VNH>9=YG]164G3*KX=9R[#;(3E;'Z'::
M!L1*6V4G[9NIS=A%VVX9(9>)Q(KZ9EA_2@YE4O"#VM7BRC#F1HQJ9LWPRB7F
MEY[KS1O7]R7;$_O:,2SS]8&VVE-3L!"@57M7'?JF>8I?^=9:@Y=45,4[JR1%
MYY@ .8?,MQ_X\1EHXR#T9Q,Q:D()'LZ_]+R@DEMO+N4ZBVGV,[5=I.25FWQV
MR=X_;+P%$72GV=%Z.9^<]>8*K>US5KW1-6KM[7*6FL[O']27+9+#V8"/<(I.
MQQ7AS/S+Q LB\>;"J2_4]OF-:\?#_\R"$.EV-9*T#'3397XA[T(1O[G&:0VN
M6]U![M2:1KNYW6A+36]7)!Y@SY6D-.D>+)PBK)A_(7A!!MY>9+08):)/$J!3
M\O:2#=-H=9I&O;W&X5 9V*#0#/CV0J$M,&"GTS9:M>+TSV]7;Y_C@",6Q)ZR
M ;]3K,VL5.5X+_DZ;ZX"B(@\EP3<1*QI&B9$FU;G]6A3W^178,9\<SW!%AFS
MUC"-MK7^G/=]W>2W734/.-756KN*2=]\$@A4VFR=5KT%&KJFZ[3RR4CM-Q__
M;9B1:H;5;!I68PVG>H=)Y8(QEK(L7;3MEA%RF4BLIB?VU1O:(W@MU_7>B#S*
ME+,*&-.AS9()7KN$8/ P.4K3^-V'"BD[W*P9G9:I8^TR,^3:E0=;9$@+0NSZ
M.Z\\U8YB_B"7R8LH*>0RD5A-1S%*V1'Z0&V'7Q46>J#[)Q,P",&8^DQ>0J@"
M"I\UU'FZ+_(EL_OFZJ:Y5,QQ1,H[[Y03,GV9Y D-[,$FLGYMTS2Z[=>GM;UX
MJ60Q_,2BL-^;RYQVSGXUPVJW@/W6/Q)\+_MIMU#[#.5 M":Q=@O)E/ESWB"I
MD#ZJ<!50]\X#H<W?]?*2;7US^62/^J[MW@?7S+]%"D@+FIC)\\LO\X;RFO\N
M2-G+6G6=L;HY=<IRP 1O+F'<#!-T7I_N6L!^';X,-H0(E_GTGLVILX!XLS (
MJ8M762NNVY2QOQLHYFV_N<HP(N>QH.;E;-)G_M5(</M50LRW!AI2;#XW:D:K
M91EF78_$5P3R#KCRS26&N^)*S+LTNX9IKC'&2'%'MF!<JJQ\%&V[981<)A*K
MZ4V^%!@/;6<&-D %Y.4J*GIS)7-F5(2WT@A"K!\DEVB"D;+LT'ES/?*FV4&E
M<'EGF;^UPF6U-9XR=GD#H4GGS5.&7@I-%B.3M+"\*W+N-@RKL<9TF#(P2:'9
M\\VCBG;.GJJ'T!_#OC=\PC_Q##T%Y,O5Y5WE]OS?O2/"H1#^P9?CK^<7?QZ1
M13CDZ_'-S^>71WA)W">2(B;.(;%'3Y\B\(3#WS24 <.F2P!RRQA@+(2G0H^,
M;)>Z YLZ (V&?'A24-T*_,5=<B <HQ&@ON</F<^)"OQU5.-4X_1;@B+YH%;[
M*W YB-"4#I$GD;_@I8)<F8;\("U^XVE_["?K>=D%F+/T"_4??0?<@U3I+[GK
M_>O_L_?MS6DC6=]?1>69W4FJA(/$/9E-%;'QC.=-C!^;9"[_; G4&&UDB96$
M/=Y/_Y[3W1("!$@R$@WTULX,YJ*^G%^?/O<SJ%S?7/9N!FPGD@AQ56FD&G1.
MBY^F<" K0X\8WRO&&)[R7C'L9^/%_^EC&C6-/XT\?OS94"8>GL$? G<TAC,X
MH(1PQ\H%\@R:EV# H_"K*0["ZT_;9B#$=L\FXZ! 8+@VC KBIJZ=I93J=GT\
M?\8)A @U N,AFHAI^5/;>'FO6(YM.>2,<GORW^#LXT7O<^7^XEJYZ-_=]N^Z
M@^O^S<_O\#GI82'"TN\'W4'O"YR9>Z5_I=P/^A?_[]?^9SAH]S\IO?_[>CWX
M\Z"6\V>O>W>O]( +7"KWO5M8VJ?>G5*KJ@K*ADKWYA)?5#.<W )EH+)%GXG)
M1)\YG<JVGI4N9LHMEEM\N"N66RRW^,!7+._7XZ.IW.)3W^*MQK*Y:E68J-\%
M+1,-5H8MZ22/@MQB>4D?%7MC66/RW(E,(YK3)TDD,HEN#<NL7,MS)#21NJ/1
M['%F&^NB*"2AI*!Q("M<I6FR^S)/S:+PO,1A4N3MQH*=DC8SL<S0R9S2@Z5H
M]]&=.8DEYR5!#Y*@%\;4"I(-()*B!TG12S*V1I8\H\=#T8$KW@G=IQRV]\C/
M_0G9)QQN*S==;KK<]&-;NMQTH1-"2\N7^M3]W+VYZ*DK,9=:1X1-$PFIF>VO
M6_-.ZK6EM*BNWQ_3O!.::_)OGF3R[U@=PB\$$TR6LU"8P>?:]V>ORRUIJ'I-
M4UNMIG"Y)4*-O-_DTPUPTG<$IUC%R]Y_9U;PDK?/9*VAJS5-9M(=)IQJJ> T
M#^=!E]VUPTU;Q4.KK3:JV,8T0]J[A)<XJ?+U6CT5ONY(8%@.,</\^(*!%6\E
M4E-;>E/5&\7V]))H2<.,&IO 4AR;::A:K:8VF^+549.EG,76#XYMN:<XLB3Q
MT8\L27ST(TL2'_W(IT1B,2W)7=.=AOTZN_<72KNNJ\IG8OA$L.9+$IW'N]&2
MQ$>_T9+$1[_1PI)X%W:LU$7:4QI L75M>/?VQUU_!!<ONW;SFKQT5:LW5:TC
M7H6Y$QVY!%0F%C'>UC'Y5& G9BWO6\\%V=[TE3%\I@03HO@&*TL7UKQ=F^0H
M#\\N#T\]=<GG[2YX/%8A8?$Y@PFY!ZKVQ[%?A+6><\=Y:&I=U^&?CG G[41'
M+@&CB068\V$T=++%<8JQ1X8S6@1JWIM JZNZ+MXU<*(CEP#.U.67\P6=% ?4
M&C;Q574M0X# *4#FJ,&:V.7\%0I<3I3^CWBN:?B3C0"M2%R*,7()N,S=_KQ0
M]M@!0;,FGJ II@_E=\/S#"=0+$X%Z3G9U;FI"+"64QRY!+Z7V)HZO_;-SV#(
M"'UYZQ[NR"6@+W5/[&RJRW8DIK^&V]6&VFK(*'E!1BX!E(GMJ5_I8Y)\\7A&
M+@&"F7M1GP+'$].1%&H=Y&_BC2P9KU7*^4CM<,TDM?9"$N[ 1]32-+7=$N\0
MG>C(Q6.RL6,_YC(F61&[W,:DEJK)3&)11BX!C=D]EEDUJUTALZ%J.J!3S]!P
M^10P<M3HS.ZR3*UB;82E5+0.:>02@)C:'5DL ZQCR^RJ<+@3T\_SQ36M,3PV
MS)=Y9N20BI=T]QSVR"7PN]1N[G1*2OPH]L><+\J;]^!'+@&)V1V/J164]*C,
M4LFDD:60S2F 1%AX'MMR3W'D$CA0:C_?:?(6,=TM]:KVYOM;2CC/&LYPIWQE
M"O>!8CDR=:?D$Y0]&S-=]4Q6B_5RYEG.PRWQ+-=DCI7>X]1V7PCY1!PRMH);
MVW!>XZ2IJ>V6>$KWB8Y< EQWZ#7< M=OACTCNT$KCP46+PCX1$<N'J?-[)[$
M[%5D2\!LLZ;"M"5NQ1BY!-QF]SEFJ$Z;%[#2\'1((Y> TM2^QSWRS9IT!J6<
M)24*3?DAIA*XL'Z'<%KX2 #%)]Z3-2*"X/NH3U;VW,[7J8/L_2O7NV<T?DW$
M7JNC=AKB';H3';D$L.[0$Y;F@M@%5NGUT.I(55"0D4M :4%>LE(1VVEI:KLI
M@T\%&;D$U&9/ZWN](K@%KE(-/*212\!H9N]?R3Q3/ZJV*<4J@:Q)C3(T?% "
M1^[CE#@^"P^L*)$V* BT#_]0R?# PZ;?!J98GD.7LDNJ?'_"4WL1.[3RXC[<
MD4O :'8O[LY4HC1XS6#HK:J:IJL=J1J),G+QZ&UE]^V^7C62;/;81BX!J*F=
MN9*!'HRSK,]Z#,E2%26>H^RIKJ]SBM$/&:'],$/Q-6WM.QVU): W^D1'+@&P
MY7EQV96P([PRLUE'O*O@1$<N :G97;B[TP1WB=I:K:76:I+'"C)R"<C-[M;=
M@1:X';)2"3RDD4O :6I'[AYY9UNMZ>+=^F(ZRFYGWF@"ZC>6S:!9<LKP!5Z/
MK1'Q?,5P3,6T/#(*7$_JAB4<K^R59C=68X@=NH';YU3M.N9E2--5;?&&/-,?
MO"9T4J^J#4U6[Q)DY!)@NT,OX6MA^[K$:[TJ^V0),G()L"W(<;A?"&OMNMIJ
M2Q@+,G+Q,&[OVH-8!'ZE(GE((Y< VLS>Q/USU4Y'/(N<F&Y%NO51VRT@M"^+
M,<IHRP,?N02FN$/7,&67> S#[A\7> CEI7RX(^\*?V\V #"[JS>]1K0%C*GO
M8L6'U?SKK'+VL=5NJ2T]0TN-Y#U*)N%; 4A^^&#;@+7LSMH4:HOD>$<T<AD<
M+[7C]0AXF9@N**:GA14[6(6.(+#)(W$"=$N-;,O!417X%C&\T43J$V6QZ.QI
MN]OET7B1CI#,_?$%)_(=IS$]5*_ONM6HJM6J>%K[B8Y< F)W[4#-B-A7&IG4
MA@2K*".7 -;L;M-LVE:)P&TUVY+3BC-R">#-[CQ-J;Z]$K52Q3NDD8L':B>U
M>W2__+,CY.4OIG_IA@2*[?J"Z8"?^G>7O;O*I_Y@T/_R7M&F?RN^:UOF!V'.
MU989OLH+==N]O+R^^27^\'TL7**@3!1L8+O9:S]OS1J#8W_MC-Q'\AG.?B&W
MO@2Q!'$<Q-D=LID2RB2@): + /0&?T<GNX<W7:+9!BCG\(;4JJK>:*AZ?7L7
MK(T(/U"'KT0K1VMJ'_'1PC&OS^XXV;@P^(]@?FS+/<61)8F/?F1)XJ,?69+X
MZ$<^)1*+:7G_U/W<O;GHJ<I][W;0^_*I=Z> <*R@("["IHF,SEW8HY:B%;M^
M?YRK_%;,N_6*\*I:6VT!]379)DF4D4N 8'-'$,2/)JYM$L]GU?IS%WQIM]1:
M59:;$&3D$B#82@7![*7==@+'>E53M59=;;9D#KX@(Y>01]!II\)DAJ)MNP!C
MS(+9UM1VK0&,4J9+"8RP#0#K; )8<>Q,ZZ@MO0G<;+OI6V@-29K&I3HN1Y8D
MEB-+$I_<R)+$1S_R*9%83-/XK>?"4*:OC.$S)9@0Q3=L6EAW1(UA"JVO*\+^
MB0S4UZM*C6IBQ@>H2O.H(2U+$FA(6'S.8$+N@:K]<>P7KTY3UM6F)A.5!1JY
M!(PFAL?GPVBH],=Q&A:G6 !J[JJX3563X!1EY!+ F1CVOA&<F8SMA0&UCFU3
MX!^]*<$JQL@E@#4QHGTC6--9X3.B5.8=']+()> R,78]"9>ELL=F3:T+R![%
M+$WUN^%YAA/(_IAEGIO$BFSYM3=.P["OT Z*2JF-3DMMMZ1 +,C()6 RL1#:
M[C#YRNH1#;73$J_AU8F.7 (:$XN<O5X]VSTR.VJGHPG9C>U$1RX!G(E%S5ZA
MCJ5%I=2_#FGD$H"86*!LD_Y5P,V,5GV,3CYPA:LT']H7U[3&\%A*2W>L/#-R
M2+U+-@\Y[)&+YW?:CKV>\:/8'W.^*&_>@Q^Y!"1F]VVFUD_2HS*#>[.NUMHM
MB4\Q1BX!G]G=F]M5%,DNCW/D$N"8VH%YHHQ03-]0O:J]^?Z64LZSAC/<*5^9
MPNVE6(Z,^"OY"*7VM69,4&8I\JM=17N/4]M](>03<<C8"FYMPWF-1ZDE9&_1
M$QVY!+CNT,6Y!:[?#'M&=H-6W@=7XE20D4O :7:W9_:D^^(QJU>K:D?K2-R*
M,7()N,WN(,V0F)\7L%+O.Z212T!I:D_IWOBFIE8[XO%-,5U7E"AA%\O A?4[
MA-/"YUTMO2=K1 3!]U&?K-2NWQVI@[$^093&KPDO;#74=EN6#A)DY.+!JN_0
M;Y?F@M@%5NGUT&J(=S6<Z,@EH+0@GUZIB-54K5-7.W7)7049N03<[MK7MP/
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M2*(J>A;'Y&0ZG'CS^6Q68L\VG):A#0INS*>D#'I_#"K7-Y>]FP';B=A&C @
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MD"U_#T# _\7 * ^0\">N%U0"XCTJEO-$>&R:( @__+.U(3ASN7I-6@8/]!H
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M'.,<Z3=A+L:J/L7T).XMC(50(*+6JCAQ;PN>7:Y]XC%A$7F1EV5>]X_'S?
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MK=[6-@5H;Z8A$RA">>(KB!,AA^^/N5Z7(WB;/150T5!KM<Y*^+8 5!%GY&0
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M^CB<M>7,#(::76_<?V9^8(U?/BR0J;A!?O8#SW4>/G;/E=\9&U8^6\;0LJT
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MRC%U$;11IE.#7CMR_8"- .+OHVO.-9IGE(!16P;XPCSLEPWH6.XHO]TB/V]
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MIR),4MGG%?_7*^R[>E7(<R34R*(RZG:>9+DD0,E[_CA&+@%RB?6$,D*N6.%
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M^*K-F!&]6='3;&+<C7=-19]+6E7V%G[EOJXOFZ:V:ZM1'4G08R(8$[P <RN
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MIXAERU6F-J"2@A-^-YZA5? )E$)B+E\Y&?P,KW=O))\+76^G/A?+_.?6<Z?
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M\A^#?NK%:%WJ9=><K#6'FRTA44J.3LSR$=;F.K7EGN/(Y[3%1V&O7JY588A
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M'/\;20[47QH&W\RJS!/S(G_!0728":",V1X983!S/8JQ0/F&D6%,IL@@RV0
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MV"Z>QV*OOR"ZT#>P1D"5368.>,&/KVJ,Q7.O*A>&8YB&JGS]IZK\0KN(P/=
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M8%CP?>@S<"N6\PWO&QMCX%U\7O%??6RB2>D(9 >*6?XL0@MCS\7 2@9%>B)
M) S!AP&B,OE(7QAFT>F @6,QZAJ+D[N2VYXGLPKW9ZFB<^*;'E ^5.H4$TRM
MIK[>L8A2#?7FXZ-''E$$Q>NC^_873=2W7Y7O>GH/U5 DKA:,P=AS]06+4T21
M1TS%?2;,CJ08:SZXU(K/RF*0PF"ZK9S#R [%@@&3!,#D"'W&L=<R0I*@X0OG
MRU4V/)&<X\T7=./5"[K+O^86\]68J9H3\-2:^EJ\DQ9A(*WA."09=)(\T9S:
M*=N7PZSI1M$6#'I'GD!P@U!(4BANWU*QKFXP3+>"8E%H%G2/&+]ZT1SS2-/M
MU$T::@U^A#V)#W%,K*J4Z73ZZ93)/H(.+"CG#!4&9JY" <X'-/P/\[F&4?).
M@K9V$$";!S._" 9>:N!L^S# F:/-8MV 1)LM@CG+<0=3$ E;XVZ;G"P:K?;]
M;@-A1Q>2:^6&Y#;ZYK6$Y+JI"8-IE\G'$Y+3U5Y-(;D1>(^VTD[=KLU!N6X_
M*Z[4 7$I:EQ)4P?G'5KJ%D[,$2.TI+72&DI5"2UEVWZI.1UUD@14-4AIGZ+2
MT)]\)/[$L^CO&,KG,JO1<%>Q2!<+7>'\3096_5:Q?E3:W>]30SSTQ12-NW(4
MJ8V-&9@T)NB)@5T["5D;&L^@&-8FF#GO% NFT6WM;AK=8M/ LV?A7/J[(XE>
MB"3--:M^9+(],VR,_-'P9OX,B45[OB]"F<<3O+1\"E=NPCN;I,E.;3)*&S.P
MNGV<L]AV%(YE,CVI#6DTLU5W-!/&.)YH9MU!PU[A,K(]!@T[S7;*94;AH&'.
M:K6ZK^+B0,I-&/B!07L()* S^(J*F4N-[DJ4)<J'[[UYWV^NMR=5P&NT<8&'
MB(ZZG@7.*0K.$H'27N$J#;$#I?VL0.D5NV=G=^P6=N^8P/3XG8!-$GTVTB2O
M\N*&MHD4? *+8IFK!SP$I6![ H]U[DCL08QNTU0^P)BA3^@PB4;*%'Z<]C;(
MWFXJDIB&PI^LFST9"F/9ST1/E3N:V2/QAB29!$I7JC&!J"JC@IE*/M.:3F'N
M,%'V_N:RE(XBU)0 U'=V81#0B-130'8N'KANUQF=+06M>(U&+ 5.1X;U'US0
M^<GO$5[QV@U^)\$">+$&T:,WUP$68]&#;)4G<-,31[8\Y")3J]U,45T1M<S2
M\%8JJO@Y:^YFOY:Y16C5K>JVOT7(IUM*1""B6]5+A5[ABCB!+A4*Y15N$U1<
M"KGK92*>^XRO%KQ?.+?@[RC8F'R)'; FKFU'4B/J]!1U+DD&<+,%B%[K#>TB
M$(,.(WV8V<:C>&[;!!4UM3_HJ^VTJ&)Z_%6AF<L*-E;;$$@$J^XF"NN^SG&K
M@:(T(D"%D('MP0AIT$@\-VYH4@C:DX0ZI N##=UA)OCIE=2ZU0YVM+\6@D"C
M+&%C8_NNQ6Y3![3_SE\V>)#,5A 0PBUVPX3?6J -/=[2CBWL(>4],4*PN@B9
MJG$H5:6+0Y<>_$Z#=FT#&IC/EN_BJF"F!!C6HJ8<]06B.':T&D9WG,-&NDNY
M*.5BX9D4+5.X<O!6&6-1=1<\*(5$LUF':-Z<(1(O,R&7]R^6]8':J223<W;I
M).5QM##'3G]9+)3+B=A<,DKQ*L5K<;,3!1:/C*<QZ+(RQP.7QWMQ+D'PXF[R
MA"U?\<.G)X,)2</G5V_^VP/U(U5D4E:<E*7)I*Q-Z5@\Z2HE':L[Z>K]X8Z-
MHJ@Q:96*T$VG..YMF@3TW8LPS 0]+XU/M@QZGG1H1XZ9:43M"0!].S%QDJ@J
MZ0)L%0*[5PD"6^OL P,[<5$H A2VW-,:]O1RD6D@PIY6LP(6!)=L)B1Z/N@[
MM(S!R&$.=BZKW8X^?KRZ_B6YS@,@L\B]KKC7O]$S"T;8"&8(1K/"10Q1:.ZF
MW/HSVOKXFI4Z-QA$ QN5QJ:4'R@@V8^2'4Z7'49Q%M<5;+[E^.#QT-MWN>FG
MN^E2U9_/7DM5+[=>JGK)#D>HZ@^(@W=XT,],@.?>CD$?SQEI51)=$ET2_=26
M+HDNB2Z)+HE^<B.?*]%K;I:TFMY6<9:)JW?$ZUA--M.&(I!.)'Y=Y='"?0TR
M<Y=;J\BZ+'=9&R9REQ/;E%/D6Z5=&4\<3@S  JU;Y#CWU+8V@'_7FY<*L)WB
MC)S..>GS^6Z/[+@*.WA@=HP"@CP>&$6":2"X&'9"M]E=!UP5D"'.8>2:V7>M
MOK75*]RK*Y^3,0MRA?42<*IQ(!HK7:\<&H=.O.H# 1JL50$O%[\.FH.U5E\"
M;) X(PLJ'[5VC1P6A[?CZ#8-;E>%H&T/U6ZOK7:'4MX),O+NU?4@M2AY25TG
M<C'%MQXU51^VU79G'3-"@.T49V1!I6-K,!2*';>W'H=-;;TGNH ,<0XC[]QZ
M')8#Y\WDY)U;C_V41K$";) X(PLJ'[5V.;RW7 ZKV7KLJX,>&)!=\<3=CGO\
M5ISEKQ1+2U#^%T8HG]IRSW%DN<4G/[+<XI,?66[QR8^\>_NUM46X"6U6%A^Z
MF7)7G=E06X2+VFI+ZZC=E@P7':4[U!ILQTYY\9V(MXKAJ[?D=;4@(TL]=?(C
MG],6BYGXQ=M6B4 @D3FQCO2N?CWWQ77=CM"=]Z]X4X=?/-??IO5;6^WV]-3F
M90)LKC@C"VI_M;KZGIG3+\6=VU_?I?=J$Y!#SF'D<U+[9SJRW.*3'UEN\<F/
M++?XY$>66WSR(Y_3%HN9(A(Y+#+.LH?,4ZV^O/R56ZIX&[<(E R':K\CHR3'
M&24IUS1O]U&2B"%K#)3H37V]GZZ /'(.(Y^3XC[3D>46G_S(>S!Y:BQ7D":/
M-'F2E3#EK.GM:[JDR7/6(TM]>/(CG],6BYGT\\GUIL22:3][2?L9BI7VP_<^
MQ$ZVCGF)O5_I&V)]NDW-_D!F !VKH=<MYT,<GD]KR0G2)4**(".?DU5PIB/+
M+3[YD>46G_S(<HM/?F2YQ2<_\CEML:@Y0>#2R!#,'ES;?DTAF)3KL6UNQ=1^
M7U:D'&>L9'?@PDMA#"XB"D8S]':S+QYFUYF.?$[Z]4Q'EEM\\B/O(76G7%5X
MF=0=:9N<HVTR+%?)71E51]HF1SNR5%PG/_(Y;7'5')M3HH%DMG,@M-SBDR>T
MW.*3)[3<XI,GM-SBDR>TW.*3)[3<XI,GM-QBX3STO25@;.AYWFZ)0#J1>;2&
M:+6>VB9POY4&=7:M'*B]KJ[V6_+RY"@O3[I]H=AQ^Q*7?E-VQ!!EY%UWK=2T
M&O/<*G>MO*3_S6UXOJBVERTKCT<X:NV: .QS6E;F\U&)'I;=GJH-=;4C>_:*
M,O(>4FE2>PC5#$^R1UM25]O#OMIN2VR28Q27K6%'*';<WI;L-@=2F@HR\NYM
MR8$ '= WVI+]9D>V/S]"X:BU4[,4@:46[*4=J/UY>ZBVABVUUVL+)^S$1!.2
M_<_/+J!_IB/++3[YD>46G_S(<HM/?N0]-*S>PKO?3?_S3DM3ASUYVW.4_E!K
M\SWX7OJ?]YIMV?]<D)&EGCKYD<]IB\5, N/]SY4?C!]%()+(W%@'&'*K5-CO
MZ'J@]UI=B8!\I#98J[=OYMQW#_1VJ]D=2-X48^1S4OUG.K+<XI,?66[QR8\L
MM_CD1Y9;?/(CG],6BYDF(GN@[S$5NEV/*[NCAJ!:9ZCV!](5/<XP26I'T .&
M27;0$;33'$KN%&3D<]+<9SJRW.*3'WD/*13E]-*^FZ!+F^=X;1Y@KGIX2]H\
MQ\R=PDC+4UON.8Y\3ELL9NJ/[(*^Q\2?F@)2Q] %'0R]@2Y>\:!0(PMJZ+5Z
MQ\:GV]M]PV97IGP+,O(Y&05G.K+<XI,?66[QR8\LM_CD1Y9;?/(CG],6BYH4
M))N@[RDEJ*;JEKH;C>K]CO0^CS)44@[":T]-T/OMINQ<*\K(YZ1?SW1DN<4G
M/_(>4G>Z.TO=D;;)&=HF\$]]#"5MDY,<62JNDQ_YG+98S!2;32W6-!%()S*/
MUN&GIR,5[C6-H<ZV&)JFMC"7NB7[8ARC;=;J=87BQ^T3:+16LR4SIP49>=>-
M,5K]&N/HE1MC?"!  V=3;XRA+GMC')^ U-JI;?RJ<=C.^ZQUU$%'5]L#Z=<*
M,O(>HG6]C0K\J/JL==5NIZ6VVE*''Z6XU-I"L6,=?=;Z?<F*8HR\^SYK-5Y]
M[-2<[#6'/6E.'J%\;-?(8;LV)\&4[ Z&:E? 2F0:8/TI&+OF*_X?Z?-^[3QL
M.^@?2__0P>E(T6O'KF<2CRX6J/RV]2YMG&?#LPP'R(Y;8+//7E@\./D1?67T
M28*C;#(-WMF60QJSI1]Q@K=:WP,_ ;/.#1.W&G<19LGHDAJ ?K.^;?H:9]<4
M<&:[E@'FOILAKYR)'9KPM:8.^FV$_U;FQ*/\[TR(,D:307&9G:!8OA_"7P-7
M<:=3L @\7X%SHYB61R:!Z_FJTF\/Z#O6?T&>YK;[2@C[23?C*1#V?F@'B!S=
MW,"]-1Z14^72G:J.5'X<*7[X!+]_!0Y1@AD2U0A"/_H;VJ>&\_I??QNTM?X[
M&--U&L^TP4O,"\!Z]-'@Q550=_L*<4SX?OWV!=A&F8/-26@+A#&QW9>W.^>7
M!#W2C:*VWNX555E)Y70_F1$SM,G-]-IU6-,;;IX_X/P?X&T?;'?R[8U"_(DQ
MAU\%7DC>;&+>5:;#U=)U*^EK;>!3;XTP<*,/J(YFGS#&&G0K<>=.S9A]F]0S
M<\GB^7!S]_'RKO'AYN'AYLM;Y6\M^H^BS?]2?->V3$ZY80&3:(+L[+U#%K)A
M0<X_WK23*_ET<_W0N+_Z?Y=O%;H4A7[P:?3EZO/O;]?V5/DRNOOEZOJM LMY
MIZ2,\OYG/_!<Y_$]BT/@.>5<]_-/_)LT>M^./GZ\NOXE7C L] "VJ]ST+3<]
M<KD4[G,IM&>#\A%,9.6387D*M8]%Y00Q:T*^.ERAI60,:$-!O3\Q0A)%3LHF
MCW$X3+WA2FO]GI9W&>T>%X+IH862@!KJH-U5A_VN<$ZA4"/7'X"H@YW %*_$
M3RO!+"I74:RB5*5"-<%91:*J>K,O7L*(B%E;2O0OLSME=_=:C\D/V6(W%7IF
MTS%9\G.JRUC%ATG^XTT#FYBUM([:;95H)%M&\/PHP%X*RT4GM5P1C<L5V<:;
M/XI +9'9L@:3LE-%MO'MV;Z2IZUV>[ILS"C.R%(."F7C"8J$N1(>6@T+"<"Q
M&V98DV&8&@W?)#SC/:W1-M0&A81H:D1+&HM22!Z7L9@?B6RW1*#;F0K+;%DY
MJ#%V63F799%9JG=[:J= %7FNR#P'87<TP<S"E>6[#&9VFGWQ,'N/P-"5P<Q]
M!3,+@T/M.)C9:6GJL">#F=(^/3G[5 8S#Q3,+)Q0O:-@9J_5E<%,<4:6<E H
M&T\&,P_OG^<8AOTJPG,7P<R";7ID,%,*R1,P%C<$,P4#8EH113J((M,-QS81
M5EJN3;$>4[,P%,1^PIG=UE#M#39[TZM"4Y?A3$'#F97B-!O#F1&K%2MWU\0K
M=R]7[5E3=<&_0S^PIJ_O9&7=MN=N@P:M?;]^QI*3Z.WT">!\E[7J>PO*GGA(
M4%HK2IS >B;*?>!.OBD?7"?TE5O;<'[^"5_Q7J&%?=H[Y<9)4=*JDGF2A_IF
M6+5X=#HX'1N'3H?$N'"?GER'/LE.ZB@,9JX'F[1-;\P>S2U=#UW$Q8[T.>61
M!4L42CKZ1;NE=91L\BD>!3M0W$4ENHKO!'$QF>50K5>XTK X!1>1[,CGJ%[Y
MT-/5=C>%7)Q.\!]E&MKVJ\(T?5-Y6! 1OQP3A-XDAN<@->>P=B2F,9E9Y)D"
MFR"1)G!:D'APX. MK@._M8E!03L#E_Y@ LR L # ]_^A3)U5COHEM /K&_ Z
MG)/)S $3]_$5-@+$PAP6.K5@%I8S\8CAPR 6FPT<Z6\D4.:(D)+U7A_IS58W
MQ;*J9]0R*TS#%T=Y1S&Q NO%\!60 I/0-B@W^71)BR'Y6Q*_:]#?804M5E1C
M ;<//$2 DI1N =(I(ENRRGOB@5H"L8L5M;;UC<".8)$V&]%0OB"+*1>&9[O*
MO?6$\T$B;C=.Z/"-8W1)K'N91)P\48GX#.S_]=.B&+3$.*5&&(EHS.>>^Q<P
M:H K^R[G//7KD4)XAF+\D@2\1&QAW$Q+':Y&=P5J0O&!,6"@WIOW@^;Z72J>
M!1O^P$@;N(%AI_&<JEA3?KI4W!)^W/Y"""&LR'[FTLLC?X:6#UNG^,1[1CZ?
MT^ZMK%B;P'E<'#X53H+[;)ETK_)^BN?;P])N#T='7 [/A'?X3.X1^+&79';8
M%M-B%>+XRR<2-)5K%X]V#'@$?_$#7(<'VNO105E/)V@@U%&20;,FA;]UW"">
M5E/Y&'I, L$2.>DVU*3CN4$1K"8% 9V1A[_@Q(4/\! M1%1TCG 4V)D I F>
M>2HXE'GHX;=!]/ <508\6)BO]7*8?(5Y_(K/^F9Z%\^9_J8&OFXUUT'Y%GP]
M2HL"+--\9J"02?#"$J]$&U&&C)U6O4;*1S(EGK>,VG4)K!F\5D:@2;]:X88$
ML#<NFW(6L-(XTKX)&G&EYL 2E3]#PP-QO0F' P=#JEA.:##O9Z_('.E@!EN:
M^U'!]WP\\Q;SR8^.O<D) 8UM \[Q(B:M/%S^ZZ%Q=?WQ\OJ!6>9I9=J?&NUV
MH5$7)/_['#S:QAA,E&\-8PJO>:L8]HOQZO_]?9$('W\;>7K_LZ',/.2KOP$C
M3\&8HR@4>%P0CPMFZ/_\DP&OPD?WB[F1Y#5Z./&#/[J3KMX?;H3#D!ZG$!YG
M29B8A$:<4,>.*T9N%$YA7/J[' ]K6UB9/4 1%8&6J73_M("66:CIA(-\1:F(
MKP)K,4.!T87BL&.)02/A2&J&(UE@SS"OZ+#4E=NYY786194Y$C"9W0N.@U\*
M)OCBM.^V)=%/+Z&@=N-4(C@=-$,5/*;4>OO,<-5*[(DBF_O9K36C[66V1AT(
M3WHK_5I(@,T29V11<PC:J3D$:35W99BM[I(I36\*"""VXWS:ZI)]*:DV0\P+
MFFE[Q!*](<!:SG'D0V:GBE#Z*ZR!640,B5C4>5;9_FM22P26%H$+A-ELZ1;O
MU7BJX!9+.!$!X43 D4ZM]=S6MSF\(RTE])$XU]IAG.NS\:E%,V:E3[TWD!*0
M[N6ROPL>+G8ZXHVL"92Y3'14EJ4>@[DL@@X6UH26CO\1V,UYHC45B&];T5I/
M64T"T+2KI=;72!" DY.V0DM6P>_L)3R D/  X!VFMM;9S3W_UO !586M! \0
M-3:1VK%F6^X[_=C$KKM(GQEZP"[1%XX$5V"U6,/G< )%?Z_PYR/T@5%&,?!Z
M?2 O(#%XC2S\*KOZ;[7V(J7Z;[EFPB\(3<#J+[8)FV-[F$%*&7!46CY=+IN)
MZV76"$_+5VG)= R7@)6"E$Q*.,<_YU29]G9$H%JP&_H#7>WWLL$(5HG$P!NL
MP%^G4E,9V?:BH;F:;( >-497D111*W.5TM4PGRW?]5@!,X&S8J%T8X68$60$
MF\QJR66AO/1MCN]2.:)>1K;L4Y+MAQ8G)523I<5)I):B;_&W1W8I*#:3,]V[
M<.CIG?3":2X<7A Z("$3L9HP]$E4+KU:KYA!>[\0J$M[L%N";:UNM&Y'U8;K
MUND2L2+-"G(O@=-!,1M2'EO12.N40S&9$*AT ^;&:P0RPG$<?,5D@ V;@1K4
M&*GA4/7MZ_]5\FH_V^D=-O-J/Q,L$)-SY)B77'%]( Z96@&E[P.\]4.%TLZC
ML\$/(Z[I+L*BIV:K,^C )K4ZO5:CH_<ZC;&I&8W>N-LQAZ;9,7OZFR7NXNSD
MOSZ-7?M-W+E]N&C*SO_?5!)]VIF,%T);L2E=?KG]?//[Y:7RX?+Z\M/5@W+[
M>72=TEA>FCO2W%F:R4/"8T- )42, @L:5-34<B@>@!-XUCBDJL(C 5CB5"D@
M1HZ*$"8VO =5 K/G[PE3MYV6]L.W'R.\@2NL7'7  ;PCS\0)<423J(H?CO\-
MST>P.Y'<A*?B8:X<<!H(OA843_"JC"94'VG#?D=%4"J0PZB F+:9(*(2S@5>
MC!HQL R$7X'_Q$N,G8JF<HF@0W,#R6W!=T%L72PMV?*!+ $6^"OCUR7_]L4*
M9EG.#871FAG/8-1P8"B"I,*5HH"-Z+)I=)7")<&/R%\3PA&?$,.)%7-G(^GT
M.X4KO)*QM0=TTI/*K"I,CM9*M_; J,B9<Z7&";<+$B[//"L*>!MZ),9!:K3!
M-EV;9^[^L$A&$NN(H8"MVJA+7+3*'\!5E"U,!GW%D8"4L>$G@?@FMDL1XL:6
MF8]_EWQW#*H5V6@Y)EK.9J0"8>1U2HN,H03D!9O(+<7^8L;M-7FA7VV#>JCU
MU>%P@RL1H=FYJ>3BPFD>X988#-FL!%15OU,X\2X%E H%ZT6"/=!"Y,+/^VCY
M$Q2SKF-XK\F'1D]NZ 153R3,+?5(%N:65BZW%,Z4VC^WZ.J@?W!NJ>Q:'(9;
MM(Q^V$5<N?JO*I1U'^[<8<MT"5N6C^34+M]B+AG0L0*T/GUPYB]H9.*1.!.+
M^'C<0">#!9'ESRL\DD',4<"1TXR)KHV-T_/TX]NVW32D6';LM2DA6JNC-_3!
MN-_HD$F_,6Q/NPV],VUIO4YGT-8GA1Q[K56K9\]_=W'SY<O5PQ<XMO?*Z/JC
M<@%>V=7U+Y?7%U>7]\G72Q]<^N#K01R0EA=P3G%,<'Y],,/ *1@]>H0ZP3X7
MIS*&(_DG=297CC("_]!&_!Q]^1*>V@P4=Q:L6[1<&R9Y)K8[I]$5#)IX/"2#
M!C%%^H[8C@4X+KU']PFAFK_&8/OQ$VKT+3QJVPN/-[K*SK:(!\4;)=,+&3[.
M>CI0=&SNV07% ^A+NR@X<B\;'%E+\1@X-C(LC.%=I_D*MS/PX)6KJRLP%?EY
M]H/0?(TNLG!B:"RYTRF+5)E@4:"ECI&V^!?198N%,,J3F0'F!_<\,!P -H1I
M/5H!@FJC38@(</#*&"&<[:K[:MC!:W2'XZM\2XP(:G^B/!G@NH1/BD%=A:8"
M7'0S"5ST^8"/NKE\Y!/$"Z_.3FPYCH*&!_5>;.6[=D1AE2\VSAGY3FLO(ZY'
MLS(F$?$B^-%2,P+ZXAL\DR*#T_F-[B^406M KV/;K7<7KFT;8WIO^TR4D>?A
M7E""T@>T=\OS,0E0Z8G&35GXB!$?"1\M'',3<"3.$+#[<[I].'!?;T4#QUH
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MF"%()U[Q'M\B5-: O70!P] 5#3\!'X94-@E0"M7<LV4"<3'4Q:(^%(F;!GJ
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MMYPLNKK09.%,9-==P9HLP[ZE5+[A1*ZCG^VPV<EKQAPP] 8\ (R+:6W,"\A
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MFG$RK+18VK+OQ?.\HC5FV7,<4&C)!(IS$OTHB2>8N7Z,"@F4#B?X>1CX ;P
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MW6XQ.]\R8RS='01#TF"Q3V9CBM7V=B=M;6ML6SOH%,;32^I0MB%W?#\>V':
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M2-N52-NA'OJ)OWD6/-GO_S]02P,$%     @ /(254YZ7-ZWYA0  ^(@   \
M  !C=FU?,3!K:6UG,2YJ<&>LNF54G,'S+CB$$"!H<'<"R>#N! @>($"P&30X
M9'#7!();@  )&EP'@@SN[LX @P_N@SO<_/[WWMW[8>^>W3U;[ZGW2_>IZN=T
MG:JGNOMI[FD50*BBH*P 0$-# YC^^P!/"P Y ,;S?X+^G_\+#(P76'A86)B8
M6(0XN-AXQ(0DQ$2$1$0DY+24)&0T9$1$5,Q4-'3TC(R,))0L;"P,KVD9&!G^
M8P0-X\4++$PL BPL @92(E*&_]?RU YXA85&_HP+'8T)\.P5&OHKM*=N #T
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M767A==697$H/B OF+57GNS8B*:CL<!]^V#W1V-\IJ+/Z:I-.XZJEM.R$/.Q
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M5.JP*XN'NO"/ 'S.I^1>.J9:1D@W'P >[$6YUR ZY_63CJ*,X&#&B.:JO!\
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MPGUQ3&&K:TQZ1]M3&[;I9=>/V".OK+TKCGP\97.L'AXF*;'BT8QU340<2+'
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M3T_N <J(!$:&4+GBFGG<$W"3?%PXG*".0@318.[HN;HQ0TPV N0,IZ/DS?R
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M"L7HRA@,E*^N?YG[1F!9 )$&J^4@T>TMSV%G3VJ$'6Y6W")X5D//LK5-B.V
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MI.ATG]IFZ_BD^K.K".-FZ'@3*9C]_TT 4$L#!!0    ( #R$E5-D(-AE*@,
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MJS.=L-/>I\;7TSX[U2;7ACNI<3]"*=1A;L1=BSWEZ!T?*#'K::!-# C8G$>
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M*W7<;^6?@^@?4$L! A0#%     @ /(254[UW-.^O%P  1A4! !
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M2P$"% ,4    "  \A)537PL M&E9  "DX00 %               @ $EQ@
M8W9M+3(P,C$P.3,P7W!R92YX;6Q02P$"% ,4    "  \A)53A<%F0%"' @#)
MW!P "P              @ ' 'P$ 8W9M7S$P:RYH=&U02P$"% ,4    "  \
MA)53GI<WK?F%  #XB   #P              @ $YIP, 8W9M7S$P:VEM9S$N
M:G!G4$L! A0#%     @ /(254V0@V&4J P  _0T   T              ( !
M7RT$ &-V;5]E>#(S,2YH=&U02P$"% ,4    "  \A)539@1+)C (  !(9
M#               @ &T, 0 8W9M7V5X,S$N:'1M4$L! A0#%     @ /(25
M4RPUR6:] P  >@P   P              ( !#CD$ &-V;5]E>#,R+FAT;5!+
4!08     "@ * &L"  #U/ 0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
